<SEC-DOCUMENT>0001683168-26-002644.txt : 20260403
<SEC-HEADER>0001683168-26-002644.hdr.sgml : 20260403
<ACCEPTANCE-DATETIME>20260403115823
ACCESSION NUMBER:		0001683168-26-002644
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		86
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260403
DATE AS OF CHANGE:		20260403

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sunshine Biopharma Inc.
		CENTRAL INDEX KEY:			0001402328
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				205566275
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41282
		FILM NUMBER:		26837255

	BUSINESS ADDRESS:	
		STREET 1:		333 LAS OLAS WAY
		STREET 2:		CU4 SUITE 433
		CITY:			FORT LAUDERDALE
		STATE:			FL
		ZIP:			33301
		BUSINESS PHONE:		954-330-0684

	MAIL ADDRESS:	
		STREET 1:		333 LAS OLAS WAY
		STREET 2:		CU4 SUITE 433
		CITY:			FORT LAUDERDALE
		STATE:			FL
		ZIP:			33301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Sunshine Biopharma, Inc
		DATE OF NAME CHANGE:	20091102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Mountain West Business Solutions, Inc
		DATE OF NAME CHANGE:	20071030

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	mountain west business solutions,inc
		DATE OF NAME CHANGE:	20070607
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sunshine_i10k-123125.htm
<DESCRIPTION>FORM 10-K FOR DEC 2025
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:SBFM="http://sunshinebiopharma.com/20251231">
<head>
     <title>SUNSHINE BIOPHARMA INC. Form 10-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2025%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_037_SBFM_sunshinebiopharma.com_20251231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20250101_20251231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DDocumentFiscalYearFocus_2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0001402328 -->
<!-- Field: Set; Name: xdx; ID: xdx_07E_SO_sunshine__i10k%2D123125.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_Segment_0_Segment -->
<!-- Field: Set; Name: xdx; ID: xdx_06E_CAD_0_iso4217%2D%2DCAD -->
<body style="font: 10pt Arial, Helvetica, Sans-Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000004" name="dei:DocumentFiscalYearFocus">2025</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000005" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000006" name="dei:EntityCentralIndexKey">0001402328</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2025-12-31" id="xdx2ixbrl1167" decimals="0" scale="0" unitRef="USD">8445713</ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="xdx2ixbrl1169" decimals="0" scale="0" unitRef="USD">6967294</ix:nonFraction>
  <ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1203" decimals="INF" unitRef="Segment">1</ix:nonFraction>
  <ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1205" decimals="INF" unitRef="Segment">1</ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="sbfm-20251231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2025-01-01to2025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-04-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-04-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_ComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_VehiclesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_LicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">SBFM:LicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WebsiteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">SBFM:WebsiteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-192022-10-20_custom_NoraPharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">SBFM:NoraPharmaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-19</xbrli:startDate>
        <xbrli:endDate>2022-10-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-20_custom_NoraPharmaMember_custom_MalekChamounMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">SBFM:NoraPharmaMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:MalekChamounMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_NoraPharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">SBFM:NoraPharmaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-212024-04-22_custom_NoraPharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">SBFM:NoraPharmaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-21</xbrli:startDate>
        <xbrli:endDate>2024-04-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_NoraPharmaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">SBFM:NoraPharmaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_VehiclesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_VehiclesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_FinishedGoodsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:FinishedGoodsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_FinishedGoodsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:FinishedGoodsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_ProfessionalAllowancesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:ProfessionalAllowancesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ProfessionalAllowancesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:ProfessionalAllowancesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_OtherAllowancesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:OtherAllowancesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_OtherAllowancesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:OtherAllowancesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WholesalersFeesAndDiscountsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:WholesalersFeesAndDiscountsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WholesalersFeesAndDiscountsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:WholesalersFeesAndDiscountsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_InventoryAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:InventoryAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_InventoryAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:InventoryAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_FreightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:FreightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_FreightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:FreightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-072024-02-08_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-07</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-08_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-142024-02-15_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-14</xbrli:startDate>
        <xbrli:endDate>2024-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PreFundedWarrants2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SBFM:PreFundedWarrants2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-032024-03-04_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-03</xbrli:startDate>
        <xbrli:endDate>2024-03-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-04_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-04-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-05-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-152024-08-16_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-15</xbrli:startDate>
        <xbrli:endDate>2024-08-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-012024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-08-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-08-31_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-012024-09-30_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-08-31_custom_SeriesBWarrantsMember614656125">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-012024-09-30_custom_SeriesBWarrantsMember614656125">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012024-11-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012024-11-30_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-012024-12-31_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012024-11-30_custom_SeriesBWarrantsMember614656125">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-012024-12-31_custom_SeriesBWarrantsMember614656125">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-022025-01-03_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-02</xbrli:startDate>
        <xbrli:endDate>2025-01-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-022025-01-03_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-02</xbrli:startDate>
        <xbrli:endDate>2025-01-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-022025-01-03_custom_SeriesBWarrantsMember614656140">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-02</xbrli:startDate>
        <xbrli:endDate>2025-01-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-04-02_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-04-02_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-04-02_custom_SeriesBWarrantsMember614656140">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-012025-04-03_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SBFM:RegisteredDirectOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-04-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-152025-10-16_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-15</xbrli:startDate>
        <xbrli:endDate>2025-10-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-152025-10-16_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-15</xbrli:startDate>
        <xbrli:endDate>2025-10-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-152025-10-16_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SBFM:RegisteredDirectOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-15</xbrli:startDate>
        <xbrli:endDate>2025-10-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_TradeableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:TradeableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_TradeableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:TradeableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PreFunded2022WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2022WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PreFunded2022WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2022WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_InvestorWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:InvestorWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_InvestorWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:InvestorWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_AprilWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:AprilWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_AprilWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:AprilWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_MayPreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:MayPreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_MayPreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:MayPreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_MayInvestorWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:MayInvestorWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_MayInvestorWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:MayInvestorWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PreFunded2024WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2024WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PreFunded2024WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2024WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PreFunded2025WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2025WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PreFunded2025WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2025WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-102024-02-11_custom_AprilWarrantsAndMayInvestorWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:AprilWarrantsAndMayInvestorWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-10</xbrli:startDate>
        <xbrli:endDate>2024-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_TradeableWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:TradeableWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_TradeableWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:TradeableWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_InvestorWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:InvestorWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_InvestorWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:InvestorWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesBWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesBWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesBWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesBWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_AdvanomicsCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SBFM:AdvanomicsCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AdvanomicsCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SBFM:AdvanomicsCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-012025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001402328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>SBFM:Segment</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="CAD">
      <xbrli:measure>iso4217:CAD</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 7pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><a href="#a_004">Table of Contents</a></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_906_edei--DocumentType_c20250101__20251231_zpS3nG2K6kYh"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000015" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">(Mark one)</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span id="xdx_903_edei--DocumentAnnualReport_c20250101__20251231_zdoHl1dai3ob"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000016" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span> ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 20pt">FOR THE FISCAL YEAR ENDED <span id="xdx_902_edei--DocumentPeriodEndDate_c20250101__20251231_zfdeJKosLS3e"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:datemonthdayyearen" id="Fact000017" name="dei:DocumentPeriodEndDate"><span id="xdx_905_edei--CurrentFiscalYearEndDate_c20250101__20251231_zjLs0h4LDsHk"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:datemonthdayen" id="Fact000018" name="dei:CurrentFiscalYearEndDate">DECEMBER 31</ix:nonNumeric></span>, 2025</ix:nonNumeric></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span id="xdx_90D_edei--DocumentTransitionReport_c20250101__20251231_zsET5paBGROe"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000019" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span> TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 20pt">for the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">Commission File Number <b><span style="text-decoration: underline"><span id="xdx_902_edei--EntityFileNumber_c20250101__20251231_z0hloqNowZ0e"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000020" name="dei:EntityFileNumber">001-41282</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><img src="image_001.jpg" alt=""/></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90F_edei--EntityRegistrantName_c20250101__20251231_zS0qEPnwr0Eg"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000021" name="dei:EntityRegistrantName">SUNSHINE BIOPHARMA INC.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 50%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20250101__20251231_zXfhSf8wCISl"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:stateprovnameen" id="Fact000022" name="dei:EntityIncorporationStateCountryCode">Colorado</ix:nonNumeric></span></b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityTaxIdentificationNumber_c20250101__20251231_zfwrCHfszuw5"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000023" name="dei:EntityTaxIdentificationNumber">20-5566275</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(State or other jurisdiction of incorporation or organization)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(I.R.S. Employer Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityAddressAddressLine1_c20250101__20251231_zndWu3Slycf7"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000024" name="dei:EntityAddressAddressLine1">333 Las Olas Way</ix:nonNumeric></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_906_edei--EntityAddressAddressLine2_c20250101__20251231_znqUty6RAZs7"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000025" name="dei:EntityAddressAddressLine2">CU4 Suite 433</ix:nonNumeric></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90C_edei--EntityAddressCityOrTown_c20250101__20251231_zV63UkYd0BM8"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000026" name="dei:EntityAddressCityOrTown">Fort Lauderdale</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20250101__20251231_zSX7bHXagP64"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000027" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span> <span id="xdx_902_edei--EntityAddressPostalZipCode_c20250101__20251231_zHyRucKlrvug"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000028" name="dei:EntityAddressPostalZipCode">33301</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">(<span id="xdx_905_edei--CityAreaCode_c20250101__20251231_zABnTcPri9F3"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000029" name="dei:CityAreaCode">954</ix:nonNumeric></span>) <span id="xdx_90C_edei--LocalPhoneNumber_c20250101__20251231_zrhBYVKERNQd"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000030" name="dei:LocalPhoneNumber">330-0684</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s Telephone Number, including
area code)</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 36%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Title of each class:</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 26%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="vertical-align: bottom; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 36%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span id="xdx_90C_edei--Security12bTitle_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z09FIlOwlSSh"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000031" name="dei:Security12bTitle">Common Stock, par value $0.001</ix:nonNumeric></span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span id="xdx_905_edei--Security12bTitle_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSrHGEP757ff" title="Title of 12(b) Security"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember" id="Fact000033" name="dei:Security12bTitle">Warrants</ix:nonNumeric></span></p></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span id="xdx_90D_edei--TradingSymbol_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYoNg5hqBhqe"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000034" name="dei:TradingSymbol">SBFM</ix:nonNumeric></span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span id="xdx_90B_edei--TradingSymbol_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkDrID8IpEd3" title="Trading Symbol"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember" id="Fact000036" name="dei:TradingSymbol">SBFMW</ix:nonNumeric></span></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span id="xdx_904_edei--SecurityExchangeName_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zb7sA0io3Fke"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" format="ixt-sec:exchnameen" id="Fact000037" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span id="xdx_90C_edei--SecurityExchangeName_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjOjPuXqkAKe" title="Security Exchange Name"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember" format="ixt-sec:exchnameen" id="Fact000039" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</p></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><b>Securities registered pursuant to Section&#160;12(g)&#160;of
the Act:</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">None</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is a well-known seasoned issuer,
as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_900_edei--EntityWellKnownSeasonedIssuer_c20250101__20251231_zF9xFIWAm0Di"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000040" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is not required to file reports
pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes &#9744; <span id="xdx_909_edei--EntityVoluntaryFilers_c20250101__20251231_z1EuxgagccPb"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000041" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that
the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <span id="xdx_905_edei--EntityCurrentReportingStatus_c20250101__20251231_znoEjHRm7uu3"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000042" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746;&#160;&#160;&#160;No&#160;&#9744;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to Regulation S-T (&#167; 232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant was required to submit such files).&#160;<span id="xdx_90E_edei--EntityInteractiveDataCurrent_c20250101__20251231_z5oMwkFDbjO2"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000043" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746;&#160;&#160;&#160;No&#160;&#9744;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of &#8220;large
accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221;
in Rule 12b-2 of the Exchange Act. (Check one):</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 30%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Large&#160;accelerated&#160;filer</span></td>
    <td style="width: 35%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9744;</span></td>
    <td style="width: 30%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Accelerated&#160;filer</span></td>
    <td style="width: 5%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_904_edei--EntityFilerCategory_c20250101__20251231_zNxqZFZKj7P2"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000044" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#9746;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Smaller&#160;reporting&#160;company</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_901_edei--EntitySmallBusiness_c20250101__20251231_zkGoQ2Egnprd"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000045" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Emerging growth company</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityEmergingGrowthCompany_c20250101__20251231_zEuxFRn0iNzb"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000046" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant has filed a report on
and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section
404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
<span id="xdx_907_edei--IcfrAuditorAttestationFlag_c20250101__20251231_zgiUgaWUwFh5"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000047" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">If securities are registered pursuant to Section 12(b) of the Act, indicate
by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously
issued financial statements. <span id="xdx_906_edei--DocumentFinStmtErrorCorrectionFlag_c20250101__20251231_zClFVt6iupye"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000048" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether any of those error corrections are restatements
that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during
the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Act). Yes &#9744;&#160;&#160;&#160;No <span id="xdx_903_edei--EntityShellCompany_dbF_c20250101__20251231_z4jWS9DuHOya"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000049" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The aggregate market value of the voting and non-voting common equity
held by non-affiliates computed by reference to the price at which the common equity was last sold on June 30, 2025, was $<span id="xdx_902_edei--EntityPublicFloat_iI_c20250630_z4Qak6EbhAm9"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2025-06-30" id="Fact000050" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,061,719</ix:nonFraction></span>.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">As of April 2, 2026, the Registrant had <span id="xdx_900_edei--EntityCommonStockSharesOutstanding_iI_c20260402_zFN3m1kXOo5b"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2026-04-02" id="Fact000051" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,905,945</ix:nonFraction></span> shares of common
stock, par value $0.001 issued and outstanding.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Documents Incorporated by reference: None</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">&#160;</td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #00487F"><b><span id="a_004"></span>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Page </b></span></td></tr>
  <tr>
    <td colspan="2" style="vertical-align: top"><a href="#a_005"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Defined Terms</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">i</span></td></tr>
  <tr>
    <td colspan="2" style="vertical-align: top"><a href="#a_006"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Forward Looking Statements</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">ii</span></td></tr>
  <tr>
    <td colspan="2" style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_013">PART I</a></span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_013">Item 1. Business</a></span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_007">Item 1A. Risk Factors</a></span></td>
    <td style="text-align: right">8</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_008">Item 1B. Unresolved Staff Comments</a></span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">18</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_009">Item 1C. Cybersecurity</a></span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">18</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_010">Item 2. Properties</a></span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">19</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_011">Item 3. Legal Proceedings</a></span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">19</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_012">Item 4. Mine Safety Disclosures</a></span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">19</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 7%">&#160;</td>
    <td style="width: 87%">&#160;</td>
    <td style="width: 6%; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><a href="#a_014"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">PART II</span></a></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">20</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_015">Item 5. Market for the Registrant&#8217;s
Common Equity Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="text-align: right">20</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_016">Item 6. Reserved.</a></span></td>
    <td style="text-align: right">21<span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_017">Item 7. Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">22</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_018">Item 7A. Quantitative and
Qualitative Disclosures About Market Risk</a></span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">23</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_019">Item 8. Financial Statements
and Supplementary Data</a></span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">24</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_024">Item 9. Changes in and Disagreements
with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">47</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_025">Item 9A. Controls and Procedures</a></span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">47</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_034">Item 9B. Other Information</a></span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">48</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_035">Item 9C. Disclosure Regarding
Foreign Jurisdictions that Prevent Inspections.</a></span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">48</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_027">PART III</a></span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">49</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_028">Item 10. Directors, Executive Officers and Corporate Governance</a></span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">49</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_029">Item 11. Executive Compensation</a></span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">52</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_030">Item 12. Security Ownership
of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">54</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_031">Item 13. Certain Relationships
and Related Transactions, and Director Independence</a></span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">56</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_032">Item 14. Principal Accounting
Fees and Services</a></span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">56</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_033">PART IV</a></span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">57</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_036">Item 15. Exhibits, Financial Statement Schedules</a></span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">57</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="#a_037">Signatures</a></span></td>
    <td style="text-align: right">59</td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #00487F"><b><span id="a_005"></span>DEFINED TERMS</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Unless the context requires otherwise, references
to &#8220;Sunshine,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; in this Form 10-K refer
to Sunshine Biopharma Inc. and its subsidiaries. The following are definitions for terms or abbreviations used in this Form 10-K:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 16%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">ASC</span></td>
    <td style="width: 84%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Accounting Standards Codification </span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">ANDS</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Abbreviated New Drug Submission</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">ASU</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Accounting Standards Update issued by FASB</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">CAD</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Canadian Dollar</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>CODM</td>
    <td style="text-align: justify">Chief Operating Decision Maker</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">COSO</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Committee of Sponsoring Organizations of the Treadway Commission</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">COVID-19</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Novel coronavirus disease of 2019</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">CSF</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">NIST Cybersecurity Framework</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">DIN</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Drug Identification Number, an eight-digit number issued by Health Canada authorizing the sale of a drug in Canada</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">EPS</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Earnings per share</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">EUA</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Emergency Use Authorization</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">FASB</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Financial Accounting Standards Board</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">FDA</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">U.S. Food and Drug Administration</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">FDA Form 483</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">An official list of inspectional findings that an FDA investigator
issues at the end of an inspection</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">FDIC</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Federal Deposit Insurance Corporation</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>FIFO</td>
    <td style="text-align: justify">First-In-First-Out method for inventory valuation</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">FTC</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Federal Trade Commission</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">G&amp;A</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">General and Administrative</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">GAAP</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Generally Accepted Accounting Principles</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">GDPR</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">General Data Protection Regulation</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">GMP</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Good Manufacturing Practice</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">GST</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Goods and Services Tax (Canada)</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">HPFB</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Health Products and Food Branch of Health Canada</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Health Canada</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Canadian drug regulatory body</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">HIPPA</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Health Insurance Portability and Accountability Act</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">IND</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Investigational New Drug</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">IT</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Information Technology</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">LNP</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Lipid Nano Particle</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">K1.1 mRNA</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The laboratory designation of the Company&#8217;s mRNA based anticancer therapy under development</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">MD&amp;A</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">MERS-CoV</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Middle East Respiratory Syndrome Coronavirus</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>MNPI</td>
    <td>Material Non-Public Information</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Mpro</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Coronavirus main protease</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">mRNA</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Messenger ribonucleic acid</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">NDA</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">New Drug Application</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">NOC</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Notice of Compliance issued by Health Canada</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Nora Pharma</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Nora Pharma Inc., a wholly-owned subsidiary of the Company acquired on October 20, 2022</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">NPN</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Natural Product Number, an eight-digit number issued by Health Canada authorizing the sale of a natural product or a supplement in Canada</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">OTC</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Over-The-Counter</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">pCPA</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">pan-Canadian Pharmaceutical Alliance, an alliance of the provincial, territorial and federal governments that determines generic drugs pricing</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">PCT</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Patent Cooperation Treaty</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">PLpro</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Coronavirus papain-like protease</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">QST</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Quebec Sales Tax (Canada)</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">R&amp;D</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Research and Development</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">ROU</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Right of Use</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">SAR</td>
    <td style="text-align: justify">Stock Appreciation Right</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">SARS Coronavirus</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Severe Acute Respiratory Syndrome Coronavirus, the group of coronaviruses that includes SARS-CoV-2, MERS-CoV, and SARS-CoV</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">SARS-CoV</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Severe Acute Respiratory Syndrome Coronavirus that first appeared in 2003</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">SARS-CoV-2</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Severe Acute Respiratory Syndrome Coronavirus 2, the virus that causes COVID-19</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">SBFM-PL4</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Laboratory designation of
    the Company&#8217;s SARS Coronavirus treatment under development</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">SEC</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">U.S. Securities and Exchange Commission</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">SOC</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Security Operations Center </span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Street Name</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Securities held in the name of a brokerage firm on behalf of a client</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Sunshine Canada</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Sunshine Biopharma Canada Inc., a wholly owned subsidiary of the Company</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">U.S.</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">United States of America</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">USD</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">U.S. Dollars. All applicable references in this report refer to US Dollars unless otherwise specifically stated.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">USPTO</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">United States Patent and Trademark Office</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 3 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #00487F"><b><span id="a_006"></span>FORWARD LOOKING STATEMENTS</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">This Annual Report on Form 10-K contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the
Securities Exchange Act of 1934, as amended, or the Exchange Act. The statements regarding Sunshine Biopharma Inc. contained in this Report
that are not historical in nature, particularly those that utilize terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221;
&#8220;likely,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;believes&#8221; or &#8220;plans,&#8221;
or comparable terminology, are forward-looking statements based on current expectations and assumptions, and entail various risks and
uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Important factors known to us that could cause
such material differences are identified in this Report. We undertake no obligation to correct or update any forward-looking statements,
whether as a result of new information, future events or otherwise, except as may be required under applicable law. You are advised, however,
to consult any future disclosures we make on related subjects in future reports we file with the SEC.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #00487F"><b><span id="a_013"></span>PART I</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b>ITEM 1. BUSINESS</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b>About Sunshine Biopharma</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We are a pharmaceutical company offering and researching
life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. We have two wholly owned subsidiaries:
(i) Nora Pharma Inc. (&#8220;Nora Pharma&#8221;), a Canadian corporation, through which we currently have 71 generic prescription drugs
on the market in Canada, and (ii) Sunshine Biopharma Canada Inc. (&#8220;Sunshine Canada&#8221;), a Canadian corporation which develops
and sells OTC supplements.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In addition, we are conducting a proprietary drug
development program which is comprised of (i) K1.1 mRNA, an LNP encapsulated mRNA targeted for liver cancer, and (ii) SBFM-PL4, a protease
inhibitor for treatment of SARS Coronavirus infections.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b>Commercial Operations</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our commercial operations are focused on the procurement
of rights to pharmaceutical products for sale, currently in Canada and ultimately around the world. We seek to secure such rights through
various types of strategic arrangements, including:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>In-licensing and Supply Agreements:</b> Nora Pharma acquires the rights to import, market, sell and distribute the products in Canada by purchasing the drug dossiers from strategic partners. Nora Pharma then files the dossiers with Health Canada to obtain regulatory approval prior to marketing. The approval process at Health Canada takes on average of 12 months. The products are sold under Nora Pharma label. </span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Cross-licensing:</b> Nora Pharma acquires the rights to import, market, sell and distribute the products in Canada by receiving an authorization letter from pharmaceutical partners. The partners&#8217; products are already approved in Canada but we are still required to obtain our own approval from Health Canada, which takes on average 45-60 days. The products are sold under Nora Pharma label.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Distribution Agreements:</b> Nora Pharma acquires the rights to market, sell and distribute the products in Canada by signing a distribution agreement with pharmaceutical partners. The partners&#8217; products are already approved by Health Canada. The products are sold under the partners&#8217; label.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Generic drugs are pharmaceutically equivalent to
the brand name drugs. They contain identical medicinal ingredients in the same amounts as the brands. Generic medications may have different non-medicinal ingredients than the brand name drugs, but the generic developer must show that these do not affect the safety,
efficacy, or quality of the drug compared to the brand. When a generic drugs company wants to sell a generic drug in Canada, it must file
a generic drug submission with Health Canada. The submission is called an Abbreviated New Drug Submission (ANDS). The submission is reviewed
by scientists and health care experts at Health Products and Food Branch (HPFB) of Health Canada. All generic drug submissions go through
the same process as the brand name drug submissions. If the evaluation shows that the generic drug meets all regulatory requirements (including
patent and data protection considerations), Health Canada will issue a Notice of Compliance (NOC) and a Drug Identification Number (DIN)
to the applicant. The NOC and DIN signal the drug's official approval in Canada and permit the applicant to market the drug in Canada.
Once a company obtains the NOC and DIN for a drug, then it begins the process with Pan-Canadian Pharmaceutical Alliance (pCPA) in order
to have the drug listed on the provincial and territorial formularies and federal government drug benefit plans.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We currently have the following generic prescription
drugs on the market in Canada:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 30%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Drug</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 40%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Therapeutic Area</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 30%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Brand</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Abiraterone*</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Oncology</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Zytiga&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Alendronate</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Osteoporosis</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Fosamax&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Amlodipine</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Norvasc&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Apixaban</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Eliquis&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Aripiprazole</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Antipsychotic</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Abilify&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Atorvastatin</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Lipitor&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Azithromycin</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Antibacterial</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Zithromax&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Betahistine</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Vertigo</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Serc&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Bilastine</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Allergy</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Blexten&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Candesartan</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Hypertension</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Atacand&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Candesartan HCTZ</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Hypertension</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Atacand Plus&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Celecoxib</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Anti-inflammatory</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Celebrex&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cetirizine</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Allergy</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Reactine&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Ciprofloxacin</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Antibiotic</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cipro&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Citalopram</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Celexa&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Clindamycin</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Antibiotic</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Dalacin&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Clobetasol*</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Anti-inflammatory</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Clobex&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Clopidogrel</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Plavix&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Dapagliflozin</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Diabetes</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Forxiga&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Daptomycin*</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Antibacterial</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cubicin&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Dasatinib*</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Oncology</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Sprycel&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Docusate</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Gastroenterology</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Colace&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Donepezil</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Aricept&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Doxycycline</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Antibacterial</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Vibramycin&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Duloxetine</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cymbalta&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Dutasteride</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Urology</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Avodart&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Ertapenem*</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Antibacterial</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Invanz&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Escitalopram</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cipralex&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Everolimus*</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Oncology</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Afinitor&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Ezetimibe</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Ezetrol&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Finasteride</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Urology</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Proscar&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Fluconazole</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Antifungal</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Diflucan&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Fluoxetine</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Prozac&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Gabapentin</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Neurontin&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Hanzema&#174;*</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Dermatology</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Toctino&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Hydroxychloroquine</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Antimalarial</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Plaquenil&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Letrozole</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Oncology</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Femara&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Levetiracetam</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Keppra&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Lurasidone</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Antipsychotic</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Latuda&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Metformin</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Diabetes</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Glucophage&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Mirtazapine</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Remeron&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Montelukast</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Allergy</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Singulair&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Olanzapine</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Zyprexa&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Olanzapine ODT</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Zyprexa&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Olmesartan</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Olmetec&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Olmesartan HCTZ</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Olmetec Plus&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Pantoprazole</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Gastroenterology</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Pantoloc&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Paroxetine</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Paxil&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Pegfilgrastim</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Oncology</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Neulasta&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Perindopril</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Coversyl&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Pravastatin</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Pravachol&#174;</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 30%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Pregabalin</span></td>
    <td style="width: 40%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td style="width: 30%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Lyrica&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Progesterone*</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Women's Health</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Prometrium&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Prucalopride</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Women's Health</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Resotran&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Quetiapine</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Seroquel&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Quetiapine XR</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Seroquel XR&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Ramipril</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Altace&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Rivaroxaban*</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Xarelto&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Rizatriptan ODT</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Maxalt&#174; ODT</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Rosuvastatin</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Crestor&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Sertraline</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Zoloft&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Sildenafil</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Urology</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Viagra&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Tadalafil</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Urology</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cialis&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Telmisartan</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Micardis&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Telmisartan HCTZ</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cardiovascular</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Micardis Plus&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Topiramate</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Anticonvulsant</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Topamax&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Ursodiol</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Cholelithiasis</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Urso&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Varenicline</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Smoking cessation</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Champix&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Zoledronic Acid*</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Osteoporosis</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Aclasta&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Zolmitriptan</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous system</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Zomig&#174;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Zopiclone</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Central nervous
    system</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Imovane&#174;</span></td></tr>
  </table>
<p style="font: 8pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">*Sold through distribution agreements in which we act as distributor.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In addition to the 71 drugs currently on the market,
we have 22 additional drugs in our pipeline including 12 we anticipate launching during the remainder of 2026. These additional drugs
will address various human health areas including cardiovascular, oncology, gastroenterology, central nervous system, diabetes, urology,
endocrinology, anti-infective, and anti-inflammatory.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We believe the addition of these products to our
existing portfolio will strengthen our presence in the Canadian $10.4 billion a year generic drugs market (<i>IMARC Group</i>) and provide
us with greater access to pharmacies as we become more of a go-to supplier for every-day and specialty medicines.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b>Research and Development</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The following table summarizes our proprietary
drugs in development:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 26%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Drug Candidate</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 1%">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 36%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Therapeutic Area/Indication</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 1%">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 21%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Development Stage</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 15%">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">K1.1 (mRNA LNP)</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Oncology (Liver Cancer)</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Animal Testing</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="border-bottom: black 1pt solid; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">SBFM-PL4
    (Small Molecule)</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Antiviral
    (SARS Coronavirus)</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Animal
    Testing</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: top"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b><i>K1.1 Anticancer mRNA</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In June 2021, we initiated a new research project
in which we set out to determine if certain mRNA molecules can be used as anti-cancer agents. The data collected to date have shown that
a selected group of mRNA molecules are capable of destroying cancer cells in vitro including multidrug resistant breast cancer cells (MCF-7/MDR),
ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Studies using non-transformed (normal) human cells (HMEC
cells) showed that these mRNA molecules had little cytotoxic side effects. These new mRNA molecules, bearing the laboratory name K1.1,
were adapted for delivery into patients using a lipid nanoparticle (LNP) technology similar to the one employed in the COVID-19 mRNA vaccines.
On April 20, 2022, we filed a provisional patent application in the United States covering our K1.1 mRNA molecules.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In November 2022, we concluded an agreement with
a specialized commercial partner for the purposes of formulating our K1.1 mRNA molecules into specific lipid nanoparticles for use in
test animals including xenograft mice. The initial results of our animal testing indicated that our K1.1 mRNA-LNP constructs were effective
at reducing the size of liver cancer tumors in xenograft mice. We are currently seeking to confirm these results by conducting additional
xenograft experiments on a broader scale and in more detailed dose-response studies.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b><i>SBFM-PL4 SARS Coronavirus Treatment</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The initial genome expression products following
infection by Betacoronavirus, the causative agent of COVID-19, are two large polyproteins, referred to as pp1a and pp1ab. These two polyproteins
are cleaved at 15 specific sites by two virus encoded proteases, called Mpro and PLpro, to generate 16 different non-structural proteins
essential for viral replication. Mpro and PLpro represent attractive anti-viral drug development targets as they play a central role in
the early stages of viral replication. PLpro is of particular interest as a therapeutic target in that, in addition to processing essential
viral proteins, it is also responsible for suppression of the human immune system making the virus more life-threatening. PLpro is present
only in Betacoronaviruses, the subgroup of Coronaviruses represented by the highly pathogenic SARS-CoV, MERS-CoV, and SARS-CoV-2.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our Anti-Coronavirus research effort has been focused on developing an
inhibitor of PLpro and, on May 22, 2020, we filed a provisional patent application in the United States covering composition subject matter
pertaining to small molecules for inhibition of the Coronavirus PLpro as well as Mpro. Our provisional patent application, entitled <i>Inhibitors
of Coronavirus Protease</i>, was converted into a PCT patent application on April 30, 2021. On December 23, 2025, we received a Notice
of Allowance from the USPTO for our PCT patent application. Full patents are typically issued by the USPTO 4 to 8 weeks following the
issuance of the Notice of Allowance and payment of the issue fees.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In February 2022, we expanded our PLpro inhibitors
research effort by entering into a research agreement with the University of Arizona for the purposes of conducting research focused on
determining the in vivo safety, pharmacokinetics, and dose selection properties of three University of Arizona owned PLpro inhibitors,
to be followed by efficacy testing in mice infected with SARS-CoV-2 (the &#8220;Research Project&#8221;). Under the agreement, the University
of Arizona granted us a first option to negotiate a commercial, royalty-bearing license for all intellectual property developed by University
of Arizona under the Research Project. In addition, we and the University of Arizona have entered into an option agreement (the &#8220;Option
Agreement&#8221;) whereby we were granted a first option to negotiate a royalty-bearing commercial license for the underlying technology
of the Research Project. On September 13, 2022, we exercised our options, and on February 24, 2023, we entered into an exclusive worldwide
license agreement with the University of Arizona for all of the technology related to the Research Project.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We have since broadened our objective to include
the development of a first-in-class PLpro inhibitor to treat SARS-CoV2 and potentially SARS-CoV and MERS-CoV infection in patients who
could not use Paxlovid, Molnupiravir, or Remdesivir, due to concerns about drug interactions and possible rebound infections and other
side effects.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our current lead compound has been found to
be active at sub micromolar concentrations against PLpro and exhibited antiviral activity in SRAS-CoV-2 infected cells as well as in
cells infected with several different variants of concern. In addition, our compound had favorable pharmacokinetics properties in
rodent species and exhibited preferred drug accumulation in the lungs over plasma. The compound was found to be orally active in a
K18-human-ACE2 transgenic mouse model and to significantly reduce virus load in the lungs of infected animals in a dose-dependent
manner without gross toxicities. In August 2024, we published these and other research results related to this project in the
Journal of Medicinal Chemistry (<i>J. Med. Chem. 2024, 67, 13681&#8722;13702</i>). A copy of this article is available on our
website at: www.sunshinebiopharma.com/scientific-publications. Additional research results on our lead compound have recently been submitted for publication in the Journal
of Medicinal Chemistry and the research article has been peer-reviewed and is currently in press.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 8 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b>Intellectual Property</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On May 22, 2020, we filed a provisional patent application in the United
States for a new treatment for Coronavirus infections. Our patent application, entitled <i>Inhibitors of Coronavirus Protease</i>, covers
composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease, Mpro, an enzyme that is essential
for viral replication. The patent application has a priority date of May 22, 2020. On April 30, 2021, we filed a PCT application containing
new research results and extending coverage to include the Coronavirus Papain-Like protease, PLpro. The priority date of May 22, 2020
has been maintained in the newly filed PCT application. On December 23, 2025, we received a Notice of Allowance from the USPTO for our
PCT patent application. Full patents are typically issued by the USPTO 4 to 8 weeks following the issuance of the Notice of Allowance
and payment of the issue fees.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On April 20, 2022, we filed a provisional patent
application in the United States covering mRNA molecules capable of destroying cancer cells in vitro. The patent application contains
composition and utility subject matter pertaining to the structure and sequence of the relevant mRNA molecules.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Effective February 24, 2023, we became the exclusive,
worldwide licensee of the University of Arizona for three (3) patents related to small molecules which inhibit the Coronavirus protease,
PLpro.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our wholly owned subsidiary, Nora Pharma, owns
200 DIN&#8217;s issued by Health Canada for prescription drugs currently on the market in Canada. These DIN&#8217;s were secured through
in-licenses or cross-licenses from international manufacturers of generic pharmaceutical products. Nora Pharma also owns the rights to
sell 10 generic prescription drugs in Canada through distribution agreements with various international partners under which Nora Pharma
acts as distributor and receives a percentage of sales.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In addition, we own four (4) NPN&#8217;s issued
by Health Canada including (i) NPN 80089663 which authorizes us to manufacture and sell our in-house developed OTC product, Essential&#8226;9&#8482;,
(ii) NPN 80093432 which authorizes us to manufacture and sell the OTC product, Calcium-Vitamin D, (iii) NPN 80125047 which authorizes
us to manufacture and sell the OTC product, L-Citrulline, and (iv) NPN 80127436 which authorizes us to manufacture and sell the OTC product,
Taurine.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On September 30, 2025, we received official trademark
registration from the United States Patent and Trademark Office (Registration No. 7,963,385) for &#8220;Sunshine Biopharma Inc.&#8221;
and Design.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On November 10, 2025, we received confirmation
of from the Canadian Intellectual Property Office of Canadian trademark registration (Registration No. TMA1,056,964 and TMA1,056,969)
for &#8220;Sunshine Biopharma Inc.&#8221; and Design.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b>Government Regulations</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">All of our business operations, including our generic
drugs, proprietary drugs, and OTC products operations, are subject to extensive and frequently changing federal, state, provincial and
local laws and regulations.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In the United States, the Federal Government agency
responsible for regulating prescription drugs and nonprescription OTC supplements is the U.S. Food and Drug Administration (&#8220;FDA&#8221;).
The Canadian counterpart to the FDA is Health Canada. Though the FDA and Health Canada have generally similar requirements for drugs and
OTC supplements to be approved or allowed to be marketed, approval in one jurisdiction does not automatically result in approval in the
other. In Canada, prescription drugs and nonprescription OTC supplements are authorized through the issuance by Health Canada of a Drug
Identification Number (DIN) for the former and a Natural Product Number (NPN) for the latter. In the United States, OTC supplements are
required to be registered with the FDA prior to marketing. In both the U.S. and Canada, the ingredients, manufacturing processes and facilities
for all drugs and OTC supplements must meet the guidelines for Good Manufacturing Practices (&#8220;GMP&#8221;). Moreover, all drug manufacturers
must perform a series of tests, both during and after production, to show that every drug or supplement batch made meets the regulatory
requirements for that product.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our generic prescription medicines are produced
in compliance with GMP guidelines as for brand-name drugs. Prescription drugs dossiers are filed with Health Canada in order to obtain
a manufacturing Notice of Compliance (NOC) and a Drug Identification Number (DIN). The same grant the applicant marketing authorization
in Canada. Nora Pharma secures cross-licenses from supply partners holding NOC&#8217;s
and in turn applies to Health Canada to obtain DIN&#8217;s issued in Nora Pharma&#8217;s name in order to commercialize the products in
Canada under the Nora Pharma label. In Canada, the pan-Canadian Pharmaceutical Alliance (pCPA), an alliance of the provincial, territorial
and federal governments that collaborates on a range of public drug plan initiatives to increase and manage access to clinically effective
and affordable drug treatments, determines generic drugs pricing based on a percentage of the price of the brand-name reference products.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In the area of proprietary drug development
where our Anti-Coronavirus and Anti-Cancer compounds fall, we will be subject to significant regulations in the U.S. in order to
obtain approval of the FDA to offer our products for sale. The procedure for obtaining FDA approval involves an initial
filing of an IND application following which the FDA would review and allow for the drug developer to proceed with Phase I clinical
trials. Following completion of Phase I, the results are filed with the FDA and a request is made to proceed to Phase II. Similarly,
following completion of Phase II the data are filed with the FDA and a request is made to proceed to Phase III. Following completion
of Phase III, a new drug application, or NDA is submitted and a request is made for marketing approval. Depending on various issues
and considerations, the FDA could provide &#8220;emergency use authorization&#8221; or limited approval for
&#8220;compassionate-use&#8221; if the drug treats terminally ill patients with limited or no other treatment options available. As
of the date of the filing of this report, we have not made any filings with the FDA or other regulatory bodies in other
jurisdictions in connection with our proprietary drugs in development.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In respect of OTC supplements, the FDA regulates
the formulation, manufacturing, packaging, storage, labeling, promotion, distribution, and sale of such products, while the Federal Trade
Commission (&#8220;FTC&#8221;) regulates marketing and advertising claims. In August 2007, a rule issued by the FDA went into effect requiring
companies that manufacture, package, label, distribute or hold OTC supplements to meet certain GMP requirements to ensure such products
are of the quality specified and are properly packaged and labeled. We are committed to meeting or exceeding the standards set by the
FDA and the FTC and we believe we are currently operating within both the FDA and FTC mandates.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b>Manufacturing </b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our generic drugs are manufactured by our various
international partners (licensors or distribution partners) under long-term contracts. We purchase finished goods from these partners
at varying costs. At present, approximately 75% of the drugs in our products portfolio are manufactured by three (3) suppliers overseas.</p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We currently do not have any proprietary drugs
on the market. Research quantities of our proprietary drug candidates are manufactured at the University of Arizona located in Tucson,
Arizona (Anti-Coronavirus compounds) and WuXi App Tech located in Hong Kong, China (K1.1 mRNA).</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our OTC products are manufactured under contract
by INOV Pharma Inc. located in Montreal, Canada.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b>Marketing and Sales</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Our
generic drugs are currently being sold in Canada in the province of Quebec, and to a much lesser extent in the provinces of Ontario,
Alberta and British Columbia. All of our generic drug sales are conducted by Nora Pharma&#8217;s sales representatives. A segment of
our marketing team provides human resources, commercial and technical assistance, as well as training and educational support to pharmacy
owners. We believe these pharmacy support activities, which we provide mostly free of charge, enhance our visibility in the marketplace
and bolster our sales efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Our
OTC products are sold in Canada exclusively through the Amazon marketplace, and until the third quarter of 2025, were also sold in the
United States exclusively through the Amazon marketplace. In Q3 2025, we discontinued our Amazon sales operations in the United States.
We rely on Amazon&#8217;s infrastructure for order processing, fulfillment, and customer service. Prior to our discontinuation of sales
operations in the United States, revenue from OTC product sales was derived approximately 10% from the United States and 90% from Canada.
Our personnel, together with outside consultants develop and place ads on various media platforms and manage our Amazon.ca account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b>Competition</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">According to <i>IMARC Group</i>, the Canadian generic
pharmaceuticals market was valued at approximately $10.4 billion USD in 2024 and is expected to grow to $19.7 billion USD by 2033. Generic
pharmaceutical companies produce and deliver more than 70% of the prescribed medicines with high quality at affordable prices. There are
more than 35 active generic players in the Canadian market, of which, the top 3 hold approximately 50% share of the total market. Nora
Pharma is relatively new in this space but has demonstrated one of the fastest year-over-year sales growth amongst its peers.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our Anti-Coronavirus drug development project is
in direct competition with several companies in the U.S. that have developed effective vaccines or treatment options for COVID-19. The
companies focused on treatments include Pfizer, Merck, Gilead, Eli Lilly, and Regeneron. Today two leading vaccines (Pfizer&#8217;s, and
Moderna&#8217;s) and two antibody treatments (Regeneron&#8217;s, and Eli Lilly&#8217;s) are in use. Gilead&#8217;s Remdesivir, an antiviral
injectable, was approved by the FDA for treatment of COVID-19 in October 2020. In addition, in December 2021, Pfizer received Emergency
Use Authorization (&#8220;EUA&#8221;), for its antiviral pill, Paxlovid, and, in the same month, the FDA granted Merck EUA for its antiviral
pill, Molnupiravir. While the approved vaccines, pills and injectable treatments are effective, we believe that additional treatment options
such as the one we are developing which targets a different part of the virus could potentially form an important component of the range
of anti-coronavirus treatment options available to physicians.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In the area of anticancer drug development, we
compete with large publicly and privately held companies engaged in developing new cancer therapies. There are numerous other entities
engaged in oncology therapeutics development that have greater resources than us. Nearly all major
pharmaceutical companies including Merck, Amgen, Roche, Pfizer, Bristol-Myers Squibb and Novartis, to name a few, have on-going anticancer
drug development programs and some of the drugs they may develop could be in direct competition with our own. In addition, a number of
smaller companies are working in the area of cancer therapy and could develop drugs that may be in competition with ours.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Similarly, our OTC products compete within a very
crowded and highly competitive product sector. As of the date of this report, we believe Essential&#8226;9&#8482; is the only Essential
Amino Acid supplement that comprises all 9 essential amino acids in capsule form.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b>Workforce</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">As of the date of this report, we have a total of
50 employees, all of whom are full-time.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Presently, our proprietary drug development activities
are subcontracted out to specialized service providers in the U.S., Canada and overseas. We also use consultants and outside professionals
for various other activities including marketing, accounting, and IT.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Labor laws in the Province of Quebec provide for
certain guaranteed minimum entitlements, including minimum wages, maternity leave, medical leave, employee termination conditions, and
other similar benefits. Moreover, the Province of Quebec has various language laws governing language use in the workplace. These laws
require corporate operations carried out in the Province of Quebec to be conducted to a large extent, and in some cases entirely, in French.
We and our Canadian subsidiaries operating in the Province of Quebec are fully compliant with these laws.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span id="a_007"></span><b>ITEM 1A. RISK FACTORS</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><i>Investing in our securities includes a high
degree of risk. Prior to making a decision about investing in our securities you should consider carefully the specific factors discussed
below, together with all of the other information contained in this report. Our business, financial condition, results of operations and
prospects could be materially and adversely affected by these risks.<b></b></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b>Risks Related to Our Business</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b><i>We have incurred losses and may never achieve
profitability</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We have an accumulated deficit of $75,015,126 as
of December 31, 2025. We incurred a net loss of $5,975,352 for the year ended December 31, 2025, and a net loss of $5,134,116 for the
year ended December 31, 2024. We may never achieve profitability.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b><i>We are subject to the significant risks associated
with the generic pharmaceutical business</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Since our acquisition of Nora Pharma in October
2022, we have generated revenues primarily through sales of generic pharmaceutical products in Canada, and we expect this to remain the
case for the foreseeable future. Generic pharmaceuticals are, as a general matter, significantly less profitable than innovative medicines.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In recent years, the generic pharmaceutical business
has experienced increased volatility in volumes due in large part to global supply chain issues following the COVID-19 pandemic. Since
2022, as the global economy has recovered from the impact of the COVID-19 pandemic, it has also been experiencing additional macroeconomic
pressures such as rising inflation and disruptions to the global supply chain, in part resulting from ongoing conflicts and tariff escalations.
We may experience supply discontinuities due to macroeconomic issues, regulatory actions, including sanctions and trade restrictions,
labor disturbances and approval delays, which may impact our ability to timely meet demand in certain instances. These adverse market
forces have a direct impact on our overall performance. Any such disruptions could have a material adverse impact on our business and
our results of operation and financial condition.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Other risks associated with our generic pharmaceutical
business include:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Current macroeconomic conditions are becoming increasingly less stable due to ongoing war in Ukraine, and the Middle East, and threats of war in various other areas around the world including South America, Greenland, and the Far East. Destabilized macroeconomics conditions pose a serious threat to supply chains around the world including those for the generic pharmaceutical business. Nearly all of Nora Pharma&#8217;s generic drugs are manufactured outside Canada and the United States and could experience disruptions which would adversely affect our main source of revenue.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Supply chains discontinuities due to other issues, including unforeseen regulatory actions, economic sanctions, trade restrictions, labor disturbances and approval delays, may impact our ability to timely meet customer demand in certain instances. These adverse market forces would have a direct impact on our ability to achieve our sales projections.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">If Nora Pharma encounters difficulties in executing launches of new products, it may not be able to offset the increasing price erosion on existing products resulting from pricing pressures and increasing generics approvals for competitors. Such unsuccessful launches can be caused by many factors, including delays in regulatory approvals, lack of operational or clinical readiness or patent litigation. Failure or delays to execute launches of new generic products could have a material adverse effect on Nora Pharma&#8217;s business and its ability to realize projected sales.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Nora Pharma&#8217;s sales of generic pharmaceutical products in Canada are heavily dependent on federal and provincial reimbursement frameworks, which determine pricing, formulary inclusion, and allowable markups. Any changes to these government-controlled reimbursement policies, whether through cost-containment measures, reference pricing adjustments, or formulary restrictions, could adversely affect Nora Pharma&#8217;s revenues in this market.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b><i>Sales of our generic products may be adversely
affected by the drug regulatory environment in Canada</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Currently we sell our generic drugs only in Canada.
Our net sales may be affected by fluctuations in the buying patterns of our customers resulting from government lead pricing pressures
and other factors. Our generic sales in Canada are done via retail pharmacies, pharmacy channels, distributors, and wholesalers. Pricing
pressures in Canada represent the highest risk due to ongoing and unresolved negotiations between the pharmaceutical industry and the
federal government. Any financial difficulties experienced by a single key customer, or any delay in receiving payments from such a customer,
could have a material adverse effect on our business, financial condition, and results of operations.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>Our revenues from generic
products may decline as a result of competition from other pharmaceutical companies and changes in regulatory policy</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our generic drugs face intense competition. Prices
of generic drugs may, and often do, decline, sometimes dramatically, especially as additional generic pharmaceutical companies receive
approvals and enter the market for a given product and competition intensifies. Consequently, our ability to sustain our sales and profitability
on any given product over time is affected by the number of companies selling such product, including new market entrants, and the timing
of their approvals.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Furthermore, brand pharmaceutical companies continue
to manage products in a challenging environment through marketing agreements with payers, pharmacy benefits managers and generic manufacturers.
For example, brand companies often sell or license their own generic versions of their products, either directly or through other generic
pharmaceutical companies&#160;(so-called&#160;&#8220;authorized generics&#8221;). No significant regulatory approvals are required for
authorized generics, and brand companies do not face any other significant barriers to entry into such market. Brand companies may seek
to delay introduction of generic equivalents through a variety of commercial and regulatory tactics. These actions may increase the costs
and risks of our efforts to introduce generic products and may delay or prevent such introductions altogether.&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b><i>We may experience delays in launching our new
generic products</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">If we cannot execute timely launches of new products,
we may not be able to offset the increasing price erosion on existing products resulting from pricing pressures and approvals for competing products. Such unsuccessful launches can be caused by many factors, including delays in regulatory approvals,
lack of operational or clinical readiness or patent litigation. Failure or delays in executing launches of new generic products could
have a material adverse effect on our business, financial condition, and results of operations.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>We may not receive required
regulatory approval for any of our non-generic pharmaceutical product candidates</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We have not received approval for any of our proprietary
(non-generic) drug development operations product candidates from the FDA or any other regulatory bodies in other jurisdictions. Any compounds
we discover or in-license will require extensive and costly development, preclinical testing and clinical trials prior to seeking regulatory
approval for commercial sales. Our most advanced product candidate, K1.1 mRNA and our potential Covid-19 treatment in development may
never be approved for commercial sale. We have not made any filings to date with the FDA or other regulatory bodies in other jurisdictions.
The time required to attain product sales and profitability is expensive, lengthy and highly uncertain. If we fail to obtain required
regulatory approvals for our pharmaceutical product candidates our business will be materially harmed.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>As we have no approved non-generic
pharmaceutical products on the market, we do not expect to generate significant revenues from non-generic pharmaceutical product sales
in the foreseeable future, if at all</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">To date, we have no approved non-generic pharmaceutical
products on the market and have generated product revenues largely from our generic pharmaceutical product sales. We have funded our operations
primarily from sales of our securities. We have not received, and do not expect to receive, for the foreseeable future, if at all, any
revenues from the commercialization of our non-generic pharmaceutical product candidates. To obtain revenues from sales of such pharmaceutical
product candidates we must succeed, either alone or with third parties, in developing, obtaining regulatory approval for manufacturing,
marketing and distributing drugs with commercial potential. We may never succeed in these activities, and we may not generate sufficient
revenues to continue our business operations or achieve profitability.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>We will require additional
funding to satisfy our future capital needs, which may not be available</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We will require significant additional funding
for our operations, including future preclinical and clinical testing costs, and insufficient sales revenues in the near future. We do
not know whether additional financing will be available to us on favorable terms or at all. If we cannot raise additional funds, we may
be required to reduce our capital expenditures, scale back product development programs, reduce our workforce and license to others products
or technologies that we may otherwise be able to commercialize. We are currently unable to project when or whether our operations will
generate positive cash flow.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Any additional equity securities we issue or issuances
of debt we may enter into or undertake may have rights, preferences or privileges senior to those of existing holders of common stock.
To the extent that we raise additional funds through collaboration and licensing arrangements, we may be required to relinquish some rights
to our technologies or product candidates or grant licenses on terms that are not favorable to us.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>We may be sued or become
a party to litigation, which could require significant management time and attention and result in significant legal expenses and may
result in an unfavorable outcome which could have a material adverse effect on our business, financial condition, results of operations
and cash flow</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We may be forced to incur costs and expenses in
connection with defending ourselves with respect to litigation and the payment of any settlement or judgment in connection therewith if
there is an unfavorable outcome. The expense of defending litigation may be significant. The amount of time to resolve lawsuits is unpredictable
and defending ourselves may divert management&#8217;s attention from the day-to-day operations of our business, which could adversely
affect our business, results of operations and cash flows. In addition, an unfavorable outcome in any such litigation could have a material
adverse effect on our business, results of operations and cash flows.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>If we are unable to attract
and retain qualified scientific, technical, and key management personnel, or if our key executive, Dr. Steve N. Slilaty, discontinues
his employment with us, it may delay our research and development efforts</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We rely on the services of Dr. Slilaty for strategic
and operational management, as well as for scientific and/or medical expertise in the development of our products. The loss of Dr. Slilaty
would result in a significant negative impact on our ability to implement our business plan. The loss of Dr. Slilaty would also significantly
delay or prevent the achievement of our business objectives.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>Our business exposes us to
potential product liability risks and we may be unable to acquire and maintain sufficient insurance to provide adequate coverage against
potential liabilities</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our business exposes us to potential product liability
risks that are inherent in the testing, manufacturing and marketing of pharmaceutical products. The use of our products by our customers
exposes us to the possibility of product liability claims and possible adverse publicity. These risks will increase to the extent our
pharmaceutical product candidates receive regulatory approval and are commercialized. We currently have product liability insurance for
our generic drugs and OTC products and we plan to obtain product liability insurance in connection with clinical trials of our pharmaceutical
product candidates in the near future. However, our current and future product liability insurance may not provide adequate protection
against potential liabilities.&#160;On occasion, juries have awarded large judgments in class action lawsuits based on drugs that had
unanticipated side effects. A successful product liability claim, or series of claims brought against us would decrease our cash reserves
and could cause our stock price to fall significantly.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>We face regulation and risks
related to hazardous materials and environmental laws, violations of which may subject us to claims for damages or fines that could materially
affect our business, cash flow, financial condition and results of operations</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our research and development activities involve
the use of controlled and/or hazardous materials and chemicals. The risk of accidental contamination or injury from these materials cannot
be completely eliminated. In the event of an accident, we could be held liable for any damages or fines that result, and the liability
could have a material adverse effect on our business, financial condition, and results of operations. We are also subject to federal,
state and local laws and regulations governing the use, manufacture, storage, handling and disposal of hazardous materials and waste products.
If we fail to comply with these laws and regulations or with the conditions attached to our operating licenses, the licenses could be
revoked, and we could be subjected to criminal sanctions and substantial liability or be required to suspend or modify our operations.
In addition, we may have to incur significant costs to comply with future environmental laws and regulations. We do not currently have
a pollution and remediation insurance policy.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>Third party manufacturers
may not be able to manufacture our pharmaceutical product candidates, which would prevent us from commercializing our product candidates</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">If any of our pharmaceutical product candidates
is approved by the FDA or other regulatory agencies for commercial sale, we will need third parties to manufacture the product in larger
quantities. If we are able to reach an agreement with any collaborator or third-party manufacturer in the future, of which there can be
no assurance, these collaborators and/or third-party manufacturers may not be able to increase their manufacturing capacity for any of
our product candidates in a timely or economic manner, or at all. Significant scale-up of manufacturing may require additional validation
studies, which the FDA must review and approve. If we are unable to increase the manufacturing capacity for a product candidate successfully,
the regulatory approval or commercial launch of that product candidate may be delayed or there may be a shortage in the supply of the
product candidate. Our product candidates require precise, high-quality manufacturing. The failure of collaborators or third-party manufacturers
to achieve and maintain these high manufacturing standards, including the incidence of manufacturing errors, could result in patient injury
or death, product recalls or withdrawals, delays or failures in product testing or delivery, cost overruns or other problems that could
seriously harm our business.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>If we are unable to establish
sales and marketing capabilities for our pharmaceutical product candidates or enter into agreements with third parties to sell and market
any such products we may develop, we may be unable to generate revenues from our non-generic pharmaceutical business</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We do not currently have product sales and marketing
capabilities for our non-generic pharmaceutical operations. If we receive regulatory approval to commence commercial sales of any of our
pharmaceutical product candidates, we will have to establish a sales and marketing organization with appropriate technical expertise and
distribution capabilities or make arrangements with third parties to perform these services in other jurisdictions. If we receive approval
in applicable jurisdictions to commercialize any of our pharmaceutical products candidates, we intend to engage additional pharmaceutical
or health care companies with existing distribution systems and direct sales organizations to assist us in North America and throughout
the world. We may not be able to negotiate favorable distribution partnering arrangements, if at all. To the extent we enter into co-promotion
or other licensing arrangements, any revenues we receive will depend on the efforts of third parties and will not be under our control.
If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, our
ability to generate product revenues, and become profitable, would be severely limited.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Even if we obtain required U.S. and foreign regulatory
approvals, as applicable, factors that may inhibit our efforts to commercialize our pharmaceutical product candidates without strategic
partners or licensees include:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Difficulty recruiting and retaining adequate numbers of effective sales and marketing personnel;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The inability of sales personnel to obtain access to, or persuade adequate numbers of, physicians to prescribe our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage against companies with broader product lines; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Unforeseen costs associated with creating an independent sales and marketing organization.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>Even if we successfully develop
and obtain approval for our proprietary drug product candidates, our business will not be profitable if such products do not achieve and
maintain market acceptance</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Even if our proprietary drug product candidates
are approved for commercial sale by the FDA or other regulatory authorities, the degree of market acceptance of our approved product candidates
by physicians, healthcare professionals, patients and third-party payors, and our resulting profitability and growth, will depend on a
number of factors, including:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Our ability to provide acceptable evidence of safety and efficacy;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Relative convenience and ease of administration;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The prevalence and severity of any adverse side effects;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The availability of alternative treatments;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The details of FDA labeling requirements, including the scope of approved indications and any safety warnings;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Pricing and cost effectiveness;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The effectiveness of our or our collaborators' sales and marketing strategy;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Our ability to obtain sufficient third-party insurance coverage or reimbursement; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Our ability to have the product listed on insurance company formularies.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">If our proprietary drug product candidates achieve
market acceptance, we may not maintain that market acceptance over time if new products or technologies are introduced that are received
more favorably or are more cost effective. Complications may also arise, such as development of new know-how or new medical or therapeutic
capabilities by other parties that render our product obsolete.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>Because the results of preclinical
studies for our preclinical product candidates are not necessarily predictive of future results, our pharmaceutical product candidates
may not have favorable results in later clinical trials or ultimately receive regulatory approval</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our proprietary drug product candidates have not
been tested in clinical trials. Positive results from preclinical studies are no assurance that later clinical trials will succeed. Preclinical
studies are not designed to establish the clinical efficacy of our preclinical product candidates. We will be required to demonstrate
through clinical trials that our product candidates are safe and effective for use before we can seek regulatory approvals for commercial
sale. There is typically an extremely high rate of failure as product candidates proceed through the various phases of clinical trials.&#160;If
our product candidates fail to demonstrate sufficient safety and efficacy in any clinical trial, we would experience potentially significant
delays in, or be required to abandon, development of that product candidate.&#160;This would adversely affect our ability to generate
revenues and may damage our reputation in the industry and in the investment community.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>We face or will face significant
competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Most of our pharmaceutical company competitors,
such as Merck, Bristol-Myers Squibb, Pfizer, Amgen, and others, are large pharmaceutical companies with substantially greater financial,
technical, and human resources than we have. The biotechnology and pharmaceutical industries are intensely competitive and subject to
rapid and significant technological change. The drugs that we are attempting to develop will compete with existing therapies if we receive
marketing approval. Because of their significant resources, our competitors may be able to use discovery technologies and techniques,
or partnerships with collaborators, to develop competing products that are more effective or less costly than the product candidate we
are developing. This may render our technology or product candidate obsolete and noncompetitive. Academic institutions, government agencies,
and other public and private research organizations may seek patent protection with respect to potentially competitive products or technologies
and may establish exclusive collaborative or licensing relationships with our competitors.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our competitors may succeed in obtaining FDA or
other regulatory approvals for product candidates more rapidly than us. Companies that complete clinical trials, obtain required regulatory
agency approvals and commence commercial sale of their drugs before we do may achieve a significant competitive advantage, including certain
FDA marketing exclusivity rights that would delay or prevent our ability to market certain products. Any approved drugs resulting from
our research and development efforts, or from our joint efforts with our existing or future collaborative partners, might not be able
to compete successfully with our competitors' existing or future products.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>Because our proprietary drug
product candidates and our development and collaboration efforts depend on our intellectual property rights, adverse events affecting
our intellectual property rights will harm our ability to commercialize products</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our success will depend to a large degree on our
own and our licensors&#8217; ability to obtain and defend patents for each party's respective technologies and the compounds and other
products, if any, resulting from the application of such technologies. The patent positions of pharmaceutical and biotechnology companies
can be highly uncertain and involve complex legal and technical questions. No consistent policy regarding the breadth of claims allowed
in biotechnology patents has emerged to date. Accordingly, we cannot predict the breadth of claims that will be allowed or maintained,
after challenge, in our or other companies' patents.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The degree of future protection for our proprietary
rights is uncertain, and we cannot ensure that:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">We were the first to make the inventions covered by each of our pending patent applications;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">We were the first to file patent applications for these inventions;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Others will not independently develop similar or alternative technologies or duplicate any of our technologies;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Any patents issued to us or our collaborators will provide a basis for commercially viable products, will provide us with any competitive advantages, or will not be challenged by third parties;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Our pending patent applications will result in issued patents;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">We will develop additional proprietary technologies that are patentable;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The patents of others will not have a negative effect on our ability to do business; or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Our issued patents will have sufficient useful life remaining for commercial viability of our product candidate.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">If we cannot maintain the confidentiality of our
technology and other confidential information in connection with our collaborations, then our ability to receive patent protection or
protect our proprietary information will be impaired. In addition, some of the technology we have licensed relies on inventions
developed using U.S. government resources. Under applicable law, the U.S. government has the right to require us to grant a nonexclusive,
partially exclusive or exclusive license for such technology to a responsible applicant or applicants, upon terms that are reasonable
under the circumstances, if the government determines that such action is necessary.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>Confidentiality agreements
with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information and may not adequately
protect our intellectual property</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We rely on trade secrets to protect our technology,
particularly when we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. In
order to protect our proprietary technology and processes, we rely in part on confidentiality and intellectual property assignment agreements
with our employees, consultants, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not
effectively prevent disclosure of confidential information nor result in the effective assignment to us of intellectual property and may
not provide an adequate remedy in the event of unauthorized disclosure of confidential information or other breaches of the agreements.
In addition, others may independently discover our trade secrets and proprietary information, and in such case, we could not assert any
trade secret rights against such party. Enforcing a claim that a party illegally obtained and is using our trade secrets is difficult,
expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect
trade secrets.&#160;Costly and time-consuming litigation could be necessary to seek to enforce and determine the scope of our proprietary
rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>The implementation of our
business plan may result in a period of rapid growth that will impose a significant burden on our current administrative and operational
resources</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our ability to effectively manage our growth will
require us to substantially expand the capabilities of our administrative and operational resources by attracting, training, managing,
and retaining additional qualified personnel, including additional members of management, technicians, and others. To successfully develop
our products, we will need to manage operating, producing, marketing and selling our products. There can be no assurances that we will
be able to do so. Our failure to successfully manage our growth will have a negative impact on our anticipated results of operations.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>The failure of our suppliers to supply quality materials in sufficient quantities, at a favorable price, and in a timely fashion
could adversely affect the results of our operations</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our outside manufacturers buy raw materials from
a limited number of suppliers. The loss of any of our major suppliers or of any supplier who, through our contract manufacturer, provides
us materials that are hard to obtain elsewhere at the same quality could adversely affect our business operations. Although we believe
we could establish alternate manufacturers and sources for most of our raw materials, any delay in locating and establishing relationships
with other sources could result in shortages of products we manufacture from such raw materials, with a resulting loss of sales and customers.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">A shortage of raw materials or an unexpected interruption
of supply could also result in higher prices for those materials. We have experienced increases in various raw material costs, transportation
costs and the cost of petroleum-based raw materials and packaging supplies used in our business. Increasing cost pricing pressures on
raw materials and other products occurred throughout fiscal 2024 and 2025 as a result of limited supplies of various ingredients, and
the effects of higher labor and transportation costs. We expect these upward pressures to continue through fiscal 2026. Although we may
be able to raise our prices in response to significant increases in the cost of raw materials, we may not be able to raise prices sufficiently
or quickly enough to offset the negative effects such cost increases could have on our results of operations or financial condition.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">There can be no assurance suppliers will provide
the quality raw materials we need in the quantities requested or at a price we are willing to pay. Because we do not control the actual
production of these raw materials, we are also subject to delays caused by interruption in production of materials including but not limited
to those resulting from conditions outside of our control, such as pandemics, weather, transportation interruptions, strikes, terrorism,
geopolitics, natural disasters, and other catastrophic events.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>Our business is subject to
the effects of adverse publicity, which could negatively affect our sales and revenues</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our business can be affected by adverse publicity
or negative public perception about us, our competitors, our products, or our industry or competitors generally. Adverse publicity may
include publicity about the efficacy, safety and quality of health care products or ingredients in general or our products or ingredients
specifically, and regulatory investigations, regardless of whether these investigations involve us or the business practices or products
of our competitors, or our customers. Any adverse publicity or negative public perception could have a material adverse effect on our
business, financial condition and results of operations. Our business, financial condition and results of operations could be adversely
affected if any of our products or any similar products distributed by other companies are alleged to be or are proved to be harmful to
consumers or to have unanticipated and unwanted health consequences.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>Our manufacturing and third-party
fulfillment activities are subject to certain risks</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our products are manufactured at third party manufacturing
facilities in Canada and overseas. As a result, we are dependent on the uninterrupted and efficient operation of these facilities. Such
manufacturing operations, and those of their suppliers, are subject to power failures, blackouts, border shutdowns, telecommunications
failures, computer viruses, cybersecurity vulnerabilities, human error, breakdown, failure or substandard performance. The occurrence
of these or any other operational problems, including the improper installation or operation of equipment, terrorism, pandemics, natural
or other disasters, intentional acts of violence, and the need to comply with the requirements or directives of governmental agencies,
including the FDA and Health Canada may have a material adverse effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>We are dependent on a concentrated
base of finished goods suppliers, which increases our risk of product interruption</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Approximately 75% of the drugs in our products
portfolio are manufactured by three (3) suppliers overseas. Reliance on a limited number of third-party suppliers for finished products
exposes us to material operational, regulatory, and financial risks. Because these suppliers are responsible for manufacturing, packaging,
and releasing finished pharmaceuticals under stringent regulatory requirements, any disruption in their operations can directly affect
our ability to maintain continuous product supply. Disruptions may arise from GMP non-compliance, regulatory inspection findings, quality
system failures, contamination events, batch deviations, or shortages of critical components such as active pharmaceutical ingredients,
excipients, or specialized packaging. Regulatory actions, including FDA Form 483 observations, warning letters, import alerts, or license
suspensions can halt production or delay batch release. These risks, individually or in the aggregate, could have a material adverse effect
on our business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Risks Related to Our Common
Stock</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>There is significant volatility
in the price and trading volume of our common stock, and investors may find it difficult to buy and sell our shares</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our common stock has been listed on the Nasdaq
Capital Market since February 15, 2022. The price and daily trading volume of our common stock have been very volatile and may continue
to be so, and any significant trading volume in our common stock may not be maintained. These factors may have an adverse impact on the
trading and price of our common stock.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>If we are unable to continue
to meet the listing requirements of Nasdaq, our common stock will be delisted</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Our
common stock currently trades on Nasdaq, where it is subject to various listing requirements, including Nasdaq Rule 5500(a)(2), which
requires that our common stock maintain a minimum bid price of at least $1.00 to maintain its listing on Nasdaq (the &#8220;Bid Price
Rule&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Our
common stock has recently traded at prices slightly above the $1.00 Nasdaq required minimum bid price requirement. In addition, though
we have obtained stockholder approval to authorize the board of directors to implement a reverse stock split in its discretion, in a
ratio of up to 1-for-10, there is no assurance that, even if we implement a reverse split, we will be able to maintain compliance with
the Bid Price Rule or other applicable requirements for continued listing on Nasdaq. If we are unable to maintain compliance with Nasdaq
listing requirements, we could be subject to suspension and delisting proceedings. A delisting of our common stock and our inability
to list on another national securities market could negatively impact us by: (i) reducing the liquidity and market price of our common
stock; (ii) reducing the number of investors willing to hold or acquire our common stock, which could negatively impact our ability to
raise equity financing; (iii) limiting our ability to use certain registration statements to offer and sell freely tradeable securities,
thereby limiting our ability to access the public capital markets; and (iv) impairing our ability to provide equity incentives to our
employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>We do not intend to pay dividends
on our common stock for the foreseeable future</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We have paid no dividends on our common stock to
date and we do not anticipate paying any dividends to holders of our common stock in the foreseeable future. While our future dividend
policy will be based on the operating results and capital needs of the business, we currently anticipate that we will retain any earnings
to finance our future expansion and for the implementation of our business plan. Investors should take note of the fact that a lack of
a dividend can further affect the market value of our common stock and could significantly affect the value of any investment in our Company.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>Our articles of incorporation
allow for our board to create new series of preferred stock without further approval by our stockholders, which could adversely affect
the rights of the holders of our common stock</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our board of directors has the authority to fix
and determine the relative rights and preferences of preferred stock. Our board of directors has the authority to issue up to 30,000,000
shares of our preferred stock without further stockholder approval. 1,000,000 shares of preferred stock are designated Series B Preferred
Stock and as of the date of this Report, 130,000 of such shares are outstanding and held by our Chief Executive Officer. Our board of
directors could authorize the creation of additional series of preferred stock that would grant to holders of preferred stock the right
to our assets upon liquidation, or the right to receive dividend payments before dividends are distributed to the holders of common stock.
In addition, subject to the rules of any securities exchange on which our stock is then listed, our board of directors could authorize
the creation of additional series of preferred stock that has greater voting power than our common stock or that is convertible into our
common stock, which could decrease the relative voting power of our common stock or result in dilution to our existing stockholders.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>Additional stock offerings
in the future or the issuance of stock upon exercise of outstanding warrants may dilute then-existing shareholders&#8217; percentage ownership
in our Company</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Given our plans and expectations that we will need
additional capital and personnel, we anticipate that we will need to issue additional shares of common stock or securities convertible
or exercisable for shares of common stock, including convertible preferred stock, convertible notes, stock options or warrants. In addition,
as of the date of filing of this report, we had 15,227,962 Series B Warrants issued and outstanding, each exercisable to purchase one
share of our common stock at an exercise price of $2.07 per warrant. The issuance of additional securities in the future will dilute the
percentage ownership of our current stockholders.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span id="a_008"></span><b>ITEM 1B. UNRESOLVED STAFF COMMENTS</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">None.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span id="a_009"></span><b>ITEM 1C. CYBERSECURITY</b></p>

<p id="xdx_98D_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20250101__20251231_gBFCRMPFAIAMT-OJDR_zkmkRpsxKo04" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" continuedAt="ConU000057-01" escape="true" id="Fact000057" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><b style="display: none">&#160;Risk</b></ix:nonNumeric></p>

<div id="xdx_C01_gBFCRMPFAIAMT-OJDR_zr9jUr9G2ID2"><ix:continuation continuedAt="ConU000057-02" id="ConU000057-01"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our Company recognizes the critical importance
of cybersecurity in protecting our sensitive data, intellectual property, and the personal information of our employees and partners.
We have <span id="xdx_906_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zsPPz5n79fdb" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000058" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">implemented</ix:nonNumeric></span> a comprehensive cybersecurity risk management program that includes the following key components:</p></ix:continuation></div>

<div id="xdx_C03_gBFCRMPFAIAMT-OJDR_zlDNh3kQLfn4"><ix:continuation continuedAt="ConU000057-03" id="ConU000057-02"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation></div>

<div id="xdx_C08_gBFCRMPFAIAMT-OJDR_z8km9mwqRf9a"><ix:continuation continuedAt="ConU000057-04" id="ConU000057-03"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Risk Assessment and Management</b></p></ix:continuation></div>

<div id="xdx_C01_gBFCRMPFAIAMT-OJDR_zUKi4WykvTd2"><ix:continuation continuedAt="ConU000057-05" id="ConU000057-04"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></div>

<div id="xdx_C0D_gBFCRMPFAIAMT-OJDR_zD5IgMKA8hv"><ix:continuation id="ConU000057-05"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span id="xdx_905_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250101__20251231_zepDcJYwf1hf" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000059" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock">We conduct regular risk assessments to identify
and evaluate potential cybersecurity threats and vulnerabilities. Our risk management framework is aligned with industry standards such
as the NIST Cybersecurity Framework (CSF) and ISO 27001. We continuously monitor and update our cybersecurity measures to address emerging
threats and ensure the protection of our assets.</ix:nonNumeric></span></p></ix:continuation></div>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_981_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20250101__20251231_gBFCRBODOTB-RGSBS_zRth3VZxALx" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" continuedAt="ConU000086-01" escape="true" id="Fact000086" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock"><b>Cybersecurity Governance</b></ix:nonNumeric></p>

<div id="xdx_C03_gBFCRBODOTB-RGSBS_zyrJ1r5NbSB1"><ix:continuation continuedAt="ConU000086-02" id="ConU000086-01"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p></ix:continuation></div>

<div id="xdx_C0A_gBFCRBODOTB-RGSBS_zswe9xQBMsFi"><ix:continuation continuedAt="ConU000086-03" id="ConU000086-02"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span id="xdx_901_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20250101__20251231_zSY3mF8ioZb" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000087" name="cyd:CybersecurityRiskRoleOfManagementTextBlock">Our management oversees our cybersecurity risk
management efforts. Our <span id="xdx_90E_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20250101__20251231_zAcZ9hvcJQGk" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000088" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">senior management team</ix:nonNumeric></span> is actively involved in cybersecurity policies, procedures and strategy development.</ix:nonNumeric></span></p></ix:continuation></div>

<div id="xdx_C0A_gBFCRBODOTB-RGSBS_zIwjY2gydOja"><ix:continuation continuedAt="ConU000086-04" id="ConU000086-03"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p></ix:continuation></div>

<div id="xdx_C04_gBFCRBODOTB-RGSBS_zpraEbonVkB2"><ix:continuation continuedAt="ConU000086-05" id="ConU000086-04"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b>Incident Response and Recovery</b></p></ix:continuation></div>

<div id="xdx_C0C_gBFCRBODOTB-RGSBS_z8JuYU8srLba"><ix:continuation continuedAt="ConU000086-06" id="ConU000086-05"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p></ix:continuation></div>

<div id="xdx_C08_gBFCRBODOTB-RGSBS_zN3R1nxbkUn1"><ix:continuation continuedAt="ConU000086-07" id="ConU000086-06"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span id="xdx_906_ecyd--CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_c20250101__20251231_zZ9H5PnVQzB7" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000089" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">We have a robust incident response plan in place
to quickly detect, respond to, and recover from cybersecurity incidents. We collaborate with external cybersecurity experts and law enforcement
agencies to enhance our incident response capabilities.</ix:nonNumeric></span></p></ix:continuation></div>

<div id="xdx_C02_gBFCRBODOTB-RGSBS_zDBZMbsllor2"><ix:continuation continuedAt="ConU000086-08" id="ConU000086-07"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p></ix:continuation></div>

<div id="xdx_C0E_gBFCRBODOTB-RGSBS_zDmeZegxaLrh"><ix:continuation continuedAt="ConU000086-09" id="ConU000086-08"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b>Employee Training and Awareness</b></p></ix:continuation></div>

<div id="xdx_C0A_gBFCRBODOTB-RGSBS_zAbnQWz0pnc3"><ix:continuation continuedAt="ConU000086-10" id="ConU000086-09"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p></ix:continuation></div>

<div id="xdx_C09_gBFCRBODOTB-RGSBS_zUCbTEqzwHTe"><ix:continuation continuedAt="ConU000086-11" id="ConU000086-10"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We provide ongoing cybersecurity training and awareness
programs for all employees to promote a culture of security. Our training programs cover topics such as phishing prevention, secure data
handling, and recognizing potential cyber threats.</p></ix:continuation></div>

<div id="xdx_C05_gBFCRBODOTB-RGSBS_zwRAIRHs5mvc"><ix:continuation continuedAt="ConU000086-12" id="ConU000086-11"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p></ix:continuation></div>

<div id="xdx_C02_gBFCRBODOTB-RGSBS_zRQDXafL1lU1"><ix:continuation continuedAt="ConU000086-13" id="ConU000086-12"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Third-Party Risk Management</b></p></ix:continuation></div>

<div id="xdx_C02_gBFCRBODOTB-RGSBS_zcqV0K5QgUTe"><ix:continuation continuedAt="ConU000086-14" id="ConU000086-13"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation></div>

<div id="xdx_C08_gBFCRBODOTB-RGSBS_zkBZAWATBxS7"><ix:continuation continuedAt="ConU000086-15" id="ConU000086-14"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We assess the cybersecurity practices of our <span id="xdx_90F_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250101__20251231_zIU1Zot8w70k" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000090" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag">third-party</ix:nonNumeric></span>
vendors and partners to ensure they meet our security standards. Our contracts with third parties include provisions for cybersecurity
requirements and incident reporting.</p></ix:continuation></div>

<div id="xdx_C0A_gBFCRBODOTB-RGSBS_zaiRibf0n3X3"><ix:continuation continuedAt="ConU000086-16" id="ConU000086-15"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></div>

<div id="xdx_C06_gBFCRBODOTB-RGSBS_zFMWc6sHXfo9"><ix:continuation continuedAt="ConU000086-17" id="ConU000086-16"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Regulatory Compliance</b></p></ix:continuation></div>

<div id="xdx_C00_gBFCRBODOTB-RGSBS_zvaTaYt93v8k"><ix:continuation continuedAt="ConU000086-18" id="ConU000086-17"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p></ix:continuation></div>

<div id="xdx_C0A_gBFCRBODOTB-RGSBS_zNQ81HDt0hIf"><ix:continuation continuedAt="ConU000086-19" id="ConU000086-18"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We comply with all relevant cybersecurity regulations
and standards, including the Health Insurance Portability and Accountability Act (HIPAA) and the General Data Protection Regulation (GDPR).
We regularly review and update our cybersecurity policies and procedures to ensure compliance with evolving regulatory requirements.</p></ix:continuation></div>

<div id="xdx_C04_gBFCRBODOTB-RGSBS_zz0YMlBny1Ij"><ix:continuation continuedAt="ConU000086-20" id="ConU000086-19"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p></ix:continuation></div>

<div id="xdx_C09_gBFCRBODOTB-RGSBS_zjbXPDIWOnEk"><ix:continuation continuedAt="ConU000086-21" id="ConU000086-20"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Investments in Cybersecurity</b></p></ix:continuation></div>

<div id="xdx_C01_gBFCRBODOTB-RGSBS_z3q313KaFdU6"><ix:continuation continuedAt="ConU000086-22" id="ConU000086-21"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p></ix:continuation></div>

<div id="xdx_C03_gBFCRBODOTB-RGSBS_z0o94lGCCb8h"><ix:continuation continuedAt="ConU000086-23" id="ConU000086-22"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We continuously invest in advanced cybersecurity
technologies, including threat detection and prevention systems, encryption, and secure access controls. Our cybersecurity is part of
our overall budget which is reviewed and approved by our board of directors to ensure adequate resources are allocated to protect our
assets.</p></ix:continuation></div>

<div id="xdx_C08_gBFCRBODOTB-RGSBS_zGD2HxcrCy82"><ix:continuation continuedAt="ConU000086-24" id="ConU000086-23"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></div>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<div id="xdx_C09_gBFCRBODOTB-RGSBS_zyGS1ZIJjfN9"><ix:continuation continuedAt="ConU000086-25" id="ConU000086-24"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Cybersecurity Incidents</b></p></ix:continuation></div>

<div id="xdx_C02_gBFCRBODOTB-RGSBS_zyEiFJ2jDqLj"><ix:continuation continuedAt="ConU000086-26" id="ConU000086-25"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p></ix:continuation></div>

<div id="xdx_C02_gBFCRBODOTB-RGSBS_z0OK7BTba6J2"><ix:continuation id="ConU000086-26"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span id="xdx_90E_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_c20250101__20251231_zlCoAR0PPWvl" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000091" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">During the past fiscal year, we experienced <span id="xdx_908_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20250101__20251231_zVGK4CuTdkki" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000092" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">no
cybersecurity incidents</ix:nonNumeric></span>.</ix:nonNumeric></span></p></ix:continuation></div>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span id="a_010"></span><b>ITEM 2. PROPERTIES</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our principal place of business is located at 333
Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL 33301. We are not party to a lease agreement in connection with this office space. We
pay rent month-to-month and have access to additional space on a pay-per-use basis. We believe this space is sufficient for our needs
for the next year.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our wholly owned subsidiary, Nora Pharma, currently
occupies a 23,500 square foot facility located at 1565 Boulevard Lionel-Boulet, Varennes, Quebec, Canada, J3X 1P7 pursuant to a lease
agreement that expires in January 2030, with an option to extend for 5 years. This site is composed of 18,500 square feet of warehouse
space and 5,000 square feet of executive office space. The facility houses all administrative, marketing, quality control, regulatory
affairs, and other operations personnel, as well as a Health Canada licensed warehouse space. We pay a monthly rent of $27,250 CAD (approximately
$19,900 USD), including taxes. We estimate that this facility is adequate for annual sales of approximately $50 to $75 million, past which
we will need to find additional space. We classified this lease as an operating lease but we account for liabilities and benefits resulting
therefrom.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span id="a_011"></span><b>ITEM 3. LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We are not party to, and our property is not the
subject of, any legal proceedings, except as set forth below.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On January 16, 2026, the Company received a demand
letter from the attorneys of Mr. Andrew Telsey, the Company&#8217;s former legal counsel, asserting that the Company and Mr. Telsey executed
an employment agreement and demanding payment of $3,645,750 from the Company based on the Company&#8217;s alleged termination of the
purported employment agreement without cause. The Company believes this demand is without merit and has never executed an employment
agreement with Mr. Telsey. On that basis, among other factors, the Company filed a complaint against Mr. Telsey on February 6, 2026 in
the circuit court of the 17<sup>th</sup> judicial district in Broward County, Florida seeking a declaratory judgment providing that
(i) the purported employment agreement is of no legal effect and is not binding upon the Company, (ii) no monies are owed by the Company
to Mr. Telsey under the purported employment agreement, (iii) the Company should be awarded its attorney&#8217;s fees and costs, and
(iv) the Company should be awarded such other relief as the court deems just and proper. On March 30, 2026, the court granted the Company&#8217;s motion for
entry of default and entered a default and final judgment in favor of the Company. Pursuant to the court&#8217;s order, the court declared
that the purported employment agreement is of no legal effect and not binding on the Company, because the Company never executed the agreement,
the Company did not breach the purported employment agreement, and no monies are owed by the Company to Mr. Telsey under the purported
employment agreement. The court retained jurisdiction on the issues of entitlement and amount of attorney&#8217;s fees and costs to the
Company as the prevailing party.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span id="a_012"></span><b>ITEM 4. MINE SAFETY DISCLOSURES</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Not applicable.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #00487F"><span id="a_014"></span><b>PART II</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span id="a_015"></span><b>ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER
MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">In
this section, we provide information about the market for our common equity, the number of holders of our common stock, our dividend
practices, and our repurchases of equity securities. In addition, we provide disclosures regarding our equity compensation plans and
our policies and practices for granting stock options and stock appreciation rights, including awards made in close proximity to the
release of material nonpublic information, as required under recently adopted SEC rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b>Market
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Our
common stock is listed on the Nasdaq Capital Market under the symbol &#8220;SBFM&#8221;. As of April 2, 2026, we had 4,905,945 shares
of our common stock issued and outstanding. We also have tradeable warrants exercisable to purchase shares of our common stock listed
on the Nasdaq Capital Market under the symbol &#8220;SBFMW.&#8221; As of April 2, 2026, we had 482 tradeable warrants outstanding exercisable
at $220.00 per warrant.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b>Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">As
of April 2, 2026, there were approximately 117 holders of record of our common stock. The total number of beneficial owners exceeds holders
of record due to Street-Name holdings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b>Dividend
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">We
have not paid any dividends since our incorporation and do not anticipate paying any dividends in the foreseeable future. At present,
our policy is to retain earnings, if any, to develop and market our products. Our payment of dividends in the future will depend upon,
among other factors, our earnings, capital requirements, and operating financial conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b>Repurchases of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">We
did not repurchase any shares of our common stock during the three months ended December 31, 2025. We currently do not have a Rule 10b5-1
plan or other repurchase arrangements in place.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-variant: small-caps"><b></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Equity Compensation Plan Information</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The following table sets forth information regarding
our equity compensation plans as of December 31, 2025:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="text-align: left; vertical-align: bottom">
    <td style="border: black 1pt solid; width: 43%"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b>Plan Category</b></p></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 19%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Number of Securities<br/>
 to be Issued <br/>
Upon Exercise <br/>
of Outstanding <br/>
Options, Warrants <br/>
and Rights</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 19%">
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b>Weighted-Average <br/>
Exercise Price of<br/>
 Outstanding Options,<br/>

Warrants and Rights </b></p></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 19%">
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b>Number of Securities<br/>
    Remaining Available for</b></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b>Future Issuance Under<br/>
    Equity Compensation Plans</b></p></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Equity compensation plans approved by security holders*</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#8211;</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#8211;</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">683,000</span></td></tr>
  <tr style="background-color: White">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Equity compensation plans not approved by security holders</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#8211;</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#8211;</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#8211;</span></td></tr>
  </table>
<p style="font: 8pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">*Represents our 2023 Equity Incentive Plan as amended
on December 11, 2025 at the Company&#8217;s 2025 Annual General Meeting of the shareholders.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b>Option
and SAR Grant Timing in Relation to MNPI Releases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">We
have established policies and practices governing the timing and administration of equity awards, including stock options and stock appreciation
rights (&#8220;SARs&#8221;). We may grant equity awards pursuant to our 2023 Equity Incentive Plan, as approved by the Compensation Committee,
the Board of Directors at regularly scheduled meetings or by unanimous written consent. We do not coordinate the timing of option or
SAR grants with the release of material non-public information (&#8220;MNPI&#8221;), nor do we time the public disclosure of MNPI for
the purpose of affecting the value of executive compensation. We have not granted any such awards to date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">We
have not granted stock options or SARs to any executive officer in periods proximate to the release of MNPI, as defined in Item 402(x)
of Regulation S-K. Accordingly, no tabular disclosure under Item 402(x)(2) is required for the fiscal years ended December 31, 2024 and
2025. If we were to grant options or SARs in such circumstances in the future, we would provide the required tabular disclosure in accordance
with SEC rules.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span id="a_016"></span><b>ITEM 6. [RESERVED]</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span id="a_017"></span><b>ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><i>The following discussion highlights the principal
factors that have affected our financial condition and results of operations as well as our liquidity and capital resources for the periods
described. This discussion should be read in conjunction with our financial statements and the related notes included in this report.
This discussion contains forward-looking statements. Please see &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; for
a discussion of the uncertainties, risks and assumptions associated with these forward-looking statements.</i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Results of Operations</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>Comparison of Results of
Operations for the fiscal years ended December 31, 2025 and 2024</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">During our fiscal year ended December 31, 2025,
we generated revenues of $36,305,891, compared to revenues of $34,874,283 in 2024, an increase of approximately $1.4 million. The increase
was the result of expansion of Nora Pharma sales efforts in the Provinces of Quebec, Ontario, Alberta, and British Columbia. The cost
of sales in 2025 and 2024 for generating these revenues was $24,050,214 (66.2%) and $24,204,489 (69.4%), respectively. The 3.2% decrease
in the cost of sales in 2025 was largely due to lower professional allowances incurred on the sale of products outside the Province of
Quebec. In the Province of Quebec professional allowances are set by government regulations. We also had lower wholesalers&#8217; fees
and discounts in 2025.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">General
                                                                                                                                                                   and administrative (&#8220;G&amp;A&#8221;) expenses for our fiscal
year ended December 31, 2025, were $18,482,706, compared to $16,481,915 during our fiscal year ended December 31, 2024, an increase of
$2,000,791. The increase in the year ended December 31, 2025 is primarily attributable to a non-cash charge of $1,748,247 related to the
impairment of intangible assets. In January 2026, we implemented initiatives to reduce our general and administrative expenses and better
align our cost structure with the Company&#8217;s objective of achieving profitability in the near term. Based on our current plans, we
expect these initiatives to reduce expenses by approximately $2 million to $3 million in 2026. However, there can be no assurance that
we will realize these anticipated reductions.</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Arial, Helvetica, Sans-Serif, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We had interest income of $280,901 in 2025, compared
to interest income of $496,003 in 2024. The decrease was due to reduced interest rates and less cash on hand in 2025.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">As a result of the foregoing, we incurred a net loss
of $5,975,352 for the year ended December 31, 2025, compared to a net loss of $5,134,116 for the year ended December 31, 2024.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b>&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">As of December 31, 2025, we had cash and cash equivalents of $9,123,308.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">During the fiscal years ended December 31, 2024
and 2025, we received aggregate proceeds of $6,478,624 in connection with warrant exercises.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On February 11, 2024, we redeemed certain warrants we issued on May 16, 2023, and April 28,
2022 for an aggregate purchase price of $3,139,651.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On February 15, 2024, we completed an underwritten
public offering and in connection therewith, we issued an aggregate of 35,714 shares of common stock and received net proceeds of $8,522,411.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On January 3, 2025, we issued 127,443 shares of
common stock upon the exercise of 127,443 Series B Warrants and received $355,298 in net proceeds.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On April 2, 2025, the Company issued 660,000 shares
of common stock upon the exercise of 660,000 Series B Warrants and received $1,840,014 in net proceeds.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On April 3, 2025, the Company issued an aggregate
of 1,188,404 shares of common stock in connection with a registered direct offering and received $1,828,596 in net proceeds.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 26 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On October 16, 2025, the Company issued 350,000
shares of common stock upon the exercise of 350,000 Series B Warrants and received net proceeds of <span style="font-family: Arial, Helvetica, Sans-Serif">$724,500.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Net
cash used in operations was $5,331,073 in 2025, compared to $12,524,779 in 2024. The substantial decrease was due to more streamlined
Nora Pharma operations and a significant decrease in the rate of inventory growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Cash flows used
in investing activities were $836,306 during the year ended December 31, 2025, compared to $1,979,313 during our fiscal year ended December
31, 2024. The decrease of approximately $1.7 million was due to reduced acquisition of intangible assets and purchase of equipment for
Nora Pharma&#8217;s operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Net
cash flows provided by financing activities were $4,748,408 in 2025, compared to $8,941,572 in 2024. The decrease was due to a smaller
financing event in 2025 as well as the exercise of fewer warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">We
believe our existing cash will be sufficient to fund our operations for the next 18 months. There is no assurance our estimates will
be accurate. We have no committed sources of capital and we anticipate that we will need to raise additional capital in the future to
expand our generic pharmaceutical operations. Additional capital may not be available on terms acceptable to us, or at all.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Critical Accounting Estimates</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The discussion and analysis of our financial condition
and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally
accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the
amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis,
we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not
readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Leases</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We follow the guidance in <i>ASC 842 &#8211; Accounting
for Leases</i>, as amended, which requires us to evaluate the lease agreements we enter into to determine whether they represent operating
or capital leases at the inception of the lease.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our wholly owned subsidiary, Nora Pharma, currently
occupies a 23,500 square foot facility located at 1565 Boulevard Lionel-Boulet, Varennes, Quebec, Canada, J3X 1P7 pursuant to a lease
agreement that expires in January 2030, with an option to extend for 5 years. This site is composed of 18,500 square feet of warehouse
space and 5,000 square feet of executive office space. The facility houses all administrative, marketing, quality control, regulatory
affairs, and other operations personal, as well as a Health Canada licensed warehouse space. We pay monthly rent of $27,250 CAD (approximately
$19,900 USD), including taxes. We treat this lease as an operating lease but account for liabilities and benefits resulting therefrom.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Recently Adopted Accounting
Standards</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We have adopted all new accounting standards impacting
operations.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We have not entered into any off-balance sheet
arrangements.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span id="a_018"></span><b>ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Not required for a smaller reporting company.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 27 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span id="a_019"></span><b>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><img src="image_003.jpg" alt="" style="height: 98px; width: 500px"/>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: #00487F"><span id="a_020"></span><b>Report of Independent Registered
Public Accounting Firm</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">To
the Audit Committee and Shareholders of Sunshine Biopharma Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">We
have audited the accompanying consolidated balance sheets of Sunshine Biopharma Inc. (the Company) as of December 31, 2025, and the related
consolidated statements of operations and comprehensive loss, shareholders&#8217; equity, and cash flows for the year ended December
31, 2025 and the related notes (collectively referred to as the "financial statements"). In our opinion, the consolidated financial
statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2025,
and the results of its operations and its cash flows for the year-ended December 31, 2025, in conformity with accounting principles generally
accepted in the United States of America. The financial statements of Sunshine Biopharma Inc., as of December 31, 2024, were audited
by other auditors whose report dated April 1, 2025, expressed an unqualified opinion on those financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and the significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe our audits provides
a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>Critical
Audit Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
critical audit matter communicated below is a matter arising from the current period audits of the consolidated financial statements
that were communicated, or required to be communicated, to the audit committee and that: (1) relate to accounts or disclosures that are
material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication
of critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are
not, by communicating the critical audit matter below, providing separate opinion on the critical audit matter or on the accounts or
disclosures to which they relate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><i>Improper
Revenue Recognition</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">As
discussed in the notes to the consolidated financial statements, the Company recognizes revenues related to three services derived from
the sale of pharmaceutical products, including sale of pharmaceutical products to registered pharmacy or registered wholesaler, sale
of health and wellness supplements products, and commissions related to selling pharmaceutical products. The Company recognizes revenues
when customer receives the requested products for the sale of pharmaceutical products and upon settlement date for the sale of the health
and wellness in the amount of consideration the Company expects to receive in exchange for the products or services provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Auditing
the recognition of revenue involves significant challenge due to the inherent risk of revenue recognition. Related to sales of pharmaceutical
products and health and wellness supplements, M&amp;K tested a sample of sales transactions, formal proof of delivery, and cash collections.
Related to sales commission for the sale of pharmaceutical products, M&amp;K tested a sample of sales commission transactions, validity
of commissions agreement and third-party sales data through the Company to the various parties involved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">To
evaluate the appropriateness and accuracy of the assessment by management, we evaluated management&#8217;s assessment in relationship
to the relevant agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif">/s/
<span id="xdx_909_edei--AuditorName_c20250101__20251231_zG6EzseBRgU3"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000093" name="dei:AuditorName">M&amp;K CPAS, PLLC</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif">We have served
as the Company&#8217;s auditor since 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_900_edei--AuditorLocation_c20250101__20251231_zDi1KTVaQnG6"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000094" name="dei:AuditorLocation">The Woodlands,
TX</ix:nonNumeric></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">April 3, 2026</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b style="display: none">PCAOB ID Number <span id="xdx_90B_edei--AuditorFirmId_c20250101__20251231_zaMjzi09D8p6"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000095" name="dei:AuditorFirmId">2738</ix:nonNumeric></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">Report
of Independent Registered Public Accounting Firm</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">To the Board of
Directors and Shareholders of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">Sunshine Biopharma,
Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>Opinion on
the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">We have audited
the accompanying consolidated balance sheets of Sunshine Biopharma, Inc. as of December 31, 2024 and the related consolidated statements
of operations and comprehensive loss, shareholders&#8217; equity, and cash flows, for the period ended December 31, 2024, and the related
notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements
present fairly, in all material respects, the financial position of Sunshine Biopharma, Inc. as of December 31, 2024, and the results
of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in
the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>Basis for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">These consolidated
financial statements are the responsibility of the entity&#8217;s management. Our responsibility is to express an opinion on these consolidated
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) ("PCAOB") and are required to be independent with respect to Sunshine Biopharma, Inc. in accordance with the
U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">We conducted our
audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Sunshine
Biopharma, Inc. is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As
part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of
expressing an opinion on the effectiveness of the entity&#8217;s internal control over financial reporting. Accordingly, we express no
such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">Our audits included
performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used
and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>Critical Audit
Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">Critical audit
matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated
to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved
our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">/s/ <span id="xdx_904_edei--AuditorName_c20240101__20241231_zZy7sGm41J7h"><ix:nonNumeric contextRef="From2024-01-012024-12-31" id="Fact000096" name="dei:AuditorName">Bush &amp;
Associates CPA LLC</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">We have served
as the Company&#8217;s auditor since 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_902_edei--AuditorLocation_c20240101__20241231_zJgIOSXZVEq8"><ix:nonNumeric contextRef="From2024-01-012024-12-31" id="Fact000097" name="dei:AuditorLocation">Henderson, Nevada</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">April 1, 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">PCAOB ID Number
<span id="xdx_900_edei--AuditorFirmId_c20240101__20241231_zXJO9ut8trXl"><ix:nonNumeric contextRef="From2024-01-012024-12-31" id="Fact000098" name="dei:AuditorFirmId">6797</ix:nonNumeric></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 29 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">Sunshine Biopharma Inc.</p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="a_021"></span>Consolidated Balance Sheets </p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_301_111_zRld4JFDtkm4" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Arial, Helvetica, Sans-Serif, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49D_20251231_z0VVAgQF9Kyk" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49B_20241231_zvuQZfZBHn0a" style="font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="3" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">December 31,</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="3" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">December 31,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">2025</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">2024</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsAbstract_iB_zvZtFdtexwDk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">ASSETS</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="3"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="3"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AssetsCurrentAbstract_iB_zhySsFuB1K14" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Current Assets:</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_i01I_maCzT4x_zZBiwqIMMIn" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 66%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Cash and cash equivalents</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-12-31" id="Fact000106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,123,308</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,686,529</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AccountsReceivableNetCurrent_i01I_maCzT4x_ztOOJ3Q3AOH3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Accounts receivable</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2025-12-31" id="Fact000109" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,459,864</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-12-31" id="Fact000110" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,868,418</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--InventoryNet_i01I_maCzT4x_zfwphOfor7ll" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Inventory</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2025-12-31" id="Fact000112" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,472,025</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2024-12-31" id="Fact000113" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,278,105</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseCurrent_i01I_maCzT4x_zFnj3G443bL4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Prepaid expenses</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2025-12-31" id="Fact000115" format="ixt:numdotdecimal" decimals="0" unitRef="USD">798,384</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact000116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,133,297</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AssetsCurrent_iTI_mtCzT4x_maCz8iX_z69EQQiqhrQb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Total Current Assets</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-12-31" id="Fact000118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,853,581</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000119" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,966,349</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AssetsNoncurrentAbstract_iB_z4PbW0cDl4D8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Long-Term Assets:</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iI_maCzu4a_zdvLFqtV1sFd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Property &amp; equipment</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-12-31" id="Fact000124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">557,370</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000125" format="ixt:numdotdecimal" decimals="0" unitRef="USD">546,055</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_maCzu4a_zpFtXIZIQ5xk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Intangible assets</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2025-12-31" id="Fact000127" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,889,370</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2024-12-31" id="Fact000128" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,019,717</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredIncomeTaxesAndOtherAssetsNoncurrent_iI_d0_maCzu4a_zsPnvH6tEzPi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Deferred tax asset</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" contextRef="AsOf2025-12-31" id="Fact000130" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000131" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,234</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_iI_maCzu4a_zLsJFbJMH3Pi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Right-of-use-asset</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-12-31" id="Fact000133" format="ixt:numdotdecimal" decimals="0" unitRef="USD">778,846</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">936,037</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AssetsNoncurrent_iTI_mtCzu4a_maCz8iX_zBcOHj1j0cf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Total Long-Term Assets</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2025-12-31" id="Fact000136" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,225,586</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000137" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,594,043</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--Assets_iTI_mtCz8iX_zbmE2YV6mVh3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">TOTAL
    ASSETS</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,079,167</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000140" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,560,392</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAbstract_iB_zGtMgQ41UOTg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">LIABILITIES</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_iB_zs6OWqppHLx7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Current Liabilities:</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AccountsPayableCurrent_i01I_maCzVRE_zg08SqBEJTyj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Accounts payable &amp; accrued expenses</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-12-31" id="Fact000148" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,664,212</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000149" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,543,085</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--EarnoutPayable_i01I_d0_maCzVRE_zPahuh9qRZOc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Earnout payable</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="SBFM:EarnoutPayable" contextRef="AsOf2025-12-31" id="Fact000151" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,797</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="SBFM:EarnoutPayable" contextRef="AsOf2024-12-31" id="Fact000152" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,797</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedIncomeTaxesCurrent_i01I_d0_maCzVRE_zVwc3HFvGXM6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Income tax payable</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="AsOf2025-12-31" id="Fact000154" format="ixt:numdotdecimal" decimals="0" unitRef="USD">268,276</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="AsOf2024-12-31" id="Fact000155" format="ixt:numdotdecimal" decimals="0" unitRef="USD">268,276</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_maCzVRE_zVGmzcC5qas5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Current portion - right-of-use-liability</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-12-31" id="Fact000157" format="ixt:numdotdecimal" decimals="0" unitRef="USD">215,637</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000158" format="ixt:numdotdecimal" decimals="0" unitRef="USD">207,756</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesCurrent_iTI_mtCzVRE_maCzDSO_zqIhaD32qTae" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Total Current Liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000160" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,443,922</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000161" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,314,914</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesNoncurrentAbstract_iB_zpDgBKU2qmXl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Long-Term Liabilities:</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maCzBsN_zOd8m6lJPPoh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Right-of-use-liability</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-12-31" id="Fact000166" format="ixt:numdotdecimal" decimals="0" unitRef="USD">596,785</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000167" format="ixt:numdotdecimal" decimals="0" unitRef="USD">744,724</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesNoncurrent_iTI_mtCzBsN_maCzDSO_z2v4ImZsXbi8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Total Long-Term Liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2025-12-31" id="Fact000169" format="ixt:numdotdecimal" decimals="0" unitRef="USD">596,785</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2024-12-31" id="Fact000170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">744,724</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--Liabilities_iTI_mtCzDSO_maCzWNb_z7wJVpITk153" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">TOTAL
    LIABILITIES</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-12-31" id="Fact000172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,040,707</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000173" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,059,638</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--StockholdersEquityAbstract_iB_zw3g7emwrdud" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">SHAREHOLDERS' EQUITY</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--PreferredStockValue_i01I_maCzhI7_zerXXP25GJVk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Preferred Stock, Series B $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zv2AgAqBvzwe" title="Preferred stock, par value"><span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zuEc3QrUGSza" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000181" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000183" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.10</ix:nonFraction></ix:nonFraction></span></span> par value per share; <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z92FsawXVSeb" title="Preferred stock, shares authorized"><span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zRWR3sWHDDYk" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000185" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000187" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></ix:nonFraction></span></span> shares
    authorized; <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zbzJAtqFw2gf" title="Preferred stock, shares issued"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z4uxH58V9DB9" title="Preferred stock, shares outstanding"><span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zi9nYh01byqd" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zwa23DSmSKLd" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000189" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000191" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000193" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000195" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">130,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-12-31" id="Fact000178" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="Fact000179" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--CommonStockValue_i01I_maCzhI7_z9iOML0utaJh" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Common Stock, $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_c20251231_zbl9HWmiIQ59" title="Common stock, par value"><span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_c20241231_z3kAxdCvsWt4" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000202" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value per share; <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20251231_zk28OdJKY3k9" title="Common stock, shares authorized"><span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_c20241231_z2EjIziVe3If" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000204" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000206" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000,000</ix:nonFraction></ix:nonFraction></span></span> shares
    authorized; <span id="xdx_906_eus-gaap--CommonStockSharesIssued_c20251231_zwO6Ht2mngK2" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_c20251231_zyK6RefHOZce" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-12-31" id="Fact000208" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact000210" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,905,945</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_906_eus-gaap--CommonStockSharesIssued_c20241231_zOAPF3ZgBMoc" title="Common stock, shares issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_c20241231_zsUPTnMuh2T" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000212" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000214" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,580,098</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at December 31, 2025 and December 31, 2024,
    respectively</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-12-31" id="Fact000197" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,905</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,580</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AdditionalPaidInCapital_i01I_maCzhI7_z2dF059lukZe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Capital paid in excess of par value</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-12-31" id="Fact000216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,100,990</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000217" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,354,907</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i01I_pp0p0_maCzhI7_zi8Yc21AVXIl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Accumulated comprehensive income</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2025-12-31" id="Fact000219" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">65,309</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2024-12-31" id="Fact000220" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">829,959</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maCzhI7_zA75NygLQx53" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Accumulated (Deficit)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-12-31" id="Fact000222" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">75,015,126</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000223" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">69,039,774</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquity_i01TI_mtCzhI7_maCzWNb_zSFCyUH9mo95" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">TOTAL
    SHAREHOLDERS' EQUITY</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000225" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,038,460</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000226" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,500,754</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCzWNb_zBtPFeDIg57a" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">TOTAL
    LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000228" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,079,167</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000229" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,560,392</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  </table>




<p style="margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">See Accompanying Notes
To These Consolidated Financial Statements</p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 30 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">Sunshine Biopharma Inc.</p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><span id="a_022"></span>Consolidated
Statement Of Operations and Comprehensive Loss</p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_113_zjyzMHuzIp37" summary="xdx: Statement - Consolidated Statement Of Operations and Comprehensive Loss" style="font: 10pt Arial, Helvetica, Sans-Serif, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_495_20250101__20251231_zcw5uLElgeDi" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49B_20240101__20241231_zXF5nNJxytHh" style="font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="3" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">December 31,</span></td><td style="font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="3" style="font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">December 31,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">2025</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">2024</span></td></tr>
  <tr id="xdx_402_eus-gaap--Revenues_maCznPY_zCr6R7u44k3j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%"><span style="font-family: Arial, Helvetica, Sans-Serif">Revenue:</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-01to2025-12-31" id="Fact000231" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,305,891</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-12-31" id="Fact000232" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,874,283</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--CostOfRevenue_msCznPY_zRCoxkg2tMnh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Cost of Sales</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-01-01to2025-12-31" id="Fact000234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,050,214</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-012024-12-31" id="Fact000235" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,204,489</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--GrossProfit_iT_mtCznPY_maCzDUx_zDrrMeg1G3Rf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Gross profit</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2025-01-01to2025-12-31" id="Fact000237" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,255,677</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-01-012024-12-31" id="Fact000238" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,669,794</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpenseAbstract_iB_zhPtZJPrw1u4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">General &amp; Administrative Expenses:</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ProfessionalFees_i01_maCzWTQ_zwDWbOnTEhK4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Accounting</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2025-01-01to2025-12-31" id="Fact000243" format="ixt:numdotdecimal" decimals="0" unitRef="USD">698,083</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2024-01-012024-12-31" id="Fact000244" format="ixt:numdotdecimal" decimals="0" unitRef="USD">967,614</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--ProfessionalAndContractServicesExpense_i01_maCzWTQ_z1H6FaRtTLtc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Consulting</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000246" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,571,692</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="From2024-01-012024-12-31" id="Fact000247" format="ixt:numdotdecimal" decimals="0" unitRef="USD">925,188</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--NoninterestExpenseDirectorsFees_i01_maCzWTQ_zYCmGLjOHea6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Director fees</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="From2025-01-01to2025-12-31" id="Fact000249" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="From2024-01-012024-12-31" id="Fact000250" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--GoodwillAndIntangibleAssetImpairment_i01_d0_maCzWTQ_zk6DWHoYXd7h" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Intangible assets
    impairment</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2025-01-01to2025-12-31" id="Fact000252" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,748,247</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2024-01-012024-12-31" id="Fact000253" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--LegalFees_i01_maCzWTQ_zsB8zqLbWrdj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Legal</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2025-01-01to2025-12-31" id="Fact000255" format="ixt:numdotdecimal" decimals="0" unitRef="USD">385,142</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2024-01-012024-12-31" id="Fact000256" format="ixt:numdotdecimal" decimals="0" unitRef="USD">875,698</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--MarketingExpense_i01_maCzWTQ_zdcSt9a7zXlc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Marketing</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:MarketingExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000258" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,143,929</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:MarketingExpense" contextRef="From2024-01-012024-12-31" id="Fact000259" format="ixt:numdotdecimal" decimals="0" unitRef="USD">940,278</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OtherGeneralAndAdministrativeExpense_i01_maCzWTQ_z62SIV5gByKe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Office</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000261" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,864,584</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31" id="Fact000262" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,110,026</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzWTQ_zCQStiXmwm42" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">R&amp;D</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000264" format="ixt:numdotdecimal" decimals="0" unitRef="USD">604,308</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31" id="Fact000265" format="ixt:numdotdecimal" decimals="0" unitRef="USD">933,902</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--SalariesAndWages_i01_maCzWTQ_z9L1CzNsnDp9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Salaries</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2025-01-01to2025-12-31" id="Fact000267" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,265,346</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2024-01-012024-12-31" id="Fact000268" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,718,677</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--Taxes_i01_maCzWTQ_zFFgUBgrvhv1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Taxes</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="SBFM:Taxes" contextRef="From2025-01-01to2025-12-31" id="Fact000270" format="ixt:numdotdecimal" decimals="0" unitRef="USD">469,305</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="SBFM:Taxes" contextRef="From2024-01-012024-12-31" id="Fact000271" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,005</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DepreciationDepletionAndAmortization_i01_maCzWTQ_zkRAgCVas0Y2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Depreciation
    &amp; amortization</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2025-01-01to2025-12-31" id="Fact000273" format="ixt:numdotdecimal" decimals="0" unitRef="USD">332,070</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2024-01-012024-12-31" id="Fact000274" format="ixt:numdotdecimal" decimals="0" unitRef="USD">223,527</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_i01T_mtCzWTQ_msCzDUx_z9VStWylXvqb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Total General &amp; Administrative
    Expenses</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000276" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,482,706</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31" id="Fact000277" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,481,915</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_i01T_mtCzDUx_maCzuwt_zcMd9kdLq8Yk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">(Loss) from operations</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000279" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,227,029</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000280" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,812,121</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zzuLX4tIJD1a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Other Income (Expense):</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maCz7tn_zksiznUoUokk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Foreign exchange gain (loss)</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2025-01-01to2025-12-31" id="Fact000285" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,642</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-01-012024-12-31" id="Fact000286" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,082</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--InterestIncomeDebtSecuritiesOperating_i01_maCz7tn_z8M1rWKOLW7f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Interest income</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:InterestIncomeDebtSecuritiesOperating" contextRef="From2025-01-01to2025-12-31" id="Fact000288" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,901</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:InterestIncomeDebtSecuritiesOperating" contextRef="From2024-01-012024-12-31" id="Fact000289" format="ixt:numdotdecimal" decimals="0" unitRef="USD">496,003</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--InterestExpenseNonoperating_i01N_di0_msCz7tn_zoMgW6nu3Ack" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Interest expense</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2025-01-01to2025-12-31" id="Fact000291" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-01-012024-12-31" id="Fact000292" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,774</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--GainsLossesOnSalesOfAssets_i01_d0_maCz7tn_zEH37tExt0Vg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Gain
    (Loss) on asset sale</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:GainsLossesOnSalesOfAssets" contextRef="From2025-01-01to2025-12-31" id="Fact000294" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,257</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:GainsLossesOnSalesOfAssets" contextRef="From2024-01-012024-12-31" id="Fact000295" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NonoperatingIncomeExpense_iT_mtCz7tn_maCzuwt_zBJP55AFBCWc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Total Other Income (Expense)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000297" format="ixt:numdotdecimal" decimals="0" unitRef="USD">273,286</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-012024-12-31" id="Fact000298" format="ixt:numdotdecimal" decimals="0" unitRef="USD">443,147</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzuwt_maCzLyV_zcVMzcPw0o39" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Net (loss) before income taxes</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-01to2025-12-31" id="Fact000300" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,953,743</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-012024-12-31" id="Fact000301" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,368,974</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_msCzLyV_zy0ZJSo9IjQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Provision for income taxes</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact000303" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,609</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact000304" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">234,858</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_iT_mtCzLyV_maCz3pO_zD3d7CEpbdh9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Net (Loss)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000306" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,975,352</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000307" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,134,116</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ComprehensiveIncomeNetOfTaxAbstract_iB_z8sxGHgOcbhk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">Other Comprehensive Income:</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_maCz3pO_znMshZUjIu23" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Gain (Loss) from foreign
    exchange translation</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="From2025-01-01to2025-12-31" id="Fact000312" format="ixt:numdotdecimal" decimals="0" unitRef="USD">764,650</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="From2024-01-012024-12-31" id="Fact000313" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,526,064</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--ComprehensiveIncomeNetOfTax_iT_mtCz3pO_zHxUtLNTNDP2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Comprehensive (Loss)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2025-01-01to2025-12-31" id="Fact000315" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,210,702</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-01-012024-12-31" id="Fact000316" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,660,180</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">(Loss) per common share
    (Basic)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20250101__20251231_znSKtisJUVQd" title="(Loss) per common share, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudCBPZiBPcGVyYXRpb25zIGFuZCBDb21wcmVoZW5zaXZlIExvc3MA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-01to2025-12-31" id="Fact000318" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.44</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_c20240101__20241231_z6WEhMuEYZRf" title="(Loss) per common share, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudCBPZiBPcGVyYXRpb25zIGFuZCBDb21wcmVoZW5zaXZlIExvc3MA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-12-31" id="Fact000320" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">7.32</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">Weighted average common shares outstanding
    (Basic)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20251231_z7mHyO0wb8X1" title="Weighted average common shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudCBPZiBPcGVyYXRpb25zIGFuZCBDb21wcmVoZW5zaXZlIExvc3MA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-01to2025-12-31" id="Fact000322" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,157,086</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_zOyj9GQDLHS8" title="Weighted average common shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudCBPZiBPcGVyYXRpb25zIGFuZCBDb21wcmVoZW5zaXZlIExvc3MA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-12-31" id="Fact000324" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">701,749</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  </table>





<p style="margin: 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">See Accompanying Notes
To These Consolidated Financial Statements</p>




<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">Sunshine Biopharma Inc.</p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">Consolidated Statements of Cash Flows </p>



<p style="margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_112_zUV8turDip92" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20251231_zj0ehAO32Qn9" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231_zVhw7cv0cpQ9" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_znGUeqI4IB35" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Operating Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetIncomeLoss_i01_pp0p0_maNCPBUzYoK_zKGNOoITU6x7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 66%; text-align: left">Net (Loss)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000329" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">5,975,352</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000330" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">5,134,116</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zvM9WJ50tocf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DepreciationDepletionAndAmortization_i02_pp0p0_maNCPBUzYoK_zlKvtDVvDzN3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2025-01-01to2025-12-31" id="Fact000335" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">332,070</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2024-01-012024-12-31" id="Fact000336" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">223,527</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--AssetDisposition_i02_pp0p0_d0_maNCPBUzYoK_z7DfFW3NHcOa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Disposal of tangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:AssetDisposition" contextRef="From2025-01-01to2025-12-31" id="Fact000338" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,257</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:AssetDisposition" contextRef="From2024-01-012024-12-31" id="Fact000339" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i02_pp0p0_d0_maNCPBUzYoK_zGwpLMnd2FR" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2025-01-01to2025-12-31" id="Fact000341" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2024-01-012024-12-31" id="Fact000342" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--GoodwillAndIntangibleAssetImpairment_i02_pp0p0_d0_maNCPBUzYoK_zAmyTlfTeTi5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Intangible assets impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2025-01-01to2025-12-31" id="Fact000344" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,748,247</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2024-01-012024-12-31" id="Fact000345" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_pp0p0_di_msNCPBUzYoK_zDp4VZYaYOkj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2025-01-01to2025-12-31" id="Fact000347" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">116,173</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-01-012024-12-31" id="Fact000348" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,338,195</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInInventories_i02N_pp0p0_di_msNCPBUzYoK_zH8mnMcIFbc9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2025-01-01to2025-12-31" id="Fact000350" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,637,277</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2024-01-012024-12-31" id="Fact000351" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,006,864</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_pp0p0_di0_msNCPBUzYoK_zeJKov3QYaK8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000353" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">480,798</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2024-01-012024-12-31" id="Fact000354" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">207,167</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--IncreaseDecreaseInRightOfUseAsset_i02N_pp0p0_di_msNCPBUzYoK_z77luMg4ZfN1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:IncreaseDecreaseInRightOfUseAsset" contextRef="From2025-01-01to2025-12-31" id="Fact000356" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">203,836</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SBFM:IncreaseDecreaseInRightOfUseAsset" contextRef="From2024-01-012024-12-31" id="Fact000357" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">341,534</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i02_pp0p0_maNCPBUzYoK_zBaVF4Q6Aun5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts Payable &amp; accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2025-01-01to2025-12-31" id="Fact000359" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">189,956</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2024-01-012024-12-31" id="Fact000360" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,983,749</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_pp0p0_maNCPBUzYoK_zVpySU3qRAnf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2025-01-01to2025-12-31" id="Fact000362" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">187,523</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-012024-12-31" id="Fact000363" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">347,935</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--IncreaseDecreaseInEarnoutPayable_i02_pp0p0_d0_maNCPBUzYoK_zqmMBtlVXpcd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Earn-out payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:IncreaseDecreaseInEarnoutPayable" contextRef="From2025-01-01to2025-12-31" id="Fact000365" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SBFM:IncreaseDecreaseInEarnoutPayable" contextRef="From2024-01-012024-12-31" id="Fact000366" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,252,034</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccruedIncomeTaxesPayable_i02_pp0p0_d0_maNCPBUzYoK_zkvUpc97Riqc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Income tax payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="From2025-01-01to2025-12-31" id="Fact000368" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="From2024-01-012024-12-31" id="Fact000369" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">812,080</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i02T_pp0p0_mtNCPBUzYoK_maCCERCzJTg_zK9TJrBwptYl" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Flows (Used In) Operating Activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000371" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">5,331,073</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-12-31" id="Fact000372" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">12,524,779</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zqZJmGvkbtU" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash Flows From Investing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_pp0p0_di_msNCPBUzh1S_zyYT5QcMeVLh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Purchase of intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2025-01-01to2025-12-31" id="Fact000377" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">661,815</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2024-01-012024-12-31" id="Fact000378" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">322,258</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_pp0p0_di_msNCPBUzh1S_zxyqdmX8FTEb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt">Purchase of equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2025-01-01to2025-12-31" id="Fact000380" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">174,491</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-012024-12-31" id="Fact000381" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,657,055</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_pp0p0_mtNCPBUzh1S_maCCERCzJTg_zEqB6VTU08B1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Flows (Used In) Investing Activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000383" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">836,306</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-012024-12-31" id="Fact000384" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,979,313</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_z1wkm2AsZPsb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Financing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_pp0p0_d0_maNCPBUz9PU_zXsQ3jaeQhU1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from public offering net (common stock)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-01-01to2025-12-31" id="Fact000389" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,828,596</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-12-31" id="Fact000390" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,522,411</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProceedsFromWarrantExercises_i01_pp0p0_maNCPBUz9PU_zsK6jKMQxine" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2025-01-01to2025-12-31" id="Fact000392" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,919,812</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-01-012024-12-31" id="Fact000393" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,558,812</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PaymentsForRepurchaseOfCommonStock_i01N_pp0p0_di0_msNCPBUz9PU_znd6CHcP2itd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Purchase of treasury stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2025-01-01to2025-12-31" id="Fact000395" format="ixt:zerodash" decimals="0" scale="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2024-01-012024-12-31" id="Fact000396" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,139,651</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_pp0p0_mtNCPBUz9PU_maCCERCzJTg_zg7PvkOjKi38" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Flows Provided by Financing Activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000398" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,748,408</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-012024-12-31" id="Fact000399" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,941,572</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_pp0p0_zgRpVaDoure8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash and Cash Equivalents at Beginning of Period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000401" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,686,529</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000402" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,292,347</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_pp0p0_mtCCERCzJTg_zOwHob4Rd2p8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Net (decrease) in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2025-01-01to2025-12-31" id="Fact000404" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,418,971</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2024-01-012024-12-31" id="Fact000405" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">5,562,520</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_pp0p0_znjyq6UQCcDc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2025-01-01to2025-12-31" id="Fact000407" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">855,750</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2024-01-012024-12-31" id="Fact000408" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,043,298</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_pp0p0_zCl7fJM1pjz8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and Cash Equivalents at End of Period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-12-31" id="Fact000410" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,123,308</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000411" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,686,529</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zEX9sOQqqTTc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Supplementary Disclosure of Cash Flow Information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxesPaidNet_i01_pp0p0_d0_zfskADyfm5C7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2025-01-01to2025-12-31" id="Fact000416" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-012024-12-31" id="Fact000417" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">582,483</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InterestPaidNet_i01_pp0p0_d0_zxosjfKq4ep" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2025-01-01to2025-12-31" id="Fact000419" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-012024-12-31" id="Fact000420" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,126</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--StockIssuedForServices_i01_pp0p0_d0_z9bH6SNdcNtb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Stock issued for services</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SBFM:StockIssuedForServices" contextRef="From2025-01-01to2025-12-31" id="Fact000422" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SBFM:StockIssuedForServices" contextRef="From2024-01-012024-12-31" id="Fact000423" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">See Accompanying Notes To
These Consolidated Financial Statements</p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">Sunshine Biopharma Inc.</p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt">Consolidated Statements of Shareholders' Equity </p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_114_z3ld30dA7aD5" summary="xdx: Statement - Consolidated Statements of Shareholders' Equity" style="font: 8pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zjBQNpFAENY3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z5v4TWqOEcN5" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zHaypzeBEgTl" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--ComprehensiveIncomeMember_zE8kLlWZKmq7" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zrAsRXfc7hj9" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_4BE_zpJSBvyg06bl" style="font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Common Shares</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0"></p></td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Common</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Capital Paid in Excess</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number of</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Preferred</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Shares</p></td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Preferred</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Comprehensive</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Issued</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">of Par Value</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Issued</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Income</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_436_c20250101__20251231_eus-gaap--StockholdersEquity_iS_zqMOcebeiFQf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; font-weight: bold">Balance December 31, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFe2yvMbz90i" title="Beginning balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000432" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,580,098</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000425" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,580</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000426" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,354,907</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zvcMmH9UKRLj" title="Beginning balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact000434" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">130,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact000427" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_ComprehensiveIncomeMember" id="Fact000428" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">829,959</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000429" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">69,039,774</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000430" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,500,754</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zqUFvfGhUbGa" style="vertical-align: bottom; background-color: White">
    <td>Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQzJDDBIl6p8" title="Exercise of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000443" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,137,443</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000436" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,137</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000437" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,918,675</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2025-01-01to2025-12-31" id="Fact000441" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,919,812</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zaAsWwvloPvh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Underwritten offering, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0TRO04viEI2" title="Underwritten offering, net of issuance costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000452" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,188,404</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000445" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,188</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000446" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,827,408</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><b style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0447">&#8211;</span></b></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-01to2025-12-31" id="Fact000450" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,828,596</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ComprehensiveIncomeNetOfTax_z8jsAhmIbjx3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net (loss)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2025-01-012025-12-31_us-gaap_ComprehensiveIncomeMember" id="Fact000457" format="ixt:numdotdecimal" decimals="0" unitRef="USD">764,650</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="Fact000458" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,975,352</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2025-01-01to2025-12-31" id="Fact000459" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,210,702</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_435_c20250101__20251231_eus-gaap--StockholdersEquity_iE_zOCbs0mIY3vg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYPMa6QFwnb9" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="Fact000468" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,905,945</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="Fact000461" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,905</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000462" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,100,990</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zQDfyUDf4nG4" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember" id="Fact000470" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">130,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember" id="Fact000463" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_ComprehensiveIncomeMember" id="Fact000464" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">65,309</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember" id="Fact000465" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">75,015,126</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000466" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,038,460</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43A_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zATSIPHeQpza" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUpSeBZ239G" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000479" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,012</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000472" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000473" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,415,900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zvp3sU3btiLd" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="Fact000481" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="Fact000474" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_ComprehensiveIncomeMember" id="Fact000475" format="ixt:numdotdecimal" decimals="0" unitRef="USD">696,105</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000476" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">63,905,658</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000477" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,207,361</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--PreferredStockIssuedToRelatedParty_iP3us-gaap--SharesOutstanding_zZLGggNuPDyc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Preferred Stock issued to related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--PreferredStockIssuedToRelatedPartyShares_iP3custom--PreferredStockIssuedToRelatedParty_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zx1rT8tHZlOj" title="Preferred Stock issued to related party, shares" style="text-align: right"><ix:nonFraction name="SBFM:PreferredStockIssuedToRelatedPartyShares" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="Fact000490" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:PreferredStockIssuedToRelatedParty" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" id="Fact000485" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SBFM:PreferredStockIssuedToRelatedParty" contextRef="From2024-01-012024-12-31" id="Fact000488" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zE47thCkDmdh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Underwritten offering, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zd6pW73zP0xa" title="Underwritten offering, net of issuance costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000499" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,214</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000492" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000493" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,522,398</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31" id="Fact000497" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,522,411</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zO8JIR8dDT5a" style="vertical-align: bottom; background-color: White">
    <td>Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkqzDZptqc09" title="Exercise of warrants, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000508" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,552,872</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000501" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,554</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000502" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,556,260</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31" id="Fact000506" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,558,812</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--RepurchaseOfWarrants_iNP3us-gaap--StockIssuedDuringPeriodSharesIssuedForServices_di_z1Qu3d4qWCtl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Repurchase of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SBFM:RepurchaseOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000511" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,139,651</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SBFM:RepurchaseOfWarrants" contextRef="From2024-01-012024-12-31" id="Fact000515" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,139,651</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--ComprehensiveIncomeNetOfTax_zPhGI4hhYwLa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net (loss)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_ComprehensiveIncomeMember" id="Fact000520" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,526,064</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000521" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,134,116</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-01-012024-12-31" id="Fact000522" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,660,180</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_439_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zdXVarMIMF43" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzZ767fvSG5i" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000531" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,580,098</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000524" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,580</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000525" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,354,907</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zEJDkxvfYHo4" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact000533" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">130,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact000526" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_ComprehensiveIncomeMember" id="Fact000527" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">829,959</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000528" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">69,039,774</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000529" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,500,754</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>




<p style="margin: 0">&#160;</p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">See Accompanying Notes
To These Consolidated Financial Statements</p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b>Sunshine Biopharma Inc.</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span id="a_023"></span>Notes to Consolidated Financial Statements</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">December 31, 2025 and 2024</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000535" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_804_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ztlJvqQy1i1i" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 1 &#8211;
<span id="xdx_826_zLbKaT2LDpsk">Description of Business</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company was incorporated under the name Mountain
West Business Solutions, Inc. on August 31, 2006, in the State of Colorado. Effective October 15, 2009, the Company acquired Sunshine
Biopharma Inc. in a transaction classified as a reverse acquisition. Upon completion of the reverse acquisition transaction, the Company
changed its name to Sunshine Biopharma Inc. and began operating as a pharmaceutical company.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Sunshine Biopharma has two wholly owned subsidiaries:
(i) Nora Pharma Inc. (&#8220;Nora Pharma&#8221;), a Canadian corporation with a portfolio of pharmaceutical products consisting of 71
generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc. (&#8220;Sunshine Canada&#8221;), a Canadian
corporation which develops and sells nonprescription, over-the-counter (&#8220;OTC&#8221;) supplements. The Company operates the two subsidiaries
as a single business segment. Sales of the OTC supplements represent less than 3% of the Company&#8217;s total annual sales.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company is not subject to material customer
concentration risks as it sells its products directly to pharmacies in several Canadian Provinces. However, Provincial governments in
Canada reimburse patients for their prescription drug expenditures to various degrees under drug reimbursement programs, making generic
drugs prices highly dependent on government policies which may change over time. The most recent negotiations between the pan-Canadian
Pharmaceutical Alliance (&#8220;pCPA&#8221;), the entity that negotiates drug prices on behalf of the government, and the Canadian Generic
Pharmaceutical Association (&#8220;CGPA&#8221;) resulted in updated generic pricing for certain products which took effect on October
1, 2023. The updated prices are valid for three years and the agreement contains an option to extend for an additional two years. On February
10, 2024, the Canadian federal government joined the generic drug reimbursement program as a payor under the Pharmacare Act. This development
further strengthened the Canadian generic drug market, which is the Company&#8217;s current focus.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In addition, the Company is engaged in the development
of the following proprietary drugs:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">K1.1 mRNA, a lipid nano-particle (LNP) targeted for liver cancer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">SBFM-PL4, a protease inhibitor for treatment of Coronavirus infections</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23C_zaQKFXiXaUc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zZzhF6a2YBB8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zJ4KAfPveU29" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 34 -->
    <div id="xdx_23F_zQvObgkDD3s" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_233_zVaBV0VMjns9" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zX5e5met5VPi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000541" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_zgD5rf74uufd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 2 &#8211; <span id="xdx_822_zBMN69LnS9Te">Summary
of Significant Accounting Policies</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">This summary of significant accounting policies
is presented to assist the reader in understanding the Company's financial statements. The consolidated financial statements and notes
are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform
to Generally Accepted Accounting Principles in the United States (&#8220;GAAP&#8221;) and have been consistently applied in the preparation
of the financial statements.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000543" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zT1F7GpEIqY4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_861_z1kzjesDd906">PRINCIPLES OF CONSOLIDATION</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of the Company and its subsidiaries, Nora Pharma Inc. and Sunshine Biopharma Canada Inc., both wholly owned. All
intercompany accounts and transactions have been eliminated in consolidation.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000545" name="us-gaap:UseOfEstimates"><p id="xdx_84C_eus-gaap--UseOfEstimates_zyHfdlWNtT88" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_866_zImZqZi6xGl7">USE OF ESTIMATES</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation
of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic
environment has increased the degree of uncertainty inherent in these estimates and assumptions.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000547" name="us-gaap:ReceivablesPolicyTextBlock"><p id="xdx_840_eus-gaap--ReceivablesPolicyTextBlock_zYKL1sSaiBga" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_86C_zJD4NE4ec4Q4">TRADE ACCOUNTS RECEIVABLE AND
ALLOWANCE FOR DOUBTFUL ACCOUNTS</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Trade accounts receivable are stated at net realizable
value. The majority of customers are not extended credit and therefore time to maturity for receivables is short. On a periodic basis,
management evaluates its trade accounts receivable and determines whether to record an allowance for doubtful accounts. Management analysis for the periods ended December 31, 2024 and 2025 determined
that no allowance for doubtful accounts needed to be recorded. A receivable is considered past
due if the Company has not received payments based on agreed-upon terms. The Company generally does not require any security or collateral
to support its receivables. As of December 31, 2025 and 2024, the balances of accounts receivable were $<span id="xdx_90E_eus-gaap--AccountsReceivableNetCurrent_iI_c20251231_zxRvzZJX0ytg" title="Accounts receivable"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2025-12-31" id="Fact000549" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,459,864</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--AccountsReceivableNetCurrent_iI_c20241231_zP5gVULZNYQ9" title="Accounts receivable"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-12-31" id="Fact000551" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,868,418</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000553" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_84B_eus-gaap--InventoryPolicyTextBlock_zhKeMppuF1H9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_868_zZcWtBQ8Dp5j">INVENTORY VALUATION</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company&#8217;s inventory is comprised of finished goods. Inventory is valued at the lower of cost and net realizable value. Cost is
determined using the first in, first out method. Net realizable value is the estimated selling price in the ordinary course of business,
less the costs necessary to make the sale. The cost of inventory includes the purchase price and other costs directly attributable to
the acquisition of the finished goods. The Company regularly reviews inventories to determine if the carrying value exceeds net realizable
value and, when determined necessary, an allowance to reduce the carrying value to net realizable value is recorded. The net realizable value is calculated based
on a combination of factors, including (i) aging, (ii) historical sell-through patterns, and (iii) product-specific considerations. Write-downs
are recorded within cost of goods sold and are not subsequently reversed. As of December 31,
2025 and 2024, there were allowances for obsolescence of $<span id="xdx_90F_eus-gaap--InventoryValuationReserves_iI_c20251231_zn3STckJuycl" title="Reserve for obsolescence"><ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2025-12-31" id="Fact000555" format="ixt:numdotdecimal" decimals="0" unitRef="USD">475,153</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--InventoryValuationReserves_iI_do_c20241231_z4tfq3nPi0A1" title="Reserve for obsolescence"><ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2024-12-31" id="Fact000557" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, respectively.</span></p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000559" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zqx7JbOvORg9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_867_zvRq9k5Pfwj4">CASH AND CASH EQUIVALENTS</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">For the Balance Sheets and Statements of Cash
Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance
of $<span id="xdx_90E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_c20251231_zZ32dlvJqe14"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-12-31" id="Fact000560" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,123,308</ix:nonFraction></span>
and $<span id="xdx_903_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_c20241231_zMseaXCo4B98"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000561" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,686,529</ix:nonFraction></span>
as of December 31, 2025 and December 31, 2024, respectively. At times such cash balances may be in excess of the FDIC limit of $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20251231_zEg0oLiqljR6"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2025-12-31" id="Fact000562" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>
in the U.S. or the $<span id="xdx_902_ecustom--CashCanadaInsuredAmount_iI_uCAD_c20251231_zrEqCn8XOX4b" title="Cash insured in Canada (CAD)"><ix:nonFraction name="SBFM:CashCanadaInsuredAmount" contextRef="AsOf2025-12-31" id="Fact000564" format="ixt:numdotdecimal" decimals="0" unitRef="CAD">100,000</ix:nonFraction></span> CAD (approximately $<span id="xdx_906_ecustom--CashCanadaInsuredAmount_iI_uUSD_c20251231_zfQHCvrRj3M6" title="Cash insured in Canada (USD)"><ix:nonFraction name="SBFM:CashCanadaInsuredAmount" contextRef="AsOf2025-12-31" id="Fact000566" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,000</ix:nonFraction></span> USD) limit in Canada. At December 31, 2025, the Company had deposits totaling
approximately $7 million in the U.S and $2 million in Canada.</p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23F_zrDRB59NnTjg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_z4RP6H8bluXf" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zm1iATo7Dtxd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 35 -->
    <div id="xdx_237_zimOpZXB9mqh" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_232_z1SzDVSihYw" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zK5HziOS5o4e" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000572" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zsuJ7ILjYGJe" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_869_z7AlXLRHR128">PROPERTY AND EQUIPMENT</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Property and equipment are reviewed for recoverability
when events or changes in circumstances indicate that its carrying value may exceed future undiscounted cash inflows. As of December 31,
2025 and 2024, the Company had not identified any such impairment. Repairs and maintenance are charged to operations when incurred and
improvements and renewals are capitalized.&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost. Depreciation
is calculated according to the following methods at the following annual rates and period for financial reporting purposes and accelerated
methods for tax purposes. Their estimated useful lives are as follows:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000574" name="SBFM:PropertyPlantAndEquipmentUsefulLivesTableTextBlock"><table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Estimated lives)" id="xdx_89D_ecustom--PropertyPlantAndEquipmentUsefulLivesTableTextBlock_zfpByWkhn958" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span id="xdx_8BD_z9C9GBNH5mFa" style="display: none">Schedule of estimated useful lives</span></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 28%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Office Equipment:</span></td>
    <td style="width: 49%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line and Declining balance method</span></td>
    <td style="width: 23%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_903_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zws3TJ6m2Zq8" title="Property and equipment estimated useful lives"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_OfficeEquipmentMember" id="Fact000576" name="SBFM:PropertyPlantAndEquipmentEstimatedUsefulLives1">5-7 Years / 20%</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Computer Equipment:</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Declining balance method</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90C_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z3voB4yZCgM1" title="Property and equipment estimated useful lives"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_ComputerEquipmentMember" id="Fact000578" name="SBFM:PropertyPlantAndEquipmentEstimatedUsefulLives1">55%</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Laboratory Equipment:</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line method</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_909_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z8Bu5xz1asmb" title="Property and equipment estimated useful lives"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_EquipmentMember" id="Fact000580" name="SBFM:PropertyPlantAndEquipmentEstimatedUsefulLives1">5 Years</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Vehicles:</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line and Declining balance method</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_901_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zwa1guchFnc3" title="Property and equipment estimated useful lives"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_VehiclesMember" id="Fact000582" name="SBFM:PropertyPlantAndEquipmentEstimatedUsefulLives1">5 Years / 30%</ix:nonNumeric></span></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AC_zRN7iHB7Gs8a" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000584" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_84D_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zAW5triZDyJ4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_86A_zoiXI3c1RV5">INTANGIBLE ASSETS</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Intangible assets are amortized over their estimated
useful lives according to the following methods at the following annual rates and period:<i></i></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000586" name="SBFM:ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock"><table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Intangible assets)" id="xdx_895_ecustom--ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock_zwwokJM4aN8b" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span id="xdx_8B8_zXYTAxBJiTFk" style="display: none">Schedule of intangible assets   estimated
useful lives</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 25%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Licenses:</span></td>
    <td style="width: 50%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line method</span></td>
    <td style="width: 25%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_904_ecustom--IntangibleAssetsEstimatedUsefulLives_c20250101__20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zMExfiVHmH5" title="Intangible asset estimated useful lives"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_LicensesMember" id="Fact000588" name="SBFM:IntangibleAssetsEstimatedUsefulLives">5 Years</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Website:</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Declining balance method</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_902_ecustom--IntangibleAssetsEstimatedUsefulLives_c20250101__20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_zmGJhForVFM6" title="Intangible asset estimated useful lives"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WebsiteMember" id="Fact000590" name="SBFM:IntangibleAssetsEstimatedUsefulLives">55%</ix:nonNumeric></span></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_zdDRfgKG2d0a" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Intangible assets are tested for recoverability
when events or changes in circumstances indicate that their carrying amount may not be recoverable. The carrying amount of a long-lived
asset is not recoverable when it exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposal.
In such a case, an impairment loss must be recognized and is equivalent to the excess of the carrying amount of a long-lived asset over
its fair value.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000592" name="us-gaap:RevenueRecognitionServicesLicensingFees"><p id="xdx_847_eus-gaap--RevenueRecognitionServicesLicensingFees_zFoxoCN8IsL9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_863_zEFf1loBhPih">INTELLECTUAL PROPERTY RIGHTS
- PATENTS AND LICENSES</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The cost of patents and licenses acquired is capitalized
and is amortized over the remaining life of the patents or licenses.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company evaluates recoverability of identifiable
intangible assets whenever events or changes in circumstances indicate that intangible assets carrying amount may not be recoverable.
Such circumstances include but are not limited to: (i) a significant decrease in the market value of an asset, (ii) a significant adverse
change in the extent or manner in which an asset is used, or (iii) an accumulation of cost significantly in excess of the amount originally
expected for the acquisition of an asset. The Company measures the carrying amount of such assets against the estimated undiscounted future
cash flows associated with it.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000594" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zjLUIuWQo3ne" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_861_zHZZKwtmYnd">BASIC AND DILUTED NET GAIN (LOSS)
PER SHARE</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company computes gain or loss per share in
accordance with <i>ASC 260 &#8211; Earnings per Share</i>. ASC 260 requires presentation of both basic and diluted earnings per share
(&#8220;EPS&#8221;) on the face of the income statement. Basic net income (loss) per share is calculated by dividing net income (loss)
by the weighted-average common shares outstanding. Diluted net income (loss) per share is calculated by dividing net income (loss) by
the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is
more dilutive. As the Company incurred net losses for the years ended December 31, 2025 and 2024, <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20250101__20251231_zMgAksl5zuZ8"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20240101__20241231_zVDywucsa3l5"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-01to2025-12-31" id="Fact000595" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31" id="Fact000596" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> potentially dilutive securities were
included in the calculation of diluted earnings per share as the impact would have been anti-dilutive. Accordingly, diluted EPS information
is not included in this report.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_231_zV32ssJombce" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zML14CZOtLXb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zxAA5ALIIRId" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 36 -->
    <div id="xdx_23D_zGmvn9wtUo0c" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23A_zUojDfvxuqW5" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zxYuaW7HDQ18" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000602" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zE2uzKHkm4ye" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_86A_zQ119tDTcXH3">INCOME TAXES</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In accordance with <i>ASC 740 &#8211; Income Taxes</i>,
the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by
applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities
and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities have been adjusted to reflect
changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not
be realized.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company expects to recognize the financial
statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position
in an examination. For tax positions meeting a &#8220;more-likely-than-not&#8221; threshold, the amount to be recognized in the financial
statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold,
no financial statement benefit is recognized. As of December 31, 2025, the Company had no uncertain tax positions. The Company recognizes
interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. The Company currently has no
federal or state tax examinations nor has it had any federal or state examinations since its inception. To date, the Company has not incurred
any interest or tax penalties.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">For Canadian and U.S. tax purposes, the Company&#8217;s
2022 through 2024 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000604" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_847_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zLvoc9nuCaNi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_860_zAQtqlDLp9Kd">FUNCTIONAL CURRENCY</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The U.S. dollar is the functional currency of the
Company which is operating in the United States. The functional currency for the Company's Canadian subsidiaries is the Canadian dollar.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company translates its Canadian subsidiaries'
financial statements into U.S. dollars as follows:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 24px">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Income statement accounts are translated using the weighted average exchange rate for the period.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company includes translation adjustments from
currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate
component of shareholders&#8217; equity. There are currently no transactions of a long-term investment nature, nor any gains or losses
from non-U.S. currency transactions.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000606" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_z4IY1iD7yuz4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_86E_zVNk6KqUUrP3">CONCENTRATION OF CREDIT RISKS</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash
equivalents with high credit quality financial institutions.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000608" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zqhSLybT8Yj6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_86F_zMlFgM8LrI46">FINANCIAL INSTRUMENTS AND FAIR
VALUE OF FINANCIAL INSTRUMENTS</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company applies the provisions of accounting
guidance, <i>ASC 825 &#8211; Financial Instruments</i>. ASC 825 requires all entities to disclose the fair value of financial instruments,
both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and
defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between
willing parties. As of December 31, 2025 and 2024, the fair value of cash, accounts receivable and notes receivable, accounts payable,
accrued expenses, and other payables approximated carrying value due to the short maturity of the instruments, quoted market prices or
interest rates which fluctuate with market rates.&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23B_zRiYXbWvkyW6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zRB1unmxZihk" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zTvF9XItTvSa" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 37 -->
    <div id="xdx_231_zlpOgapbAN01" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_238_zuOIj6v9XOd9" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zEWicbhAbVY7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company defines fair value as the price that
would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement
date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels
and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement.
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to unobservable inputs (Level 3 measurements).</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 24px">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Level 1 &#8211; Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Level 2 &#8211; Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Level 3 &#8211; Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The carrying value of financial assets and liabilities
recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring
basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried
and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are
those that are adjusted to fair value each time a financial statement is prepared.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000614" name="us-gaap:DebtPolicyTextBlock"><p id="xdx_843_eus-gaap--DebtPolicyTextBlock_zdTevLIoVj79" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_86D_z3bO4ctqItoh">NOTES PAYABLE</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Borrowings are recognized initially at fair value,
net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of
transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective
interest method. The Company had <span id="xdx_90E_eus-gaap--NotesPayable_iI_do_c20251231_zZlHXYFnQKoc"><span id="xdx_904_eus-gaap--NotesPayable_iI_do_c20241231_zOTBND7FG1Re"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2025-12-31" id="Fact000615" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2024-12-31" id="Fact000616" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> notes payable as of December 31, 2025 and 2024.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000618" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_844_eus-gaap--RevenueRecognitionPolicyTextBlock_zhVi7YOtMiFg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_86E_zYbxKFVNkQKf">REVENUE RECOGNITION</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Over 97% of the Company&#8217;s revenues are derived
from the sale of pharmaceutical products. Pharmaceutical products can only be sold to a specific customer that is either a registered
pharmacy or a registered wholesaler. The Company therefore sells only to customers registered with Health Canada, the Canadian equivalent
of the FDA. Contracts are drawn up between the wholesalers and the Company for all indirect sales. In the case of direct sales to pharmacies,
purchase orders are used instead of contracts. A purchase order, forecast, or other written instructions to purchase any of the Company&#8217;s
products placed by the customer constitutes an irrevocable offer to purchase. The customer is responsible for ensuring that the terms
of any such order are complete and accurate. The purchase order is only deemed to be accepted when the Company (in its sole discretion)
accepts the purchase order and delivers on the purchase. The acceptance of any purchase order can be full or partial, at the sole discretion
of the Company. No variations to these conditions are binding on the Company unless agreed to in writing between the customer and the
Company.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">No significant judgments are made in connection
with any contracts as the price is already determined, the collection is reasonably assured, and performance obligation is fulfilled when
the customer receives the goods. The Company is not required to apply any specific judgments, estimations, or assumptions to determine
the price of its products.&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_234_ze87lyw4FKI2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_z8MZwym990Ig" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_z6kUZ6pZAOy4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 38 -->
    <div id="xdx_230_zQvYmCQjySV6" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_237_zBqDkB3KMUEd" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zRZbStOCBjF5" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Taxes assessed by a governmental authority that
are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are
excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has been transferred
to a customer are accounted for as a fulfillment cost and are included in cost of revenues. The amount invoiced for each product is fixed
at the Company&#8217;s current price list on the date of shipping and known in advance by the customer and does not vary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company fulfills its performance obligation
when the customer receives the requested products. When the products leave the Company's warehouse, the transport to the customer is insured
and the transfer of ownership to the customer takes place when the customer receives the goods. At this point, the Company issues an invoice
for the products and remits the applicable sales taxes (GST and QST) to the appropriate governmental agency. The revenue is recognized
when the invoice is issued. Unless otherwise agreed to and signed by both parties, payment terms are within 30 days from the date of the
invoice. The collection is reasonably assured because of the nature of the Company&#8217;s customers. The Company is conducting sales
only in Canada. Prices are listed in Canadian dollars and may vary from one Province or Territory to another within Canada. All products
sold by the Company are labelled and approved for sale in Canada only and are not intended for export outside of Canada.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In the event of any breach by the Company of any
product warranty (whether by reason of defective materials, production faults or otherwise), the Company&#8217;s liability is limited
to, at Company&#8217;s option, (i) replacement of the product(s) in question, or (ii) reimbursement of the purchase price. The Company
carries product liability insurance and is not liable for products&#8217; failure to comply with the warranty of products if the failure
or damage arises because of the customer&#8217;s negligence, deliberate damage, misuse or failure to store the products in conditions
per Health Canada specifications. The Company is not liable (whether in contract, in tort or otherwise) for any (i) indirect, special
or consequential loss or damage, or (ii) loss of profit, goodwill, business or revenue (in each case whether direct or indirect). These
conditions also apply to any replacement products supplied by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company warrants to the customer that, at
the time of delivery, the products are compliant with all mandatory quality standards required by applicable regulatory and legal requirements.
In return, the customer is required to warrant to the Company that it holds all relevant permits and approvals required under applicable
laws to purchase, store, distribute, sell and use the Company&#8217;s products. Visible defects or damages must be reported to the Company
in writing immediately, but no later than five (5) business days after receipt of the products. Hidden defects must be reported to the
Company in writing immediately, but no later than five (5) business days after the customer becomes aware of such defects. The Company
is not be deemed to be in breach of the terms or otherwise liable to customer for any delay in performance or non-performance of its obligations
due to circumstances beyond its control, including but not limited to, acts of God, floods, droughts, earthquakes or other natural disasters,
terrorist attacks, wars, preparations for war, armed conflicts, civil commotions or riots, epidemics or pandemics, fires, strikes, lockouts,
shortages of material or labor, breakdown or damage to machinery or equipment, accidents, any law or governmental order or other regulations
or action taken by a governmental entity, or default of any third party suppliers or provider of services or products, or any causes not
within the Company&#8217;s control.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23A_zKfAI6qpGMQg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zY3FPZtF347d" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zQAuQDavCPrb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 39 -->
    <div id="xdx_235_zLznsbBcOhPf" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_231_zUHsHon24Hr4" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_z2eEiqcrVF6b" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000628" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_zReBenJzGuG8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_863_zVrQsWh3ZXef">LEASES</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company recognizes and measures its leases
in accordance with <i>ASC 842 &#8211; Leases</i>. The Company is a lessee in a non-cancellable operating lease for office space. The Company
determines if an arrangement is a lease, or contains a lease, at inception of a contract and when the terms of an existing contract are
changed. The Company recognizes a lease liability and a right-of-use (ROU) asset at the commencement date. The lease liability is initially
and subsequently recognized based on the present value of its future lease payments. Variable payments are included in the future lease
payments when those variable payments depend on an index or a rate. The discount rate is the implicit rate if it is readily determinable
or otherwise the Company uses its incremental borrowing rate. The implicit rates of the Company's lease are not readily determinable and
accordingly, the Company uses its incremental borrowing rate based on the information available at the commencement date for all leases.
The Company&#8217;s incremental borrowing rate for a lease is the 6% interest it would have to pay on a collateralized basis to borrow
an amount equal to the lease payments under similar terms and in a similar economic environment. The ROU asset is subsequently measured
throughout the lease term at the remaining amount (i.e. present value of the remaining lease payments), plus unamortized initial direct
costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received, and any impairment
recognized. Lease cost for lease payments is recognized on a straight-line basis over the lease term.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company has elected, for all underlying classes
of assets, not to recognize ROU assets and lease liabilities for short-term leases that have a lease term of 12 months or less at lease
commencement, and do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company
recognizes the lease cost associated with its short-term leases on a straight-line basis over the lease term.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Under the available practical expedient, we account
for the lease and non-lease components as a single lease component for all classes of underlying assets as both a lessee and lessor. Further,
we elected a short-term lease exception policy on all classes of underlying assets, permitting us to not apply the recognition requirements&#160;of
this standard to short-term leases (i.e. leases with terms of 12 months or less).</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zbAdSEayDv92" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_869_zpTUaX0BKCC6">RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><i>ASU
2023-09 &#8211; Income Taxes (Topic 740): Improvements to Income Tax Disclosures,</i> enhances the transparency and decision usefulness
of income tax disclosures. Adjustments to the annual disclosure of income taxes include: (1) a tabular rate reconciliation comprised
of eight specific categories, (2) incomes taxes paid, disaggregated between significant national, state, and foreign jurisdictions, (3)
eliminates requirements to disclose the nature and estimate of reasonably possible changes to unrecognized tax benefits in the next 12
months or that an estimated range cannot be made, and (4) adds a requirement to disclose income (or loss) from continuing operations
before income tax expense (or benefit) by national and foreign, and income tax expense (or benefit) from continuing operations disaggregated
between national, state and foreign. The <i>ASU 2023-09</i> is effective for public business entities for fiscal years beginning on or
after December 15, 2024, and for all other entities for fiscal years beginning on or after December 31, 2025, with early adoption permitted.
The amendments in <i>ASU 2023-09</i> were adopted by the Company on a prospective&#160;basis. There was no material change&#160;to the
Company's financial statements reporting as a result of adopting <i>ASU 2023-09</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><i>ASU
2024-03 &#8211; Income Statement (Reporting Comprehensive Income) Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation
of Income Statement Expenses</i>, requires disaggregation of specific expense categories in the notes to the financial statements and
a qualitative description of the remaining expense amounts not separately disaggregated. This standard is effective for annual reporting
periods beginning after December 15. 2026, and requires prospective application with the option to apply it retrospectively. We intend
to adopt this standard in our Annual Report on Form 10-K for the year ending December 31. 2027.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company has implemented all other new accounting
pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements
that have been issued that might have a material impact on its financial position or results of operations.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_239_z2NVstpjhSEb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zeDSkj9u60Q4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zvaiBriL9UO6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 40 -->
    <div id="xdx_23F_zIIVrrLT9lv" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_237_zKv7mTqXw7Rd" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zE8C2CAyw7N1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000636" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock"><p id="xdx_80D_eus-gaap--MergersAcquisitionsAndDispositionsDisclosuresTextBlock_zQcKcggUnAX8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 3 &#8211;
<span id="xdx_82D_zlJRNplSnCq3">Acquisition of Nora Pharma Inc.</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On October 20, 2022, the Company acquired all of
the issued and outstanding shares of Nora Pharma Inc. (&#8220;Nora Pharma&#8221;), a Canadian privately held pharmaceutical company. The
purchase price for the shares was $<span id="xdx_90C_eus-gaap--BusinessCombinationConsiderationTransferred1_pp0p0_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zRmts2czf7Ag" title="Purchase price of shares"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2022-10-192022-10-20_custom_NoraPharmaMember" id="Fact000638" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,860,637</ix:nonFraction></span> which was paid in cash ($<span id="xdx_902_eus-gaap--PaymentsToAcquireBusinessesGross_pp0p0_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zkK2Pvvvv9h5" title="Payments to acquire shares"><ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="From2022-10-192022-10-20_custom_NoraPharmaMember" id="Fact000640" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,346,637</ix:nonFraction></span>) and by the issuance of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zs6biGNvBj76" title="Stock issued for acquisition"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-10-192022-10-20_custom_NoraPharmaMember" id="Fact000642" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,850</ix:nonFraction></span> shares of the Company&#8217;s
common stock valued at $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zR1HMq5jpAf5" title="Stock issued for acquisition, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2022-10-192022-10-20_custom_NoraPharmaMember" id="Fact000644" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,514,000</ix:nonFraction></span> or $2,440.00 per share. Nora Pharma sells generic pharmaceutical products in Canada. Nora Pharma&#8217;s
operations are authorized by a Drug Establishment License issued by Health Canada.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">As part of the consideration for Nora Pharma, the
Company agreed to a $<span id="xdx_90E_ecustom--EarnoutPayable_iI_uCAD_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember__srt--CounterpartyNameAxis__custom--MalekChamounMember_zXh3kKIAPNMj" title="Earnout payable"><ix:nonFraction name="SBFM:EarnoutPayable" contextRef="AsOf2022-10-20_custom_NoraPharmaMember_custom_MalekChamounMember" id="Fact000646" format="ixt:numdotdecimal" decimals="0" unitRef="CAD">5,000,000</ix:nonFraction></span> CAD ($<span id="xdx_90A_ecustom--EarnoutPayable_iI_uUSD_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember__srt--CounterpartyNameAxis__custom--MalekChamounMember_zwMaoaN2vc5e" title="Earnout payable"><ix:nonFraction name="SBFM:EarnoutPayable" contextRef="AsOf2022-10-20_custom_NoraPharmaMember_custom_MalekChamounMember" id="Fact000648" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,632,000</ix:nonFraction></span> USD) earnout amount payable to Mr. Malek Chamoun, the seller of Nora Pharma. The earnout
is payable in the form of twenty (20) payments of $250,000 CAD for every $1,000,000 CAD increase in gross sales (as defined in the Purchase
Agreement) above Nora Pharma&#8217;s June 30, 2022 gross sales, provided that his employment with the Company is not terminated pursuant
to the Company&#8217;s employment agreement with him. The total earnout amount of $3,632,000 has been recorded as a salary payable. During
the fiscal year ended December 31, 2023, the Company paid an earnout amount of $<span id="xdx_90E_ecustom--EarnoutLiabilityExpenseFirstInstallment_uCAD_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zRQ0sscXVxxd" title="Earnout liability expense, first installment"><ix:nonFraction name="SBFM:EarnoutLiabilityExpenseFirstInstallment" contextRef="From2023-01-012023-12-31_custom_NoraPharmaMember" id="Fact000650" format="ixt:numdotdecimal" decimals="0" unitRef="CAD">1,426,914</ix:nonFraction></span> CAD (approximately $<span id="xdx_903_ecustom--EarnoutLiabilityExpenseFirstInstallment_uUSD_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zPq9GLcPrndi"><ix:nonFraction name="SBFM:EarnoutLiabilityExpenseFirstInstallment" contextRef="From2023-01-012023-12-31_custom_NoraPharmaMember" id="Fact000651" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,036,500</ix:nonFraction></span> USD) for the fiscal
year ended December 31, 2022. On April 22, 2024, the Company paid another earnout amount of $<span id="xdx_902_ecustom--EarnoutLiabilityExpenseSecondInstallment_uCAD_c20240421__20240422__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zOHJn8V4G7f9" title="Earnout liability expense, second installment"><ix:nonFraction name="SBFM:EarnoutLiabilityExpenseSecondInstallment" contextRef="From2024-04-212024-04-22_custom_NoraPharmaMember" id="Fact000653" format="ixt:numdotdecimal" decimals="0" unitRef="CAD">3,093,878</ix:nonFraction></span> CAD (approximately $<span id="xdx_902_ecustom--EarnoutLiabilityExpenseSecondInstallment_uUSD_c20240421__20240422__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_znsXS3kmYCk8"><ix:nonFraction name="SBFM:EarnoutLiabilityExpenseSecondInstallment" contextRef="From2024-04-212024-04-22_custom_NoraPharmaMember" id="Fact000654" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,247,400</ix:nonFraction></span> USD)
for the fiscal year ended December 31, 2023. As of December 31, 2025, the remaining earnout balance was $<span id="xdx_90F_ecustom--EarnoutLiabilityBalance_uCAD_c20250101__20251231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zKxlzBBpqfc1" title="Remaining earnout balance"><ix:nonFraction name="SBFM:EarnoutLiabilityBalance" contextRef="From2025-01-012025-12-31_custom_NoraPharmaMember" id="Fact000656" format="ixt:numdotdecimal" decimals="0" unitRef="CAD">479,208</ix:nonFraction></span> CAD ($<span id="xdx_908_ecustom--EarnoutLiabilityBalance_uUSD_c20250101__20251231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_znJt8oQQGAxj"><ix:nonFraction name="SBFM:EarnoutLiabilityBalance" contextRef="From2025-01-012025-12-31_custom_NoraPharmaMember" id="Fact000657" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,797</ix:nonFraction></span> USD).
This remaining earnout amount is currently in dispute following dismissal of Mr. Chamoun by the Company on April 14, 2025 (See Note 17).</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000659" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_805_eus-gaap--IntangibleAssetsDisclosureTextBlock_z2mEREOVVzc4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 4 &#8211; <span id="xdx_828_zdbwXSAMzRD3">Intangible
Assets</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Intangible assets consisted of the following:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000661" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z5D12SH1l7Tf" summary="xdx: Disclosure - Intangible Assets (Details - Intangible assets)" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B8_zARQeKuiadCk"><b style="display: none">Schedule of intangible assets</b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom">
    <td><span style="font-size: 10pt"><b>Year Ended December 31,</b></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td><td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%"><span style="font-size: 9pt">Balance as of December 31, 2023</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_c20240101__20241231_z4aIpydvROwc" title="Intangible assets gross beginning" style="width: 13%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31" id="Fact000663" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,444,259</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">License fees additions</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20240101__20241231_zKT7dd1swT83" title="Dossier fee additions" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2024-01-012024-12-31" id="Fact000665" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,651,617</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 9pt">Balance at December 31, 2024</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20240101__20241231_znMab21WM46e" title="Intangible assets gross ending" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-12-31" id="Fact000667" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,095,876</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">Less: accumulated
    amortization</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20241231_zm6JDlrF9s19" title="Less accumulated amortization" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31" id="Fact000669" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,159</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 9pt">Intangible assets,
    net at December 31, 2024</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20241231_z7M0m6T2UhO1" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-12-31" id="Fact000670" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,019,717</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom">
    <td><span style="font-size: 10pt"><b>Year Ended December 31,</b></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-size: 10pt"><b>2025</b></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 9pt">Balance as of December 31, 2024</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_c20250101__20251231_zVAzTGr1F4T8" title="Intangible assets gross beginning" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-12-31" id="Fact000672" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,019,717</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">License fees additions</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20250101__20251231_zN0uT8HFEKZk" title="Dossier fee additions" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2025-01-01to2025-12-31" id="Fact000674" format="ixt:numdotdecimal" decimals="0" unitRef="USD">774,355</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 9pt">Balance at December 31, 2025</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20250101__20251231_zK6DyE1AxOJc" title="Intangible assets gross ending" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2025-12-31" id="Fact000676" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,794,072</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Less: impairment*</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_988_ecustom--ImpairmentOfIntangibleAssetFinitelived_c20250101__20251231_fKg_____zeMZ3FRiKHQb" title="Impairment" style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="SBFM:ImpairmentOfIntangibleAssetFinitelived" contextRef="From2025-01-01to2025-12-31" id="Fact000678" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,748,247</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">Less accumulated amortization</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20251231_zpoSTbAJblHf" title="Less accumulated amortization" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2025-12-31" id="Fact000680" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,455</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 9pt">Intangible assets,
    net at December 31, 2025</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20251231_zldscGOvl866" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2025-12-31" id="Fact000681" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,889,370</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*
The impairment was a result of the determination by the Company that certain product licenses could not be commercialized</span></p>

</ix:nonNumeric><p id="xdx_8AF_zJZdm9rd5sle" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The amortization amounts of intangible assets for
2025 and 2024 were $<span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_c20250101__20251231_zxwDWScR5nFk" title="Amortization of Intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2025-01-01to2025-12-31" id="Fact000683" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,758</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231_zRNxRPGX66F"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-012024-12-31" id="Fact000684" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,009</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">As of December 31, 2025, the estimated amortization
expense of the Company&#8217;s intangible assets for each of the next five years is as follows:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000686" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zf7fcQ3rgnga" summary="xdx: Disclosure - Intangible Assets (Details - Amortization expense)" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BF_z0VaQsmwAtLl" style="display: none">Schedule of estimated amortization
expense</span></td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49B_20251231_zoyGnTrrT71j" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 83%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2026</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right; width: 13%"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2025-12-31" id="Fact000688" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">212,414</ix:nonFraction></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2027</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2025-12-31" id="Fact000690" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">212,414</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0" style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2028</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2025-12-31" id="Fact000692" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">212,414</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0" style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2029</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2025-12-31" id="Fact000694" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">212,414</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0" style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2030</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2025-12-31" id="Fact000696" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">58,093</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_zXrdwrP36e45" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<ix:exclude><p id="xdx_232_znp2H9YEWbUh" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zKUs1zc0xyde" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zwG2CjZOLjZa" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 41 -->
    <div id="xdx_23F_zhxyWWdNCGAj" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_232_zAooeGmANDfa" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zJ5GdzH8n5ga" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000702" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_802_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zRh2S5yqMTT8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b><span style="text-decoration: underline">Note 5 &#8211; <span id="xdx_82B_zjR8nuLXTQP9">Plant, Property and Equipment</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Property, plant and equipment are stated at cost.
Depreciation of property, plant and equipment begins in the month when the asset is placed into service and is provided using the straight-line
method for financial reporting purposes at rates based on the estimated useful lives of the assets. Estimated useful lives range from
three to twenty years. Property, plant and equipment consist of the following:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000704" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_zjSmaOzymed" summary="xdx: Disclosure - Plant, Property and Equipment (Details)" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B9_zlLqrsze668d"><b style="display: none">Schedule
    of plant property and equipment</b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20251231_zvUW7nf8qT7e" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20241231_zRS5duG11dCj" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">Year Ended December 31,</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z7e2Z7PTzGSb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%"><span style="font-size: 9pt">Equipment</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31_us-gaap_EquipmentMember" id="Fact000706" format="ixt:numdotdecimal" decimals="0" unitRef="USD">335,464</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_EquipmentMember" id="Fact000707" format="ixt:numdotdecimal" decimals="0" unitRef="USD">336,880</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zkRaJyW5vgFa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Computer equipment</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31_us-gaap_ComputerEquipmentMember" id="Fact000709" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,139</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember" id="Fact000710" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,531</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zq8i8exjRqcf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Furniture and fixtures</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact000712" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,462</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact000713" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,686</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_d0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zz9eiYVtLt0e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Leasehold improvements</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000715" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,706</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000716" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,306</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zdbJw2YZbrW9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">Vehicles</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31_us-gaap_VehiclesMember" id="Fact000718" format="ixt:numdotdecimal" decimals="0" unitRef="USD">507,478</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_VehiclesMember" id="Fact000719" format="ixt:numdotdecimal" decimals="0" unitRef="USD">353,185</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzbhx_zZL0hAVXmCg1" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">Total</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31" id="Fact000721" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,070,249</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31" id="Fact000722" format="ixt:numdotdecimal" decimals="0" unitRef="USD">882,588</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzbhx_zyAwf42kNNNg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">Less: Accumulated depreciation</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2025-12-31" id="Fact000724" format="ixt:numdotdecimal" decimals="0" unitRef="USD">512,879</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact000725" format="ixt:numdotdecimal" decimals="0" unitRef="USD">336,533</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzbhx_zZLDdgCzEJBk" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">Plant, property and equipment, net</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"/>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-12-31" id="Fact000727" format="ixt:numdotdecimal" decimals="0" unitRef="USD">557,370</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"/>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000728" format="ixt:numdotdecimal" decimals="0" unitRef="USD">546,055</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8AE_zGrR8IoOi7Gd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Depreciation expense for the years ended December
31, 2025 and 2024 amounted to $<span id="xdx_909_eus-gaap--Depreciation_c20250101__20251231_z4FNJqlfh329" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2025-01-01to2025-12-31" id="Fact000730" format="ixt:numdotdecimal" decimals="0" unitRef="USD">176,346</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--Depreciation_c20240101__20241231_zD3aplQ5nBld" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-12-31" id="Fact000732" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,518</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000734" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_808_eus-gaap--InventoryDisclosureTextBlock_zKBbxEOIXoZi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 6 &#8211; <span id="xdx_821_zZtP34jTZS07">Inventory</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Inventory
consists solely of finished goods purchased for resale. Inventory is stated at the lower of cost or net realizable value. Cost represents
the amount paid to acquire the finished goods. The Company uses the first in, first out (FIFO) method to determine cost. Under the FIFO
method, the earliest purchased units are deemed sold first, so ending inventory reflects the most recent purchase costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company evaluates inventory for potential obsolescence based on a combination of factors, including (i) aging, (ii) historical sell-through
patterns, and (iii) product-specific considerations. When estimated net realizable value is lower than cost, the Company records an allowance
for obsolescence for the difference. Write-downs are recorded within cost of goods sold and are not subsequently reversed.</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Inventory is comprised of the following:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000736" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zzDX5BpbkvF5" summary="xdx: Disclosure - Inventory (Details)" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;<span id="xdx_8BB_zZZ30kgCSXL" style="display: none">Schedule of inventory</span></td><td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20251231_zTt1XC2RFmy7" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20241231_zE9klaG2m0zd" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">Year Ended December 31,</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2025</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_z7NvjDWLhkHc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left"><span style="font-size: 9pt">Finished goods</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2025-12-31" id="Fact000738" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,947,178</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2024-12-31" id="Fact000739" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,278,105</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--AllowanceForObsoleteInventory_iI_d0_msARNCzj7C_z4r2TebdB9h3" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">Allowance for obsolete inventory</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="SBFM:AllowanceForObsoleteInventory" contextRef="AsOf2025-12-31" id="Fact000741" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">475,153</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="SBFM:AllowanceForObsoleteInventory" contextRef="AsOf2024-12-31" id="Fact000742" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--InventoryNet_iI_zb69lc9SnqR3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">Total Inventory, net of allowance</span></td><td style="border-bottom: Black 2.5pt double"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2025-12-31" id="Fact000744" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,472,025</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2024-12-31" id="Fact000745" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,278,105</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zZaFdlvlFle9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000747" name="SBFM:PrepaidExpensesTextBlock"><p id="xdx_80E_ecustom--PrepaidExpensesTextBlock_zqxLm2EPLgt7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b><span style="text-decoration: underline">Note 7 &#8211; <span id="xdx_824_zoAcQy2ygSli">Prepaid Expenses</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif">The prepaid
expenses category is comprised of the following:</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000749" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"><table cellspacing="0" cellpadding="0" id="xdx_89B_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zLKcxzx2pJ75" summary="xdx: Disclosure - Prepaid Expenses (Details)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="display: none; font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_8BF_zJvwc6gQePH2">Schedule of prepaid expenses</span></span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20251231_zCqB86j6PFKg" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20241231_zkK5Cxcj0Ih4" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Year Ended
    December 31,</b></span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>2025</b></span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidTaxes_iI_z3TGIVrV5W42" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Prepaid taxes</span></td>
    <td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:PrepaidTaxes" contextRef="AsOf2025-12-31" id="Fact000751" format="ixt:numdotdecimal" decimals="0" unitRef="USD">206,242</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:PrepaidTaxes" contextRef="AsOf2024-12-31" id="Fact000752" format="ixt:numdotdecimal" decimals="0" unitRef="USD">657,437</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--PermitsAndInsurance_iI_z2a3zSdH9Dj2" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Permits and insurance </span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="SBFM:PermitsAndInsurance" contextRef="AsOf2025-12-31" id="Fact000754" format="ixt:numdotdecimal" decimals="0" unitRef="USD">486,797</ix:nonFraction></span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="SBFM:PermitsAndInsurance" contextRef="AsOf2024-12-31" id="Fact000755" format="ixt:numdotdecimal" decimals="0" unitRef="USD">399,176</ix:nonFraction></span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--OtherPrepaidExpenseCurrent_iI_zz3lDFPZE9q8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Other prepaid
    expenses</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2025-12-31" id="Fact000757" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,345</ix:nonFraction></span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact000758" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,684</ix:nonFraction></span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidExpenseCurrent_iI_zC6hejyG8Qj1" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Total</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2025-12-31" id="Fact000760" format="ixt:numdotdecimal" decimals="0" unitRef="USD">798,384</ix:nonFraction></span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact000761" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,133,297</ix:nonFraction></span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_z4boHq19UqJ6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<ix:exclude><p id="xdx_23E_zlNPN6fk7g6g" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_z8CF8BE9l6pf" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_233_zxdTYvajp61c" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zk1G7Lh2Nccb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 42 -->
    <div id="xdx_239_zxoPAAJ9MHJ9" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_238_zgLJ9tWCDOnj" style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zYkB2VUxT7fi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000768" name="SBFM:CostOfSalesDisclosureTextBlock"><p id="xdx_805_ecustom--CostOfSalesDisclosureTextBlock_ziIO0NtSCv85" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b><span style="text-decoration: underline">Note 8 &#8211; <span id="xdx_824_zXXPCUiHwTt4">Cost of Sales</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Cost of Sales is accounted for in accordance with
<i>ASC 705 &#8211; Cost of Sales and Services</i>. The Company purchases all commercial inventory as finished pharmaceutical products
from third party suppliers and does not conduct internal manufacturing.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">These costs are capitalized into inventory in accordance
with <i>ASC 330</i> and recognized in Cost of Sales when control of the related inventory transfers to the customer under <i>ASC 606</i>.
Inventory is recorded at cost.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company evaluates inventory for excess, expiration,
and obsolescence at each reporting period. Inventory that becomes unsalable due to shelf-life limitations, regulatory changes, product
discontinuation, or forecasted demand shortfalls is written down to its net realizable value, with the charge recorded in Cost of Sales.
Previously recorded write downs are not reversed.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The Company&#8217;s Cost of Sales category is comprised of the following:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000770" name="SBFM:ScheduleOfCostOfSalesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfCostOfSalesTableTextBlock_zgmBqlypqjnf" summary="xdx: Disclosure - Cost of Sales (Details)" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span id="xdx_8B4_zkM25TGXKVBf" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b style="display: none">Schedule
    of cost of sales</b></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif">&#160;</td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left">&#160;</td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right">&#160;</td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left">&#160;</td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif">&#160;</td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left">&#160;</td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right">&#160;</td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; font-weight: bold">Year Ended December 31,</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&#160;</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; font-weight: bold; text-align: center">2024</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">Finished
    goods</span></td><td style="width: 2%; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_900_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--FinishedGoodsMember_zC1dpV2q2owh" title="Cost of goods sold"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-01-012025-12-31_custom_FinishedGoodsMember" id="Fact000772" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,866,208</ix:nonFraction></span></span></td><td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_90E_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--FinishedGoodsMember_z9mxmdsKwta" title="Cost of goods sold"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-012024-12-31_custom_FinishedGoodsMember" id="Fact000774" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,116,534</ix:nonFraction></span></span></td><td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">Professional allowances</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_906_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--ProfessionalAllowancesMember_zCxI0iKKSX13" title="Cost of goods sold"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-01-012025-12-31_custom_ProfessionalAllowancesMember" id="Fact000776" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,909,812</ix:nonFraction></span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_905_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--ProfessionalAllowancesMember_zs0JDixty4Ej" title="Cost of goods sold"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-012024-12-31_custom_ProfessionalAllowancesMember" id="Fact000778" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,714,009</ix:nonFraction></span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">Other allowances</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_90B_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--OtherAllowancesMember_zyhSFVWnzerc" title="Cost of goods sold"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-01-012025-12-31_custom_OtherAllowancesMember" id="Fact000780" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,086,575</ix:nonFraction></span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_90E_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--OtherAllowancesMember_ztAj2iFrvpwd" title="Cost of goods sold"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-012024-12-31_custom_OtherAllowancesMember" id="Fact000782" format="ixt:numdotdecimal" decimals="0" unitRef="USD">666,913</ix:nonFraction></span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">Wholesalers&#8217; fees
    &amp; discounts</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_909_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--WholesalersFeesAndDiscountsMember_z2pShOzDa9V3" title="Cost of goods sold"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-01-012025-12-31_custom_WholesalersFeesAndDiscountsMember" id="Fact000784" format="ixt:numdotdecimal" decimals="0" unitRef="USD">650,333</ix:nonFraction></span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_902_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--WholesalersFeesAndDiscountsMember_z5LsYYEpljC4" title="Cost of goods sold"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-012024-12-31_custom_WholesalersFeesAndDiscountsMember" id="Fact000786" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,699,286</ix:nonFraction></span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">Inventory adjustment</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_905_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--InventoryAdjustmentMember_zhrPlvUarXTc" title="Cost of goods sold"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-01-012025-12-31_custom_InventoryAdjustmentMember" id="Fact000788" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,162,303</ix:nonFraction></span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_90C_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--InventoryAdjustmentMember_zmHR2saVlJXi" title="Cost of goods sold"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-012024-12-31_custom_InventoryAdjustmentMember" id="Fact000790" format="ixt:numdotdecimal" decimals="0" unitRef="USD">236,555</ix:nonFraction></span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">Freight</span></td><td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_90A_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--FreightMember_zjsLYsmhbVm9" title="Cost of goods sold"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-01-012025-12-31_custom_FreightMember" id="Fact000792" format="ixt:numdotdecimal" decimals="0" unitRef="USD">374,983</ix:nonFraction></span></span></td><td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_907_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--FreightMember_zxd9h50SYTR6" title="Cost of goods sold"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-012024-12-31_custom_FreightMember" id="Fact000794" format="ixt:numdotdecimal" decimals="0" unitRef="USD">438,105</ix:nonFraction></span></span></td><td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">Total</span></td><td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_90B_eus-gaap--CostOfRevenue_c20250101__20251231_zM9dDu1Rudqd" title="Cost of goods sold"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-01-01to2025-12-31" id="Fact000796" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,050,214</ix:nonFraction></span></span></td><td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_903_eus-gaap--CostOfRevenue_c20240101__20241231_zcoORuRVF9Ie" title="Cost of goods sold"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-012024-12-31" id="Fact000798" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,204,489</ix:nonFraction></span></span></td><td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zBbqsG7Nvcp6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000800" name="SBFM:ReverseStockSplitTextBlock"><p id="xdx_802_ecustom--ReverseStockSplitTextBlock_zWkkHCKauZLh" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 9 &#8211; <span id="xdx_823_z5z1WmLA0ma5">Reverse
Stock Splits</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Effective April 17, 2024 and August 8, 2024, the
Company completed 1-for-100 and 1-for-20 reverse splits of its common stock, respectively. The Company had previously completed three
(3) reverse stock splits including a 1-for-200 reverse split on February 9, 2022, and two 1-for-20 reverse splits, one in 2019 and the
other in 2020. The Company&#8217;s financial statements included in this report reflect all five (5) reverse stock splits on a retroactive
basis for all periods presented and for all references to common stock, unless specifically stated otherwise.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000802" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zi58iXrIyqS1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 10
&#8211; <span id="xdx_82B_zHnnICAzdPLi">Capital Stock</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s authorized capital is comprised
of <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_z0fbd8yM9eBd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000804" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000,000</ix:nonFraction></span> shares of common stock, par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zd4VxAqWgQo3" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31" id="Fact000806" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>, and <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__srt--TitleOfIndividualAxis__srt--DirectorMember_z1z5qw0yfv29" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31_srt_DirectorMember" id="Fact000808" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000,000</ix:nonFraction></span> shares of preferred stock, $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20251231__srt--TitleOfIndividualAxis__srt--DirectorMember_zoH6tYku8qHj" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31_srt_DirectorMember" id="Fact000810" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.10</ix:nonFraction></span> par value. As of December 31,
2024, the Company had authorized <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsOXxx3CwFR4" title="Preferred stock, shares authorized"><span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zQBeJgrHXgD4" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000812" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000814" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></ix:nonFraction></span></span> shares of Series B Preferred Stock. The Series B Preferred Stock is
non-convertible and non-redeemable. It has a liquidation preference equal to the stated value of $0.10 per share, relative to the common
stock and gives the holder the right to 1,000 votes per share. As of December 31, 2024 and 2025, <span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zFFQB1KPsCd" title="Preferred stock, shares outstanding"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zYJw5jdOWqSg" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember" id="Fact000816" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember" id="Fact000818" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">130,000</ix:nonFraction></ix:nonFraction></span></span> shares of Series B Preferred
Stock were outstanding and held by the Company&#8217;s Chief Executive Officer.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On February 8, 2024, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240207__20240208__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zfX9WH8kZwkf" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-02-072024-02-08_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember" id="Fact000820" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span>
shares of Series B Preferred Stock to the Company&#8217;s CEO for a purchase price of $<span id="xdx_908_eus-gaap--SharePrice_iI_c20240208__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zcBt4d5s17Vf" title="Purchase price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-02-08_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember" id="Fact000822" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.10</ix:nonFraction></span> per share.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_233_zJPpwZBP0qki" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zGJ5HbVQAS46" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zBY01iUWnvab" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zYEdDA0oEbpj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 43 -->
    <div id="xdx_233_zWbZwCr29gTl" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_237_zXd5BPAAzCIb" style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_z5myoaGpNbSb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On February 15, 2024, the Company completed an
underwritten public offering and in connection therewith it issued an aggregate of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240214__20240215__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zNJ7oVUUTGuj" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-02-142024-02-15_us-gaap_CommonStockMember" id="Fact000829" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,714</ix:nonFraction></span> shares of common stock and received $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueOther_c20240214__20240215__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zjHAGmTfxaI2" title="Net proceeds"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-02-142024-02-15_us-gaap_CommonStockMember" id="Fact000831" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,522,411</ix:nonFraction></span>
in net proceeds. In connection with this offering, the Company issued 22,500 pre-funded warrants (the &#8220;2024 Pre-Funded Warrants&#8221;)
exercisable at $2.00 per share, 3,986 Series A Warrants exercisable at $4,200.00 per share (subject to adjustment), or pursuant to an
alternative cashless exercise provision, and 7,973 Series B Warrants exercisable at $4,760.00 per share, subject to adjustment. As of
December 31, 2025, <span id="xdx_907_ecustom--WarrantsExercisedDescription_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrants2024Member_zsSdIGPHoF34" title="Warrants exercised, description"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_PreFundedWarrants2024Member" id="Fact000833" name="SBFM:WarrantsExercisedDescription">(i) all of the 2024 Pre-Funded Warrants have been exercised resulting in the Company receiving net proceeds of $45,000,
(ii) all of the Series A Warrants have been exercised pursuant to the alternative cashless provision resulting in the Company receiving
$0 in proceeds, and (iii) 15,577,965 Series B Warrants remained outstanding and their exercise price had been adjusted to $2.07 as a result
of two reverse stock splits and a financing event which were conducted subsequent to their issuance. The Series B Warrants expire in February
2029.</ix:nonNumeric></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On March 4, 2024, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240303__20240304__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z8DuwQhlX4Ng" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-03-032024-03-04_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember" id="Fact000835" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares
of Series B Preferred Stock to the Company&#8217;s CEO for a purchase price of $<span id="xdx_906_eus-gaap--SharePrice_iI_c20240304__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zeVMQgiqxrql" title="Purchase price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-03-04_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember" id="Fact000837" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.10</ix:nonFraction></span> per share.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In April and May 2024, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240401__20240430__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zbePDqyRZeA4" title="Conversion of common stock shares"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240501__20240531__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zdXZcGIjTTdh" title="Conversion of common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2024-04-012024-04-30_us-gaap_CommonStockMember" id="Fact000839" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2024-05-012024-05-31_us-gaap_CommonStockMember" id="Fact000841" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,120,784</ix:nonFraction></ix:nonFraction></span>
</span>shares of common stock in connection with the cashless exercise of all of the Series A Warrants and received $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20240401__20240430__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z6bzCt8v7Npc" title="Conversion of common stock value"><span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20240501__20240531__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zlVYWmjiBJ6" title="Conversion of common stock value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-04-012024-04-30_us-gaap_CommonStockMember" id="Fact000843" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-05-012024-05-31_us-gaap_CommonStockMember" id="Fact000845" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span> in proceeds.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On August 16, 2024, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_c20240815__20240816__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zptbds4nuwSe" title="Stock issued for rounding of reverse stock split"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" contextRef="From2024-08-152024-08-16_us-gaap_CommonStockMember" id="Fact000847" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,285</ix:nonFraction></span>
shares of common stock in connection with the rounding up of fractional shares following the reverse stock splits of April 17, 2024 and
August 8, 2024.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In August and September 2024, the Company issued
<span id="xdx_90E_eus-gaap--ConversionOfStockSharesIssued1_c20240901__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zMU8Unl40ZQa" title="Stock converted, shares issued"><span id="xdx_90B_eus-gaap--ConversionOfStockSharesIssued1_c20240801__20240831__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zPWsDy7BKUIi" title="Stock converted, shares issued"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2024-09-012024-09-30_us-gaap_CommonStockMember" id="Fact000849" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2024-08-012024-08-31_us-gaap_CommonStockMember" id="Fact000851" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">678,865</ix:nonFraction></ix:nonFraction></span></span> shares of common stock in connection with the exercise of <span id="xdx_908_eus-gaap--ConversionOfStockSharesConverted1_c20240801__20240831__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_znpKqGJ0kTfe" title="Stock converted, shares converted"><span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_c20240901__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zNBbYxF9Vjqe" title="Stock converted, shares converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2024-08-012024-08-31_custom_SeriesBWarrantsMember" id="Fact000853" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2024-09-012024-09-30_custom_SeriesBWarrantsMember" id="Fact000855" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">678,865</ix:nonFraction></ix:nonFraction></span></span> Series B Warrants and received aggregate net proceed of $<span id="xdx_905_eus-gaap--ProceedsFromWarrantExercises_c20240801__20240831__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_z5xVQehkhFD6" title="Proceeds from warrant exercise"><span id="xdx_903_eus-gaap--ProceedsFromWarrantExercises_c20240901__20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zbqIe079Tna2" title="Proceeds from warrant exercise"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-08-012024-08-31_custom_SeriesBWarrantsMember614656125" id="Fact000857" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-09-012024-09-30_custom_SeriesBWarrantsMember614656125" id="Fact000859" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,895,610</ix:nonFraction></ix:nonFraction></span></span>.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In November and December 2024, the Company issued
<span id="xdx_901_eus-gaap--ConversionOfStockSharesIssued1_c20241101__20241130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z184pmA3llJb" title="Stock converted, shares issued"><span id="xdx_906_eus-gaap--ConversionOfStockSharesIssued1_c20241201__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zcTWT2m5ik3i" title="Stock converted, shares issued"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2024-11-012024-11-30_us-gaap_CommonStockMember" id="Fact000861" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2024-12-012024-12-31_us-gaap_CommonStockMember" id="Fact000863" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">580,438</ix:nonFraction></ix:nonFraction></span></span> shares of common stock in connection with the exercise of <span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_c20241101__20241130__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zZsP9zfSo6Fk" title="Stock converted, shares converted"><span id="xdx_908_eus-gaap--ConversionOfStockSharesConverted1_c20241201__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zprm6LxHDT2b" title="Stock converted, shares converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2024-11-012024-11-30_custom_SeriesBWarrantsMember" id="Fact000865" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2024-12-012024-12-31_custom_SeriesBWarrantsMember" id="Fact000867" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">580,438</ix:nonFraction></ix:nonFraction></span></span> Series B Warrants and received aggregate net proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_c20241101__20241130__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zw9eCDOydvV7" title="Proceeds from warrant exercise"><span id="xdx_901_eus-gaap--ProceedsFromWarrantExercises_c20241201__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_z0jCTUFOJi18" title="Proceeds from warrant exercise"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-11-012024-11-30_custom_SeriesBWarrantsMember614656125" id="Fact000869" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-12-012024-12-31_custom_SeriesBWarrantsMember614656125" id="Fact000871" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,618,203</ix:nonFraction></ix:nonFraction></span></span>.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On January 3, 2025, the Company issued <span id="xdx_907_eus-gaap--ConversionOfStockSharesIssued1_c20250102__20250103__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zGbX01e4TyVg" title="Stock converted, shares issued"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2025-01-022025-01-03_us-gaap_CommonStockMember" id="Fact000873" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,443</ix:nonFraction></span>
shares of common stock upon the exercise of <span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_c20250102__20250103__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zUVgoF5uOtX6" title="Stock converted, shares converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2025-01-022025-01-03_custom_SeriesBWarrantsMember" id="Fact000875" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,443</ix:nonFraction></span> Series B Warrants and received $<span id="xdx_90A_eus-gaap--ProceedsFromWarrantExercises_c20250102__20250103__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zSxXHUNs7rj9" title="Proceeds from warrant exercise"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2025-01-022025-01-03_custom_SeriesBWarrantsMember614656140" id="Fact000877" format="ixt:numdotdecimal" decimals="0" unitRef="USD">355,298</ix:nonFraction></span> in net proceeds.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On April 2, 2025, the Company issued <span id="xdx_90B_eus-gaap--ConversionOfStockSharesIssued1_c20250401__20250402__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z0pUfwZa0caj" title="Stock converted, shares issued"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2025-04-012025-04-02_us-gaap_CommonStockMember" id="Fact000879" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">660,000</ix:nonFraction></span> shares
of common stock upon the exercise of <span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_c20250401__20250402__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zOCNsWtlQjda" title="Stock converted, shares converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2025-04-012025-04-02_custom_SeriesBWarrantsMember" id="Fact000881" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">660,000</ix:nonFraction></span> Series B Warrants and received $<span id="xdx_905_eus-gaap--ProceedsFromWarrantExercises_c20250401__20250402__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zpUNKJxKvvJd" title="Proceeds from warrant exercise"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2025-04-012025-04-02_custom_SeriesBWarrantsMember614656140" id="Fact000883" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,840,014</ix:nonFraction></span> in net proceeds.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On April 3, 2025, the Company issued an aggregate
of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250401__20250403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zefPwnICdhZf" title="Aggregate shares Issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-04-012025-04-03_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember" id="Fact000885" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,188,404</ix:nonFraction></span> shares of common stock in connection with a registered direct offering and received $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250401__20250403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zN63QBwvR8Pe" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-04-012025-04-03_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember" id="Fact000887" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,828,596</ix:nonFraction></span> in net proceeds.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On October 16, 2025, the Company issued <span id="xdx_90F_eus-gaap--ConversionOfStockSharesIssued1_c20251015__20251016__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zKR72AEXwusd" title="Stock converted, shares issued"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2025-10-152025-10-16_us-gaap_CommonStockMember" id="Fact000889" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span>
shares of common stock upon the exercise of <span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_c20251015__20251016__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zeFsW2GdBZ83" title="Stock converted, shares converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2025-10-152025-10-16_custom_SeriesBWarrantsMember" id="Fact000891" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span> Series B Warrants and received net proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20251015__20251016__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zEz7ARazH0Pf" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-10-152025-10-16_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember" id="Fact000893" format="ixt:numdotdecimal" decimals="0" unitRef="USD">724,500</ix:nonFraction></span>.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">As of December 31, 2025 and 2024, the Company had
<span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20251231_z9Vn7ak7e3m8"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20251231_zJXXdPx7mFSk"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-12-31" id="Fact000894" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact000895" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,905,945</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20241231_zQYqgpEw6MMd" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_z5wFqj3DAH9" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000897" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000899" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,580,098</ix:nonFraction></ix:nonFraction></span></span> shares of common stock issued and outstanding, respectively.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company has declared no dividends since inception.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_231_zglPC2QjWEXa" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zEbtjmKmVUnf" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_z7KyRWQxOgR7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zRzpeoABNB4f" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 44 -->
    <div id="xdx_232_zG9xQzZLVC7l" style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23C_zdQly2vzabJi" style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_z2F1E3heH2H6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000906" name="SBFM:WarrantsDisclosureTextBlock"><p id="xdx_806_ecustom--WarrantsDisclosureTextBlock_zGrqruCEMns2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 11 &#8211;<span id="xdx_82F_zPQEzVKBpmsg">Warrants</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company accounts for issued warrants either
as a liability or equity in accordance with <i>ASC 480-10</i> or <i>ASC 815-40</i>. Under <i>ASC 480-10</i>, warrants are considered a
liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants
do not meet liability classification under <i>ASC 480-10</i>, the Company considers the requirements of <i>ASC 815-40</i> to determine
whether the warrants should be classified as a liability or as equity. Under <i>ASC 815-40</i>, contracts that may require settlement
for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured
at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance
date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under
<i>ASC 815-40</i>, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed
to its common stock and whether the warrants are classified as equity under <i>ASC 815-40</i> or other applicable GAAP standard. Equity-classified
warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In 2022, 2023, 2024, and 2025, the Company completed
six (6) financing events, and in connection therewith, it issued warrants as follows:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000908" name="SBFM:ScheduleOfWarrantsIssuedWithFinancingTableTextBlock"><table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - Warrants (Details - Warrants issued with financing)" id="xdx_89D_ecustom--ScheduleOfWarrantsIssuedWithFinancingTableTextBlock_zf23S3xtYnR7" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: White">
    <td style="vertical-align: top"><span id="xdx_8BD_zxaUosbINNi9" style="display: none">Schedule of warrants issued with financing</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 37%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Issuance
    Date/Type</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 20%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Number</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 20%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Exercise
    Price</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 20%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Expiry
    Date</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Feb 17, 2022 (&#8220;Tradeable
    Warrants&#8221;)*</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_fKg_____zRJmmhSDjxg1" title="Warrants outstanding" style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_TradeableWarrantsMember" id="Fact000910" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,051</ix:nonFraction></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_zJ7hQBUczKVc" title="Warrant expiration date"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_TradeableWarrantsMember" id="Fact000912" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4,440.00</ix:nonFraction></span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_902_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_zri3sNVV0BEa" title="Warrant expiration date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_TradeableWarrantsMember" id="Fact000914" name="SBFM:WarrantExpirationDate">February 2027</ix:nonNumeric></span></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Mar 14, 2022 (&#8220;2022
    Pre-Funded Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zXkDAJSSNTp3" title="Warrants outstanding" style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_PreFunded2022WarrantsMember" id="Fact000916" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,846</ix:nonFraction></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_z5lKbZ3mE7i8" title="Warrant expiration date"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_PreFunded2022WarrantsMember" id="Fact000918" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction></span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_908_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zgAd3WXF37Hg" title="Warrant expiration date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_PreFunded2022WarrantsMember" id="Fact000920" name="SBFM:WarrantExpirationDate">Unlimited</ix:nonNumeric></span></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Mar 14, 2022 (&#8220;Investor
    Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_fKio___z8rlX91kfMUa"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_InvestorWarrantsMember" id="Fact000921" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,801</ix:nonFraction></span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zIt7rRkk6wih"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_InvestorWarrantsMember" id="Fact000922" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4,440.00</ix:nonFraction></span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_900_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zjycrXvHyRde"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_InvestorWarrantsMember" id="Fact000923" name="SBFM:WarrantExpirationDate">March 2027</ix:nonNumeric></span></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Apr 28, 2022 (&#8220;April
    Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zIAC9PaveSzf" style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_AprilWarrantsMember" id="Fact000924" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,862</ix:nonFraction></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zPyZpyxtyOff"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_AprilWarrantsMember" id="Fact000925" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7,520.00</ix:nonFraction></span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90C_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zRQVtHaNJxX"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_AprilWarrantsMember" id="Fact000926" name="SBFM:WarrantExpirationDate">April 2027</ix:nonNumeric></span></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">May 16, 2023 (&#8220;May
    Pre-Funded Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_zhANlkukxRal" style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_MayPreFundedWarrantsMember" id="Fact000927" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,751</ix:nonFraction></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_z9abUUb14TMg"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_MayPreFundedWarrantsMember" id="Fact000928" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction></span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90F_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_zs5tHlVRMsq4"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_MayPreFundedWarrantsMember" id="Fact000929" name="SBFM:WarrantExpirationDate">Unlimited</ix:nonNumeric></span></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">May 16, 2023 (&#8220;May
    Investor Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zHNYOdyTqTik" style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_MayInvestorWarrantsMember" id="Fact000930" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,952</ix:nonFraction></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zodUIQszAYXd"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_MayInvestorWarrantsMember" id="Fact000931" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,180.00</ix:nonFraction></span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_903_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zpUGWEvueJ71"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_MayInvestorWarrantsMember" id="Fact000932" name="SBFM:WarrantExpirationDate">November 2028</ix:nonNumeric></span></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Feb 15, 2024 (&#8220;2024
    Pre-Funded Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_zSD89QoTOAje" style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_PreFunded2024WarrantsMember" id="Fact000933" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,500</ix:nonFraction></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_z6dzjg7bJ2Zj"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_PreFunded2024WarrantsMember" id="Fact000934" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction></span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_900_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_zThqiw8IEW6f"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_PreFunded2024WarrantsMember" id="Fact000935" name="SBFM:WarrantExpirationDate">Unlimited</ix:nonNumeric></span></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Feb 15, 2024 (&#8220;Series
    A Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_fKio___zTZixmjv9x1f"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_SeriesAWarrantsMember" id="Fact000936" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,986</ix:nonFraction></span>**</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_z2bD7SjgAQW1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesAWarrantsMember" id="Fact000937" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4,200.00</ix:nonFraction></span>**</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90D_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_zbw4SgeKDOe2"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_SeriesAWarrantsMember" id="Fact000938" name="SBFM:WarrantExpirationDate">August 2026</ix:nonNumeric></span></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Feb 15, 2024 (&#8220;Series
    B Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_fKio___zLPvVuZuWsVb"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_SeriesBWarrantsMember" id="Fact000939" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,973</ix:nonFraction></span>**</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_z2EsF8yAYUS8"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesBWarrantsMember" id="Fact000940" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4,760.00</ix:nonFraction></span>**</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_901_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zEtNA3TLnbPa"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_SeriesBWarrantsMember" id="Fact000941" name="SBFM:WarrantExpirationDate">February 2029</ix:nonNumeric></span></span></td></tr>
  <tr style="background-color: White">
    <td style="border-bottom: black 1pt solid; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Apr
    03, 2025 (&#8220;2025 Pre-Funded Warrants&#8221;)</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_zF0lbbU5ssCl" style="border-bottom: black 1pt solid; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_PreFunded2025WarrantsMember" id="Fact000942" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">260,000</ix:nonFraction></span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_zUagTailpb3i" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_PreFunded2025WarrantsMember" id="Fact000944" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span></span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90E_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_z4xq5njTl4u3"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_PreFunded2025WarrantsMember" id="Fact000945" name="SBFM:WarrantExpirationDate">Unlimited</ix:nonNumeric></span></span></td></tr>
  </table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-size: 8pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13px"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">These warrants trade under
    the ticker symbol SBFMW</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">**</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Subject to adjustment</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AE_zeMQyOuCKpVg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On February 11, 2024, the Company redeemed all
of the April Warrants and all of the May Investor Warrants for an aggregate purchase price of $<span id="xdx_90D_eus-gaap--PaymentsForRepurchaseOfWarrants_pp0p0_c20240210__20240211__us-gaap--AwardTypeAxis__custom--AprilWarrantsAndMayInvestorWarrantsMember_zwrDE7NyoSma" title="Payments for repurchase of warrants"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfWarrants" contextRef="From2024-02-102024-02-11_custom_AprilWarrantsAndMayInvestorWarrantsMember" id="Fact000947" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,139,651</ix:nonFraction></span>.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">As of December 31, 2025, all of the 2022 Pre-Funded
Warrants, all of the May Pre-Funded Warrants, all of the 2024 Pre-Funded Warrants, all of the 2025 Pre-Funded Warrants, a total of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_z4vMiyLrFuwe" title="Warrants exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2025-01-012025-12-31_custom_TradeableWarrantsMember" id="Fact000949" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,569</ix:nonFraction></span>
Tradeable Warrants, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zZ3YufmJwMCb" title="Warrants exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2025-01-012025-12-31_custom_InvestorWarrantsMember" id="Fact000951" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,401</ix:nonFraction></span> Investor Warrants, all of the Series A Warrants, and <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_z4Zh4CZNMvl9" title="Warrants exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2025-01-012025-12-31_custom_SeriesBWarrantsMember" id="Fact000953" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,269,303</ix:nonFraction></span> Series B Warrants (as adjusted) were exercised
resulting in aggregate net proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromWarrantExercises_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zC3F4enTucr4" title="Proceeds from warrant exercises"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2025-01-012025-12-31_custom_SeriesBWarrantsMember" id="Fact000955" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,136,992</ix:nonFraction></span> received by the Company.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s outstanding warrants as of
December 31, 2025 consisted of the following:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000957" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - Warrants (Details - Warrants outstanding)" id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zeYsZQUP4hv7" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td id="xdx_8BA_z1RvAy1G5Fde"><span style="display: none; font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; color: White">Schedule of warrants outstanding</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Type</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Number</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Exercise Price</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Expiry Date</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 25%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Tradeable Warrants*</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_fKg_____z3IDyqg91rhe" title="Number of warrants outstanding" style="width: 24%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_TradeableWarrants1Member" id="Fact000959" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">482</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_fKg_____zS5tu4SC2Mhh" title="Warrant exercise price" style="width: 24%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_TradeableWarrants1Member" id="Fact000961" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">220.00</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 24%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_908_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_fKg_____zJXIKtPODttg" title="Expiry date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_TradeableWarrants1Member" id="Fact000963" name="SBFM:WarrantExpirationDate">February 2027</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Investor Warrants</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_fKio___z1FzCr0udrfb"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_InvestorWarrants1Member" id="Fact000964" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400</ix:nonFraction></span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_fKio___z5jwWjBD1aOh"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_InvestorWarrants1Member" id="Fact000965" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4,000.00</ix:nonFraction></span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_909_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_zI17tbbMeEag"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_InvestorWarrants1Member" id="Fact000966" name="SBFM:WarrantExpirationDate">March 2027</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Series B Warrants</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_fKioq_zddOnbprW6S4"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_SeriesBWarrants1Member" id="Fact000967" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,227,962</ix:nonFraction></span>**</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_fKioq_zzomno5A8t3g"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesBWarrants1Member" id="Fact000968" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.07</ix:nonFraction></span>**</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90A_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_zowPp9E6Wrl9" title="Expiry date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_SeriesBWarrants1Member" id="Fact000970" name="SBFM:WarrantExpirationDate">February 2029</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 12px"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*</span></td>
    <td><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-size: 8pt">These warrants trade under the
        ticker symbol SBFMW</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">**</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">As adjusted following the financing event of April 3,
    2025 and subject to further adjustment of the number of warrants and exercise price upon certain corporate actions such that the
    aggregate exercise price of the warrants remains unchanged</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A0_zHP2e4LMlrh4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<ix:exclude><p id="xdx_230_zXUTBe7l9jx2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zpQN01S9oBB" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zVdRzb23GNF2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 45 -->
    <div id="xdx_23F_zBI20UFl1TZa" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_238_zfnKPNx6kgM4" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zJNwDYGiHvxf" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000976" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zFlbt1QS4vtg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 12 &#8211;
<span id="xdx_82D_zapNf0OBUWMh">Earnings Per Share</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The following table* sets forth the computation
of basic net income (loss) per share:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000978" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zoF14LQs6e9c" summary="xdx: Disclosure - Earnings Per Share (Details)" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid"><span id="xdx_8BB_zcB3fbVL3Pg3" style="display: none">Schedule of computation of basic and diluted net income per share</span></td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20251231_zNjJZReYAdP8" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20241231_zQ8xUjEedt1i" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Year Ended December 31,</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zo9DXGDEbT0a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left"><span style="font-size: 9pt">Net gain (loss) attributable to common stock</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-01-01to2025-12-31" id="Fact000980" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,975,352</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">)</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-012024-12-31" id="Fact000981" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,134,116</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">Weighted average outstanding shares of common stock (Basic)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20251231_zjgPcCo4Jch9" title="Weighted average common shares outstanding - basic"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-01to2025-12-31" id="Fact000983" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,157,086</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_zr4GvQjHOk55" title="Weighted average common shares outstanding - basic"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-12-31" id="Fact000985" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">701,749</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">Net gain (loss) per share attributable
    to common stock  (Basic)</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20250101__20251231_zagpytq9nff6" title="Basic gain (loss) per share attributable to common stock">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-01to2025-12-31" id="Fact000987" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.44</ix:nonFraction></span></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_c20240101__20241231_z7kjPcFLEWhe" title="Basic gain (loss) per share attributable to common stock">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-12-31" id="Fact000989" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">7.32</ix:nonFraction></span></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  </table>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">* Diluted net
gain (loss) per share is not included in this table as the Company incurred net losses for the years ended December 31, 2025 and 2024
and inclusion of dilutive instruments would have an anti-dilutive effect.</span></p>

</ix:nonNumeric><p id="xdx_8A3_zCFUPMs9CN7f" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000991" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zYOM4SNbtj6i" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 13 &#8211; <span id="xdx_821_zS1RCCDP2ao8">Income Taxes</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The components of the provision for income taxes
were as follows:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000993" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zSlolKCSNVKe" summary="xdx: Disclosure - Income Taxes (Details - Provision for income taxes)" style="font: 10pt Arial, Helvetica, Sans-Serif, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; font-weight: 400; font-style: normal"><span id="xdx_8BE_z17siEj3VfHj" style="display: none">Schedule of provision for income taxes</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20250101__20251231_zOXxjZTzzVy2" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20240101__20241231_zm6eTh6hwpOc" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">Year
    Ended December 31,</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">2025</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">2024</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zp47PcoK83yj" style="vertical-align: bottom">
    <td style="font-weight: 400; font-style: normal"><span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif">Current:</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--CurrentFederalTaxExpenseBenefit_d0_zAWQxDmAgCH9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: 400; font-style: normal"><span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif">Federal</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact000998" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact000999" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_d0_zX7IUdAka1La" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 66%; font-weight: 400; font-style: normal"><span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif">State</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact001001" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact001002" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--CurrentForeignTaxExpenseBenefit_d0_z3sNsCXyXvja" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Foreign</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact001004" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">73,330</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact001005" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">90,434</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td></tr>
  <tr id="xdx_400_ecustom--CurrentIncomeTaxExpenseBenefits_d0_zeSEQn5bbZNc" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Total Current</span></td><td style="border-bottom: Black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(<ix:nonFraction name="SBFM:CurrentIncomeTaxExpenseBenefits" contextRef="From2025-01-01to2025-12-31" id="Fact001007" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">73,330</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td><td style="border-bottom: Black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(<ix:nonFraction name="SBFM:CurrentIncomeTaxExpenseBenefits" contextRef="From2024-01-012024-12-31" id="Fact001008" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">90,384</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--ComponentsOfDeferredTaxAssetsAbstract_iB_zhxWm94QytN5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: 400; font-style: normal"><span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif">Deferred:
    </span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_d0_zpRTBkbCCAw8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: 400; font-style: normal"><span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif">Federal</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact001013" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact001014" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_d0_zA2OB1a7umil" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: 400; font-style: normal"><span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif">State</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact001016" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact001017" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_zBz31bBeriqh" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Foreign</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact001019" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,939</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact001020" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">144,474</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_zMkegtqPYTm3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Total Deferred</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact001022" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,939</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact001023" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">144,474</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_z2C16lRLK7cf" style="vertical-align: bottom; background-color: White">
    <td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; font-weight: 400; font-style: normal; text-align: left; padding-bottom: 2.5pt"><span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif">Total
    Income Tax Expense / (Benefit)</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact001025" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,609</ix:nonFraction></span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8239;</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact001026" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">234,858</ix:nonFraction></span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_233_zJ2kSgmotMU5" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zQXCq5aunhN6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_z07VmnyubV4i" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 46 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zmQxtJOqOrUb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: normal 400 10pt Arial, Helvetica, Sans-Serif, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font: normal 400 10pt Arial, Helvetica, Sans-Serif">The
Company&#8217;s effective tax rate differs from the federal statutory rate as follows:</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001032" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zTmAjy5a8YKd" summary="xdx: Disclosure - Income Taxes (Details - Reconcilation of tax rate)" style="font: 10pt Arial, Helvetica, Sans-Serif, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B0_zNWpTBKDYc86" style="display: none">Schedule of income tax expense</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20250101__20251231_zrNuxyoK5bN1" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20240101__20241231_zFU0USJw6U14" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>Year Ended December 31, </b></span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></td><td colspan="5" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>2025</b></span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></td><td colspan="5" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>2024</b></span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_iN_di_msITEBzYLG_zFtvPdBPSJog" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 40%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Pre-Tax Book Income</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2025-01-01to2025-12-31" id="Fact001034" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,250,286</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right; width: 11%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_mataxrate_c20250101__20251231_zRkHIWzlSJlj" title="Pre-Tax Book Income, Rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2025-01-01to2025-12-31" id="Fact001037" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.00</ix:nonFraction></span>%&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right; width: 11%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2024-01-012024-12-31" id="Fact001035" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,121,714</ix:nonFraction></span></td><td style="text-align: left; width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right; width: 11%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_mataxrate_c20240101__20241231_z3jMSOJZlTR6" title="Pre-Tax Book Income, Rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-012024-12-31" id="Fact001039" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20.89</ix:nonFraction></span>%&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzYLG_z6Ud25g2ZyKb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">State and Local Income Taxes</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2025-01-01to2025-12-31" id="Fact001041" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,533</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_mataxrate_c20250101__20251231_zbEQIRyNVuIk" title="State Taxes, Rate">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2025-01-01to2025-12-31" id="Fact001044" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.75</ix:nonFraction></span>%)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-012024-12-31" id="Fact001042" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_mataxrate_c20240101__20241231_z0tOZ8ZIqWw1" title="State and Local Income Taxes, Rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-012024-12-31" id="Fact001046" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span>%&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory_maITEBzYLG_z28KOH3J5tX7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Effect of Rates Different than
    Statutory</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="SBFM:IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory" contextRef="From2025-01-01to2025-12-31" id="Fact001048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,341</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_902_ecustom--EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate_dp_mataxrate_c20250101__20251231_zP0lUII4to5f" title="Effect of Rates Different than Statutory, Rate">(<ix:nonFraction name="SBFM:EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate" contextRef="From2025-01-01to2025-12-31" id="Fact001051" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2.54</ix:nonFraction></span>%)</span></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="SBFM:IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory" contextRef="From2024-01-012024-12-31" id="Fact001049" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,181</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_907_ecustom--EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate_dp_mataxrate_c20240101__20241231_zRDxIr2Jtrt8" title="Effect of Rates Different than Statutory, Rate">(<ix:nonFraction name="SBFM:EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate" contextRef="From2024-01-012024-12-31" id="Fact001053" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">1.16</ix:nonFraction></span>%)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxReconciliationOtherForeignTaxes_d0_maITEBzYLG_zVnKryNCUFYe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Other Foreign Taxes</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="SBFM:IncomeTaxReconciliationOtherForeignTaxes" contextRef="From2025-01-01to2025-12-31" id="Fact001055" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_900_ecustom--EffectiveIncomeTaxRateReconciliationOtherForeignTaxes_dp_mataxrate_c20250101__20251231_zUrzTEU1Yw4l" title="State Taxes, Rate"><ix:nonFraction name="SBFM:EffectiveIncomeTaxRateReconciliationOtherForeignTaxes" contextRef="From2025-01-01to2025-12-31" id="Fact001058" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span>%&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(<ix:nonFraction name="SBFM:IncomeTaxReconciliationOtherForeignTaxes" contextRef="From2024-01-012024-12-31" id="Fact001056" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">119,181</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_902_ecustom--EffectiveIncomeTaxRateReconciliationOtherForeignTaxes_dp_mataxrate_c20240101__20241231_zAdyo88InPP9" title="Other Foreign Taxes, Rate"><ix:nonFraction name="SBFM:EffectiveIncomeTaxRateReconciliationOtherForeignTaxes" contextRef="From2024-01-012024-12-31" id="Fact001060" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.22</ix:nonFraction></span>%&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzYLG_zk77XgudRr45" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Permanent Adjustments</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="From2025-01-01to2025-12-31" id="Fact001062" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,987</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_dp_mataxrate_c20250101__20251231_zM923qvT7u55" title="Permanent Adjustments, Rate">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="From2025-01-01to2025-12-31" id="Fact001065" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.92</ix:nonFraction></span>%</span><span style="font-size: 9pt">)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="From2024-01-012024-12-31" id="Fact001063" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,092</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_dp_mataxrate_c20240101__20241231_zQnsZlYTq2i8" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="From2024-01-012024-12-31" id="Fact001066" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">1.04</ix:nonFraction></span><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">%)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzYLG_zUmJGP63IfH5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Change in Valuation Allowance</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2025-01-01to2025-12-31" id="Fact001068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,107,342</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_mataxrate_c20250101__20251231_zsD04FbHJr6f" title="Change in Valuation Allowance, Rate">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2025-01-01to2025-12-31" id="Fact001071" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">18.60</ix:nonFraction></span>%)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-012024-12-31" id="Fact001069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">569,920</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_mataxrate_c20240101__20241231_zwVv6mm2wQOe" title="Change in Valuation Allowance, Rate">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-012024-12-31" id="Fact001073" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">10.62</ix:nonFraction></span>%)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_d0_maITEBzYLG_zt1G3pOi6Eeb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Rate Change</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="From2025-01-01to2025-12-31" id="Fact001075" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_mataxrate_c20250101__20251231_zqndcwtTjTB" title="Rate Change, Rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="From2025-01-01to2025-12-31" id="Fact001078" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span>%&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="From2024-01-012024-12-31" id="Fact001076" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,237</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_mataxrate_c20240101__20241231_zuIZwvmx65D" title="Rate Change, Rate">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="From2024-01-012024-12-31" id="Fact001080" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2.78</ix:nonFraction></span>%)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_maITEBzYLG_zOGC9gT7DcM4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Prior Year True up</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="From2025-01-01to2025-12-31" id="Fact001082" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">86,308</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_mataxrate_c20250101__20251231_zR2fzaodesGl" title="Provision to Return Adjustments, Rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" contextRef="From2025-01-01to2025-12-31" id="Fact001085" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.45</ix:nonFraction></span>%&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="From2024-01-012024-12-31" id="Fact001083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,540</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_mataxrate_c20240101__20241231_zRuwRHMimiHh" title="Prior Year True up, Rate">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" contextRef="From2024-01-012024-12-31" id="Fact001087" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2.92</ix:nonFraction></span>%)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationOtherAdjustments_d0_maITEBzYLG_zA6W4drHzp4e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Other</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2025-01-01to2025-12-31" id="Fact001089" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp0_mataxrate_c20250101__20251231_zwfOu8U4fay7" title="Other Adjustments, Rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2025-01-01to2025-12-31" id="Fact001092" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8211;</ix:nonFraction></span>%&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2024-01-012024-12-31" id="Fact001090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,027</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_mataxrate_c20240101__20241231_zqGqjYo6fMk7" title="Other, Rate">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2024-01-012024-12-31" id="Fact001094" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.22</ix:nonFraction></span>%)</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_pp0p0_mtITEBzYLG_zaUaz0m7oDMd" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: right; padding-bottom: 2.5pt"><b style="display: none">Total</b><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact001096" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,609</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"> &#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_mttaxrate_c20250101__20251231_zLjVKxhpO4Wc" title="Total effective income tax rate, Rate">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2025-01-01to2025-12-31" id="Fact001099" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.36</ix:nonFraction></span>%)&#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact001097" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">234,858</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_mttaxrate_c20240101__20241231_znXbb0haqTy6" title="Total effective income tax rate, Rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2024-01-012024-12-31" id="Fact001101" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.37</ix:nonFraction></span>%&#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A6_zf9SNAK5SOCc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
components of the net deferred tax assets were as follows:</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001103" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zyfgIXjQsyG6" summary="xdx: Disclosure - Income Taxes (Details - Deferred taxes)" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BE_zGTqCJT2qOo7" style="display: none">Schedule of components of net deferred tax assets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20251231_zpE8XPcZsNDk" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20241231_zlfIv9iz8Auc" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">Year Ended December 31,</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&#160;</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredIncomeTaxesAbstract_iB_z3tOGuZyfitk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Deferred Tax Assets:</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zumjhyC9af99" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 66%; text-align: left"><span style="font-size: 9pt">Net Operating Loss, Credits and Carryforwards</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2025-12-31" id="Fact001108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,785,678</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact001109" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,460,638</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_d0_zC53hPzKoThc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Fixed Assets</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2025-12-31" id="Fact001111" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,818</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact001112" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_zINrGFdrD3j8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-size: 9pt">Intangibles</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2025-12-31" id="Fact001114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">622,658</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2024-12-31" id="Fact001115" format="ixt:numdotdecimal" decimals="0" unitRef="USD">614,734</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsResearchAndDevelopment_iI_zOzxtS8zokq9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Research and Development</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="SBFM:DeferredTaxAssetsResearchAndDevelopment" contextRef="AsOf2025-12-31" id="Fact001117" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,327</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="SBFM:DeferredTaxAssetsResearchAndDevelopment" contextRef="AsOf2024-12-31" id="Fact001118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,327</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsOther_iI_d0_z23gL0zjQm7c" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Other deferred tax assets</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2025-12-31" id="Fact001120" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2024-12-31" id="Fact001121" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,935</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_zAqY8dWeHgh2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Lease Liability</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="AsOf2025-12-31" id="Fact001123" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,232</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="AsOf2024-12-31" id="Fact001124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,407</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zF9fhMMOVcX8" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Valuation Allowance</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2025-12-31" id="Fact001126" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,445,713</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001127" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,967,294</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iI_d0_zWlV9hzfx5nj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">Total Deferred Tax Assets</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2025-12-31" id="Fact001129" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31" id="Fact001130" format="ixt:numdotdecimal" decimals="0" unitRef="USD">481,747</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_ziAh1nkWfpwb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Deferred Tax Liabilities:</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesOther_iI_d0_zqjk0J8O8p0b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Other deferred tax liabilities</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="AsOf2025-12-31" id="Fact001135" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="AsOf2024-12-31" id="Fact001136" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">67</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_di0_z98JcGBP3jWh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Fixed Assets</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="AsOf2025-12-31" id="Fact001138" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact001139" format="ixt:numdotdecimal" decimals="0" unitRef="USD">141,396</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di0_zh5BCO1c8kO3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-size: 9pt">Intangibles</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="AsOf2025-12-31" id="Fact001141" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="AsOf2024-12-31" id="Fact001142" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di0_zSMMie9sK3N6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Right-of-Use Assets</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="AsOf2025-12-31" id="Fact001144" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="AsOf2024-12-31" id="Fact001145" format="ixt:numdotdecimal" decimals="0" unitRef="USD">248,050</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxLiabilities_iNI_di0_z5MQhd60g1R5" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">Total Deferred Tax Liabilities</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2025-12-31" id="Fact001147" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2024-12-31" id="Fact001148" format="ixt:numdotdecimal" decimals="0" unitRef="USD">389,513</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredIncomeTaxesAndOtherAssetsNoncurrent_iI_d0_zadJx6S3mESd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">Net Deferred Tax Liability</span></td><td style="border-bottom: Black 2.5pt double"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" contextRef="AsOf2025-12-31" id="Fact001150" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact001151" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,234</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A3_zPggAiyFUOj9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<ix:exclude><p id="xdx_23A_zlszD0HQyULi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_233_zW6SMWspukc8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zrJbd20P5VAl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 47 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zfLc7VMJI2V" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">As
of December 31, 2025, the Company has federal, state, foreign and provincial net operating loss carryforwards of approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn6n6_c20251231_zGbcM7DUTP12" title="Federal net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2025-12-31" id="Fact001157" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">26</ix:nonFraction></span>
million, $<span id="xdx_901_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20251231_zLnKEUaF7xj4" title="State net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2025-12-31" id="Fact001159" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.1</ix:nonFraction></span> million, $<span id="xdx_906_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pn5n6_c20251231_zXl85m5cDOt" title="Foreign net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" contextRef="AsOf2025-12-31" id="Fact001161" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.3</ix:nonFraction></span> million, and $<span id="xdx_908_ecustom--DeferredTaxAssetsOperatingLossCarryforwardsProvincial_iI_pn5n6_c20251231_zep7R5qkfs63" title="Provincial net operating loss carryforwards"><ix:nonFraction name="SBFM:DeferredTaxAssetsOperatingLossCarryforwardsProvincial" contextRef="AsOf2025-12-31" id="Fact001163" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.3</ix:nonFraction></span> million, respectively. Of the federal net operating loss forwards, approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_pn5n6_c20251231_z5ewUNrOqC6j" title="Net operating loss carryforwards, subject to expiration"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" contextRef="AsOf2025-12-31" id="Fact001165" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">9.4</ix:nonFraction></span>
million have expiration dates from 2027 to 2037. The remainder can be carried forward indefinitely but limited to 80% of taxable
income. The foreign and provincial net operating loss carryforwards have a carryforward period of 20 years.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of a deferred tax asset
will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during
the periods in which those temporary differences are deductible. In making this determination, management considers all available positive
and negative evidence affecting specific deferred assets, including the Company's past and anticipated future performance, the reversal
of deferred tax liabilities, the length of carry&#173;back and carry-forward periods, and the implementation of the tax planning strategies.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Objective positive evidence is necessary to support a conclusion that a valuation allowance is not needed for all or a portion of deferred
tax assets when significant negative evidence exists. Cumulative losses in recent years are the most compelling form of negative evidence
considered by management in making this determination. For the years ended December 31, 2025 and 2024, management has determined that
based on all available evidence, a valuation allowance of $<span id="xdx_904_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_dxL_c20251231_zglVmE607M4e" title="Valuation allowance::XDX::8445713"><span style="-sec-ix-hidden: xdx2ixbrl1167">8.4</span></span> million and $<span id="xdx_904_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_dxL_c20241231_zwlfUzfonkV1" title="Valuation allowance::XDX::6967294"><span style="-sec-ix-hidden: xdx2ixbrl1169">7.0</span></span>, respectively is appropriate.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s evaluation of uncertain tax matters was performed for tax years ended through December 31, 2025. Generally, the Company
is subject to U.S. audit for the years ended December 31, 2024, 2023, and 2022 and may be subject to examination for amounts relating to
net operating loss carryforwards generated in periods prior to December 31, 2024. The company is subject to Canada audit for the years
ended December 31, 2024, 2023, 2022 and 2021 for Sunshine Biopharma Canada Inc and subject to Canada audit for the years ended December
31, 2024, 2023 and 2022 and June 30, 2022 for Nora Pharma Inc and may be subject to examination for amounts relating to net operating
loss carryforwards generated in periods prior to December 31, 2024.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On July 4, 2025, the One Big Beautiful Bill Act ("OBBBA") was enacted in the U.S. The OBBBA makes permanent key elements of the Tax Cuts
and Jobs Act, including 100% bonus depreciation, domestic research cost expensing, and the business interest expense limitation. ASC Topic
740, Income Taxes, requires the tax effects of changes in tax rates and laws to be recognized in the period in which the legislation is
enacted. Those effects, both current tax and deferred tax, are reported as part of continuing operations. The Company is currently assessing the impact of OBBBA on its Consolidated
Financial Statements but currently does not believe that the OBBBA will have a material impact on the Company's income tax expense.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001171" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_805_eus-gaap--LesseeOperatingLeasesTextBlock_ziG7oyeejZJ6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 14 &#8211;
<span id="xdx_82A_zNY5ZuryDKA3">Leases</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company has obligations as a lessee for office
space with initial non-cancellable terms in excess of one year. The Company classified the lease as an operating lease. The lease contains
a renewal option for a period of five years. Because the Company is certain to exercise the renewal option, the optional period is included
in determining the lease term, and associated payments under the renewal option are included in the lease payments. The Company&#8217;s
lease does not include termination options for either party to the lease or restrictive financial or other covenants. Payments due under
the lease contract include fixed payments plus a variable Payment. The Company&#8217;s office space lease requires it to make variable
payments for the Company&#8217;s proportionate share of building&#8217;s property taxes, insurance, and common area maintenance. These
variable lease payments are not included in lease payments used to determine lease liability and are recognized as variable costs when
incurred.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_236_zdkEz35Zvzt1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zmymMAdkXUd9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zsRA48HKxBg7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 48 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_z9sU7SQ3QTGj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Amounts reported on the balance sheet as of December
31, 2025 were as follows:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001177" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--LeaseCostTableTextBlock_zc5uTDlVwVO2" summary="xdx: Disclosure - Leases (Details - Lease information)" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_z8a10fbE4Kuk" style="display: none">Schedule of lease information</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%; text-align: left">Operating lease ROU asset</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_90A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20251231_znN516YrLZJb" title="Operating lease ROU asset"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-12-31" id="Fact001179" format="ixt:numdotdecimal" decimals="0" unitRef="USD">778,846</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating Lease liability - Short-term</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20251231_zMXZ6W1tW7o3" title="Operating Lease liability - Short-term"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-12-31" id="Fact001181" format="ixt:numdotdecimal" decimals="0" unitRef="USD">215,637</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liability - Long-term</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20251231_zHoAs1t7ojK8" title="Operating lease liability - Long-term"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-12-31" id="Fact001183" format="ixt:numdotdecimal" decimals="0" unitRef="USD">596,785</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Remaining lease term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20251231_zBrTXHZBaedd" title="Remaining lease term"><ix:nonNumeric contextRef="AsOf2025-12-31" format="ixt-sec:duryear" id="Fact001185" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">4</ix:nonNumeric>
                                            </span>years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20251231_zVqM28wFKSg5" title="Discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2025-12-31" id="Fact001187" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_z0CpgakbkrMe" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Amounts disclosed for ROU assets obtained in exchange
for lease obligations and reductions of ROU assets resulting from reductions of lease obligations include amounts reduced from the carrying
amount of ROU assets resulting from deferred rent.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Maturities of lease liabilities under non-cancellable
operating leases at December 31, 2025 are as follows:</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001189" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zbpnS8ofBPqj" summary="xdx: Disclosure - Leases (Details - Maturities of lease payments)" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BA_zXSZyhv1lWr4" style="display: none">Schedule of maturities of lease liabilities</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20251231_zx3GPLCsdNae" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zZNf4PRdSUIh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%; text-align: left">2026</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2025-12-31" id="Fact001191" format="ixt:numdotdecimal" decimals="0" unitRef="USD">215,637</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zU1z62k9eUm5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2025-12-31" id="Fact001193" format="ixt:numdotdecimal" decimals="0" unitRef="USD">204,428</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_zVnXlJT7ckKj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2025-12-31" id="Fact001195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">193,794</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_zMgDYshGGD1g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2025-12-31" id="Fact001197" format="ixt:numdotdecimal" decimals="0" unitRef="USD">183,705</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_zlXmjXveiLUj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Thereafter</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="SBFM:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" contextRef="AsOf2025-12-31" id="Fact001199" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,858</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001201" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_807_eus-gaap--SegmentReportingDisclosureTextBlock_zpkUJLDQCeZg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 15 &#8211; <span id="xdx_829_z1PD5yhen4h2">Segment
Reporting</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company operates as <span id="xdx_90D_eus-gaap--NumberOfOperatingSegments_dxH_uSegment_c20250101__20251231_zYmrM12qvzRf" title="Number of operating segments::XDX::1">one</span> operating segment,
which is also its <span id="xdx_90D_eus-gaap--NumberOfReportableSegments_dxH_uSegment_c20250101__20251231_zcP1UQUfp83e" title="Number of reportable segments::XDX::1">one</span> reportable segment, as the Chief Executive Officer, acting as the Chief Operating Decision Maker (&#8220;CODM&#8221;),
evaluates financial performance and allocates resources on a consolidated, enterprise-wide basis. The Company&#8217;s operations are
managed as an integrated pharmaceutical business focused on the research, development, and commercialization of prescription drugs and
supplements.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Although the Company conducts activities through
multiple legal entities &#8212; including Sunshine Biopharma Inc. (U.S.), Sunshine Biopharma Canada Inc. (Canada), and Nora Pharma Inc.
(Canada) &#8212; these entities operate under a unified management structure with shared economic characteristics, common product development
objectives, and centralized decision making. As such, they do not meet the criteria for separate operating segments under <i>ASC 280
&#8211; Segment Reporting</i>.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In accordance with <i>ASU 2023-07</i>, the Company
provides the following information regarding its single reportable segment:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Measure of Segment Profit (Loss): The CODM evaluates
performance using consolidated operating income (loss), which is consistent with the amounts presented in the accompanying consolidated
financial statements.</span></td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Significant Segment Expenses: Research and development
expenses, and supply chain costs, selling and marketing expenses, and general and administrative expenses are all incurred and reviewed
on a consolidated basis.</span></td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Other Segment Items: Interest income, interest
expense, foreign exchange gains and losses, and other non-operating items are also managed and reviewed on a consolidated basis.</span></td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Reconciliation: As the Company has only one reportable
segment, no additional reconciliation to consolidated totals is required beyond what is presented in the consolidated statements of operations.</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s operations are conducted primarily
in Canada and substantially all long-lived assets are located in this jurisdiction. Revenues are generated from customers located in Canada.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23C_z9VcnvYX5waj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zDN5EQNZp15j" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zFCR4arJDwtg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 49 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_z5AUcgxW87h9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001211" name="SBFM:ManagementAndDirectorCompensationTextBlock"><p id="xdx_80F_ecustom--ManagementAndDirectorCompensationTextBlock_zr12By3LXNae" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 16 &#8211;
<span id="xdx_82E_zN8xqraR0XQ7">Management and Director Compensation</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company paid its officers cash compensation
totaling $<span id="xdx_90A_eus-gaap--SalariesWagesAndOfficersCompensation_c20250101__20251231_z4PAnRiwzvof" title="Officers compensation"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2025-01-01to2025-12-31" id="Fact001213" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,425,942</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--SalariesWagesAndOfficersCompensation_c20240101__20241231_zv4d9zDbhIp3" title="Officers compensation"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2024-01-012024-12-31" id="Fact001215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,850,243</ix:nonFraction></span> for the years ended December 31, 2025 and 2024, respectively. Of these amounts attributable to the
Company&#8217;s CEO, $<span id="xdx_902_eus-gaap--SalariesWagesAndOfficersCompensation_c20250101__20251231__custom--RelatedPartyTransactionsByRelatedPartyAxis__custom--AdvanomicsCorporationMember_zxq9MLmBdXe2" title="Officers compensation"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2025-01-012025-12-31_custom_AdvanomicsCorporationMember" id="Fact001217" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--SalariesWagesAndOfficersCompensation_c20240101__20241231__custom--RelatedPartyTransactionsByRelatedPartyAxis__custom--AdvanomicsCorporationMember_zYPQLvDpSqH" title="Officers compensation"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2024-01-012024-12-31_custom_AdvanomicsCorporationMember" id="Fact001219" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800,000</ix:nonFraction></span>, respectively was paid to Advanomics Corporation, a company controlled by the CEO of the Company.
In addition, the Company&#8217;s CEO was paid $12,000 in 2024 through the issuance of 120,000 shares of Series B Preferred Stock valued
at $12,000.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company paid its five directors cash compensation
of $80,000 each, totaling $<span id="xdx_907_eus-gaap--NoninterestExpenseDirectorsFees_c20250101__20251231_zpBJvn9CC8ki" title="Directors compensation"><span id="xdx_90F_eus-gaap--NoninterestExpenseDirectorsFees_c20240101__20241231_zZ6M8ehV1rYd" title="Directors compensation"><ix:nonFraction name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="From2025-01-01to2025-12-31" id="Fact001221" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:NoninterestExpenseDirectorsFees" contextRef="From2024-01-012024-12-31" id="Fact001223" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,000</ix:nonFraction></ix:nonFraction></span></span> for each of the years ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001225" name="us-gaap:LegalMattersAndContingenciesTextBlock"><p id="xdx_80A_eus-gaap--LegalMattersAndContingenciesTextBlock_zFb4Kc5Apiod" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 17 &#8211;
<span id="xdx_821_z30YGgVgpD5e">Legal Matters</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
                                            April 14, 2025, the Company terminated the employment of Mr. Malek Chamoun, president of
                                            the Company&#8217;s wholly owned Canadian subsidiary, Nora Pharma. On April 17, 2025, the
                                            Company received a demand letter (the &#8220;Demand Letter&#8221;) from the attorneys of
                                            Mr. Chamoun requesting that the Company pay to Mr. Chamoun $7,307,025 CAD (approximately
                                            $5,300,000 USD) within five (5) days. In response to the Demand Letter, the Company issued
                                            a letter on May 1, 2025 advising that the demands contained in the Demand Letter, including
                                            the sum of $7,307,025 CAD (approximately $5,300,000 USD), are completely unfounded and that
                                            it intends to defend itself vigorously. No provision or accrual was made in the financial
                                            statements for any litigation liability or legal expense which the Company may incur in connection
                                            with this alleged claim.</span></p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001227" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_zswwIHfzg0ah" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 18 &#8211;
<span id="xdx_821_z5DPDOoBmWii">Subsequent Events</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
                                            January 16, 2026, the Company received a demand letter from the attorneys of Mr. Andrew Telsey,
                                            the Company&#8217;s former legal counsel, asserting that the Company and Mr. Telsey executed
                                            an employment agreement and demanding payment of $3,645,750 from the Company based on the
                                            Company&#8217;s alleged termination of the purported employment agreement without cause.
                                            The Company believes this demand is without merit and has never executed an employment agreement
                                            with Mr. Telsey. On that basis, among other factors, the Company filed a complaint against
                                            Mr. Telsey on February 6, 2026 in the circuit court of the 7<sup>th</sup> judicial district
                                            in Broward County, Florida seeking a declaratory judgment providing that (i) the purported
                                            employment agreement is of no legal effect and is not binding upon the Company, (ii) no monies
                                            are owed by the Company to Mr. Telsey under the purported employment agreement, (iii) the
                                            Company should be awarded its attorney&#8217;s fees and costs, and (iv) the Company should
                                            be awarded such other relief as the court deems just and proper. On March 30, 2026, the court granted the Company&#8217;s motion for entry of default and entered a default and
final judgment in favor of the Company. Pursuant to the court&#8217;s order, the court declared that the purported employment agreement
is of no legal effect and not binding on the Company, because the Company never executed the agreement, the Company did not breach the
purported employment agreement, and no monies are owed by the Company to Mr. Telsey under the purported employment agreement. The court
retained jurisdiction on the issues of entitlement and amount of attorney&#8217;s fees and costs to the Company as the prevailing party. </span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><p id="xdx_814_zyLFyMIgW6n2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 50 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span id="a_024"></span><b>ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">None.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span id="a_025"></span><b>ITEM 9A. CONTROLS AND PROCEDURES</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Disclosure Controls and Procedures</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our management, with the participation of our Chief
Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term
is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">These controls are designed to ensure that information
required to be disclosed in the reports we file or submit pursuant to the Exchange Act is recorded, processed, summarized and reported
within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated
and communicated to our management, including our CEO and CFO, to allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Based on this evaluation, our management, including
our CEO and CFO concluded that our disclosure controls and procedures were effective as of December 31, 2025, at reasonable assurance
levels.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><span id="a_026"></span><b>Management&#8217;s Annual Report
on Internal Control Over Financial Reporting</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our management is responsible for establishing
and maintaining adequate &#8220;internal control over financial reporting,&#8221; as defined in Rule 13a-15(f) and 15d-15(f) under the
Exchange Act. Our system of internal control over financial reporting is a process designed to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of consolidated financial statements for external reporting purposes in accordance
with US GAAP.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our internal control over financial reporting includes
those policies and procedures that: (a) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect
the transactions and dispositions of our assets; (b) provide reasonable assurance that transactions are recorded as necessary to permit
preparation of consolidated financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only
in accordance with authorizations of our management and directors; and (c) provide reasonable assurance regarding prevention or timely
detection of unauthorized use, acquisition, or disposition of our assets that could have a material effect on the consolidated financial
statements.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our management, with the participation of our Chief
Executive Officer and Chief Financial Officer, evaluated the effectiveness of our internal control over financial reporting as of December
31, 2025, and they concluded that our internal control over financial reporting was effective as of December 31, 2025. In making this
assessment, we utilized the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;)
in Internal Control &#8212; Integrated Framework (2013).</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 51 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="border-bottom: Black 1pt solid; vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>No Attestation Report by Independent
Registered Accountant</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The effectiveness of our internal control over
financial reporting as of December 31, 2025, has not been audited by our independent registered public accounting firm by virtue of our
exemption from such requirement as a smaller reporting company.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Changes in Internal Controls
over Financial Reporting</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">There were no changes in our internal control over
financial reporting during the three months ended December 31, 2025.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span id="a_034"></span><b>ITEM 9B. OTHER INFORMATION</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">During the quarter ended December 31, 2025, no
director or officer of the Company <span id="xdx_909_eecd--Rule10b51ArrAdoptedFlag_dbF_c20251001__20251231_z9mZ9i6MDoE2" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_901_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20251001__20251231_zkKNtZQGU1q2" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-10-012025-12-31" format="ixt:booleanfalse" id="Fact001228" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2025-10-012025-12-31" format="ixt:booleanfalse" id="Fact001229" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span> or <span id="xdx_903_eecd--Rule10b51ArrTrmntdFlag_dbF_c20251001__20251231_zt7Qeu0balXf" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90D_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20251001__20251231_zgyXy48gIDdj" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-10-012025-12-31" format="ixt:booleanfalse" id="Fact001230" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2025-10-012025-12-31" format="ixt:booleanfalse" id="Fact001231" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span> a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading
arrangement,&#8221; as each term is defined in Item 408(a) of Regulation S-K.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span id="a_035"></span><b>ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT
INSPECTIONS</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Not applicable.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 52 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #00487F"><span id="a_027"></span><b>PART III</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span id="a_028"></span><b>ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Directors and Officers</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The following individuals currently serve as our Board of Directors
and executive officers.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; width: 23%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 1%">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; width: 5%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 1%">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; width: 70%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Position(s)</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Dr. Steve N. Slilaty</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">73</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">President, Chief Executive
    Officer and Chairman of the Board</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Mr. Camille Sebaaly</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">64</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Chief Financial Officer,
    Director and Secretary</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Dr. Rabi Kiderchah</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">53</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Director</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Mr. David Natan</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">72</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Director</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Dr. Andrew Keller</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">72</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Director</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Mr.
    Michel Roy</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">58</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Chief
    Commercial Officer</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b><i>Dr.
Steve N. Slilaty</i></b> was appointed as our chief executive officer and chairman of our board of directors on October 15, 2009. Dr.
Slilaty is an accomplished scientist and business executive. His scientific publications are widely cited. Sunshine Biopharma is the
third in a line of biotechnology companies that Dr. Slilaty founded and managed. The first, <i>Quantum Biotechnologies Inc.</i> later
known as <i>Qbiogene Inc.</i>, was founded in 1991 and is now a member of a family of companies owned by <i>MP Biomedicals</i>, a global
life science company headquartered in Santa Ana, California. The second company which Dr. Slilaty founded, <i>Genomics One Corporation</i>,
conducted an initial public offering of its capital stock in 1999 and, on the basis of its ownership of Dr. Slilaty&#8217;s patented
TrueBlue&#174; Technology, <i>Genomics One</i> became one of the key participants in the Human Genome Project and reached a market capitalization
of $1 billion in 2000. Formerly, Dr. Slilaty was a research team leader at the <i>Biotechnology Research Institute (Montreal)</i>, a
division of the <i>National Research Council of Canada</i>. Dr. Slilaty is one of the pioneers of Gene Therapy having developed the first
gene delivery system applicable to humans in 1983 [<i>Science <b>220:</b> 725-727 (1983)</i>]. Dr. Slilaty's other distinguished scientific
career accomplishments included (i) the discovery of a new class of enzymes, the S24 Family of Proteases (IUBMB Enzyme: EC 3.4.21.88)
[<i>Proc. Natl. Acad. Sci. U.S.A. <b>84:</b> 3987-3991 (1987)</i>]. In addition, Dr. Slilaty (i) developed the first site-directed mutagenesis
system applicable to double-stranded DNA [<i>Analyt. Biochem. <b>185:</b> 194-200 (1990)</i>], (ii) cloned the gene for the first yeast-lytic
enzyme (lytic b-1,3-glucanase) [<i>J. Biol. Chem. <b>266:</b> 1058-1063 (1991)</i>], (iii) developed a new molecular strategy for increasing
the rate of enzyme reactions [<i>Protein Engineering <b>4:</b> 919-922 (1991)</i>], and (iv) constructed a powerful new cloning system
for genomic sequencing (TrueBlue&#174; Technology) [<i>Gene <b>213:</b> 83-91 (1998)</i>]. Most recently, Dr. Slilaty helped a team of
researchers at the University of Arizona in the design and testing of a novel series of Coronavirus PLpro inhibitors [<i>J. Med. Chem.
2024, <b>67:</b> 13681&#8722;13702</i>]. Additional works of Dr. Slilaty in the area of PLpro inhibitors has recently been submitted
for publication [<i>J. Med. Chem. In press</i>]. <i>These</i> and other works of Dr. Slilaty are cited in research papers, editorials,
review articles and textbooks. Dr. Slilaty is the author of 20 original research papers and 12 issued and pending. These and other works
of Dr. Slilaty are cited in research papers, editorials, review articles and textbooks. Dr. Slilaty received his Ph.D. degree in Molecular
Biology from the University of Arizona in 1983 and Bachelor of Science degree in Genetics and Biochemistry from Cornell University in
1976. Dr. Slilaty has received research grants from the NIH and NSF and he is the recipient of the 1981 University of Arizona Foundation
award for Meritorious Performance in Teaching</span>. Dr. Slilaty&#8217;s scientific and executive experience qualify him to serve on
our board of directors.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 53 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b><i>Mr. Camille Sebaaly</i></b> was
appointed as our chief financial officer, secretary and a director of our Company on October 15, 2009. He resigned as a director of
the Company in October 2021. Mr. Sebaaly held a number of senior executive positions in various areas including financial
management, business development, project management and finance. As an executive and an entrepreneur, he combines expertise in
strategic planning and finance with strong skills in business development and deal structure and negotiations. In addition, Mr.
Sebaaly worked in operations, general management, investor relations, marketing and business development with emphasis on
international business and marketing of advanced technologies including hydrogen generation and energy saving. In the area of
marketing, Mr. Sebaaly has evaluated market demands and opportunities, created strategic marketing and business development plans,
designed marketing communications and launched market penetration programs. Mr. Sebaaly graduated from State University of New York
at Buffalo with an Electrical and Computer Engineering Degree in 1987. Mr. Sebaaly&#8217;s technical and business experience qualify him to
serve on our board of directors.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b><i>Dr. Rabi Kiderchah </i></b>has served as
a director of our Company since October 2021. Dr. Kiderchah is a licensed physician in Canada. From 2000 until August 2021, he was working
at Argenteuil Hospital, Lachute, Quebec, Canada, as an emergency room physician. He has also worked as what is referred to in Canada as
a &#8220;medecins depanneurs&#8221;, working in rural areas where there are not enough ER doctors. Since August 2011 he has worked at
Rabi Kiderchah Medecin Inc. as a freelance physician in the Quebec, Canada area. He received a Bachelor of Science degree in 1994 and
an MD degree in 1998 from the University of Montreal. Dr. Kidercha&#8217;s medical knowledge and experience qualify him to
serve on our board of directors.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b><i>Mr.
                                            David Natan </i></b> <span style="background-color: white">currently serves as President and
                                            Chief Executive Officer of Natan &amp; Associates, LLC, a financial consulting firm offering
                                            chief financial officer services to public and private companies in a variety of industries,
                                            both domestically and internationally, since 2007. From 2010 to May&#160;2020, Mr.&#160;Natan
                                            served as Chief Executive Officer of ForceField Energy, Inc. (OTCMKTS: FNRG), a company focused
                                            on the solar industry and LED lighting products. From February&#160;2002 to November&#160;2007,
                                            Mr. Natan served as Executive Vice President of Reporting and Chief Financial Officer
                                            of PharmaNet Development Group, Inc., a drug development services and clinical trials company,
                                            and, from June&#160;1995 to February 2002, as Chief Financial Officer and Vice President
                                            of Global Technovations, Inc., a manufacturer and marketer of oil analysis instruments and
                                            speakers and speaker components. Before that, Mr.&#160;Natan served various roles in increasing
                                            responsibility with Deloitte &amp; Touche LLP, a global accounting and consulting firm. Mr.&#160;Natan
                                            currently serves as a member of the Board of Directors and Chair of the Audit Committees
                                            of Sow Good Inc. (Nasdaq: SOWG), a candy distributor, and Indaptus Therapuetics (Nasdaq:
                                            INDP), since December 2025. Additionally, since April 2025, Mr. Natan has served as a member
                                            of the Board of Directors and Audit Committee Chair of FIEE, Inc., a technology company specializing
                                            in SAAS solutions and AI software development. Previously, Mr.&#160;Natan has served as a
                                            director for the following public companies: Global Technovations, Forcefield Energy, Black
                                            Titan (Nasdaq: BTTC), Vivakor Inc. (Nasdaq: VIVK), NetBrands Corp. (OTC: NBND), OpGen Inc.
                                            (OTC: OPGN), and Bio Green Med Solutions (Nasdaq: BGMS). Mr.&#160;Natan is a CPA (inactive),
                                            holds a B.A. in Economics from Boston University, and was appointed to Omicron Delta Epsilon,
                                            an international honor society in the field of Economics.&#160;</span>Mr. Natan&#8217;s financial
                                            knowledge and experience qualify him to serve on our board of directors.</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b><i>Dr. Andrew M. Keller </i></b>has served as
a director of our Company since February 2022. From 2016 through November 2019, Dr. Keller was the Chief Medical Officer at the Western
Connecticut Medical Group, Bethel CT, a multispecialty organization. He was employed by this group beginning in 1989, and in 2003 became
Chief &#8211; Section of Cardiovascular Diseases. In 2014 he was appointed Chief Medical Informatics Officer. Previously, Dr. Keller was
an Assistant Professor of Medicine/Radiology at Columbia University, The College of Physicians and Surgeons, NY, NY. Dr. Keller retired
as a practicing physician in 2019. Upon his retirement as a practicing physician Dr. Keller enrolled as a full-time student at Quinnipiac
University College of Law, where he graduated with a Juris Doctor degree in 2023. In July 2023, Dr. Keller passed the Bar exam and was
admitted to practice law in the State of Connecticut in November 2023. Since November 2023 he has been employed at the Law Office of Robin
P. Keller LLC, Norwalk, CT advocating for the educational needs of disabled children with medically complex diagnoses. Dr. Keller received
a Doctor of Medicine degree in 1979 from The Ohio State University and a Bachelor of Arts degree in Physics, Magna Cum Laude from Ithaca
College in 1975. Dr. Keller&#8217;s medical knowledge and experience qualify him to
serve on our board of directors.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b><i>Mr. Michel Roy</i></b> was appointed as our
Chief Commercial Officer in January 2025. Mr. has held various leadership roles in business development, licensing, sales and operations
management in various pharmaceutical companies. From July 2020 to November 2024, Mr. Roy founded and led the Canadian operations of Shilpa
Medicare Ltd., a large multinational pharmaceutical company headquartered in Karnataka, India. From 2014 to June 2020, Mr. Roy was Vice
President, Business Development and Sales for Intas Pharmaceuticals Ltd., a major pharmaceutical company having its head office in Ahmedabad
(India) with a strong presence in over 85 countries. During his tenure at Intas, Mr. Roy was responsible for strategic planning, business
development, sales, financial management, and regulatory affairs. At the beginning of his career, he worked as a consultant and had positions
with various international Contract Research Organization companies. Mr. Roy received his Executive Master of Business Administration
(EMBA) at John Molson School of Business in 2010 and his Master of Science (M.Sc.) at Universit&#233; de Montr&#233;al in 1999. He
also received a Bachelor of Commerce, Major in Economics, at Concordia University in 1990.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 54 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Corporate Governance</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>Board of Directors Term of
Office</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Directors are elected at our annual meeting of
shareholders and serve for one year until the next annual meeting of shareholders or until their successors are elected and qualified.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>Committees of our Board of
Directors</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We have established an audit committee, a compensation
committee, and a corporate governance and nominating committee of our board of directors. Each committee is comprised of each of our independent
directors. David Natan is our audit committee financial expert.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>No Family Relationships</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">There is no family relationship between any director
and executive officer or among any directors or executive officers.&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>Involvement in Certain Legal
Proceedings</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our directors and executive officers have not been
involved in any of the following events during the past ten years:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">any bankruptcy petition filed by or against such person or any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from or otherwise limiting his involvement in any type of business, securities or banking activities or to be associated with any person practicing in banking or securities activities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">being found by a court of competent jurisdiction in a civil action, the SEC or the CFTC to have violated a Federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">being subject of, or a party to, any Federal or state judicial or administrative order, judgment decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of any Federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">being subject of or party to any sanction or order, not subsequently reversed, suspended, or vacated, of any self-regulatory organization, any registered entity or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 55 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>Code of Ethics</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We have adopted a Code of Ethics that applies to
our principal executive officer, principal financial officer, and principal accounting officer. Our Code of Ethics is available on our
website at www.sunshinebiopharma.com.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><i>Insider Trading Policy</i></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We have <span id="xdx_90C_eecd--InsiderTrdPoliciesProcAdoptedFlag_dbT_c20250101__20251231_zsdOzSHBy0J6" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBQb2xpY2llcyBhbmQgUHJvY2VkdXJlcwA_"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact001232" name="ecd:InsiderTrdPoliciesProcAdoptedFlag">adopted</ix:nonNumeric></span> an insider trading policy governing
the purchase, sale, and other dispositions of our securities by directors, senior management, and employees. A copy of the Insider Trading
Policy has been incorporated by reference as an exhibit to this report.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span id="a_029"></span><b>ITEM 11. EXECUTIVE COMPENSATION</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The following table sets forth compensation information
for services rendered by our executive officers in all capacities during the last two completed fiscal years.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Name and Principal Position</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td colspan="2" style="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Year</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td colspan="2" style="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Salary ($)</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td colspan="2" style="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Bonus ($)</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td colspan="2" style="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Options ($)</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td colspan="2" style="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Other ($)</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td colspan="2" style="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Total ($)</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 34%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Dr. Steve N. Slilaty</b></span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 8%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">2024</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 8%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">411,587</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 8%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">800,000</span></td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">*</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 8%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 8%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 8%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1,211,587</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Chief Executive Officer and Director</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">2025</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">465,953</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">--</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">465,953</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Camille Sebaaly</b></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">2024</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">302,031</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">50,000</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">352,031</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Chief Financial Officer and Director</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">2025</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">412,278</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">--</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">412,278</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Dr. Abderrazzak Merzouki**</b></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">2024</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">241,625</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">45,000</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">286,625</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Former Chief Operating Officer</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">2025</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">264,545</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">--</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">264,545</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Mr. Michel Roy</b></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">2024</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Chief Commercial
    Officer</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">2025</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">283,166</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">--</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">--</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">--</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">283,166</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">* This amount was paid to
    Advanomics Corporation, a company controlled by Dr. Slilaty.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 8pt">** Dr. Merzouki resigned as chief operating officer on February 5, 2026.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We have not granted stock options or stock appreciation rights (&#8220;SARs&#8221;) to any of our executive officers during the last fiscal
year or in prior years. <span id="xdx_905_eecd--AwardTmgMnpiDiscTextBlock_c20250101__20251231_zE38kZBIon12"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001233" name="ecd:AwardTmgMnpiDiscTextBlock">We do not maintain any policies or practices regarding the timing of option or SAR grants in relation to the disclosure
of material nonpublic information because we do not utilize these forms of compensation and we do not currently anticipate granting stock
options or SARs in the foreseeable future.</ix:nonNumeric></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Because we did not grant any stock options or SARs during the applicable period, no Item 402(x)
tabular disclosure is required or provided in this report.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 56 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Employment Agreements</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On October 21, 2024, we entered into an amended
employment agreement with Dr. Steve N. Slilaty, our Chief Executive Officer. Pursuant to the amended employment agreement, deemed effective
January 1, 2024, Dr. Slilaty will continue to serve as our CEO, and will also serve as the chief executive officer of our wholly-owned
subsidiary, Nora Pharma. Dr. Slilaty will receive an annual base salary of $386,000, which will increase annually in the amount of 5%
or the change in the U.S. Consumer Price Index, whichever is greater. Dr. Slilaty will also be entitled to an annual bonus in an amount
to be determined by our board of directors. The agreement has an indefinite term. If the agreement is terminated by us &#8220;without
cause&#8221;, or by Dr. Slilaty for &#8220;good reason&#8221; (each as defined in the agreement), Dr. Slilaty will be entitled to a severance
payment of $14 million. In the event the employment agreement is terminated for other reasons, we will pay Dr. Slilaty $3 million.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white">On October 21, 2024,
we entered into an employment agreement with Mr. Camille Sebaaly, our Chief Financial Officer. Pursuant to the employment agreement, deemed
effective January 1, 2024, Mr. Sebaaly will continue to serve as our Chief Financial Officer and will also serve as Secretary of Nora
Pharma. Mr. Sebaaly will receive an annual base salary of $411,000 CAD (approximately $287,700 USD), which will increase annually in the
minimum amount of 5% or the change in the U.S. Consumer Price Index, whichever is greater. Mr. Sebaaly will also be entitled to an annual
bonus in an amount to be determined by our Board of Directors. The employment agreement has an indefinite term. If the employment agreement
is terminated by us without cause, Mr. Sebaaly will be entitled to a severance payment of $2 million CAD (approximately $1.4 million USD).</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white">On January 13, 2025,
we appointed Mr. Michel Roy as our Chief Commercial Officer, and in connection therewith, entered into an employment agreement with Mr.
Roy. Pursuant to the employment agreement, Mr. Roy will receive an initial annual base salary of $400,000 CAD (approximately $280,000
USD), which will increase annually by the greater of 5% or the increase in the U.S. Consumer Price Index. In the event we terminate Mr.
Roy&#8217;s employment without cause, Mr. Roy will receive a severance payment of $500,000 CAD (approximately $350,000 USD), plus the
minimum notice of termination (or compensation in lieu thereof) to which he would be entitled under applicable law. The employment agreement
has an indefinite term.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Outstanding Equity Awards at
2025 Fiscal Year-End</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We did not have any outstanding equity awards as
of December 31, 2025.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 57 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Director Compensation</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The following table sets forth the compensation
we paid to our directors for services as director during the years ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td colspan="2" style="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Cash ($)</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td colspan="2" style="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Options ($)</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td colspan="2" style="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Other ($)</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td colspan="2" style="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Total ($)</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 48%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Dr. Andrew Keller</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 10%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">80,000</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 10%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 10%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 10%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">80,000</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Dr. Rabi Kiderchah</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">80,000</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">80,000</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Dr. Abderrazzak Merzouki</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">80,000</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">80,000</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Mr. David Natan</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">80,000</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">80,000</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Dr. Steve N. Slilaty</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">80,000</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">80,000</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span id="a_030"></span><b>ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
AND RELATED STOCKHOLDER MATTERS</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The following table sets forth certain
information, as of April 2, 2026, with respect to the beneficial ownership of the outstanding common stock and Series B Preferred
Stock by (i) any holder of more than five (5%) percent; (ii) each of our executive officers and directors; and (iii) our directors
and executive officers as a group.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We have determined beneficial ownership in
accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole
or shared voting power or investment power with respect to those securities. The table lists applicable percentage ownership based
on 4,905,945 shares of common stock and 130,000 shares of Series B Preferred Stock outstanding as of April 2, 2026. In addition,
under SEC rules, beneficial ownership of common stock includes shares of our common stock issuable pursuant to the conversion or
exercise of securities that are either immediately exercisable or convertible into common stock or exercisable or convertible into
common stock within 60 days of April 2, 2026. These shares are deemed to be outstanding and beneficially owned by the person holding
those securities for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for
the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the persons or entities
identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them,
subject to applicable community property laws.&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 58 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Title of Class</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Name and Address of Beneficial Owner</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td colspan="2" style="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Amount</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td colspan="2" style="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Percent of Class </b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; width: 18%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Common</b></span></td>
    <td style="vertical-align: top; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top; width: 45%"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-size: 9pt">Dr.
                                            Steve N. Slilaty<sup>(1)</sup></span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-size: 9pt">c/o Sunshine Biopharma Inc.</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-size: 9pt">333 Las Olas Way, CU4 Suite 433</span></p></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 14%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 14%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; width: 2%"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Fort Lauderdale, FL 33301</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1,911</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><sup>(3)</sup>&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">*</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Series B Preferred</b></span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">130,000</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><sup>(2)</sup>&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">100%</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Common</b></span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-size: 9pt">Camille
                                    Sebaaly<sup>(1)</sup></span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-size: 9pt">c/o Sunshine Biopharma Inc.</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-size: 9pt">333 Las Olas Way, CU4 Suite 433</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-size: 9pt">Fort Lauderdale, FL 33301</span></p></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">60</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">*</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Common</b></span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-size: 9pt">Dr.
                                    Andrew Keller<sup>(1)</sup></span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-size: 9pt">c/o Sunshine Biopharma Inc.<br/>
    333 Las Olas Way, CU4 Suite 433<br/>
    Fort Lauderdale, FL 33301</span></p></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">0</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">*</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Common</b></span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Mr. David Natan<sup>(1)</sup><br/>
    c/o Sunshine Biopharma Inc. <br/>
    333 Las Olas Way, CU4 Suite 433<br/>
    Fort Lauderdale, FL 33301</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">0</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">*</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Common</b></span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Dr. Rabi Kiderchah<sup>(1)</sup><br/>
    c/o Sunshine Biopharma Inc. <br/>
    333 Las Olas Way, CU4 Suite 433<br/>
    Fort Lauderdale, FL 33301</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">*</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Common</b></span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-size: 9pt">Mr.
                                    Michel Roy<sup>(1)</sup></span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-size: 9pt">c/o Sunshine Biopharma Inc.<br/>
    333 Las Olas Way, CU4 Suite 433</span></p></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Fort Lauderdale, FL 33301</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">*</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">All Officers and Directors
    as Group (6 persons)</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1,973</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">*</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="border-bottom: Black 1pt solid; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Common</b></span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: top"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Intracoastal Capital LLC<sup>(4)</sup></span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">544,500</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">9.99%</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-size: 8pt">* Less than 1%.</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 18px"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><sup>(1)</sup></span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Officer and/or director of our Company.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><sup>(2)</sup></span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Each share of Series B Preferred
    Stock gives the holder the right to 1,000 votes per share.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><sup>(3)</sup></span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Includes (i) 2 shares owned
    by Advanomics Corporation, a company controlled by Dr. Slilaty and (ii) 1,850 shares owned by Malek Chamoun which Dr. Slilaty controls
    through a voting agreement dated October 20, 2022.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><sup>(4)</sup></span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Represents shares of common
    stock issuable upon exercise of a warrant (the &#8220;Intracoastal Warrant&#8221;) held by Intracoastal Capital LLC ("Intracoastal"),
    and all such shares represent beneficial ownership of approximately 9.99% of the common stock, based on (1) 4,905,945 shares of common
    stock outstanding, plus (2) 544,500 shares issuable upon exercise of the Intracoastal Warrant. Based on Schedule 13G filed with the
    SEC on May 23, 2025, such shares may be deemed beneficially owned by Intracoastal, Mitchell P. Kopin and Daniel B. Asher (the &#8220;Reporting
    Persons&#8221;).The foregoing excludes 1,882,009 shares of common stock issuable upon exercise of the Intracoastal Warrant because
    the Intracoastal Warrant contains a blocker provision under which the holder thereof does not have the right to exercise the Intracoastal
    Warrant to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together
    with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates,
    of more than 9.99% of the common stock. Without such blocker provision, each of the Reporting Persons may have been deemed to have
    beneficial ownership of 2,426,509 shares of common stock. The address of the stockholder is 245 Palm Trail, Delray Beach, Florida
    33483.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 59 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span id="a_031"></span><b>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Related Transactions</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On February 8, 2024, we sold 20,000 shares of Series
B Preferred Stock to Dr. Slilaty for a purchase price equal to the stated value of $0.10 per share.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On March 4, 2024, we sold 100,000 shares of Series
B Preferred Stock to Dr. Slilaty for a purchase price equal to the stated value of $0.10 per share.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Director Independence</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our independent directors consist of Dr. Kiderchah,
Mr. Natan and Dr. Keller.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span id="a_032"></span><b>ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The amounts presented in the following table represent
fees billed by the Company&#8217;s independent registered public accounting firm during each fiscal year, regardless of the period in
which the related services were performed. Fees are categorized in accordance with SEC rules as Audit Fees, Audit-Related Fees, Tax Fees,
and All Other Fees. Audit Fees include the audit of the Company&#8217;s annual financial statements, reviews of interim financial statements,
and services normally provided in connection with statutory and regulatory filings. Audit-Related Fees consist of assurance and related
services that are reasonably related to the performance of the audit or review of the Company&#8217;s financial statements but are not
reported as Audit Fees. Tax Fees include tax compliance, tax planning, and tax advisory services. All Other Fees include permissible advisory
services and access to accounting research tools:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">Fiscal Years Ended December 31,</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&#160;</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left"><span style="font-size: 9pt">Audit Fees &#8211; M&amp;K</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">119,909</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Audit Fees &#8211; Bush &amp; Associates</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">180,863</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">339,000</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Audit Fees &#8211; Borgers</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">225,500</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Audit-Related Fees &#8211; M&amp;K</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-left: 10pt; text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Audit-Related Fees &#8211; Bush &amp; Associates</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Audit-Related Fees &#8211; Borgers</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">110,000</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Tax Fees &#8211; M&amp;K</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Tax Fees &#8211; Bush &amp; Associates</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Tax Fees &#8211; Borgers</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">All Other Fees &#8211; M&amp;K</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-left: 10pt; text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">All Other Fees &#8211; Bush &amp; Associates</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">All Other Fees &#8211; Borgers</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Total &#8211; M&amp;K</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">119,909</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Total &#8211; Bush &amp; Associates</span></td><td style="text-align: right"/>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">180,863</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"/>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">339,000</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">Total &#8211; Borgers</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"/>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"/>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">335,500</span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 60 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #00487F"><b><span id="a_033"></span>PART IV</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span id="a_036"></span><b>ITEM 15. EXHIBITS</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 10%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3.1</span></td>
    <td style="vertical-align: bottom; width: 90%; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000107997407000547/mountainwsb2ex31_10182007.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Articles of Incorporation</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(2)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3.2</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000101359609000030/exh3-3.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Certificate of Amendment to Articles of Incorporation filed November 2, 2009</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(3)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3.3</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000101359610000075/exh3-4.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Statement of Share and Equity Capital Exchange</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(4)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3.4</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000101359610000075/exh3-5.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Articles of Amendment to Articles of Incorporation filed July 13, 2010</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(4)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3.5</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000135448815002794/sbfm_ex35.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Articles of Amendment to Articles of Incorporation filed May 27, 2015</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(5)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3.6 </span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000165495420006915/sbfm_ex36.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Articles of Amendment to Articles of Incorporation</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(6)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3.7 </span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000168316822000809/sunshine_ex0307.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Articles of Amendment to Articles of Incorporation</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(7)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3.8</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1402328/000168316824002616/sunshine_ex0301.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Articles of Amendment to Articles of Incorporation</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(25)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3.9</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1402328/000168316824005496/sunshine_ex0301.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Articles of Amendment to Articles of Incorporation</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(26)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3.10</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1402328/000168316824007657/sunshine_ex0310.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Certificate of Correction</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(27)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">3.11</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000107997407000547/mountainwsb2ex32_10182007.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Bylaws</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(14)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">4.1</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000168316822001788/sunshine_ex0401.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Description of Registrant&#8217;s Securities</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(16)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">10.1</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000135448815004592/sbfm_ex109.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Patent Purchase Agreement with Advanomics Corporation</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(8)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">10.2</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000135448815005669/sbfm_ex109.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Second Patent Purchase Agreement with Advanomics Corporation</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(9)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">10.3</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000165495416000160/sbfm_ex1010.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Amendment No. 1 to Patent Purchase Agreement with Advanomics Corporation dated October 8, 2016, including Secured Convertible Promissory Note</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(10)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">10.4</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000165495416000160/sbfm_ex1011.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Amendment No. 1 to Patent Purchase Agreement with Advanomics Corporation dated December 28, 2016, including Secured Convertible Promissory Note</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(10)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">10.5 </span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1402328/000168316822001090/sunshine_ex0401.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Form of Warrant, dated February 17, 2022</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(1) </span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">10.6 </span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000168316822001090/sunshine_ex1001.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Warrant Agent Agreement between the Company and Equiniti, dated February 17, 2022</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(1)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">10.7 </span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000168316822000418/sunshine_ex1007.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Sponsored Research Agreement, dated October 6, 2020, between the Company and the University of Georgia Research Foundation, Inc.</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(11) *</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">10.8</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000168316822001271/sunshine_ex1001.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Research Agreement between the Company and Arizona Board of Regents on behalf of the University of Arizona</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(12)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">10.9</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000168316822001654/sunshine_ex1003.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Form of Warrant, dated March 14, 2022</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(15)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">10.10</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000168316822001920/sunshine_ex9901.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Form of Amendment to Warrant, dated March 24, 2022</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(17)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">10.11</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000168316822002473/sunshine_ex1001.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Amended Employment Agreement, dated October 21, 2024 between Sunshine Biopharma Inc. and Dr. Steve Slilaty</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(18)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">10.12</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1402328/000168316824007323/sunshine_ex1002.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Employment Agreement, dated October 21, 2024, between the Company and Camille Sebaaly</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(18)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">10.13</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000168316822006971/sunshine_ex1001.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Share Purchase Agreement between Sunshine Biopharma Inc., Malek Chamoun and Nora Pharma Inc.</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(19)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">10.14</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000168316823001172/sunshine_ex1001.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">License Agreement between the Company and the University of Arizona</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(20) *</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">10.15</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000168316823007302/sunshine_1001.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Amendment No. 1 to Warrant Agent Agreement, dated October 18, 2023</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(21)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">10.16</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000168316824000105/sunshine_ex0401.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2023 Equity Incentive Plan</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(22)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">10.17</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1402328/000168316824000849/sunshine_ex1019.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Form of Warrant Agency Agreement</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(28)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">10.18</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1402328/000168316824001009/sunshine_ex1003.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Form of Series B Warrant</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(23)</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">10.19</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1402328/000168316825000357/sunshine_ex1001.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Employment Agreement between the Company and Michael Roy</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(29)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">14.1</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1402328/000165495420004731/sbfm_ex14.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Code of Ethics</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(13)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">19</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1402328/000168316825002184/sunshine_ex1900.htm" style="-sec-extract: exhibit">Insider Trading Policy</a></span> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(30)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">21</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1402328/000168316823002128/sunshine_ex2100.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Subsidiaries</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(24)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">23.1</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="sunshine_ex2301.htm">Consent of Bush &amp; Associates CPA LLC</a></span> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(filed herewith)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">23.2</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="sunshine_ex2302.htm">Consent of M&amp;K CPAS, PLLC</a> (filed herewith)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">31.1</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="sunshine_ex3101.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act</a></span> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(filed herewith)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">31.2</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="sunshine_ex3102.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act</a></span> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(filed herewith)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">32.1</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><a href="sunshine_ex3201.htm">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(furnished herewith)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">97.1</span></td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1402328/000168316824001818/sunshine_ex9701.htm"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Clawback policy</span></a> <span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(24)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">EX-101</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">EX-104</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Cover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101).</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;_______________________</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 27px"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Portions of the exhibit have been omitted.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 61 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(1)</span></td>
    <td style="width: 95%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 8-K filed with the SEC on February 17, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to SB-2 filed with the SEC on October 19, 2007.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 8-K filed with the SEC on November 6, 2009.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 10-Q filed with the SEC on August 4, 2010.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 8-K filed with the SEC on June 1, 2015.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 8-K filed with the SEC on June 24, 2020.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 8-K filed February 9, 2022.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(8)</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 8-K filed with the SEC on October 9, 2015.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(9)</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 8-K filed with the SEC on December 28, 2015.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(10)</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 8-K filed with the SEC on March 14, 2016.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(11)</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to S-1/A filed with the SEC on January 24, 2022.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(12)</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 8-K filed with the SEC on February 25, 2022.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(13)</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 10-K filed with the SEC on May 1, 2020.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(14)</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 8-K filed with the SEC on April 19, 2023.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(15)</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 8-K filed with the SEC on March 15, 2022.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(16)</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 10-K filed with the SEC on March 21, 2022.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(17)</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 8-K filed with the SEC on March 24, 2022.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(18)</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 8-K filed with the SEC on October 23, 2024.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(19)</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 8-K filed with the SEC on October 20, 2022.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(20)</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 8-K filed with the SEC on February 28, 2023.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(21)</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 8-K filed with the SEC on October 20, 2023.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(22)</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to S-8 filed with the SEC on January 8, 2024.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(23)</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 8-K filed with the SEC on February 15, 2024.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(24)</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 10-K filed with the SEC on March 28, 2024.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(25)</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 8-K filed with the April 23, 2024.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(26)</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 8-K filed with the August 12, 2024.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(27)</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to post-effective Amendment No. 1 to Form S-1 filed with the SEC on November 6, 2024.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(28)</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to S-1/A filed with the SEC on February 9, 2024.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(29)</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Incorporated by reference to 8-K filed with the SEC on January 15, 2025.</span></td></tr>
  <tr style="vertical-align: top">
    <td>(30)</td>
    <td>Incorporated by reference to 10-K filed with the SEC on April 1, 2025.</td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 62 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><b><span id="a_037"></span>SIGNATURES</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>SUNSHINE BIOPHARMA INC.</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 54%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 35%">&#160;</td>
    <td style="width: 10%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: white 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dated: April 3, 2026</span></td>
    <td style="border-bottom: white 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">/s/&#160;Dr. Steve N. Slilaty</span></td>
    <td style="border-bottom: white 2.25pt double">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dr. Steve N. Slilaty, Chief Executive Officer (principal executive officer)</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">/s/ Camille Sebaaly</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Camille Sebaaly, Chief Financial Officer (principal financial and accounting officer)</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and
on the dates indicated.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 30%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 41%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 25%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">/s/ Dr. Steve N. Slilaty</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Chief Executive Officer and Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">April 3, 2026</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dr. Steve N. Slilaty</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(Principal Executive Officer)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">/s/ Camille Sebaaly </span></td>
    <td>&#160;</td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Chief Financial Officer and Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">April 3, 2026</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Camille Sebaaly</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">/s/ David Natan</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Director </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">April 3, 2026</span></td></tr>
  <tr>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">David Natan</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">/s/ Dr. Andrew Keller</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Director </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">April 3, 2026</span></td></tr>
  <tr>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dr. Andrew Keller</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">/s/ Dr. Rabi Kiderchah </span></td>
    <td>&#160;</td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Director </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">April 3, 2026</span></td></tr>
  <tr>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dr. Rabi Kiderchah</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 63; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>sunshine_ex2301.htm
<DESCRIPTION>CONSENT OF BUSH & ASSOCIATES CPA LLC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><IMG SRC="bushheader.jpg" ALT="" STYLE="height: 74px; width: 525px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">To Whom It May
Concern:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">We hereby consent
to the incorporation by reference in (i) the Registration Statement on Form S-3 (File Number 333-284142), (ii) the Registration Statement
on Form S-3 (File Number 333-272197), (iii) the Registration Statement on Form S-3 (File Number 333-264830), (iv) the Registration Statement
on Form S-3 (File Number 333-263998), (v) the Registration Statement on Form S-8 (File Number 333-276417), and (vi) the Registration
Statement on Form S-1 (File Number 333-289230) for Sunshine Biopharma Inc. (the &quot;Company&quot;) of our report dated April 1, 2025,
relating to the consolidated financial statements of the Company for the year ended December 31, 2024, which appears in this Annual Report
on Form 10-K.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Very truly yours,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">/s/ Bush &amp; Associates CPA LLC</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Bush &amp; Associates CPA LLC (PCAOB 6797)</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Henderson, Nevada</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">April 3, 2026</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>sunshine_ex2302.htm
<DESCRIPTION>CONSENT OF M&K CPAS, PLLC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Exhibit 23.2</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 78px; width: 400px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">To Whom It
May Concern:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">We hereby
consent to the incorporation by reference in (i) the Registration Statement on Form S-3 (File Number 333-284142), (ii) S-3 (File Number
333-272197), (iii) S-3 (File Number 333-264830), (iv) S-3 File Number 333-263998), (v) S-8 (File Number 333-276417), and (vi) S-1 (File
Number 333-289230) for Sunshine Biopharma Inc. (the &ldquo;Company&rdquo;) of our report dated April 3, 2026, relating to the consolidated
financial statements of the Company, which appear in this Annual Report on Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Very truly
yours,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><I>/s/ M&amp;K CPA&rsquo;s, PLLC</I></FONT> <FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT> <FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><BR>
The Woodlands, Texas</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">April 3, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>sunshine_ex3101.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Arial, Helvetica, Sans-Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>18
USC, SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>SECTION
302 OF THE SARBANES OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">I,
Steve N. Slilaty, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
have reviewed this annual report on Form 10-K of Sunshine Biopharma Inc.;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed
such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evaluated
the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosed
in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the
equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal
control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dated:
    April 3, 2026</FONT></TD>
    <TD STYLE="width: 52%; border-bottom: black 1pt solid; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">/s/
    Steve N. Slilaty</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Steve N.
    Slilaty, Chief Executive Officer</FONT></TD></TR>
  </TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>sunshine_ex3102.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Arial, Helvetica, Sans-Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>18
USC, SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>SECTION
302 OF THE SARBANES OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">I,
Camille Sebaaly, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
have reviewed this annual report on Form 10-K of Sunshine Biopharma Inc.;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed
such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evaluated
the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosed
in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the
equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal
control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dated:
    April 3, 2026</FONT></TD>
    <TD STYLE="width: 52%; border-bottom: black 1pt solid; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">/s/
    Camille Sebaaly</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Camille
    Sebaaly, Chief Financial Officer</FONT></TD></TR>
  </TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>sunshine_ex3201.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>18
USC, SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">In
connection with this annual report of Sunshine Biopharma Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the fiscal year ended December
31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), we, the undersigned, in
the capacities and on the date indicated below, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that to the best of our knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">1.&nbsp;The
Report fully complies with the requirements of Rule 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">2.&nbsp;The
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dated: April
    3, 2026</FONT></TD>
    <TD STYLE="width: 52%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">/s/
    Steve N. Slilaty</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Steve N. Slilaty, Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Dated: April 3, 2026</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">/s/ Camille Sebaaly</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Camille Sebaaly, Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>sbfm-20251231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOaiJ2aPty552uYkxvmR4fRmKjysm63Yh7S2xAb120fwK -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:SBFM="http://sunshinebiopharma.com/20251231" elementFormDefault="qualified" targetNamespace="http://sunshinebiopharma.com/20251231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss" id="StatementOfOperationsAndComprehensiveLoss">
          <link:definition>00000004 - Statement - Consolidated Statement Of Operations and Comprehensive Loss</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000005 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity" id="StatementsOfShareholdersEquity">
          <link:definition>00000006 - Statement - Consolidated Statements of Shareholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/DescriptionOfBusiness" id="DescriptionOfBusiness">
          <link:definition>999014 - Disclosure - Description of Business</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999015 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc." id="AcquisitionOfNoraPharmaInc.">
          <link:definition>999016 - Disclosure - Acquisition of Nora Pharma Inc.</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/IntangibleAssets" id="IntangibleAssets">
          <link:definition>999017 - Disclosure - Intangible Assets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipment" id="PlantPropertyAndEquipment">
          <link:definition>999018 - Disclosure - Plant, Property and Equipment</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/Inventory" id="Inventory">
          <link:definition>999019 - Disclosure - Inventory</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/PrepaidExpenses" id="PrepaidExpenses">
          <link:definition>999020 - Disclosure - Prepaid Expenses</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/CostOfSales" id="CostOfSales">
          <link:definition>999021 - Disclosure - Cost of Sales</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/ReverseStockSplits" id="ReverseStockSplits">
          <link:definition>999022 - Disclosure - Reverse Stock Splits</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/CapitalStock" id="CapitalStock">
          <link:definition>999023 - Disclosure - Capital Stock</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/Warrants" id="Warrants">
          <link:definition>999024 - Disclosure - Warrants</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/EarningsPerShare" id="EarningsPerShare">
          <link:definition>999025 - Disclosure - Earnings Per Share</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999026 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/Leases" id="Leases">
          <link:definition>999027 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/SegmentReporting" id="SegmentReporting">
          <link:definition>999028 - Disclosure - Segment Reporting</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" id="ManagementAndDirectorCompensation">
          <link:definition>999029 - Disclosure - Management and Director Compensation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/LegalMatters" id="LegalMatters">
          <link:definition>999030 - Disclosure - Legal Matters</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999031 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999032 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999033 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
          <link:definition>999034 - Disclosure - Intangible Assets (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables" id="PlantPropertyAndEquipmentTables">
          <link:definition>999035 - Disclosure - Plant, Property and Equipment (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/InventoryTables" id="InventoryTables">
          <link:definition>999036 - Disclosure - Inventory (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/PrepaidExpensesTables" id="PrepaidExpensesTables">
          <link:definition>999037 - Disclosure - Prepaid Expenses (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/CostOfSalesTables" id="CostOfSalesTables">
          <link:definition>999038 - Disclosure - Cost of Sales (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/WarrantsTables" id="WarrantsTables">
          <link:definition>999039 - Disclosure - Warrants (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/EarningsPerShareTables" id="EarningsPerShareTables">
          <link:definition>999040 - Disclosure - Earnings Per Share (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999041 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/LeasesTables" id="LeasesTables">
          <link:definition>999042 - Disclosure - Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives" id="SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives">
          <link:definition>999043 - Disclosure - Summary of Significant Accounting Policies (Details - Estimated lives)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets" id="SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets">
          <link:definition>999044 - Disclosure - Summary of Significant Accounting Policies (Details - Intangible assets)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999045 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative" id="AcquisitionOfNoraPharmaInc.DetailsNarrative">
          <link:definition>999046 - Disclosure - Acquisition of Nora Pharma Inc. (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets" id="IntangibleAssetsDetails-IntangibleAssets">
          <link:definition>999047 - Disclosure - Intangible Assets (Details - Intangible assets)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsDetails-AmortizationExpense" id="IntangibleAssetsDetails-AmortizationExpense">
          <link:definition>999048 - Disclosure - Intangible Assets (Details - Amortization expense)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
          <link:definition>999049 - Disclosure - Intangible Assets (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails" id="PlantPropertyAndEquipmentDetails">
          <link:definition>999050 - Disclosure - Plant, Property and Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetailsNarrative" id="PlantPropertyAndEquipmentDetailsNarrative">
          <link:definition>999051 - Disclosure - Plant, Property and Equipment (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/InventoryDetails" id="InventoryDetails">
          <link:definition>999052 - Disclosure - Inventory (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/PrepaidExpensesDetails" id="PrepaidExpensesDetails">
          <link:definition>999053 - Disclosure - Prepaid Expenses (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/CostOfSalesDetails" id="CostOfSalesDetails">
          <link:definition>999054 - Disclosure - Cost of Sales (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" id="CapitalStockDetailsNarrative">
          <link:definition>999055 - Disclosure - Capital Stock (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing" id="WarrantsDetails-WarrantsIssuedWithFinancing">
          <link:definition>999056 - Disclosure - Warrants (Details - Warrants issued with financing)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding" id="WarrantsDetails-WarrantsOutstanding">
          <link:definition>999057 - Disclosure - Warrants (Details - Warrants outstanding)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" id="WarrantsDetailsNarrative">
          <link:definition>999058 - Disclosure - Warrants (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/EarningsPerShareDetails" id="EarningsPerShareDetails">
          <link:definition>999059 - Disclosure - Earnings Per Share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes" id="IncomeTaxesDetails-ProvisionForIncomeTaxes">
          <link:definition>999060 - Disclosure - Income Taxes (Details - Provision for income taxes)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" id="IncomeTaxesDetails-ReconcilationOfTaxRate">
          <link:definition>999061 - Disclosure - Income Taxes (Details - Reconcilation of tax rate)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes" id="IncomeTaxesDetails-DeferredTaxes">
          <link:definition>999062 - Disclosure - Income Taxes (Details - Deferred taxes)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999063 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation" id="LeasesDetails-LeaseInformation">
          <link:definition>999064 - Disclosure - Leases (Details - Lease information)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments" id="LeasesDetails-MaturitiesOfLeasePayments">
          <link:definition>999065 - Disclosure - Leases (Details - Maturities of lease payments)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/SegmentReportingDetailsNarrative" id="SegmentReportingDetailsNarrative">
          <link:definition>999066 - Disclosure - Segment Reporting (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" id="ManagementAndDirectorCompensationDetailsNarrative">
          <link:definition>999067 - Disclosure - Management and Director Compensation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="sbfm-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="sbfm-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="sbfm-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="sbfm-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" />
    <element id="SBFM_LicensesMember" name="LicensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_WebsiteMember" name="WebsiteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_NoraPharmaMember" name="NoraPharmaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_MalekChamounMember" name="MalekChamounMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_FinishedGoodsMember" name="FinishedGoodsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_ProfessionalAllowancesMember" name="ProfessionalAllowancesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_OtherAllowancesMember" name="OtherAllowancesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_WholesalersFeesAndDiscountsMember" name="WholesalersFeesAndDiscountsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_InventoryAdjustmentMember" name="InventoryAdjustmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_FreightMember" name="FreightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_PreFundedWarrants2024Member" name="PreFundedWarrants2024Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_SeriesBWarrantsMember" name="SeriesBWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_RegisteredDirectOfferingMember" name="RegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_TradeableWarrantsMember" name="TradeableWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_PreFunded2022WarrantsMember" name="PreFunded2022WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_InvestorWarrantsMember" name="InvestorWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_AprilWarrantsMember" name="AprilWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_MayPreFundedWarrantsMember" name="MayPreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_MayInvestorWarrantsMember" name="MayInvestorWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_PreFunded2024WarrantsMember" name="PreFunded2024WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_SeriesAWarrantsMember" name="SeriesAWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_PreFunded2025WarrantsMember" name="PreFunded2025WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_AprilWarrantsAndMayInvestorWarrantsMember" name="AprilWarrantsAndMayInvestorWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_TradeableWarrants1Member" name="TradeableWarrants1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_InvestorWarrants1Member" name="InvestorWarrants1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_SeriesBWarrants1Member" name="SeriesBWarrants1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_AdvanomicsCorporationMember" name="AdvanomicsCorporationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_EarnoutPayable" name="EarnoutPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_Taxes" name="Taxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_AssetDisposition" name="AssetDisposition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_IncreaseDecreaseInRightOfUseAsset" name="IncreaseDecreaseInRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_IncreaseDecreaseInEarnoutPayable" name="IncreaseDecreaseInEarnoutPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_StockIssuedForServices" name="StockIssuedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_PreferredStockIssuedToRelatedParty" name="PreferredStockIssuedToRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_PreferredStockIssuedToRelatedPartyShares" name="PreferredStockIssuedToRelatedPartyShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_RepurchaseOfWarrants" name="RepurchaseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_DisclosurePrepaidExpensesAbstract" name="DisclosurePrepaidExpensesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_PrepaidExpensesTextBlock" name="PrepaidExpensesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_DisclosureCostOfSalesAbstract" name="DisclosureCostOfSalesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_CostOfSalesDisclosureTextBlock" name="CostOfSalesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_DisclosureReverseStockSplitsAbstract" name="DisclosureReverseStockSplitsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_ReverseStockSplitTextBlock" name="ReverseStockSplitTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_DisclosureWarrantsAbstract" name="DisclosureWarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_WarrantsDisclosureTextBlock" name="WarrantsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_DisclosureManagementAndDirectorCompensationAbstract" name="DisclosureManagementAndDirectorCompensationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_ManagementAndDirectorCompensationTextBlock" name="ManagementAndDirectorCompensationTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" name="PropertyPlantAndEquipmentUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock" name="ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_ScheduleOfCostOfSalesTableTextBlock" name="ScheduleOfCostOfSalesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_ScheduleOfWarrantsIssuedWithFinancingTableTextBlock" name="ScheduleOfWarrantsIssuedWithFinancingTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_PropertyPlantAndEquipmentEstimatedUsefulLives1" name="PropertyPlantAndEquipmentEstimatedUsefulLives1" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_IntangibleAssetsEstimatedUsefulLives" name="IntangibleAssetsEstimatedUsefulLives" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_CashCanadaInsuredAmount" name="CashCanadaInsuredAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_EarnoutLiabilityExpenseFirstInstallment" name="EarnoutLiabilityExpenseFirstInstallment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_EarnoutLiabilityExpenseSecondInstallment" name="EarnoutLiabilityExpenseSecondInstallment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_EarnoutLiabilityBalance" name="EarnoutLiabilityBalance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_ImpairmentOfIntangibleAssetFinitelived" name="ImpairmentOfIntangibleAssetFinitelived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_AllowanceForObsoleteInventory" name="AllowanceForObsoleteInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_PermitsAndInsurance" name="PermitsAndInsurance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_WarrantsExercisedDescription" name="WarrantsExercisedDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_WarrantExpirationDate" name="WarrantExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_CurrentIncomeTaxExpenseBenefits" name="CurrentIncomeTaxExpenseBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory" name="IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate" name="EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_IncomeTaxReconciliationOtherForeignTaxes" name="IncomeTaxReconciliationOtherForeignTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_EffectiveIncomeTaxRateReconciliationOtherForeignTaxes" name="EffectiveIncomeTaxRateReconciliationOtherForeignTaxes" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_DeferredTaxAssetsResearchAndDevelopment" name="DeferredTaxAssetsResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_DeferredTaxAssetsOperatingLossCarryforwardsProvincial" name="DeferredTaxAssetsOperatingLossCarryforwardsProvincial" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>sbfm-20251231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#Cover" roleURI="http://sunshinebiopharma.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#BalanceSheets" roleURI="http://sunshinebiopharma.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#BalanceSheetsParenthetical" roleURI="http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#StatementOfOperationsAndComprehensiveLoss" roleURI="http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#StatementsOfCashFlows" roleURI="http://sunshinebiopharma.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#StatementsOfShareholdersEquity" roleURI="http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#DescriptionOfBusiness" roleURI="http://sunshinebiopharma.com/role/DescriptionOfBusiness" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#AcquisitionOfNoraPharmaInc." roleURI="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc." />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IntangibleAssets" roleURI="http://sunshinebiopharma.com/role/IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#PlantPropertyAndEquipment" roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#Inventory" roleURI="http://sunshinebiopharma.com/role/Inventory" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#PrepaidExpenses" roleURI="http://sunshinebiopharma.com/role/PrepaidExpenses" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#CostOfSales" roleURI="http://sunshinebiopharma.com/role/CostOfSales" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#ReverseStockSplits" roleURI="http://sunshinebiopharma.com/role/ReverseStockSplits" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#CapitalStock" roleURI="http://sunshinebiopharma.com/role/CapitalStock" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#Warrants" roleURI="http://sunshinebiopharma.com/role/Warrants" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#EarningsPerShare" roleURI="http://sunshinebiopharma.com/role/EarningsPerShare" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IncomeTaxes" roleURI="http://sunshinebiopharma.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#Leases" roleURI="http://sunshinebiopharma.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SegmentReporting" roleURI="http://sunshinebiopharma.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#ManagementAndDirectorCompensation" roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#LegalMatters" roleURI="http://sunshinebiopharma.com/role/LegalMatters" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SubsequentEvents" roleURI="http://sunshinebiopharma.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IntangibleAssetsTables" roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#PlantPropertyAndEquipmentTables" roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#InventoryTables" roleURI="http://sunshinebiopharma.com/role/InventoryTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#PrepaidExpensesTables" roleURI="http://sunshinebiopharma.com/role/PrepaidExpensesTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#CostOfSalesTables" roleURI="http://sunshinebiopharma.com/role/CostOfSalesTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#WarrantsTables" roleURI="http://sunshinebiopharma.com/role/WarrantsTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#EarningsPerShareTables" roleURI="http://sunshinebiopharma.com/role/EarningsPerShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IncomeTaxesTables" roleURI="http://sunshinebiopharma.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#LeasesTables" roleURI="http://sunshinebiopharma.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives" roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets" roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#AcquisitionOfNoraPharmaInc.DetailsNarrative" roleURI="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IntangibleAssetsDetails-IntangibleAssets" roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IntangibleAssetsDetails-AmortizationExpense" roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsDetails-AmortizationExpense" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IntangibleAssetsDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#PlantPropertyAndEquipmentDetails" roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#PlantPropertyAndEquipmentDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#InventoryDetails" roleURI="http://sunshinebiopharma.com/role/InventoryDetails" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#PrepaidExpensesDetails" roleURI="http://sunshinebiopharma.com/role/PrepaidExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#CostOfSalesDetails" roleURI="http://sunshinebiopharma.com/role/CostOfSalesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#CapitalStockDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#WarrantsDetails-WarrantsIssuedWithFinancing" roleURI="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#WarrantsDetails-WarrantsOutstanding" roleURI="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#WarrantsDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#EarningsPerShareDetails" roleURI="http://sunshinebiopharma.com/role/EarningsPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IncomeTaxesDetails-ProvisionForIncomeTaxes" roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IncomeTaxesDetails-ReconcilationOfTaxRate" roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IncomeTaxesDetails-DeferredTaxes" roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IncomeTaxesDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#LeasesDetails-LeaseInformation" roleURI="http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#LeasesDetails-MaturitiesOfLeasePayments" roleURI="http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SegmentReportingDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/SegmentReportingDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#ManagementAndDirectorCompensationDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:label="loc_us-gaapDeferredIncomeTaxesAndOtherAssetsNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_EarnoutPayable" xlink:label="loc_SBFMEarnoutPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_SBFMEarnoutPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaapAccruedIncomeTaxesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedIncomeTaxesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statement Of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaapProfessionalAndContractServicesExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapProfessionalAndContractServicesExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaapNoninterestExpenseDirectorsFees" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapNoninterestExpenseDirectorsFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetImpairment" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetImpairment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaapMarketingExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapMarketingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_Taxes" xlink:label="loc_SBFMTaxes" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_SBFMTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeDebtSecuritiesOperating" xlink:label="loc_us-gaapInterestIncomeDebtSecuritiesOperating" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeDebtSecuritiesOperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="loc_us-gaapGainsLossesOnSalesOfAssets" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnSalesOfAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_AssetDisposition" xlink:label="loc_SBFMAssetDisposition" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SBFMAssetDisposition" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetImpairment" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetImpairment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_IncreaseDecreaseInRightOfUseAsset" xlink:label="loc_SBFMIncreaseDecreaseInRightOfUseAsset" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SBFMIncreaseDecreaseInRightOfUseAsset" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_IncreaseDecreaseInEarnoutPayable" xlink:label="loc_SBFMIncreaseDecreaseInEarnoutPayable" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SBFMIncreaseDecreaseInEarnoutPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity" xlink:title="00000006 - Statement - Consolidated Statements of Shareholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/DescriptionOfBusiness" xlink:title="999014 - Disclosure - Description of Business" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc." xlink:title="999016 - Disclosure - Acquisition of Nora Pharma Inc." />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssets" xlink:title="999017 - Disclosure - Intangible Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PlantPropertyAndEquipment" xlink:title="999018 - Disclosure - Plant, Property and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Inventory" xlink:title="999019 - Disclosure - Inventory" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PrepaidExpenses" xlink:title="999020 - Disclosure - Prepaid Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/CostOfSales" xlink:title="999021 - Disclosure - Cost of Sales" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ReverseStockSplits" xlink:title="999022 - Disclosure - Reverse Stock Splits" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/CapitalStock" xlink:title="999023 - Disclosure - Capital Stock" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Warrants" xlink:title="999024 - Disclosure - Warrants" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/EarningsPerShare" xlink:title="999025 - Disclosure - Earnings Per Share" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxes" xlink:title="999026 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Leases" xlink:title="999027 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SegmentReporting" xlink:title="999028 - Disclosure - Segment Reporting" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" xlink:title="999029 - Disclosure - Management and Director Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LegalMatters" xlink:title="999030 - Disclosure - Legal Matters" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SubsequentEvents" xlink:title="999031 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999032 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999033 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssetsTables" xlink:title="999034 - Disclosure - Intangible Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables" xlink:title="999035 - Disclosure - Plant, Property and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/InventoryTables" xlink:title="999036 - Disclosure - Inventory (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PrepaidExpensesTables" xlink:title="999037 - Disclosure - Prepaid Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/CostOfSalesTables" xlink:title="999038 - Disclosure - Cost of Sales (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsTables" xlink:title="999039 - Disclosure - Warrants (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/EarningsPerShareTables" xlink:title="999040 - Disclosure - Earnings Per Share (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxesTables" xlink:title="999041 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LeasesTables" xlink:title="999042 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives" xlink:title="999043 - Disclosure - Summary of Significant Accounting Policies (Details - Estimated lives)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets" xlink:title="999044 - Disclosure - Summary of Significant Accounting Policies (Details - Intangible assets)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999045 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative" xlink:title="999046 - Disclosure - Acquisition of Nora Pharma Inc. (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets" xlink:title="999047 - Disclosure - Intangible Assets (Details - Intangible assets)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssetsDetails-AmortizationExpense" xlink:title="999048 - Disclosure - Intangible Assets (Details - Amortization expense)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssetsDetailsNarrative" xlink:title="999049 - Disclosure - Intangible Assets (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails" xlink:title="999050 - Disclosure - Plant, Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetailsNarrative" xlink:title="999051 - Disclosure - Plant, Property and Equipment (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/InventoryDetails" xlink:title="999052 - Disclosure - Inventory (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PrepaidExpensesDetails" xlink:title="999053 - Disclosure - Prepaid Expenses (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/CostOfSalesDetails" xlink:title="999054 - Disclosure - Cost of Sales (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" xlink:title="999055 - Disclosure - Capital Stock (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing" xlink:title="999056 - Disclosure - Warrants (Details - Warrants issued with financing)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding" xlink:title="999057 - Disclosure - Warrants (Details - Warrants outstanding)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" xlink:title="999058 - Disclosure - Warrants (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/EarningsPerShareDetails" xlink:title="999059 - Disclosure - Earnings Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes" xlink:title="999060 - Disclosure - Income Taxes (Details - Provision for income taxes)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" xlink:title="999061 - Disclosure - Income Taxes (Details - Reconcilation of tax rate)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory" xlink:label="loc_SBFMIncomeTaxReconciliationEffectOfRatesDifferentThanStatutory" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_SBFMIncomeTaxReconciliationEffectOfRatesDifferentThanStatutory" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_IncomeTaxReconciliationOtherForeignTaxes" xlink:label="loc_SBFMIncomeTaxReconciliationOtherForeignTaxes" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_SBFMIncomeTaxReconciliationOtherForeignTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate" xlink:label="loc_SBFMEffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_SBFMEffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_EffectiveIncomeTaxRateReconciliationOtherForeignTaxes" xlink:label="loc_SBFMEffectiveIncomeTaxRateReconciliationOtherForeignTaxes" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_SBFMEffectiveIncomeTaxRateReconciliationOtherForeignTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes" xlink:title="999062 - Disclosure - Income Taxes (Details - Deferred taxes)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="999063 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation" xlink:title="999064 - Disclosure - Leases (Details - Lease information)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments" xlink:title="999065 - Disclosure - Leases (Details - Maturities of lease payments)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SegmentReportingDetailsNarrative" xlink:title="999066 - Disclosure - Segment Reporting (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" xlink:title="999067 - Disclosure - Management and Director Compensation (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>sbfm-20251231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#Cover" roleURI="http://sunshinebiopharma.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#BalanceSheets" roleURI="http://sunshinebiopharma.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#BalanceSheetsParenthetical" roleURI="http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#StatementOfOperationsAndComprehensiveLoss" roleURI="http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#StatementsOfCashFlows" roleURI="http://sunshinebiopharma.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#StatementsOfShareholdersEquity" roleURI="http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#DescriptionOfBusiness" roleURI="http://sunshinebiopharma.com/role/DescriptionOfBusiness" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#AcquisitionOfNoraPharmaInc." roleURI="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc." />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IntangibleAssets" roleURI="http://sunshinebiopharma.com/role/IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#PlantPropertyAndEquipment" roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#Inventory" roleURI="http://sunshinebiopharma.com/role/Inventory" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#PrepaidExpenses" roleURI="http://sunshinebiopharma.com/role/PrepaidExpenses" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#CostOfSales" roleURI="http://sunshinebiopharma.com/role/CostOfSales" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#ReverseStockSplits" roleURI="http://sunshinebiopharma.com/role/ReverseStockSplits" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#CapitalStock" roleURI="http://sunshinebiopharma.com/role/CapitalStock" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#Warrants" roleURI="http://sunshinebiopharma.com/role/Warrants" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#EarningsPerShare" roleURI="http://sunshinebiopharma.com/role/EarningsPerShare" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IncomeTaxes" roleURI="http://sunshinebiopharma.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#Leases" roleURI="http://sunshinebiopharma.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SegmentReporting" roleURI="http://sunshinebiopharma.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#ManagementAndDirectorCompensation" roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#LegalMatters" roleURI="http://sunshinebiopharma.com/role/LegalMatters" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SubsequentEvents" roleURI="http://sunshinebiopharma.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IntangibleAssetsTables" roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#PlantPropertyAndEquipmentTables" roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#InventoryTables" roleURI="http://sunshinebiopharma.com/role/InventoryTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#PrepaidExpensesTables" roleURI="http://sunshinebiopharma.com/role/PrepaidExpensesTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#CostOfSalesTables" roleURI="http://sunshinebiopharma.com/role/CostOfSalesTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#WarrantsTables" roleURI="http://sunshinebiopharma.com/role/WarrantsTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#EarningsPerShareTables" roleURI="http://sunshinebiopharma.com/role/EarningsPerShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IncomeTaxesTables" roleURI="http://sunshinebiopharma.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#LeasesTables" roleURI="http://sunshinebiopharma.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives" roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets" roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#AcquisitionOfNoraPharmaInc.DetailsNarrative" roleURI="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IntangibleAssetsDetails-IntangibleAssets" roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IntangibleAssetsDetails-AmortizationExpense" roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsDetails-AmortizationExpense" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IntangibleAssetsDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#PlantPropertyAndEquipmentDetails" roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#PlantPropertyAndEquipmentDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#InventoryDetails" roleURI="http://sunshinebiopharma.com/role/InventoryDetails" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#PrepaidExpensesDetails" roleURI="http://sunshinebiopharma.com/role/PrepaidExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#CostOfSalesDetails" roleURI="http://sunshinebiopharma.com/role/CostOfSalesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#CapitalStockDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#WarrantsDetails-WarrantsIssuedWithFinancing" roleURI="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#WarrantsDetails-WarrantsOutstanding" roleURI="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#WarrantsDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#EarningsPerShareDetails" roleURI="http://sunshinebiopharma.com/role/EarningsPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IncomeTaxesDetails-ProvisionForIncomeTaxes" roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IncomeTaxesDetails-ReconcilationOfTaxRate" roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IncomeTaxesDetails-DeferredTaxes" roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IncomeTaxesDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#LeasesDetails-LeaseInformation" roleURI="http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#LeasesDetails-MaturitiesOfLeasePayments" roleURI="http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SegmentReportingDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/SegmentReportingDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#ManagementAndDirectorCompensationDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_70" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_70" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_70" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_70" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_70" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_70" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_70" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_70" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_70" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_70" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_70" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_70" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_70" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_70" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_70" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_70" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_70" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_70" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_70" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_70" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_70" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_70" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_70" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_70" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_70" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_70" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_70" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_70" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag_70" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag_70" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName_70" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation_70" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId_70" xlink:type="arc" order="62" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statement Of Operations and Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity" xlink:title="00000006 - Statement - Consolidated Statements of Shareholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="loc_us-gaapComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PreferredStockIssuedToRelatedParty" xlink:label="loc_SBFMPreferredStockIssuedToRelatedParty_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SBFMPreferredStockIssuedToRelatedParty_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PreferredStockIssuedToRelatedPartyShares" xlink:label="loc_SBFMPreferredStockIssuedToRelatedPartyShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SBFMPreferredStockIssuedToRelatedPartyShares_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_RepurchaseOfWarrants" xlink:label="loc_SBFMRepurchaseOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SBFMRepurchaseOfWarrants_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax_70" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/DescriptionOfBusiness" xlink:title="999014 - Disclosure - Description of Business" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc." xlink:title="999016 - Disclosure - Acquisition of Nora Pharma Inc." />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssets" xlink:title="999017 - Disclosure - Intangible Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PlantPropertyAndEquipment" xlink:title="999018 - Disclosure - Plant, Property and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Inventory" xlink:title="999019 - Disclosure - Inventory" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PrepaidExpenses" xlink:title="999020 - Disclosure - Prepaid Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/CostOfSales" xlink:title="999021 - Disclosure - Cost of Sales" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ReverseStockSplits" xlink:title="999022 - Disclosure - Reverse Stock Splits" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/CapitalStock" xlink:title="999023 - Disclosure - Capital Stock" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Warrants" xlink:title="999024 - Disclosure - Warrants" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/EarningsPerShare" xlink:title="999025 - Disclosure - Earnings Per Share" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxes" xlink:title="999026 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Leases" xlink:title="999027 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SegmentReporting" xlink:title="999028 - Disclosure - Segment Reporting" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" xlink:title="999029 - Disclosure - Management and Director Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LegalMatters" xlink:title="999030 - Disclosure - Legal Matters" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SubsequentEvents" xlink:title="999031 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999032 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999033 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssetsTables" xlink:title="999034 - Disclosure - Intangible Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables" xlink:title="999035 - Disclosure - Plant, Property and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/InventoryTables" xlink:title="999036 - Disclosure - Inventory (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PrepaidExpensesTables" xlink:title="999037 - Disclosure - Prepaid Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/CostOfSalesTables" xlink:title="999038 - Disclosure - Cost of Sales (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsTables" xlink:title="999039 - Disclosure - Warrants (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/EarningsPerShareTables" xlink:title="999040 - Disclosure - Earnings Per Share (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxesTables" xlink:title="999041 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LeasesTables" xlink:title="999042 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives" xlink:title="999043 - Disclosure - Summary of Significant Accounting Policies (Details - Estimated lives)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaapVehiclesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapVehiclesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PropertyPlantAndEquipmentEstimatedUsefulLives1" xlink:label="loc_SBFMPropertyPlantAndEquipmentEstimatedUsefulLives1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_SBFMPropertyPlantAndEquipmentEstimatedUsefulLives1_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets" xlink:title="999044 - Disclosure - Summary of Significant Accounting Policies (Details - Intangible assets)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_LicensesMember" xlink:label="loc_SBFMLicensesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_SBFMLicensesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_WebsiteMember" xlink:label="loc_SBFMWebsiteMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_SBFMWebsiteMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_IntangibleAssetsEstimatedUsefulLives" xlink:label="loc_SBFMIntangibleAssetsEstimatedUsefulLives_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_SBFMIntangibleAssetsEstimatedUsefulLives_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999045 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative" xlink:title="999046 - Disclosure - Acquisition of Nora Pharma Inc. (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_NoraPharmaMember" xlink:label="loc_SBFMNoraPharmaMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_SBFMNoraPharmaMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_MalekChamounMember" xlink:label="loc_SBFMMalekChamounMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_SBFMMalekChamounMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesGross_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_EarnoutPayable" xlink:label="loc_SBFMEarnoutPayable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SBFMEarnoutPayable_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_EarnoutLiabilityExpenseFirstInstallment" xlink:label="loc_SBFMEarnoutLiabilityExpenseFirstInstallment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SBFMEarnoutLiabilityExpenseFirstInstallment_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_EarnoutLiabilityExpenseSecondInstallment" xlink:label="loc_SBFMEarnoutLiabilityExpenseSecondInstallment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SBFMEarnoutLiabilityExpenseSecondInstallment_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_EarnoutLiabilityBalance" xlink:label="loc_SBFMEarnoutLiabilityBalance_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SBFMEarnoutLiabilityBalance_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets" xlink:title="999047 - Disclosure - Intangible Assets (Details - Intangible assets)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssetsDetails-AmortizationExpense" xlink:title="999048 - Disclosure - Intangible Assets (Details - Amortization expense)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssetsDetailsNarrative" xlink:title="999049 - Disclosure - Intangible Assets (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails" xlink:title="999050 - Disclosure - Plant, Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaapVehiclesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapVehiclesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_130" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetailsNarrative" xlink:title="999051 - Disclosure - Plant, Property and Equipment (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/InventoryDetails" xlink:title="999052 - Disclosure - Inventory (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PrepaidExpensesDetails" xlink:title="999053 - Disclosure - Prepaid Expenses (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/CostOfSalesDetails" xlink:title="999054 - Disclosure - Cost of Sales (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapTransactionTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_FinishedGoodsMember" xlink:label="loc_SBFMFinishedGoodsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_SBFMFinishedGoodsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_ProfessionalAllowancesMember" xlink:label="loc_SBFMProfessionalAllowancesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_SBFMProfessionalAllowancesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_OtherAllowancesMember" xlink:label="loc_SBFMOtherAllowancesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_SBFMOtherAllowancesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_WholesalersFeesAndDiscountsMember" xlink:label="loc_SBFMWholesalersFeesAndDiscountsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_SBFMWholesalersFeesAndDiscountsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_InventoryAdjustmentMember" xlink:label="loc_SBFMInventoryAdjustmentMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_SBFMInventoryAdjustmentMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_FreightMember" xlink:label="loc_SBFMFreightMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_SBFMFreightMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapCostOfRevenue_150" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" xlink:title="999055 - Disclosure - Capital Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_SeriesBWarrantsMember" xlink:label="loc_SBFMSeriesBWarrantsMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMSeriesBWarrantsMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PreFundedWarrants2024Member" xlink:label="loc_SBFMPreFundedWarrants2024Member_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_SBFMPreFundedWarrants2024Member_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_SeriesBWarrantsMember" xlink:label="loc_SBFMSeriesBWarrantsMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_SBFMSeriesBWarrantsMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_RegisteredDirectOfferingMember" xlink:label="loc_SBFMRegisteredDirectOfferingMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_SBFMRegisteredDirectOfferingMember_330" xlink:type="arc" order="332" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_390" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_390" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_390" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_390" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_390" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_390" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_390" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_390" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_WarrantsExercisedDescription" xlink:label="loc_SBFMWarrantsExercisedDescription_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_SBFMWarrantsExercisedDescription_390" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_390" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_390" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPeriodIncreaseDecrease_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPeriodIncreaseDecrease_390" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_390" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_390" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_390" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_390" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_390" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_390" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_390" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing" xlink:title="999056 - Disclosure - Warrants (Details - Warrants issued with financing)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_TradeableWarrantsMember" xlink:label="loc_SBFMTradeableWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMTradeableWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PreFunded2022WarrantsMember" xlink:label="loc_SBFMPreFunded2022WarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMPreFunded2022WarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_InvestorWarrantsMember" xlink:label="loc_SBFMInvestorWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMInvestorWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_AprilWarrantsMember" xlink:label="loc_SBFMAprilWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMAprilWarrantsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_MayPreFundedWarrantsMember" xlink:label="loc_SBFMMayPreFundedWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMMayPreFundedWarrantsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_MayInvestorWarrantsMember" xlink:label="loc_SBFMMayInvestorWarrantsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMMayInvestorWarrantsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PreFunded2024WarrantsMember" xlink:label="loc_SBFMPreFunded2024WarrantsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMPreFunded2024WarrantsMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_SeriesAWarrantsMember" xlink:label="loc_SBFMSeriesAWarrantsMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMSeriesAWarrantsMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_SeriesBWarrantsMember" xlink:label="loc_SBFMSeriesBWarrantsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMSeriesBWarrantsMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PreFunded2025WarrantsMember" xlink:label="loc_SBFMPreFunded2025WarrantsMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMPreFunded2025WarrantsMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_WarrantExpirationDate" xlink:label="loc_SBFMWarrantExpirationDate_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SBFMWarrantExpirationDate_210" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding" xlink:title="999057 - Disclosure - Warrants (Details - Warrants outstanding)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_TradeableWarrants1Member" xlink:label="loc_SBFMTradeableWarrants1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMTradeableWarrants1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_InvestorWarrants1Member" xlink:label="loc_SBFMInvestorWarrants1Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMInvestorWarrants1Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_SeriesBWarrants1Member" xlink:label="loc_SBFMSeriesBWarrants1Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMSeriesBWarrants1Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_WarrantExpirationDate" xlink:label="loc_SBFMWarrantExpirationDate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SBFMWarrantExpirationDate_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" xlink:title="999058 - Disclosure - Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_AprilWarrantsAndMayInvestorWarrantsMember" xlink:label="loc_SBFMAprilWarrantsAndMayInvestorWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMAprilWarrantsAndMayInvestorWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_TradeableWarrantsMember" xlink:label="loc_SBFMTradeableWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMTradeableWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_InvestorWarrantsMember" xlink:label="loc_SBFMInvestorWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMInvestorWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_SeriesBWarrantsMember" xlink:label="loc_SBFMSeriesBWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMSeriesBWarrantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaapPaymentsForRepurchaseOfWarrants_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfWarrants_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/EarningsPerShareDetails" xlink:title="999059 - Disclosure - Earnings Per Share (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes" xlink:title="999060 - Disclosure - Income Taxes (Details - Provision for income taxes)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" xlink:title="999061 - Disclosure - Income Taxes (Details - Reconcilation of tax rate)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes" xlink:title="999062 - Disclosure - Income Taxes (Details - Deferred taxes)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="999063 - Disclosure - Income Taxes (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation" xlink:title="999064 - Disclosure - Leases (Details - Lease information)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments" xlink:title="999065 - Disclosure - Leases (Details - Maturities of lease payments)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SegmentReportingDetailsNarrative" xlink:title="999066 - Disclosure - Segment Reporting (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" xlink:title="999067 - Disclosure - Management and Director Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_AdvanomicsCorporationMember" xlink:label="loc_SBFMAdvanomicsCorporationMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SBFMAdvanomicsCorporationMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaapNoninterestExpenseDirectorsFees_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNoninterestExpenseDirectorsFees_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_TradeableWarrantsMember" xlink:label="loc_SBFMTradeableWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMTradeableWarrantsMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PreFunded2022WarrantsMember" xlink:label="loc_SBFMPreFunded2022WarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMPreFunded2022WarrantsMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_InvestorWarrantsMember" xlink:label="loc_SBFMInvestorWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMInvestorWarrantsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_AprilWarrantsMember" xlink:label="loc_SBFMAprilWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMAprilWarrantsMember" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_MayPreFundedWarrantsMember" xlink:label="loc_SBFMMayPreFundedWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMMayPreFundedWarrantsMember" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_MayInvestorWarrantsMember" xlink:label="loc_SBFMMayInvestorWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMMayInvestorWarrantsMember" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PreFunded2024WarrantsMember" xlink:label="loc_SBFMPreFunded2024WarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMPreFunded2024WarrantsMember" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_SeriesAWarrantsMember" xlink:label="loc_SBFMSeriesAWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMSeriesAWarrantsMember" xlink:type="arc" order="70" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_SeriesBWarrantsMember" xlink:label="loc_SBFMSeriesBWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMSeriesBWarrantsMember" xlink:type="arc" order="80" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PreFunded2025WarrantsMember" xlink:label="loc_SBFMPreFunded2025WarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMPreFunded2025WarrantsMember" xlink:type="arc" order="90" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_AprilWarrantsAndMayInvestorWarrantsMember" xlink:label="loc_SBFMAprilWarrantsAndMayInvestorWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMAprilWarrantsAndMayInvestorWarrantsMember" xlink:type="arc" order="100" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_TradeableWarrants1Member" xlink:label="loc_SBFMTradeableWarrants1Member" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMTradeableWarrants1Member" xlink:type="arc" order="110" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_InvestorWarrants1Member" xlink:label="loc_SBFMInvestorWarrants1Member" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMInvestorWarrants1Member" xlink:type="arc" order="120" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_SeriesBWarrants1Member" xlink:label="loc_SBFMSeriesBWarrants1Member" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMSeriesBWarrants1Member" xlink:type="arc" order="130" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>sbfm-20251231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="us-gaap_ComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeMember" xlink:to="us-gaap_ComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeMember_lbl" xml:lang="en-US">Comprehensive Income [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US">Vehicles [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_LicensesMember" xlink:label="SBFM_LicensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_LicensesMember" xlink:to="SBFM_LicensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_LicensesMember_lbl" xml:lang="en-US">Licenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_WebsiteMember" xlink:label="SBFM_WebsiteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_WebsiteMember" xlink:to="SBFM_WebsiteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_WebsiteMember_lbl" xml:lang="en-US">Website [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Combination [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_NoraPharmaMember" xlink:label="SBFM_NoraPharmaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_NoraPharmaMember" xlink:to="SBFM_NoraPharmaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_NoraPharmaMember_lbl" xml:lang="en-US">Nora Pharma [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_MalekChamounMember" xlink:label="SBFM_MalekChamounMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_MalekChamounMember" xlink:to="SBFM_MalekChamounMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_MalekChamounMember_lbl" xml:lang="en-US">Malek Chamoun [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransactionTypeAxis_lbl" xml:lang="en-US">Transaction Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_FinishedGoodsMember" xlink:label="SBFM_FinishedGoodsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_FinishedGoodsMember" xlink:to="SBFM_FinishedGoodsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_FinishedGoodsMember_lbl" xml:lang="en-US">Finished Goods [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_ProfessionalAllowancesMember" xlink:label="SBFM_ProfessionalAllowancesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_ProfessionalAllowancesMember" xlink:to="SBFM_ProfessionalAllowancesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_ProfessionalAllowancesMember_lbl" xml:lang="en-US">Professional Allowances [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_OtherAllowancesMember" xlink:label="SBFM_OtherAllowancesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_OtherAllowancesMember" xlink:to="SBFM_OtherAllowancesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_OtherAllowancesMember_lbl" xml:lang="en-US">Other Allowances [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_WholesalersFeesAndDiscountsMember" xlink:label="SBFM_WholesalersFeesAndDiscountsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_WholesalersFeesAndDiscountsMember" xlink:to="SBFM_WholesalersFeesAndDiscountsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_WholesalersFeesAndDiscountsMember_lbl" xml:lang="en-US">Wholesalers Fees And Discounts [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_InventoryAdjustmentMember" xlink:label="SBFM_InventoryAdjustmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_InventoryAdjustmentMember" xlink:to="SBFM_InventoryAdjustmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_InventoryAdjustmentMember_lbl" xml:lang="en-US">Inventory Adjustment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_FreightMember" xlink:label="SBFM_FreightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_FreightMember" xlink:to="SBFM_FreightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_FreightMember_lbl" xml:lang="en-US">Freight [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PreFundedWarrants2024Member" xlink:label="SBFM_PreFundedWarrants2024Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PreFundedWarrants2024Member" xlink:to="SBFM_PreFundedWarrants2024Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_PreFundedWarrants2024Member_lbl" xml:lang="en-US">Pre Funded Warrants 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_SeriesBWarrantsMember" xlink:label="SBFM_SeriesBWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_SeriesBWarrantsMember" xlink:to="SBFM_SeriesBWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_RegisteredDirectOfferingMember" xlink:label="SBFM_RegisteredDirectOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_RegisteredDirectOfferingMember" xlink:to="SBFM_RegisteredDirectOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_RegisteredDirectOfferingMember_lbl" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_TradeableWarrantsMember" xlink:label="SBFM_TradeableWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_TradeableWarrantsMember" xlink:to="SBFM_TradeableWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_TradeableWarrantsMember_lbl" xml:lang="en-US">Tradeable Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PreFunded2022WarrantsMember" xlink:label="SBFM_PreFunded2022WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PreFunded2022WarrantsMember" xlink:to="SBFM_PreFunded2022WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_PreFunded2022WarrantsMember_lbl" xml:lang="en-US">Pre Funded 2022 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_InvestorWarrantsMember" xlink:label="SBFM_InvestorWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_InvestorWarrantsMember" xlink:to="SBFM_InvestorWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_InvestorWarrantsMember_lbl" xml:lang="en-US">Investor Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_AprilWarrantsMember" xlink:label="SBFM_AprilWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_AprilWarrantsMember" xlink:to="SBFM_AprilWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_AprilWarrantsMember_lbl" xml:lang="en-US">April Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_MayPreFundedWarrantsMember" xlink:label="SBFM_MayPreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_MayPreFundedWarrantsMember" xlink:to="SBFM_MayPreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_MayPreFundedWarrantsMember_lbl" xml:lang="en-US">May Pre Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_MayInvestorWarrantsMember" xlink:label="SBFM_MayInvestorWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_MayInvestorWarrantsMember" xlink:to="SBFM_MayInvestorWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_MayInvestorWarrantsMember_lbl" xml:lang="en-US">May Investor Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PreFunded2024WarrantsMember" xlink:label="SBFM_PreFunded2024WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PreFunded2024WarrantsMember" xlink:to="SBFM_PreFunded2024WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_PreFunded2024WarrantsMember_lbl" xml:lang="en-US">Pre Funded 2024 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_SeriesAWarrantsMember" xlink:label="SBFM_SeriesAWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_SeriesAWarrantsMember" xlink:to="SBFM_SeriesAWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_SeriesAWarrantsMember_lbl" xml:lang="en-US">Series A Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PreFunded2025WarrantsMember" xlink:label="SBFM_PreFunded2025WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PreFunded2025WarrantsMember" xlink:to="SBFM_PreFunded2025WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_PreFunded2025WarrantsMember_lbl" xml:lang="en-US">Pre Funded 2025 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_AprilWarrantsAndMayInvestorWarrantsMember" xlink:label="SBFM_AprilWarrantsAndMayInvestorWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_AprilWarrantsAndMayInvestorWarrantsMember" xlink:to="SBFM_AprilWarrantsAndMayInvestorWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_AprilWarrantsAndMayInvestorWarrantsMember_lbl" xml:lang="en-US">April Warrants And May Investor Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_TradeableWarrants1Member" xlink:label="SBFM_TradeableWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_TradeableWarrants1Member" xlink:to="SBFM_TradeableWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_TradeableWarrants1Member_lbl" xml:lang="en-US">Tradeable Warrants 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_InvestorWarrants1Member" xlink:label="SBFM_InvestorWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_InvestorWarrants1Member" xlink:to="SBFM_InvestorWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_InvestorWarrants1Member_lbl" xml:lang="en-US">Investor Warrants 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_SeriesBWarrants1Member" xlink:label="SBFM_SeriesBWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_SeriesBWarrants1Member" xlink:to="SBFM_SeriesBWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_SeriesBWarrants1Member_lbl" xml:lang="en-US">Series B Warrants 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_AdvanomicsCorporationMember" xlink:label="SBFM_AdvanomicsCorporationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_AdvanomicsCorporationMember" xlink:to="SBFM_AdvanomicsCorporationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_AdvanomicsCorporationMember_lbl" xml:lang="en-US">Advanomics Corporation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Long-Term Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property &amp; equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:label="us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:to="us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_lbl" xml:lang="en-US">Deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use-asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total Long-Term Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable &amp; accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_EarnoutPayable" xlink:label="SBFM_EarnoutPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_EarnoutPayable" xlink:to="SBFM_EarnoutPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_EarnoutPayable_lbl" xml:lang="en-US">Earnout payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Income tax payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion - right-of-use-liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Long-Term Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Right-of-use-liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total Long-Term Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Series B $0.10 par value per share; 1,000,000 shares authorized; 130,000 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, $0.001 par value per share; 3,000,000,000 shares authorized; 4,905,945 and 2,580,098 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Capital paid in excess of par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL SHAREHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">General &amp; Administrative Expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Accounting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US">Consulting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="us-gaap_NoninterestExpenseDirectorsFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseDirectorsFees" xlink:to="us-gaap_NoninterestExpenseDirectorsFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoninterestExpenseDirectorsFees_lbl" xml:lang="en-US">Director fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xml:lang="en-US">Intangible assets impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketingExpense" xlink:label="us-gaap_MarketingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingExpense" xlink:to="us-gaap_MarketingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketingExpense_lbl" xml:lang="en-US">Marketing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Office</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">R&amp;D</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Salaries</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_Taxes" xlink:label="SBFM_Taxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_Taxes" xlink:to="SBFM_Taxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_Taxes_lbl" xml:lang="en-US">Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation &amp; amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Total General &amp; Administrative Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">(Loss) from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Income (Expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeDebtSecuritiesOperating" xlink:label="us-gaap_InterestIncomeDebtSecuritiesOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDebtSecuritiesOperating" xlink:to="us-gaap_InterestIncomeDebtSecuritiesOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeDebtSecuritiesOperating_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="us-gaap_GainsLossesOnSalesOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnSalesOfAssets" xlink:to="us-gaap_GainsLossesOnSalesOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnSalesOfAssets_lbl" xml:lang="en-US">Gain (Loss) on asset sale</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other Income (Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net (loss) before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Other Comprehensive Income:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_lbl" xml:lang="en-US">Gain (Loss) from foreign exchange translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">(Loss) per common share, Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding, Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_2_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_AssetDisposition" xlink:label="SBFM_AssetDisposition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_AssetDisposition" xlink:to="SBFM_AssetDisposition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_AssetDisposition_lbl" xml:lang="en-US">Disposal of tangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Stock issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_IncreaseDecreaseInRightOfUseAsset" xlink:label="SBFM_IncreaseDecreaseInRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_IncreaseDecreaseInRightOfUseAsset" xlink:to="SBFM_IncreaseDecreaseInRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SBFM_IncreaseDecreaseInRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts Payable &amp; accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_IncreaseDecreaseInEarnoutPayable" xlink:label="SBFM_IncreaseDecreaseInEarnoutPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_IncreaseDecreaseInEarnoutPayable" xlink:to="SBFM_IncreaseDecreaseInEarnoutPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_IncreaseDecreaseInEarnoutPayable_lbl" xml:lang="en-US">Earn-out payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US">Income tax payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Flows (Used In) Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Investing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Purchase of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Flows (Used In) Investing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from public offering net (common stock)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Purchase of treasury stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Flows Provided by Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and Cash Equivalents at Beginning of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net (decrease) in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash and Cash Equivalents at End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplementary Disclosure of Cash Flow Information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_StockIssuedForServices" xlink:label="SBFM_StockIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_StockIssuedForServices" xlink:to="SBFM_StockIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SBFM_StockIssuedForServices_lbl" xml:lang="en-US">Stock issued for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PreferredStockIssuedToRelatedParty" xlink:label="SBFM_PreferredStockIssuedToRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PreferredStockIssuedToRelatedParty" xlink:to="SBFM_PreferredStockIssuedToRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_PreferredStockIssuedToRelatedParty_lbl" xml:lang="en-US">Preferred Stock issued to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PreferredStockIssuedToRelatedPartyShares" xlink:label="SBFM_PreferredStockIssuedToRelatedPartyShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PreferredStockIssuedToRelatedPartyShares" xlink:to="SBFM_PreferredStockIssuedToRelatedPartyShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_PreferredStockIssuedToRelatedPartyShares_lbl" xml:lang="en-US">Preferred Stock issued to related party, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Underwritten offering, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Underwritten offering, net of issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_RepurchaseOfWarrants" xlink:label="SBFM_RepurchaseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_RepurchaseOfWarrants" xlink:to="SBFM_RepurchaseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SBFM_RepurchaseOfWarrants_lbl" xml:lang="en-US">Repurchase of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Net (loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Description of Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US">Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xml:lang="en-US">Acquisition of Nora Pharma Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Plant, Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosurePrepaidExpensesAbstract" xlink:label="SBFM_DisclosurePrepaidExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_DisclosurePrepaidExpensesAbstract" xlink:to="SBFM_DisclosurePrepaidExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_DisclosurePrepaidExpensesAbstract_lbl" xml:lang="en-US">Prepaid Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PrepaidExpensesTextBlock" xlink:label="SBFM_PrepaidExpensesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PrepaidExpensesTextBlock" xlink:to="SBFM_PrepaidExpensesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SBFM_PrepaidExpensesTextBlock_lbl" xml:lang="en-US">Prepaid Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosureCostOfSalesAbstract" xlink:label="SBFM_DisclosureCostOfSalesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_DisclosureCostOfSalesAbstract" xlink:to="SBFM_DisclosureCostOfSalesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_DisclosureCostOfSalesAbstract_lbl" xml:lang="en-US">Cost Of Sales</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_CostOfSalesDisclosureTextBlock" xlink:label="SBFM_CostOfSalesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_CostOfSalesDisclosureTextBlock" xlink:to="SBFM_CostOfSalesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SBFM_CostOfSalesDisclosureTextBlock_lbl" xml:lang="en-US">Cost of Sales</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosureReverseStockSplitsAbstract" xlink:label="SBFM_DisclosureReverseStockSplitsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_DisclosureReverseStockSplitsAbstract" xlink:to="SBFM_DisclosureReverseStockSplitsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_DisclosureReverseStockSplitsAbstract_lbl" xml:lang="en-US">Reverse Stock Splits</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_ReverseStockSplitTextBlock" xlink:label="SBFM_ReverseStockSplitTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_ReverseStockSplitTextBlock" xlink:to="SBFM_ReverseStockSplitTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SBFM_ReverseStockSplitTextBlock_lbl" xml:lang="en-US">Reverse Stock Splits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Capital Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosureWarrantsAbstract" xlink:label="SBFM_DisclosureWarrantsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_DisclosureWarrantsAbstract" xlink:to="SBFM_DisclosureWarrantsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_DisclosureWarrantsAbstract_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_WarrantsDisclosureTextBlock" xlink:label="SBFM_WarrantsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_WarrantsDisclosureTextBlock" xlink:to="SBFM_WarrantsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SBFM_WarrantsDisclosureTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosureLeasesAbstract" xlink:label="SBFM_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_DisclosureLeasesAbstract" xlink:to="SBFM_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosureManagementAndDirectorCompensationAbstract" xlink:label="SBFM_DisclosureManagementAndDirectorCompensationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_DisclosureManagementAndDirectorCompensationAbstract" xlink:to="SBFM_DisclosureManagementAndDirectorCompensationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_DisclosureManagementAndDirectorCompensationAbstract_lbl" xml:lang="en-US">Management And Director Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_ManagementAndDirectorCompensationTextBlock" xlink:label="SBFM_ManagementAndDirectorCompensationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_ManagementAndDirectorCompensationTextBlock" xlink:to="SBFM_ManagementAndDirectorCompensationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_ManagementAndDirectorCompensationTextBlock_lbl" xml:lang="en-US">Management and Director Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xml:lang="en-US">Legal Matters</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">PRINCIPLES OF CONSOLIDATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">USE OF ESTIMATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US">TRADE ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">INVENTORY VALUATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionServicesLicensingFees" xlink:label="us-gaap_RevenueRecognitionServicesLicensingFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionServicesLicensingFees" xlink:to="us-gaap_RevenueRecognitionServicesLicensingFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionServicesLicensingFees_lbl" xml:lang="en-US">INTELLECTUAL PROPERTY RIGHTS - PATENTS AND LICENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">BASIC AND DILUTED NET GAIN (LOSS) PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">FUNCTIONAL CURRENCY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">CONCENTRATION OF CREDIT RISKS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">NOTES PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">REVENUE RECOGNITION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="SBFM_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:to="SBFM_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock" xlink:label="SBFM_ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock" xlink:to="SBFM_ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of plant property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_ScheduleOfCostOfSalesTableTextBlock" xlink:label="SBFM_ScheduleOfCostOfSalesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_ScheduleOfCostOfSalesTableTextBlock" xlink:to="SBFM_ScheduleOfCostOfSalesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_ScheduleOfCostOfSalesTableTextBlock_lbl" xml:lang="en-US">Schedule of cost of sales</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_ScheduleOfWarrantsIssuedWithFinancingTableTextBlock" xlink:label="SBFM_ScheduleOfWarrantsIssuedWithFinancingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_ScheduleOfWarrantsIssuedWithFinancingTableTextBlock" xlink:to="SBFM_ScheduleOfWarrantsIssuedWithFinancingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_ScheduleOfWarrantsIssuedWithFinancingTableTextBlock_lbl" xml:lang="en-US">Schedule of warrants issued with financing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of computation of basic and diluted net income per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of components of net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of lease information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PropertyPlantAndEquipmentEstimatedUsefulLives1" xlink:label="SBFM_PropertyPlantAndEquipmentEstimatedUsefulLives1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PropertyPlantAndEquipmentEstimatedUsefulLives1" xlink:to="SBFM_PropertyPlantAndEquipmentEstimatedUsefulLives1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_PropertyPlantAndEquipmentEstimatedUsefulLives1_lbl" xml:lang="en-US">Property and equipment estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_IntangibleAssetsEstimatedUsefulLives" xlink:label="SBFM_IntangibleAssetsEstimatedUsefulLives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_IntangibleAssetsEstimatedUsefulLives" xlink:to="SBFM_IntangibleAssetsEstimatedUsefulLives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_IntangibleAssetsEstimatedUsefulLives_lbl" xml:lang="en-US">Intangible asset estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Reserve for obsolescence</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash, FDIC Insured Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_CashCanadaInsuredAmount" xlink:label="SBFM_CashCanadaInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_CashCanadaInsuredAmount" xlink:to="SBFM_CashCanadaInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_CashCanadaInsuredAmount_lbl" xml:lang="en-US">Cash insured in Canada (USD)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US">Business Combination [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Business Combination [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Purchase price of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US">Payments to acquire shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Stock issued for acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Stock issued for acquisition, value</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_EarnoutLiabilityExpenseFirstInstallment" xlink:label="SBFM_EarnoutLiabilityExpenseFirstInstallment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_EarnoutLiabilityExpenseFirstInstallment" xlink:to="SBFM_EarnoutLiabilityExpenseFirstInstallment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_EarnoutLiabilityExpenseFirstInstallment_lbl" xml:lang="en-US">Earnout liability expense, first installment</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_EarnoutLiabilityExpenseSecondInstallment" xlink:label="SBFM_EarnoutLiabilityExpenseSecondInstallment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_EarnoutLiabilityExpenseSecondInstallment" xlink:to="SBFM_EarnoutLiabilityExpenseSecondInstallment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_EarnoutLiabilityExpenseSecondInstallment_lbl" xml:lang="en-US">Earnout liability expense, second installment</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_EarnoutLiabilityBalance" xlink:label="SBFM_EarnoutLiabilityBalance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_EarnoutLiabilityBalance" xlink:to="SBFM_EarnoutLiabilityBalance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_EarnoutLiabilityBalance_lbl" xml:lang="en-US">Remaining earnout balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Intangible assets gross beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Dossier fee additions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_2_lbl" xml:lang="en-US">Intangible assets gross ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Intangible assets gross beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_ImpairmentOfIntangibleAssetFinitelived" xlink:label="SBFM_ImpairmentOfIntangibleAssetFinitelived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_ImpairmentOfIntangibleAssetFinitelived" xlink:to="SBFM_ImpairmentOfIntangibleAssetFinitelived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_ImpairmentOfIntangibleAssetFinitelived_lbl" xml:lang="en-US">Impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2029</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2030</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Plant, property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_AllowanceForObsoleteInventory" xlink:label="SBFM_AllowanceForObsoleteInventory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_AllowanceForObsoleteInventory" xlink:to="SBFM_AllowanceForObsoleteInventory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_AllowanceForObsoleteInventory_lbl" xml:lang="en-US">Allowance for obsolete inventory</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">Total Inventory, net of allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidTaxes" xlink:to="us-gaap_PrepaidTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidTaxes_lbl" xml:lang="en-US">Prepaid taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PermitsAndInsurance" xlink:label="SBFM_PermitsAndInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PermitsAndInsurance" xlink:to="SBFM_PermitsAndInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_PermitsAndInsurance_lbl" xml:lang="en-US">Permits and insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfRevenue_2_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_WarrantsExercisedDescription" xlink:label="SBFM_WarrantsExercisedDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_WarrantsExercisedDescription" xlink:to="SBFM_WarrantsExercisedDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_WarrantsExercisedDescription_lbl" xml:lang="en-US">Warrants exercised, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Conversion of common stock shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Conversion of common stock value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_lbl" xml:lang="en-US">Stock issued for rounding of reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Stock converted, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Stock converted, shares converted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_2_lbl" xml:lang="en-US">Proceeds from warrant exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Aggregate shares Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_WarrantExpirationDate" xlink:label="SBFM_WarrantExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_WarrantExpirationDate" xlink:to="SBFM_WarrantExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_WarrantExpirationDate_lbl" xml:lang="en-US">Warrant expiration date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Number of warrants outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_WarrantExpirationDate" xlink:to="SBFM_WarrantExpirationDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SBFM_WarrantExpirationDate_2_lbl" xml:lang="en-US">Expiry date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants_lbl" xml:lang="en-US">Payments for repurchase of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_3_lbl" xml:lang="en-US">Proceeds from warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net gain (loss) attributable to common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted average common shares outstanding - basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Basic gain (loss) per share attributable to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Current:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_CurrentIncomeTaxExpenseBenefits" xlink:label="SBFM_CurrentIncomeTaxExpenseBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_CurrentIncomeTaxExpenseBenefits" xlink:to="SBFM_CurrentIncomeTaxExpenseBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_CurrentIncomeTaxExpenseBenefits_lbl" xml:lang="en-US">Total Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total Deferred</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Total Income Tax Expense / (Benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Pre-Tax Book Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Pre-Tax Book Income, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State and Local Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State and Local Income Taxes, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory" xlink:label="SBFM_IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory" xlink:to="SBFM_IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory_lbl" xml:lang="en-US">Effect of Rates Different than Statutory</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate" xlink:label="SBFM_EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate" xlink:to="SBFM_EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate_lbl" xml:lang="en-US">Effect of Rates Different than Statutory, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_IncomeTaxReconciliationOtherForeignTaxes" xlink:label="SBFM_IncomeTaxReconciliationOtherForeignTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_IncomeTaxReconciliationOtherForeignTaxes" xlink:to="SBFM_IncomeTaxReconciliationOtherForeignTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_IncomeTaxReconciliationOtherForeignTaxes_lbl" xml:lang="en-US">Other Foreign Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_EffectiveIncomeTaxRateReconciliationOtherForeignTaxes" xlink:label="SBFM_EffectiveIncomeTaxRateReconciliationOtherForeignTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_EffectiveIncomeTaxRateReconciliationOtherForeignTaxes" xlink:to="SBFM_EffectiveIncomeTaxRateReconciliationOtherForeignTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_EffectiveIncomeTaxRateReconciliationOtherForeignTaxes_lbl" xml:lang="en-US">Other Foreign Taxes, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Permanent Adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Permanent Adjustments, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in Valuation Allowance, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Rate Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Rate Change, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Prior Year True up</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Prior Year True up, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other, Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xml:lang="en-US">Total&#160;</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Total effective income tax rate, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxesAbstract" xlink:label="us-gaap_DeferredIncomeTaxesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAbstract" xlink:to="us-gaap_DeferredIncomeTaxesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxesAbstract_lbl" xml:lang="en-US">Deferred Tax Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net Operating Loss, Credits and Carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Fixed Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangibles</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DeferredTaxAssetsResearchAndDevelopment" xlink:label="SBFM_DeferredTaxAssetsResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_DeferredTaxAssetsResearchAndDevelopment" xlink:to="SBFM_DeferredTaxAssetsResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_DeferredTaxAssetsResearchAndDevelopment_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Lease Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Total Deferred Tax Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred Tax Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US">Other deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Fixed Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US">Intangibles</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US">Right-of-Use Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Total Deferred Tax Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:to="us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_2_lbl" xml:lang="en-US">Net Deferred Tax Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">Federal net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">State net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xml:lang="en-US">Foreign net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DeferredTaxAssetsOperatingLossCarryforwardsProvincial" xlink:label="SBFM_DeferredTaxAssetsOperatingLossCarryforwardsProvincial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_DeferredTaxAssetsOperatingLossCarryforwardsProvincial" xlink:to="SBFM_DeferredTaxAssetsOperatingLossCarryforwardsProvincial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_DeferredTaxAssetsOperatingLossCarryforwardsProvincial_lbl" xml:lang="en-US">Provincial net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US">Net operating loss carryforwards, subject to expiration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating lease ROU asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Operating Lease liability - Short-term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating lease liability - Long-term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2029</link:label>
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xml:lang="en-US">Officers compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseDirectorsFees" xlink:to="us-gaap_NoninterestExpenseDirectorsFees_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NoninterestExpenseDirectorsFees_2_lbl" xml:lang="en-US">Directors compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_2_lbl" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_IncreaseDecreaseInRightOfUseAsset" xlink:to="SBFM_IncreaseDecreaseInRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_IncreaseDecreaseInRightOfUseAsset_2_lbl" xml:lang="en-US">IncreaseDecreaseInRightOfUseAsset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_2_lbl" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_StockIssuedForServices" xlink:to="SBFM_StockIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_StockIssuedForServices_2_lbl" xml:lang="en-US">StockIssuedForServices</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_RepurchaseOfWarrants" xlink:to="SBFM_RepurchaseOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_RepurchaseOfWarrants_2_lbl" xml:lang="en-US">RepurchaseOfWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_2_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_PrepaidExpensesTextBlock" xlink:to="SBFM_PrepaidExpensesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_PrepaidExpensesTextBlock_2_lbl" xml:lang="en-US">PrepaidExpensesTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_CostOfSalesDisclosureTextBlock" xlink:to="SBFM_CostOfSalesDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_CostOfSalesDisclosureTextBlock_2_lbl" xml:lang="en-US">CostOfSalesDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_ReverseStockSplitTextBlock" xlink:to="SBFM_ReverseStockSplitTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_ReverseStockSplitTextBlock_2_lbl" xml:lang="en-US">ReverseStockSplitTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBFM_WarrantsDisclosureTextBlock" xlink:to="SBFM_WarrantsDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SBFM_WarrantsDisclosureTextBlock_2_lbl" xml:lang="en-US">WarrantsDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_3_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>sbfm-20251231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#Cover" roleURI="http://sunshinebiopharma.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#BalanceSheets" roleURI="http://sunshinebiopharma.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#BalanceSheetsParenthetical" roleURI="http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#StatementOfOperationsAndComprehensiveLoss" roleURI="http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#StatementsOfCashFlows" roleURI="http://sunshinebiopharma.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#StatementsOfShareholdersEquity" roleURI="http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#DescriptionOfBusiness" roleURI="http://sunshinebiopharma.com/role/DescriptionOfBusiness" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#AcquisitionOfNoraPharmaInc." roleURI="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc." />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IntangibleAssets" roleURI="http://sunshinebiopharma.com/role/IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#PlantPropertyAndEquipment" roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#Inventory" roleURI="http://sunshinebiopharma.com/role/Inventory" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#PrepaidExpenses" roleURI="http://sunshinebiopharma.com/role/PrepaidExpenses" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#CostOfSales" roleURI="http://sunshinebiopharma.com/role/CostOfSales" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#ReverseStockSplits" roleURI="http://sunshinebiopharma.com/role/ReverseStockSplits" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#CapitalStock" roleURI="http://sunshinebiopharma.com/role/CapitalStock" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#Warrants" roleURI="http://sunshinebiopharma.com/role/Warrants" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#EarningsPerShare" roleURI="http://sunshinebiopharma.com/role/EarningsPerShare" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IncomeTaxes" roleURI="http://sunshinebiopharma.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#Leases" roleURI="http://sunshinebiopharma.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SegmentReporting" roleURI="http://sunshinebiopharma.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#ManagementAndDirectorCompensation" roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#LegalMatters" roleURI="http://sunshinebiopharma.com/role/LegalMatters" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SubsequentEvents" roleURI="http://sunshinebiopharma.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IntangibleAssetsTables" roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#PlantPropertyAndEquipmentTables" roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#InventoryTables" roleURI="http://sunshinebiopharma.com/role/InventoryTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#PrepaidExpensesTables" roleURI="http://sunshinebiopharma.com/role/PrepaidExpensesTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#CostOfSalesTables" roleURI="http://sunshinebiopharma.com/role/CostOfSalesTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#WarrantsTables" roleURI="http://sunshinebiopharma.com/role/WarrantsTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#EarningsPerShareTables" roleURI="http://sunshinebiopharma.com/role/EarningsPerShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IncomeTaxesTables" roleURI="http://sunshinebiopharma.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#LeasesTables" roleURI="http://sunshinebiopharma.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives" roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets" roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#AcquisitionOfNoraPharmaInc.DetailsNarrative" roleURI="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IntangibleAssetsDetails-IntangibleAssets" roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IntangibleAssetsDetails-AmortizationExpense" roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsDetails-AmortizationExpense" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IntangibleAssetsDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/IntangibleAssetsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#PlantPropertyAndEquipmentDetails" roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#PlantPropertyAndEquipmentDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#InventoryDetails" roleURI="http://sunshinebiopharma.com/role/InventoryDetails" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#PrepaidExpensesDetails" roleURI="http://sunshinebiopharma.com/role/PrepaidExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#CostOfSalesDetails" roleURI="http://sunshinebiopharma.com/role/CostOfSalesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#CapitalStockDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#WarrantsDetails-WarrantsIssuedWithFinancing" roleURI="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#WarrantsDetails-WarrantsOutstanding" roleURI="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#WarrantsDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#EarningsPerShareDetails" roleURI="http://sunshinebiopharma.com/role/EarningsPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IncomeTaxesDetails-ProvisionForIncomeTaxes" roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IncomeTaxesDetails-ReconcilationOfTaxRate" roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IncomeTaxesDetails-DeferredTaxes" roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#IncomeTaxesDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#LeasesDetails-LeaseInformation" roleURI="http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#LeasesDetails-MaturitiesOfLeasePayments" roleURI="http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#SegmentReportingDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/SegmentReportingDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="sbfm-20251231.xsd#ManagementAndDirectorCompensationDetailsNarrative" roleURI="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpPensionBenefitsAdjustments" roleURI="http://xbrl.sec.gov/ecd/role/PvpPensionBenefitsAdjustments" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:label="loc_us-gaapDeferredIncomeTaxesAndOtherAssetsNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaapLiabilitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_EarnoutPayable" xlink:label="loc_SBFMEarnoutPayable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_SBFMEarnoutPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaapAccruedIncomeTaxesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedIncomeTaxesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statement Of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaapProfessionalAndContractServicesExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapProfessionalAndContractServicesExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaapNoninterestExpenseDirectorsFees" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapNoninterestExpenseDirectorsFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetImpairment" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetImpairment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaapMarketingExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapMarketingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_Taxes" xlink:label="loc_SBFMTaxes" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_SBFMTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeDebtSecuritiesOperating" xlink:label="loc_us-gaapInterestIncomeDebtSecuritiesOperating" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeDebtSecuritiesOperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="loc_us-gaapGainsLossesOnSalesOfAssets" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnSalesOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_AssetDisposition" xlink:label="loc_SBFMAssetDisposition" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SBFMAssetDisposition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetImpairment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetImpairment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_IncreaseDecreaseInRightOfUseAsset" xlink:label="loc_SBFMIncreaseDecreaseInRightOfUseAsset" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SBFMIncreaseDecreaseInRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_IncreaseDecreaseInEarnoutPayable" xlink:label="loc_SBFMIncreaseDecreaseInEarnoutPayable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SBFMIncreaseDecreaseInEarnoutPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_StockIssuedForServices" xlink:label="loc_SBFMStockIssuedForServices" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_SBFMStockIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity" xlink:title="00000006 - Statement - Consolidated Statements of Shareholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeMember" xlink:label="loc_us-gaapComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PreferredStockIssuedToRelatedParty" xlink:label="loc_SBFMPreferredStockIssuedToRelatedParty" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SBFMPreferredStockIssuedToRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PreferredStockIssuedToRelatedPartyShares" xlink:label="loc_SBFMPreferredStockIssuedToRelatedPartyShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SBFMPreferredStockIssuedToRelatedPartyShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_RepurchaseOfWarrants" xlink:label="loc_SBFMRepurchaseOfWarrants" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SBFMRepurchaseOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="loc_ecdEqtyAwrdsAdjFnTextBlock" />
      <link:presentationArc order="2290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdEqtyAwrdsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/DescriptionOfBusiness" xlink:title="999014 - Disclosure - Description of Business">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc." xlink:title="999016 - Disclosure - Acquisition of Nora Pharma Inc.">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="loc_us-gaapMergersAcquisitionsAndDispositionsDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapMergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssets" xlink:title="999017 - Disclosure - Intangible Assets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PlantPropertyAndEquipment" xlink:title="999018 - Disclosure - Plant, Property and Equipment">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Inventory" xlink:title="999019 - Disclosure - Inventory">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PrepaidExpenses" xlink:title="999020 - Disclosure - Prepaid Expenses">
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosurePrepaidExpensesAbstract" xlink:label="loc_SBFMDisclosurePrepaidExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PrepaidExpensesTextBlock" xlink:label="loc_SBFMPrepaidExpensesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosurePrepaidExpensesAbstract" xlink:to="loc_SBFMPrepaidExpensesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/CostOfSales" xlink:title="999021 - Disclosure - Cost of Sales">
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosureCostOfSalesAbstract" xlink:label="loc_SBFMDisclosureCostOfSalesAbstract" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_CostOfSalesDisclosureTextBlock" xlink:label="loc_SBFMCostOfSalesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureCostOfSalesAbstract" xlink:to="loc_SBFMCostOfSalesDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ReverseStockSplits" xlink:title="999022 - Disclosure - Reverse Stock Splits">
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosureReverseStockSplitsAbstract" xlink:label="loc_SBFMDisclosureReverseStockSplitsAbstract" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_ReverseStockSplitTextBlock" xlink:label="loc_SBFMReverseStockSplitTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureReverseStockSplitsAbstract" xlink:to="loc_SBFMReverseStockSplitTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/CapitalStock" xlink:title="999023 - Disclosure - Capital Stock">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Warrants" xlink:title="999024 - Disclosure - Warrants">
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosureWarrantsAbstract" xlink:label="loc_SBFMDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_WarrantsDisclosureTextBlock" xlink:label="loc_SBFMWarrantsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureWarrantsAbstract" xlink:to="loc_SBFMWarrantsDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/EarningsPerShare" xlink:title="999025 - Disclosure - Earnings Per Share">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxes" xlink:title="999026 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/Leases" xlink:title="999027 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosureLeasesAbstract" xlink:label="loc_SBFMDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SegmentReporting" xlink:title="999028 - Disclosure - Segment Reporting">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" xlink:title="999029 - Disclosure - Management and Director Compensation">
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosureManagementAndDirectorCompensationAbstract" xlink:label="loc_SBFMDisclosureManagementAndDirectorCompensationAbstract" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_ManagementAndDirectorCompensationTextBlock" xlink:label="loc_SBFMManagementAndDirectorCompensationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureManagementAndDirectorCompensationAbstract" xlink:to="loc_SBFMManagementAndDirectorCompensationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LegalMatters" xlink:title="999030 - Disclosure - Legal Matters">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaapLegalMattersAndContingenciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLegalMattersAndContingenciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SubsequentEvents" xlink:title="999031 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999032 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaapReceivablesPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReceivablesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionServicesLicensingFees" xlink:label="loc_us-gaapRevenueRecognitionServicesLicensingFees" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionServicesLicensingFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaapDebtPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDebtPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999033 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_SBFMPropertyPlantAndEquipmentUsefulLivesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SBFMPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock" xlink:label="loc_SBFMScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SBFMScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssetsTables" xlink:title="999034 - Disclosure - Intangible Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables" xlink:title="999035 - Disclosure - Plant, Property and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/InventoryTables" xlink:title="999036 - Disclosure - Inventory (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PrepaidExpensesTables" xlink:title="999037 - Disclosure - Prepaid Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosurePrepaidExpensesAbstract" xlink:label="loc_SBFMDisclosurePrepaidExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosurePrepaidExpensesAbstract" xlink:to="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/CostOfSalesTables" xlink:title="999038 - Disclosure - Cost of Sales (Tables)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosureCostOfSalesAbstract" xlink:label="loc_SBFMDisclosureCostOfSalesAbstract" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_ScheduleOfCostOfSalesTableTextBlock" xlink:label="loc_SBFMScheduleOfCostOfSalesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureCostOfSalesAbstract" xlink:to="loc_SBFMScheduleOfCostOfSalesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsTables" xlink:title="999039 - Disclosure - Warrants (Tables)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosureWarrantsAbstract" xlink:label="loc_SBFMDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_ScheduleOfWarrantsIssuedWithFinancingTableTextBlock" xlink:label="loc_SBFMScheduleOfWarrantsIssuedWithFinancingTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureWarrantsAbstract" xlink:to="loc_SBFMScheduleOfWarrantsIssuedWithFinancingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureWarrantsAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/EarningsPerShareTables" xlink:title="999040 - Disclosure - Earnings Per Share (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxesTables" xlink:title="999041 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LeasesTables" xlink:title="999042 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosureLeasesAbstract" xlink:label="loc_SBFMDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives" xlink:title="999043 - Disclosure - Summary of Significant Accounting Policies (Details - Estimated lives)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaapVehiclesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapVehiclesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PropertyPlantAndEquipmentEstimatedUsefulLives1" xlink:label="loc_SBFMPropertyPlantAndEquipmentEstimatedUsefulLives1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_SBFMPropertyPlantAndEquipmentEstimatedUsefulLives1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets" xlink:title="999044 - Disclosure - Summary of Significant Accounting Policies (Details - Intangible assets)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_LicensesMember" xlink:label="loc_SBFMLicensesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_SBFMLicensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_WebsiteMember" xlink:label="loc_SBFMWebsiteMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_SBFMWebsiteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_IntangibleAssetsEstimatedUsefulLives" xlink:label="loc_SBFMIntangibleAssetsEstimatedUsefulLives" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_SBFMIntangibleAssetsEstimatedUsefulLives" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999045 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryValuationReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_CashCanadaInsuredAmount" xlink:label="loc_SBFMCashCanadaInsuredAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SBFMCashCanadaInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative" xlink:title="999046 - Disclosure - Acquisition of Nora Pharma Inc. (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_NoraPharmaMember" xlink:label="loc_SBFMNoraPharmaMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_SBFMNoraPharmaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_srtCounterpartyNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_MalekChamounMember" xlink:label="loc_SBFMMalekChamounMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_SBFMMalekChamounMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_EarnoutPayable" xlink:label="loc_SBFMEarnoutPayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SBFMEarnoutPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_EarnoutLiabilityExpenseFirstInstallment" xlink:label="loc_SBFMEarnoutLiabilityExpenseFirstInstallment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SBFMEarnoutLiabilityExpenseFirstInstallment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_EarnoutLiabilityExpenseSecondInstallment" xlink:label="loc_SBFMEarnoutLiabilityExpenseSecondInstallment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SBFMEarnoutLiabilityExpenseSecondInstallment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_EarnoutLiabilityBalance" xlink:label="loc_SBFMEarnoutLiabilityBalance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_SBFMEarnoutLiabilityBalance" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets" xlink:title="999047 - Disclosure - Intangible Assets (Details - Intangible assets)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsPeriodIncreaseDecrease" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_ImpairmentOfIntangibleAssetFinitelived" xlink:label="loc_SBFMImpairmentOfIntangibleAssetFinitelived" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_SBFMImpairmentOfIntangibleAssetFinitelived" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssetsDetails-AmortizationExpense" xlink:title="999048 - Disclosure - Intangible Assets (Details - Amortization expense)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IntangibleAssetsDetailsNarrative" xlink:title="999049 - Disclosure - Intangible Assets (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails" xlink:title="999050 - Disclosure - Plant, Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaapVehiclesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapVehiclesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetailsNarrative" xlink:title="999051 - Disclosure - Plant, Property and Equipment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/InventoryDetails" xlink:title="999052 - Disclosure - Inventory (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_AllowanceForObsoleteInventory" xlink:label="loc_SBFMAllowanceForObsoleteInventory" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_SBFMAllowanceForObsoleteInventory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/PrepaidExpensesDetails" xlink:title="999053 - Disclosure - Prepaid Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosurePrepaidExpensesAbstract" xlink:label="loc_SBFMDisclosurePrepaidExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaapPrepaidTaxes" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosurePrepaidExpensesAbstract" xlink:to="loc_us-gaapPrepaidTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PermitsAndInsurance" xlink:label="loc_SBFMPermitsAndInsurance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosurePrepaidExpensesAbstract" xlink:to="loc_SBFMPermitsAndInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosurePrepaidExpensesAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosurePrepaidExpensesAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/CostOfSalesDetails" xlink:title="999054 - Disclosure - Cost of Sales (Details)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosureCostOfSalesAbstract" xlink:label="loc_SBFMDisclosureCostOfSalesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureCostOfSalesAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapTransactionTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_FinishedGoodsMember" xlink:label="loc_SBFMFinishedGoodsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_SBFMFinishedGoodsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_ProfessionalAllowancesMember" xlink:label="loc_SBFMProfessionalAllowancesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_SBFMProfessionalAllowancesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_OtherAllowancesMember" xlink:label="loc_SBFMOtherAllowancesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_SBFMOtherAllowancesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_WholesalersFeesAndDiscountsMember" xlink:label="loc_SBFMWholesalersFeesAndDiscountsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_SBFMWholesalersFeesAndDiscountsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_InventoryAdjustmentMember" xlink:label="loc_SBFMInventoryAdjustmentMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_SBFMInventoryAdjustmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_FreightMember" xlink:label="loc_SBFMFreightMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_SBFMFreightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative" xlink:title="999055 - Disclosure - Capital Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_SeriesBWarrantsMember" xlink:label="loc_SBFMSeriesBWarrantsMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_SBFMSeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PreFundedWarrants2024Member" xlink:label="loc_SBFMPreFundedWarrants2024Member" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_SBFMPreFundedWarrants2024Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_SeriesBWarrantsMember" xlink:label="loc_SBFMSeriesBWarrantsMember_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_SBFMSeriesBWarrantsMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_RegisteredDirectOfferingMember" xlink:label="loc_SBFMRegisteredDirectOfferingMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_SBFMRegisteredDirectOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_WarrantsExercisedDescription" xlink:label="loc_SBFMWarrantsExercisedDescription" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_SBFMWarrantsExercisedDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing" xlink:title="999056 - Disclosure - Warrants (Details - Warrants issued with financing)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosureWarrantsAbstract" xlink:label="loc_SBFMDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureWarrantsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_TradeableWarrantsMember" xlink:label="loc_SBFMTradeableWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMTradeableWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PreFunded2022WarrantsMember" xlink:label="loc_SBFMPreFunded2022WarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMPreFunded2022WarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_InvestorWarrantsMember" xlink:label="loc_SBFMInvestorWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMInvestorWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_AprilWarrantsMember" xlink:label="loc_SBFMAprilWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMAprilWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_MayPreFundedWarrantsMember" xlink:label="loc_SBFMMayPreFundedWarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMMayPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_MayInvestorWarrantsMember" xlink:label="loc_SBFMMayInvestorWarrantsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMMayInvestorWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PreFunded2024WarrantsMember" xlink:label="loc_SBFMPreFunded2024WarrantsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMPreFunded2024WarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_SeriesAWarrantsMember" xlink:label="loc_SBFMSeriesAWarrantsMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMSeriesAWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_SeriesBWarrantsMember" xlink:label="loc_SBFMSeriesBWarrantsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMSeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_PreFunded2025WarrantsMember" xlink:label="loc_SBFMPreFunded2025WarrantsMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMPreFunded2025WarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_WarrantExpirationDate" xlink:label="loc_SBFMWarrantExpirationDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SBFMWarrantExpirationDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding" xlink:title="999057 - Disclosure - Warrants (Details - Warrants outstanding)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosureWarrantsAbstract" xlink:label="loc_SBFMDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureWarrantsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_TradeableWarrants1Member" xlink:label="loc_SBFMTradeableWarrants1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMTradeableWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_InvestorWarrants1Member" xlink:label="loc_SBFMInvestorWarrants1Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMInvestorWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_SeriesBWarrants1Member" xlink:label="loc_SBFMSeriesBWarrants1Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMSeriesBWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_WarrantExpirationDate" xlink:label="loc_SBFMWarrantExpirationDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SBFMWarrantExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" xlink:title="999058 - Disclosure - Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosureWarrantsAbstract" xlink:label="loc_SBFMDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureWarrantsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_AprilWarrantsAndMayInvestorWarrantsMember" xlink:label="loc_SBFMAprilWarrantsAndMayInvestorWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMAprilWarrantsAndMayInvestorWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_TradeableWarrantsMember" xlink:label="loc_SBFMTradeableWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMTradeableWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_InvestorWarrantsMember" xlink:label="loc_SBFMInvestorWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMInvestorWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_SeriesBWarrantsMember" xlink:label="loc_SBFMSeriesBWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_SBFMSeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaapPaymentsForRepurchaseOfWarrants" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/EarningsPerShareDetails" xlink:title="999059 - Disclosure - Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes" xlink:title="999060 - Disclosure - Income Taxes (Details - Provision for income taxes)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaapComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_CurrentIncomeTaxExpenseBenefits" xlink:label="loc_SBFMCurrentIncomeTaxExpenseBenefits" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SBFMCurrentIncomeTaxExpenseBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaapComponentsOfDeferredTaxAssetsAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate" xlink:title="999061 - Disclosure - Income Taxes (Details - Reconcilation of tax rate)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory" xlink:label="loc_SBFMIncomeTaxReconciliationEffectOfRatesDifferentThanStatutory" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SBFMIncomeTaxReconciliationEffectOfRatesDifferentThanStatutory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate" xlink:label="loc_SBFMEffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SBFMEffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_IncomeTaxReconciliationOtherForeignTaxes" xlink:label="loc_SBFMIncomeTaxReconciliationOtherForeignTaxes" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SBFMIncomeTaxReconciliationOtherForeignTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_EffectiveIncomeTaxRateReconciliationOtherForeignTaxes" xlink:label="loc_SBFMEffectiveIncomeTaxRateReconciliationOtherForeignTaxes" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SBFMEffectiveIncomeTaxRateReconciliationOtherForeignTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes" xlink:title="999062 - Disclosure - Income Taxes (Details - Deferred taxes)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxesAbstract" xlink:label="loc_us-gaapDeferredIncomeTaxesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DeferredTaxAssetsResearchAndDevelopment" xlink:label="loc_SBFMDeferredTaxAssetsResearchAndDevelopment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SBFMDeferredTaxAssetsResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaapDeferredTaxLiabilitiesAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaapDeferredTaxLiabilitiesOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaapDeferredTaxLiabilitiesLeasingArrangements" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:label="loc_us-gaapDeferredIncomeTaxesAndOtherAssetsNoncurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="999063 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DeferredTaxAssetsOperatingLossCarryforwardsProvincial" xlink:label="loc_SBFMDeferredTaxAssetsOperatingLossCarryforwardsProvincial" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SBFMDeferredTaxAssetsOperatingLossCarryforwardsProvincial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation" xlink:title="999064 - Disclosure - Leases (Details - Lease information)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosureLeasesAbstract" xlink:label="loc_SBFMDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments" xlink:title="999065 - Disclosure - Leases (Details - Maturities of lease payments)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosureLeasesAbstract" xlink:label="loc_SBFMDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_SBFMLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureLeasesAbstract" xlink:to="loc_SBFMLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/SegmentReportingDetailsNarrative" xlink:title="999066 - Disclosure - Segment Reporting (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" xlink:title="999067 - Disclosure - Management and Director Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_DisclosureManagementAndDirectorCompensationAbstract" xlink:label="loc_SBFMDisclosureManagementAndDirectorCompensationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SBFMDisclosureManagementAndDirectorCompensationAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="sbfm-20251231.xsd#SBFM_AdvanomicsCorporationMember" xlink:label="loc_SBFMAdvanomicsCorporationMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SBFMAdvanomicsCorporationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaapNoninterestExpenseDirectorsFees" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNoninterestExpenseDirectorsFees" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !L /H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBO//B#
M\2$\-[M+TO9+JA7YW/*VX/3([MCH/Q/H;A!S=D1.<8*\CK=<\3:1X<@$NJ7L
M<&X92/J[_11R?KTKSB^^,EU>W8M/#FBF61SA&N269O\ @"]/^^J\K1=2\1ZR
MJM)+=WUR_+R-DGW)[ ?H*]Q\,^$]%\.605)GDNW4>=/Y?+'T'H/:N7,\90R^
MG9M.H]DY**]7Y?F8T/:XF7NZ1[VN/TB3Q-<JMQKFNK 3S]CM+=-H]F<@D_0'
M\370KJ#K_P OI/UA%0>78?\ />7_ +XH\NP_Y[R_]\5\!6S''5I\\IP7I.R^
MY/\ S/;A1IP5DG\U<T(]7B _>/N/JJ$?UJW;7MO=Y$,@+#DJ>&'X5B>78?\
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MP_KAECU6VC;H[1M+M'WLC!##N/Q]<:G@ZWFT_P"&1U&S\V?4Y[.2<,[M(7D
M8H "2/08'6E*DX[[A&JI:K8[NBO"_"%QX;\1:?=6GB'4;F+7IY#Y=W/<..OW
M=ISM&#V/7/Y=]XNTV2#X9N+R9Y+^PLUQ/%*ZYD  +<$9S[U4J7++E;%&MS1<
MDCMJ*\J^&>IZ%#X6EDU;6;=+VY=XY5NK_:VSH  6X[\CFLOP+!;W_P 4M3MU
MO)[G3[,2SV@6Z=D^650ASGY@ W?.:'1MS:["5>_+9;^9[317CGQH1M.O=+N[
M.:>":[$HF*3. VP1A>,X'!/2NP\8Z!9V_@&[CMFN(C80/- ZW#[@PY.3GYL^
M^>M+V:M%WW*]J[R5MCLZ*\8\%>*[[PKJA\.^*&D%K= 207$C$[-PX.[^X?7L
M?QQU7A?1+6W\?>(BCW#1V+0"U1[AV6/S(MS<$\]>,YQ1*ERWNQ1K<UK+_@'>
MT5X?K=O:P?&$:7<7L]MI4C*TBF[=%!,>[[Q;C+>_>NX\,Z9I,?BRYGT'4YY[
M>UM_)N8VN#-&S.0RE6)/(VG/U'O1*DHJ]^EPC5<G:W6VYT%U?ZC!/=A+?S8X
M?+*!8'S(&;Y@#G!(4'\2,XJ[IMS/=6K2W,!AD\V10A4@A5<A3SUR #GIS5NB
MLKZ&R6NX4444AGS/\1YFG^(.L.W42JGX*BC^E86D(LFM6$;_ '&N(PW&>"P[
M5M_$.-HO'^L*XP3,&_ J"/T-8>E7"VFL65R^-D-Q'(V?0,#7L*_LM.WZ'AR_
MB._?]3Z>^V:9_P ^W_C@H^V:9_S[?^."IO[1L_\ G@__ '[%']HV?_/!_P#O
MV*_-?:0_Y_TO_!9]59_RO[R'[9IG_/M_XX*/MFF?\^W_ (X*F_M&S_YX/_W[
M%']HV?\ SP?_ +]BCVD/^?\ 2_\ !86?\K^\A^V:9_S[?^."C[9IG_/M_P".
M"IO[1L_^>#_]^Q1_:-G_ ,\'_P"_8H]I#_G_ $O_  6%G_*_O(?MFF?\^W_C
M@KD-%D6+Q9$8_N&9E';@Y%=HVI62J6,+  9/[L5PNAYG\1VK$<F7><?G7T>1
MVDJK4X25E\,>7OOW/+QSM*"LUKU?H=7XXFU.U\+3WFD&3[7;21S!(\DNJN-R
MD#J,9R/2J-O\2/"U[HAN[B^BB)C/FVD@S(#CE=O\7IQP:Z>^U"STRV-S?74-
MM #@R2N%&?3)K/LM5\.:E?K]CN].GO"-Z[&0R$>H[FO4C;EU0Y7YM&<;\'M!
MO-,T[4=0NH'MX[YT\B*0$-L7=\Q'H=W'TSWK"T6]B\$?%K6%U@&VM+XR^5,X
M.W#.'4Y],<'T/T->KR:]I,.I+ITFH6ZWK$!8"XWG/3BC5=0TFT5(M4GME\S[
MD4N&+X]%ZG\!5^T;DVUN9^R2BE%_"<T=2MO$_CS1I-(D%S::4D\MS<H,QAG3
M8J!NA/.>.U5?&7B'3++QKX9@N+V*/[-/))< G_5!H\*6],[J['2]1TO4("-+
MN;>6.([66$CY#Z$#I]#5:3Q7X?BGD@DUJQ62,X=3.HVGWYXJ4]=MBFO=WW.(
M^(7@=[X#Q/X<RE^@$LB0<&8?WUQ_%C\Q[]=;0[Z\TWX06E]IT2S7,%F)%C8$
MA@&^8<>V:ZJ\UO2]/MHKF[U"VA@E_P!7*\@"M]#T-+)JFFV6FI>R74$-D0-L
MI(5.>G-'/)Q46K_UL'LXJ3DG:Z_IGC_CE_!>OZ NKZ0\46MRNF+:$$22,3AE
M=!W')W=R.IS74:U-+I?P86UUJ817TEF(520_,S=E^H4<_0UW-C)IU\@O['[/
M,LG2>( [OQ[U/;WEM>>:;:>.812&*0HP.UQU4^XS5.KHE;9B5+5N^Z/,/A4O
MAVZ\)2QWD.GRWEN\DLWG1*76/CYB2.GO6-X$U;2+;XLZO+'/#!9W0FAM2,*C
M$RH5"]AD XKU>?Q5H%M=2VT^L64<\1Q(C3+E#WSZ5=DU*QCT_P"WM=P_8]N[
MSPX*8]<CC%-U'[UT]2535HV:]T\@^-]_:SWNDV<4Z/<VPF,\:G)CW",KGTR!
MFNT\;>)-*E^'=[<P7\#QWT#16Y!SYA/! 'J.<^E==97MKJ-HEW97$=Q;R9V2
MQL&5L'!P1[@BH6U?3DU(::U[ +T@-]GWC?@]\5//I%6V*]GK)W^(Y&^\/Z1\
M0O!-F;6XB:Y@A58;E>3&X491N^/4?C6;\)K:_L+CQ#::KO6\MW@1Q(V2%56"
M\^FT#!]*]'N+RVM/*%Q/'$9I!%&'8#>YZ*/4U*$4,S!0&;&2!R:7M'RN/1E>
MR7,I=4>#ZUK>A7'QCCU*>>"YTE2@DDV>9&?W>.F#G!Q^5=SI/B/PK;>(8[3P
MLL<]SJLR+-#!&8HHD16)<#:!G&>._M77SZ]I-MJ*Z?/J%O'>-@+ S@.<],"I
M+?6-.N[^6P@O8)+N$9D@5QO4=,D=>X_.JE.Z6CV(C3LV[K<NT52GU?3[6^BL
M9[R*.ZF_U<+-AG^@[TM_JVGZ6J-?7D-OO.$$C@%SZ*.I/TK"S.BZ+E%4+#6]
M,U262*RO89I8QEXU;YU'J5/(J_0TUN":>QX5\:-(:U\26VJ*O[J\A"LW^VG'
M_H)7\C7F=?4/C/PW'XI\-W&GG:LX_>6[G^&0=/P/(/L:^8[FVFL[J6VN(VBF
MB<I(C#!5@<$&O4PU3FA;JCR<53Y9WZ,^DO!OB8:UX4L+HPSRS+&(IF1,_O%&
M#W[]?QK>^W_].EU_W[_^O7A/PM\8+X>U=]/O"?L-Z0 ?^><O0'Z'H?P]*]Y^
MUM_SZW'_ 'R/\:^=QL:M&JTZUD]5[B>GKJ>KAJD:E-.VJWU&?;_^G2Z_[]__
M %Z/M_\ TZ77_?O_ .O3_M;?\^MQ_P!\C_&C[6W_ #ZW'_?(_P :X_:S_P"?
M_P#Y3_X!TV7\OXC/M_\ TZ77_?O_ .O1]O\ ^G2Z_P"_?_UZ?]K;_GUN/^^1
M_C3)M16WA:6:"9(T&69@,#]:/:S_ .?_ /Y3_P" *R_E_$R?$>L"'298A#-'
M)./+4NN.._Z?SK#\&6IFU=K@CY8$)S[G@?IFL_6]5?5]0,H!$2_+$A[#_$UV
M_AS3#IFE*LBXGE^>3V]!^ _K7T<(3H8?EJ2YI/R2_!=CRN95J_-%:(@\;?\
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%HH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !R D0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJEJ
M&LV.E+F[NXH/9FY_+K7,:A\4;"#*VD$MVW]YOD7]>?TII-["O8[2D+!022 !
MW->47?Q%UG4&*6PCMP?X8$WM^9S_ "JM_8GB77F#2Q7<H/>X?:OY$C^57R=Q
M<QZ;>>)])L"1/J$"M_=#[C^0K&NOB9I,.1$MQ<$?W4VC]2*YNU^%VI2@&:>W
MMAZ#+G^E:]M\*K5,?:+^:3U$:A1_6BT5U"[*US\5G.1;Z<![RR_T K,G^)NK
MRD[%MH!_LH3_ #-=C;_#S1(/O6[S'_IK*Q_EBM&W\+Z1;?ZO3K8'U,8/\Z+Q
M[!9GETOCK6[@_P#(09?:-%']*B.MZ[<]+R_?/]PM_2O9(K.WA_U<$<?^Z@%3
M4<Z[!;S/%-FO7';4WS_UTH_LG77_ .7;46^H>O:Z*.?R#E/$_P"QM<_Y]-0_
M[Y>@V&N1\^1J2_A)7ME%'/Y!RGB?FZ[!_'J4?XR4X>(-=M^M]>K_ +Y)_F*]
MJI.M'/Y"Y3QV+Q[K=OP;[?[21J?Z5H6_Q0U2,?O(K:<?[I4_H:].DM()?OPQ
MO_O*#52;0-,G'[S3[9O^V2_X4<T>P[,X^V^*RG N-.8>IBD!_0@5KVOQ'T:X
M($DDML?^FL9Q^8S5R7P/H<V<Z?&I]4)7^1JA/\,]'ER4^T0G_8ES_,&CW6&I
MO6>N:?J 'V:]@F)[*XS^76KU<#<?"B$Y,&H2*>WF1@_J,5''X0\3Z0/]!U59
M%'1#(P'Y,"*5ET879Z%17$Q:]XJTPXOM(%Z@ZO!C=^F?Y5?M/B!ILK".[6;3
M9>ZW,9 _.ERL=SIZ*BM[J&[C$D$J31GHT;!A^E2U(PHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ.:=((R[YP.P!)/T H DJ*XN
M8K2(RS2I%&.KNP %9-S=ZQ?92PM8[)#_ ,O%X<M^"#^I'TJ@/ <=]*)M7O[G
M4I1_"3L0?0"G;N*Y#JOQ+T^T8QV2/?S= 5^5/SZG\!6-)>>+_$O^IA>R@;^Z
M/*&/J>3^%=W8:)8:6N+6TB@_VE7G\^M7JJZ6R%9L\ZLOA9/,WF7]^ QY(B4L
MQ_X$?\*Z&Q^'NBV>"UNURWK.Y/Z<"NDHI.38[(@MK*WLEVV\$<"^D:!?Y5/1
M14C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HYH(KA-L
ML:2K_==014E% &._A/31(98(6LIO^>EHYB/Y#@_B*L0VM_:8"W2WD8[7"[7_
M .^EX_2M"BG<"))6*_-$RMW&0:*EHI %%%% &/XQUEO#WA35]30A7M+625"P
MR-P4XS^.*^4%_:>\<[1F[L<XY_T0?XU[_P#M$ZF-*^#WB)R<&6)(!_P-U7^M
M?"OVT^M?=9!@J->A.I5@I:VU7DO\S\@XSS7%83&4J.&JN'NW=FUNW_D>V?\
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MYVN[V_)GIW_#3OCG_G[L?_ 0?XU[W\!?B!J7Q#\(W-[JTD4M[#=O"3#&$&W
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MU:$O94K3Z:6^>G8]#+LHXAP^,A]8Q+=)/7WG+1=+2778[NBBBOCS]/"BBB@
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MC3;9)M4U)8HX)Y>8X N[+%?XC\PP.GKZ5XS_ &F/7]:[3X7?#;Q%\7];?3M
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MKLSJ=9\4V-I'W6QMWF;\V*C]*]C\"?LH>!/!<T5U/:2^(+Z/!$VJ,'0-ZB(
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MU^F]>9_&7]GKPA\<+.,:[:R0:E I6WU2R81W$0_NYP0RYYVL"/3%?!Y/CZ>
MQ#G55TU;S1^E\1955S;"*E1E:47>W1^7^1S'['.I>&;_ ."^F+H3P'4(]PU9
M%(\X7.3DR=\$8VGIC'O7M=]86VIV<MI>6\5U:S+LDAF0.CCT(/!%?#\_[!OQ
M"\#:R=3\ _$"WAG3_5RR^;93X_NDQ[U;\>/:NGLO"O[7>EP^0GB?0+M5X$EP
M878_B80?SKIQ>$P^)K2KT,3'WG?WKIK\#GP&,Q6$P\,+B<)+W5;W;-.WSZ_,
MVOB]^Q+8:RL^H^!+I-'O#ECI5T2UK(?1&Y:,^W(^E>0^%/VD/B-^SEX@_P"$
M8\8V4VHV5OC=IVH2@S1Q]FAF!.5XX!R/I7I%S\&_VGO&BM%K?Q.TS1;9^'73
M69&QWQY42'_QX5I^"O\ @G]X7T^Z-]XQU_4O%]XYW2(6-O$S=RQ#%V_[[%>I
M3QE"G1=',*L:JZ))M_\ @6G^?F>%6RS$5,0L1E-&5"75MI1?_;NO^7D> ^+O
M'_BW]K3XIVUGI%B%PK)8:<9@([6$'+R2,>IZ%B!V  K[G^"7PAL?@WX,BTF"
M07>H3'SK^]VX,\N.P[*.@'I[DU\S>/O^">M_;ZU%?_#OQ4EA$'WK;ZN\BR6Y
M[&.:,$G\0#[FO;_@SX=^-G@TP:=XUUGPYXLTA?E%XDTR7T0_WC%MD_X%@_[5
M<^:8BAB,-"G@ZB4%]G5/_@_T]3KR7 XC"8VI7Q]*4JLOMZ-?<MO\M+(]KK\F
M/CGJ)C^-'CE<GC6+@?\ CYK]9J^&_B3^P1XR\:_$+Q)X@M?$^B6]MJ=_+=Q0
MS)-O17;(#87&?I7/P_BZ&$JU)5Y<J:_4Z^*LOQ&84*4,/'F:=_P/D7^U&_O&
MOL7_ ()U71N=3\< G.(K7^<E<A_P[A\<_P#0VZ!_WQ/_ /$U[]^R?^S3KWP
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MES?^'(M/OY.6O=)8VLA/J0ORL?=E-?=8+B:T5#%QOYK]5_E]Q^89AP7&4G/
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M112OV'8:D:Q($10BJ,!5& *=114C"BBB@ HHHH **** "BBB@ HHHH ****
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MK;R?[LN/YBBT0NSN$\>:$_\ R_!?]Z-A_2I5\::(W348?QR/Z5YS)X#UV/\
MY<MW^[(I_K5=_!^M)UTV8_3!_K1RQ[A=GJ0\7:,?^8E;_B].'BO1R,C4K;_O
MX*\G/A;6!_S#+G\$S1_PC&L?] RZ_P"_9HY5W"[/5O\ A+=&'_,3MO\ OL4U
MO&6B+UU*#\#FO*_^$8U@G_D&77_?LTY?">LMTTRX_%0/ZT<J[A=GIC^.]"0?
M\?ZM_NHQ_I5:3XCZ(G2663_=B;^M<$G@G7).FGN/]YU']:LQ_#S7'ZP11_[T
MH_I1RQ[A=G4S?%+34_U=M=2?557^M4Y?BNO_ "RTUC[O*!_(5FP_"_57_P!9
M<6L?_ F/]*NP?"F4_P"NU)1[1Q9_F:+00:E>7XIWS9\NRMT_WF9O\*HS?$;6
MY?NRP0_[D0_KFNEM_A;8)_KKNYE_W=J_TK2M_A]H=OUM3,?661C_ %HO%!9G
MG$_C#69R=^IS+GLA"?RJND&JZNWRK>7A/^\P_P *]DM="TZR_P!18V\1]5C&
M?SJZ!@8' HYUT0<IY%9?#W6;O!:WCME/>9P#^0R:W['X5(,->7S-ZI F/U.?
MY5W]%2YMCY486G^"='T[!2S65Q_'.=Y_7BMM$5%"J JCH , 4ZBIO<H****0
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X98W0
MLM=AN&1I%BN"Y5!ECACP*]SKQ+1/^1IL_P#K[_\ 9C6D.I$CO_\ A9%E_P ^
M-_N]/)'^-5KGQOJ=_&R:5HER'/ EF0\>^.GYFNWHJ;KL59GG?AKX?W9OH[W5
M2$"OY@A!W,[9S\QZ#FO0+C_CWE_W3_*I*CN/^/>7_=/\J&VV"5CQGPG_ ,C/
MIW_7<5[57B/AJXCM?$-C+,ZQQ),"SL< #WKUG_A*M'_Z"=K_ -_15S6I,=C5
MHK*_X2K1_P#H)VO_ ']%6K'5;/4]_P!DN8KC9C=Y; XSTS6=BSSGXI?\AZW_
M .O8?^A-79>!?^15L/\ =;_T(UQOQ2_Y#UO_ ->P_P#0FKH_!WB#3;/PW90S
MWT$4JJ=R.X!'S&M'\*(6YUU%97_"5:/_ -!.U_[^BG1^)M)ED5$U&V9V( 42
M#)/I6=F6>0:G,]_KUP]P3NDN"KD]ANQ_*O;H(8[>&.*)0L:*%4#H!7!>-? L
M]Q<RZAIR>;YGS2VXZY]5]?I4?A_XAMIL:66L0RAHQM$H7Y@/]I3S^(K1^\M"
M%H]3T6BL>V\7:-=@%-1@&>SML/ZXJRVO::JY.H6H'_79?\:SLRR_169;>)-+
MO+M+6"^AFG?.U$;.<>]:=( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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7J\AQ&-P/L<5V%%%82W-([!1114%'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>bushheader.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bushheader.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !2 D,# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0<!<]1UH ^YZ*JZ5=-?:9:7+IY;S0I(4)SM) ./UJU0 4444 %%%% !1110
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M'U/2NEKX0_X*\?&$^ OV<XO"=K+LU'Q??K:NH;YOLL6))#]"PC7\30!\9?\
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M(H&1SFOTEA\':#;78NX=%T^*ZSGSTM(P_P"8&:U#"I.><_6@#\2_%.D7R?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
%BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !; = # 2(  A$! Q$!_\0
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MG]U_SXP?]]FNPTK4HM5TZ*[BXW##+_=;N*BKAZE)7DC6AC:%>7+3>I=HHHK
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MA3XC65E2:Q= 2%8R,,CUQMXKTZ6+I586J:'C5LNK4:G-1NUT[H]1\.^)]/\
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MHW4NOU6I5U&T;I<)^/%%@+5%1K/"_P!V5#]&%2 @]#2 **** "BBB@ HHHH
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J*^M8;=B8E*'V8U06:4L%,LF/]\T[!<ZRBLW3(D5C(,[B,$EB:TJD9__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Apr. 02, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SUNSHINE BIOPHARMA INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001402328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-5566275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">333 Las Olas Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">CU4 Suite 433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Fort Lauderdale<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">330-0684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,061,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,905,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">M&K CPAS, PLLC<span></span>
</td>
<td class="text">Bush &
Associates CPA LLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">The Woodlands,
TX<span></span>
</td>
<td class="text">Henderson, Nevada<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">2738<span></span>
</td>
<td class="text">6797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SBFM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SBFMW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,123,308<span></span>
</td>
<td class="nump">$ 9,686,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">3,459,864<span></span>
</td>
<td class="nump">3,868,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">13,472,025<span></span>
</td>
<td class="nump">11,278,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">798,384<span></span>
</td>
<td class="nump">1,133,297<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">26,853,581<span></span>
</td>
<td class="nump">25,966,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Long-Term Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property &amp; equipment</a></td>
<td class="nump">557,370<span></span>
</td>
<td class="nump">546,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">1,889,370<span></span>
</td>
<td class="nump">3,019,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent', window );">Deferred tax asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">92,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use-asset</a></td>
<td class="nump">778,846<span></span>
</td>
<td class="nump">936,037<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Long-Term Assets</a></td>
<td class="nump">3,225,586<span></span>
</td>
<td class="nump">4,594,043<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">30,079,167<span></span>
</td>
<td class="nump">30,560,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable &amp; accrued expenses</a></td>
<td class="nump">5,664,212<span></span>
</td>
<td class="nump">5,543,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_EarnoutPayable', window );">Earnout payable</a></td>
<td class="nump">295,797<span></span>
</td>
<td class="nump">295,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">268,276<span></span>
</td>
<td class="nump">268,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion - right-of-use-liability</a></td>
<td class="nump">215,637<span></span>
</td>
<td class="nump">207,756<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">6,443,922<span></span>
</td>
<td class="nump">6,314,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-Term Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Right-of-use-liability</a></td>
<td class="nump">596,785<span></span>
</td>
<td class="nump">744,724<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Long-Term Liabilities</a></td>
<td class="nump">596,785<span></span>
</td>
<td class="nump">744,724<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">7,040,707<span></span>
</td>
<td class="nump">7,059,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, Series B $0.10 par value per share; 1,000,000 shares authorized; 130,000 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.001 par value per share; 3,000,000,000 shares authorized; 4,905,945 and 2,580,098 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively</a></td>
<td class="nump">4,905<span></span>
</td>
<td class="nump">2,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Capital paid in excess of par value</a></td>
<td class="nump">98,100,990<span></span>
</td>
<td class="nump">93,354,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated comprehensive income</a></td>
<td class="num">(65,309)<span></span>
</td>
<td class="num">(829,959)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated (Deficit)</a></td>
<td class="num">(75,015,126)<span></span>
</td>
<td class="num">(69,039,774)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="nump">23,038,460<span></span>
</td>
<td class="nump">23,500,754<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="nump">$ 30,079,167<span></span>
</td>
<td class="nump">$ 30,560,392<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_EarnoutPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_EarnoutPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">3,000,000,000<span></span>
</td>
<td class="nump">3,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">4,905,945<span></span>
</td>
<td class="nump">2,580,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">4,905,945<span></span>
</td>
<td class="nump">2,580,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">130,000<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">130,000<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement Of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue:</a></td>
<td class="nump">$ 36,305,891<span></span>
</td>
<td class="nump">$ 34,874,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of Sales</a></td>
<td class="nump">24,050,214<span></span>
</td>
<td class="nump">24,204,489<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">12,255,677<span></span>
</td>
<td class="nump">10,669,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General &amp; Administrative Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Accounting</a></td>
<td class="nump">698,083<span></span>
</td>
<td class="nump">967,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Consulting</a></td>
<td class="nump">1,571,692<span></span>
</td>
<td class="nump">925,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseDirectorsFees', window );">Director fees</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Intangible assets impairment</a></td>
<td class="nump">1,748,247<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal</a></td>
<td class="nump">385,142<span></span>
</td>
<td class="nump">875,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketingExpense', window );">Marketing</a></td>
<td class="nump">1,143,929<span></span>
</td>
<td class="nump">940,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Office</a></td>
<td class="nump">3,864,584<span></span>
</td>
<td class="nump">3,110,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">R&amp;D</a></td>
<td class="nump">604,308<span></span>
</td>
<td class="nump">933,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries</a></td>
<td class="nump">7,265,346<span></span>
</td>
<td class="nump">7,718,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_Taxes', window );">Taxes</a></td>
<td class="nump">469,305<span></span>
</td>
<td class="nump">387,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation &amp; amortization</a></td>
<td class="nump">332,070<span></span>
</td>
<td class="nump">223,527<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total General &amp; Administrative Expenses</a></td>
<td class="nump">18,482,706<span></span>
</td>
<td class="nump">16,481,915<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) from operations</a></td>
<td class="num">(6,227,029)<span></span>
</td>
<td class="num">(5,812,121)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain (loss)</a></td>
<td class="nump">2,642<span></span>
</td>
<td class="num">(44,082)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeDebtSecuritiesOperating', window );">Interest income</a></td>
<td class="nump">280,901<span></span>
</td>
<td class="nump">496,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,774)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnSalesOfAssets', window );">Gain (Loss) on asset sale</a></td>
<td class="num">(10,257)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income (Expense)</a></td>
<td class="nump">273,286<span></span>
</td>
<td class="nump">443,147<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net (loss) before income taxes</a></td>
<td class="num">(5,953,743)<span></span>
</td>
<td class="num">(5,368,974)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">21,609<span></span>
</td>
<td class="num">(234,858)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (Loss)</a></td>
<td class="num">(5,975,352)<span></span>
</td>
<td class="num">(5,134,116)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other Comprehensive Income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Gain (Loss) from foreign exchange translation</a></td>
<td class="nump">764,650<span></span>
</td>
<td class="num">(1,526,064)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (Loss)</a></td>
<td class="num">$ (5,210,702)<span></span>
</td>
<td class="num">$ (6,660,180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">(Loss) per common share, Basic</a></td>
<td class="num">$ (1.44)<span></span>
</td>
<td class="num">$ (7.32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, Basic</a></td>
<td class="nump">4,157,086<span></span>
</td>
<td class="nump">701,749<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_Taxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_Taxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnSalesOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnSalesOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeDebtSecuritiesOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income, amortization of premium and accretion of discount, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading); classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeDebtSecuritiesOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseDirectorsFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for service provided by entity's director.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseDirectorsFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (Loss)</a></td>
<td class="num">$ (5,975,352)<span></span>
</td>
<td class="num">$ (5,134,116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">332,070<span></span>
</td>
<td class="nump">223,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_AssetDisposition', window );">Disposal of tangible assets</a></td>
<td class="nump">10,257<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock issued for services</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Intangible assets impairment</a></td>
<td class="nump">1,748,247<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(116,173)<span></span>
</td>
<td class="num">(2,338,195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(1,637,277)<span></span>
</td>
<td class="num">(6,006,864)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">480,798<span></span>
</td>
<td class="num">(207,167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_IncreaseDecreaseInRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">203,836<span></span>
</td>
<td class="num">(341,534)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts Payable &amp; accrued expenses</a></td>
<td class="num">(189,956)<span></span>
</td>
<td class="nump">3,983,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="num">(187,523)<span></span>
</td>
<td class="nump">347,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_IncreaseDecreaseInEarnoutPayable', window );">Earn-out payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,252,034)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(812,080)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Flows (Used In) Operating Activities</a></td>
<td class="num">(5,331,073)<span></span>
</td>
<td class="num">(12,524,779)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
<td class="num">(661,815)<span></span>
</td>
<td class="num">(322,258)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of equipment</a></td>
<td class="num">(174,491)<span></span>
</td>
<td class="num">(1,657,055)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Flows (Used In) Investing Activities</a></td>
<td class="num">(836,306)<span></span>
</td>
<td class="num">(1,979,313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering net (common stock)</a></td>
<td class="nump">1,828,596<span></span>
</td>
<td class="nump">8,522,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="nump">2,919,812<span></span>
</td>
<td class="nump">3,558,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,139,651)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Flows Provided by Financing Activities</a></td>
<td class="nump">4,748,408<span></span>
</td>
<td class="nump">8,941,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
<td class="nump">9,686,529<span></span>
</td>
<td class="nump">16,292,347<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net (decrease) in cash and cash equivalents</a></td>
<td class="num">(1,418,971)<span></span>
</td>
<td class="num">(5,562,520)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Foreign currency translation adjustment</a></td>
<td class="nump">855,750<span></span>
</td>
<td class="num">(1,043,298)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents at End of Period</a></td>
<td class="nump">9,123,308<span></span>
</td>
<td class="nump">9,686,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary Disclosure of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">582,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_StockIssuedForServices', window );">Stock issued for services</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_AssetDisposition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_AssetDisposition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_IncreaseDecreaseInEarnoutPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_IncreaseDecreaseInEarnoutPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_IncreaseDecreaseInRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_IncreaseDecreaseInRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_StockIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_StockIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Comprehensive Income [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 84,415,900<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 696,105<span></span>
</td>
<td class="num">$ (63,905,658)<span></span>
</td>
<td class="nump">$ 21,207,361<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2023</a></td>
<td class="nump">14,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_PreferredStockIssuedToRelatedParty', window );">Preferred Stock issued to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_PreferredStockIssuedToRelatedPartyShares', window );">Preferred Stock issued to related party, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Exercise of warrants</a></td>
<td class="nump">$ 2,554<span></span>
</td>
<td class="nump">3,556,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,558,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exercise of warrants, shares</a></td>
<td class="nump">2,552,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Underwritten offering, net of issuance costs</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">8,522,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,522,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Underwritten offering, net of issuance costs, shares</a></td>
<td class="nump">13,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_RepurchaseOfWarrants', window );">Repurchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,139,651)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,139,651)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,526,064)<span></span>
</td>
<td class="num">(5,134,116)<span></span>
</td>
<td class="num">(6,660,180)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2024</a></td>
<td class="nump">$ 2,580<span></span>
</td>
<td class="nump">93,354,907<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="num">(829,959)<span></span>
</td>
<td class="num">(69,039,774)<span></span>
</td>
<td class="nump">23,500,754<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2024</a></td>
<td class="nump">2,580,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Exercise of warrants</a></td>
<td class="nump">$ 1,137<span></span>
</td>
<td class="nump">2,918,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,919,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exercise of warrants, shares</a></td>
<td class="nump">1,137,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Underwritten offering, net of issuance costs</a></td>
<td class="nump">$ 1,188<span></span>
</td>
<td class="nump">1,827,408<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,828,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Underwritten offering, net of issuance costs, shares</a></td>
<td class="nump">1,188,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">764,650<span></span>
</td>
<td class="num">(5,975,352)<span></span>
</td>
<td class="num">(5,210,702)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2025</a></td>
<td class="nump">$ 4,905<span></span>
</td>
<td class="nump">$ 98,100,990<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="num">$ (65,309)<span></span>
</td>
<td class="num">$ (75,015,126)<span></span>
</td>
<td class="nump">$ 23,038,460<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2025</a></td>
<td class="nump">4,905,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_PreferredStockIssuedToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_PreferredStockIssuedToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_PreferredStockIssuedToRelatedPartyShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_PreferredStockIssuedToRelatedPartyShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_RepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_RepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (5,975,352)<span></span>
</td>
<td class="num">$ (5,134,116)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Award Timing Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardsCloseToMnpiDiscTable', window );"><strong>Awards Close in Time to MNPI Disclosures [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiDiscTextBlock', window );">Award Timing MNPI Disclosure</a></td>
<td class="text">We do not maintain any policies or practices regarding the timing of option or SAR grants in relation to the disclosure
of material nonpublic information because we do not utilize these forms of compensation and we do not currently anticipate granting stock
options or SARs in the foreseeable future.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiDiscTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiDiscTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardsCloseToMnpiDiscTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardsCloseToMnpiDiscTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><b style="display: none">&#160;Risk</b><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Our Company recognizes the critical importance
of cybersecurity in protecting our sensitive data, intellectual property, and the personal information of our employees and partners.
We have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zsPPz5n79fdb">implemented</span> a comprehensive cybersecurity risk management program that includes the following key components:</p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Risk Assessment and Management</b></p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250101__20251231_zepDcJYwf1hf">We conduct regular risk assessments to identify
and evaluate potential cybersecurity threats and vulnerabilities. Our risk management framework is aligned with industry standards such
as the NIST Cybersecurity Framework (CSF) and ISO 27001. We continuously monitor and update our cybersecurity measures to address emerging
threats and ensure the protection of our assets.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">We conduct regular risk assessments to identify
and evaluate potential cybersecurity threats and vulnerabilities. Our risk management framework is aligned with industry standards such
as the NIST Cybersecurity Framework (CSF) and ISO 27001. We continuously monitor and update our cybersecurity measures to address emerging
threats and ensure the protection of our assets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text">During the past fiscal year, we experienced <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20250101__20251231_zVGK4CuTdkki">no
cybersecurity incidents</span>.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><b>Cybersecurity Governance</b><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20250101__20251231_zSY3mF8ioZb">Our management oversees our cybersecurity risk
management efforts. Our <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20250101__20251231_zAcZ9hvcJQGk">senior management team</span> is actively involved in cybersecurity policies, procedures and strategy development.</span></p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b>Incident Response and Recovery</b></p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_c20250101__20251231_zZ9H5PnVQzB7">We have a robust incident response plan in place
to quickly detect, respond to, and recover from cybersecurity incidents. We collaborate with external cybersecurity experts and law enforcement
agencies to enhance our incident response capabilities.</span></p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b>Employee Training and Awareness</b></p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We provide ongoing cybersecurity training and awareness
programs for all employees to promote a culture of security. Our training programs cover topics such as phishing prevention, secure data
handling, and recognizing potential cyber threats.</p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Third-Party Risk Management</b></p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We assess the cybersecurity practices of our <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250101__20251231_zIU1Zot8w70k">third-party</span>
vendors and partners to ensure they meet our security standards. Our contracts with third parties include provisions for cybersecurity
requirements and incident reporting.</p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Regulatory Compliance</b></p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We comply with all relevant cybersecurity regulations
and standards, including the Health Insurance Portability and Accountability Act (HIPAA) and the General Data Protection Regulation (GDPR).
We regularly review and update our cybersecurity policies and procedures to ensure compliance with evolving regulatory requirements.</p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Investments in Cybersecurity</b></p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">We continuously invest in advanced cybersecurity
technologies, including threat detection and prevention systems, encryption, and secure access controls. Our cybersecurity is part of
our overall budget which is reviewed and approved by our board of directors to ensure adequate resources are allocated to protect our
assets.</p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b>Cybersecurity Incidents</b></p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_c20250101__20251231_zlCoAR0PPWvl">During the past fiscal year, we experienced <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20250101__20251231_zVGK4CuTdkki">no
cybersecurity incidents</span>.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">Our management oversees our cybersecurity risk
management efforts. Our <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20250101__20251231_zAcZ9hvcJQGk">senior management team</span> is actively involved in cybersecurity policies, procedures and strategy development.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">We have a robust incident response plan in place
to quickly detect, respond to, and recover from cybersecurity incidents. We collaborate with external cybersecurity experts and law enforcement
agencies to enhance our incident response capabilities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text"><p id="xdx_804_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ztlJvqQy1i1i" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 1 &#8211;
<span id="xdx_826_zLbKaT2LDpsk">Description of Business</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company was incorporated under the name Mountain
West Business Solutions, Inc. on August 31, 2006, in the State of Colorado. Effective October 15, 2009, the Company acquired Sunshine
Biopharma Inc. in a transaction classified as a reverse acquisition. Upon completion of the reverse acquisition transaction, the Company
changed its name to Sunshine Biopharma Inc. and began operating as a pharmaceutical company.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Sunshine Biopharma has two wholly owned subsidiaries:
(i) Nora Pharma Inc. (&#8220;Nora Pharma&#8221;), a Canadian corporation with a portfolio of pharmaceutical products consisting of 71
generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc. (&#8220;Sunshine Canada&#8221;), a Canadian
corporation which develops and sells nonprescription, over-the-counter (&#8220;OTC&#8221;) supplements. The Company operates the two subsidiaries
as a single business segment. Sales of the OTC supplements represent less than 3% of the Company&#8217;s total annual sales.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company is not subject to material customer
concentration risks as it sells its products directly to pharmacies in several Canadian Provinces. However, Provincial governments in
Canada reimburse patients for their prescription drug expenditures to various degrees under drug reimbursement programs, making generic
drugs prices highly dependent on government policies which may change over time. The most recent negotiations between the pan-Canadian
Pharmaceutical Alliance (&#8220;pCPA&#8221;), the entity that negotiates drug prices on behalf of the government, and the Canadian Generic
Pharmaceutical Association (&#8220;CGPA&#8221;) resulted in updated generic pricing for certain products which took effect on October
1, 2023. The updated prices are valid for three years and the agreement contains an option to extend for an additional two years. On February
10, 2024, the Canadian federal government joined the generic drug reimbursement program as a payor under the Pharmacare Act. This development
further strengthened the Canadian generic drug market, which is the Company&#8217;s current focus.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In addition, the Company is engaged in the development
of the following proprietary drugs:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">K1.1 mRNA, a lipid nano-particle (LNP) targeted for liver cancer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">SBFM-PL4, a protease inhibitor for treatment of Coronavirus infections</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_zgD5rf74uufd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 2 &#8211; <span id="xdx_822_zBMN69LnS9Te">Summary
of Significant Accounting Policies</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">This summary of significant accounting policies
is presented to assist the reader in understanding the Company's financial statements. The consolidated financial statements and notes
are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform
to Generally Accepted Accounting Principles in the United States (&#8220;GAAP&#8221;) and have been consistently applied in the preparation
of the financial statements.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zT1F7GpEIqY4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_861_z1kzjesDd906">PRINCIPLES OF CONSOLIDATION</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of the Company and its subsidiaries, Nora Pharma Inc. and Sunshine Biopharma Canada Inc., both wholly owned. All
intercompany accounts and transactions have been eliminated in consolidation.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84C_eus-gaap--UseOfEstimates_zyHfdlWNtT88" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_866_zImZqZi6xGl7">USE OF ESTIMATES</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation
of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic
environment has increased the degree of uncertainty inherent in these estimates and assumptions.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p id="xdx_840_eus-gaap--ReceivablesPolicyTextBlock_zYKL1sSaiBga" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_86C_zJD4NE4ec4Q4">TRADE ACCOUNTS RECEIVABLE AND
ALLOWANCE FOR DOUBTFUL ACCOUNTS</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Trade accounts receivable are stated at net realizable
value. The majority of customers are not extended credit and therefore time to maturity for receivables is short. On a periodic basis,
management evaluates its trade accounts receivable and determines whether to record an allowance for doubtful accounts. Management analysis for the periods ended December 31, 2024 and 2025 determined
that no allowance for doubtful accounts needed to be recorded. A receivable is considered past
due if the Company has not received payments based on agreed-upon terms. The Company generally does not require any security or collateral
to support its receivables. As of December 31, 2025 and 2024, the balances of accounts receivable were $<span id="xdx_90E_eus-gaap--AccountsReceivableNetCurrent_iI_c20251231_zxRvzZJX0ytg" title="Accounts receivable">3,459,864</span> and $<span id="xdx_90B_eus-gaap--AccountsReceivableNetCurrent_iI_c20241231_zP5gVULZNYQ9" title="Accounts receivable">3,868,418</span>, respectively.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84B_eus-gaap--InventoryPolicyTextBlock_zhKeMppuF1H9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_868_zZcWtBQ8Dp5j">INVENTORY VALUATION</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company&#8217;s inventory is comprised of finished goods. Inventory is valued at the lower of cost and net realizable value. Cost is
determined using the first in, first out method. Net realizable value is the estimated selling price in the ordinary course of business,
less the costs necessary to make the sale. The cost of inventory includes the purchase price and other costs directly attributable to
the acquisition of the finished goods. The Company regularly reviews inventories to determine if the carrying value exceeds net realizable
value and, when determined necessary, an allowance to reduce the carrying value to net realizable value is recorded. The net realizable value is calculated based
on a combination of factors, including (i) aging, (ii) historical sell-through patterns, and (iii) product-specific considerations. Write-downs
are recorded within cost of goods sold and are not subsequently reversed. As of December 31,
2025 and 2024, there were allowances for obsolescence of $<span id="xdx_90F_eus-gaap--InventoryValuationReserves_iI_c20251231_zn3STckJuycl" title="Reserve for obsolescence">475,153</span> and $<span id="xdx_904_eus-gaap--InventoryValuationReserves_iI_do_c20241231_z4tfq3nPi0A1" title="Reserve for obsolescence">0</span>, respectively.</span></p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zqx7JbOvORg9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_867_zvRq9k5Pfwj4">CASH AND CASH EQUIVALENTS</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">For the Balance Sheets and Statements of Cash
Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance
of $<span id="xdx_90E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_c20251231_zZ32dlvJqe14">9,123,308</span>
and $<span id="xdx_903_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_c20241231_zMseaXCo4B98">9,686,529</span>
as of December 31, 2025 and December 31, 2024, respectively. At times such cash balances may be in excess of the FDIC limit of $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20251231_zEg0oLiqljR6">250,000</span>
in the U.S. or the $<span id="xdx_902_ecustom--CashCanadaInsuredAmount_iI_uCAD_c20251231_zrEqCn8XOX4b" title="Cash insured in Canada (CAD)">100,000</span> CAD (approximately $<span id="xdx_906_ecustom--CashCanadaInsuredAmount_iI_uUSD_c20251231_zfQHCvrRj3M6" title="Cash insured in Canada (USD)">73,000</span> USD) limit in Canada. At December 31, 2025, the Company had deposits totaling
approximately $7 million in the U.S and $2 million in Canada.</p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zsuJ7ILjYGJe" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_869_z7AlXLRHR128">PROPERTY AND EQUIPMENT</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Property and equipment are reviewed for recoverability
when events or changes in circumstances indicate that its carrying value may exceed future undiscounted cash inflows. As of December 31,
2025 and 2024, the Company had not identified any such impairment. Repairs and maintenance are charged to operations when incurred and
improvements and renewals are capitalized.&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost. Depreciation
is calculated according to the following methods at the following annual rates and period for financial reporting purposes and accelerated
methods for tax purposes. Their estimated useful lives are as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--PropertyPlantAndEquipmentUsefulLivesTableTextBlock_zfpByWkhn958" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Estimated lives)">
  <tr style="vertical-align: top">
    <td><span id="xdx_8BD_z9C9GBNH5mFa" style="display: none">Schedule of estimated useful lives</span></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 28%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Office Equipment:</span></td>
    <td style="width: 49%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line and Declining balance method</span></td>
    <td style="width: 23%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_903_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zws3TJ6m2Zq8" title="Property and equipment estimated useful lives">5-7 Years / 20%</span></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Computer Equipment:</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Declining balance method</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90C_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z3voB4yZCgM1" title="Property and equipment estimated useful lives">55%</span></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Laboratory Equipment:</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line method</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_909_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z8Bu5xz1asmb" title="Property and equipment estimated useful lives">5 Years</span></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Vehicles:</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line and Declining balance method</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_901_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zwa1guchFnc3" title="Property and equipment estimated useful lives">5 Years / 30%</span></span></td></tr>
  </table>
<p id="xdx_8AC_zRN7iHB7Gs8a" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F">&#160;</p>

<p id="xdx_84D_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zAW5triZDyJ4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_86A_zoiXI3c1RV5">INTANGIBLE ASSETS</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Intangible assets are amortized over their estimated
useful lives according to the following methods at the following annual rates and period:<i></i></p>

<table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock_zwwokJM4aN8b" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Intangible assets)">
  <tr style="vertical-align: top">
    <td><span id="xdx_8B8_zXYTAxBJiTFk" style="display: none">Schedule of intangible assets   estimated
useful lives</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 25%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Licenses:</span></td>
    <td style="width: 50%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line method</span></td>
    <td style="width: 25%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_904_ecustom--IntangibleAssetsEstimatedUsefulLives_c20250101__20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zMExfiVHmH5" title="Intangible asset estimated useful lives">5 Years</span></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Website:</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Declining balance method</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_902_ecustom--IntangibleAssetsEstimatedUsefulLives_c20250101__20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_zmGJhForVFM6" title="Intangible asset estimated useful lives">55%</span></span></td></tr>
  </table>
<p id="xdx_8A4_zdDRfgKG2d0a" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Intangible assets are tested for recoverability
when events or changes in circumstances indicate that their carrying amount may not be recoverable. The carrying amount of a long-lived
asset is not recoverable when it exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposal.
In such a case, an impairment loss must be recognized and is equivalent to the excess of the carrying amount of a long-lived asset over
its fair value.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_847_eus-gaap--RevenueRecognitionServicesLicensingFees_zFoxoCN8IsL9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_863_zEFf1loBhPih">INTELLECTUAL PROPERTY RIGHTS
- PATENTS AND LICENSES</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The cost of patents and licenses acquired is capitalized
and is amortized over the remaining life of the patents or licenses.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company evaluates recoverability of identifiable
intangible assets whenever events or changes in circumstances indicate that intangible assets carrying amount may not be recoverable.
Such circumstances include but are not limited to: (i) a significant decrease in the market value of an asset, (ii) a significant adverse
change in the extent or manner in which an asset is used, or (iii) an accumulation of cost significantly in excess of the amount originally
expected for the acquisition of an asset. The Company measures the carrying amount of such assets against the estimated undiscounted future
cash flows associated with it.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zjLUIuWQo3ne" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_861_zHZZKwtmYnd">BASIC AND DILUTED NET GAIN (LOSS)
PER SHARE</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company computes gain or loss per share in
accordance with <i>ASC 260 &#8211; Earnings per Share</i>. ASC 260 requires presentation of both basic and diluted earnings per share
(&#8220;EPS&#8221;) on the face of the income statement. Basic net income (loss) per share is calculated by dividing net income (loss)
by the weighted-average common shares outstanding. Diluted net income (loss) per share is calculated by dividing net income (loss) by
the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is
more dilutive. As the Company incurred net losses for the years ended December 31, 2025 and 2024, <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20250101__20251231_zMgAksl5zuZ8"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20240101__20241231_zVDywucsa3l5">no</span></span> potentially dilutive securities were
included in the calculation of diluted earnings per share as the impact would have been anti-dilutive. Accordingly, diluted EPS information
is not included in this report.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zE2uzKHkm4ye" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_86A_zQ119tDTcXH3">INCOME TAXES</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In accordance with <i>ASC 740 &#8211; Income Taxes</i>,
the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by
applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities
and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities have been adjusted to reflect
changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not
be realized.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company expects to recognize the financial
statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position
in an examination. For tax positions meeting a &#8220;more-likely-than-not&#8221; threshold, the amount to be recognized in the financial
statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold,
no financial statement benefit is recognized. As of December 31, 2025, the Company had no uncertain tax positions. The Company recognizes
interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. The Company currently has no
federal or state tax examinations nor has it had any federal or state examinations since its inception. To date, the Company has not incurred
any interest or tax penalties.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">For Canadian and U.S. tax purposes, the Company&#8217;s
2022 through 2024 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_847_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zLvoc9nuCaNi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_860_zAQtqlDLp9Kd">FUNCTIONAL CURRENCY</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The U.S. dollar is the functional currency of the
Company which is operating in the United States. The functional currency for the Company's Canadian subsidiaries is the Canadian dollar.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company translates its Canadian subsidiaries'
financial statements into U.S. dollars as follows:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 24px">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Income statement accounts are translated using the weighted average exchange rate for the period.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company includes translation adjustments from
currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate
component of shareholders&#8217; equity. There are currently no transactions of a long-term investment nature, nor any gains or losses
from non-U.S. currency transactions.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_z4IY1iD7yuz4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_86E_zVNk6KqUUrP3">CONCENTRATION OF CREDIT RISKS</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash
equivalents with high credit quality financial institutions.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zqhSLybT8Yj6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_86F_zMlFgM8LrI46">FINANCIAL INSTRUMENTS AND FAIR
VALUE OF FINANCIAL INSTRUMENTS</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company applies the provisions of accounting
guidance, <i>ASC 825 &#8211; Financial Instruments</i>. ASC 825 requires all entities to disclose the fair value of financial instruments,
both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and
defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between
willing parties. As of December 31, 2025 and 2024, the fair value of cash, accounts receivable and notes receivable, accounts payable,
accrued expenses, and other payables approximated carrying value due to the short maturity of the instruments, quoted market prices or
interest rates which fluctuate with market rates.&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company defines fair value as the price that
would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement
date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels
and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement.
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to unobservable inputs (Level 3 measurements).</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 24px">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Level 1 &#8211; Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Level 2 &#8211; Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Level 3 &#8211; Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The carrying value of financial assets and liabilities
recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring
basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried
and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are
those that are adjusted to fair value each time a financial statement is prepared.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_843_eus-gaap--DebtPolicyTextBlock_zdTevLIoVj79" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_86D_z3bO4ctqItoh">NOTES PAYABLE</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Borrowings are recognized initially at fair value,
net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of
transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective
interest method. The Company had <span id="xdx_90E_eus-gaap--NotesPayable_iI_do_c20251231_zZlHXYFnQKoc"><span id="xdx_904_eus-gaap--NotesPayable_iI_do_c20241231_zOTBND7FG1Re">no</span></span> notes payable as of December 31, 2025 and 2024.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_844_eus-gaap--RevenueRecognitionPolicyTextBlock_zhVi7YOtMiFg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_86E_zYbxKFVNkQKf">REVENUE RECOGNITION</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Over 97% of the Company&#8217;s revenues are derived
from the sale of pharmaceutical products. Pharmaceutical products can only be sold to a specific customer that is either a registered
pharmacy or a registered wholesaler. The Company therefore sells only to customers registered with Health Canada, the Canadian equivalent
of the FDA. Contracts are drawn up between the wholesalers and the Company for all indirect sales. In the case of direct sales to pharmacies,
purchase orders are used instead of contracts. A purchase order, forecast, or other written instructions to purchase any of the Company&#8217;s
products placed by the customer constitutes an irrevocable offer to purchase. The customer is responsible for ensuring that the terms
of any such order are complete and accurate. The purchase order is only deemed to be accepted when the Company (in its sole discretion)
accepts the purchase order and delivers on the purchase. The acceptance of any purchase order can be full or partial, at the sole discretion
of the Company. No variations to these conditions are binding on the Company unless agreed to in writing between the customer and the
Company.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">No significant judgments are made in connection
with any contracts as the price is already determined, the collection is reasonably assured, and performance obligation is fulfilled when
the customer receives the goods. The Company is not required to apply any specific judgments, estimations, or assumptions to determine
the price of its products.&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Taxes assessed by a governmental authority that
are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are
excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has been transferred
to a customer are accounted for as a fulfillment cost and are included in cost of revenues. The amount invoiced for each product is fixed
at the Company&#8217;s current price list on the date of shipping and known in advance by the customer and does not vary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company fulfills its performance obligation
when the customer receives the requested products. When the products leave the Company's warehouse, the transport to the customer is insured
and the transfer of ownership to the customer takes place when the customer receives the goods. At this point, the Company issues an invoice
for the products and remits the applicable sales taxes (GST and QST) to the appropriate governmental agency. The revenue is recognized
when the invoice is issued. Unless otherwise agreed to and signed by both parties, payment terms are within 30 days from the date of the
invoice. The collection is reasonably assured because of the nature of the Company&#8217;s customers. The Company is conducting sales
only in Canada. Prices are listed in Canadian dollars and may vary from one Province or Territory to another within Canada. All products
sold by the Company are labelled and approved for sale in Canada only and are not intended for export outside of Canada.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In the event of any breach by the Company of any
product warranty (whether by reason of defective materials, production faults or otherwise), the Company&#8217;s liability is limited
to, at Company&#8217;s option, (i) replacement of the product(s) in question, or (ii) reimbursement of the purchase price. The Company
carries product liability insurance and is not liable for products&#8217; failure to comply with the warranty of products if the failure
or damage arises because of the customer&#8217;s negligence, deliberate damage, misuse or failure to store the products in conditions
per Health Canada specifications. The Company is not liable (whether in contract, in tort or otherwise) for any (i) indirect, special
or consequential loss or damage, or (ii) loss of profit, goodwill, business or revenue (in each case whether direct or indirect). These
conditions also apply to any replacement products supplied by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company warrants to the customer that, at
the time of delivery, the products are compliant with all mandatory quality standards required by applicable regulatory and legal requirements.
In return, the customer is required to warrant to the Company that it holds all relevant permits and approvals required under applicable
laws to purchase, store, distribute, sell and use the Company&#8217;s products. Visible defects or damages must be reported to the Company
in writing immediately, but no later than five (5) business days after receipt of the products. Hidden defects must be reported to the
Company in writing immediately, but no later than five (5) business days after the customer becomes aware of such defects. The Company
is not be deemed to be in breach of the terms or otherwise liable to customer for any delay in performance or non-performance of its obligations
due to circumstances beyond its control, including but not limited to, acts of God, floods, droughts, earthquakes or other natural disasters,
terrorist attacks, wars, preparations for war, armed conflicts, civil commotions or riots, epidemics or pandemics, fires, strikes, lockouts,
shortages of material or labor, breakdown or damage to machinery or equipment, accidents, any law or governmental order or other regulations
or action taken by a governmental entity, or default of any third party suppliers or provider of services or products, or any causes not
within the Company&#8217;s control.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_zReBenJzGuG8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_863_zVrQsWh3ZXef">LEASES</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company recognizes and measures its leases
in accordance with <i>ASC 842 &#8211; Leases</i>. The Company is a lessee in a non-cancellable operating lease for office space. The Company
determines if an arrangement is a lease, or contains a lease, at inception of a contract and when the terms of an existing contract are
changed. The Company recognizes a lease liability and a right-of-use (ROU) asset at the commencement date. The lease liability is initially
and subsequently recognized based on the present value of its future lease payments. Variable payments are included in the future lease
payments when those variable payments depend on an index or a rate. The discount rate is the implicit rate if it is readily determinable
or otherwise the Company uses its incremental borrowing rate. The implicit rates of the Company's lease are not readily determinable and
accordingly, the Company uses its incremental borrowing rate based on the information available at the commencement date for all leases.
The Company&#8217;s incremental borrowing rate for a lease is the 6% interest it would have to pay on a collateralized basis to borrow
an amount equal to the lease payments under similar terms and in a similar economic environment. The ROU asset is subsequently measured
throughout the lease term at the remaining amount (i.e. present value of the remaining lease payments), plus unamortized initial direct
costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received, and any impairment
recognized. Lease cost for lease payments is recognized on a straight-line basis over the lease term.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company has elected, for all underlying classes
of assets, not to recognize ROU assets and lease liabilities for short-term leases that have a lease term of 12 months or less at lease
commencement, and do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company
recognizes the lease cost associated with its short-term leases on a straight-line basis over the lease term.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Under the available practical expedient, we account
for the lease and non-lease components as a single lease component for all classes of underlying assets as both a lessee and lessor. Further,
we elected a short-term lease exception policy on all classes of underlying assets, permitting us to not apply the recognition requirements&#160;of
this standard to short-term leases (i.e. leases with terms of 12 months or less).</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zbAdSEayDv92" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_869_zpTUaX0BKCC6">RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><i>ASU
2023-09 &#8211; Income Taxes (Topic 740): Improvements to Income Tax Disclosures,</i> enhances the transparency and decision usefulness
of income tax disclosures. Adjustments to the annual disclosure of income taxes include: (1) a tabular rate reconciliation comprised
of eight specific categories, (2) incomes taxes paid, disaggregated between significant national, state, and foreign jurisdictions, (3)
eliminates requirements to disclose the nature and estimate of reasonably possible changes to unrecognized tax benefits in the next 12
months or that an estimated range cannot be made, and (4) adds a requirement to disclose income (or loss) from continuing operations
before income tax expense (or benefit) by national and foreign, and income tax expense (or benefit) from continuing operations disaggregated
between national, state and foreign. The <i>ASU 2023-09</i> is effective for public business entities for fiscal years beginning on or
after December 15, 2024, and for all other entities for fiscal years beginning on or after December 31, 2025, with early adoption permitted.
The amendments in <i>ASU 2023-09</i> were adopted by the Company on a prospective&#160;basis. There was no material change&#160;to the
Company's financial statements reporting as a result of adopting <i>ASU 2023-09</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><i>ASU
2024-03 &#8211; Income Statement (Reporting Comprehensive Income) Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation
of Income Statement Expenses</i>, requires disaggregation of specific expense categories in the notes to the financial statements and
a qualitative description of the remaining expense amounts not separately disaggregated. This standard is effective for annual reporting
periods beginning after December 15. 2026, and requires prospective application with the option to apply it retrospectively. We intend
to adopt this standard in our Annual Report on Form 10-K for the year ending December 31. 2027.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company has implemented all other new accounting
pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements
that have been issued that might have a material impact on its financial position or results of operations.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Nora Pharma Inc.<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisition of Nora Pharma Inc.</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--MergersAcquisitionsAndDispositionsDisclosuresTextBlock_zQcKcggUnAX8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 3 &#8211;
<span id="xdx_82D_zlJRNplSnCq3">Acquisition of Nora Pharma Inc.</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On October 20, 2022, the Company acquired all of
the issued and outstanding shares of Nora Pharma Inc. (&#8220;Nora Pharma&#8221;), a Canadian privately held pharmaceutical company. The
purchase price for the shares was $<span id="xdx_90C_eus-gaap--BusinessCombinationConsiderationTransferred1_pp0p0_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zRmts2czf7Ag" title="Purchase price of shares">18,860,637</span> which was paid in cash ($<span id="xdx_902_eus-gaap--PaymentsToAcquireBusinessesGross_pp0p0_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zkK2Pvvvv9h5" title="Payments to acquire shares">14,346,637</span>) and by the issuance of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zs6biGNvBj76" title="Stock issued for acquisition">1,850</span> shares of the Company&#8217;s
common stock valued at $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zR1HMq5jpAf5" title="Stock issued for acquisition, value">4,514,000</span> or $2,440.00 per share. Nora Pharma sells generic pharmaceutical products in Canada. Nora Pharma&#8217;s
operations are authorized by a Drug Establishment License issued by Health Canada.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">As part of the consideration for Nora Pharma, the
Company agreed to a $<span id="xdx_90E_ecustom--EarnoutPayable_iI_uCAD_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember__srt--CounterpartyNameAxis__custom--MalekChamounMember_zXh3kKIAPNMj" title="Earnout payable">5,000,000</span> CAD ($<span id="xdx_90A_ecustom--EarnoutPayable_iI_uUSD_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember__srt--CounterpartyNameAxis__custom--MalekChamounMember_zwMaoaN2vc5e" title="Earnout payable">3,632,000</span> USD) earnout amount payable to Mr. Malek Chamoun, the seller of Nora Pharma. The earnout
is payable in the form of twenty (20) payments of $250,000 CAD for every $1,000,000 CAD increase in gross sales (as defined in the Purchase
Agreement) above Nora Pharma&#8217;s June 30, 2022 gross sales, provided that his employment with the Company is not terminated pursuant
to the Company&#8217;s employment agreement with him. The total earnout amount of $3,632,000 has been recorded as a salary payable. During
the fiscal year ended December 31, 2023, the Company paid an earnout amount of $<span id="xdx_90E_ecustom--EarnoutLiabilityExpenseFirstInstallment_uCAD_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zRQ0sscXVxxd" title="Earnout liability expense, first installment">1,426,914</span> CAD (approximately $<span id="xdx_903_ecustom--EarnoutLiabilityExpenseFirstInstallment_uUSD_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zPq9GLcPrndi">1,036,500</span> USD) for the fiscal
year ended December 31, 2022. On April 22, 2024, the Company paid another earnout amount of $<span id="xdx_902_ecustom--EarnoutLiabilityExpenseSecondInstallment_uCAD_c20240421__20240422__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zOHJn8V4G7f9" title="Earnout liability expense, second installment">3,093,878</span> CAD (approximately $<span id="xdx_902_ecustom--EarnoutLiabilityExpenseSecondInstallment_uUSD_c20240421__20240422__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_znsXS3kmYCk8">2,247,400</span> USD)
for the fiscal year ended December 31, 2023. As of December 31, 2025, the remaining earnout balance was $<span id="xdx_90F_ecustom--EarnoutLiabilityBalance_uCAD_c20250101__20251231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zKxlzBBpqfc1" title="Remaining earnout balance">479,208</span> CAD ($<span id="xdx_908_ecustom--EarnoutLiabilityBalance_uUSD_c20250101__20251231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_znJt8oQQGAxj">295,797</span> USD).
This remaining earnout amount is currently in dispute following dismissal of Mr. Chamoun by the Company on April 14, 2025 (See Note 17).</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_805_eus-gaap--IntangibleAssetsDisclosureTextBlock_z2mEREOVVzc4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 4 &#8211; <span id="xdx_828_zdbwXSAMzRD3">Intangible
Assets</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Intangible assets consisted of the following:</p>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z5D12SH1l7Tf" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details - Intangible assets)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B8_zARQeKuiadCk"><b style="display: none">Schedule of intangible assets</b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom">
    <td><span style="font-size: 10pt"><b>Year Ended December 31,</b></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td><td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%"><span style="font-size: 9pt">Balance as of December 31, 2023</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_c20240101__20241231_z4aIpydvROwc" style="width: 13%; text-align: right" title="Intangible assets gross beginning"><span style="font-size: 9pt">1,444,259</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">License fees additions</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20240101__20241231_zKT7dd1swT83" style="border-bottom: Black 1pt solid; text-align: right" title="Dossier fee additions"><span style="font-size: 9pt">1,651,617</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 9pt">Balance at December 31, 2024</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20240101__20241231_znMab21WM46e" style="text-align: right" title="Intangible assets gross ending"><span style="font-size: 9pt">3,095,876</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">Less: accumulated
    amortization</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20241231_zm6JDlrF9s19" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization"><span style="font-size: 9pt">(76,159</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 9pt">Intangible assets,
    net at December 31, 2024</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20241231_z7M0m6T2UhO1" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">3,019,717</span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom">
    <td><span style="font-size: 10pt"><b>Year Ended December 31,</b></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-size: 10pt"><b>2025</b></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 9pt">Balance as of December 31, 2024</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_c20250101__20251231_zVAzTGr1F4T8" style="text-align: right" title="Intangible assets gross beginning"><span style="font-size: 9pt">3,019,717</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">License fees additions</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20250101__20251231_zN0uT8HFEKZk" style="border-bottom: Black 1pt solid; text-align: right" title="Dossier fee additions"><span style="font-size: 9pt">774,355</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 9pt">Balance at December 31, 2025</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20250101__20251231_zK6DyE1AxOJc" style="text-align: right" title="Intangible assets gross ending"><span style="font-size: 9pt">3,794,072</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Less: impairment*</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_988_ecustom--ImpairmentOfIntangibleAssetFinitelived_c20250101__20251231_fKg_____zeMZ3FRiKHQb" style="text-align: right" title="Impairment"><span style="font-size: 9pt">(1,748,247</span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">Less accumulated amortization</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20251231_zpoSTbAJblHf" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization"><span style="font-size: 9pt">(156,455</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 9pt">Intangible assets,
    net at December 31, 2025</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20251231_zldscGOvl866" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">1,889,370</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*
The impairment was a result of the determination by the Company that certain product licenses could not be commercialized</span></p>

<p id="xdx_8AF_zJZdm9rd5sle" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The amortization amounts of intangible assets for
2025 and 2024 were $<span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_c20250101__20251231_zxwDWScR5nFk" title="Amortization of Intangible assets">37,758</span> and $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231_zRNxRPGX66F">77,009</span>, respectively.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">As of December 31, 2025, the estimated amortization
expense of the Company&#8217;s intangible assets for each of the next five years is as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zf7fcQ3rgnga" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details - Amortization expense)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BF_z0VaQsmwAtLl" style="display: none">Schedule of estimated amortization
expense</span></td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49B_20251231_zoyGnTrrT71j" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 83%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2026</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right; width: 13%">212,414</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2027</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">212,414</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0" style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2028</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">212,414</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0" style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2029</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">212,414</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0" style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2030</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">58,093</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A4_zXrdwrP36e45" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Plant, Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Plant, Property and Equipment</a></td>
<td class="text"><p id="xdx_802_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zRh2S5yqMTT8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b><span style="text-decoration: underline">Note 5 &#8211; <span id="xdx_82B_zjR8nuLXTQP9">Plant, Property and Equipment</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Property, plant and equipment are stated at cost.
Depreciation of property, plant and equipment begins in the month when the asset is placed into service and is provided using the straight-line
method for financial reporting purposes at rates based on the estimated useful lives of the assets. Estimated useful lives range from
three to twenty years. Property, plant and equipment consist of the following:</p>

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_zjSmaOzymed" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Plant, Property and Equipment (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B9_zlLqrsze668d"><b style="display: none">Schedule
    of plant property and equipment</b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20251231_zvUW7nf8qT7e" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20241231_zRS5duG11dCj" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">Year Ended December 31,</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z7e2Z7PTzGSb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%"><span style="font-size: 9pt">Equipment</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">335,464</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">336,880</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zkRaJyW5vgFa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Computer equipment</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">69,139</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">53,531</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zq8i8exjRqcf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Furniture and fixtures</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">45,462</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">50,686</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_d0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zz9eiYVtLt0e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Leasehold improvements</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">92,706</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">88,306</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zdbJw2YZbrW9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">Vehicles</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">507,478</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">353,185</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzbhx_zZL0hAVXmCg1" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">Total</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">1,070,249</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">882,588</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzbhx_zyAwf42kNNNg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">Less: Accumulated depreciation</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(512,879</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(336,533</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzbhx_zZLDdgCzEJBk" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">Plant, property and equipment, net</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">557,370</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">546,055</span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>



<p id="xdx_8AE_zGrR8IoOi7Gd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Depreciation expense for the years ended December
31, 2025 and 2024 amounted to $<span id="xdx_909_eus-gaap--Depreciation_c20250101__20251231_z4FNJqlfh329" title="Depreciation expense">176,346</span> and $<span id="xdx_90A_eus-gaap--Depreciation_c20240101__20241231_zD3aplQ5nBld" title="Depreciation expense">146,518</span>, respectively.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><p id="xdx_808_eus-gaap--InventoryDisclosureTextBlock_zKBbxEOIXoZi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 6 &#8211; <span id="xdx_821_zZtP34jTZS07">Inventory</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Inventory
consists solely of finished goods purchased for resale. Inventory is stated at the lower of cost or net realizable value. Cost represents
the amount paid to acquire the finished goods. The Company uses the first in, first out (FIFO) method to determine cost. Under the FIFO
method, the earliest purchased units are deemed sold first, so ending inventory reflects the most recent purchase costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company evaluates inventory for potential obsolescence based on a combination of factors, including (i) aging, (ii) historical sell-through
patterns, and (iii) product-specific considerations. When estimated net realizable value is lower than cost, the Company records an allowance
for obsolescence for the difference. Write-downs are recorded within cost of goods sold and are not subsequently reversed.</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Inventory is comprised of the following:</p>

<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zzDX5BpbkvF5" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventory (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;<span id="xdx_8BB_zZZ30kgCSXL" style="display: none">Schedule of inventory</span></td><td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20251231_zTt1XC2RFmy7" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20241231_zE9klaG2m0zd" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">Year Ended December 31,</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2025</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_z7NvjDWLhkHc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left"><span style="font-size: 9pt">Finished goods</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">13,947,178</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">11,278,105</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--AllowanceForObsoleteInventory_iI_d0_msARNCzj7C_z4r2TebdB9h3" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">Allowance for obsolete inventory</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(475,153</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--InventoryNet_iI_zb69lc9SnqR3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">Total Inventory, net of allowance</span></td><td style="border-bottom: Black 2.5pt double"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">13,472,025</span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">11,278,105</span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A9_zZaFdlvlFle9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DisclosurePrepaidExpensesAbstract', window );"><strong>Prepaid Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_PrepaidExpensesTextBlock', window );">Prepaid Expenses</a></td>
<td class="text"><p id="xdx_80E_ecustom--PrepaidExpensesTextBlock_zqxLm2EPLgt7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b><span style="text-decoration: underline">Note 7 &#8211; <span id="xdx_824_zoAcQy2ygSli">Prepaid Expenses</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif">The prepaid
expenses category is comprised of the following:</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zLKcxzx2pJ75" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Prepaid Expenses (Details)">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="display: none; font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_8BF_zJvwc6gQePH2">Schedule of prepaid expenses</span></span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20251231_zCqB86j6PFKg" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20241231_zkK5Cxcj0Ih4" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Year Ended
    December 31,</b></span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>2025</b></span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidTaxes_iI_z3TGIVrV5W42" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Prepaid taxes</span></td>
    <td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">206,242</span></td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">657,437</span></td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--PermitsAndInsurance_iI_z2a3zSdH9Dj2" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Permits and insurance </span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">486,797</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">399,176</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--OtherPrepaidExpenseCurrent_iI_zz3lDFPZE9q8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Other prepaid
    expenses</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">105,345</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">76,684</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidExpenseCurrent_iI_zC6hejyG8Qj1" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Total</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">798,384</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1,133,297</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A8_z4boHq19UqJ6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>













<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosurePrepaidExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosurePrepaidExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_PrepaidExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_PrepaidExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cost of Sales<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DisclosureCostOfSalesAbstract', window );"><strong>Cost Of Sales</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_CostOfSalesDisclosureTextBlock', window );">Cost of Sales</a></td>
<td class="text"><p id="xdx_805_ecustom--CostOfSalesDisclosureTextBlock_ziIO0NtSCv85" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"><b><span style="text-decoration: underline">Note 8 &#8211; <span id="xdx_824_zXXPCUiHwTt4">Cost of Sales</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Cost of Sales is accounted for in accordance with
<i>ASC 705 &#8211; Cost of Sales and Services</i>. The Company purchases all commercial inventory as finished pharmaceutical products
from third party suppliers and does not conduct internal manufacturing.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">These costs are capitalized into inventory in accordance
with <i>ASC 330</i> and recognized in Cost of Sales when control of the related inventory transfers to the customer under <i>ASC 606</i>.
Inventory is recorded at cost.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company evaluates inventory for excess, expiration,
and obsolescence at each reporting period. Inventory that becomes unsalable due to shelf-life limitations, regulatory changes, product
discontinuation, or forecasted demand shortfalls is written down to its net realizable value, with the charge recorded in Cost of Sales.
Previously recorded write downs are not reversed.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The Company&#8217;s Cost of Sales category is comprised of the following:</p>

<table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfCostOfSalesTableTextBlock_zgmBqlypqjnf" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Cost of Sales (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span id="xdx_8B4_zkM25TGXKVBf" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b style="display: none">Schedule
    of cost of sales</b></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif">&#160;</td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left">&#160;</td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right">&#160;</td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left">&#160;</td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif">&#160;</td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left">&#160;</td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right">&#160;</td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; font-weight: bold">Year Ended December 31,</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&#160;</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; font-weight: bold; text-align: center">2024</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">Finished
    goods</span></td><td style="width: 2%; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_900_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--FinishedGoodsMember_zC1dpV2q2owh" title="Cost of goods sold">8,866,208</span></span></td><td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_90E_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--FinishedGoodsMember_z9mxmdsKwta" title="Cost of goods sold">8,116,534</span></span></td><td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">Professional allowances</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_906_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--ProfessionalAllowancesMember_zCxI0iKKSX13" title="Cost of goods sold">11,909,812</span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_905_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--ProfessionalAllowancesMember_zs0JDixty4Ej" title="Cost of goods sold">13,714,009</span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">Other allowances</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_90B_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--OtherAllowancesMember_zyhSFVWnzerc" title="Cost of goods sold">1,086,575</span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_90E_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--OtherAllowancesMember_ztAj2iFrvpwd" title="Cost of goods sold">666,913</span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">Wholesalers&#8217; fees
    &amp; discounts</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_909_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--WholesalersFeesAndDiscountsMember_z2pShOzDa9V3" title="Cost of goods sold">650,333</span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_902_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--WholesalersFeesAndDiscountsMember_z5LsYYEpljC4" title="Cost of goods sold">1,699,286</span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">Inventory adjustment</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_905_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--InventoryAdjustmentMember_zhrPlvUarXTc" title="Cost of goods sold">1,162,303</span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_90C_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--InventoryAdjustmentMember_zmHR2saVlJXi" title="Cost of goods sold">236,555</span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">Freight</span></td><td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_90A_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--FreightMember_zjsLYsmhbVm9" title="Cost of goods sold">374,983</span></span></td><td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_907_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--FreightMember_zxd9h50SYTR6" title="Cost of goods sold">438,105</span></span></td><td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">Total</span></td><td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_90B_eus-gaap--CostOfRevenue_c20250101__20251231_zM9dDu1Rudqd" title="Cost of goods sold">24,050,214</span></span></td><td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_903_eus-gaap--CostOfRevenue_c20240101__20241231_zcoORuRVF9Ie" title="Cost of goods sold">24,204,489</span></span></td><td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A4_zBbqsG7Nvcp6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_CostOfSalesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_CostOfSalesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureCostOfSalesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureCostOfSalesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Stock Splits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DisclosureReverseStockSplitsAbstract', window );"><strong>Reverse Stock Splits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_ReverseStockSplitTextBlock', window );">Reverse Stock Splits</a></td>
<td class="text"><p id="xdx_802_ecustom--ReverseStockSplitTextBlock_zWkkHCKauZLh" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 9 &#8211; <span id="xdx_823_z5z1WmLA0ma5">Reverse
Stock Splits</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Effective April 17, 2024 and August 8, 2024, the
Company completed 1-for-100 and 1-for-20 reverse splits of its common stock, respectively. The Company had previously completed three
(3) reverse stock splits including a 1-for-200 reverse split on February 9, 2022, and two 1-for-20 reverse splits, one in 2019 and the
other in 2020. The Company&#8217;s financial statements included in this report reflect all five (5) reverse stock splits on a retroactive
basis for all periods presented and for all references to common stock, unless specifically stated otherwise.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureReverseStockSplitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureReverseStockSplitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_ReverseStockSplitTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_ReverseStockSplitTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capital Stock</a></td>
<td class="text"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zi58iXrIyqS1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 10
&#8211; <span id="xdx_82B_zHnnICAzdPLi">Capital Stock</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s authorized capital is comprised
of <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_z0fbd8yM9eBd" title="Common stock, shares authorized">3,000,000,000</span> shares of common stock, par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zd4VxAqWgQo3" title="Common stock, par value">0.001</span>, and <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__srt--TitleOfIndividualAxis__srt--DirectorMember_z1z5qw0yfv29" title="Preferred stock, shares authorized">30,000,000</span> shares of preferred stock, $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20251231__srt--TitleOfIndividualAxis__srt--DirectorMember_zoH6tYku8qHj" title="Preferred stock, par value">0.10</span> par value. As of December 31,
2024, the Company had authorized <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsOXxx3CwFR4" title="Preferred stock, shares authorized"><span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zQBeJgrHXgD4" title="Preferred stock, shares authorized">1,000,000</span></span> shares of Series B Preferred Stock. The Series B Preferred Stock is
non-convertible and non-redeemable. It has a liquidation preference equal to the stated value of $0.10 per share, relative to the common
stock and gives the holder the right to 1,000 votes per share. As of December 31, 2024 and 2025, <span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zFFQB1KPsCd" title="Preferred stock, shares outstanding"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zYJw5jdOWqSg" title="Preferred stock, shares outstanding">130,000</span></span> shares of Series B Preferred
Stock were outstanding and held by the Company&#8217;s Chief Executive Officer.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On February 8, 2024, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240207__20240208__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zfX9WH8kZwkf" title="Number of shares issued">20,000</span>
shares of Series B Preferred Stock to the Company&#8217;s CEO for a purchase price of $<span id="xdx_908_eus-gaap--SharePrice_iI_c20240208__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zcBt4d5s17Vf" title="Purchase price">0.10</span> per share.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>













<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On February 15, 2024, the Company completed an
underwritten public offering and in connection therewith it issued an aggregate of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240214__20240215__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zNJ7oVUUTGuj" title="Number of shares issued">35,714</span> shares of common stock and received $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueOther_c20240214__20240215__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zjHAGmTfxaI2" title="Net proceeds">8,522,411</span>
in net proceeds. In connection with this offering, the Company issued 22,500 pre-funded warrants (the &#8220;2024 Pre-Funded Warrants&#8221;)
exercisable at $2.00 per share, 3,986 Series A Warrants exercisable at $4,200.00 per share (subject to adjustment), or pursuant to an
alternative cashless exercise provision, and 7,973 Series B Warrants exercisable at $4,760.00 per share, subject to adjustment. As of
December 31, 2025, <span id="xdx_907_ecustom--WarrantsExercisedDescription_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrants2024Member_zsSdIGPHoF34" title="Warrants exercised, description">(i) all of the 2024 Pre-Funded Warrants have been exercised resulting in the Company receiving net proceeds of $45,000,
(ii) all of the Series A Warrants have been exercised pursuant to the alternative cashless provision resulting in the Company receiving
$0 in proceeds, and (iii) 15,577,965 Series B Warrants remained outstanding and their exercise price had been adjusted to $2.07 as a result
of two reverse stock splits and a financing event which were conducted subsequent to their issuance. The Series B Warrants expire in February
2029.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On March 4, 2024, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240303__20240304__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z8DuwQhlX4Ng" title="Number of shares issued">100,000</span> shares
of Series B Preferred Stock to the Company&#8217;s CEO for a purchase price of $<span id="xdx_906_eus-gaap--SharePrice_iI_c20240304__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zeVMQgiqxrql" title="Purchase price">0.10</span> per share.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In April and May 2024, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240401__20240430__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zbePDqyRZeA4" title="Conversion of common stock shares"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240501__20240531__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zdXZcGIjTTdh" title="Conversion of common stock shares">1,120,784</span>
</span>shares of common stock in connection with the cashless exercise of all of the Series A Warrants and received $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20240401__20240430__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z6bzCt8v7Npc" title="Conversion of common stock value"><span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20240501__20240531__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zlVYWmjiBJ6" title="Conversion of common stock value">0</span></span> in proceeds.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On August 16, 2024, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_c20240815__20240816__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zptbds4nuwSe" title="Stock issued for rounding of reverse stock split">150,285</span>
shares of common stock in connection with the rounding up of fractional shares following the reverse stock splits of April 17, 2024 and
August 8, 2024.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In August and September 2024, the Company issued
<span id="xdx_90E_eus-gaap--ConversionOfStockSharesIssued1_c20240901__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zMU8Unl40ZQa" title="Stock converted, shares issued"><span id="xdx_90B_eus-gaap--ConversionOfStockSharesIssued1_c20240801__20240831__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zPWsDy7BKUIi" title="Stock converted, shares issued">678,865</span></span> shares of common stock in connection with the exercise of <span id="xdx_908_eus-gaap--ConversionOfStockSharesConverted1_c20240801__20240831__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_znpKqGJ0kTfe" title="Stock converted, shares converted"><span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_c20240901__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zNBbYxF9Vjqe" title="Stock converted, shares converted">678,865</span></span> Series B Warrants and received aggregate net proceed of $<span id="xdx_905_eus-gaap--ProceedsFromWarrantExercises_c20240801__20240831__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_z5xVQehkhFD6" title="Proceeds from warrant exercise"><span id="xdx_903_eus-gaap--ProceedsFromWarrantExercises_c20240901__20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zbqIe079Tna2" title="Proceeds from warrant exercise">1,895,610</span></span>.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In November and December 2024, the Company issued
<span id="xdx_901_eus-gaap--ConversionOfStockSharesIssued1_c20241101__20241130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z184pmA3llJb" title="Stock converted, shares issued"><span id="xdx_906_eus-gaap--ConversionOfStockSharesIssued1_c20241201__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zcTWT2m5ik3i" title="Stock converted, shares issued">580,438</span></span> shares of common stock in connection with the exercise of <span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_c20241101__20241130__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zZsP9zfSo6Fk" title="Stock converted, shares converted"><span id="xdx_908_eus-gaap--ConversionOfStockSharesConverted1_c20241201__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zprm6LxHDT2b" title="Stock converted, shares converted">580,438</span></span> Series B Warrants and received aggregate net proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_c20241101__20241130__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zw9eCDOydvV7" title="Proceeds from warrant exercise"><span id="xdx_901_eus-gaap--ProceedsFromWarrantExercises_c20241201__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_z0jCTUFOJi18" title="Proceeds from warrant exercise">1,618,203</span></span>.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On January 3, 2025, the Company issued <span id="xdx_907_eus-gaap--ConversionOfStockSharesIssued1_c20250102__20250103__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zGbX01e4TyVg" title="Stock converted, shares issued">127,443</span>
shares of common stock upon the exercise of <span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_c20250102__20250103__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zUVgoF5uOtX6" title="Stock converted, shares converted">127,443</span> Series B Warrants and received $<span id="xdx_90A_eus-gaap--ProceedsFromWarrantExercises_c20250102__20250103__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zSxXHUNs7rj9" title="Proceeds from warrant exercise">355,298</span> in net proceeds.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On April 2, 2025, the Company issued <span id="xdx_90B_eus-gaap--ConversionOfStockSharesIssued1_c20250401__20250402__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z0pUfwZa0caj" title="Stock converted, shares issued">660,000</span> shares
of common stock upon the exercise of <span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_c20250401__20250402__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zOCNsWtlQjda" title="Stock converted, shares converted">660,000</span> Series B Warrants and received $<span id="xdx_905_eus-gaap--ProceedsFromWarrantExercises_c20250401__20250402__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zpUNKJxKvvJd" title="Proceeds from warrant exercise">1,840,014</span> in net proceeds.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On April 3, 2025, the Company issued an aggregate
of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250401__20250403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zefPwnICdhZf" title="Aggregate shares Issued">1,188,404</span> shares of common stock in connection with a registered direct offering and received $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250401__20250403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zN63QBwvR8Pe" title="Net proceeds">1,828,596</span> in net proceeds.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On October 16, 2025, the Company issued <span id="xdx_90F_eus-gaap--ConversionOfStockSharesIssued1_c20251015__20251016__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zKR72AEXwusd" title="Stock converted, shares issued">350,000</span>
shares of common stock upon the exercise of <span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_c20251015__20251016__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zeFsW2GdBZ83" title="Stock converted, shares converted">350,000</span> Series B Warrants and received net proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20251015__20251016__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zEz7ARazH0Pf" title="Net proceeds">724,500</span>.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">As of December 31, 2025 and 2024, the Company had
<span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20251231_z9Vn7ak7e3m8"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20251231_zJXXdPx7mFSk">4,905,945</span></span> and <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20241231_zQYqgpEw6MMd" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_z5wFqj3DAH9" title="Common stock, shares outstanding">2,580,098</span></span> shares of common stock issued and outstanding, respectively.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company has declared no dividends since inception.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>













<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DisclosureWarrantsAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantsDisclosureTextBlock', window );">Warrants</a></td>
<td class="text"><p id="xdx_806_ecustom--WarrantsDisclosureTextBlock_zGrqruCEMns2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 11 &#8211;<span id="xdx_82F_zPQEzVKBpmsg">Warrants</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company accounts for issued warrants either
as a liability or equity in accordance with <i>ASC 480-10</i> or <i>ASC 815-40</i>. Under <i>ASC 480-10</i>, warrants are considered a
liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants
do not meet liability classification under <i>ASC 480-10</i>, the Company considers the requirements of <i>ASC 815-40</i> to determine
whether the warrants should be classified as a liability or as equity. Under <i>ASC 815-40</i>, contracts that may require settlement
for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured
at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance
date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under
<i>ASC 815-40</i>, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed
to its common stock and whether the warrants are classified as equity under <i>ASC 815-40</i> or other applicable GAAP standard. Equity-classified
warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In 2022, 2023, 2024, and 2025, the Company completed
six (6) financing events, and in connection therewith, it issued warrants as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfWarrantsIssuedWithFinancingTableTextBlock_zf23S3xtYnR7" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details - Warrants issued with financing)">
  <tr style="background-color: White">
    <td style="vertical-align: top"><span id="xdx_8BD_zxaUosbINNi9" style="display: none">Schedule of warrants issued with financing</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 37%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Issuance
    Date/Type</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 20%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Number</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 20%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Exercise
    Price</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 20%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Expiry
    Date</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Feb 17, 2022 (&#8220;Tradeable
    Warrants&#8221;)*</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_fKg_____zRJmmhSDjxg1" style="vertical-align: top" title="Warrants outstanding"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">2,051</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_zJ7hQBUczKVc" title="Warrant expiration date">4,440.00</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_902_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_zri3sNVV0BEa" title="Warrant expiration date">February 2027</span></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Mar 14, 2022 (&#8220;2022
    Pre-Funded Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zXkDAJSSNTp3" style="vertical-align: top" title="Warrants outstanding"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1,846</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_z5lKbZ3mE7i8" title="Warrant expiration date">2.00</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_908_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zgAd3WXF37Hg" title="Warrant expiration date">Unlimited</span></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Mar 14, 2022 (&#8220;Investor
    Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_fKio___z8rlX91kfMUa">1,801</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zIt7rRkk6wih">4,440.00</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_900_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zjycrXvHyRde">March 2027</span></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Apr 28, 2022 (&#8220;April
    Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zIAC9PaveSzf" style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">4,862</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zPyZpyxtyOff">7,520.00</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90C_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zRQVtHaNJxX">April 2027</span></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">May 16, 2023 (&#8220;May
    Pre-Funded Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_zhANlkukxRal" style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1,751</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_z9abUUb14TMg">2.00</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90F_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_zs5tHlVRMsq4">Unlimited</span></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">May 16, 2023 (&#8220;May
    Investor Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zHNYOdyTqTik" style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">5,952</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zodUIQszAYXd">1,180.00</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_903_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zpUGWEvueJ71">November 2028</span></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Feb 15, 2024 (&#8220;2024
    Pre-Funded Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_zSD89QoTOAje" style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">22,500</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_z6dzjg7bJ2Zj">2.00</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_900_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_zThqiw8IEW6f">Unlimited</span></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Feb 15, 2024 (&#8220;Series
    A Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_fKio___zTZixmjv9x1f">3,986</span>**</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_z2bD7SjgAQW1">4,200.00</span>**</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90D_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_zbw4SgeKDOe2">August 2026</span></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Feb 15, 2024 (&#8220;Series
    B Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_fKio___zLPvVuZuWsVb">7,973</span>**</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_z2EsF8yAYUS8">4,760.00</span>**</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_901_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zEtNA3TLnbPa">February 2029</span></span></td></tr>
  <tr style="background-color: White">
    <td style="border-bottom: black 1pt solid; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Apr
    03, 2025 (&#8220;2025 Pre-Funded Warrants&#8221;)</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_zF0lbbU5ssCl" style="border-bottom: black 1pt solid; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">260,000</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_zUagTailpb3i" title="Exercise price">0.001</span></span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90E_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_z4xq5njTl4u3">Unlimited</span></span></td></tr>
  </table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-size: 8pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13px"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">These warrants trade under
    the ticker symbol SBFMW</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">**</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Subject to adjustment</span></td></tr>
  </table>
<p id="xdx_8AE_zeMQyOuCKpVg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On February 11, 2024, the Company redeemed all
of the April Warrants and all of the May Investor Warrants for an aggregate purchase price of $<span id="xdx_90D_eus-gaap--PaymentsForRepurchaseOfWarrants_pp0p0_c20240210__20240211__us-gaap--AwardTypeAxis__custom--AprilWarrantsAndMayInvestorWarrantsMember_zwrDE7NyoSma" title="Payments for repurchase of warrants">3,139,651</span>.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">As of December 31, 2025, all of the 2022 Pre-Funded
Warrants, all of the May Pre-Funded Warrants, all of the 2024 Pre-Funded Warrants, all of the 2025 Pre-Funded Warrants, a total of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_z4vMiyLrFuwe" title="Warrants exercised">1,569</span>
Tradeable Warrants, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zZ3YufmJwMCb" title="Warrants exercised">1,401</span> Investor Warrants, all of the Series A Warrants, and <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_z4Zh4CZNMvl9" title="Warrants exercised">2,269,303</span> Series B Warrants (as adjusted) were exercised
resulting in aggregate net proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromWarrantExercises_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zC3F4enTucr4" title="Proceeds from warrant exercises">18,136,992</span> received by the Company.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s outstanding warrants as of
December 31, 2025 consisted of the following:</p>

<table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zeYsZQUP4hv7" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details - Warrants outstanding)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8BA_z1RvAy1G5Fde"><span style="display: none; font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; color: White">Schedule of warrants outstanding</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Type</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Number</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Exercise Price</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Expiry Date</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 25%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Tradeable Warrants*</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_fKg_____z3IDyqg91rhe" style="width: 24%" title="Number of warrants outstanding"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">482</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_fKg_____zS5tu4SC2Mhh" style="width: 24%" title="Warrant exercise price"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$220.00</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 24%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_908_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_fKg_____zJXIKtPODttg" title="Expiry date">February 2027</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Investor Warrants</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_fKio___z1FzCr0udrfb">400</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_fKio___z5jwWjBD1aOh">4,000.00</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_909_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_zI17tbbMeEag">March 2027</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Series B Warrants</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_fKioq_zddOnbprW6S4">15,227,962</span>**</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_fKioq_zzomno5A8t3g">2.07</span>**</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90A_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_zowPp9E6Wrl9" title="Expiry date">February 2029</span></span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 12px"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*</span></td>
    <td><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-size: 8pt">These warrants trade under the
        ticker symbol SBFMW</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">**</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">As adjusted following the financing event of April 3,
    2025 and subject to further adjustment of the number of warrants and exercise price upon certain corporate actions such that the
    aggregate exercise price of the warrants remains unchanged</span></td></tr>
  </table>
<p id="xdx_8A0_zHP2e4LMlrh4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_WarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_WarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zFlbt1QS4vtg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 12 &#8211;
<span id="xdx_82D_zapNf0OBUWMh">Earnings Per Share</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The following table* sets forth the computation
of basic net income (loss) per share:</p>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zoF14LQs6e9c" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings Per Share (Details)">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid"><span id="xdx_8BB_zcB3fbVL3Pg3" style="display: none">Schedule of computation of basic and diluted net income per share</span></td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20251231_zNjJZReYAdP8" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20241231_zQ8xUjEedt1i" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Year Ended December 31,</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zo9DXGDEbT0a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left"><span style="font-size: 9pt">Net gain (loss) attributable to common stock</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">(5,975,352</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">)</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">(5,134,116</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">Weighted average outstanding shares of common stock (Basic)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20251231_zjgPcCo4Jch9" title="Weighted average common shares outstanding - basic">4,157,086</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_zr4GvQjHOk55" title="Weighted average common shares outstanding - basic">701,749</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">Net gain (loss) per share attributable
    to common stock  (Basic)</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20250101__20251231_zagpytq9nff6" title="Basic gain (loss) per share attributable to common stock">(1.44</span></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_c20240101__20241231_z7kjPcFLEWhe" title="Basic gain (loss) per share attributable to common stock">(7.32</span></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  </table>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">* Diluted net
gain (loss) per share is not included in this table as the Company incurred net losses for the years ended December 31, 2025 and 2024
and inclusion of dilutive instruments would have an anti-dilutive effect.</span></p>

<p id="xdx_8A3_zCFUPMs9CN7f" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zYOM4SNbtj6i" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 13 &#8211; <span id="xdx_821_zS1RCCDP2ao8">Income Taxes</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The components of the provision for income taxes
were as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zSlolKCSNVKe" style="font: 10pt Arial, Helvetica, Sans-Serif, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Provision for income taxes)">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; font-weight: 400; font-style: normal"><span id="xdx_8BE_z17siEj3VfHj" style="display: none">Schedule of provision for income taxes</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20250101__20251231_zOXxjZTzzVy2" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20240101__20241231_zm6eTh6hwpOc" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">Year
    Ended December 31,</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">2025</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">2024</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zp47PcoK83yj" style="vertical-align: bottom">
    <td style="font-weight: 400; font-style: normal"><span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif">Current:</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--CurrentFederalTaxExpenseBenefit_d0_zAWQxDmAgCH9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: 400; font-style: normal"><span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif">Federal</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#8211;<span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_d0_zX7IUdAka1La" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 66%; font-weight: 400; font-style: normal"><span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif">State</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">50</span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--CurrentForeignTaxExpenseBenefit_d0_z3sNsCXyXvja" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Foreign</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(73,330</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(90,434</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td></tr>
  <tr id="xdx_400_ecustom--CurrentIncomeTaxExpenseBenefits_d0_zeSEQn5bbZNc" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Total Current</span></td><td style="border-bottom: Black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(73,330</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td><td style="border-bottom: Black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(90,384</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--ComponentsOfDeferredTaxAssetsAbstract_iB_zhxWm94QytN5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: 400; font-style: normal"><span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif">Deferred:
    </span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_d0_zpRTBkbCCAw8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: 400; font-style: normal"><span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif">Federal</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_d0_zA2OB1a7umil" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: 400; font-style: normal"><span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif">State</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_zBz31bBeriqh" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Foreign</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">94,939</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(144,474</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_zMkegtqPYTm3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Total Deferred</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">94,939</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(144,474</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_z2C16lRLK7cf" style="vertical-align: bottom; background-color: White">
    <td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; font-weight: 400; font-style: normal; text-align: left; padding-bottom: 2.5pt"><span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif">Total
    Income Tax Expense / (Benefit)</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">21,609</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8239;</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(234,858</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td></tr>
  </table>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: normal 400 10pt Arial, Helvetica, Sans-Serif, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font: normal 400 10pt Arial, Helvetica, Sans-Serif">The
Company&#8217;s effective tax rate differs from the federal statutory rate as follows:</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zTmAjy5a8YKd" style="font: 10pt Arial, Helvetica, Sans-Serif, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Reconcilation of tax rate)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B0_zNWpTBKDYc86" style="display: none">Schedule of income tax expense</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20250101__20251231_zrNuxyoK5bN1" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20240101__20241231_zFU0USJw6U14" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>Year Ended December 31, </b></span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></td><td colspan="5" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>2025</b></span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></td><td colspan="5" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>2024</b></span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_iN_di_msITEBzYLG_zFtvPdBPSJog" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 40%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Pre-Tax Book Income</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(1,250,286</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right; width: 11%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_mataxrate_c20250101__20251231_zRkHIWzlSJlj" title="Pre-Tax Book Income, Rate">21.00</span>%&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right; width: 11%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(1,121,714</span></td><td style="text-align: left; width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right; width: 11%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_mataxrate_c20240101__20241231_z3jMSOJZlTR6" title="Pre-Tax Book Income, Rate">20.89</span>%&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzYLG_z6Ud25g2ZyKb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">State and Local Income Taxes</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">44,533</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_mataxrate_c20250101__20251231_zbEQIRyNVuIk" title="State Taxes, Rate">(0.75</span>%)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">40</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_mataxrate_c20240101__20241231_z0tOZ8ZIqWw1" title="State and Local Income Taxes, Rate">0.00</span>%&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory_maITEBzYLG_z28KOH3J5tX7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Effect of Rates Different than
    Statutory</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">151,341</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_902_ecustom--EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate_dp_mataxrate_c20250101__20251231_zP0lUII4to5f" title="Effect of Rates Different than Statutory, Rate">(2.54</span>%)</span></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">62,181</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_907_ecustom--EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate_dp_mataxrate_c20240101__20241231_zRDxIr2Jtrt8" title="Effect of Rates Different than Statutory, Rate">(1.16</span>%)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxReconciliationOtherForeignTaxes_d0_maITEBzYLG_zVnKryNCUFYe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Other Foreign Taxes</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_900_ecustom--EffectiveIncomeTaxRateReconciliationOtherForeignTaxes_dp_mataxrate_c20250101__20251231_zUrzTEU1Yw4l" title="State Taxes, Rate">0.00</span>%&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(119,181</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_902_ecustom--EffectiveIncomeTaxRateReconciliationOtherForeignTaxes_dp_mataxrate_c20240101__20241231_zAdyo88InPP9" title="Other Foreign Taxes, Rate">2.22</span>%&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzYLG_zk77XgudRr45" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Permanent Adjustments</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">54,987</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_dp_mataxrate_c20250101__20251231_zM923qvT7u55" title="Permanent Adjustments, Rate">(0.92</span>%</span><span style="font-size: 9pt">)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">56,092</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_dp_mataxrate_c20240101__20241231_zQnsZlYTq2i8" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(1.04</span><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">%)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzYLG_zUmJGP63IfH5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Change in Valuation Allowance</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1,107,342</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_mataxrate_c20250101__20251231_zsD04FbHJr6f" title="Change in Valuation Allowance, Rate">(18.60</span>%)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">569,920</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_mataxrate_c20240101__20241231_zwVv6mm2wQOe" title="Change in Valuation Allowance, Rate">(10.62</span>%)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_d0_maITEBzYLG_zt1G3pOi6Eeb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Rate Change</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_mataxrate_c20250101__20251231_zqndcwtTjTB" title="Rate Change, Rate">0.00</span>%&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">149,237</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_mataxrate_c20240101__20241231_zuIZwvmx65D" title="Rate Change, Rate">(2.78</span>%)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_maITEBzYLG_zOGC9gT7DcM4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Prior Year True up</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(86,308</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_mataxrate_c20250101__20251231_zR2fzaodesGl" title="Provision to Return Adjustments, Rate">1.45</span>%&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">156,540</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_mataxrate_c20240101__20241231_zRuwRHMimiHh" title="Prior Year True up, Rate">(2.92</span>%)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationOtherAdjustments_d0_maITEBzYLG_zA6W4drHzp4e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Other</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp0_mataxrate_c20250101__20251231_zwfOu8U4fay7" title="Other Adjustments, Rate">&#8211;</span>%&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">12,027</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_mataxrate_c20240101__20241231_zqGqjYo6fMk7" title="Other, Rate">(0.22</span>%)</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_pp0p0_mtITEBzYLG_zaUaz0m7oDMd" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: right; padding-bottom: 2.5pt"><b style="display: none">Total</b><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">21,609</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"> &#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_mttaxrate_c20250101__20251231_zLjVKxhpO4Wc" title="Total effective income tax rate, Rate">(0.36</span>%)&#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(234,858</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_mttaxrate_c20240101__20241231_znXbb0haqTy6" title="Total effective income tax rate, Rate">4.37</span>%&#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  </table>


<p id="xdx_8A6_zf9SNAK5SOCc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
components of the net deferred tax assets were as follows:</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zyfgIXjQsyG6" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Deferred taxes)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BE_zGTqCJT2qOo7" style="display: none">Schedule of components of net deferred tax assets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20251231_zpE8XPcZsNDk" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20241231_zlfIv9iz8Auc" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">Year Ended December 31,</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&#160;</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredIncomeTaxesAbstract_iB_z3tOGuZyfitk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Deferred Tax Assets:</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zumjhyC9af99" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 66%; text-align: left"><span style="font-size: 9pt">Net Operating Loss, Credits and Carryforwards</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">7,785,678</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">6,460,638</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_d0_zC53hPzKoThc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Fixed Assets</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">2,818</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_zINrGFdrD3j8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-size: 9pt">Intangibles</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">622,658</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">614,734</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsResearchAndDevelopment_iI_zOzxtS8zokq9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Research and Development</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">25,327</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">25,327</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsOther_iI_d0_z23gL0zjQm7c" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Other deferred tax assets</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">95,935</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_zAqY8dWeHgh2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Lease Liability</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">9,232</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">252,407</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zF9fhMMOVcX8" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Valuation Allowance</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(8,445,713</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(6,967,294</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iI_d0_zWlV9hzfx5nj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">Total Deferred Tax Assets</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">481,747</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_ziAh1nkWfpwb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Deferred Tax Liabilities:</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesOther_iI_d0_zqjk0J8O8p0b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Other deferred tax liabilities</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(67</span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_di0_z98JcGBP3jWh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Fixed Assets</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(141,396</span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di0_zh5BCO1c8kO3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-size: 9pt">Intangibles</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di0_zSMMie9sK3N6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Right-of-Use Assets</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(248,050</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxLiabilities_iNI_di0_z5MQhd60g1R5" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">Total Deferred Tax Liabilities</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(389,513</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredIncomeTaxesAndOtherAssetsNoncurrent_iI_d0_zadJx6S3mESd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">Net Deferred Tax Liability</span></td><td style="border-bottom: Black 2.5pt double"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">92,234</span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>


<p id="xdx_8A3_zPggAiyFUOj9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>











<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">As
of December 31, 2025, the Company has federal, state, foreign and provincial net operating loss carryforwards of approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn6n6_c20251231_zGbcM7DUTP12" title="Federal net operating loss carryforwards">26</span>
million, $<span id="xdx_901_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20251231_zLnKEUaF7xj4" title="State net operating loss carryforwards">16.1</span> million, $<span id="xdx_906_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pn5n6_c20251231_zXl85m5cDOt" title="Foreign net operating loss carryforwards">4.3</span> million, and $<span id="xdx_908_ecustom--DeferredTaxAssetsOperatingLossCarryforwardsProvincial_iI_pn5n6_c20251231_zep7R5qkfs63" title="Provincial net operating loss carryforwards">3.3</span> million, respectively. Of the federal net operating loss forwards, approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_pn5n6_c20251231_z5ewUNrOqC6j" title="Net operating loss carryforwards, subject to expiration">9.4</span>
million have expiration dates from 2027 to 2037. The remainder can be carried forward indefinitely but limited to 80% of taxable
income. The foreign and provincial net operating loss carryforwards have a carryforward period of 20 years.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of a deferred tax asset
will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during
the periods in which those temporary differences are deductible. In making this determination, management considers all available positive
and negative evidence affecting specific deferred assets, including the Company's past and anticipated future performance, the reversal
of deferred tax liabilities, the length of carry&#173;back and carry-forward periods, and the implementation of the tax planning strategies.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Objective positive evidence is necessary to support a conclusion that a valuation allowance is not needed for all or a portion of deferred
tax assets when significant negative evidence exists. Cumulative losses in recent years are the most compelling form of negative evidence
considered by management in making this determination. For the years ended December 31, 2025 and 2024, management has determined that
based on all available evidence, a valuation allowance of $<span id="xdx_904_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_dxL_c20251231_zglVmE607M4e" title="Valuation allowance::XDX::8445713"><span style="-sec-ix-hidden: xdx2ixbrl1167">8.4</span></span> million and $<span id="xdx_904_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_dxL_c20241231_zwlfUzfonkV1" title="Valuation allowance::XDX::6967294"><span style="-sec-ix-hidden: xdx2ixbrl1169">7.0</span></span>, respectively is appropriate.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s evaluation of uncertain tax matters was performed for tax years ended through December 31, 2025. Generally, the Company
is subject to U.S. audit for the years ended December 31, 2024, 2023, and 2022 and may be subject to examination for amounts relating to
net operating loss carryforwards generated in periods prior to December 31, 2024. The company is subject to Canada audit for the years
ended December 31, 2024, 2023, 2022 and 2021 for Sunshine Biopharma Canada Inc and subject to Canada audit for the years ended December
31, 2024, 2023 and 2022 and June 30, 2022 for Nora Pharma Inc and may be subject to examination for amounts relating to net operating
loss carryforwards generated in periods prior to December 31, 2024.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">On July 4, 2025, the One Big Beautiful Bill Act ("OBBBA") was enacted in the U.S. The OBBBA makes permanent key elements of the Tax Cuts
and Jobs Act, including 100% bonus depreciation, domestic research cost expensing, and the business interest expense limitation. ASC Topic
740, Income Taxes, requires the tax effects of changes in tax rates and laws to be recognized in the period in which the legislation is
enacted. Those effects, both current tax and deferred tax, are reported as part of continuing operations. The Company is currently assessing the impact of OBBBA on its Consolidated
Financial Statements but currently does not believe that the OBBBA will have a material impact on the Company's income tax expense.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_805_eus-gaap--LesseeOperatingLeasesTextBlock_ziG7oyeejZJ6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 14 &#8211;
<span id="xdx_82A_zNY5ZuryDKA3">Leases</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company has obligations as a lessee for office
space with initial non-cancellable terms in excess of one year. The Company classified the lease as an operating lease. The lease contains
a renewal option for a period of five years. Because the Company is certain to exercise the renewal option, the optional period is included
in determining the lease term, and associated payments under the renewal option are included in the lease payments. The Company&#8217;s
lease does not include termination options for either party to the lease or restrictive financial or other covenants. Payments due under
the lease contract include fixed payments plus a variable Payment. The Company&#8217;s office space lease requires it to make variable
payments for the Company&#8217;s proportionate share of building&#8217;s property taxes, insurance, and common area maintenance. These
variable lease payments are not included in lease payments used to determine lease liability and are recognized as variable costs when
incurred.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Amounts reported on the balance sheet as of December
31, 2025 were as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--LeaseCostTableTextBlock_zc5uTDlVwVO2" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Lease information)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_z8a10fbE4Kuk" style="display: none">Schedule of lease information</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%; text-align: left">Operating lease ROU asset</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_90A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20251231_znN516YrLZJb" title="Operating lease ROU asset">778,846</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating Lease liability - Short-term</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20251231_zMXZ6W1tW7o3" title="Operating Lease liability - Short-term">215,637</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liability - Long-term</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20251231_zHoAs1t7ojK8" title="Operating lease liability - Long-term">596,785</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Remaining lease term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20251231_zBrTXHZBaedd" title="Remaining lease term">4
                                            </span>years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20251231_zVqM28wFKSg5" title="Discount rate">6</span>%</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_z0CpgakbkrMe" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Amounts disclosed for ROU assets obtained in exchange
for lease obligations and reductions of ROU assets resulting from reductions of lease obligations include amounts reduced from the carrying
amount of ROU assets resulting from deferred rent.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Maturities of lease liabilities under non-cancellable
operating leases at December 31, 2025 are as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zbpnS8ofBPqj" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Maturities of lease payments)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BA_zXSZyhv1lWr4" style="display: none">Schedule of maturities of lease liabilities</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20251231_zx3GPLCsdNae" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zZNf4PRdSUIh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%; text-align: left">2026</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">215,637</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zU1z62k9eUm5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">204,428</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_zVnXlJT7ckKj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">193,794</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_zMgDYshGGD1g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">183,705</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_zlXmjXveiLUj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Thereafter</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14,858</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p id="xdx_807_eus-gaap--SegmentReportingDisclosureTextBlock_zpkUJLDQCeZg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 15 &#8211; <span id="xdx_829_z1PD5yhen4h2">Segment
Reporting</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company operates as <span id="xdx_90D_eus-gaap--NumberOfOperatingSegments_dxH_uSegment_c20250101__20251231_zYmrM12qvzRf" title="Number of operating segments::XDX::1">one</span> operating segment,
which is also its <span id="xdx_90D_eus-gaap--NumberOfReportableSegments_dxH_uSegment_c20250101__20251231_zcP1UQUfp83e" title="Number of reportable segments::XDX::1">one</span> reportable segment, as the Chief Executive Officer, acting as the Chief Operating Decision Maker (&#8220;CODM&#8221;),
evaluates financial performance and allocates resources on a consolidated, enterprise-wide basis. The Company&#8217;s operations are
managed as an integrated pharmaceutical business focused on the research, development, and commercialization of prescription drugs and
supplements.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Although the Company conducts activities through
multiple legal entities &#8212; including Sunshine Biopharma Inc. (U.S.), Sunshine Biopharma Canada Inc. (Canada), and Nora Pharma Inc.
(Canada) &#8212; these entities operate under a unified management structure with shared economic characteristics, common product development
objectives, and centralized decision making. As such, they do not meet the criteria for separate operating segments under <i>ASC 280
&#8211; Segment Reporting</i>.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In accordance with <i>ASU 2023-07</i>, the Company
provides the following information regarding its single reportable segment:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Measure of Segment Profit (Loss): The CODM evaluates
performance using consolidated operating income (loss), which is consistent with the amounts presented in the accompanying consolidated
financial statements.</span></td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Significant Segment Expenses: Research and development
expenses, and supply chain costs, selling and marketing expenses, and general and administrative expenses are all incurred and reviewed
on a consolidated basis.</span></td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Other Segment Items: Interest income, interest
expense, foreign exchange gains and losses, and other non-operating items are also managed and reviewed on a consolidated basis.</span></td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Reconciliation: As the Company has only one reportable
segment, no additional reconciliation to consolidated totals is required beyond what is presented in the consolidated statements of operations.</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s operations are conducted primarily
in Canada and substantially all long-lived assets are located in this jurisdiction. Revenues are generated from customers located in Canada.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Management and Director Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DisclosureManagementAndDirectorCompensationAbstract', window );"><strong>Management And Director Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_ManagementAndDirectorCompensationTextBlock', window );">Management and Director Compensation</a></td>
<td class="text"><p id="xdx_80F_ecustom--ManagementAndDirectorCompensationTextBlock_zr12By3LXNae" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 16 &#8211;
<span id="xdx_82E_zN8xqraR0XQ7">Management and Director Compensation</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company paid its officers cash compensation
totaling $<span id="xdx_90A_eus-gaap--SalariesWagesAndOfficersCompensation_c20250101__20251231_z4PAnRiwzvof" title="Officers compensation">1,425,942</span> and $<span id="xdx_901_eus-gaap--SalariesWagesAndOfficersCompensation_c20240101__20241231_zv4d9zDbhIp3" title="Officers compensation">1,850,243</span> for the years ended December 31, 2025 and 2024, respectively. Of these amounts attributable to the
Company&#8217;s CEO, $<span id="xdx_902_eus-gaap--SalariesWagesAndOfficersCompensation_c20250101__20251231__custom--RelatedPartyTransactionsByRelatedPartyAxis__custom--AdvanomicsCorporationMember_zxq9MLmBdXe2" title="Officers compensation">0</span> and $<span id="xdx_90A_eus-gaap--SalariesWagesAndOfficersCompensation_c20240101__20241231__custom--RelatedPartyTransactionsByRelatedPartyAxis__custom--AdvanomicsCorporationMember_zYPQLvDpSqH" title="Officers compensation">800,000</span>, respectively was paid to Advanomics Corporation, a company controlled by the CEO of the Company.
In addition, the Company&#8217;s CEO was paid $12,000 in 2024 through the issuance of 120,000 shares of Series B Preferred Stock valued
at $12,000.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company paid its five directors cash compensation
of $80,000 each, totaling $<span id="xdx_907_eus-gaap--NoninterestExpenseDirectorsFees_c20250101__20251231_zpBJvn9CC8ki" title="Directors compensation"><span id="xdx_90F_eus-gaap--NoninterestExpenseDirectorsFees_c20240101__20241231_zZ6M8ehV1rYd" title="Directors compensation">400,000</span></span> for each of the years ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureManagementAndDirectorCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureManagementAndDirectorCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_ManagementAndDirectorCompensationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_ManagementAndDirectorCompensationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Matters<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Matters</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--LegalMattersAndContingenciesTextBlock_zFb4Kc5Apiod" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 17 &#8211;
<span id="xdx_821_z30YGgVgpD5e">Legal Matters</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
                                            April 14, 2025, the Company terminated the employment of Mr. Malek Chamoun, president of
                                            the Company&#8217;s wholly owned Canadian subsidiary, Nora Pharma. On April 17, 2025, the
                                            Company received a demand letter (the &#8220;Demand Letter&#8221;) from the attorneys of
                                            Mr. Chamoun requesting that the Company pay to Mr. Chamoun $7,307,025 CAD (approximately
                                            $5,300,000 USD) within five (5) days. In response to the Demand Letter, the Company issued
                                            a letter on May 1, 2025 advising that the demands contained in the Demand Letter, including
                                            the sum of $7,307,025 CAD (approximately $5,300,000 USD), are completely unfounded and that
                                            it intends to defend itself vigorously. No provision or accrual was made in the financial
                                            statements for any litigation liability or legal expense which the Company may incur in connection
                                            with this alleged claim.</span></p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_zswwIHfzg0ah" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><b><span style="text-decoration: underline">Note 18 &#8211;
<span id="xdx_821_z5DPDOoBmWii">Subsequent Events</span></span></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">On
                                            January 16, 2026, the Company received a demand letter from the attorneys of Mr. Andrew Telsey,
                                            the Company&#8217;s former legal counsel, asserting that the Company and Mr. Telsey executed
                                            an employment agreement and demanding payment of $3,645,750 from the Company based on the
                                            Company&#8217;s alleged termination of the purported employment agreement without cause.
                                            The Company believes this demand is without merit and has never executed an employment agreement
                                            with Mr. Telsey. On that basis, among other factors, the Company filed a complaint against
                                            Mr. Telsey on February 6, 2026 in the circuit court of the 7<sup>th</sup> judicial district
                                            in Broward County, Florida seeking a declaratory judgment providing that (i) the purported
                                            employment agreement is of no legal effect and is not binding upon the Company, (ii) no monies
                                            are owed by the Company to Mr. Telsey under the purported employment agreement, (iii) the
                                            Company should be awarded its attorney&#8217;s fees and costs, and (iv) the Company should
                                            be awarded such other relief as the court deems just and proper. On March 30, 2026, the court granted the Company&#8217;s motion for entry of default and entered a default and
final judgment in favor of the Company. Pursuant to the court&#8217;s order, the court declared that the purported employment agreement
is of no legal effect and not binding on the Company, because the Company never executed the agreement, the Company did not breach the
purported employment agreement, and no monies are owed by the Company to Mr. Telsey under the purported employment agreement. The court
retained jurisdiction on the issues of entitlement and amount of attorney&#8217;s fees and costs to the Company as the prevailing party. </span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">PRINCIPLES OF CONSOLIDATION</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zT1F7GpEIqY4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_861_z1kzjesDd906">PRINCIPLES OF CONSOLIDATION</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of the Company and its subsidiaries, Nora Pharma Inc. and Sunshine Biopharma Canada Inc., both wholly owned. All
intercompany accounts and transactions have been eliminated in consolidation.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">USE OF ESTIMATES</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--UseOfEstimates_zyHfdlWNtT88" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_866_zImZqZi6xGl7">USE OF ESTIMATES</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation
of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic
environment has increased the degree of uncertainty inherent in these estimates and assumptions.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">TRADE ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ReceivablesPolicyTextBlock_zYKL1sSaiBga" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_86C_zJD4NE4ec4Q4">TRADE ACCOUNTS RECEIVABLE AND
ALLOWANCE FOR DOUBTFUL ACCOUNTS</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Trade accounts receivable are stated at net realizable
value. The majority of customers are not extended credit and therefore time to maturity for receivables is short. On a periodic basis,
management evaluates its trade accounts receivable and determines whether to record an allowance for doubtful accounts. Management analysis for the periods ended December 31, 2024 and 2025 determined
that no allowance for doubtful accounts needed to be recorded. A receivable is considered past
due if the Company has not received payments based on agreed-upon terms. The Company generally does not require any security or collateral
to support its receivables. As of December 31, 2025 and 2024, the balances of accounts receivable were $<span id="xdx_90E_eus-gaap--AccountsReceivableNetCurrent_iI_c20251231_zxRvzZJX0ytg" title="Accounts receivable">3,459,864</span> and $<span id="xdx_90B_eus-gaap--AccountsReceivableNetCurrent_iI_c20241231_zP5gVULZNYQ9" title="Accounts receivable">3,868,418</span>, respectively.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">INVENTORY VALUATION</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--InventoryPolicyTextBlock_zhKeMppuF1H9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_868_zZcWtBQ8Dp5j">INVENTORY VALUATION</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The
Company&#8217;s inventory is comprised of finished goods. Inventory is valued at the lower of cost and net realizable value. Cost is
determined using the first in, first out method. Net realizable value is the estimated selling price in the ordinary course of business,
less the costs necessary to make the sale. The cost of inventory includes the purchase price and other costs directly attributable to
the acquisition of the finished goods. The Company regularly reviews inventories to determine if the carrying value exceeds net realizable
value and, when determined necessary, an allowance to reduce the carrying value to net realizable value is recorded. The net realizable value is calculated based
on a combination of factors, including (i) aging, (ii) historical sell-through patterns, and (iii) product-specific considerations. Write-downs
are recorded within cost of goods sold and are not subsequently reversed. As of December 31,
2025 and 2024, there were allowances for obsolescence of $<span id="xdx_90F_eus-gaap--InventoryValuationReserves_iI_c20251231_zn3STckJuycl" title="Reserve for obsolescence">475,153</span> and $<span id="xdx_904_eus-gaap--InventoryValuationReserves_iI_do_c20241231_z4tfq3nPi0A1" title="Reserve for obsolescence">0</span>, respectively.</span></p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">CASH AND CASH EQUIVALENTS</a></td>
<td class="text"><p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zqx7JbOvORg9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_867_zvRq9k5Pfwj4">CASH AND CASH EQUIVALENTS</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">For the Balance Sheets and Statements of Cash
Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance
of $<span id="xdx_90E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_c20251231_zZ32dlvJqe14">9,123,308</span>
and $<span id="xdx_903_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_c20241231_zMseaXCo4B98">9,686,529</span>
as of December 31, 2025 and December 31, 2024, respectively. At times such cash balances may be in excess of the FDIC limit of $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20251231_zEg0oLiqljR6">250,000</span>
in the U.S. or the $<span id="xdx_902_ecustom--CashCanadaInsuredAmount_iI_uCAD_c20251231_zrEqCn8XOX4b" title="Cash insured in Canada (CAD)">100,000</span> CAD (approximately $<span id="xdx_906_ecustom--CashCanadaInsuredAmount_iI_uUSD_c20251231_zfQHCvrRj3M6" title="Cash insured in Canada (USD)">73,000</span> USD) limit in Canada. At December 31, 2025, the Company had deposits totaling
approximately $7 million in the U.S and $2 million in Canada.</p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zsuJ7ILjYGJe" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_869_z7AlXLRHR128">PROPERTY AND EQUIPMENT</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Property and equipment are reviewed for recoverability
when events or changes in circumstances indicate that its carrying value may exceed future undiscounted cash inflows. As of December 31,
2025 and 2024, the Company had not identified any such impairment. Repairs and maintenance are charged to operations when incurred and
improvements and renewals are capitalized.&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost. Depreciation
is calculated according to the following methods at the following annual rates and period for financial reporting purposes and accelerated
methods for tax purposes. Their estimated useful lives are as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--PropertyPlantAndEquipmentUsefulLivesTableTextBlock_zfpByWkhn958" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Estimated lives)">
  <tr style="vertical-align: top">
    <td><span id="xdx_8BD_z9C9GBNH5mFa" style="display: none">Schedule of estimated useful lives</span></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 28%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Office Equipment:</span></td>
    <td style="width: 49%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line and Declining balance method</span></td>
    <td style="width: 23%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_903_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zws3TJ6m2Zq8" title="Property and equipment estimated useful lives">5-7 Years / 20%</span></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Computer Equipment:</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Declining balance method</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90C_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z3voB4yZCgM1" title="Property and equipment estimated useful lives">55%</span></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Laboratory Equipment:</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line method</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_909_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z8Bu5xz1asmb" title="Property and equipment estimated useful lives">5 Years</span></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Vehicles:</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line and Declining balance method</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_901_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zwa1guchFnc3" title="Property and equipment estimated useful lives">5 Years / 30%</span></span></td></tr>
  </table>
<p id="xdx_8AC_zRN7iHB7Gs8a" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zAW5triZDyJ4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_86A_zoiXI3c1RV5">INTANGIBLE ASSETS</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Intangible assets are amortized over their estimated
useful lives according to the following methods at the following annual rates and period:<i></i></p>

<table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock_zwwokJM4aN8b" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Intangible assets)">
  <tr style="vertical-align: top">
    <td><span id="xdx_8B8_zXYTAxBJiTFk" style="display: none">Schedule of intangible assets   estimated
useful lives</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 25%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Licenses:</span></td>
    <td style="width: 50%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line method</span></td>
    <td style="width: 25%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_904_ecustom--IntangibleAssetsEstimatedUsefulLives_c20250101__20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zMExfiVHmH5" title="Intangible asset estimated useful lives">5 Years</span></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Website:</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Declining balance method</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_902_ecustom--IntangibleAssetsEstimatedUsefulLives_c20250101__20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_zmGJhForVFM6" title="Intangible asset estimated useful lives">55%</span></span></td></tr>
  </table>
<p id="xdx_8A4_zdDRfgKG2d0a" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Intangible assets are tested for recoverability
when events or changes in circumstances indicate that their carrying amount may not be recoverable. The carrying amount of a long-lived
asset is not recoverable when it exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposal.
In such a case, an impairment loss must be recognized and is equivalent to the excess of the carrying amount of a long-lived asset over
its fair value.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionServicesLicensingFees', window );">INTELLECTUAL PROPERTY RIGHTS - PATENTS AND LICENSES</a></td>
<td class="text"><p id="xdx_847_eus-gaap--RevenueRecognitionServicesLicensingFees_zFoxoCN8IsL9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_863_zEFf1loBhPih">INTELLECTUAL PROPERTY RIGHTS
- PATENTS AND LICENSES</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The cost of patents and licenses acquired is capitalized
and is amortized over the remaining life of the patents or licenses.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company evaluates recoverability of identifiable
intangible assets whenever events or changes in circumstances indicate that intangible assets carrying amount may not be recoverable.
Such circumstances include but are not limited to: (i) a significant decrease in the market value of an asset, (ii) a significant adverse
change in the extent or manner in which an asset is used, or (iii) an accumulation of cost significantly in excess of the amount originally
expected for the acquisition of an asset. The Company measures the carrying amount of such assets against the estimated undiscounted future
cash flows associated with it.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">BASIC AND DILUTED NET GAIN (LOSS) PER SHARE</a></td>
<td class="text"><p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zjLUIuWQo3ne" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_861_zHZZKwtmYnd">BASIC AND DILUTED NET GAIN (LOSS)
PER SHARE</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company computes gain or loss per share in
accordance with <i>ASC 260 &#8211; Earnings per Share</i>. ASC 260 requires presentation of both basic and diluted earnings per share
(&#8220;EPS&#8221;) on the face of the income statement. Basic net income (loss) per share is calculated by dividing net income (loss)
by the weighted-average common shares outstanding. Diluted net income (loss) per share is calculated by dividing net income (loss) by
the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is
more dilutive. As the Company incurred net losses for the years ended December 31, 2025 and 2024, <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20250101__20251231_zMgAksl5zuZ8"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20240101__20241231_zVDywucsa3l5">no</span></span> potentially dilutive securities were
included in the calculation of diluted earnings per share as the impact would have been anti-dilutive. Accordingly, diluted EPS information
is not included in this report.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zE2uzKHkm4ye" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_86A_zQ119tDTcXH3">INCOME TAXES</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In accordance with <i>ASC 740 &#8211; Income Taxes</i>,
the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by
applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities
and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities have been adjusted to reflect
changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not
be realized.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company expects to recognize the financial
statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position
in an examination. For tax positions meeting a &#8220;more-likely-than-not&#8221; threshold, the amount to be recognized in the financial
statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold,
no financial statement benefit is recognized. As of December 31, 2025, the Company had no uncertain tax positions. The Company recognizes
interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. The Company currently has no
federal or state tax examinations nor has it had any federal or state examinations since its inception. To date, the Company has not incurred
any interest or tax penalties.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">For Canadian and U.S. tax purposes, the Company&#8217;s
2022 through 2024 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">FUNCTIONAL CURRENCY</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zLvoc9nuCaNi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_860_zAQtqlDLp9Kd">FUNCTIONAL CURRENCY</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The U.S. dollar is the functional currency of the
Company which is operating in the United States. The functional currency for the Company's Canadian subsidiaries is the Canadian dollar.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company translates its Canadian subsidiaries'
financial statements into U.S. dollars as follows:</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 24px">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Income statement accounts are translated using the weighted average exchange rate for the period.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company includes translation adjustments from
currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate
component of shareholders&#8217; equity. There are currently no transactions of a long-term investment nature, nor any gains or losses
from non-U.S. currency transactions.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">CONCENTRATION OF CREDIT RISKS</a></td>
<td class="text"><p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_z4IY1iD7yuz4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_86E_zVNk6KqUUrP3">CONCENTRATION OF CREDIT RISKS</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash
equivalents with high credit quality financial institutions.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS</a></td>
<td class="text"><p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zqhSLybT8Yj6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_86F_zMlFgM8LrI46">FINANCIAL INSTRUMENTS AND FAIR
VALUE OF FINANCIAL INSTRUMENTS</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company applies the provisions of accounting
guidance, <i>ASC 825 &#8211; Financial Instruments</i>. ASC 825 requires all entities to disclose the fair value of financial instruments,
both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and
defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between
willing parties. As of December 31, 2025 and 2024, the fair value of cash, accounts receivable and notes receivable, accounts payable,
accrued expenses, and other payables approximated carrying value due to the short maturity of the instruments, quoted market prices or
interest rates which fluctuate with market rates.&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company defines fair value as the price that
would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement
date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels
and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement.
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to unobservable inputs (Level 3 measurements).</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 24px">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Level 1 &#8211; Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Level 2 &#8211; Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Level 3 &#8211; Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The carrying value of financial assets and liabilities
recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring
basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried
and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are
those that are adjusted to fair value each time a financial statement is prepared.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">NOTES PAYABLE</a></td>
<td class="text"><p id="xdx_843_eus-gaap--DebtPolicyTextBlock_zdTevLIoVj79" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_86D_z3bO4ctqItoh">NOTES PAYABLE</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Borrowings are recognized initially at fair value,
net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of
transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective
interest method. The Company had <span id="xdx_90E_eus-gaap--NotesPayable_iI_do_c20251231_zZlHXYFnQKoc"><span id="xdx_904_eus-gaap--NotesPayable_iI_do_c20241231_zOTBND7FG1Re">no</span></span> notes payable as of December 31, 2025 and 2024.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text"><p id="xdx_844_eus-gaap--RevenueRecognitionPolicyTextBlock_zhVi7YOtMiFg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_86E_zYbxKFVNkQKf">REVENUE RECOGNITION</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Over 97% of the Company&#8217;s revenues are derived
from the sale of pharmaceutical products. Pharmaceutical products can only be sold to a specific customer that is either a registered
pharmacy or a registered wholesaler. The Company therefore sells only to customers registered with Health Canada, the Canadian equivalent
of the FDA. Contracts are drawn up between the wholesalers and the Company for all indirect sales. In the case of direct sales to pharmacies,
purchase orders are used instead of contracts. A purchase order, forecast, or other written instructions to purchase any of the Company&#8217;s
products placed by the customer constitutes an irrevocable offer to purchase. The customer is responsible for ensuring that the terms
of any such order are complete and accurate. The purchase order is only deemed to be accepted when the Company (in its sole discretion)
accepts the purchase order and delivers on the purchase. The acceptance of any purchase order can be full or partial, at the sole discretion
of the Company. No variations to these conditions are binding on the Company unless agreed to in writing between the customer and the
Company.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">No significant judgments are made in connection
with any contracts as the price is already determined, the collection is reasonably assured, and performance obligation is fulfilled when
the customer receives the goods. The Company is not required to apply any specific judgments, estimations, or assumptions to determine
the price of its products.&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Taxes assessed by a governmental authority that
are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are
excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has been transferred
to a customer are accounted for as a fulfillment cost and are included in cost of revenues. The amount invoiced for each product is fixed
at the Company&#8217;s current price list on the date of shipping and known in advance by the customer and does not vary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company fulfills its performance obligation
when the customer receives the requested products. When the products leave the Company's warehouse, the transport to the customer is insured
and the transfer of ownership to the customer takes place when the customer receives the goods. At this point, the Company issues an invoice
for the products and remits the applicable sales taxes (GST and QST) to the appropriate governmental agency. The revenue is recognized
when the invoice is issued. Unless otherwise agreed to and signed by both parties, payment terms are within 30 days from the date of the
invoice. The collection is reasonably assured because of the nature of the Company&#8217;s customers. The Company is conducting sales
only in Canada. Prices are listed in Canadian dollars and may vary from one Province or Territory to another within Canada. All products
sold by the Company are labelled and approved for sale in Canada only and are not intended for export outside of Canada.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In the event of any breach by the Company of any
product warranty (whether by reason of defective materials, production faults or otherwise), the Company&#8217;s liability is limited
to, at Company&#8217;s option, (i) replacement of the product(s) in question, or (ii) reimbursement of the purchase price. The Company
carries product liability insurance and is not liable for products&#8217; failure to comply with the warranty of products if the failure
or damage arises because of the customer&#8217;s negligence, deliberate damage, misuse or failure to store the products in conditions
per Health Canada specifications. The Company is not liable (whether in contract, in tort or otherwise) for any (i) indirect, special
or consequential loss or damage, or (ii) loss of profit, goodwill, business or revenue (in each case whether direct or indirect). These
conditions also apply to any replacement products supplied by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company warrants to the customer that, at
the time of delivery, the products are compliant with all mandatory quality standards required by applicable regulatory and legal requirements.
In return, the customer is required to warrant to the Company that it holds all relevant permits and approvals required under applicable
laws to purchase, store, distribute, sell and use the Company&#8217;s products. Visible defects or damages must be reported to the Company
in writing immediately, but no later than five (5) business days after receipt of the products. Hidden defects must be reported to the
Company in writing immediately, but no later than five (5) business days after the customer becomes aware of such defects. The Company
is not be deemed to be in breach of the terms or otherwise liable to customer for any delay in performance or non-performance of its obligations
due to circumstances beyond its control, including but not limited to, acts of God, floods, droughts, earthquakes or other natural disasters,
terrorist attacks, wars, preparations for war, armed conflicts, civil commotions or riots, epidemics or pandemics, fires, strikes, lockouts,
shortages of material or labor, breakdown or damage to machinery or equipment, accidents, any law or governmental order or other regulations
or action taken by a governmental entity, or default of any third party suppliers or provider of services or products, or any causes not
within the Company&#8217;s control.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_zReBenJzGuG8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_863_zVrQsWh3ZXef">LEASES</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company recognizes and measures its leases
in accordance with <i>ASC 842 &#8211; Leases</i>. The Company is a lessee in a non-cancellable operating lease for office space. The Company
determines if an arrangement is a lease, or contains a lease, at inception of a contract and when the terms of an existing contract are
changed. The Company recognizes a lease liability and a right-of-use (ROU) asset at the commencement date. The lease liability is initially
and subsequently recognized based on the present value of its future lease payments. Variable payments are included in the future lease
payments when those variable payments depend on an index or a rate. The discount rate is the implicit rate if it is readily determinable
or otherwise the Company uses its incremental borrowing rate. The implicit rates of the Company's lease are not readily determinable and
accordingly, the Company uses its incremental borrowing rate based on the information available at the commencement date for all leases.
The Company&#8217;s incremental borrowing rate for a lease is the 6% interest it would have to pay on a collateralized basis to borrow
an amount equal to the lease payments under similar terms and in a similar economic environment. The ROU asset is subsequently measured
throughout the lease term at the remaining amount (i.e. present value of the remaining lease payments), plus unamortized initial direct
costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received, and any impairment
recognized. Lease cost for lease payments is recognized on a straight-line basis over the lease term.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company has elected, for all underlying classes
of assets, not to recognize ROU assets and lease liabilities for short-term leases that have a lease term of 12 months or less at lease
commencement, and do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company
recognizes the lease cost associated with its short-term leases on a straight-line basis over the lease term.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Under the available practical expedient, we account
for the lease and non-lease components as a single lease component for all classes of underlying assets as both a lessee and lessor. Further,
we elected a short-term lease exception policy on all classes of underlying assets, permitting us to not apply the recognition requirements&#160;of
this standard to short-term leases (i.e. leases with terms of 12 months or less).</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zbAdSEayDv92" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"><i><span id="xdx_869_zpTUaX0BKCC6">RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</span></i></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><i>ASU
2023-09 &#8211; Income Taxes (Topic 740): Improvements to Income Tax Disclosures,</i> enhances the transparency and decision usefulness
of income tax disclosures. Adjustments to the annual disclosure of income taxes include: (1) a tabular rate reconciliation comprised
of eight specific categories, (2) incomes taxes paid, disaggregated between significant national, state, and foreign jurisdictions, (3)
eliminates requirements to disclose the nature and estimate of reasonably possible changes to unrecognized tax benefits in the next 12
months or that an estimated range cannot be made, and (4) adds a requirement to disclose income (or loss) from continuing operations
before income tax expense (or benefit) by national and foreign, and income tax expense (or benefit) from continuing operations disaggregated
between national, state and foreign. The <i>ASU 2023-09</i> is effective for public business entities for fiscal years beginning on or
after December 15, 2024, and for all other entities for fiscal years beginning on or after December 31, 2025, with early adoption permitted.
The amendments in <i>ASU 2023-09</i> were adopted by the Company on a prospective&#160;basis. There was no material change&#160;to the
Company's financial statements reporting as a result of adopting <i>ASU 2023-09</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><i>ASU
2024-03 &#8211; Income Statement (Reporting Comprehensive Income) Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation
of Income Statement Expenses</i>, requires disaggregation of specific expense categories in the notes to the financial statements and
a qualitative description of the remaining expense amounts not separately disaggregated. This standard is effective for annual reporting
periods beginning after December 15. 2026, and requires prospective application with the option to apply it retrospectively. We intend
to adopt this standard in our Annual Report on Form 10-K for the year ending December 31. 2027.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Company has implemented all other new accounting
pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements
that have been issued that might have a material impact on its financial position or results of operations.</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionServicesLicensingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition for licensing fees, which is consideration paid to the entity (licensor) by another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, or trademark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionServicesLicensingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_PropertyPlantAndEquipmentUsefulLivesTableTextBlock', window );">Schedule of estimated useful lives</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--PropertyPlantAndEquipmentUsefulLivesTableTextBlock_zfpByWkhn958" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Estimated lives)">
  <tr style="vertical-align: top">
    <td><span id="xdx_8BD_z9C9GBNH5mFa" style="display: none">Schedule of estimated useful lives</span></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 28%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Office Equipment:</span></td>
    <td style="width: 49%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line and Declining balance method</span></td>
    <td style="width: 23%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_903_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zws3TJ6m2Zq8" title="Property and equipment estimated useful lives">5-7 Years / 20%</span></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Computer Equipment:</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Declining balance method</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90C_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z3voB4yZCgM1" title="Property and equipment estimated useful lives">55%</span></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Laboratory Equipment:</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line method</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_909_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z8Bu5xz1asmb" title="Property and equipment estimated useful lives">5 Years</span></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Vehicles:</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line and Declining balance method</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_901_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zwa1guchFnc3" title="Property and equipment estimated useful lives">5 Years / 30%</span></span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock', window );">Schedule of intangible assets estimated useful lives</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock_zwwokJM4aN8b" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Intangible assets)">
  <tr style="vertical-align: top">
    <td><span id="xdx_8B8_zXYTAxBJiTFk" style="display: none">Schedule of intangible assets   estimated
useful lives</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 25%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Licenses:</span></td>
    <td style="width: 50%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Straight-line method</span></td>
    <td style="width: 25%; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_904_ecustom--IntangibleAssetsEstimatedUsefulLives_c20250101__20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zMExfiVHmH5" title="Intangible asset estimated useful lives">5 Years</span></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Website:</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Declining balance method</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_902_ecustom--IntangibleAssetsEstimatedUsefulLives_c20250101__20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_zmGJhForVFM6" title="Intangible asset estimated useful lives">55%</span></span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_PropertyPlantAndEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_PropertyPlantAndEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z5D12SH1l7Tf" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details - Intangible assets)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B8_zARQeKuiadCk"><b style="display: none">Schedule of intangible assets</b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom">
    <td><span style="font-size: 10pt"><b>Year Ended December 31,</b></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td><td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%"><span style="font-size: 9pt">Balance as of December 31, 2023</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_c20240101__20241231_z4aIpydvROwc" style="width: 13%; text-align: right" title="Intangible assets gross beginning"><span style="font-size: 9pt">1,444,259</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">License fees additions</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20240101__20241231_zKT7dd1swT83" style="border-bottom: Black 1pt solid; text-align: right" title="Dossier fee additions"><span style="font-size: 9pt">1,651,617</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 9pt">Balance at December 31, 2024</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20240101__20241231_znMab21WM46e" style="text-align: right" title="Intangible assets gross ending"><span style="font-size: 9pt">3,095,876</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">Less: accumulated
    amortization</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20241231_zm6JDlrF9s19" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization"><span style="font-size: 9pt">(76,159</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 9pt">Intangible assets,
    net at December 31, 2024</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20241231_z7M0m6T2UhO1" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">3,019,717</span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom">
    <td><span style="font-size: 10pt"><b>Year Ended December 31,</b></span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-size: 10pt"><b>2025</b></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 9pt">Balance as of December 31, 2024</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_c20250101__20251231_zVAzTGr1F4T8" style="text-align: right" title="Intangible assets gross beginning"><span style="font-size: 9pt">3,019,717</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">License fees additions</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20250101__20251231_zN0uT8HFEKZk" style="border-bottom: Black 1pt solid; text-align: right" title="Dossier fee additions"><span style="font-size: 9pt">774,355</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 9pt">Balance at December 31, 2025</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20250101__20251231_zK6DyE1AxOJc" style="text-align: right" title="Intangible assets gross ending"><span style="font-size: 9pt">3,794,072</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Less: impairment*</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_988_ecustom--ImpairmentOfIntangibleAssetFinitelived_c20250101__20251231_fKg_____zeMZ3FRiKHQb" style="text-align: right" title="Impairment"><span style="font-size: 9pt">(1,748,247</span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">Less accumulated amortization</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20251231_zpoSTbAJblHf" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization"><span style="font-size: 9pt">(156,455</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 9pt">Intangible assets,
    net at December 31, 2025</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20251231_zldscGOvl866" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">1,889,370</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*
The impairment was a result of the determination by the Company that certain product licenses could not be commercialized</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of estimated amortization expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zf7fcQ3rgnga" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details - Amortization expense)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BF_z0VaQsmwAtLl" style="display: none">Schedule of estimated amortization
expense</span></td>
    <td>&#160;</td>
    <td colspan="2" id="xdx_49B_20251231_zoyGnTrrT71j" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 83%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2026</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right; width: 13%">212,414</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2027</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">212,414</td>
    <td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0" style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2028</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">212,414</td>
    <td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0" style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2029</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">212,414</td>
    <td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0" style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">2030</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">58,093</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Plant, Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of plant property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_zjSmaOzymed" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Plant, Property and Equipment (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B9_zlLqrsze668d"><b style="display: none">Schedule
    of plant property and equipment</b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20251231_zvUW7nf8qT7e" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20241231_zRS5duG11dCj" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">Year Ended December 31,</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z7e2Z7PTzGSb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%"><span style="font-size: 9pt">Equipment</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">335,464</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">336,880</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zkRaJyW5vgFa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Computer equipment</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">69,139</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">53,531</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zq8i8exjRqcf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Furniture and fixtures</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">45,462</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">50,686</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_d0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zz9eiYVtLt0e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Leasehold improvements</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">92,706</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">88,306</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zdbJw2YZbrW9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">Vehicles</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">507,478</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">353,185</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzbhx_zZL0hAVXmCg1" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">Total</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">1,070,249</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">882,588</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzbhx_zyAwf42kNNNg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">Less: Accumulated depreciation</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(512,879</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(336,533</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzbhx_zZLDdgCzEJBk" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">Plant, property and equipment, net</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">557,370</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">546,055</span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zzDX5BpbkvF5" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventory (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;<span id="xdx_8BB_zZZ30kgCSXL" style="display: none">Schedule of inventory</span></td><td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20251231_zTt1XC2RFmy7" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20241231_zE9klaG2m0zd" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">Year Ended December 31,</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2025</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_z7NvjDWLhkHc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left"><span style="font-size: 9pt">Finished goods</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">13,947,178</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">11,278,105</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--AllowanceForObsoleteInventory_iI_d0_msARNCzj7C_z4r2TebdB9h3" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">Allowance for obsolete inventory</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(475,153</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--InventoryNet_iI_zb69lc9SnqR3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">Total Inventory, net of allowance</span></td><td style="border-bottom: Black 2.5pt double"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">13,472,025</span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">11,278,105</span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DisclosurePrepaidExpensesAbstract', window );"><strong>Prepaid Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zLKcxzx2pJ75" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Prepaid Expenses (Details)">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="display: none; font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_8BF_zJvwc6gQePH2">Schedule of prepaid expenses</span></span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20251231_zCqB86j6PFKg" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20241231_zkK5Cxcj0Ih4" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Year Ended
    December 31,</b></span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>2025</b></span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>2024</b></span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidTaxes_iI_z3TGIVrV5W42" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Prepaid taxes</span></td>
    <td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">206,242</span></td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">657,437</span></td>
    <td style="width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--PermitsAndInsurance_iI_z2a3zSdH9Dj2" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Permits and insurance </span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">486,797</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">399,176</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--OtherPrepaidExpenseCurrent_iI_zz3lDFPZE9q8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Other prepaid
    expenses</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">105,345</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">76,684</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidExpenseCurrent_iI_zC6hejyG8Qj1" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Total</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">798,384</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1,133,297</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosurePrepaidExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosurePrepaidExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cost of Sales (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DisclosureCostOfSalesAbstract', window );"><strong>Cost Of Sales</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_ScheduleOfCostOfSalesTableTextBlock', window );">Schedule of cost of sales</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfCostOfSalesTableTextBlock_zgmBqlypqjnf" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Cost of Sales (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span id="xdx_8B4_zkM25TGXKVBf" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b style="display: none">Schedule
    of cost of sales</b></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif">&#160;</td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left">&#160;</td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right">&#160;</td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left">&#160;</td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif">&#160;</td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left">&#160;</td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right">&#160;</td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; font-weight: bold">Year Ended December 31,</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&#160;</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; font-weight: bold; text-align: center">2024</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">Finished
    goods</span></td><td style="width: 2%; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_900_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--FinishedGoodsMember_zC1dpV2q2owh" title="Cost of goods sold">8,866,208</span></span></td><td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_90E_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--FinishedGoodsMember_z9mxmdsKwta" title="Cost of goods sold">8,116,534</span></span></td><td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">Professional allowances</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_906_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--ProfessionalAllowancesMember_zCxI0iKKSX13" title="Cost of goods sold">11,909,812</span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_905_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--ProfessionalAllowancesMember_zs0JDixty4Ej" title="Cost of goods sold">13,714,009</span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">Other allowances</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_90B_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--OtherAllowancesMember_zyhSFVWnzerc" title="Cost of goods sold">1,086,575</span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_90E_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--OtherAllowancesMember_ztAj2iFrvpwd" title="Cost of goods sold">666,913</span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">Wholesalers&#8217; fees
    &amp; discounts</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_909_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--WholesalersFeesAndDiscountsMember_z2pShOzDa9V3" title="Cost of goods sold">650,333</span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_902_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--WholesalersFeesAndDiscountsMember_z5LsYYEpljC4" title="Cost of goods sold">1,699,286</span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">Inventory adjustment</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_905_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--InventoryAdjustmentMember_zhrPlvUarXTc" title="Cost of goods sold">1,162,303</span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_90C_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--InventoryAdjustmentMember_zmHR2saVlJXi" title="Cost of goods sold">236,555</span></span></td><td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">Freight</span></td><td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_90A_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--FreightMember_zjsLYsmhbVm9" title="Cost of goods sold">374,983</span></span></td><td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_907_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--FreightMember_zxd9h50SYTR6" title="Cost of goods sold">438,105</span></span></td><td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">Total</span></td><td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_90B_eus-gaap--CostOfRevenue_c20250101__20251231_zM9dDu1Rudqd" title="Cost of goods sold">24,050,214</span></span></td><td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"><span style="font-size: 9pt"><span id="xdx_903_eus-gaap--CostOfRevenue_c20240101__20241231_zcoORuRVF9Ie" title="Cost of goods sold">24,204,489</span></span></td><td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureCostOfSalesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureCostOfSalesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_ScheduleOfCostOfSalesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_ScheduleOfCostOfSalesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DisclosureWarrantsAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_ScheduleOfWarrantsIssuedWithFinancingTableTextBlock', window );">Schedule of warrants issued with financing</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfWarrantsIssuedWithFinancingTableTextBlock_zf23S3xtYnR7" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details - Warrants issued with financing)">
  <tr style="background-color: White">
    <td style="vertical-align: top"><span id="xdx_8BD_zxaUosbINNi9" style="display: none">Schedule of warrants issued with financing</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 37%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Issuance
    Date/Type</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 20%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Number</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 20%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Exercise
    Price</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 20%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Expiry
    Date</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Feb 17, 2022 (&#8220;Tradeable
    Warrants&#8221;)*</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_fKg_____zRJmmhSDjxg1" style="vertical-align: top" title="Warrants outstanding"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">2,051</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_zJ7hQBUczKVc" title="Warrant expiration date">4,440.00</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_902_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_zri3sNVV0BEa" title="Warrant expiration date">February 2027</span></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Mar 14, 2022 (&#8220;2022
    Pre-Funded Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zXkDAJSSNTp3" style="vertical-align: top" title="Warrants outstanding"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1,846</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_z5lKbZ3mE7i8" title="Warrant expiration date">2.00</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_908_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zgAd3WXF37Hg" title="Warrant expiration date">Unlimited</span></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Mar 14, 2022 (&#8220;Investor
    Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_fKio___z8rlX91kfMUa">1,801</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zIt7rRkk6wih">4,440.00</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_900_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zjycrXvHyRde">March 2027</span></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Apr 28, 2022 (&#8220;April
    Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zIAC9PaveSzf" style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">4,862</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zPyZpyxtyOff">7,520.00</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90C_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zRQVtHaNJxX">April 2027</span></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">May 16, 2023 (&#8220;May
    Pre-Funded Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_zhANlkukxRal" style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1,751</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_z9abUUb14TMg">2.00</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90F_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_zs5tHlVRMsq4">Unlimited</span></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">May 16, 2023 (&#8220;May
    Investor Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zHNYOdyTqTik" style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">5,952</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zodUIQszAYXd">1,180.00</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_903_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zpUGWEvueJ71">November 2028</span></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Feb 15, 2024 (&#8220;2024
    Pre-Funded Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_zSD89QoTOAje" style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">22,500</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_z6dzjg7bJ2Zj">2.00</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_900_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_zThqiw8IEW6f">Unlimited</span></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Feb 15, 2024 (&#8220;Series
    A Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_fKio___zTZixmjv9x1f">3,986</span>**</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_z2bD7SjgAQW1">4,200.00</span>**</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90D_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_zbw4SgeKDOe2">August 2026</span></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Feb 15, 2024 (&#8220;Series
    B Warrants&#8221;)</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_fKio___zLPvVuZuWsVb">7,973</span>**</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_z2EsF8yAYUS8">4,760.00</span>**</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_901_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zEtNA3TLnbPa">February 2029</span></span></td></tr>
  <tr style="background-color: White">
    <td style="border-bottom: black 1pt solid; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Apr
    03, 2025 (&#8220;2025 Pre-Funded Warrants&#8221;)</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_zF0lbbU5ssCl" style="border-bottom: black 1pt solid; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">260,000</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_zUagTailpb3i" title="Exercise price">0.001</span></span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90E_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_z4xq5njTl4u3">Unlimited</span></span></td></tr>
  </table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-size: 8pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13px"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">These warrants trade under
    the ticker symbol SBFMW</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">**</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Subject to adjustment</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zeYsZQUP4hv7" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details - Warrants outstanding)">
  <tr style="vertical-align: bottom">
    <td id="xdx_8BA_z1RvAy1G5Fde"><span style="display: none; font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; color: White">Schedule of warrants outstanding</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Type</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Number</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Exercise Price</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Expiry Date</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 25%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Tradeable Warrants*</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_fKg_____z3IDyqg91rhe" style="width: 24%" title="Number of warrants outstanding"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">482</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_fKg_____zS5tu4SC2Mhh" style="width: 24%" title="Warrant exercise price"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$220.00</span></td>
    <td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 24%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_908_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_fKg_____zJXIKtPODttg" title="Expiry date">February 2027</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Investor Warrants</span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_fKio___z1FzCr0udrfb">400</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_fKio___z5jwWjBD1aOh">4,000.00</span></span></td>
    <td><span style="font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_909_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_zI17tbbMeEag">March 2027</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Series B Warrants</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_fKioq_zddOnbprW6S4">15,227,962</span>**</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">$<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_fKioq_zzomno5A8t3g">2.07</span>**</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90A_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_zowPp9E6Wrl9" title="Expiry date">February 2029</span></span></td></tr>
  </table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 12px"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">*</span></td>
    <td><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-size: 8pt">These warrants trade under the
        ticker symbol SBFMW</span></p>
    <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">**</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">As adjusted following the financing event of April 3,
    2025 and subject to further adjustment of the number of warrants and exercise price upon certain corporate actions such that the
    aggregate exercise price of the warrants remains unchanged</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_ScheduleOfWarrantsIssuedWithFinancingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_ScheduleOfWarrantsIssuedWithFinancingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted net income per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zoF14LQs6e9c" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings Per Share (Details)">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid"><span id="xdx_8BB_zcB3fbVL3Pg3" style="display: none">Schedule of computation of basic and diluted net income per share</span></td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td colspan="2" id="xdx_497_20250101__20251231_zNjJZReYAdP8" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20241231_zQ8xUjEedt1i" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Year Ended December 31,</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zo9DXGDEbT0a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left"><span style="font-size: 9pt">Net gain (loss) attributable to common stock</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">(5,975,352</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">)</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">(5,134,116</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">Weighted average outstanding shares of common stock (Basic)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20251231_zjgPcCo4Jch9" title="Weighted average common shares outstanding - basic">4,157,086</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_zr4GvQjHOk55" title="Weighted average common shares outstanding - basic">701,749</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">Net gain (loss) per share attributable
    to common stock  (Basic)</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20250101__20251231_zagpytq9nff6" title="Basic gain (loss) per share attributable to common stock">(1.44</span></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_c20240101__20241231_z7kjPcFLEWhe" title="Basic gain (loss) per share attributable to common stock">(7.32</span></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  </table>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">* Diluted net
gain (loss) per share is not included in this table as the Company incurred net losses for the years ended December 31, 2025 and 2024
and inclusion of dilutive instruments would have an anti-dilutive effect.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of provision for income taxes</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zSlolKCSNVKe" style="font: 10pt Arial, Helvetica, Sans-Serif, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Provision for income taxes)">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; font-weight: 400; font-style: normal"><span id="xdx_8BE_z17siEj3VfHj" style="display: none">Schedule of provision for income taxes</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20250101__20251231_zOXxjZTzzVy2" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20240101__20241231_zm6eTh6hwpOc" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">Year
    Ended December 31,</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">2025</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">2024</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold"><span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zp47PcoK83yj" style="vertical-align: bottom">
    <td style="font-weight: 400; font-style: normal"><span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif">Current:</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--CurrentFederalTaxExpenseBenefit_d0_zAWQxDmAgCH9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: 400; font-style: normal"><span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif">Federal</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 9pt">&#8211;<span style="font-family: Arial, Helvetica, Sans-Serif">&#160;</span></span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_d0_zX7IUdAka1La" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 66%; font-weight: 400; font-style: normal"><span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif">State</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="width: 13%; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">50</span></td><td style="width: 1%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--CurrentForeignTaxExpenseBenefit_d0_z3sNsCXyXvja" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Foreign</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(73,330</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(90,434</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td></tr>
  <tr id="xdx_400_ecustom--CurrentIncomeTaxExpenseBenefits_d0_zeSEQn5bbZNc" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Total Current</span></td><td style="border-bottom: Black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(73,330</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td><td style="border-bottom: Black 1pt solid"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(90,384</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--ComponentsOfDeferredTaxAssetsAbstract_iB_zhxWm94QytN5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: 400; font-style: normal"><span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif">Deferred:
    </span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_d0_zpRTBkbCCAw8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: 400; font-style: normal"><span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif">Federal</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_d0_zA2OB1a7umil" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: 400; font-style: normal"><span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif">State</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_zBz31bBeriqh" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; padding-left: 10pt; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Foreign</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">94,939</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(144,474</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_zMkegtqPYTm3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Total Deferred</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">94,939</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(144,474</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_z2C16lRLK7cf" style="vertical-align: bottom; background-color: White">
    <td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; font-weight: 400; font-style: normal; text-align: left; padding-bottom: 2.5pt"><span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif">Total
    Income Tax Expense / (Benefit)</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">21,609</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8239;</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(234,858</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of income tax expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zTmAjy5a8YKd" style="font: 10pt Arial, Helvetica, Sans-Serif, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Reconcilation of tax rate)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B0_zNWpTBKDYc86" style="display: none">Schedule of income tax expense</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20250101__20251231_zrNuxyoK5bN1" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20240101__20241231_zFU0USJw6U14" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>Year Ended December 31, </b></span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></td><td colspan="5" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>2025</b></span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></td><td colspan="5" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>2024</b></span></td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#160;</b></span></td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_iN_di_msITEBzYLG_zFtvPdBPSJog" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 40%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Pre-Tax Book Income</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(1,250,286</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right; width: 11%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_mataxrate_c20250101__20251231_zRkHIWzlSJlj" title="Pre-Tax Book Income, Rate">21.00</span>%&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right; width: 11%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(1,121,714</span></td><td style="text-align: left; width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td><td style="width: 2%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right; width: 11%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_mataxrate_c20240101__20241231_z3jMSOJZlTR6" title="Pre-Tax Book Income, Rate">20.89</span>%&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzYLG_z6Ud25g2ZyKb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">State and Local Income Taxes</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">44,533</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_mataxrate_c20250101__20251231_zbEQIRyNVuIk" title="State Taxes, Rate">(0.75</span>%)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">40</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_mataxrate_c20240101__20241231_z0tOZ8ZIqWw1" title="State and Local Income Taxes, Rate">0.00</span>%&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory_maITEBzYLG_z28KOH3J5tX7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Effect of Rates Different than
    Statutory</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">151,341</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="font-family: Arial, Helvetica, Sans-Serif"><span id="xdx_902_ecustom--EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate_dp_mataxrate_c20250101__20251231_zP0lUII4to5f" title="Effect of Rates Different than Statutory, Rate">(2.54</span>%)</span></span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">62,181</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_907_ecustom--EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate_dp_mataxrate_c20240101__20241231_zRDxIr2Jtrt8" title="Effect of Rates Different than Statutory, Rate">(1.16</span>%)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxReconciliationOtherForeignTaxes_d0_maITEBzYLG_zVnKryNCUFYe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Other Foreign Taxes</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_900_ecustom--EffectiveIncomeTaxRateReconciliationOtherForeignTaxes_dp_mataxrate_c20250101__20251231_zUrzTEU1Yw4l" title="State Taxes, Rate">0.00</span>%&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(119,181</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_902_ecustom--EffectiveIncomeTaxRateReconciliationOtherForeignTaxes_dp_mataxrate_c20240101__20241231_zAdyo88InPP9" title="Other Foreign Taxes, Rate">2.22</span>%&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzYLG_zk77XgudRr45" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Permanent Adjustments</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">54,987</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_dp_mataxrate_c20250101__20251231_zM923qvT7u55" title="Permanent Adjustments, Rate">(0.92</span>%</span><span style="font-size: 9pt">)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">56,092</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_dp_mataxrate_c20240101__20241231_zQnsZlYTq2i8" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(1.04</span><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">%)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzYLG_zUmJGP63IfH5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Change in Valuation Allowance</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">1,107,342</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_mataxrate_c20250101__20251231_zsD04FbHJr6f" title="Change in Valuation Allowance, Rate">(18.60</span>%)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">569,920</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_mataxrate_c20240101__20241231_zwVv6mm2wQOe" title="Change in Valuation Allowance, Rate">(10.62</span>%)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_d0_maITEBzYLG_zt1G3pOi6Eeb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Rate Change</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_mataxrate_c20250101__20251231_zqndcwtTjTB" title="Rate Change, Rate">0.00</span>%&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">149,237</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_mataxrate_c20240101__20241231_zuIZwvmx65D" title="Rate Change, Rate">(2.78</span>%)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_maITEBzYLG_zOGC9gT7DcM4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Prior Year True up</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(86,308</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_mataxrate_c20250101__20251231_zR2fzaodesGl" title="Provision to Return Adjustments, Rate">1.45</span>%&#160;</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">156,540</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_mataxrate_c20240101__20241231_zRuwRHMimiHh" title="Prior Year True up, Rate">(2.92</span>%)</span></td><td style="text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationOtherAdjustments_d0_maITEBzYLG_zA6W4drHzp4e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">Other</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp0_mataxrate_c20250101__20251231_zwfOu8U4fay7" title="Other Adjustments, Rate">&#8211;</span>%&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">12,027</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_mataxrate_c20240101__20241231_zqGqjYo6fMk7" title="Other, Rate">(0.22</span>%)</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_pp0p0_mtITEBzYLG_zaUaz0m7oDMd" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: right; padding-bottom: 2.5pt"><b style="display: none">Total</b><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">21,609</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"> &#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_mttaxrate_c20250101__20251231_zLjVKxhpO4Wc" title="Total effective income tax rate, Rate">(0.36</span>%)&#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">(234,858</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">)</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_mttaxrate_c20240101__20241231_znXbb0haqTy6" title="Total effective income tax rate, Rate">4.37</span>%&#160;</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#160;</span></td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of components of net deferred tax assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zyfgIXjQsyG6" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Deferred taxes)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BE_zGTqCJT2qOo7" style="display: none">Schedule of components of net deferred tax assets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20251231_zpE8XPcZsNDk" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20241231_zlfIv9iz8Auc" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">Year Ended December 31,</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&#160;</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredIncomeTaxesAbstract_iB_z3tOGuZyfitk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Deferred Tax Assets:</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zumjhyC9af99" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 66%; text-align: left"><span style="font-size: 9pt">Net Operating Loss, Credits and Carryforwards</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">7,785,678</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">6,460,638</span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_d0_zC53hPzKoThc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Fixed Assets</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">2,818</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_zINrGFdrD3j8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-size: 9pt">Intangibles</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">622,658</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">614,734</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsResearchAndDevelopment_iI_zOzxtS8zokq9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Research and Development</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">25,327</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">25,327</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsOther_iI_d0_z23gL0zjQm7c" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Other deferred tax assets</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">95,935</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_zAqY8dWeHgh2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Lease Liability</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">9,232</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">252,407</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zF9fhMMOVcX8" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Valuation Allowance</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(8,445,713</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(6,967,294</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iI_d0_zWlV9hzfx5nj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">Total Deferred Tax Assets</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">481,747</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_ziAh1nkWfpwb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Deferred Tax Liabilities:</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesOther_iI_d0_zqjk0J8O8p0b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Other deferred tax liabilities</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(67</span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_di0_z98JcGBP3jWh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Fixed Assets</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(141,396</span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di0_zh5BCO1c8kO3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-size: 9pt">Intangibles</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di0_zSMMie9sK3N6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Right-of-Use Assets</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(248,050</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxLiabilities_iNI_di0_z5MQhd60g1R5" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">Total Deferred Tax Liabilities</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(389,513</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredIncomeTaxesAndOtherAssetsNoncurrent_iI_d0_zadJx6S3mESd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">Net Deferred Tax Liability</span></td><td style="border-bottom: Black 2.5pt double"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">92,234</span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--LeaseCostTableTextBlock_zc5uTDlVwVO2" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Lease information)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_z8a10fbE4Kuk" style="display: none">Schedule of lease information</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%; text-align: left">Operating lease ROU asset</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_90A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20251231_znN516YrLZJb" title="Operating lease ROU asset">778,846</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating Lease liability - Short-term</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20251231_zMXZ6W1tW7o3" title="Operating Lease liability - Short-term">215,637</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liability - Long-term</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20251231_zHoAs1t7ojK8" title="Operating lease liability - Long-term">596,785</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Remaining lease term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20251231_zBrTXHZBaedd" title="Remaining lease term">4
                                            </span>years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20251231_zVqM28wFKSg5" title="Discount rate">6</span>%</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of lease liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zbpnS8ofBPqj" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Maturities of lease payments)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BA_zXSZyhv1lWr4" style="display: none">Schedule of maturities of lease liabilities</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20251231_zx3GPLCsdNae" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zZNf4PRdSUIh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 83%; text-align: left">2026</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">215,637</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zU1z62k9eUm5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">204,428</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_zVnXlJT7ckKj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">193,794</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_zMgDYshGGD1g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">183,705</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_zlXmjXveiLUj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Thereafter</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14,858</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details - Estimated lives)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_PropertyPlantAndEquipmentEstimatedUsefulLives1', window );">Property and equipment estimated useful lives</a></td>
<td class="text">5-7 Years / 20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_PropertyPlantAndEquipmentEstimatedUsefulLives1', window );">Property and equipment estimated useful lives</a></td>
<td class="text">55%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_PropertyPlantAndEquipmentEstimatedUsefulLives1', window );">Property and equipment estimated useful lives</a></td>
<td class="text">5 Years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_PropertyPlantAndEquipmentEstimatedUsefulLives1', window );">Property and equipment estimated useful lives</a></td>
<td class="text">5 Years / 30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_PropertyPlantAndEquipmentEstimatedUsefulLives1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_PropertyPlantAndEquipmentEstimatedUsefulLives1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details - Intangible assets)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=SBFM_LicensesMember', window );">Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_IntangibleAssetsEstimatedUsefulLives', window );">Intangible asset estimated useful lives</a></td>
<td class="text">5 Years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=SBFM_WebsiteMember', window );">Website [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_IntangibleAssetsEstimatedUsefulLives', window );">Intangible asset estimated useful lives</a></td>
<td class="text">55%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_IntangibleAssetsEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_IntangibleAssetsEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 24: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=SBFM_LicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=SBFM_LicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=SBFM_WebsiteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=SBFM_WebsiteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 3,459,864<span></span>
</td>
<td class="nump">$ 3,868,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserve for obsolescence</a></td>
<td class="nump">475,153<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</a></td>
<td class="nump">9,123,308<span></span>
</td>
<td class="nump">$ 9,686,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,292,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC Insured Amount</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_CashCanadaInsuredAmount', window );">Cash insured in Canada (USD)</a></td>
<td class="nump">$ 73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_CashCanadaInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_CashCanadaInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Nora Pharma Inc. (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 22, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 22, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Oct. 20, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 20, 2022 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_EarnoutPayable', window );">Earnout payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 295,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 295,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=SBFM_NoraPharmaMember', window );">Nora Pharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase price of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,860,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,346,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued for acquisition | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued for acquisition, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,514,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_EarnoutLiabilityExpenseFirstInstallment', window );">Earnout liability expense, first installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,036,500<span></span>
</td>
<td class="nump">$ 1,426,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_EarnoutLiabilityExpenseSecondInstallment', window );">Earnout liability expense, second installment</a></td>
<td class="nump">$ 2,247,400<span></span>
</td>
<td class="nump">$ 3,093,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_EarnoutLiabilityBalance', window );">Remaining earnout balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 295,797<span></span>
</td>
<td class="nump">$ 479,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=SBFM_NoraPharmaMember', window );">Nora Pharma [Member] | Malek Chamoun [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_EarnoutPayable', window );">Earnout payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,632,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_EarnoutLiabilityBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_EarnoutLiabilityBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_EarnoutLiabilityExpenseFirstInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_EarnoutLiabilityExpenseFirstInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_EarnoutLiabilityExpenseSecondInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_EarnoutLiabilityExpenseSecondInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_EarnoutPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_EarnoutPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=SBFM_NoraPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=SBFM_NoraPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=SBFM_MalekChamounMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=SBFM_MalekChamounMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details - Intangible assets) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets gross beginning</a></td>
<td class="nump">$ 3,095,876<span></span>
</td>
<td class="nump">$ 1,444,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Dossier fee additions</a></td>
<td class="nump">774,355<span></span>
</td>
<td class="nump">1,651,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets gross ending</a></td>
<td class="nump">3,794,072<span></span>
</td>
<td class="nump">3,095,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="num">(156,455)<span></span>
</td>
<td class="num">(76,159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">1,889,370<span></span>
</td>
<td class="nump">$ 3,019,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets gross beginning</a></td>
<td class="nump">3,019,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_ImpairmentOfIntangibleAssetFinitelived', window );">Impairment</a></td>
<td class="num">$ (1,748,247)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_ImpairmentOfIntangibleAssetFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_ImpairmentOfIntangibleAssetFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details - Amortization expense)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 212,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2027</a></td>
<td class="nump">212,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2028</a></td>
<td class="nump">212,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2029</a></td>
<td class="nump">212,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2030</a></td>
<td class="nump">$ 58,093<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible assets</a></td>
<td class="nump">$ 37,758<span></span>
</td>
<td class="nump">$ 77,009<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Plant, Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 1,070,249<span></span>
</td>
<td class="nump">$ 882,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(512,879)<span></span>
</td>
<td class="num">(336,533)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Plant, property and equipment, net</a></td>
<td class="nump">557,370<span></span>
</td>
<td class="nump">546,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">335,464<span></span>
</td>
<td class="nump">336,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">69,139<span></span>
</td>
<td class="nump">53,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">45,462<span></span>
</td>
<td class="nump">50,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">92,706<span></span>
</td>
<td class="nump">88,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 507,478<span></span>
</td>
<td class="nump">$ 353,185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Plant, Property and Equipment (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 176,346<span></span>
</td>
<td class="nump">$ 146,518<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">$ 13,947,178<span></span>
</td>
<td class="nump">$ 11,278,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_AllowanceForObsoleteInventory', window );">Allowance for obsolete inventory</a></td>
<td class="num">(475,153)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total Inventory, net of allowance</a></td>
<td class="nump">$ 13,472,025<span></span>
</td>
<td class="nump">$ 11,278,105<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_AllowanceForObsoleteInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_AllowanceForObsoleteInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DisclosurePrepaidExpensesAbstract', window );"><strong>Prepaid Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">$ 206,242<span></span>
</td>
<td class="nump">$ 657,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_PermitsAndInsurance', window );">Permits and insurance</a></td>
<td class="nump">486,797<span></span>
</td>
<td class="nump">399,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">105,345<span></span>
</td>
<td class="nump">76,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Total</a></td>
<td class="nump">$ 798,384<span></span>
</td>
<td class="nump">$ 1,133,297<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosurePrepaidExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosurePrepaidExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_PermitsAndInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_PermitsAndInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cost of Sales (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods sold</a></td>
<td class="nump">$ 24,050,214<span></span>
</td>
<td class="nump">$ 24,204,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=SBFM_FinishedGoodsMember', window );">Finished Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods sold</a></td>
<td class="nump">8,866,208<span></span>
</td>
<td class="nump">8,116,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=SBFM_ProfessionalAllowancesMember', window );">Professional Allowances [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods sold</a></td>
<td class="nump">11,909,812<span></span>
</td>
<td class="nump">13,714,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=SBFM_OtherAllowancesMember', window );">Other Allowances [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods sold</a></td>
<td class="nump">1,086,575<span></span>
</td>
<td class="nump">666,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=SBFM_WholesalersFeesAndDiscountsMember', window );">Wholesalers Fees And Discounts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods sold</a></td>
<td class="nump">650,333<span></span>
</td>
<td class="nump">1,699,286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=SBFM_InventoryAdjustmentMember', window );">Inventory Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods sold</a></td>
<td class="nump">1,162,303<span></span>
</td>
<td class="nump">236,555<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=SBFM_FreightMember', window );">Freight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods sold</a></td>
<td class="nump">$ 374,983<span></span>
</td>
<td class="nump">$ 438,105<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-12<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-21<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-15<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=SBFM_FinishedGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=SBFM_FinishedGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=SBFM_ProfessionalAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=SBFM_ProfessionalAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=SBFM_OtherAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=SBFM_OtherAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=SBFM_WholesalersFeesAndDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=SBFM_WholesalersFeesAndDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=SBFM_InventoryAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=SBFM_InventoryAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=SBFM_FreightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=SBFM_FreightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 16, 2025</div></th>
<th class="th"><div>Apr. 03, 2025</div></th>
<th class="th"><div>Apr. 02, 2025</div></th>
<th class="th"><div>Jan. 03, 2025</div></th>
<th class="th"><div>Aug. 16, 2024</div></th>
<th class="th"><div>Mar. 04, 2024</div></th>
<th class="th"><div>Feb. 15, 2024</div></th>
<th class="th"><div>Feb. 08, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000,000<span></span>
</td>
<td class="nump">3,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of common stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,919,812<span></span>
</td>
<td class="nump">$ 3,558,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,919,812<span></span>
</td>
<td class="nump">3,558,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,828,596<span></span>
</td>
<td class="nump">$ 8,522,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,580,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,905,945<span></span>
</td>
<td class="nump">2,580,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,580,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,905,945<span></span>
</td>
<td class="nump">2,580,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=SBFM_PreFundedWarrants2024Member', window );">Pre Funded Warrants 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantsExercisedDescription', window );">Warrants exercised, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) all of the 2024 Pre-Funded Warrants have been exercised resulting in the Company receiving net proceeds of $45,000,
(ii) all of the Series A Warrants have been exercised pursuant to the alternative cashless provision resulting in the Company receiving
$0 in proceeds, and (iii) 15,577,965 Series B Warrants remained outstanding and their exercise price had been adjusted to $2.07 as a result
of two reverse stock splits and a financing event which were conducted subsequent to their issuance. The Series B Warrants expire in February
2029.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=SBFM_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,840,014<span></span>
</td>
<td class="nump">$ 355,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,618,203<span></span>
</td>
<td class="nump">$ 1,618,203<span></span>
</td>
<td class="nump">$ 1,895,610<span></span>
</td>
<td class="nump">$ 1,895,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,522,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,120,784<span></span>
</td>
<td class="nump">1,120,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of common stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease', window );">Stock issued for rounding of reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Stock converted, shares issued</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">660,000<span></span>
</td>
<td class="nump">127,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">580,438<span></span>
</td>
<td class="nump">580,438<span></span>
</td>
<td class="nump">678,865<span></span>
</td>
<td class="nump">678,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,188,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="nump">$ 724,500<span></span>
</td>
<td class="nump">$ 1,828,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=SBFM_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Stock converted, shares converted</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">660,000<span></span>
</td>
<td class="nump">127,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">580,438<span></span>
</td>
<td class="nump">580,438<span></span>
</td>
<td class="nump">678,865<span></span>
</td>
<td class="nump">678,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_WarrantsExercisedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_WarrantsExercisedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the number of shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=SBFM_PreFundedWarrants2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=SBFM_PreFundedWarrants2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=SBFM_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=SBFM_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=SBFM_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=SBFM_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=SBFM_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=SBFM_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details - Warrants issued with financing)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_TradeableWarrantsMember', window );">Tradeable Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">2,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 4,440.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">February 2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_PreFunded2022WarrantsMember', window );">Pre Funded 2022 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">1,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">Unlimited<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_InvestorWarrantsMember', window );">Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">1,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 4,440.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">March 2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_AprilWarrantsMember', window );">April Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">4,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 7,520.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">April 2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_MayPreFundedWarrantsMember', window );">May Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">1,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">Unlimited<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_MayInvestorWarrantsMember', window );">May Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">5,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 1,180.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">November 2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_PreFunded2024WarrantsMember', window );">Pre Funded 2024 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">22,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">Unlimited<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">3,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 4,200.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">August 2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">7,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 4,760.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">February 2029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_PreFunded2025WarrantsMember', window );">Pre Funded 2025 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">260,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">Unlimited<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_WarrantExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_WarrantExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_TradeableWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_TradeableWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_PreFunded2022WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_PreFunded2022WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_InvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_InvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_AprilWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_AprilWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_MayPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_MayPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_MayInvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_MayInvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_PreFunded2024WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_PreFunded2024WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_PreFunded2025WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_PreFunded2025WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details - Warrants outstanding)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_TradeableWarrants1Member', window );">Tradeable Warrants 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding | shares</a></td>
<td class="nump">482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="nump">$ 220.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Expiry date</a></td>
<td class="text">February 2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_InvestorWarrants1Member', window );">Investor Warrants 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding | shares</a></td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="nump">$ 4,000.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Expiry date</a></td>
<td class="text">March 2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_SeriesBWarrants1Member', window );">Series B Warrants 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding | shares</a></td>
<td class="nump">15,227,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="nump">$ 2.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_WarrantExpirationDate', window );">Expiry date</a></td>
<td class="text">February 2029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_WarrantExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_WarrantExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_TradeableWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_TradeableWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_InvestorWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_InvestorWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_SeriesBWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_SeriesBWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 11, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,919,812<span></span>
</td>
<td class="nump">$ 3,558,812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_AprilWarrantsAndMayInvestorWarrantsMember', window );">April Warrants And May Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Payments for repurchase of warrants</a></td>
<td class="nump">$ 3,139,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_TradeableWarrantsMember', window );">Tradeable Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_InvestorWarrantsMember', window );">Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=SBFM_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,269,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,136,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_AprilWarrantsAndMayInvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_AprilWarrantsAndMayInvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_TradeableWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_TradeableWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_InvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_InvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=SBFM_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=SBFM_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net gain (loss) attributable to common stock</a></td>
<td class="num">$ (5,975,352)<span></span>
</td>
<td class="num">$ (5,134,116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic</a></td>
<td class="nump">4,157,086<span></span>
</td>
<td class="nump">701,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic gain (loss) per share attributable to common stock</a></td>
<td class="num">$ (1.44)<span></span>
</td>
<td class="num">$ (7.32)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details - Provision for income taxes) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(73,330)<span></span>
</td>
<td class="num">(90,434)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_CurrentIncomeTaxExpenseBenefits', window );">Total Current</a></td>
<td class="num">(73,330)<span></span>
</td>
<td class="num">(90,384)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">94,939<span></span>
</td>
<td class="num">(144,474)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total Deferred</a></td>
<td class="nump">94,939<span></span>
</td>
<td class="num">(144,474)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total Income Tax Expense / (Benefit)</a></td>
<td class="nump">$ 21,609<span></span>
</td>
<td class="num">$ (234,858)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_CurrentIncomeTaxExpenseBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_CurrentIncomeTaxExpenseBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details - Reconcilation of tax rate) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Pre-Tax Book Income</a></td>
<td class="num">$ (1,250,286)<span></span>
</td>
<td class="num">$ (1,121,714)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Pre-Tax Book Income, Rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">20.89%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and Local Income Taxes</a></td>
<td class="nump">$ 44,533<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and Local Income Taxes, Rate</a></td>
<td class="num">(0.75%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory', window );">Effect of Rates Different than Statutory</a></td>
<td class="nump">$ 151,341<span></span>
</td>
<td class="nump">$ 62,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate', window );">Effect of Rates Different than Statutory, Rate</a></td>
<td class="num">(2.54%)<span></span>
</td>
<td class="num">(1.16%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_IncomeTaxReconciliationOtherForeignTaxes', window );">Other Foreign Taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (119,181)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_EffectiveIncomeTaxRateReconciliationOtherForeignTaxes', window );">Other Foreign Taxes, Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.22%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Permanent Adjustments</a></td>
<td class="nump">$ 54,987<span></span>
</td>
<td class="nump">$ 56,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Permanent Adjustments, Rate</a></td>
<td class="num">(0.92%)<span></span>
</td>
<td class="num">(1.04%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in Valuation Allowance</a></td>
<td class="nump">$ 1,107,342<span></span>
</td>
<td class="nump">$ 569,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in Valuation Allowance, Rate</a></td>
<td class="num">(18.60%)<span></span>
</td>
<td class="num">(10.62%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Rate Change</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 149,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Rate Change, Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(2.78%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Prior Year True up</a></td>
<td class="num">$ (86,308)<span></span>
</td>
<td class="nump">$ 156,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Prior Year True up, Rate</a></td>
<td class="nump">1.45%<span></span>
</td>
<td class="num">(2.92%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.22%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total&#160;</a></td>
<td class="nump">$ 21,609<span></span>
</td>
<td class="num">$ (234,858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total effective income tax rate, Rate</a></td>
<td class="num">(0.36%)<span></span>
</td>
<td class="nump">4.37%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_EffectiveIncomeTaxRateReconciliationOtherForeignTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_EffectiveIncomeTaxRateReconciliationOtherForeignTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_IncomeTaxReconciliationOtherForeignTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_IncomeTaxReconciliationOtherForeignTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details - Deferred taxes) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAbstract', window );"><strong>Deferred Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net Operating Loss, Credits and Carryforwards</a></td>
<td class="nump">$ 7,785,678<span></span>
</td>
<td class="nump">$ 6,460,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed Assets</a></td>
<td class="nump">2,818<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">622,658<span></span>
</td>
<td class="nump">614,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DeferredTaxAssetsResearchAndDevelopment', window );">Research and Development</a></td>
<td class="nump">25,327<span></span>
</td>
<td class="nump">25,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">95,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Lease Liability</a></td>
<td class="nump">9,232<span></span>
</td>
<td class="nump">252,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="num">(8,445,713)<span></span>
</td>
<td class="num">(6,967,294)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total Deferred Tax Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">481,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other deferred tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(141,396)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-Use Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(248,050)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total Deferred Tax Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(389,513)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent', window );">Net Deferred Tax Liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 92,234<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DeferredTaxAssetsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DeferredTaxAssetsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">16,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Foreign net operating loss carryforwards</a></td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DeferredTaxAssetsOperatingLossCarryforwardsProvincial', window );">Provincial net operating loss carryforwards</a></td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards, subject to expiration</a></td>
<td class="nump">9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 8,445,713<span></span>
</td>
<td class="nump">$ 6,967,294<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DeferredTaxAssetsOperatingLossCarryforwardsProvincial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DeferredTaxAssetsOperatingLossCarryforwardsProvincial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details - Lease information) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU asset</a></td>
<td class="nump">$ 778,846<span></span>
</td>
<td class="nump">$ 936,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease liability - Short-term</a></td>
<td class="nump">215,637<span></span>
</td>
<td class="nump">207,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability - Long-term</a></td>
<td class="nump">$ 596,785<span></span>
</td>
<td class="nump">$ 744,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Discount rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details - Maturities of lease payments)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 215,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">204,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">193,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">183,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">$ 14,858<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SBFM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Management and Director Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Officers compensation</a></td>
<td class="nump">$ 1,425,942<span></span>
</td>
<td class="nump">$ 1,850,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseDirectorsFees', window );">Directors compensation</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SBFM_AdvanomicsCorporationMember', window );">Advanomics Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Officers compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (j)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (m)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseDirectorsFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for service provided by entity's director.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseDirectorsFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SBFM_AdvanomicsCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SBFM_AdvanomicsCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>132</ContextCount>
  <ElementCount>300</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>45</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statement Of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statement Of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995443 - Disclosure - Award Timing Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure</Role>
      <ShortName>Award Timing Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999014 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/DescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Acquisition of Nora Pharma Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.</Role>
      <ShortName>Acquisition of Nora Pharma Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Plant, Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/PlantPropertyAndEquipment</Role>
      <ShortName>Plant, Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Prepaid Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/PrepaidExpenses</Role>
      <ShortName>Prepaid Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Cost of Sales</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/CostOfSales</Role>
      <ShortName>Cost of Sales</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Reverse Stock Splits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/ReverseStockSplits</Role>
      <ShortName>Reverse Stock Splits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Capital Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/CapitalStock</Role>
      <ShortName>Capital Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Management and Director Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation</Role>
      <ShortName>Management and Director Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Legal Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/LegalMatters</Role>
      <ShortName>Legal Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/IntangibleAssets</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Plant, Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables</Role>
      <ShortName>Plant, Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/PlantPropertyAndEquipment</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/Inventory</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Prepaid Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/PrepaidExpensesTables</Role>
      <ShortName>Prepaid Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/PrepaidExpenses</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Cost of Sales (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/CostOfSalesTables</Role>
      <ShortName>Cost of Sales (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/CostOfSales</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/Warrants</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/EarningsPerShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/Leases</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Summary of Significant Accounting Policies (Details - Estimated lives)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives</Role>
      <ShortName>Summary of Significant Accounting Policies (Details - Estimated lives)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Summary of Significant Accounting Policies (Details - Intangible assets)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets</Role>
      <ShortName>Summary of Significant Accounting Policies (Details - Intangible assets)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999046 - Disclosure - Acquisition of Nora Pharma Inc. (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative</Role>
      <ShortName>Acquisition of Nora Pharma Inc. (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Intangible Assets (Details - Intangible assets)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets</Role>
      <ShortName>Intangible Assets (Details - Intangible assets)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/IntangibleAssetsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999048 - Disclosure - Intangible Assets (Details - Amortization expense)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/IntangibleAssetsDetails-AmortizationExpense</Role>
      <ShortName>Intangible Assets (Details - Amortization expense)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/IntangibleAssetsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999049 - Disclosure - Intangible Assets (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>Intangible Assets (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/IntangibleAssetsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999050 - Disclosure - Plant, Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails</Role>
      <ShortName>Plant, Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999051 - Disclosure - Plant, Property and Equipment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>Plant, Property and Equipment (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999052 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/InventoryTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999053 - Disclosure - Prepaid Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/PrepaidExpensesDetails</Role>
      <ShortName>Prepaid Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/PrepaidExpensesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999054 - Disclosure - Cost of Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/CostOfSalesDetails</Role>
      <ShortName>Cost of Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/CostOfSalesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999055 - Disclosure - Capital Stock (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative</Role>
      <ShortName>Capital Stock (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/CapitalStock</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999056 - Disclosure - Warrants (Details - Warrants issued with financing)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing</Role>
      <ShortName>Warrants (Details - Warrants issued with financing)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/WarrantsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999057 - Disclosure - Warrants (Details - Warrants outstanding)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding</Role>
      <ShortName>Warrants (Details - Warrants outstanding)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/WarrantsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999058 - Disclosure - Warrants (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/WarrantsDetailsNarrative</Role>
      <ShortName>Warrants (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/WarrantsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999059 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/EarningsPerShareTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999060 - Disclosure - Income Taxes (Details - Provision for income taxes)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes</Role>
      <ShortName>Income Taxes (Details - Provision for income taxes)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999061 - Disclosure - Income Taxes (Details - Reconcilation of tax rate)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate</Role>
      <ShortName>Income Taxes (Details - Reconcilation of tax rate)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999062 - Disclosure - Income Taxes (Details - Deferred taxes)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes</Role>
      <ShortName>Income Taxes (Details - Deferred taxes)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999063 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999064 - Disclosure - Leases (Details - Lease information)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation</Role>
      <ShortName>Leases (Details - Lease information)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/LeasesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999065 - Disclosure - Leases (Details - Maturities of lease payments)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments</Role>
      <ShortName>Leases (Details - Maturities of lease payments)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/LeasesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999066 - Disclosure - Segment Reporting (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/SegmentReportingDetailsNarrative</Role>
      <ShortName>Segment Reporting (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/SegmentReporting</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="sunshine_i10k-123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>999067 - Disclosure - Management and Director Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative</Role>
      <ShortName>Management and Director Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation</ParentRole>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>sbfm-20251231.xsd</File>
    <File>sbfm-20251231_cal.xml</File>
    <File>sbfm-20251231_def.xml</File>
    <File>sbfm-20251231_lab.xml</File>
    <File>sbfm-20251231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="sunshine_i10k-123125.htm">sunshine_i10k-123125.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="519">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="10">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="44">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="6">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>88
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sunshine_i10k-123125.htm": {
   "nsprefix": "SBFM",
   "nsuri": "http://sunshinebiopharma.com/20251231",
   "dts": {
    "schema": {
     "local": [
      "sbfm-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "sbfm-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sbfm-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sbfm-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sbfm-20251231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "sunshine_i10k-123125.htm"
     ]
    }
   },
   "keyStandard": 263,
   "keyCustom": 37,
   "axisStandard": 12,
   "axisCustom": 0,
   "memberStandard": 15,
   "memberCustom": 27,
   "hidden": {
    "total": 9,
    "http://fasb.org/us-gaap/2025": 5,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "contextCount": 132,
   "entityCount": 1,
   "segmentCount": 45,
   "elementCount": 541,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 519,
    "http://xbrl.sec.gov/dei/2025": 44,
    "http://xbrl.sec.gov/cyd/2025": 10,
    "http://xbrl.sec.gov/ecd/2025": 6
   },
   "report": {
    "R1": {
     "role": "http://sunshinebiopharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://sunshinebiopharma.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss",
     "longName": "00000004 - Statement - Consolidated Statement Of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statement Of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://sunshinebiopharma.com/role/StatementsOfCashFlows",
     "longName": "00000005 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "SBFM:AssetDisposition",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity",
     "longName": "00000006 - Statement - Consolidated Statements of Shareholders' Equity",
     "shortName": "Consolidated Statements of Shareholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
     "longName": "995443 - Disclosure - Award Timing Disclosure",
     "shortName": "Award Timing Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2025-10-012025-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-10-012025-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://sunshinebiopharma.com/role/DescriptionOfBusiness",
     "longName": "999014 - Disclosure - Description of Business",
     "shortName": "Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999015 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.",
     "longName": "999016 - Disclosure - Acquisition of Nora Pharma Inc.",
     "shortName": "Acquisition of Nora Pharma Inc.",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://sunshinebiopharma.com/role/IntangibleAssets",
     "longName": "999017 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://sunshinebiopharma.com/role/PlantPropertyAndEquipment",
     "longName": "999018 - Disclosure - Plant, Property and Equipment",
     "shortName": "Plant, Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://sunshinebiopharma.com/role/Inventory",
     "longName": "999019 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://sunshinebiopharma.com/role/PrepaidExpenses",
     "longName": "999020 - Disclosure - Prepaid Expenses",
     "shortName": "Prepaid Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "SBFM:PrepaidExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "SBFM:PrepaidExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://sunshinebiopharma.com/role/CostOfSales",
     "longName": "999021 - Disclosure - Cost of Sales",
     "shortName": "Cost of Sales",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "SBFM:CostOfSalesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "SBFM:CostOfSalesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://sunshinebiopharma.com/role/ReverseStockSplits",
     "longName": "999022 - Disclosure - Reverse Stock Splits",
     "shortName": "Reverse Stock Splits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "SBFM:ReverseStockSplitTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "SBFM:ReverseStockSplitTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://sunshinebiopharma.com/role/CapitalStock",
     "longName": "999023 - Disclosure - Capital Stock",
     "shortName": "Capital Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://sunshinebiopharma.com/role/Warrants",
     "longName": "999024 - Disclosure - Warrants",
     "shortName": "Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "SBFM:WarrantsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "SBFM:WarrantsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://sunshinebiopharma.com/role/EarningsPerShare",
     "longName": "999025 - Disclosure - Earnings Per Share",
     "shortName": "Earnings Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://sunshinebiopharma.com/role/IncomeTaxes",
     "longName": "999026 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://sunshinebiopharma.com/role/Leases",
     "longName": "999027 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://sunshinebiopharma.com/role/SegmentReporting",
     "longName": "999028 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation",
     "longName": "999029 - Disclosure - Management and Director Compensation",
     "shortName": "Management and Director Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "SBFM:ManagementAndDirectorCompensationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "SBFM:ManagementAndDirectorCompensationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://sunshinebiopharma.com/role/LegalMatters",
     "longName": "999030 - Disclosure - Legal Matters",
     "shortName": "Legal Matters",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://sunshinebiopharma.com/role/SubsequentEvents",
     "longName": "999031 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999032 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999033 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "SBFM:PropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "SBFM:PropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://sunshinebiopharma.com/role/IntangibleAssetsTables",
     "longName": "999034 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables",
     "longName": "999035 - Disclosure - Plant, Property and Equipment (Tables)",
     "shortName": "Plant, Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://sunshinebiopharma.com/role/InventoryTables",
     "longName": "999036 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://sunshinebiopharma.com/role/PrepaidExpensesTables",
     "longName": "999037 - Disclosure - Prepaid Expenses (Tables)",
     "shortName": "Prepaid Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "SBFM:PrepaidExpensesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "SBFM:PrepaidExpensesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://sunshinebiopharma.com/role/CostOfSalesTables",
     "longName": "999038 - Disclosure - Cost of Sales (Tables)",
     "shortName": "Cost of Sales (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "SBFM:ScheduleOfCostOfSalesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "SBFM:CostOfSalesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "SBFM:ScheduleOfCostOfSalesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "SBFM:CostOfSalesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://sunshinebiopharma.com/role/WarrantsTables",
     "longName": "999039 - Disclosure - Warrants (Tables)",
     "shortName": "Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "SBFM:ScheduleOfWarrantsIssuedWithFinancingTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "SBFM:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "SBFM:ScheduleOfWarrantsIssuedWithFinancingTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "SBFM:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://sunshinebiopharma.com/role/EarningsPerShareTables",
     "longName": "999040 - Disclosure - Earnings Per Share (Tables)",
     "shortName": "Earnings Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://sunshinebiopharma.com/role/IncomeTaxesTables",
     "longName": "999041 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://sunshinebiopharma.com/role/LeasesTables",
     "longName": "999042 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives",
     "longName": "999043 - Disclosure - Summary of Significant Accounting Policies (Details - Estimated lives)",
     "shortName": "Summary of Significant Accounting Policies (Details - Estimated lives)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2025-01-012025-12-31_us-gaap_OfficeEquipmentMember",
      "name": "SBFM:PropertyPlantAndEquipmentEstimatedUsefulLives1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "SBFM:PropertyPlantAndEquipmentUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_us-gaap_OfficeEquipmentMember",
      "name": "SBFM:PropertyPlantAndEquipmentEstimatedUsefulLives1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "SBFM:PropertyPlantAndEquipmentUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets",
     "longName": "999044 - Disclosure - Summary of Significant Accounting Policies (Details - Intangible assets)",
     "shortName": "Summary of Significant Accounting Policies (Details - Intangible assets)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_LicensesMember",
      "name": "SBFM:IntangibleAssetsEstimatedUsefulLives",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "SBFM:ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_LicensesMember",
      "name": "SBFM:IntangibleAssetsEstimatedUsefulLives",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "SBFM:ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999045 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:InventoryValuationReserves",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InventoryPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative",
     "longName": "999046 - Disclosure - Acquisition of Nora Pharma Inc. (Details Narrative)",
     "shortName": "Acquisition of Nora Pharma Inc. (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "SBFM:EarnoutPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-192022-10-20_custom_NoraPharmaMember",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets",
     "longName": "999047 - Disclosure - Intangible Assets (Details - Intangible assets)",
     "shortName": "Intangible Assets (Details - Intangible assets)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-AmortizationExpense",
     "longName": "999048 - Disclosure - Intangible Assets (Details - Amortization expense)",
     "shortName": "Intangible Assets (Details - Amortization expense)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://sunshinebiopharma.com/role/IntangibleAssetsDetailsNarrative",
     "longName": "999049 - Disclosure - Intangible Assets (Details Narrative)",
     "shortName": "Intangible Assets (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails",
     "longName": "999050 - Disclosure - Plant, Property and Equipment (Details)",
     "shortName": "Plant, Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetailsNarrative",
     "longName": "999051 - Disclosure - Plant, Property and Equipment (Details Narrative)",
     "shortName": "Plant, Property and Equipment (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://sunshinebiopharma.com/role/InventoryDetails",
     "longName": "999052 - Disclosure - Inventory (Details)",
     "shortName": "Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:InventoryFinishedGoods",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:InventoryFinishedGoods",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://sunshinebiopharma.com/role/PrepaidExpensesDetails",
     "longName": "999053 - Disclosure - Prepaid Expenses (Details)",
     "shortName": "Prepaid Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:PrepaidTaxes",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "SBFM:PrepaidExpensesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:PrepaidTaxes",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "SBFM:PrepaidExpensesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://sunshinebiopharma.com/role/CostOfSalesDetails",
     "longName": "999054 - Disclosure - Cost of Sales (Details)",
     "shortName": "Cost of Sales (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_FinishedGoodsMember",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "SBFM:ScheduleOfCostOfSalesTableTextBlock",
       "SBFM:CostOfSalesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative",
     "longName": "999055 - Disclosure - Capital Stock (Details Narrative)",
     "shortName": "Capital Stock (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_PreFundedWarrants2024Member",
      "name": "SBFM:WarrantsExercisedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing",
     "longName": "999056 - Disclosure - Warrants (Details - Warrants issued with financing)",
     "shortName": "Warrants (Details - Warrants issued with financing)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31_custom_TradeableWarrantsMember",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "SBFM:ScheduleOfWarrantsIssuedWithFinancingTableTextBlock",
       "SBFM:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_custom_TradeableWarrantsMember",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "SBFM:ScheduleOfWarrantsIssuedWithFinancingTableTextBlock",
       "SBFM:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding",
     "longName": "999057 - Disclosure - Warrants (Details - Warrants outstanding)",
     "shortName": "Warrants (Details - Warrants outstanding)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31_custom_TradeableWarrants1Member",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "SBFM:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_custom_TradeableWarrants1Member",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "SBFM:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative",
     "longName": "999058 - Disclosure - Warrants (Details Narrative)",
     "shortName": "Warrants (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-02-102024-02-11_custom_AprilWarrantsAndMayInvestorWarrantsMember",
      "name": "us-gaap:PaymentsForRepurchaseOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "SBFM:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://sunshinebiopharma.com/role/EarningsPerShareDetails",
     "longName": "999059 - Disclosure - Earnings Per Share (Details)",
     "shortName": "Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes",
     "longName": "999060 - Disclosure - Income Taxes (Details - Provision for income taxes)",
     "shortName": "Income Taxes (Details - Provision for income taxes)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate",
     "longName": "999061 - Disclosure - Income Taxes (Details - Reconcilation of tax rate)",
     "shortName": "Income Taxes (Details - Reconcilation of tax rate)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes",
     "longName": "999062 - Disclosure - Income Taxes (Details - Deferred taxes)",
     "shortName": "Income Taxes (Details - Deferred taxes)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999063 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation",
     "longName": "999064 - Disclosure - Leases (Details - Lease information)",
     "shortName": "Leases (Details - Lease information)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments",
     "longName": "999065 - Disclosure - Leases (Details - Maturities of lease payments)",
     "shortName": "Leases (Details - Maturities of lease payments)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://sunshinebiopharma.com/role/SegmentReportingDetailsNarrative",
     "longName": "999066 - Disclosure - Segment Reporting (Details Narrative)",
     "shortName": "Segment Reporting (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R65": {
     "role": "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative",
     "longName": "999067 - Disclosure - Management and Director Compensation (Details Narrative)",
     "shortName": "Management and Director Compensation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SalariesWagesAndOfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "SBFM:ManagementAndDirectorCompensationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SalariesWagesAndOfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "SBFM:ManagementAndDirectorCompensationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sunshine_i10k-123125.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable &amp; accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r677"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets",
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax payable",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r79"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r110",
      "r509"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r56",
      "r116",
      "r504",
      "r522",
      "r523",
      "r881"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital paid in excess of par value",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r677",
      "r899"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r838",
      "r839",
      "r840",
      "r841",
      "r882",
      "r904"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_AdvanomicsCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "AdvanomicsCorporationMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanomics Corporation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r731",
      "r745",
      "r772"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r734",
      "r748",
      "r775"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r724",
      "r735",
      "r749",
      "r767",
      "r776",
      "r780",
      "r788"
     ]
    },
    "SBFM_AllowanceForObsoleteInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "AllowanceForObsoleteInventory",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for obsolete inventory"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Intangible assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r135",
      "r235",
      "r242",
      "r608",
      "r616",
      "r617",
      "r619",
      "r621"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "SBFM_AprilWarrantsAndMayInvestorWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "AprilWarrantsAndMayInvestorWarrantsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April Warrants And May Investor Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_AprilWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "AprilWarrantsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_AssetDisposition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "AssetDisposition",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal of tangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r88",
      "r112",
      "r145",
      "r146",
      "r147",
      "r186",
      "r198",
      "r208",
      "r211",
      "r223",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r435",
      "r437",
      "r456",
      "r494",
      "r495",
      "r500",
      "r568",
      "r633",
      "r634",
      "r639",
      "r677",
      "r678",
      "r679",
      "r690",
      "r859",
      "r860",
      "r891"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r120",
      "r145",
      "r146",
      "r147",
      "r223",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r435",
      "r437",
      "r456",
      "r677",
      "r859",
      "r860",
      "r891"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Long-Term Assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r223",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r435",
      "r437",
      "r456",
      "r859",
      "r860",
      "r891"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r704",
      "r727"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r704",
      "r727"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r704",
      "r727"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing",
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r525",
      "r641",
      "r642",
      "r873",
      "r874",
      "r875"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r525",
      "r641",
      "r642",
      "r873",
      "r874",
      "r875"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r380",
      "r381",
      "r382",
      "r383",
      "r389",
      "r390",
      "r391",
      "r392",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r427",
      "r428",
      "r429",
      "r432",
      "r644",
      "r646",
      "r873",
      "r874",
      "r875"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price of shares",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r429",
      "r644",
      "r645"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH AND CASH EQUIVALENTS",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "SBFM_CashCanadaInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "CashCanadaInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash insured in Canada (USD)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets",
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows",
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodStartLabel": "Cash and Cash Equivalents at Beginning of Period",
        "periodEndLabel": "Cash and Cash Equivalents at End of Period",
        "verboseLabel": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r65",
      "r142"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r65"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, FDIC Insured Amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r113",
      "r114",
      "r115",
      "r145",
      "r147",
      "r174",
      "r175",
      "r178",
      "r180",
      "r188",
      "r189",
      "r223",
      "r250",
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r263",
      "r264",
      "r266",
      "r267",
      "r269",
      "r272",
      "r275",
      "r276",
      "r279",
      "r282",
      "r289",
      "r456",
      "r530",
      "r531",
      "r532",
      "r533",
      "r536",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r556",
      "r576",
      "r594",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r808",
      "r832",
      "r833",
      "r842"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r188",
      "r266",
      "r275",
      "r276",
      "r277",
      "r279",
      "r282",
      "r287",
      "r289",
      "r439",
      "r530",
      "r531",
      "r532",
      "r533",
      "r640",
      "r808",
      "r830",
      "r832"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing",
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "verboseLabel": "Warrant exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r150",
      "r290"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing",
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding",
        "verboseLabel": "Number of warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative",
      "http://sunshinebiopharma.com/role/Cover",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r680",
      "r681",
      "r682",
      "r684",
      "r685",
      "r686",
      "r687",
      "r838",
      "r839",
      "r841",
      "r882",
      "r897",
      "r904"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r556"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r47",
      "r556",
      "r574",
      "r904",
      "r906"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, $0.001 par value per share; 3,000,000,000 shares authorized; 4,905,945 and 2,580,098 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r264",
      "r271",
      "r503",
      "r677"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income [Member]",
        "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive (Loss)",
        "label": "Net (loss)",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r122",
      "r124",
      "r130",
      "r492",
      "r514",
      "r515"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails",
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONCENTRATION OF CREDIT RISKS",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r455"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PRINCIPLES OF CONSOLIDATION",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r623"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock converted, shares converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock converted, shares issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/CostOfSalesDetails",
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Sales",
        "verboseLabel": "Cost of goods sold",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r145",
      "r146",
      "r147",
      "r223",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r456",
      "r633",
      "r859"
     ]
    },
    "SBFM_CostOfSalesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "CostOfSalesDisclosureTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/CostOfSales"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cost of Sales",
        "label": "CostOfSalesDisclosureTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r153",
      "r154",
      "r259",
      "r277",
      "r481",
      "r484",
      "r499",
      "r613",
      "r614",
      "r615",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r876",
      "r878",
      "r879",
      "r880"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r810",
      "r830",
      "r835",
      "r871"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r810",
      "r830",
      "r835"
     ]
    },
    "SBFM_CurrentIncomeTaxExpenseBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "CurrentIncomeTaxExpenseBenefits",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r810",
      "r830",
      "r835",
      "r871"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r799"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r799"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r801"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r801"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r716",
      "r803"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r801"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r794"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r795"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r795"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r706",
      "r793"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r796"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r798"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r798"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r799"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r802"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r800"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r797"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NOTES PAYABLE",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/PrepaidExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of prepaid expenses",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r835",
      "r870",
      "r871"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r835",
      "r870"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Deferred",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r96",
      "r830",
      "r835"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxesAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets",
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax asset",
        "verboseLabel": "Net Deferred Tax Liability",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r835",
      "r870",
      "r871"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangibles",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Deferred Tax Assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Operating Loss, Credits and Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "SBFM_DeferredTaxAssetsOperatingLossCarryforwardsProvincial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsProvincial",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provincial net operating loss carryforwards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards, subject to expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other deferred tax assets",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "SBFM_DeferredTaxAssetsResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "DeferredTaxAssetsResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Liability",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes",
      "http://sunshinebiopharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation Allowance",
        "label": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Total Deferred Tax Liabilities",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangibles",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-Use Assets",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-DeferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fixed Assets",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r24",
      "r134",
      "r616",
      "r617",
      "r619",
      "r621"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss",
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation &amp; amortization",
        "verboseLabel": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r136",
      "r186",
      "r202",
      "r211",
      "r616",
      "r633",
      "r634"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "DirectorMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r850",
      "r898"
     ]
    },
    "SBFM_DisclosureCostOfSalesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "DisclosureCostOfSalesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost Of Sales"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_DisclosureManagementAndDirectorCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "DisclosureManagementAndDirectorCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Management And Director Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_DisclosurePrepaidExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "DisclosurePrepaidExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_DisclosureReverseStockSplitsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "DisclosureReverseStockSplitsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Stock Splits"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_DisclosureWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "DisclosureWarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r704",
      "r727"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r704",
      "r727",
      "r768"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://sunshinebiopharma.com/role/EarningsPerShareDetails",
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Loss) per common share, Basic",
        "verboseLabel": "Basic gain (loss) per share attributable to common stock",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r131",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r172",
      "r174",
      "r178",
      "r179",
      "r180",
      "r185",
      "r262",
      "r343",
      "r378",
      "r434",
      "r452",
      "r453",
      "r493",
      "r516",
      "r626"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIC AND DILUTED NET GAIN (LOSS) PER SHARE",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r182"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/EarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r181",
      "r183",
      "r184"
     ]
    },
    "SBFM_EarnoutLiabilityBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "EarnoutLiabilityBalance",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining earnout balance"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_EarnoutLiabilityExpenseFirstInstallment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "EarnoutLiabilityExpenseFirstInstallment",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout liability expense, first installment"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_EarnoutLiabilityExpenseSecondInstallment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "EarnoutLiabilityExpenseSecondInstallment",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout liability expense, second installment"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_EarnoutPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "EarnoutPayable",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative",
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustment",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total effective income tax rate, Rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r643"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Tax Book Income, Rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r149",
      "r351",
      "r369",
      "r643"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Valuation Allowance, Rate",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r643",
      "r830",
      "r836",
      "r864"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rate Change, Rate",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r643",
      "r830",
      "r836",
      "r864"
     ]
    },
    "SBFM_EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate",
     "calculation": {
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Rates Different than Statutory, Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent Adjustments, Rate",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r643",
      "r830",
      "r836",
      "r864",
      "r866"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other, Rate",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r643",
      "r830",
      "r836",
      "r864",
      "r865"
     ]
    },
    "SBFM_EffectiveIncomeTaxRateReconciliationOtherForeignTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherForeignTaxes",
     "calculation": {
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Foreign Taxes, Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "calculation": {
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year True up, Rate",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r836",
      "r864",
      "r865"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Income Taxes, Rate",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r643",
      "r830",
      "r836",
      "r864"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquipmentMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails",
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r99",
      "r100",
      "r101",
      "r126",
      "r127",
      "r128",
      "r155",
      "r156",
      "r157",
      "r159",
      "r166",
      "r168",
      "r170",
      "r187",
      "r224",
      "r225",
      "r249",
      "r261",
      "r291",
      "r343",
      "r367",
      "r368",
      "r375",
      "r376",
      "r377",
      "r379",
      "r433",
      "r434",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r451",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r470",
      "r478",
      "r513",
      "r518",
      "r519",
      "r520",
      "r536",
      "r594"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r731",
      "r745",
      "r772"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r728",
      "r742",
      "r769"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "SBFM_FinishedGoodsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "FinishedGoodsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/CostOfSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finished Goods [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r231",
      "r241",
      "r608"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-AmortizationExpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r607",
      "r608"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of estimated amortization expense",
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-AmortizationExpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2030",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r607",
      "r608"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-AmortizationExpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r607",
      "r608"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-AmortizationExpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r607",
      "r608"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-AmortizationExpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r607",
      "r608"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r244",
      "r245",
      "r490",
      "r491",
      "r525",
      "r607",
      "r608",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Intangible assets gross beginning",
        "periodEndLabel": "Intangible assets gross ending",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r241",
      "r491",
      "r608"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r241",
      "r244",
      "r245",
      "r247",
      "r490",
      "r607",
      "r608",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r244",
      "r245",
      "r525",
      "r607",
      "r608",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net",
        "periodStartLabel": "Intangible assets gross beginning",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r857"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "presentation": [
      "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dossier fee additions",
        "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign exchange gain (loss)",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r458",
      "r459",
      "r460",
      "r461",
      "r591"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FUNCTIONAL CURRENCY",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r735",
      "r749",
      "r776"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r735",
      "r749",
      "r776"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r735",
      "r749",
      "r776"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r735",
      "r749",
      "r776"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r735",
      "r749",
      "r776"
     ]
    },
    "SBFM_FreightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "FreightMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/CostOfSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Freight [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnSalesOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainsLossesOnSalesOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on asset sale",
        "documentation": "Amount of gain (loss) on sale or disposal of assets utilized in financial service operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total General &amp; Administrative Expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r578"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General &amp; Administrative Expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss",
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets impairment",
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r59",
      "r87",
      "r145",
      "r146",
      "r147",
      "r223",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r456",
      "r629",
      "r633",
      "r844",
      "r846",
      "r847",
      "r848",
      "r849",
      "r859"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r704",
      "r727"
     ]
    },
    "SBFM_ImpairmentOfIntangibleAssetFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "ImpairmentOfIntangibleAssetFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/IntangibleAssetsDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Pre-Tax Book Income",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r148",
      "r350"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r83",
      "r87",
      "r494",
      "r496",
      "r511",
      "r618",
      "r620",
      "r622",
      "r629",
      "r633",
      "r844",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r149",
      "r345",
      "r351",
      "r356",
      "r357",
      "r358",
      "r359",
      "r363",
      "r370",
      "r372",
      "r373",
      "r374",
      "r498",
      "r524",
      "r535",
      "r643"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ProvisionForIncomeTaxes",
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate",
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for income taxes",
        "verboseLabel": "Total Income Tax Expense / (Benefit)",
        "totalLabel": "Total",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r97",
      "r145",
      "r169",
      "r170",
      "r186",
      "r203",
      "r211",
      "r349",
      "r351",
      "r371",
      "r517",
      "r618",
      "r620",
      "r622",
      "r643"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r347",
      "r348",
      "r359",
      "r360",
      "r362",
      "r366",
      "r529"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Valuation Allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r643",
      "r864"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rate Change",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r351",
      "r354",
      "r643"
     ]
    },
    "SBFM_IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Rates Different than Statutory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent Adjustments",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r643",
      "r864",
      "r866"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r643",
      "r864",
      "r865"
     ]
    },
    "SBFM_IncomeTaxReconciliationOtherForeignTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "IncomeTaxReconciliationOtherForeignTaxes",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Foreign Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year True up",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r864",
      "r865"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesDetails-ReconcilationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Income Taxes",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r643",
      "r864"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r141",
      "r364",
      "r365"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable &amp; accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income tax payable",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "SBFM_IncreaseDecreaseInEarnoutPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "IncreaseDecreaseInEarnoutPayable",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earn-out payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r809",
      "r829"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "SBFM_IncreaseDecreaseInRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "IncreaseDecreaseInRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use asset",
        "label": "IncreaseDecreaseInRightOfUseAsset"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r735",
      "r749",
      "r767",
      "r776",
      "r780",
      "r788"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r792"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r792"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r792"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r246",
      "r248",
      "r606",
      "r607"
     ]
    },
    "SBFM_IntangibleAssetsEstimatedUsefulLives": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "IntangibleAssetsEstimatedUsefulLives",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible asset estimated useful lives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r487",
      "r488",
      "r490",
      "r624",
      "r855"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r857",
      "r858"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r618",
      "r622",
      "r827"
     ]
    },
    "us-gaap_InterestIncomeDebtSecuritiesOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeDebtSecuritiesOperating",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount of interest income, amortization of premium and accretion of discount, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading); classified as operating."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r139",
      "r140"
     ]
    },
    "SBFM_InventoryAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "InventoryAdjustmentMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/CostOfSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Adjustment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finished goods",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets",
      "http://sunshinebiopharma.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory",
        "verboseLabel": "Total Inventory, net of allowance",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r609",
      "r677"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORY VALUATION",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r108",
      "r117",
      "r226",
      "r227",
      "r228",
      "r485",
      "r625"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserve for obsolescence",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r815"
     ]
    },
    "SBFM_InvestorWarrants1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "InvestorWarrants1Member",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor Warrants 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_InvestorWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "InvestorWarrantsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued for services",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of lease information",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r476"
     ]
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LegalFees",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r811",
      "r901",
      "r903"
     ]
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LegalMattersAndContingenciesTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/LegalMatters"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Matters",
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of maturities of lease liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "SBFM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r831",
      "r837",
      "r894"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r831",
      "r837",
      "r894"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r831",
      "r837",
      "r894"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/LeasesDetails-MaturitiesOfLeasePayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r831",
      "r837",
      "r894"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining lease term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r886"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r145",
      "r146",
      "r147",
      "r223",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r436",
      "r437",
      "r438",
      "r456",
      "r555",
      "r628",
      "r639",
      "r690",
      "r859",
      "r891",
      "r892"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r81",
      "r506",
      "r677",
      "r678",
      "r679",
      "r830",
      "r834",
      "r853",
      "r884"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r107",
      "r145",
      "r146",
      "r147",
      "r223",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r436",
      "r437",
      "r438",
      "r456",
      "r677",
      "r859",
      "r891",
      "r892"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Long-Term Liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r42",
      "r43",
      "r44",
      "r45",
      "r145",
      "r146",
      "r147",
      "r223",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r436",
      "r437",
      "r438",
      "r456",
      "r859",
      "r891",
      "r892"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_LicensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "LicensesMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_MalekChamounMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "MalekChamounMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Malek Chamoun [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_ManagementAndDirectorCompensationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "ManagementAndDirectorCompensationTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management and Director Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketing",
        "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r739"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r740"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r741"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r741"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r741"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r741"
     ]
    },
    "SBFM_MayInvestorWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "MayInvestorWarrantsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May Investor Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_MayPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "MayPreFundedWarrantsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May Pre Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc."
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition of Nora Pharma Inc.",
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r872"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Flows Provided by Financing Activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Flows (Used In) Investing Activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Investing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Flows (Used In) Operating Activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r67"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Operating Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss",
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (Loss)",
        "label": "Net (Loss)",
        "verboseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r67",
      "r84",
      "r101",
      "r105",
      "r121",
      "r123",
      "r128",
      "r145",
      "r146",
      "r147",
      "r152",
      "r158",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r169",
      "r170",
      "r176",
      "r223",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r262",
      "r265",
      "r268",
      "r273",
      "r343",
      "r378",
      "r434",
      "r453",
      "r456",
      "r512",
      "r575",
      "r592",
      "r593",
      "r618",
      "r620",
      "r622",
      "r688",
      "r859"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/EarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net gain (loss) attributable to common stock",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r132",
      "r162",
      "r163",
      "r164",
      "r165",
      "r172",
      "r173",
      "r177",
      "r180",
      "r265",
      "r268",
      "r273",
      "r434"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_NoninterestExpenseDirectorsFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoninterestExpenseDirectorsFees",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative",
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director fees",
        "verboseLabel": "Directors compensation",
        "documentation": "Amount of expense for service provided by entity's director."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r902",
      "r903"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Income (Expense)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income (Expense):"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_NoraPharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "NoraPharmaMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nora Pharma [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r80",
      "r895",
      "r896"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://sunshinebiopharma.com/role/SegmentReportingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r634",
      "r845"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://sunshinebiopharma.com/role/SegmentReportingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r630",
      "r637",
      "r845"
     ]
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OffsettingAssetsLineItems",
     "presentation": [
      "http://sunshinebiopharma.com/role/CostOfSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r613",
      "r614",
      "r615",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r876",
      "r878",
      "r879",
      "r880"
     ]
    },
    "us-gaap_OffsettingAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OffsettingAssetsTable",
     "presentation": [
      "http://sunshinebiopharma.com/role/CostOfSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Table]",
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r613",
      "r614",
      "r615",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r876",
      "r878",
      "r879",
      "r880"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss) from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r618",
      "r622",
      "r629",
      "r844",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets",
      "http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion - right-of-use-liability",
        "verboseLabel": "Operating Lease liability - Short-term",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets",
      "http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use-liability",
        "verboseLabel": "Operating lease liability - Long-term",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets",
      "http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use-asset",
        "verboseLabel": "Operating lease ROU asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://sunshinebiopharma.com/role/LeasesDetails-LeaseInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r676"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/DescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r102",
      "r103",
      "r104",
      "r526",
      "r527"
     ]
    },
    "SBFM_OtherAllowancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "OtherAllowancesMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/CostOfSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Allowances [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) from foreign exchange translation",
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r56",
      "r513"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r903"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/PrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r816",
      "r854"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r733",
      "r747",
      "r774"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r725",
      "r736",
      "r750",
      "r777"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r725",
      "r736",
      "r750",
      "r777"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of treasury stock",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for repurchase of warrants",
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to acquire shares",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r418",
      "r644",
      "r645",
      "r674"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "SBFM_PermitsAndInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "PermitsAndInsurance",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/PrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permits and insurance"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "SBFM_PreFunded2022WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "PreFunded2022WarrantsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded 2022 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_PreFunded2024WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "PreFunded2024WarrantsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded 2024 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_PreFunded2025WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "PreFunded2025WarrantsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded 2025 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_PreFundedWarrants2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "PreFundedWarrants2024Member",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrants 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_PreferredStockIssuedToRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "PreferredStockIssuedToRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock issued to related party"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_PreferredStockIssuedToRelatedPartyShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "PreferredStockIssuedToRelatedPartyShares",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock issued to related party, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r680",
      "r681",
      "r684",
      "r685",
      "r686",
      "r687",
      "r897",
      "r904"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r275"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r556"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r275"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r556",
      "r574",
      "r904",
      "r906"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Series B $0.10 par value per share; 1,000,000 shares authorized; 130,000 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r264",
      "r270",
      "r502",
      "r677"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets",
      "http://sunshinebiopharma.com/role/PrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "verboseLabel": "Total",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r229",
      "r230",
      "r610"
     ]
    },
    "SBFM_PrepaidExpensesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "PrepaidExpensesTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/PrepaidExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid Expenses",
        "label": "PrepaidExpensesTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidTaxes",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/PrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid taxes",
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r638",
      "r854"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative",
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from public offering net (common stock)",
        "verboseLabel": "Net proceeds",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative",
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants",
        "verboseLabel": "Proceeds from warrant exercise",
        "terseLabel": "Proceeds from warrant exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "SBFM_ProfessionalAllowancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "ProfessionalAllowancesMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/CostOfSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional Allowances [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfessionalAndContractServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalAndContractServicesExpense",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting",
        "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r633",
      "r688",
      "r901",
      "r903"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails",
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r476"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plant, Property and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r93",
      "r94",
      "r95"
     ]
    },
    "SBFM_PropertyPlantAndEquipmentEstimatedUsefulLives1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives1",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment estimated useful lives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r109",
      "r510"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails",
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets",
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property &amp; equipment",
        "totalLabel": "Plant, property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r476",
      "r497",
      "r510",
      "r677"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r93",
      "r94",
      "r508"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of plant property and equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails",
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r476"
     ]
    },
    "SBFM_PropertyPlantAndEquipmentUsefulLivesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "PropertyPlantAndEquipmentUsefulLivesTableTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of estimated useful lives"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TRADE ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r852"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r717",
      "r728",
      "r742",
      "r769"
     ]
    },
    "SBFM_RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "RegisteredDirectOfferingMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registered Direct Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r151",
      "r152",
      "r218",
      "r292",
      "r309",
      "r479",
      "r480",
      "r501",
      "r507",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r573",
      "r599",
      "r900"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r151",
      "r152",
      "r218",
      "r292",
      "r309",
      "r479",
      "r480",
      "r501",
      "r507",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r573",
      "r599",
      "r890",
      "r900"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "auth_ref": [
      "r145",
      "r153",
      "r154",
      "r259",
      "r277",
      "r481",
      "r484",
      "r499",
      "r613",
      "r614",
      "r615",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r876",
      "r878",
      "r879",
      "r880"
     ]
    },
    "SBFM_RepurchaseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "RepurchaseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of warrants",
        "label": "RepurchaseOfWarrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R&amp;D",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r607",
      "r618",
      "r619",
      "r633",
      "r893"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r729",
      "r743",
      "r770"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r730",
      "r744",
      "r771"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r726",
      "r737",
      "r751",
      "r778"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated (Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r76",
      "r505",
      "r521",
      "r523",
      "r534",
      "r557",
      "r677"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r155",
      "r156",
      "r157",
      "r159",
      "r166",
      "r168",
      "r170",
      "r224",
      "r225",
      "r249",
      "r261",
      "r343",
      "r367",
      "r368",
      "r375",
      "r376",
      "r377",
      "r379",
      "r433",
      "r434",
      "r440",
      "r442",
      "r443",
      "r445",
      "r451",
      "r468",
      "r470",
      "r518",
      "r520",
      "r536",
      "r904"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUE RECOGNITION",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_RevenueRecognitionServicesLicensingFees": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionServicesLicensingFees",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTELLECTUAL PROPERTY RIGHTS - PATENTS AND LICENSES",
        "documentation": "Disclosure of accounting policy for revenue recognition for licensing fees, which is consideration paid to the entity (licensor) by another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, or trademark."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue:",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r129",
      "r145",
      "r146",
      "r147",
      "r186",
      "r199",
      "r200",
      "r207",
      "r211",
      "r214",
      "r216",
      "r217",
      "r223",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r456",
      "r494",
      "r496",
      "r633",
      "r675",
      "r678",
      "r679",
      "r859"
     ]
    },
    "SBFM_ReverseStockSplitTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "ReverseStockSplitTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/ReverseStockSplits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reverse Stock Splits",
        "label": "ReverseStockSplitTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_SalariesAndWages": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalariesAndWages",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salaries",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalariesWagesAndOfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officers compensation",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r380",
      "r381",
      "r382",
      "r383",
      "r389",
      "r390",
      "r391",
      "r392",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r427",
      "r428",
      "r429",
      "r432",
      "r644",
      "r646",
      "r873",
      "r874",
      "r875"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of provision for income taxes",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "SBFM_ScheduleOfCostOfSalesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "ScheduleOfCostOfSalesTableTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/CostOfSalesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of cost of sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of components of net deferred tax assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r32",
      "r33",
      "r34",
      "r35",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/EarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of computation of basic and diluted net income per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of income tax expense",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r643",
      "r864"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r241",
      "r244",
      "r245",
      "r247",
      "r490",
      "r607",
      "r608",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of intangible assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r856"
     ]
    },
    "SBFM_ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of intangible assets estimated useful lives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r53",
      "r54",
      "r55"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails",
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r476"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing",
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r74",
      "r75",
      "r76",
      "r113",
      "r114",
      "r115",
      "r188",
      "r275",
      "r276",
      "r277",
      "r279",
      "r282",
      "r287",
      "r289",
      "r439",
      "r530",
      "r531",
      "r532",
      "r533",
      "r640",
      "r808",
      "r830",
      "r832"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrants outstanding",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "SBFM_ScheduleOfWarrantsIssuedWithFinancingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "ScheduleOfWarrantsIssuedWithFinancingTableTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrants issued with financing"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r186",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r204",
      "r205",
      "r206",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r217",
      "r630",
      "r631",
      "r632",
      "r633",
      "r635",
      "r636",
      "r637"
     ]
    },
    "SBFM_SeriesAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "SeriesAWarrantsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r812",
      "r813",
      "r861",
      "r862"
     ]
    },
    "SBFM_SeriesBWarrants1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "SeriesBWarrants1Member",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrants 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative",
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing",
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing",
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r113",
      "r114",
      "r115",
      "r145",
      "r147",
      "r174",
      "r175",
      "r178",
      "r180",
      "r188",
      "r189",
      "r223",
      "r250",
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r263",
      "r264",
      "r266",
      "r267",
      "r269",
      "r272",
      "r275",
      "r276",
      "r279",
      "r282",
      "r289",
      "r456",
      "r530",
      "r531",
      "r532",
      "r533",
      "r536",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r556",
      "r576",
      "r594",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r808",
      "r832",
      "r833",
      "r842"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r47",
      "r50",
      "r51",
      "r99",
      "r100",
      "r101",
      "r126",
      "r127",
      "r128",
      "r155",
      "r156",
      "r157",
      "r159",
      "r166",
      "r168",
      "r170",
      "r187",
      "r224",
      "r225",
      "r249",
      "r261",
      "r291",
      "r343",
      "r367",
      "r368",
      "r375",
      "r376",
      "r377",
      "r379",
      "r433",
      "r434",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r451",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r470",
      "r478",
      "r513",
      "r518",
      "r519",
      "r520",
      "r536",
      "r594"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/Cover",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r187",
      "r263",
      "r264",
      "r266",
      "r269",
      "r470",
      "r489",
      "r528",
      "r537",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r556",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r594",
      "r620",
      "r622",
      "r683",
      "r900"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical",
      "http://sunshinebiopharma.com/role/Cover",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r187",
      "r218",
      "r263",
      "r264",
      "r266",
      "r269",
      "r470",
      "r489",
      "r528",
      "r537",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r556",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r594",
      "r620",
      "r622",
      "r683",
      "r900"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r732",
      "r746",
      "r773"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued for acquisition",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r76"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants, shares",
        "verboseLabel": "Conversion of common stock shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r28",
      "r47",
      "r50",
      "r76",
      "r260"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwritten offering, net of issuance costs, shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate shares Issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r46",
      "r47",
      "r76",
      "r530",
      "r594",
      "r601"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesPeriodIncreaseDecrease",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued for rounding of reverse stock split",
        "documentation": "The increase (decrease) during the period in the number of shares issued."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r904",
      "r905"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/AcquisitionOfNoraPharmaInc.DetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued for acquisition, value",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r47",
      "r50",
      "r51",
      "r76"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise of warrants",
        "label": "Conversion of common stock value",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r47",
      "r50",
      "r51",
      "r76"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwritten offering, net of issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r46",
      "r47",
      "r76",
      "r536",
      "r594",
      "r601",
      "r689"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_StockIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "StockIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock issued for services",
        "label": "StockIssuedForServices"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://sunshinebiopharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets",
      "http://sunshinebiopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL SHAREHOLDERS' EQUITY",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r50",
      "r51",
      "r68",
      "r558",
      "r574",
      "r595",
      "r596",
      "r677",
      "r690",
      "r830",
      "r833",
      "r834",
      "r853",
      "r884",
      "r904"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r274",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r291",
      "r439",
      "r450",
      "r597",
      "r598",
      "r605"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r483"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplementary Disclosure of Cash Flow Information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "SBFM_Taxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "Taxes",
     "crdr": "debit",
     "calculation": {
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r850",
      "r889"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "SBFM_TradeableWarrants1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "TradeableWarrants1Member",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tradeable Warrants 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_TradeableWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "TradeableWarrantsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing",
      "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tradeable Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransactionDomain",
     "presentation": [
      "http://sunshinebiopharma.com/role/CostOfSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r876",
      "r878",
      "r879",
      "r880"
     ]
    },
    "us-gaap_TransactionTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransactionTypeAxis",
     "presentation": [
      "http://sunshinebiopharma.com/role/CostOfSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Type [Axis]",
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r877",
      "r878",
      "r879",
      "r880"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "USE OF ESTIMATES",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r190",
      "r191",
      "r192",
      "r193",
      "r494",
      "r496",
      "r627"
     ]
    },
    "us-gaap_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VehiclesMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/PlantPropertyAndEquipmentDetails",
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EstimatedLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vehicles [Member]",
        "documentation": "Equipment used primarily for road transportation."
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_WarrantExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "WarrantExpirationDate",
     "presentation": [
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsIssuedWithFinancing",
      "http://sunshinebiopharma.com/role/WarrantsDetails-WarrantsOutstanding"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant expiration date",
        "verboseLabel": "Expiry date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r680",
      "r681",
      "r684",
      "r685",
      "r686",
      "r687"
     ]
    },
    "SBFM_WarrantsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "WarrantsDisclosureTextBlock",
     "presentation": [
      "http://sunshinebiopharma.com/role/Warrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants",
        "label": "WarrantsDisclosureTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_WarrantsExercisedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "WarrantsExercisedDescription",
     "presentation": [
      "http://sunshinebiopharma.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised, description"
       }
      }
     },
     "auth_ref": []
    },
    "SBFM_WebsiteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "WebsiteMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Website [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://sunshinebiopharma.com/role/EarningsPerShareDetails",
      "http://sunshinebiopharma.com/role/StatementOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding, Basic",
        "verboseLabel": "Weighted average common shares outstanding - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r180"
     ]
    },
    "SBFM_WholesalersFeesAndDiscountsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sunshinebiopharma.com/20251231",
     "localname": "WholesalersFeesAndDiscountsMember",
     "presentation": [
      "http://sunshinebiopharma.com/role/CostOfSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Wholesalers Fees And Discounts [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://sunshinebiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-7"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>89
<FILENAME>0001683168-26-002644-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-26-002644-xbrl.zip
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M!06#Z!V6.Z+_:\&U -0DP&O@'(3'">!3XX&H\7 = #L X!'B_2W ?PD>/HB
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M![_SK_4W4)?O[_CYHG@E"+68:+\-M:PI9)'/4F%7WG"$0VXZ9.RL(L/='YW
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M;@O2%,<<VV=Y1XDJ5UR&QHS-?_R>YET$)<LNGZ,6-@?5/-G!J*]2+\"3(NF
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M9!DZ_'+7$44SQW;HM, HF"@MA%BYIVU;HOV]I' 9;E**T(@JBQ@MEQ12S77
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M 035DV3G#W/^I'O/"RPDLYIVCX#Q*Z<LE8@90PJ;?C^8\LVV,J&=WQ8XC.U
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M\AFN'T#V39):R!?'O65U\^=,O@WN<MJOV_U36Q8[*)*52 [4S5S2Y:5^TY6
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M2F,Z@)1SXGKXG.1!T)I73?T+M5@PE>I B28I>IGW'Y;>T12OEA<&/0[4$@V
M7,L9[%V9\;ED *O$XH?QY!14M^S*N_3VQ?5;C28F)SK!1#(Y;]& CZ]_Y%:
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MFJES]DOXDLT/.B 8?2#AY->I<,SE2 =@?_RK_1M!S&'1IM7XF7?*.#W>DL)
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MDLRD2%#X\C]I'D]"I(4VUPWXE,:] ^L3?2__'%GP?)1LR,V0?=M,R9N9?&N
M%O7PE&M<*=)?WVYQ^=/ZJD]+@[N@W5,28\W#F-4X;H;P_WAUU9(E,>"T52P'
M\<5%XU,NMW%/Z^.AG-H='"E_XF7/->1K(SK&4AW[%J1=$^$_7MBJ)C[=?]%3
MIL/2SVL'UI<8UK[R?>)5>H+]V=+? 8+37)6=(;P6]B9!=[=.99*>$7WBOP%0
M2P,$%     @ 2%^#7+!<(O?>#@  >ZT  !$   !S8F9M+3(P,C4Q,C,Q+GAS
M9.U=67/C-A)^WZK]#UR_;%*[LBQ[/)-Q9I*2#Z6\L2.7[622IQ1$@A(R%*$
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MPRQ^O5?%RJ95#C3 I\8-D?*P6.RX5%:RH-HH UPT5T5UV<S"L\/Z61$:/=@
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MU#70]$4J7UUPR3!/Y],5WP^8Q=&S=,;W  *?8$K1,[S&U$VN#EA[9X1.Y^>
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MDVQ,3BHBEYHH^;*[UL9*-NQ)1>0VC9;T'!?;(O_/(U,O^^;_ %!+ P04
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M)38KV)Y']AC@/U9,\TL^:=7UO8K">AW%#AW&]AU'M>_>H\>ZTVF]BKMR+1L
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MGW*5-GVJZ QYB$WW;)F)MQO]^2>+3JQ#:Z-V]&:1'Q#/=;C'8"7R5EK!D5;
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M5FUPE(KVM*TA[QN@)V[P?L;(<2*3(6^"7.?:/T=+-T1>%2%2L0XZ5>OL5"L
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MZAU-+C<(TE14,&[;+@^Z?H]3DQ\@?\WZ76_A0%'C&Z_"($2^P^;F>ATO(SA
MY@ =S%N^R9[&B"[)R,XW5,D.@CA5-2#NFN;3WYT[CG!"76$F]U2Y39EA<%&
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M^FQLR!"8S7_RH9C_))7/OO2X^9T;56H]LUJM:5IM3QE1(J+.V +,X8^O8#]
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M_ZO\$'/RR#H^S12H1M[I]G83[,X&=Y6P=U+9(E3F8:CS>M!VZ;$,6<XY1_I
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M,J8G!(@I<F0*AC3"J)3V<T"[S![1!%FLP9.F@-&+.SZNK07=.[4ME07$&2U
MU1GN*N?'(38NM3P=L2PP8;<<O>";H @J;$I_5>*N#U7J0/=/4\ID 5%("U!Y
M?K+18:EB@II3WE+&D&L::JTSS2[QGI3[Q#$"1#%W3","B!XR7)H,,@35LEZX
ML-@$27*UR^,4Y^J.J"?EE@M2B%TN=$0 <4&&2\$%+HIJ62]<F&XP6=/N[0/)
M/A?/57Y6I6\*:;?<T$+N<D0J"H@K.GP*SM0JJ-2I4^KZ(<_K(:%XF651[:E$
MU#%ME&![G!'D(!%&!4Y@2X)#-M]RGQ5HF:%/.4;%,T9\.RN[8;Z5";ZTX^NF
MD3!D!R+*J#R- B*CD$[8^:TC2L#"W2.") @B&>&I[R%I-%"MXI@U<\IATA['
M<1#L+CWE:0>SBBL&V8*O>622!\$F2Y!]3G&U[N":*_)[$7UF,VHGMU>'>!TA
MQY&Q!& O,&Y)@."($I8J+&[?%> G=][N*8G#VR0+U+,L'1G'&?-$>+UD>0<!
M0 P04:E2Y'%!Q"6]E/]5D/Y.=MLBW#^0+,28[;+*F];*-/]FJ>V6,X-<ZK+)
M2A40SX;@53#P8 *U;%RT>BR?DWELTSC+YI:%OR^> _H!Y[LB9STH!::>!=<J
M.5Y>L'"@M\B@T0!$/0N8J@4'KHFXZ@4JE5%+V]/X+#]D <31U?X1KS!AYPZ6
M^+6XHB_Z73/"L-!U/7JS=J<_F#,J@B#A4+2JH5Z.V@;0$]LC5IE OS(CB%MQ
M?7_Y+%P1OI$D(Y.BP+1J\$U,\M,&.F%7M#,#KGFFE@1!+".\/I-FU[>/J-)
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MG_>XF*5AML%W69Y/7H(X83/_RZRU3O><)1']-I2N<:CX-(.MN&SD1KK8INE
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M2:()(8H"ZCP$4B)R3$+&%A+PJM&Z,M+WUSZL]90KV/L#$Y;XM;A*%#,N.GD
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M6MB=]Q_L:=1HCSXB5MH&=O7K9-QY.J(33ZYZ_4MOY]S;"5<GV,];+X_^W 0
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MU%3+/*SH9) > ='Q!!@!H/+(_=I,5OVY#BM<7.J"4_^/+<W=@K/%7<R\>5:
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M=PFW*0GLM\:6%9Y6 M".N+G4(2OI0=5]L9&-HYHD%-TO]3:RA5;7N>M-'(D
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MHI\CCL62%BM7K[([<* T+C\#I4H!C'C?6H]X#0DH5R>_G #@AG]X*$O  #M
M-$HB7^OMSTL/2;/BXI4I:4/+0*+LWLK^ETGQVT07$->N.N>=6KW: 13>86^=
M7+YN*,OTO/!2U0NBBK+8EX7[YTNC[.E$!\@&F$I4P%^LH@+B0V7OL0#OL0#O
ML0#OL0 G?5+\'@OPUAE^CP5XCP4XT5B 3W;! )_^]-$ GU!.E_4T*4O_6<(
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M<"I0K]7/*N62I#%2XBLH%HQ90")FN?&2<<)#7'F@MGR5036&A:\--5//*)%
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M;ZN><S8KD%ZW]-]Y.>>K6*WI_'V4BY$4&>O>BZ2DRP)V'<3L^C4^\#$9PO.
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M0M))(O&X:U^Y_>XS;H2#%I BAY!,0  3P/,PE91B1ZY9!F8F=J;G6-HHU;9
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M^<&01W"$.-)NN5HOU_<R@Y1#8><&@K\K??_FP7'>EALU,\[4X>1WBC]W>9A
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MU7_9N_Y] ,,!%7F^1VQ2VDQ?29=( 7E](_(SM[NZ^T%\JN*UO/N*>1SO;EC
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M<$HA5*9]08U\I9R")YH/)Y85CIM_*Y#]091_"<UWQG:GBVE/'D<W$/RZW!7
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M8WH0[+?+33T+V-KZD<@EO+5)ZGG+C>:?@[HHLKB4-V@OQ-JZB[VREW@ O_%
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MH M07:5P[UGP>""<V#:W)M(OSD*7HA$"HGCH!R213*[QFU#B3.*#"X6@H!0
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M$#=@-- .!GX?PPZ)4Y3;_J\E=GID/N%1F^_+]75BBX53G,,%1ZV]LPPQL0G
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M\;AT\%[JCT+>KFX'S*N73FIJ,GM4D?2ZD*\Q7((>$Y#)A,+K<S>8,5[",EP
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M>!XA"E9I=*#6_;4-BJ2D_\2B*^R22;GD;(BRE(O^M$!Y]*/)UX@EG7L17F#
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MB1=FC=\I.CMB)1*OW-.X^2LFQ<K*#)2[@B:X38AZ,FI3%1-8L#I:)JY=C_I
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MF% 'KSHV4E=4[T;#>J$!Q&W#9ZD(FT"IE$0R?ZCKCU<P-H><21P930IG22J
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MD&2BXS8T9(GF:.HK+8*D1$N=4MPM83_2(?LXBY&O^^X/ 9.0\!#9PRKV:V,
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M81EJPJ6)JMT%WXH(A2*24<@9N1S^GT8)#650YTRR2(K"[.BF?)H>/6W\250
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M'RYV+ZX?SX-NX<N/A_K1PZMR>A+TT@J=H&IYCA-4+<_D^_G7@WHTSC(?$%T
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MV&*/W1"R@1R<80# (N.OY(3F,R0ESI5<-;GWKYY*3B-Q;)9QB%@9)ZZH(!(
M=<D94F^S/C]'C08<4G4M I\&7,0Y;(2,?^SMZ'6G[;%[_9)Q6WD4>YI ^<.:
M FZ6BJ,&!O5)^/D,JP>DR(F6@0WC_-GT4"&V 1'/$?5TU%8>ZAR"?.T++$(!
MSXDBL6"4BR6CPD52N /YDABL]/B2N?1G-R!X$$96'?^L<?4'90_\CXEKD;BN
M.%V45$OX1K)O?!)GM&"@3?D5L-T#841QBH6Q-N'>]=C>M?C[E,/:T4\=.E"T
MJ_@Q<S5Q([20F+@6O_..W<,+QYPGC*GAF[%@ +-Z!7S[X?PY03E<C1!PJ.VU
MN!$*%XMY"GRX6?F//QS\$W2Y'.+_RTFP;>.824)'Q8&Z^J[GWH,%L@<RF]/.
M8<_U;*[[?,9NL;024#][ED?Y5OZ(&PDU<6>W)>%H,&B&9I_,O!>T8P$%G<A0
M#%46-X SZFB6*>%<*@=DT"0:_DWH0I9HN/=RZ&WX.2A65TZ,1K[.7Y@A!LJH
M5R*PP6&"$1P0]"Y![8U@O8BO)+A*R_5I>&Q;PRDOLY^%-:1$$!Y09$<7?=IT
M@VV^+A]EALR/#Q#*UX%QA/R;8,9%DH.^@P"\K)W(2GV71L6ZG@8SF4>8B&(=
M"T!9J1N;,YD0.=%O 7:]%]TYIY:.=>=ZDKXD&+E^IABCX7K"=V-$WXAM#@B*
MBY)0YJ0F&Y5FQBFF&0T7#B]BC)]I?*LD DW]9-L63_<0B7(1&J(%S:%0?2Z%
M:DE/)R%&YT<@^?S)/X>>[7.>)LGHA)BQ9!%"_C/H1<*9"Z$A2>0Y1"RN40LU
M@9AKY'%?A8 ^4<V_>DT<M]?R$_9:<4<_;IP<Z!?UPX/+[_I^XV+OZ/3BZGR5
M,8YGB=^<P R)<)+:J[^WM_&*!;*RA2PK^P)9V5J6E=U\-J(;3LB1QF1Z497I
M9_7S2[W1>%6R>R'-59K07"6NN>KG_QY<ZH>GY_KYP8?&Q>5Y_>12*/P+1&4]
M/=$//E\U+K\;_!-']4N$;#W=^_?CZ='^P;EV7+^\/#B_T.LG^WKCXN+JX%P_
MNSK?^UB_.+C03P_%=W4!';JRP/^:#W7Y:8=/G:.8<EAM QP[B,!2)@!SC+(;
M3@5ZM)K@M2KCAV1\7D"BTRQ)8VQVYXR1-32P(IH#);M5HI".QR00.]F9-*TR
MPDL?&WFK+!Q&T/9< HCRN"WOM27FI7@(^+_,\6EK(4@_5MV-%0S+'AK8+GH^
MX0R)$,&>ZJ,1$7[ C5?N^N)C:0"-&H%%IPS&)N#9ZK!$7/,##/L<27,8*K(M
MFKK0%\E#P#L5XSZ5.\&8<C@=F"S\<,RPU>;+@PDQ!WLT7>091GFN>:+SBRPO
ML3SF&%E :T1W04)I(W>PX0><,"_;]L50&^ELBDG8>V(R!AV_XM/ZHW[3[<FI
MYA>[A\=BEOF.7D?941]X=D_/RV"&&!A1-&JYDE$KEL20"RUQJEWBX A*L_9\
MEW*@T3#?<#C*M)D2\4E1L5?1IK74F_ZZ([8]>]?5?-)ZU0DORMHU*]!_XR^
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MTY2</98A!G4_]&' D-[E]-DC!X: '03\H2:*< F[ALKX!(0F.BL)A;9BLAV
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M]_FTX3.8L'4 +(^,0-GW>^,B-OH]BVP9+O:X?=%S?6R?_ZUDU"HEHU#*AR[
M;,&OBOGH43H]RN2FK6F6%WE4\94C#R8Z6T>QL(8$!3F788VU^TJQ%/YJ@W#U
MY': $+ $F8N".?P'2"_=<8/4(2_[MYIAY@O<-:JNZ-:?TRU<-'FG":>'SB0"
M[KZY@9:+@$E,<SH1;B!5JD:9NT@)0SX$?HN$>&&K*.)Y6?ETJL!5FZ&MA^<$
M\,8PX)/B5Q'6S3V3L#XN(!V'".D%<D<%"$G5@(1I7HQ!4$];=A4/1#4[8(^;
MA9I1+IEOZSA+RG$B9C@3\.28FQ9E')HHE' ['>;)0I@XZ:&=!?1G*&<?.U-^
MB(624>&>>M0V'FL9IP"PH'Q0#C&:KQJE?-XHFF_B_*6M7U $H3@S,U\QBL5"
M=$AQY*P0SURR-PY2$=^!1?#O[.JQUHKP3'\KE$I&OE:%JU//]RV<J HK5(I#
MXHN#+9=S-$4F1 *;?[#R._,.UC2J1?Y)L_AVC[8PXVA5/H>#-0VSRKW[W%16
M3U!;8('"X#1$CZ?1QG%Y$SMM+KI+M?*;.^VW\8H%"A+*64'""Q0DY+."A%?$
M1ESTGK8"%\OZRS.D;Z&$2DJ;(FL3%9OXSCS%-FZ%I0T>_5;A)F8IEWN&$L#-
M+W9=*Q91VLV?L$!#[WOH4_&"4G^!F;:24>#.:JY2F R^4=0^SPWTHE&IU.+!
M-AAZ&$! %<8%)03>^BYDK0+^^WX/*FLU->VH%H% ?%OW^6[M#E^]$T1/$\%G
M3W@9MG/'A20,&;KQW/N@FY57IUS>'M!#I^?>^T@5D""%L_4Q&PN-$G<TCX_R
M.57,7Y=5Y*_%HX'<IJM5:D;!+"R6\]'"2& \HIN4_JZ$Z8&$>*_5^C6T?5OV
M<DRD9J@M1(8#1+?'H"_FEZK$&B5,0J)]'OBQ3:&^=4HEHD)1A8Y-+*(F*XD2
MBYB&*^:J4T15U:@53:-4R<]/"UB$1\,)+GH?%" $4;5"5)PVKF0[[#["4\Z(
M807='G*F,*+//-@DB9! ,(O79.I\81A'.A23!MS):B4<-&Q6!3 ADH#':'R<
MDB7$-XEIJCZ^16OB9-(AJ!NUS0>M+@B7<2-:5"*"*2;B^"!&[M7,(I5&CL]/
M]2R@'66 JOQ^' $U<#4LU6E'*6"[I0]0#K78$+T150[I]<DG0F,9SB7C[POA
M)\!49%[?QYG/@S#=/00X50^ZP#@S/(L1]S(YF#TH4X*SJ]/H62"O WG[;Z%:
M#>5<5 "*1A4GBI%OAS">";6YVHS:7(^)V9OH9TRKEC5H7C#Q2I,Q!R"$22+'
M6H9$+"@Z?5%2#*58HM*A-]*(.&61+>"9V#@) UY'G"P>KX[ZA&K5I#I>T<X$
M-@[:H]8M4S@>=B[G%HIR9JIDQKH.FH1'8Y/17##40<5&5*R&HQ%%/8,A?"RJ
M$(DW'T)5,-\V3MJ+[ _EF3BZ$2!0G6W,SXK!H%#(P* G$6W@F,P*)Z-VN;QT
M/21O6 IW_!PQ7IO_$?#7H'&3<%75PE_:LQ<.=&\+R"30E5R@@(0(1Q9HL6XR
M0ZDNQ#,B&H!&3?P++AWE,3]TV$MTT-$PFA97GXA/C1V7RE&/GTRT4"[5-*CG
MQL*= 5 96&LP,99V)\0SM.@%0RH=QQ6"1&S;$',,Y\OZ*BW0-ND3XH;"4W*]
M.&;T:Q83R>EII2G]-6\.ZTNHF0'IZV9HD^3ALN0_]C_UBSV]6LSK @1"400:
M$*H\!?L?0X%@D-)M3)2$# GO$?/.Y1A.3%%B+ ]\#I?@T6D^,1>"78:$RO\?
M3'$6F! 14+D&U";4.($%2+P'J!0=*$*/_OS*Z1$'R&"A*F=HF.;0QJB"W;8M
M;V2H=<I&A"&MN=Q&&V!COYXO0/!)]W\-03QT7&[U=*P65:[UW!;*87Z 9JE<
MTG?=88]?G-?6C_@QLMXV_B(P]"\@1QR0:K+4>8^KSC9_YZ?"-]T\J\1:\BTZ
M>66T,XHG+GB10&RUW@]F\)+><V03/%#/0P  ]T!U)2H>$/TKW%M%.Q5\&A=E
M>X?;L;$=,H:5//>(Y,%]=PTBXR3K2Y0$BW]PO"]:Q\^3)@U/"I^$P[3'"@T-
M@>:/Y4+\P3V"ZW$"S^T9LO[8];C>[G0LVY.P^TCBBBG!?P*%TC-4G\KB9&/U
M^-G087.!WP(EVH[V)M?Z%2<9D#G? [810\/S%2-?RNE[]7W]72PVH/UFUHP:
M/XRKB_T_5-R&P'I@5"L-8:F ^G@$__IT2;(FG7[;Y+I*V"QX7ZI6HMI+&$:"
MM@9H&A$>\1AHF5?.FU-Z9,2,LKJ84:9(T0M  P3T@S>B2JBY3>S30E?N7C5@
M?;E?J.>U6B2^U0C1:SZ!9,";3F=[U^JA4KWH@H2I*]C\;^G:P7V6 \]1BT-6
MADO0[:;8O@_;U]31!*_GPL=[9ZN3O;/U'?WS5?WDLG%9OVQ\.<!>6?Z+(_EO
M9="U7M\]O;J4PT3/&Q?_O@5".,&9& I81Q@O%'V?&)\2T^TWL7IQLY^V0"%!
M)2LD>(%"@D)62/#BZ/E2+M<FY')U1T$IN."R&,$-: #SQ=79V1'^NW[^7=^O
M7]97"06SLN?$X>12/C1IS+=*+;D$:LD)Q/#_V'UNNWFMO[>XMW##KG.YPL[/
MP<T6-_&"O[="J=!EA&!9JPX>0D;GGMC@8>O/56QA+>>RP!FDF)&>SZF$>([J
M#QRPAD.CVL ?.P]+_+0S*BE6 NV'MM=_>:/@!1-<ERYBSM6Y%QI$F'SH05XH
MH)P()SYT_"Z$BG9ME](^ /JWV2G&-6%$KF>EIP/;@<R'J)TZ##,'$:S&:]C&
M*SEP">1G >DSPE4!'QH-9[*A';2S,%07\ZYFL8/^3BF7^V/:5!)C',I%B[U-
M216-I;Z@88D_FS,F<WP(GD$WFQ$#T)4M]83=:41-3E30,*/738LA9DP"S;P#
M^U+"&?"_=9@G.^NH$F$K*=NU]0?V&E-*'"G<$* 'RH[#+VJQ-)GRAJ9[Q^00
M4!UB>H!Q"(F\7B]"YQ1X"R(-%*UFX$;U-FHYX[3KT:(#"#-)$$P;NPKXU92C
MW9Y:@T2%Z)"1@ICETY./.)2[#]EX 7&1F'*<3K'&E%,HBJYYP2!:<R0S=? +
M0%JZ[[J(CH%JE^Z1"O?#O;('N#%?MO=@H+9C0_R8*(&0*MPI>=+-UBVOH'R%
M2^-=2'AB'DFHEXT7S*_@7"\A2ZLE"S"5Z2#?(:3(@'_8%L@%<2$4%O'Q35@4
MLJ.QQ&/?HF''@J,H)1"S%\8?E[BB,#,/XA@962"T *-+<&)%''6X@:QVR820
M#<*6EH)4B;:?WG$E!"Z* '5^%Y-6?^COSO;JI[L$F@.OC;!=,<=O*[8[ODW(
M=(F0&U:B3]9PH&C<N=C1.ZR-R"=^. %'[UGW$7Z:-1CPQ6,H!F%B175$"%HC
M;RB:H(.?.'AH=2&J2H9R5,Z"YP&;R@36TXTR*&D8AJA]2*+3[CK*<XC[HDO@
M2A T2O1706%A^1L.],4B6^:%E2'$# AMWH3&7DTI-HEJ\ZA(1$F63V?\#HP@
M5J'#@63D1XSP&:+JDQLZ@&<#92!\):3(!:EKMB\F(4>, J8KX8NCCL;$_@V7
M'OA'L2W$IJ$#%.8+(DTX5&8%F5(=()N4'80!Y!V][NL#B[SI2%1@S<\XS])Q
MA?V[X>@M*FU>['T&YC-ADR&28H2"+D0>->6-2SU&$.EWW%;R_6F2=9E]JQ#:
M]RR4MXY+V-7B]1FG/W&)7,%I@N5"_$I!MP+JI\7:0X_0>:#ZRA? <8@4.8VM
M0BR1*?6 DRRG298S5(DPOH0N#B, =2SPE=#PA:7L<+.:DX7RX7 [[,'JXZPU
M Q2NQ<_/#T3MG,Z@J!P$2C3>$H60*.Z32&A4I1=AI"<9R6@KB*-$H+5H 50,
M)%LCDKV,(5GGI,647A<M*D+K6VT&]>^1@1*KEQA[#? 6.&7"5U/K(:=LX&M8
MZ*?(&EEY[VN66O<7%? I#F7&C4]W%&0=LD:QP&,+L+LR9V$ESH+6DD7>I([[
M>+A8O3]T;"H&XQS@WH.1;\D_ P8JVN"B,#2"-&. ,BSY1+#67&]$$^:/QV(O
MQBK[,1L\_G=A>-/26[$8,3SR+_V=^8>(%*&P;@D 1]>+R3!9*ZN%DEL\>"K4
M,8ZF<.[<WIVP!M$3L"$D A!XO1ZW>5"\^D,)&&=052R BCQ$M;T2^E/N"NV'
MCIY\*VV7B3%O/2J5Q!*+>VND2AP)L3GWU/GQ6;>,AF<1\*41-F;PL^#O,4"T
M*FL38C1Y<4@EAI"-6.M#->=L8F&)7P>QZ:C* &Y)B]V2*PI+12%H;[7#8M8A
MN^Q0"MB;+:SX2AM]?G6<?[5S*M/7SUG+O7%L&NR]X>M_!<*V[FNBUR2*EE+P
M6@B;11A6B3)X=#V/S(\:*V) F^#D^<R[PPE>W/W!'G:0V%H,@3?>)B4!>6.3
MNV9_E!I(PSB,^-2(A'<4G@F1=0U\($BY+A6SDM#I]=!/\H<# ?3I*XL1V041
MVHAMU.??1,,Q>74Q?S7IT#1N>SM<@?F!V\=*)>SVEUC0O_@GX$7A9J47..]0
M8,78!.2S(* -82!ZX@'P,QV$%CL(02)D=XMN&(!(%FT\*BD0?*BX"%P^?)O)
MF%#HN(9@RUY$&+*+=+,EZ6O@;]!FTEOR(MD)5R=H39H,?JQS7]H+3'I_U+K0
MI;8:<.741RA/WJ%QB8(-$*![@B"U&$'.83A#/T9(XW_1(42$2]\"@R5"  \\
MOF6K)2:]XY0Y)'H(QG2XE.EQXO/4U)Y,S$%YKS:QWHBG%V6L!=:H/#2^7.X-
M(J:DA+N2TB1J2R#+T?;:VQ!B&HD'<KZU0*"ZPYL8*K"\+-DN!M^QT2<FRS#C
MJ:?7@,3:AK!C8>#!X V'4@UMT7W<"G,7%)'!VQP+#"A=@6WE#V$L3ODF%Y^>
M&$7J=^V!ILS NP.>C3J7_OON./UJ_O3_U*(JJ8?VPW4M5[MF;69O;]<I=0O%
ME=<M2-'FS)QY?0T_F?F">?WXH7SPZ+/=\YNK MBK#W\YKG,RQ.PR!D_YL9VS
MSM];A]S"@6]MYTS^W\#%G\W\=L'<PM<><G&0X_^I%;9TA[_M[RW^_K^4UV_]
M(R7,WEG]PM#/CH[VN &LOC RAC?C8-<X0B]-IH3Z <#$8&U-%&",![Y%JIYK
M0H@UPB5EAYGDF(VQ2R[.+D<NQ0R266;?-O^]_&)]=CZ45\,RQ026D4N@=OJO
MKMON<;'L&]KEM]1<LQR>LH+(6%XS*+1\+/?D!CV+WQ[?'1<8F-W3&_LZWRG4
MJ8S?VF[\UJ"VL]%.OC/K^.>CG:OM5P<KNK-2PIW1 K;^R5<*U:F7])P(V\^!
MP/@*'QZKSYW5^%%-;/R8UZ6QOL:0_X[&CV+6^/'ZV&AUD'(A[:34[=05H$WM
M"M"G=06LRD[:'+_B*2XBFI=4T.5VM'T$2X8:T(1.@4U8\&2MJZ&MMEOA+5QK
MU'2@NX[V/$T';^'<PAY\41K]]-X!@YH'IE1B3]3C3^D6T%;=+6",3;:=-08M
MWL^P8,> &/(V-RLCQ[\MTTJ@'LPJ&@>6O37U4+"+0%NXBX!94&K6";L)\+ <
M72#_+-]!H"L=!-K,#H)-8*_-87190*^OK8!^X_+>3ZR*C_&BEJ(JGG^$_^NI
M1?&BS&&A]:R_)EX?JXG7)FKBMS"XL96J*GZJ7$HNF];4$GG]%9?(OP4!\Q4)
M-"IXCVIBGZGB7:G@CJHLM5D%[XNUO3RM^EV2M#9!TB]2"J\EE,+K:RJ%GU$)
MKR56PNNS*N''I.E*"N&U-17"OP5^5FJQ91FVMKJR]@6*EZ8PEO9J:MSG[G$5
M!>]8!*26AZRCV'W^3C2E\AW/?[+\77_6ZO<W9(W&H+7A2#4J:<_"&9-#-V*U
MPAK5"I,:CWY>H!9]5I>'GEQ]/J?X7%MQ[;F>JO9<>UKM^5<6X>S2L@F*4P!'
M)Y=JK[+D1034;70?^+]MYRU0[9_^GQ,IX.*4.I=BF  N4@+XQZCB?^@7S4^5
M[B()X"(E@/&GI/1O>6J5R^[0[^I8Z:+5?=]MV:AD]L[J^G,4O+R%>TY9Z5+<
M"+6X.<<XSBKY&34N$^SRZ:9Q>O'MQY>#7]55L$ME9H7+1X;.$P1W3[BYU;8V
MF$UB>">;L*"Q(IF)2L#<U"*9B4O_]NFT-@RJ@?>MMXI+K\XHD2E7:I7GJ&-Z
MH<+/5P$LNT !3"U#/GV! IA25@#S'&S4='OM%4%9)M4?"+#$M;\Y#I!IA@"9
M>VHT(H:5[NNT+'5ABB:*G=EB7"S538$K%-/DJN2\URY^.MP/;OM%SN/#/G_\
M"#_R5U1GH&_K,]:XM20]A#IU,5&Q!=0X0SC0$6\)FHTX#@7,O4!DA7N<)AEF
M?S!\+%\<W-;?6X7H%(NU?:5T-??E2_WF\V'MW]'MUM2')TN?-:QL5[$7[H:?
M?W1^['YT<M935@:2:667L2+-/O?$5O>>Q -?[C33+D:M8,BV_FJI\;TN9'.H
M&,Q(,:S[GN99;FN^QY@;EIW3K',J3J/S4+KG]J[9T-^^L:P!=QAQ EZ]"1.8
M6L&UO<L%_H_@L,U7=;\?J:)D[N!JF._OQG.'3GM;0'I[-\UW^5S1R!>J1KY4
M^F.M'%2_N#BXO!BCC#5?]6K9_14M-I&6RA.TM$<IA!A)=4<7_N%PU_S7+*8@
MJ:]=.V"3=)3@U*7-E(BL!VW@KV>XHI5O8:8N27 :U_Z>-6PGNXB-N(A$.5!5
MY,">Y7?A_PY^#>T[JP?ILG/&I8$-Y5#PA[K3CO]"^>2UG3,;UWUK[_&R^'#]
M^&/7OO_5.#YN.&O11=)4@$,B]S/T'\OEWQ,#1VEE#)0"AV78+-KPE"L4J\C_
MOA;3)?X2<Z4[_6WVCLPI8:ST)0H87S[T"*I"1*,%,?[U)%K<B@7$Z_YI9TJG
MJ)DK;Q&@1_#WEOT0_.4,^VTW:+.6W;=Z6[KXP<<PRM"QZ8%7%_M;_]0,[F8;
MA5S82RHW\L^<8USIG<V4)ADI;B@I)F5DS%PE/2F6JV6CE*]M&BDF:IR*:GF*
M I%S1'""8.8)"X15-Z90@M/33X7/A?KIQ\+J3-$D-;*Z$Y&[$P!5L+W,,DK+
MA;-(90EY7TO+9 6C6*H9U7)Q42;+C.I72SJ)\MG,I2>=:KEJ%,V%387G%\IY
M12@WG#M^,*XWXJ<T)H0[]X/N*3^$2J_W3&9]^JV'V\@8)RWCJ)2PN(PU\VD9
MQ>1"MI(W,&B\ 9R2T<HJ:259J!92TXIIY"M5P\QM!JTD2E53D:IG'AM8=OO@
M8< <GR7;N(?.S\*'8K'0/%IAN'41&W?%N1>Q5\1HY9N=%BIYKGS/@CF>9^+(
M99:Q5HY-I,@EQ'PI+>M6:E6C4%W8D$X@DV>[K(Q$7PF))FN7U-$]TS +!2,?
ME<%N'I$F:IS:M+3>M7W)%4U B@843M7^=OU8KAU\_FS_ZGJ?FVNQY]>L9R[=
MP.KI\2Q@QLB;R,@Q6EQ"QU33,G"^;%1+!:-4-3>7@S/J?#74F:Q>4@<3\R6C
M5BX;A>+"(?L-T2^Y"?URXCJMA,J1XEGS:ZZUWRON5S>Q<N3(Y6=YR;Q^5CNR
MR24+V45LR$4D"H-Z++P!,&K!Z*QG<4G@M"$%.H ^ @PB4XQC6+2N']MW1X>_
M@B^F?]A^MLJ0U1V-W";U$&,Y".XRH]KT+MYTPEG<4,P7TZKB4JEB%"JYC0@B
M9H2S3L))M.'RJ:-8I6+9R)4V./I<C>7T LNYL9L])JPV%AP\B%EG'URW?6_W
M>C$Q/3@,OC5^-#Z7'M(4D[](N46T1X1RF@@%9+RU1#)G/KDL(9Q35S:91K5:
MR\3S?Q4))8OIU(&@@I$S:T;%7#B2^_R"^D 1U/L"E+GAM-P^N[0>F,]UVRD@
M%(W[VR"OV[E(9/MGSMW'<G#P>&:_0LMZ/T2CMAY(?F>\EY;WEB"BQ:5X8:S^
MZ9%Y;MORNS.Y#P&!S/<;P7L9"3TC"25*<?AWRA+G/!=,FU%Z.;>H^93PY)V;
M(V;Y[!QNZ;1SY9,>C!G91_ZGP^:GXX^%5!)["2-[I?D%W-&VV]D>^FP[25)G
M68V-R&K,I,,EY'[J$JU*I6I4B^7-37%DI/IJ2359OZ2. M8*92-7>&W5'I49
MV;BPX ,T35CPL=LZ_?C3_)EK=5YOO<=X[BYCZ4UDZ2<X&JFKM@I&/E\R2M5,
MY63TN1+Z3-8RJ<.91:-4*QJY8F%SZ7/!JH]0NZ!6:?8/\M^_E/M?NBOLS9P#
MN9.L7O([I2<IF-/+^A$N)!&A9MJU//&M*9D7WZJWW6&SQYZC^7K)13P#]RZA
M4]+W?>:,7*5FF.74QB$>T8NIE8PV-X@V$_5),7UC:<XHE7-&H9;?9-I<%+/O
MQ5')LICQYA:@91>Q(1<Q%YGPR+9P&J3-XO"$'X+CF\]%\^KT\F:-1N(32H(;
M]=W&4>.R<? <P(09Y64BX+5>Q-S.,T4$)*%*^N73K[\&@X]'#Y5GB4*FW[QL
M+5,VE'4*;"1-9A>Q(1<QORU5H/&<62. XIE 0OAR?G#]>).K7OS:/?AT.?KY
M6LI/0[2O 6U,M A8K98W9%.Q$%X%U4[SNI\=P2E.,XN'?XJIRP=+1KG,=8VY
ML(>=2;G712_)(9G4X<*242H6C%QU@_L"BM>L-?2YZ-S>/K \QQT&XIA(!HN2
M4A3#9U9WV*W].O]QVGJ%):5B=U(@OT9.>MEBP(O=P^._XC2RN,PMI2[VR]=*
M1F5QZ(U,XKX6.DF4M:74<'&;1"=S&V3K9 <J];0QRU>5NE_N6X6/AW<?OAV7
M7XOQ2]O"VOU,VC[=>$FFE"5D;^I"N'R9Z^K*P@4TF>Q]G523+(E3]\)N$M7,
MK6")%YO*T-XH.1#QY4/_L;57^F7YI1>S@%=<12F#F@/70SK:)L*4%?T]>2!9
MW=HFUJW-IMXE5$3J*K:\63+*FUPKG='JZZ759,64'@8N5S$JI0VN!T[45H<S
M<VEA[24H*%!4^Q>GUX^_&EUKOY#_=6FQ]0%NK16_4=EIQLZ;R,Z3I+BXNBFG
M+G(K&\5BP:CE4]>X90HGH] %E$PY=;RR;!3,HE$S-QC1>JY3I)S<%$3'P?[-
M[K]7^5_];^N9_;$.<,>L;F/3RP6RB]B0BY@[P&**,:]VG,K(R:Y_<OUXVJ[V
MR[U/9V=N][6"&V2AD(W6]G,I<@GS-'7/::E6-BJ+I_LSXS0CUZ7(-=E631V\
MJQ2+1B7_VBS5^CQ+-8R)@.H)8R+YNV*C_\/_UK33@)!O'-Q!%B#9< Y/),TE
ME%#ZJK-,"64DNF(2350\E=1AO->I>*9TM83J!M0,J)NO)\WKQ\K]IR^#QN6M
M67II&(2GJ9T0!&%Z2US&S9O&S8NKF4KJ@KN*D2OFC$HNR_UFI/E4TDQ6+^FQ
M!HU<J6:4"PO/V'Y1!;-"7R0+QK[!8&QV$1MR$7.C$1>!V[KM<K.,>3Y,( E&
ML:39?>&FPOKW7GN89MI1>I,P_2%<?*R?'WP\/=H_.+_X7_W@\U7C\GM&FYM(
MF]E%;,A%+#+[G=#445I\L7I#%B7+NHW*]2/SOGT[RY<^?/J29MS.@I%*VVES
M9_\O?3N>-Z-<6C[WQ(GO8GP#;I'_D?^>^?JN_AL]4AY,+9>?>C!GEG?J7016
MP-IX1F?,N^A:'@/,]!9X,V:^8%Y?*[*7?Q0F/NWU+)];E?B0^H/MJY_!=>S&
M7W3,^DWF73_>Y>LW]5^[=X_W;$L/[  V'>W$IYT,+$^_@^7(TWG25F ?Q57O
M8WC0*GSVKCY</%J+[6/>T.T%=C++WY3+OIZQZKCA7UVT^*9Q<A@W_<]P-?X:
M-U5,O:E%O9GIF\KMF$FSCZ:Y./@_T4WK \9]#7C4>WV<=FM3:9?>71\&7=>S
M'UE[/;Q7RQ_ZUOVW+Q>L.9UF<>V^;H5KF>3!P^7VL7+>._]Z7O"_?MS?_WZ[
MW#Z6(-?QG:R8]Q9M^XF3:1J^6V@CZ?EMT:QH\D9,@S\$_F]IAJ/K19T;7?$D
MRU7GD&K#]X><3->E[9J/G^K!K\/[_$UG+J7:N)1);LO-V<+I,/ #RP&[8CV;
M* X?/I:J7VK[N[6YFW"CQ2R_D_AEK%QLV#7G>S=G-D>_VJDOH[+D9:Q\$_=6
MOK!_T;_X]VC^)N*7L;3,H.M8L>!;--^Z*L&G7,AJ=U)+9SZEW\F,ZT@MOFOI
MS*7U74?ZG3Q-HYJ%A=70<HHJ46T)\:+S@U"95+<"?9^U<'=ZP31TH$_\T/AO
MBX;.'S-@_(UWK#=>*YG%*!9.F22$"9;(ZJ7ND3,+4Z@M"VF]"7))SK2EKC7:
M('*9&YW?<_M]UYD:=:O9I\='N6%@?5IAB?JZ0VVT)QEGFPBO59*W/S,@15;Z
M8[-7^_BU;S<^ER+;6KQM?BQL-\5[R2!]+'"CL[UWYW\-B@N\=R9/+/#FA45J
M/K=HL5/:H%3:U29Q-/_U"J)-7#*L)]Q432:/&;&FQ]M\];3]Z=_OA=MIY+A
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M<@UPAC:"(3)2>3JIS)&=E?1QJ&K%R&T(H21*SD/%6MUG X]O!;%3^<\]!C]
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M'?I%P'\!>5R?EJP]X4QP)7HNO@G($]N=T8J.??8KUOKP9UC_\QW1_]G>YD3
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MB@,=H\"4_!XC2CI(?*@78ZO\,"Y/ZW&J%]>:7>7=-B=I,B=Y]KOE>UC,IJ(
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M\ G_9?!?P>848FNMT#$_SV=S<>9Q'FP5\N=F_N[-[(F&PZN$,BOTT]C.1(M
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M,B"(;SL(L;8G!E.Q51*!3PD%/BO&,:1BYD&\S\O^W,R[V,QV:'*&VF(',3=
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M'XEORG>LRQL2=^,!W3<@WG3R7\\?R&]2_W[G,0!+DB;A!> V*0+#G;TJ5A^
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M((5<!XV"S],SP T!W]")TTD9XW\?LX2) %C AB$#)H'!0%P.$CAM,=:@(9S
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MEV"0 U42[>_:=V?KB%>5MZ[R<#8X$QT5<9;Q;%0YI/MH^;<QP\K]GHTHD/K
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M/ D $LKSX@E5?XAS[KOC8.7IMR058 &N2!K%A,@^Z<GN0,B];OI[ M2N@A<
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MQ'H44:,$TFQ]/37J-FF:G=\/;V_R')V[]1 L/$FJD2%!W=U6%":P[&B!NI1
M76WD)^)HBZ9+B2L82'Y.GN(SZ2Q?2&46<W+/V%QU,G^Q0HR+M;G]1B_VYJ5P
M>MFY,319.;@[2L7EV)C9"5E>7,:Q;5\3I>#$ @I.'W/7&E<<&HK*@6?-G<D\
M0]0LM68Y9:>7(D #<M'D0-+.)#-IB@'P4WH]#+@^.]?R#YG37+<0A;1-LJUU
M:7ON<(&(DSE*9H[2*>>G=$3$$>(2M\ G"P*?S^77(NY8=VM3]T;O5C-_-X3G
MP9_2<_[P;FD%<]9/WFD^G<GQF27DG?"3]T(!'3J!G9]-P&&$8=?X!/JGJ^'W
M?T+?<TE9=)BYN#XSOWA3IR<GPY=N)^60\EW8WE=""+;OP/L7'?8NKL3>8QM3
MF5R!3R>7T.C<K>0CW(I-A!N]%>W<RNNWMZ?%MZ>]PSP7F^8*(I\KA#OV@>(@
MXY.4)LUBG-UZU>FA2KLHRHHY'%G>*<CX-P/%-"4R9QC,)F8P!22&4F&<RK I
M-M\:""P2O%HJ]Y&J0\3";&RXIEF2UH/4[2(ISG$#MV&!8*\_-L+;K6EZ4+FK
M7#\\3#M;2;K90-0WXZ2.SD9]\ZVIW'[]W2A>3>_* C1\M ^<H"=^'W%>[\;M
M\B_B$"1=1IF'T"&<'VYZUT:Q+YN:Q;Y&IX_DD8JNNU6HHD674,TZBU1-,)*]
MV!@M>\BYQ$+2&T%8_8NMJ5A.I1MG*377A+XTHP&&[80L_L.3(LP=<1X@TX6X
M;V5D28IJ^O](;^#[ZM00+=7)GJ8=EMQ$LW"^+!S@RO*=_.1P@LFA>'>++D:*
M))?@*MKVN\!]56GR VH5,5G98*;U,C,'IU3BF8NZ>(+M_+:"\ZV6)#E%79 ,
M:?5 C\&<Y#*%Y9Z%YJ8M WU ^JTO0ZW]\P\HFI4Y13,(AHO7FDG8]0(:8Q'\
M]O]]<8OT A/6ENT5E/9-;,PSXW@Q#N,+P #O&= L_HB) :/7_I9.9OBTD.?3
MHOA]'L\9J>0A=2]L:P78&=.90H;="3/'G%D^O6SU!1?B7RGU-3 7<=':_YG=
MFZ.YYHL>;KB !])<"*7!S$A;@V6C%C-2;3B1QW?7KQW'-I@7,=1CZQ0 ?)D]
M5TAJXL*3+8ZD+CM08$Q "!JNF(UC]C-_42:#T4\LA$]4#$28&->\8=+YU<?
MFZ>794QN=M/_<DPN.Z^DALM.8D=CNP@:[<BL]6\(P)9M:/7/+Z?%58&P^LWY
MJ#0?C4IIHD"-!6 PAR+_#:;9BV9.EE/F:S,O.#1;AKI-:)H*Y?\VU"-G7N^,
M=H./&>8_8K9LX,S4K!B?K+,B_K]4J-6Z*I;NE];#Q61$F6C-"<1,5+D?D>0V
M3%+5E01?)9B(M"NIG4[]NLIDT5+!1XO& E6J/4FZ8)*([<8!![?(YW/9J"3Q
M]XHW9)H_R&C- 70O1C+9!.OR1+P2?Z^HRT:CRZ(+O*(';BVE7FO)BG<.^"![
M7E:-:L%,N3&H2])/R5W"!_NM";QOL6DXY+0K4'4A+E7GLGPJNO*Z863YOD,[
M,'#KZ6,1;U[61_@JHM ^>7[)H>8$!$^VHM$6D<O$Z K;C;.YF/Q@,9RV;I[6
MD05):QZJSUTE!]EF^KY_G5I,S^$[WZI4QCN.3KVY.!DEMDQ.%?C<FFKJ6K>[
M7;$=0]@<A"(:4PN,O-BF+N8O\'>N#+U01V7P8JLX3,6 DVUP@WLU$0/=IGNV
M$A>(GO0*HJ<1&-F?/A2GS5,C5<TT\S'\H@<JBZ+6"*TOBPY*T*QA@JTL,C_=
MG[%\-0O<GW.D64^.FOFS:N7B\?D#NS\#0_(^:HZ=*)?+97A!%#_=GR'N3_$0
MM4Z7I'(QW)]S1'21+4\JJ>+;]?GRN-_AN3^#"2).YB 3;[E"AD_FTN]:O*TJ
MJ8@GT^TS_W\/&^L]>9HU9\_7W1F<H=@$LS+E0+SO7O1:\+\INGH4JG?*Q=EM
MV\5_9]W8N![B)R2)G-&V'5,8K-*G 9_F_WTYF@^+Y3)Y2*'>$A'LW2&X:4UO
MD2/Z[U7X*AL+ C!)-=0;S7;QO*V>=?^*($ @?>=CNQ%38I;/[$W9VQS1KV+3
M[=_U/ZM"_EVN_]3*KG]&ZZIL=DZOQVH^FWU7KO]@FEVC4#&?+_!"+K22:5-H
MM4GCC;4=/*3&TKY6D7G8__]-L %B3!,CE5K>[MZ0/^],"B/(,5-C0LK4[=DZ
MK*D)IU*O#^3BP^0MUN*>#/LQH-DK]"_Q=]B=+1#Q%&84JZWI^:,\*!BR:$+W
M@WEH'EJ?.=K2W15L3B?JH*QQ((H$J<Z!/E'@K*3=WA<V^_**S3GUV0RV<=]>
MR[\:G3M1J[J.(N\Z'&GT/;.[9=QA\4;B:>_YV"FJ0H[/B>$E;P#@H"+S5< Z
MESEU5W^[NSG]G<U6MP"K)5E_^36<7GPR&9H, 2W=/6W'/T#+H/"R57<FAY=D
M$W83^> N7\%DS"&IT[??(%- NM#MG<Z+4,AD*EJ,9&ZK%"D_UR1UD1KN.2^K
M9=YH3=(ZGVY-N[ENYU8P>EI/BE^<Y.-O[$H/ICYIK@P)2[KD@W1K#EZ+UJ7J
M;'-!#=)BY W2@ ,KDKR%,O9V,H43C_#0)Z=:TS":N=33PEJ:@-7GJY HE)P/
M):-FRLTC31UOH?D*EW:EP[ =4*!)C[POJYM4_U,J52K5ZJIU-2MK7C2F#1,B
M(M3(I+\&PG3FJ=0F=_:?J&Y,8ENX%$# $]LEL/QN5S U-M"F-9U*\YG _C6+
MKV$ILA=B(SNDD#1?]75P_'5ISE%\=,Y%93=1BR)MVW6#.,5 &!V5"AOH$1L)
ME98C3L0TCK!3]PV$-LH>-XH\^?>"/ #&%=!GA1R3+:-/?,T,SEW51\:A,I["
M.\$=@.$*J+.!1K8;0AUQ/=3!SQXLXQ&2[P5Y\+,K(,\*P?\PY!'ST.<K!N[8
MKL^%7KU,:_K;D%^-&R&+,N)FO7H+)B5IP_19X4_E5_N^O\%O1IW84FQ-+^[-
MU+23?)O(FW1E1MV T)J^GJ9+3X_7ET^/TMH;6&< 4VK! *;^V^37+[E>.BVZ
MUN;G!*;M3F#*[6\"$Z;+HJZCTT&Q7NZZ6'GX$YARK>FY>"I/S_*:V%N?G*(/
M6]JPWS"73,_Z#6\,:#UO36Y42;.*FEQY&2E#B!$M[Z3EFTJRPC*MZ5T_W1 G
M+U?-YOJ#E-;NGB6&=L\Z:4V?[O+:Z/)W\_:F\.4G.1S/V6<E<0;GH-OJI+4_
M=[I]3IX;PL'I_&S[N&1, 9DP2<9>='33.DZ4T=# *H<39AHN7($4$#CC8<D4
M;6P_(/I/XFT'9SI^LT,:<%LZ9R)C# .$R+!JTVVB#6T(>[2-N&5(P)Z.X((3
M V3U=9G-=+8G4+HCCH<C8ZA#_!(?P"!CQ-N2"0W%M)F( 1W SD&FFC,/A(8#
MCF$J0]!3=/ W3,Q.6&!+DL&WM$TYB1,<<XO!R]J;[:JY62Z9B<P9UHD;I*+P
M# ^G>&H,I.OI9  9@@N" PLITPD4[#DBL(&D5C>&4&A-U<L7PYRB;#8O1VAE
M1CX!-$F0;>B%%')YV&8[F[DQAK0GQC"^_Y73NOF79@Y%C3&L\-$-;3CG#?TV
M1'ETFDK)I<A!D=CMVJ(VNUNKS)$HLJ\(&"5\0<7X$UJW&)ARLZ'/!JNURR)7
M.]P*S6G;( @B-_G[^P"=V2@( G.= _!^J5-,B"*Q6-5)K=5?_NS)!"PTVB?9
M>=KYJ]TG.8?2C[F;YO2TT8[A2XO<1#";7=;F;U[!#;02#ZM=X,R*FV_4MQ@3
M%CGP[#MOS5SYC#H6OZI'$/E,-G0@1QB(-M*\[Q,K5L:*S$I8$;_5E9#E\_G(
MF;7;:NGHLM7*3M@JI'.-L("98Z_/=]+YY)<X[E6E&.QU,Z5H]N:\^O?AU:)M
MI?QQ ^PSY&IG""9V%ZEL@4\)D;M(;0+2G[>]@"U&NNU4['(A4>!%(;67.EB7
M)99WPA*K(P,??60@_&050PEFW-M<\26OY-';T]U+I[L5I7-%P#E;)5Z*+MOL
M)]E$9Y+AESU#.;%[I&1 V]QA!?GGA2_DDY$O/';MA9CDL_G]=$QU664D-[+#
M*N5D;&YY"9U*^KHJUP80;2!S-!UV.2T@Y<^#=6DET=Z42&>#4-[E[/"39*+S
MR 57/$,SL7MO%](\MN@_F>2!,,GH-Q[;"Y//\\(N;SR02^9WHE ^H+[245TE
M4FZ?OZ;_/+:-7X6M*)&+/;]+0&=O-E8?@/?1E"+&MPZ"#_OQ:(808\\K%Y,Y
M/A,^PG3+C2#6N*%/9-NF"%B(;+&=1H(H\*G\8;:8"R[#6RX6!M+-3;%2G[;[
M;ZWIXV6R7WSX/2CU4NMKO(M/TX3Q])]:S6K=X'+I=<:$YY)\.O/I\]PSCYJY
MT-B>F7P^S8OYR))O2\SFQ-MVP>T'Y<T4Q#^KB,P.UGQ]HD)!:+?+&I@>UC0I
MOG8SZ>=ZO=[;@]H9JX_:#\X#$7R5+DAB"HR(R19_L6*QI)G9IC!T!88=N[6'
MF$KS^=QA##KY1-&/@:+!(BBVWPNR#D0AJ+8L%B0WT;\RM#7?BG$XTL6MB=5C
MRZ<>E^5>:5HY/WG>G$-X\SWL6+9T< XP#\W]-C-KA6+[/_OHRK?.AK>B]JW2
M0R^7CIWG(XJY#7?06Q4^J_/*3P1:!X&"679\?UDFRR?7;)RZK>E+3J_%)9T$
M*ZWIJ7&7K^G72NY4?@^=!'V%4W9+,BA;@MH?VE<,^7+S$W9S,[>;(&T^B)^Q
M]/GN=]YN--Z/!;<0S%3KYR]JMR^DW0F$05M<ALS>=V+U",P)\3L Y[*\D D-
MP00W"2PN M-<2\"R( W56U$[4>7M@FEQ>\"<$-M'D,+4+J9"?01[ZP^X[3I8
M8:[:K::-,9/5C<GRNE=O6&W1:ZWIQ4G[K7)=^ZT_*FO7N08 ;0/%K]G0XE>,
MWX_6C9!Y:CXVDCGH!,U.NI="UZ4\.&JGW05?BM=NQ .9!"O:-,%@P00#Y79=
M15/,/N;*/5V732@Y[?1)D2EP=TQ=DHJ..6<%J&IUBVJ!^:OZ*S)@(:BPY? [
MT'K;0-!<EY1>CB5UA%<HP5\-X",F!+,3%FU-.X)2/TDA,D'J8%7"0+2<U+>K
M8Z[I:?4[@HI8^I"!%U4P+.E/^LCBOE5KU>OO'"NLQ:O:78,1+0'F[@'!R.OP
M)*O 91TX)8QY""_D @&XD4E*B66$!O@7)F2RD,_Q^&<V@P7OP8:/@;HJYD<F
M*QDFAP:?@;,FV89Y[&\[?& (,Z/B'.(6,4(D;(1 @&.D/-J]!\#>(68@F@4E
MU7H;$-[LD$X23@VU!*V@VW9#:: %S'UU Q] T:#C =SL-^4[)^%3]'C\(_ZY
MC\E'-\!>YDRDJD=6'YO(O7YB*%D8SS3\+LAM_"A^EK6A/@()I72I7# 5C'[D
M@QBK?T$QN5O%'40Y0'"4Q*P^!A0@#^]K?&T \\2$B_\H00DV3$]*P.E]9[95
M-5GI=I$!O\)?-[ Y?R3KKQK%<+H2WL>K8O45C1%TES$&@OAP-G@4.FF;H[9)
MFG-8*NQBC P,5A]>K\MP-ZO9>O@@ !5?_=!0"";LJ()=F.N):Y<^0Q-FMK72
MR#"@PGS=_K?>:511/].:3LN_Q9-A^WE<%9?TNK4A^1%*UQF6^?6+DQ.L7SP*
MR>=>J?'[,DH/7&5. 5D:O]M,*7C>8QDUK=3O4OJN.ICDME"[OO6C)#W62Z7P
MK$JGZ4%R*G]6M6^MI'MKA=7S5Q4(@7=:P;XGH+[[:O54D&U:9=K^*6@:D-,S
MS=7'3^5?E_WGL\Z6J\M7]O]5?:;)9WEQD(_"=Z'1PPI";*]P2N +F1R?BIY(
M^5E7OI^+#W80QLYH3*7X="[/IY*1(P([*1VW9V(6;9.LJAO7Q""SD ,L5OHS
M,(MW]=+T*5=J33-&NHG:\DFA+VPY0!L_V< Y$^>:F19:JOYN.@WAKTRR(!-+
M%R)5=&Z;62$5,V0X:28G\BEQ8_D3.TKQ^<2TY9P])J(%<O?,3/AGB@Q=ELS^
M0L;.W/X'GJJ>#%)GV0#%:3M;4#N%AO9R%X>9Q\SX7"NV37+:7>\.2;4!UX;C
M68P;9=\.A7V,C HOWJS O6/G96)=.9-+\\3N/J DBD]LV@TV!;/HV"F4JRO@
M^TG)69B04VA-'Z6JK([5JHH*FTW(V7:J0";WQ2NS;PP$ 54VL<$,RQ'PV"AA
M;[2F+V^7@W3EYK)GY?;?!CL7F@F0:4WU8N=VDI[T&JH"?:')@3C[1-M*"-AT
M?&J-6"@WI&>V)^Z97$>R4"]*K,L;Y-TX;A9F0UYEU$6&@63(!S!+TE"Q)#*&
ME]U949.O\08-.H(D.-7%#85Y0U^SH3$W%';BRYE:[_.MZ>5%YVWZEAZ>YQ:'
MR&:1<'&D;$DDW3?E(31NMNK<QQ"&W%Y8Y^L+@#$?<#0T#9@R>3Y^[61[M^CF
M+.V/I3%TMA/4YDAXN4Q??(KXR1!AWGTWAE7QA.-*+R?Y[%/VIGK1FPT A&PT
M:KG)VIO?']@.[<*\0<?G"['TUGE*UOJ9O_["O";O-EE*Y$T&3;AI>V*H9!?^
M.&K[D'G&SO$K&( T!'MPD/J\(_\=90[GCH*=8?YY.T2 -Z4W1".Z0O.T]F \
MB+\RZ3WT"U\9\+0.C6DA%IPB0JPN..H7[]LK! @W]]&%(Y=7#A_&V\.R\B,7
MKZ([R\3872?2R2R?SBSN'[F#BXF,#9\HN'\4#/2PB;%K8+)BCL\(N<-#P6 I
M4/5XEB#SWC*Q55W3L%D, 00B"]*2,&W(9X7R4QQ9L+Q+3TQN3W=+AW?9^^6"
MH+P#"MLA$>^<D*B?<AXW5N#GL8,?F7R6SQ6B$=/'N.9/3%K(EN/WCB@4^%1N
M<0O-'=S!\K@T\6CZG?PL_9\PXZF@EJLWCY7"2WX74>IMN ((:,@Q'3\X;&+.
M>;@SFRD.\;R7G>Q1\PK'Y!5$1^S6%:FDR N9Q6'.]WJIGSMYSX@>+-EB)U/G
MLGPVOWA U^'<:;#\*\Z[H@)$7RG;1T^3T_SMTP:ZA2X$1?HXO3A])1XXYGJ0
M[G,S,>EM2[M9Z$=8OI']^Q?B"KAL[(XDN4*>%S9!^'\%@AW6;OX&= \4<]DU
M&@JG!(%/1W0&' :*K9C7EF]-,VW]["55N'\YSZZ=U[;)?A)XU^@-NBP@[Y;3
M0J4U5>LW]6SW.=?+]@YGRP3.]HX7[+_4FN9+U?Q)I:!FA]WWMW^A-7V3FW_&
MTM,PF^J\O_V76]/GU&GNLI^N=SKMO>T_XL[_S]$15U60*O_@;J0>9L,-TE*C
M@SE )LT='3'V(RMCSQ$+^(KTFV+QO'!U=EX("U'/E4#0DSE_SQ+6'*VOA/\+
M2SHV! 6PPS-(+'T8F.\[%\L0A*]AE=SV$YFO(8%X#YAM /_+P:@8N$:IK73^
MY>I8*-%+J.L >"'O?>L?^S7X4]CG0Z)2LS71-N_^[S_X6@,O&+/MWN5YP?I5
M*E]K3R[X#20]'[41%G=XJT."+^Q2254WO5$G#=6#R=Y,5>]GO2>$H]/312.T
M5&OZY_DD_7#_ULQUUVT?MD5&L>W\ZVS>EW\-F:77W8:DHI#T56\6MNC&RA:_
MUYHJM>MDW6J4QGEQ_[G8^46YV+]_WY3NE;/7II6!&<*TB1 YV/M(Q [I5.4[
M"6152YT.:V@)=;"*1GYAR"1J""V4,.G\+#9*7"XI.N#R+P*11KR#L=(!V"@_
M_7W.[(YA)I1?00XWQMC._\_>ES<GKFQY_L^GT%2_.U/5@?V0$%O=UQ6!P7L9
MO."E/#%!")2 ;"%A+;;ATT^>3$E(0D(+"&-?.KK[NFQ)>3+S['GR=P#-:HYR
M)>ASI+3)2,!><!^91+W:X%-Z;H"YFC%&DH8?$0!-63<G$UE"&AU?5/$ @.>$
M)0%>P%\'("O\A;&@F("(96K8#&P06S&;(?#*VN!K!,*J/R_^ABFKKE7U;&4.
MMI*QMK)8!.1BBLT)<%E#Q7K?M[%O .P%JD539;OF7D.TC<)\'$/#<QC 1N#A
MX1&J"Y!&Y<T>M$SZM/W:SWGPJQRT+L&@R'9?8(.8*$0WK-:1KN?A9$>BNBF?
M@[WP8)WA!4%"?P1H@P SKPR9":9"%=TPAL8(/]7#2PAE]Z:B"S+Q@T03P5Y@
M>9('>[(T0(PLC3&;$+PV !L= K ]? !+IC*$"GU+SG(B5MIX.23%I'0!%"(8
MZKZ@T^898R!4'V&2!EB>B09YTR3#P)P"&&PP+E0?!(' Y8D^H2R"I7SHPFKS
ML]Y^#L?3KY)JZO+4A>@&4&_,'.H-Y-T%V;9].MC##D1Y5O[6?4(6^X9+)E=;
M*@6/V9]CK+D,^<HH;MS</X@Q /8:QP<O\G3R\J0,EEY.\2[DY\-PB^T?.C=H
MPFX4SJ^C8,_E^8(K=8X?SN\.O(%[^KI=^RLAL'%D7@YVZH#1J9?D+?-=8=Y+
M8=G6L8C!\=AJ7UX*VK4]1._6-HKHCP/92S0)\L;F8?D"AMTN!+GUPO(MG^Y6
M[?[&MF$U0C<$_;?N)8U]JVQU9+_UN0EN#1F !4B(B(4'F)RH=0+)9;X@<:#G
MUF+!EB-D>%R[FJ<:DGK/USCX44P4V%UDWCF\ P$Z/1.<]Q6W'7(/U)W=6[S!
MBI,[[H53WT9.QXW& HYVU)&HA\9E?4E<7:HI6=T JGQQ2_I^G?EJN9SG"DL@
M%I?N_2;X+QXVXTX(/T (#Y<*H;]WS2I"6!N_CT7]_,T0,I7!A:8W\64P]?6%
M:IYEH67ADB*=;93!54Q^YBF D&E<:NH Z3I>6T&> Z"%&?B-*Y2/5:6;5Q_E
M+&RX>X\=L,.Y,7\_+4CGYS</;/%CC/DR\GP:I;P"?E>M4,M7V25W7#-@@4TS
MX$[>$LI;*0MSO5S>],)9$S/OE#]\^AC#G4#>5D$JK[!\OE!8TAA[:^0MVU ]
M\QG1*V$[V_W1NN0@"]M-@=H6E,AT='-T=Z_,D-;_&*,=2)=7>U33-PW-%ZK8
M_Z\LN86V-<IC)V"?.[8.$3"C_L1)1]KKY$W\&"L=1\#2@VV4R_D:NP31?FO$
MZS/&U/<C*-,19*3I5E$',T!()W3\;V$\^9LA932F8NQL]0>IDEH6MMJU[T=X
MO^N*V+3WV58KW.1FU)XUA=K=!P7;D33Z5$SJ'%ZY5,@7BY]!Q>S$;F-BQV5A
MP6.(7>FW_N?/X41^:O ?8\V3BEWZ1%>^7*OEN>H2Q):M$;Q/'G?/ZVP%$>I[
MQ_A?.\6RC7F\E/;<V>"ZL[^V0AEIE_+KK: ]=#XH_@ZES:=(TF?P\FR9RQ<+
M.PN^$S27H#6RL.!+!&U\<LWIPIU\]B!]C.6.*6BUU,DNKEC.ETJ?(=6502R^
M[K*\J$HVC=3K)6G9DQTQJS?<^UCEDRUU:913/9,*.,HSMD)ZTG__T<>CWMVX
M]D&U;VYZ?$HH=4*P6.'SM6I26__/XL^=.&]8G"N9U-)YQ?E=K(U*A9L_G>OR
M!Y71+1'G]/B_Q8A>=9]&G+/-$<1HTK=F+;& 9?>AU*REA^2'5?IF3EOV50"S
MBYK8--EK4WS)]IPQ\-ZO1]FD3CER?+Y0*N0Y-FFY[C;PUFHM6G<"N?T"64SD
M1<SZ:OO:O+X[JIVBS3H$/G%,G;C#X@A&CZ\F+;W;!LY:&0N0[\X.>B_Z<:7U
MVI^LC@6XR1ZWU8(7;.&:0E?<&&K_^68B2T88OI(+/R'\G>[L_OGYI'$NF(^_
M1RMC*P5@FZP!<*D6"KA4[,Y*,_9^_+M>& NE;[^L>>;(1!DRT\QPESX.+.9P
M,$!8<E\14Y]HDLRPE3P#"H,@\]3-(7Z.J=)?Y0$/)&<CRP!0B(P D87=PUID
MCRT4R#OT7US!AD5A=+)RH-O@/X"^I,)VX44%'!A]0H>7IU[,II$@0@L"&X!E
M/IHQTA#*?2_^F ] -L@:1E( KPRP:@2'%!\M#![_"/4T4]"F3(W,C<L3VHTW
M-8S^/'X+ 4@,5V!K]&&\&"JIBR6_Y0J>"3A0*P-)$12"-J4;@H$@N6M325%G
MC!$!(0*('?R?@8S7@^!4#6!3OI="YHGG(."_&)HJD/7+]00=?P>P?>!E"M2C
MPQ+JB$!K <GV7S5HW@L0/P0PR;LEIB(C'5L@O"_2 ((@O/J$<I$ALWV3=+1!
MB*3,%2+G;ZQ,Y'V$#3!>],,74S*FH#BB(>C<]VIB?Z,[DTI5Z4$[G;[<L%NJ
M,ME"+DQG'G1G)XIRVJC/Q,O?TK=?5B-HALS_ZRG+(/D63&.D:@2]S$)"\\ H
MY;#>6W[ !<)'C>E(P-):=[X'R/K]>1A7&/3$ZO2BA@[<89Q;='7R 1=%T2YD
MZ."Q8=*KA;@II-/6D<N1I -^^U7,XX_8_Q?F3MI3(P@_[BE/!(TB>S'_6IZI
M=R9Z*6AM[88HM#MX\1)IA!3?:HO\W7O]Y7YXI19#5ML9.L$JAPV>8+7CQM#>
MU<9N^Z6]XH7]0H$-6VEJ")?5,EYJ5NOW&$S;U35C;Z\#R]<>G"JB]"J)IB#3
M="GY6U/2L,%3-3M9RLY*+V^%Z>"5FY]].".F9O3E-"];?:"RZR72MR%QHZ@0
M]D_"^Q/_0BPP?3-TH^+Q??(-4T_*QI]GL_IR\A2^8;%E)1[-*VT8&_<8?9D$
ML>';Y<QUGZF377,#'^4<1]KCZ;J,B']'^;2BYW)&++^S(0LZ7BOR,MW1^3/8
M""+]P#N <YVP_?#^7FR\'5WSR61RB=V+-Q7_L<O*4[DZ0&=#[>1AV$PXE:S4
MB_6)[A*J?>P;]P V6-^L?2)\ZHFLYC>P2_3FTIR42Y]26ID#9LX"A%P:R87]
M%?MW.?SY/;P8Y* (D"C!:,+O\$,(C2&+M,^<&EBV,1LQLH1# )%XUY8*)_"J
MZ 5K5ANQU@JQJ"^#2?L7Z!@(XRBY>8IZ"R&A#7%+O(H<#0IA^"'^HT[^1 ,/
MBI4+V4QXA2P7\ZH"%*SSU2 --8_^@4OSB?51VS3P7!0(P;-22-%&JC&2T.#P
M'?5-6++V  >RR+%81T=7!^SYI=X0(U6 .I_,\F.8F"NQ;GVVXDK\.7LK/8GM
M^Y>;8<*E2*Q%7(NQJCXD%G[)O'QJ)IW#G%Y?1LTT@<),.-/5/%&VN'YU:B5/
MW[#&<S,042\C)(M,;^KVA>;XQ#!GQIDT8\WZTT-SMUV91W=6U7$&)5TW(YQ
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M2QR7Y]G00\(<EE#%-7-H".466:O)DJ0[<AT8Y>)!2H4"I$3W!B;I$?$F:)H
M!3+?X7&(6KC"WR0AB=WLO2/ZT+WU$/DS^_>/''J'?FXZL<F"P?R+VR]X4J?%
M?*U:MD.ENO,^XW\/JAH+GG>9[[K9>X**'!Q/S:_@_R!-J7 $I9OX0^1O2DZ0
M2;LWDJ_H"_J(E-%80T $HKY*.NEG!8Q>R=<JQ7GTMH2D2KG@FTX@258J-^=/
MY09D<"OS6CY[W$.+3+&)]+XF36 7(RZT6;)C?:&M78/9]H-4(KIE]C"PD\ZA
MTHUX>GQYHAX5YR<Q_F5 8A[SJ4/1M_CE/T$0L*'$^.2FZ"F17+9$WWY]EWZ0
MBBJK6588JS(C 7-%#V&#YTP-BM],F;15(U5@<_&@6A#^X!8R$J+S)7+LD?LN
M>0=>9.Z@$=T<"V\%LJS#J3$(S/VK '^S2:2\C6G#Q&%'H%3!;%XN!;"YAL:"
MI$!)F2\IB$>1-+?40&X"3DC)3"B[0Q&@2J2\PI#S%4HG5-I  5]@N1Q\6[!K
M\?!84#5M,&\CJ3^BV4FK:2.DO<V>3MQ6>YDP0:"P "/-=S#DXM>)I)'R0-L1
M@H/>VOY"^9JG<_=G3F->"!I>.CY!#O,PC4]6Q(:_:_W$;T^RJ=HTWZY&\@/?
M&GZ<;U?$_^O\Q*\_+U4LK7:>$*NL)9=U$K,<D<3<*KY"=Q=70^GE77N1,TMB
M9L0LE:^7Q,QF".PJTU)[L$D7PC0##=H@E0E@PZ')I5.E<(.W$8?=>,,MWN?M
M>TD%OEA8/4#JH<OFR_3Z$=7=$&@V*0L!GVX?L2ZI85O+-$O.-$N)3]\#IBD^
M//:/3Y\Z'7&4:)KIS4#D1,-,!&]?_\(_X1V.&SFN%OY_Q$1+SD1+[K/UB(GR
M<4/DL!(D/&:^4@U*=80$SM9_0U(@4E 4'11-XA>7.O_+<RF5F+F4#U(CY=ZL
M851?*ZU)/XY\V76E2W @US')-2L1^>[/_?A).C@K)YECZOS2AC4(7TR;>_J
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M4LE*=X_!R>PM[[ZX44;;AIU=,/21%049YIT7!.%6&'8$29[TBI)S$]$>GYD
M 5N1CE[.L*NGH\$/2'25:TLY-VMOXC#SM/8"A_+O+R7EJ2/S9G%M:>WE[)1=
M6ML"-E\'X',88U7)MMF#$V3+F""2">EQH3/Z(1AC ?_9[Q<G[VOA5S+Q0)?=
M_FYP X(UC=P9(=V%06L .HJ%H0MD$'QBJ?^,\")-QSU59H"Y[B-\SZ4+N;Y%
MBQOHI/O\C=E[@J:AALH((JP[@!8O%8\%D7+AQ]</NS-T<35MFXWSR=UP16CX
M"#GR*>AL6TLZL0K+VGBX;A1<BE(.B,"RG+- I.G5"5N948!J6;8AIJ&.<J%<
MD@(4N_H&,Q-3ZX\$V]P']KYSWQJ_%*8$=?I(U:Z1_>[<Q'<GD\*D0)LM%3BV
M0.P _)3TLDI=$9=4$+UIS<-*:ZK>C.<H1S9E9(J:0YL;E#6RJ]WRR07VM(-N
MV'MLP?DI^'[,LNGX[$^"CJPZ5@XHH)U=,<\6:_ER^#6"3X\?'=+0+N\6 '(Y
M=1[[YNQ5S_NE)" ^]G^(C_-08*2-'\*ZSQ#DH ZB[@0Q<48/,,.)(/-(T8F[
M48>O# G2^\%T_HC%J4226JK2)FV?*$KYJ:(;FDGXV/;#Q36#C/&O%]+TMW9D
MOJ%%@">[8VIT_^T,)QS62WD%,#-^M0PVFR^5:V'RF',H</%-0"YOBYDE3%4_
M%O^8@_'9VT6C]R5X)8X.+ZV*+,*'AZ.+-MVCAJP^MW7W7P.:-9:WFI="\LO\
MXXAO/+8N7N7:EV"E&'GNTHK5FWFN7,L7"Z%'9P%]D;]#!Q'BJ2/Q!_.&M'D3
M;#&'OVK*I-N)Y'8B(]LG'X2T3W;":SJ OE9^:12/>*1TS+[&S[U$F\H!'MUV
M#)T))NI[[*=]_9L?]^K\@@/(5K$'6,[7:J&78>:MKWM3=Z"Q)L]PTRVI2">N
MRM\>>$E/NP]UD%ML?TS:* &?V]J3-@7![V;5%J14^>971TYC#=*?=:3*T->)
MJACH,^9/GFZN/XAK*3U=03Q.:UKJ<1C_1W^\NKWD1Z\;:PX2EB]=.)JJ'M2[
M,_;ZM3YECTM'!#S(G2CP]/^P4AZ)LR,P2Z<-G76H&-A)Q+4/<?N'9/F[&(FJ
MA77UYK/3M -82ZK.ZK;9^Y5Q0X_ _BI;MPB9M^7X',O@G'=EW5CCLRP'M,>(
MVQHC6/(QQ0ME$__5:!P>'AV%G@1PI36V^5@,IY<>#:RAX<F\J"$2S7B-'3%8
M?TN,XFES^C*LL=IHGIEI.4TI@TS*-_\^\.MLM[+YGAALH">]6NZ&K\:[5)X)
M/Y4^NG/% I/=E R3OVEP%Z-1 'ZQIWH@2^;ZU[9TQPADN?+JE\^Y"-2S;#@O
M2W6P6/2ZB=X8"PQ\]G!Z;ERVFX8Q=)6]$+NW_L88P=P1"RQT#9TQXAOH-V]=
MX]HV?2%?N<ZZVLQ8,Q*M:GU(V:RO>)\]FC6T@BEJ@XT4[X>0X^/7%6% -W/=
M-[NJ/?:#T;#]/%)Z>KM_.FBR0GM[4+&#&6=U^$\>"DHW=&$\,WU2VPCNM<TF
MLU.V8O1Z%^A0&*YDS>+M<2R@SU61K]<0:FX@CB:;OW"HLK4UI-GY=I$-]]9V
M]\VM&U^Z,U%L*[V)=E^^X3=A/H.)\0G(BHB@I3S'5?*U<"3MX!J^+\9A']ZB
M8CG?S=2QHI;J5:/X<9BBL9AQ+7BBE7\T*P9 (&1_S<XQ[NK;Y:1V6+[77'40
MZPI?XW!0)5:[J-27[YPZX-6KY#]#!3R7>07\KXSO&X07O\.A.J&"%,$O*8"?
M6,2N9<N_=#U]?5Z=,R]7H,4+DB(HP-X,>D6* 0E_6B%>S!,J2,D#%(/I\Y+\
M@:GA5S57:;Y="J$LGAK N][\+F-.L''KXW45)/Q?59NH&M0#49.@XY&PRV^,
M!,-AA'G-D.]+UK#.8!H:XV_JF(_Z(ZC,$M/?&2AT9R>7'.)_7\C:B%_YSH"G
ML@4/B][[LBDB]YA<$8_Y<-LY0!6Y]O3.K7%,,E-[R"4$-+NSR56KP-[4U(.#
M#QB_V)W=B=>S'E<\;AVMO@!10_^OO3WF2$*R^).Y%(;H;^8&O9A(Z6.QX4O,
MWIXEB*+TZJ+QJ#L[..4*MT<RVWD4'!KIT/0LM@Q%&M8O;+>B3%R N55Q6Q&_
ME0EV3 Y"3G@72UA\I2Z+)[9+U9NW<$I& _*&WP05BW]YSJ8#GN#_\GZJCS4%
M=@L\ZVZO^-\,N#*@UX2>U/^;:6%7@>Y*2X6=X%GW6_^V7X,_A0U?] VO@4O\
M;:$JQ58'__DWWN? ':]V9P/E_++U7GX>7LQ504]#PO->#V&_&),Z(0P4CPLF
M7J8A_.H5ESDI[EG#<M 9QQ.G<G=VUGIK_CF63E[?!QG*LU^1KKL"KE+V5\ =
M"IJ"Q46_1!H),-P5;BXU7G ?A(:^TYT=R3V#O;KA7XU5KX<%EATZ)5O_52CP
MU<H1*9KP&'?R$@ZC5.H-_Z2ND"PI!&486SZ68TB](OMWSAM(5#FLM85):U!H
M']S>7XR^_;+GR>"),F2F?L^YE^W-M V5<;H\&9#@_V9T1&]R&2/B%O35\<0T
MR'K"[;>>H&-FA*IC2<%_0LQW6=7U'\P$_$M8I:SJ-RO5\/I-/T\> )%U16Q*
MLHF]M0Y,++AZ<YD!F===%@+K+A.-BF/'(Y;_?:674:V_M#)TD?&<&M$?R<4J
MGGE+7*X9R[CZH_7JP4%WUC\H#GIWOXN7PZ(S&T]5I[<6T\5^C,-^X Z+=)7=
MK.CPH,=AC4]M4)$87B[XUO]\X^8,P=<JW8"LPJSU=/9XC?[4Q<MJ;/<CR+0'
M.P0)J,]DSG5ZH=2>,T_G?%5]OWTZ1*+!2A\\YY6+8T/I):[?&P+/!SXBXX'_
M($%C#LEU0W=Q>S+Z [\<M2%IOQR\[,"\ZR7ZD\V>7_/L75SHB(['?VHAXY2H
MJ]_8;M9?L5HG=D)MJ..QJKAK^8D]P7:CUGPX;A[V.@4A%$(__$0N&GK2,@/E
M\E^!,<NRM#">"S.$_(/E! B&H4D]DYI70P7EC>>$W\:3"M')=K'3VLJFV.33
M^-=RVMB0&&CI-[\O/X=(R 7++CAY'2BWRU2-B]4'T3*>V?]\V_-?9RKE:Y52
MOAC1VF<MN_!CQR'KYA#>.6O@ _DC;J'D,OY@BWR>94-AMK/BCU6J%.XCZ^U<
MP]X350_P'W@ 2!VX[[D1;U.W_%1'U3'?R9;X&7I5]DVX7HL?#/E6'&8-:+/@
M6#1[A>IT@6C1>WM CRQ=9_K4G@6=Q\V>AI?]ALJ?]4>N^\7^A;>7V%ISUS;L
MT;@@ZO W$:$I5>YJMX:Q*)4J^4(X:GV,[4S+&E^)/<LKL>="D*/QQZ]73R?M
M9[@7O,7L&:7OTU4$.DC0!39?X4.1-#)CS554?;3[FR183>$2.SD)CW-,H<F\
M#C(38C:2Y5K65<"QZCJ$>4Q)AEG5, 4FZ((-D#"<3(V7FC(8E!T))X_'V$S_
M1D:Z=H%TI;0WB>K; IVX><?%?9Y/*-QK9IH=ZZ_"^FPLUE\P;I7GI\O^T>_#
M>]?%Q2U@_2A;ENA>X7+&K^P7E\2WFV?\!=32S Z EA87_3?3G.?8<\',(.F,
MHI($/)QBBH!-8XSP+REW"+H'21$_96J:E;.'+R$*&0C/3)&@Z0Q:R*C.:V>
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M30!U*%"5^R\:Q"8A&\E;:9(;P55.K-%C\%5\-5_:P!6M5!N3H&1KQT4;Y*)
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M&E:LNCD!$0)%J,*^ZA+A:L$(DTN=B)&"D$A5-Q4[_)^Y*,YW-.?N>S=""CD
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M51D)RD"0=?_5AJI]M0%/^F?(A+.EH.:F('S5O_T2Z#\BFV]X+^-BSO1O<3&
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M\/(5?6C0%7X[UT"LC/F3"KNC-A7"KA\P* T?WFV.<1<8(9CHHK DY:7E!/P
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MIJ0@3(DML_D1=BDR4BK 6<@W.&^;,'% #&69%._ L6'.F14(3Y& TT0C7[4
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M^=#C0>)^VJJ>+&L!D#S\C)UB*Y2&D,X+19#B5=S)L!;%.60-OI^^<<F@6)P
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MRY>%;+:4&=FAN *O)$45EZJRAF5-K3_OVNT32/R76]O;6,/X,!_HM3A3K^8
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M  !I;6%G95\P,#,N:G!G4$L! A0#%     @ 2%^#7+!<(O?>#@  >ZT  !$
M             ( !5TT  '-B9FTM,C R-3$R,S$N>'-D4$L! A0#%     @
M2%^#7!)Q(XL.%   )P4! !4              ( !9%P  '-B9FTM,C R-3$R
M,S%?8V%L+GAM;%!+ 0(4 Q0    ( $A?@UQ.3!:G&B,  .,= @ 5
M      "  :5P  !S8F9M+3(P,C4Q,C,Q7V1E9BYX;6Q02P$"% ,4    " !(
M7X-<[TSX]#!@  !ADP4 %0              @ 'RDP  <V)F;2TR,#(U,3(S
M,5]L86(N>&UL4$L! A0#%     @ 2%^#7+VU$$IR2   GJ<$ !4
M     ( !5?0  '-B9FTM,C R-3$R,S%?<')E+GAM;%!+ 0(4 Q0    ( $A?
M@US7$/!K0P,  ',0   3              "  ?H\ 0!S=6YS:&EN95]E>#(S
M,#$N:'1M4$L! A0#%     @ 2%^#7 V_.YW/ @  R0X  !,
M ( !;D ! '-U;G-H:6YE7V5X,C,P,BYH=&U02P$"% ,4    " !(7X-<=!X%
M4CT'  #M*   $P              @ %N0P$ <W5N<VAI;F5?97@S,3 Q+FAT
M;5!+ 0(4 Q0    ( $A?@USS/GI=-0<  .HH   3              "  =Q*
M 0!S=6YS:&EN95]E>#,Q,#(N:'1M4$L! A0#%     @ 2%^#7+/!N6<#!
MU!,  !,              ( !0E(! '-U;G-H:6YE7V5X,S(P,2YH=&U02P$"
M% ,4    " !(7X-<Z3<U64G@ 0 =>1  &               @ %V5@$ <W5N
K<VAI;F5?:3$P:RTQ,C,Q,C4N:'1M4$L%!@     -  T 3 ,  /4V P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>sunshine_i10k-123125_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:SBFM="http://sunshinebiopharma.com/20251231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sbfm-20251231.xsd" xlink:type="simple"/>
    <context id="From2025-01-01to2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-04-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2026-04-02</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_ComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_LicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">SBFM:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WebsiteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">SBFM:WebsiteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-192022-10-20_custom_NoraPharmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">SBFM:NoraPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-19</startDate>
            <endDate>2022-10-20</endDate>
        </period>
    </context>
    <context id="AsOf2022-10-20_custom_NoraPharmaMember_custom_MalekChamounMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SBFM:MalekChamounMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">SBFM:NoraPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-20</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_NoraPharmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">SBFM:NoraPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-04-212024-04-22_custom_NoraPharmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">SBFM:NoraPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-21</startDate>
            <endDate>2024-04-22</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_NoraPharmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">SBFM:NoraPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_FinishedGoodsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:FinishedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_FinishedGoodsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:FinishedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_ProfessionalAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:ProfessionalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ProfessionalAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:ProfessionalAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_OtherAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:OtherAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_OtherAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:OtherAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WholesalersFeesAndDiscountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:WholesalersFeesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WholesalersFeesAndDiscountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:WholesalersFeesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_InventoryAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:InventoryAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_InventoryAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:InventoryAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_FreightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:FreightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_FreightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">SBFM:FreightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-02-072024-02-08_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-07</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-08_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-08</instant>
        </period>
    </context>
    <context id="From2024-02-142024-02-15_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-14</startDate>
            <endDate>2024-02-15</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PreFundedWarrants2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SBFM:PreFundedWarrants2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-03-032024-03-04_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-03</startDate>
            <endDate>2024-03-04</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-04_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-04</instant>
        </period>
    </context>
    <context id="From2024-04-012024-04-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-05-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="From2024-08-152024-08-16_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-16</endDate>
        </period>
    </context>
    <context id="From2024-09-012024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-08-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-08-31_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="From2024-09-012024-09-30_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-08-31_custom_SeriesBWarrantsMember614656125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="From2024-09-012024-09-30_custom_SeriesBWarrantsMember614656125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-11-012024-11-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="From2024-12-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-11-012024-11-30_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="From2024-12-012024-12-31_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-11-012024-11-30_custom_SeriesBWarrantsMember614656125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="From2024-12-012024-12-31_custom_SeriesBWarrantsMember614656125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-022025-01-03_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-03</endDate>
        </period>
    </context>
    <context id="From2025-01-022025-01-03_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-03</endDate>
        </period>
    </context>
    <context id="From2025-01-022025-01-03_custom_SeriesBWarrantsMember614656140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-03</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-04-02_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-02</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-04-02_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-02</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-04-02_custom_SeriesBWarrantsMember614656140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-02</endDate>
        </period>
    </context>
    <context id="From2025-04-012025-04-03_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SBFM:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-03</endDate>
        </period>
    </context>
    <context id="From2025-10-152025-10-16_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-15</startDate>
            <endDate>2025-10-16</endDate>
        </period>
    </context>
    <context id="From2025-10-152025-10-16_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-15</startDate>
            <endDate>2025-10-16</endDate>
        </period>
    </context>
    <context id="From2025-10-152025-10-16_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SBFM:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-15</startDate>
            <endDate>2025-10-16</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TradeableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:TradeableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_TradeableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:TradeableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PreFunded2022WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PreFunded2022WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_InvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:InvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_InvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:InvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_AprilWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:AprilWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_AprilWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:AprilWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_MayPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:MayPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_MayPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:MayPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_MayInvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:MayInvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_MayInvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:MayInvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PreFunded2024WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2024WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PreFunded2024WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2024WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PreFunded2025WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2025WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PreFunded2025WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:PreFunded2025WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-02-102024-02-11_custom_AprilWarrantsAndMayInvestorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:AprilWarrantsAndMayInvestorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-10</startDate>
            <endDate>2024-02-11</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TradeableWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:TradeableWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_TradeableWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:TradeableWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_InvestorWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:InvestorWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_InvestorWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:InvestorWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesBWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesBWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesBWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">SBFM:SeriesBWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_AdvanomicsCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SBFM:AdvanomicsCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AdvanomicsCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SBFM:AdvanomicsCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001402328</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Segment">
        <measure>SBFM:Segment</measure>
    </unit>
    <unit id="CAD">
        <measure>iso4217:CAD</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-01-01to2025-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2025-01-01to2025-12-31" id="Fact000004">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-01-01to2025-12-31" id="Fact000005">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2025-01-01to2025-12-31" id="Fact000006">0001402328</dei:EntityCentralIndexKey>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="xdx2ixbrl1167"
      unitRef="USD">8445713</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="xdx2ixbrl1169"
      unitRef="USD">6967294</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="xdx2ixbrl1203"
      unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="xdx2ixbrl1205"
      unitRef="Segment">1</us-gaap:NumberOfReportableSegments>
    <dei:DocumentType contextRef="From2025-01-01to2025-12-31" id="Fact000015">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2025-01-01to2025-12-31" id="Fact000016">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-01-01to2025-12-31" id="Fact000017">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-01-01to2025-12-31" id="Fact000018">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="From2025-01-01to2025-12-31" id="Fact000019">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2025-01-01to2025-12-31" id="Fact000020">001-41282</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-01-01to2025-12-31" id="Fact000021">SUNSHINE BIOPHARMA INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-01-01to2025-12-31" id="Fact000022">CO</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-01-01to2025-12-31" id="Fact000023">20-5566275</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-01-01to2025-12-31" id="Fact000024">333 Las Olas Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-01-01to2025-12-31" id="Fact000025">CU4 Suite 433</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-01-01to2025-12-31" id="Fact000026">Fort Lauderdale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-01-01to2025-12-31" id="Fact000027">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-01-01to2025-12-31" id="Fact000028">33301</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-01-01to2025-12-31" id="Fact000029">954</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-01-01to2025-12-31" id="Fact000030">330-0684</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="Fact000031">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:Security12bTitle
      contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember"
      id="Fact000033">Warrants</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="Fact000034">SBFM</dei:TradingSymbol>
    <dei:TradingSymbol
      contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember"
      id="Fact000036">SBFMW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="Fact000037">NASDAQ</dei:SecurityExchangeName>
    <dei:SecurityExchangeName
      contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember"
      id="Fact000039">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2025-01-01to2025-12-31" id="Fact000040">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2025-01-01to2025-12-31" id="Fact000041">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2025-01-01to2025-12-31" id="Fact000042">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-01-01to2025-12-31" id="Fact000043">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2025-01-01to2025-12-31" id="Fact000044">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-01-01to2025-12-31" id="Fact000045">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-01-01to2025-12-31" id="Fact000046">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2025-01-01to2025-12-31" id="Fact000047">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2025-01-01to2025-12-31" id="Fact000048">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2025-01-01to2025-12-31" id="Fact000049">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000050"
      unitRef="USD">7061719</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-04-02"
      decimals="INF"
      id="Fact000051"
      unitRef="Shares">4905945</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000057">&lt;b style="display: none"&gt;&#160;Risk&lt;/b&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Our Company recognizes the critical importance
of cybersecurity in protecting our sensitive data, intellectual property, and the personal information of our employees and partners.
We have &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zsPPz5n79fdb"&gt;implemented&lt;/span&gt; a comprehensive cybersecurity risk management program that includes the following key components:&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;b&gt;Risk Assessment and Management&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250101__20251231_zepDcJYwf1hf"&gt;We conduct regular risk assessments to identify
and evaluate potential cybersecurity threats and vulnerabilities. Our risk management framework is aligned with industry standards such
as the NIST Cybersecurity Framework (CSF) and ISO 27001. We continuously monitor and update our cybersecurity measures to address emerging
threats and ensure the protection of our assets.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000058">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000059">We conduct regular risk assessments to identify
and evaluate potential cybersecurity threats and vulnerabilities. Our risk management framework is aligned with industry standards such
as the NIST Cybersecurity Framework (CSF) and ISO 27001. We continuously monitor and update our cybersecurity measures to address emerging
threats and ensure the protection of our assets.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000086">&lt;b&gt;Cybersecurity Governance&lt;/b&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20250101__20251231_zSY3mF8ioZb"&gt;Our management oversees our cybersecurity risk
management efforts. Our &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20250101__20251231_zAcZ9hvcJQGk"&gt;senior management team&lt;/span&gt; is actively involved in cybersecurity policies, procedures and strategy development.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"&gt;&lt;b&gt;Incident Response and Recovery&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_c20250101__20251231_zZ9H5PnVQzB7"&gt;We have a robust incident response plan in place
to quickly detect, respond to, and recover from cybersecurity incidents. We collaborate with external cybersecurity experts and law enforcement
agencies to enhance our incident response capabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"&gt;&lt;b&gt;Employee Training and Awareness&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;We provide ongoing cybersecurity training and awareness
programs for all employees to promote a culture of security. Our training programs cover topics such as phishing prevention, secure data
handling, and recognizing potential cyber threats.&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;b&gt;Third-Party Risk Management&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;We assess the cybersecurity practices of our &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250101__20251231_zIU1Zot8w70k"&gt;third-party&lt;/span&gt;
vendors and partners to ensure they meet our security standards. Our contracts with third parties include provisions for cybersecurity
requirements and incident reporting.&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;b&gt;Regulatory Compliance&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;We comply with all relevant cybersecurity regulations
and standards, including the Health Insurance Portability and Accountability Act (HIPAA) and the General Data Protection Regulation (GDPR).
We regularly review and update our cybersecurity policies and procedures to ensure compliance with evolving regulatory requirements.&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;b&gt;Investments in Cybersecurity&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;We continuously invest in advanced cybersecurity
technologies, including threat detection and prevention systems, encryption, and secure access controls. Our cybersecurity is part of
our overall budget which is reviewed and approved by our board of directors to ensure adequate resources are allocated to protect our
assets.&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;b&gt;Cybersecurity Incidents&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_c20250101__20251231_zlCoAR0PPWvl"&gt;During the past fiscal year, we experienced &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20250101__20251231_zVGK4CuTdkki"&gt;no
cybersecurity incidents&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000087">Our management oversees our cybersecurity risk
management efforts. Our &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20250101__20251231_zAcZ9hvcJQGk"&gt;senior management team&lt;/span&gt; is actively involved in cybersecurity policies, procedures and strategy development.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="From2025-01-01to2025-12-31" id="Fact000088">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000089">We have a robust incident response plan in place
to quickly detect, respond to, and recover from cybersecurity incidents. We collaborate with external cybersecurity experts and law enforcement
agencies to enhance our incident response capabilities.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000090">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000091">During the past fiscal year, we experienced &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20250101__20251231_zVGK4CuTdkki"&gt;no
cybersecurity incidents&lt;/span&gt;.</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="From2025-01-01to2025-12-31" id="Fact000092">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <dei:AuditorName contextRef="From2025-01-01to2025-12-31" id="Fact000093">M&amp;K CPAS, PLLC</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2025-01-01to2025-12-31" id="Fact000094">The Woodlands, TX</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="From2025-01-01to2025-12-31" id="Fact000095">2738</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2024-01-012024-12-31" id="Fact000096">Bush &amp; Associates CPA LLC</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-01-012024-12-31" id="Fact000097">Henderson, Nevada</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="From2024-01-012024-12-31" id="Fact000098">6797</dei:AuditorFirmId>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000106"
      unitRef="USD">9123308</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000107"
      unitRef="USD">9686529</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000109"
      unitRef="USD">3459864</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000110"
      unitRef="USD">3868418</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000112"
      unitRef="USD">13472025</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000113"
      unitRef="USD">11278105</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000115"
      unitRef="USD">798384</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000116"
      unitRef="USD">1133297</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000118"
      unitRef="USD">26853581</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000119"
      unitRef="USD">25966349</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000124"
      unitRef="USD">557370</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000125"
      unitRef="USD">546055</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000127"
      unitRef="USD">1889370</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000128"
      unitRef="USD">3019717</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000130"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000131"
      unitRef="USD">92234</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000133"
      unitRef="USD">778846</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000134"
      unitRef="USD">936037</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000136"
      unitRef="USD">3225586</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000137"
      unitRef="USD">4594043</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000139"
      unitRef="USD">30079167</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000140"
      unitRef="USD">30560392</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000148"
      unitRef="USD">5664212</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000149"
      unitRef="USD">5543085</us-gaap:AccountsPayableCurrent>
    <SBFM:EarnoutPayable
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000151"
      unitRef="USD">295797</SBFM:EarnoutPayable>
    <SBFM:EarnoutPayable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000152"
      unitRef="USD">295797</SBFM:EarnoutPayable>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000154"
      unitRef="USD">268276</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000155"
      unitRef="USD">268276</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000157"
      unitRef="USD">215637</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000158"
      unitRef="USD">207756</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000160"
      unitRef="USD">6443922</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000161"
      unitRef="USD">6314914</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000166"
      unitRef="USD">596785</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000167"
      unitRef="USD">744724</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000169"
      unitRef="USD">596785</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000170"
      unitRef="USD">744724</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000172"
      unitRef="USD">7040707</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000173"
      unitRef="USD">7059638</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000181"
      unitRef="USDPShares">0.10</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000183"
      unitRef="USDPShares">0.10</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000185"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000187"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000189"
      unitRef="Shares">130000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000191"
      unitRef="Shares">130000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000193"
      unitRef="Shares">130000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000195"
      unitRef="Shares">130000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000178"
      unitRef="USD">13000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000179"
      unitRef="USD">13000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000200"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000202"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000204"
      unitRef="Shares">3000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000206"
      unitRef="Shares">3000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000208"
      unitRef="Shares">4905945</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000210"
      unitRef="Shares">4905945</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000212"
      unitRef="Shares">2580098</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000214"
      unitRef="Shares">2580098</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000197"
      unitRef="USD">4905</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000198"
      unitRef="USD">2580</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000216"
      unitRef="USD">98100990</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000217"
      unitRef="USD">93354907</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000219"
      unitRef="USD">-65309</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000220"
      unitRef="USD">-829959</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000222"
      unitRef="USD">-75015126</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000223"
      unitRef="USD">-69039774</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000225"
      unitRef="USD">23038460</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000226"
      unitRef="USD">23500754</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000228"
      unitRef="USD">30079167</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000229"
      unitRef="USD">30560392</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000231"
      unitRef="USD">36305891</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000232"
      unitRef="USD">34874283</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000234"
      unitRef="USD">24050214</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000235"
      unitRef="USD">24204489</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000237"
      unitRef="USD">12255677</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000238"
      unitRef="USD">10669794</us-gaap:GrossProfit>
    <us-gaap:ProfessionalFees
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000243"
      unitRef="USD">698083</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000244"
      unitRef="USD">967614</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000246"
      unitRef="USD">1571692</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000247"
      unitRef="USD">925188</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000249"
      unitRef="USD">400000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000250"
      unitRef="USD">400000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000252"
      unitRef="USD">1748247</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000253"
      unitRef="USD">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:LegalFees
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000255"
      unitRef="USD">385142</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000256"
      unitRef="USD">875698</us-gaap:LegalFees>
    <us-gaap:MarketingExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000258"
      unitRef="USD">1143929</us-gaap:MarketingExpense>
    <us-gaap:MarketingExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000259"
      unitRef="USD">940278</us-gaap:MarketingExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000261"
      unitRef="USD">3864584</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000262"
      unitRef="USD">3110026</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000264"
      unitRef="USD">604308</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000265"
      unitRef="USD">933902</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SalariesAndWages
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000267"
      unitRef="USD">7265346</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000268"
      unitRef="USD">7718677</us-gaap:SalariesAndWages>
    <SBFM:Taxes
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000270"
      unitRef="USD">469305</SBFM:Taxes>
    <SBFM:Taxes
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000271"
      unitRef="USD">387005</SBFM:Taxes>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000273"
      unitRef="USD">332070</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000274"
      unitRef="USD">223527</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000276"
      unitRef="USD">18482706</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000277"
      unitRef="USD">16481915</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000279"
      unitRef="USD">-6227029</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000280"
      unitRef="USD">-5812121</us-gaap:OperatingIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000285"
      unitRef="USD">2642</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000286"
      unitRef="USD">-44082</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestIncomeDebtSecuritiesOperating
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000288"
      unitRef="USD">280901</us-gaap:InterestIncomeDebtSecuritiesOperating>
    <us-gaap:InterestIncomeDebtSecuritiesOperating
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000289"
      unitRef="USD">496003</us-gaap:InterestIncomeDebtSecuritiesOperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000291"
      unitRef="USD">-0</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000292"
      unitRef="USD">8774</us-gaap:InterestExpenseNonoperating>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000294"
      unitRef="USD">-10257</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:GainsLossesOnSalesOfAssets
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000295"
      unitRef="USD">0</us-gaap:GainsLossesOnSalesOfAssets>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000297"
      unitRef="USD">273286</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000298"
      unitRef="USD">443147</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000300"
      unitRef="USD">-5953743</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000301"
      unitRef="USD">-5368974</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000303"
      unitRef="USD">21609</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000304"
      unitRef="USD">-234858</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000306"
      unitRef="USD">-5975352</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000307"
      unitRef="USD">-5134116</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000312"
      unitRef="USD">764650</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000313"
      unitRef="USD">-1526064</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000315"
      unitRef="USD">-5210702</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000316"
      unitRef="USD">-6660180</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000318"
      unitRef="USDPShares">-1.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000320"
      unitRef="USDPShares">-7.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000322"
      unitRef="Shares">4157086</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000324"
      unitRef="Shares">701749</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000329"
      unitRef="USD">-5975352</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000330"
      unitRef="USD">-5134116</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000335"
      unitRef="USD">332070</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000336"
      unitRef="USD">223527</us-gaap:DepreciationDepletionAndAmortization>
    <SBFM:AssetDisposition
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000338"
      unitRef="USD">10257</SBFM:AssetDisposition>
    <SBFM:AssetDisposition
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000339"
      unitRef="USD">0</SBFM:AssetDisposition>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000341"
      unitRef="USD">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000342"
      unitRef="USD">12000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000344"
      unitRef="USD">1748247</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000345"
      unitRef="USD">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000347"
      unitRef="USD">116173</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000348"
      unitRef="USD">2338195</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000350"
      unitRef="USD">1637277</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000351"
      unitRef="USD">6006864</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000353"
      unitRef="USD">-480798</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000354"
      unitRef="USD">207167</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <SBFM:IncreaseDecreaseInRightOfUseAsset
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000356"
      unitRef="USD">-203836</SBFM:IncreaseDecreaseInRightOfUseAsset>
    <SBFM:IncreaseDecreaseInRightOfUseAsset
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000357"
      unitRef="USD">341534</SBFM:IncreaseDecreaseInRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000359"
      unitRef="USD">-189956</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000360"
      unitRef="USD">3983749</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000362"
      unitRef="USD">-187523</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000363"
      unitRef="USD">347935</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <SBFM:IncreaseDecreaseInEarnoutPayable
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000365"
      unitRef="USD">0</SBFM:IncreaseDecreaseInEarnoutPayable>
    <SBFM:IncreaseDecreaseInEarnoutPayable
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000366"
      unitRef="USD">-2252034</SBFM:IncreaseDecreaseInEarnoutPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000368"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000369"
      unitRef="USD">-812080</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000371"
      unitRef="USD">-5331073</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000372"
      unitRef="USD">-12524779</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000377"
      unitRef="USD">661815</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000378"
      unitRef="USD">322258</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000380"
      unitRef="USD">174491</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000381"
      unitRef="USD">1657055</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000383"
      unitRef="USD">-836306</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000384"
      unitRef="USD">-1979313</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000389"
      unitRef="USD">1828596</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000390"
      unitRef="USD">8522411</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000392"
      unitRef="USD">2919812</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000393"
      unitRef="USD">3558812</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000395"
      unitRef="USD">-0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000396"
      unitRef="USD">3139651</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000398"
      unitRef="USD">4748408</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000399"
      unitRef="USD">8941572</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000401"
      unitRef="USD">9686529</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000402"
      unitRef="USD">16292347</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000404"
      unitRef="USD">-1418971</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000405"
      unitRef="USD">-5562520</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000407"
      unitRef="USD">855750</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000408"
      unitRef="USD">-1043298</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000410"
      unitRef="USD">9123308</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000411"
      unitRef="USD">9686529</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000416"
      unitRef="USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000417"
      unitRef="USD">582483</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000419"
      unitRef="USD">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000420"
      unitRef="USD">8126</us-gaap:InterestPaidNet>
    <SBFM:StockIssuedForServices
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000422"
      unitRef="USD">0</SBFM:StockIssuedForServices>
    <SBFM:StockIssuedForServices
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000423"
      unitRef="USD">12000</SBFM:StockIssuedForServices>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000432"
      unitRef="Shares">2580098</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000425"
      unitRef="USD">2580</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000426"
      unitRef="USD">93354907</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000434"
      unitRef="Shares">130000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000427"
      unitRef="USD">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      id="Fact000428"
      unitRef="USD">-829959</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000429"
      unitRef="USD">-69039774</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000430"
      unitRef="USD">23500754</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000443"
      unitRef="Shares">1137443</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000436"
      unitRef="USD">1137</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000437"
      unitRef="USD">2918675</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000441"
      unitRef="USD">2919812</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000452"
      unitRef="Shares">1188404</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000445"
      unitRef="USD">1188</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000446"
      unitRef="USD">1827408</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000450"
      unitRef="USD">1828596</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2025-01-012025-12-31_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      id="Fact000457"
      unitRef="USD">764650</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000458"
      unitRef="USD">-5975352</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000459"
      unitRef="USD">-5210702</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000468"
      unitRef="Shares">4905945</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000461"
      unitRef="USD">4905</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000462"
      unitRef="USD">98100990</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000470"
      unitRef="Shares">130000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000463"
      unitRef="USD">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      id="Fact000464"
      unitRef="USD">-65309</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000465"
      unitRef="USD">-75015126</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000466"
      unitRef="USD">23038460</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000479"
      unitRef="Shares">14012</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000472"
      unitRef="USD">14</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000473"
      unitRef="USD">84415900</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000481"
      unitRef="Shares">10000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000474"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      id="Fact000475"
      unitRef="USD">696105</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000476"
      unitRef="USD">-63905658</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000477"
      unitRef="USD">21207361</us-gaap:StockholdersEquity>
    <SBFM:PreferredStockIssuedToRelatedPartyShares
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000490"
      unitRef="Shares">120000</SBFM:PreferredStockIssuedToRelatedPartyShares>
    <SBFM:PreferredStockIssuedToRelatedParty
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000485"
      unitRef="USD">12000</SBFM:PreferredStockIssuedToRelatedParty>
    <SBFM:PreferredStockIssuedToRelatedParty
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000488"
      unitRef="USD">12000</SBFM:PreferredStockIssuedToRelatedParty>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000499"
      unitRef="Shares">13214</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000492"
      unitRef="USD">13</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000493"
      unitRef="USD">8522398</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000497"
      unitRef="USD">8522411</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000508"
      unitRef="Shares">2552872</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000501"
      unitRef="USD">2554</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000502"
      unitRef="USD">3556260</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000506"
      unitRef="USD">3558812</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <SBFM:RepurchaseOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000511"
      unitRef="USD">3139651</SBFM:RepurchaseOfWarrants>
    <SBFM:RepurchaseOfWarrants
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000515"
      unitRef="USD">3139651</SBFM:RepurchaseOfWarrants>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      id="Fact000520"
      unitRef="USD">-1526064</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000521"
      unitRef="USD">-5134116</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000522"
      unitRef="USD">-6660180</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000531"
      unitRef="Shares">2580098</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000524"
      unitRef="USD">2580</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000525"
      unitRef="USD">93354907</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000533"
      unitRef="Shares">130000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000526"
      unitRef="USD">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_ComprehensiveIncomeMember"
      decimals="0"
      id="Fact000527"
      unitRef="USD">-829959</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000528"
      unitRef="USD">-69039774</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000529"
      unitRef="USD">23500754</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000535">&lt;p id="xdx_804_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ztlJvqQy1i1i" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 1 &#x2013;
&lt;span id="xdx_826_zLbKaT2LDpsk"&gt;Description of Business&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company was incorporated under the name Mountain
West Business Solutions, Inc. on August 31, 2006, in the State of Colorado. Effective October 15, 2009, the Company acquired Sunshine
Biopharma Inc. in a transaction classified as a reverse acquisition. Upon completion of the reverse acquisition transaction, the Company
changed its name to Sunshine Biopharma Inc. and began operating as a pharmaceutical company.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Sunshine Biopharma has two wholly owned subsidiaries:
(i) Nora Pharma Inc. (&#x201c;Nora Pharma&#x201d;), a Canadian corporation with a portfolio of pharmaceutical products consisting of 71
generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc. (&#x201c;Sunshine Canada&#x201d;), a Canadian
corporation which develops and sells nonprescription, over-the-counter (&#x201c;OTC&#x201d;) supplements. The Company operates the two subsidiaries
as a single business segment. Sales of the OTC supplements represent less than 3% of the Company&#x2019;s total annual sales.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company is not subject to material customer
concentration risks as it sells its products directly to pharmacies in several Canadian Provinces. However, Provincial governments in
Canada reimburse patients for their prescription drug expenditures to various degrees under drug reimbursement programs, making generic
drugs prices highly dependent on government policies which may change over time. The most recent negotiations between the pan-Canadian
Pharmaceutical Alliance (&#x201c;pCPA&#x201d;), the entity that negotiates drug prices on behalf of the government, and the Canadian Generic
Pharmaceutical Association (&#x201c;CGPA&#x201d;) resulted in updated generic pricing for certain products which took effect on October
1, 2023. The updated prices are valid for three years and the agreement contains an option to extend for an additional two years. On February
10, 2024, the Canadian federal government joined the generic drug reimbursement program as a payor under the Pharmacare Act. This development
further strengthened the Canadian generic drug market, which is the Company&#x2019;s current focus.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;In addition, the Company is engaged in the development
of the following proprietary drugs:&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;K1.1 mRNA, a lipid nano-particle (LNP) targeted for liver cancer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;SBFM-PL4, a protease inhibitor for treatment of Coronavirus infections&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000541">&lt;p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_zgD5rf74uufd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 2 &#x2013; &lt;span id="xdx_822_zBMN69LnS9Te"&gt;Summary
of Significant Accounting Policies&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;This summary of significant accounting policies
is presented to assist the reader in understanding the Company's financial statements. The consolidated financial statements and notes
are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform
to Generally Accepted Accounting Principles in the United States (&#x201c;GAAP&#x201d;) and have been consistently applied in the preparation
of the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zT1F7GpEIqY4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_861_z1kzjesDd906"&gt;PRINCIPLES OF CONSOLIDATION&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
include the accounts of the Company and its subsidiaries, Nora Pharma Inc. and Sunshine Biopharma Canada Inc., both wholly owned. All
intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zyHfdlWNtT88" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_866_zImZqZi6xGl7"&gt;USE OF ESTIMATES&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation
of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic
environment has increased the degree of uncertainty inherent in these estimates and assumptions.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ReceivablesPolicyTextBlock_zYKL1sSaiBga" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_86C_zJD4NE4ec4Q4"&gt;TRADE ACCOUNTS RECEIVABLE AND
ALLOWANCE FOR DOUBTFUL ACCOUNTS&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Trade accounts receivable are stated at net realizable
value. The majority of customers are not extended credit and therefore time to maturity for receivables is short. On a periodic basis,
management evaluates its trade accounts receivable and determines whether to record an allowance for doubtful accounts. Management analysis for the periods ended December 31, 2024 and 2025 determined
that no allowance for doubtful accounts needed to be recorded. A receivable is considered past
due if the Company has not received payments based on agreed-upon terms. The Company generally does not require any security or collateral
to support its receivables. As of December 31, 2025 and 2024, the balances of accounts receivable were $&lt;span id="xdx_90E_eus-gaap--AccountsReceivableNetCurrent_iI_c20251231_zxRvzZJX0ytg" title="Accounts receivable"&gt;3,459,864&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--AccountsReceivableNetCurrent_iI_c20241231_zP5gVULZNYQ9" title="Accounts receivable"&gt;3,868,418&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--InventoryPolicyTextBlock_zhKeMppuF1H9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_868_zZcWtBQ8Dp5j"&gt;INVENTORY VALUATION&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;The
Company&#x2019;s inventory is comprised of finished goods. Inventory is valued at the lower of cost and net realizable value. Cost is
determined using the first in, first out method. Net realizable value is the estimated selling price in the ordinary course of business,
less the costs necessary to make the sale. The cost of inventory includes the purchase price and other costs directly attributable to
the acquisition of the finished goods. The Company regularly reviews inventories to determine if the carrying value exceeds net realizable
value and, when determined necessary, an allowance to reduce the carrying value to net realizable value is recorded. The net realizable value is calculated based
on a combination of factors, including (i) aging, (ii) historical sell-through patterns, and (iii) product-specific considerations. Write-downs
are recorded within cost of goods sold and are not subsequently reversed. As of December 31,
2025 and 2024, there were allowances for obsolescence of $&lt;span id="xdx_90F_eus-gaap--InventoryValuationReserves_iI_c20251231_zn3STckJuycl" title="Reserve for obsolescence"&gt;475,153&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--InventoryValuationReserves_iI_do_c20241231_z4tfq3nPi0A1" title="Reserve for obsolescence"&gt;0&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zqx7JbOvORg9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_867_zvRq9k5Pfwj4"&gt;CASH AND CASH EQUIVALENTS&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;For the Balance Sheets and Statements of Cash
Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance
of $&lt;span id="xdx_90E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_c20251231_zZ32dlvJqe14"&gt;9,123,308&lt;/span&gt;
and $&lt;span id="xdx_903_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_c20241231_zMseaXCo4B98"&gt;9,686,529&lt;/span&gt;
as of December 31, 2025 and December 31, 2024, respectively. At times such cash balances may be in excess of the FDIC limit of $&lt;span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20251231_zEg0oLiqljR6"&gt;250,000&lt;/span&gt;
in the U.S. or the $&lt;span id="xdx_902_ecustom--CashCanadaInsuredAmount_iI_uCAD_c20251231_zrEqCn8XOX4b" title="Cash insured in Canada (CAD)"&gt;100,000&lt;/span&gt; CAD (approximately $&lt;span id="xdx_906_ecustom--CashCanadaInsuredAmount_iI_uUSD_c20251231_zfQHCvrRj3M6" title="Cash insured in Canada (USD)"&gt;73,000&lt;/span&gt; USD) limit in Canada. At December 31, 2025, the Company had deposits totaling
approximately $7 million in the U.S and $2 million in Canada.&lt;/p&gt;


&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zsuJ7ILjYGJe" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_869_z7AlXLRHR128"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment are reviewed for recoverability
when events or changes in circumstances indicate that its carrying value may exceed future undiscounted cash inflows. As of December 31,
2025 and 2024, the Company had not identified any such impairment. Repairs and maintenance are charged to operations when incurred and
improvements and renewals are capitalized.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment are stated at cost. Depreciation
is calculated according to the following methods at the following annual rates and period for financial reporting purposes and accelerated
methods for tax purposes. Their estimated useful lives are as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--PropertyPlantAndEquipmentUsefulLivesTableTextBlock_zfpByWkhn958" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Estimated lives)"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span id="xdx_8BD_z9C9GBNH5mFa" style="display: none"&gt;Schedule of estimated useful lives&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="width: 28%; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Office Equipment:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 49%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Straight-line and Declining balance method&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 23%; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zws3TJ6m2Zq8" title="Property and equipment estimated useful lives"&gt;5-7 Years / 20%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Computer Equipment:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Declining balance method&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z3voB4yZCgM1" title="Property and equipment estimated useful lives"&gt;55%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Laboratory Equipment:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Straight-line method&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z8Bu5xz1asmb" title="Property and equipment estimated useful lives"&gt;5 Years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Vehicles:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Straight-line and Declining balance method&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zwa1guchFnc3" title="Property and equipment estimated useful lives"&gt;5 Years / 30%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AC_zRN7iHB7Gs8a" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zAW5triZDyJ4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_86A_zoiXI3c1RV5"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Intangible assets are amortized over their estimated
useful lives according to the following methods at the following annual rates and period:&lt;i&gt;&lt;/i&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock_zwwokJM4aN8b" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Intangible assets)"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span id="xdx_8B8_zXYTAxBJiTFk" style="display: none"&gt;Schedule of intangible assets   estimated
useful lives&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="width: 25%; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Licenses:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 50%; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Straight-line method&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 25%; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--IntangibleAssetsEstimatedUsefulLives_c20250101__20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zMExfiVHmH5" title="Intangible asset estimated useful lives"&gt;5 Years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Website:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Declining balance method&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--IntangibleAssetsEstimatedUsefulLives_c20250101__20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_zmGJhForVFM6" title="Intangible asset estimated useful lives"&gt;55%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_zdDRfgKG2d0a" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Intangible assets are tested for recoverability
when events or changes in circumstances indicate that their carrying amount may not be recoverable. The carrying amount of a long-lived
asset is not recoverable when it exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposal.
In such a case, an impairment loss must be recognized and is equivalent to the excess of the carrying amount of a long-lived asset over
its fair value.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--RevenueRecognitionServicesLicensingFees_zFoxoCN8IsL9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_863_zEFf1loBhPih"&gt;INTELLECTUAL PROPERTY RIGHTS
- PATENTS AND LICENSES&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The cost of patents and licenses acquired is capitalized
and is amortized over the remaining life of the patents or licenses.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluates recoverability of identifiable
intangible assets whenever events or changes in circumstances indicate that intangible assets carrying amount may not be recoverable.
Such circumstances include but are not limited to: (i) a significant decrease in the market value of an asset, (ii) a significant adverse
change in the extent or manner in which an asset is used, or (iii) an accumulation of cost significantly in excess of the amount originally
expected for the acquisition of an asset. The Company measures the carrying amount of such assets against the estimated undiscounted future
cash flows associated with it.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zjLUIuWQo3ne" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_861_zHZZKwtmYnd"&gt;BASIC AND DILUTED NET GAIN (LOSS)
PER SHARE&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company computes gain or loss per share in
accordance with &lt;i&gt;ASC 260 &#x2013; Earnings per Share&lt;/i&gt;. ASC 260 requires presentation of both basic and diluted earnings per share
(&#x201c;EPS&#x201d;) on the face of the income statement. Basic net income (loss) per share is calculated by dividing net income (loss)
by the weighted-average common shares outstanding. Diluted net income (loss) per share is calculated by dividing net income (loss) by
the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is
more dilutive. As the Company incurred net losses for the years ended December 31, 2025 and 2024, &lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20250101__20251231_zMgAksl5zuZ8"&gt;&lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20240101__20241231_zVDywucsa3l5"&gt;no&lt;/span&gt;&lt;/span&gt; potentially dilutive securities were
included in the calculation of diluted earnings per share as the impact would have been anti-dilutive. Accordingly, diluted EPS information
is not included in this report.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zE2uzKHkm4ye" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_86A_zQ119tDTcXH3"&gt;INCOME TAXES&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with &lt;i&gt;ASC 740 &#x2013; Income Taxes&lt;/i&gt;,
the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by
applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities
and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities have been adjusted to reflect
changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not
be realized.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company expects to recognize the financial
statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position
in an examination. For tax positions meeting a &#x201c;more-likely-than-not&#x201d; threshold, the amount to be recognized in the financial
statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold,
no financial statement benefit is recognized. As of December 31, 2025, the Company had no uncertain tax positions. The Company recognizes
interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. The Company currently has no
federal or state tax examinations nor has it had any federal or state examinations since its inception. To date, the Company has not incurred
any interest or tax penalties.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;For Canadian and U.S. tax purposes, the Company&#x2019;s
2022 through 2024 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zLvoc9nuCaNi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_860_zAQtqlDLp9Kd"&gt;FUNCTIONAL CURRENCY&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The U.S. dollar is the functional currency of the
Company which is operating in the United States. The functional currency for the Company's Canadian subsidiaries is the Canadian dollar.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company translates its Canadian subsidiaries'
financial statements into U.S. dollars as follows:&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Income statement accounts are translated using the weighted average exchange rate for the period.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company includes translation adjustments from
currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate
component of shareholders&#x2019; equity. There are currently no transactions of a long-term investment nature, nor any gains or losses
from non-U.S. currency transactions.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_z4IY1iD7yuz4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_86E_zVNk6KqUUrP3"&gt;CONCENTRATION OF CREDIT RISKS&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments that potentially subject
the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash
equivalents with high credit quality financial institutions.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zqhSLybT8Yj6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_86F_zMlFgM8LrI46"&gt;FINANCIAL INSTRUMENTS AND FAIR
VALUE OF FINANCIAL INSTRUMENTS&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company applies the provisions of accounting
guidance, &lt;i&gt;ASC 825 &#x2013; Financial Instruments&lt;/i&gt;. ASC 825 requires all entities to disclose the fair value of financial instruments,
both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and
defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between
willing parties. As of December 31, 2025 and 2024, the fair value of cash, accounts receivable and notes receivable, accounts payable,
accrued expenses, and other payables approximated carrying value due to the short maturity of the instruments, quoted market prices or
interest rates which fluctuate with market rates.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company defines fair value as the price that
would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement
date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels
and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement.
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to unobservable inputs (Level 3 measurements).&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Level 1 &#x2013; Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Level 2 &#x2013; Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Level 3 &#x2013; Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The carrying value of financial assets and liabilities
recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring
basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried
and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are
those that are adjusted to fair value each time a financial statement is prepared.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--DebtPolicyTextBlock_zdTevLIoVj79" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_86D_z3bO4ctqItoh"&gt;NOTES PAYABLE&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Borrowings are recognized initially at fair value,
net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of
transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective
interest method. The Company had &lt;span id="xdx_90E_eus-gaap--NotesPayable_iI_do_c20251231_zZlHXYFnQKoc"&gt;&lt;span id="xdx_904_eus-gaap--NotesPayable_iI_do_c20241231_zOTBND7FG1Re"&gt;no&lt;/span&gt;&lt;/span&gt; notes payable as of December 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--RevenueRecognitionPolicyTextBlock_zhVi7YOtMiFg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_86E_zYbxKFVNkQKf"&gt;REVENUE RECOGNITION&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Over 97% of the Company&#x2019;s revenues are derived
from the sale of pharmaceutical products. Pharmaceutical products can only be sold to a specific customer that is either a registered
pharmacy or a registered wholesaler. The Company therefore sells only to customers registered with Health Canada, the Canadian equivalent
of the FDA. Contracts are drawn up between the wholesalers and the Company for all indirect sales. In the case of direct sales to pharmacies,
purchase orders are used instead of contracts. A purchase order, forecast, or other written instructions to purchase any of the Company&#x2019;s
products placed by the customer constitutes an irrevocable offer to purchase. The customer is responsible for ensuring that the terms
of any such order are complete and accurate. The purchase order is only deemed to be accepted when the Company (in its sole discretion)
accepts the purchase order and delivers on the purchase. The acceptance of any purchase order can be full or partial, at the sole discretion
of the Company. No variations to these conditions are binding on the Company unless agreed to in writing between the customer and the
Company.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;No significant judgments are made in connection
with any contracts as the price is already determined, the collection is reasonably assured, and performance obligation is fulfilled when
the customer receives the goods. The Company is not required to apply any specific judgments, estimations, or assumptions to determine
the price of its products.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Taxes assessed by a governmental authority that
are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are
excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has been transferred
to a customer are accounted for as a fulfillment cost and are included in cost of revenues. The amount invoiced for each product is fixed
at the Company&#x2019;s current price list on the date of shipping and known in advance by the customer and does not vary.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company fulfills its performance obligation
when the customer receives the requested products. When the products leave the Company's warehouse, the transport to the customer is insured
and the transfer of ownership to the customer takes place when the customer receives the goods. At this point, the Company issues an invoice
for the products and remits the applicable sales taxes (GST and QST) to the appropriate governmental agency. The revenue is recognized
when the invoice is issued. Unless otherwise agreed to and signed by both parties, payment terms are within 30 days from the date of the
invoice. The collection is reasonably assured because of the nature of the Company&#x2019;s customers. The Company is conducting sales
only in Canada. Prices are listed in Canadian dollars and may vary from one Province or Territory to another within Canada. All products
sold by the Company are labelled and approved for sale in Canada only and are not intended for export outside of Canada.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;In the event of any breach by the Company of any
product warranty (whether by reason of defective materials, production faults or otherwise), the Company&#x2019;s liability is limited
to, at Company&#x2019;s option, (i) replacement of the product(s) in question, or (ii) reimbursement of the purchase price. The Company
carries product liability insurance and is not liable for products&#x2019; failure to comply with the warranty of products if the failure
or damage arises because of the customer&#x2019;s negligence, deliberate damage, misuse or failure to store the products in conditions
per Health Canada specifications. The Company is not liable (whether in contract, in tort or otherwise) for any (i) indirect, special
or consequential loss or damage, or (ii) loss of profit, goodwill, business or revenue (in each case whether direct or indirect). These
conditions also apply to any replacement products supplied by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company warrants to the customer that, at
the time of delivery, the products are compliant with all mandatory quality standards required by applicable regulatory and legal requirements.
In return, the customer is required to warrant to the Company that it holds all relevant permits and approvals required under applicable
laws to purchase, store, distribute, sell and use the Company&#x2019;s products. Visible defects or damages must be reported to the Company
in writing immediately, but no later than five (5) business days after receipt of the products. Hidden defects must be reported to the
Company in writing immediately, but no later than five (5) business days after the customer becomes aware of such defects. The Company
is not be deemed to be in breach of the terms or otherwise liable to customer for any delay in performance or non-performance of its obligations
due to circumstances beyond its control, including but not limited to, acts of God, floods, droughts, earthquakes or other natural disasters,
terrorist attacks, wars, preparations for war, armed conflicts, civil commotions or riots, epidemics or pandemics, fires, strikes, lockouts,
shortages of material or labor, breakdown or damage to machinery or equipment, accidents, any law or governmental order or other regulations
or action taken by a governmental entity, or default of any third party suppliers or provider of services or products, or any causes not
within the Company&#x2019;s control.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_zReBenJzGuG8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_863_zVrQsWh3ZXef"&gt;LEASES&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes and measures its leases
in accordance with &lt;i&gt;ASC 842 &#x2013; Leases&lt;/i&gt;. The Company is a lessee in a non-cancellable operating lease for office space. The Company
determines if an arrangement is a lease, or contains a lease, at inception of a contract and when the terms of an existing contract are
changed. The Company recognizes a lease liability and a right-of-use (ROU) asset at the commencement date. The lease liability is initially
and subsequently recognized based on the present value of its future lease payments. Variable payments are included in the future lease
payments when those variable payments depend on an index or a rate. The discount rate is the implicit rate if it is readily determinable
or otherwise the Company uses its incremental borrowing rate. The implicit rates of the Company's lease are not readily determinable and
accordingly, the Company uses its incremental borrowing rate based on the information available at the commencement date for all leases.
The Company&#x2019;s incremental borrowing rate for a lease is the 6% interest it would have to pay on a collateralized basis to borrow
an amount equal to the lease payments under similar terms and in a similar economic environment. The ROU asset is subsequently measured
throughout the lease term at the remaining amount (i.e. present value of the remaining lease payments), plus unamortized initial direct
costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received, and any impairment
recognized. Lease cost for lease payments is recognized on a straight-line basis over the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company has elected, for all underlying classes
of assets, not to recognize ROU assets and lease liabilities for short-term leases that have a lease term of 12 months or less at lease
commencement, and do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company
recognizes the lease cost associated with its short-term leases on a straight-line basis over the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Under the available practical expedient, we account
for the lease and non-lease components as a single lease component for all classes of underlying assets as both a lessee and lessor. Further,
we elected a short-term lease exception policy on all classes of underlying assets, permitting us to not apply the recognition requirements&#160;of
this standard to short-term leases (i.e. leases with terms of 12 months or less).&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zbAdSEayDv92" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_869_zpTUaX0BKCC6"&gt;RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;i&gt;ASU
2023-09 &#x2013; Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&lt;/i&gt; enhances the transparency and decision usefulness
of income tax disclosures. Adjustments to the annual disclosure of income taxes include: (1) a tabular rate reconciliation comprised
of eight specific categories, (2) incomes taxes paid, disaggregated between significant national, state, and foreign jurisdictions, (3)
eliminates requirements to disclose the nature and estimate of reasonably possible changes to unrecognized tax benefits in the next 12
months or that an estimated range cannot be made, and (4) adds a requirement to disclose income (or loss) from continuing operations
before income tax expense (or benefit) by national and foreign, and income tax expense (or benefit) from continuing operations disaggregated
between national, state and foreign. The &lt;i&gt;ASU 2023-09&lt;/i&gt; is effective for public business entities for fiscal years beginning on or
after December 15, 2024, and for all other entities for fiscal years beginning on or after December 31, 2025, with early adoption permitted.
The amendments in &lt;i&gt;ASU 2023-09&lt;/i&gt; were adopted by the Company on a prospective&#160;basis. There was no material change&#160;to the
Company's financial statements reporting as a result of adopting &lt;i&gt;ASU 2023-09&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;i&gt;ASU
2024-03 &#x2013; Income Statement (Reporting Comprehensive Income) Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation
of Income Statement Expenses&lt;/i&gt;, requires disaggregation of specific expense categories in the notes to the financial statements and
a qualitative description of the remaining expense amounts not separately disaggregated. This standard is effective for annual reporting
periods beginning after December 15. 2026, and requires prospective application with the option to apply it retrospectively. We intend
to adopt this standard in our Annual Report on Form 10-K for the year ending December 31. 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company has implemented all other new accounting
pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements
that have been issued that might have a material impact on its financial position or results of operations.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000543">&lt;p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zT1F7GpEIqY4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_861_z1kzjesDd906"&gt;PRINCIPLES OF CONSOLIDATION&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
include the accounts of the Company and its subsidiaries, Nora Pharma Inc. and Sunshine Biopharma Canada Inc., both wholly owned. All
intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2025-01-01to2025-12-31" id="Fact000545">&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zyHfdlWNtT88" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_866_zImZqZi6xGl7"&gt;USE OF ESTIMATES&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation
of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic
environment has increased the degree of uncertainty inherent in these estimates and assumptions.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000547">&lt;p id="xdx_840_eus-gaap--ReceivablesPolicyTextBlock_zYKL1sSaiBga" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_86C_zJD4NE4ec4Q4"&gt;TRADE ACCOUNTS RECEIVABLE AND
ALLOWANCE FOR DOUBTFUL ACCOUNTS&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Trade accounts receivable are stated at net realizable
value. The majority of customers are not extended credit and therefore time to maturity for receivables is short. On a periodic basis,
management evaluates its trade accounts receivable and determines whether to record an allowance for doubtful accounts. Management analysis for the periods ended December 31, 2024 and 2025 determined
that no allowance for doubtful accounts needed to be recorded. A receivable is considered past
due if the Company has not received payments based on agreed-upon terms. The Company generally does not require any security or collateral
to support its receivables. As of December 31, 2025 and 2024, the balances of accounts receivable were $&lt;span id="xdx_90E_eus-gaap--AccountsReceivableNetCurrent_iI_c20251231_zxRvzZJX0ytg" title="Accounts receivable"&gt;3,459,864&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--AccountsReceivableNetCurrent_iI_c20241231_zP5gVULZNYQ9" title="Accounts receivable"&gt;3,868,418&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000549"
      unitRef="USD">3459864</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000551"
      unitRef="USD">3868418</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000553">&lt;p id="xdx_84B_eus-gaap--InventoryPolicyTextBlock_zhKeMppuF1H9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_868_zZcWtBQ8Dp5j"&gt;INVENTORY VALUATION&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;The
Company&#x2019;s inventory is comprised of finished goods. Inventory is valued at the lower of cost and net realizable value. Cost is
determined using the first in, first out method. Net realizable value is the estimated selling price in the ordinary course of business,
less the costs necessary to make the sale. The cost of inventory includes the purchase price and other costs directly attributable to
the acquisition of the finished goods. The Company regularly reviews inventories to determine if the carrying value exceeds net realizable
value and, when determined necessary, an allowance to reduce the carrying value to net realizable value is recorded. The net realizable value is calculated based
on a combination of factors, including (i) aging, (ii) historical sell-through patterns, and (iii) product-specific considerations. Write-downs
are recorded within cost of goods sold and are not subsequently reversed. As of December 31,
2025 and 2024, there were allowances for obsolescence of $&lt;span id="xdx_90F_eus-gaap--InventoryValuationReserves_iI_c20251231_zn3STckJuycl" title="Reserve for obsolescence"&gt;475,153&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--InventoryValuationReserves_iI_do_c20241231_z4tfq3nPi0A1" title="Reserve for obsolescence"&gt;0&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryValuationReserves
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000555"
      unitRef="USD">475153</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000557"
      unitRef="USD">0</us-gaap:InventoryValuationReserves>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000559">&lt;p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zqx7JbOvORg9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_867_zvRq9k5Pfwj4"&gt;CASH AND CASH EQUIVALENTS&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;For the Balance Sheets and Statements of Cash
Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance
of $&lt;span id="xdx_90E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_c20251231_zZ32dlvJqe14"&gt;9,123,308&lt;/span&gt;
and $&lt;span id="xdx_903_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_c20241231_zMseaXCo4B98"&gt;9,686,529&lt;/span&gt;
as of December 31, 2025 and December 31, 2024, respectively. At times such cash balances may be in excess of the FDIC limit of $&lt;span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20251231_zEg0oLiqljR6"&gt;250,000&lt;/span&gt;
in the U.S. or the $&lt;span id="xdx_902_ecustom--CashCanadaInsuredAmount_iI_uCAD_c20251231_zrEqCn8XOX4b" title="Cash insured in Canada (CAD)"&gt;100,000&lt;/span&gt; CAD (approximately $&lt;span id="xdx_906_ecustom--CashCanadaInsuredAmount_iI_uUSD_c20251231_zfQHCvrRj3M6" title="Cash insured in Canada (USD)"&gt;73,000&lt;/span&gt; USD) limit in Canada. At December 31, 2025, the Company had deposits totaling
approximately $7 million in the U.S and $2 million in Canada.&lt;/p&gt;


&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000560"
      unitRef="USD">9123308</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000561"
      unitRef="USD">9686529</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000562"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <SBFM:CashCanadaInsuredAmount
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000564"
      unitRef="CAD">100000</SBFM:CashCanadaInsuredAmount>
    <SBFM:CashCanadaInsuredAmount
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000566"
      unitRef="USD">73000</SBFM:CashCanadaInsuredAmount>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000572">&lt;p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zsuJ7ILjYGJe" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_869_z7AlXLRHR128"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment are reviewed for recoverability
when events or changes in circumstances indicate that its carrying value may exceed future undiscounted cash inflows. As of December 31,
2025 and 2024, the Company had not identified any such impairment. Repairs and maintenance are charged to operations when incurred and
improvements and renewals are capitalized.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment are stated at cost. Depreciation
is calculated according to the following methods at the following annual rates and period for financial reporting purposes and accelerated
methods for tax purposes. Their estimated useful lives are as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--PropertyPlantAndEquipmentUsefulLivesTableTextBlock_zfpByWkhn958" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Estimated lives)"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span id="xdx_8BD_z9C9GBNH5mFa" style="display: none"&gt;Schedule of estimated useful lives&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="width: 28%; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Office Equipment:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 49%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Straight-line and Declining balance method&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 23%; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zws3TJ6m2Zq8" title="Property and equipment estimated useful lives"&gt;5-7 Years / 20%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Computer Equipment:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Declining balance method&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z3voB4yZCgM1" title="Property and equipment estimated useful lives"&gt;55%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Laboratory Equipment:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Straight-line method&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z8Bu5xz1asmb" title="Property and equipment estimated useful lives"&gt;5 Years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Vehicles:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Straight-line and Declining balance method&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zwa1guchFnc3" title="Property and equipment estimated useful lives"&gt;5 Years / 30%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AC_zRN7iHB7Gs8a" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <SBFM:PropertyPlantAndEquipmentUsefulLivesTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000574">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--PropertyPlantAndEquipmentUsefulLivesTableTextBlock_zfpByWkhn958" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Estimated lives)"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span id="xdx_8BD_z9C9GBNH5mFa" style="display: none"&gt;Schedule of estimated useful lives&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="width: 28%; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Office Equipment:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 49%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Straight-line and Declining balance method&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 23%; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zws3TJ6m2Zq8" title="Property and equipment estimated useful lives"&gt;5-7 Years / 20%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Computer Equipment:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Declining balance method&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z3voB4yZCgM1" title="Property and equipment estimated useful lives"&gt;55%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Laboratory Equipment:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Straight-line method&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z8Bu5xz1asmb" title="Property and equipment estimated useful lives"&gt;5 Years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Vehicles:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Straight-line and Declining balance method&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--PropertyPlantAndEquipmentEstimatedUsefulLives1_c20250101__20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zwa1guchFnc3" title="Property and equipment estimated useful lives"&gt;5 Years / 30%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</SBFM:PropertyPlantAndEquipmentUsefulLivesTableTextBlock>
    <SBFM:PropertyPlantAndEquipmentEstimatedUsefulLives1
      contextRef="From2025-01-012025-12-31_us-gaap_OfficeEquipmentMember"
      id="Fact000576">5-7 Years / 20%</SBFM:PropertyPlantAndEquipmentEstimatedUsefulLives1>
    <SBFM:PropertyPlantAndEquipmentEstimatedUsefulLives1
      contextRef="From2025-01-012025-12-31_us-gaap_ComputerEquipmentMember"
      id="Fact000578">55%</SBFM:PropertyPlantAndEquipmentEstimatedUsefulLives1>
    <SBFM:PropertyPlantAndEquipmentEstimatedUsefulLives1
      contextRef="From2025-01-012025-12-31_us-gaap_EquipmentMember"
      id="Fact000580">5 Years</SBFM:PropertyPlantAndEquipmentEstimatedUsefulLives1>
    <SBFM:PropertyPlantAndEquipmentEstimatedUsefulLives1
      contextRef="From2025-01-012025-12-31_us-gaap_VehiclesMember"
      id="Fact000582">5 Years / 30%</SBFM:PropertyPlantAndEquipmentEstimatedUsefulLives1>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2025-01-01to2025-12-31" id="Fact000584">&lt;p id="xdx_84D_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zAW5triZDyJ4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_86A_zoiXI3c1RV5"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Intangible assets are amortized over their estimated
useful lives according to the following methods at the following annual rates and period:&lt;i&gt;&lt;/i&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock_zwwokJM4aN8b" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Intangible assets)"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span id="xdx_8B8_zXYTAxBJiTFk" style="display: none"&gt;Schedule of intangible assets   estimated
useful lives&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="width: 25%; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Licenses:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 50%; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Straight-line method&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 25%; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--IntangibleAssetsEstimatedUsefulLives_c20250101__20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zMExfiVHmH5" title="Intangible asset estimated useful lives"&gt;5 Years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Website:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Declining balance method&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--IntangibleAssetsEstimatedUsefulLives_c20250101__20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_zmGJhForVFM6" title="Intangible asset estimated useful lives"&gt;55%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_zdDRfgKG2d0a" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Intangible assets are tested for recoverability
when events or changes in circumstances indicate that their carrying amount may not be recoverable. The carrying amount of a long-lived
asset is not recoverable when it exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposal.
In such a case, an impairment loss must be recognized and is equivalent to the excess of the carrying amount of a long-lived asset over
its fair value.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <SBFM:ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000586">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock_zwwokJM4aN8b" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Intangible assets)"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span id="xdx_8B8_zXYTAxBJiTFk" style="display: none"&gt;Schedule of intangible assets   estimated
useful lives&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="width: 25%; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Licenses:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 50%; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Straight-line method&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 25%; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--IntangibleAssetsEstimatedUsefulLives_c20250101__20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zMExfiVHmH5" title="Intangible asset estimated useful lives"&gt;5 Years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: white"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Website:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Declining balance method&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--IntangibleAssetsEstimatedUsefulLives_c20250101__20251231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_zmGJhForVFM6" title="Intangible asset estimated useful lives"&gt;55%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</SBFM:ScheduleOfIntangibleAssetsAmortizedOverEstimatedUsefulLivesTableTextBlock>
    <SBFM:IntangibleAssetsEstimatedUsefulLives
      contextRef="From2025-01-012025-12-31_custom_LicensesMember"
      id="Fact000588">5 Years</SBFM:IntangibleAssetsEstimatedUsefulLives>
    <SBFM:IntangibleAssetsEstimatedUsefulLives
      contextRef="From2025-01-012025-12-31_custom_WebsiteMember"
      id="Fact000590">55%</SBFM:IntangibleAssetsEstimatedUsefulLives>
    <us-gaap:RevenueRecognitionServicesLicensingFees contextRef="From2025-01-01to2025-12-31" id="Fact000592">&lt;p id="xdx_847_eus-gaap--RevenueRecognitionServicesLicensingFees_zFoxoCN8IsL9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_863_zEFf1loBhPih"&gt;INTELLECTUAL PROPERTY RIGHTS
- PATENTS AND LICENSES&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The cost of patents and licenses acquired is capitalized
and is amortized over the remaining life of the patents or licenses.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluates recoverability of identifiable
intangible assets whenever events or changes in circumstances indicate that intangible assets carrying amount may not be recoverable.
Such circumstances include but are not limited to: (i) a significant decrease in the market value of an asset, (ii) a significant adverse
change in the extent or manner in which an asset is used, or (iii) an accumulation of cost significantly in excess of the amount originally
expected for the acquisition of an asset. The Company measures the carrying amount of such assets against the estimated undiscounted future
cash flows associated with it.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionServicesLicensingFees>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000594">&lt;p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zjLUIuWQo3ne" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_861_zHZZKwtmYnd"&gt;BASIC AND DILUTED NET GAIN (LOSS)
PER SHARE&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company computes gain or loss per share in
accordance with &lt;i&gt;ASC 260 &#x2013; Earnings per Share&lt;/i&gt;. ASC 260 requires presentation of both basic and diluted earnings per share
(&#x201c;EPS&#x201d;) on the face of the income statement. Basic net income (loss) per share is calculated by dividing net income (loss)
by the weighted-average common shares outstanding. Diluted net income (loss) per share is calculated by dividing net income (loss) by
the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is
more dilutive. As the Company incurred net losses for the years ended December 31, 2025 and 2024, &lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20250101__20251231_zMgAksl5zuZ8"&gt;&lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20240101__20241231_zVDywucsa3l5"&gt;no&lt;/span&gt;&lt;/span&gt; potentially dilutive securities were
included in the calculation of diluted earnings per share as the impact would have been anti-dilutive. Accordingly, diluted EPS information
is not included in this report.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000595"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000596"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000602">&lt;p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zE2uzKHkm4ye" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_86A_zQ119tDTcXH3"&gt;INCOME TAXES&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with &lt;i&gt;ASC 740 &#x2013; Income Taxes&lt;/i&gt;,
the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by
applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities
and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities have been adjusted to reflect
changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not
be realized.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company expects to recognize the financial
statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position
in an examination. For tax positions meeting a &#x201c;more-likely-than-not&#x201d; threshold, the amount to be recognized in the financial
statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold,
no financial statement benefit is recognized. As of December 31, 2025, the Company had no uncertain tax positions. The Company recognizes
interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. The Company currently has no
federal or state tax examinations nor has it had any federal or state examinations since its inception. To date, the Company has not incurred
any interest or tax penalties.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;For Canadian and U.S. tax purposes, the Company&#x2019;s
2022 through 2024 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000604">&lt;p id="xdx_847_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zLvoc9nuCaNi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_860_zAQtqlDLp9Kd"&gt;FUNCTIONAL CURRENCY&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The U.S. dollar is the functional currency of the
Company which is operating in the United States. The functional currency for the Company's Canadian subsidiaries is the Canadian dollar.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company translates its Canadian subsidiaries'
financial statements into U.S. dollars as follows:&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Income statement accounts are translated using the weighted average exchange rate for the period.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company includes translation adjustments from
currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate
component of shareholders&#x2019; equity. There are currently no transactions of a long-term investment nature, nor any gains or losses
from non-U.S. currency transactions.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2025-01-01to2025-12-31" id="Fact000606">&lt;p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_z4IY1iD7yuz4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_86E_zVNk6KqUUrP3"&gt;CONCENTRATION OF CREDIT RISKS&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments that potentially subject
the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash
equivalents with high credit quality financial institutions.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2025-01-01to2025-12-31" id="Fact000608">&lt;p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zqhSLybT8Yj6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_86F_zMlFgM8LrI46"&gt;FINANCIAL INSTRUMENTS AND FAIR
VALUE OF FINANCIAL INSTRUMENTS&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company applies the provisions of accounting
guidance, &lt;i&gt;ASC 825 &#x2013; Financial Instruments&lt;/i&gt;. ASC 825 requires all entities to disclose the fair value of financial instruments,
both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and
defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between
willing parties. As of December 31, 2025 and 2024, the fair value of cash, accounts receivable and notes receivable, accounts payable,
accrued expenses, and other payables approximated carrying value due to the short maturity of the instruments, quoted market prices or
interest rates which fluctuate with market rates.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company defines fair value as the price that
would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement
date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels
and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement.
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to unobservable inputs (Level 3 measurements).&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Level 1 &#x2013; Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Level 2 &#x2013; Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;Level 3 &#x2013; Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The carrying value of financial assets and liabilities
recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring
basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried
and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are
those that are adjusted to fair value each time a financial statement is prepared.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:DebtPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000614">&lt;p id="xdx_843_eus-gaap--DebtPolicyTextBlock_zdTevLIoVj79" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_86D_z3bO4ctqItoh"&gt;NOTES PAYABLE&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Borrowings are recognized initially at fair value,
net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of
transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective
interest method. The Company had &lt;span id="xdx_90E_eus-gaap--NotesPayable_iI_do_c20251231_zZlHXYFnQKoc"&gt;&lt;span id="xdx_904_eus-gaap--NotesPayable_iI_do_c20241231_zOTBND7FG1Re"&gt;no&lt;/span&gt;&lt;/span&gt; notes payable as of December 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:DebtPolicyTextBlock>
    <us-gaap:NotesPayable
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000615"
      unitRef="USD">0</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000616"
      unitRef="USD">0</us-gaap:NotesPayable>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000618">&lt;p id="xdx_844_eus-gaap--RevenueRecognitionPolicyTextBlock_zhVi7YOtMiFg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_86E_zYbxKFVNkQKf"&gt;REVENUE RECOGNITION&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Over 97% of the Company&#x2019;s revenues are derived
from the sale of pharmaceutical products. Pharmaceutical products can only be sold to a specific customer that is either a registered
pharmacy or a registered wholesaler. The Company therefore sells only to customers registered with Health Canada, the Canadian equivalent
of the FDA. Contracts are drawn up between the wholesalers and the Company for all indirect sales. In the case of direct sales to pharmacies,
purchase orders are used instead of contracts. A purchase order, forecast, or other written instructions to purchase any of the Company&#x2019;s
products placed by the customer constitutes an irrevocable offer to purchase. The customer is responsible for ensuring that the terms
of any such order are complete and accurate. The purchase order is only deemed to be accepted when the Company (in its sole discretion)
accepts the purchase order and delivers on the purchase. The acceptance of any purchase order can be full or partial, at the sole discretion
of the Company. No variations to these conditions are binding on the Company unless agreed to in writing between the customer and the
Company.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;No significant judgments are made in connection
with any contracts as the price is already determined, the collection is reasonably assured, and performance obligation is fulfilled when
the customer receives the goods. The Company is not required to apply any specific judgments, estimations, or assumptions to determine
the price of its products.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Taxes assessed by a governmental authority that
are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are
excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has been transferred
to a customer are accounted for as a fulfillment cost and are included in cost of revenues. The amount invoiced for each product is fixed
at the Company&#x2019;s current price list on the date of shipping and known in advance by the customer and does not vary.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company fulfills its performance obligation
when the customer receives the requested products. When the products leave the Company's warehouse, the transport to the customer is insured
and the transfer of ownership to the customer takes place when the customer receives the goods. At this point, the Company issues an invoice
for the products and remits the applicable sales taxes (GST and QST) to the appropriate governmental agency. The revenue is recognized
when the invoice is issued. Unless otherwise agreed to and signed by both parties, payment terms are within 30 days from the date of the
invoice. The collection is reasonably assured because of the nature of the Company&#x2019;s customers. The Company is conducting sales
only in Canada. Prices are listed in Canadian dollars and may vary from one Province or Territory to another within Canada. All products
sold by the Company are labelled and approved for sale in Canada only and are not intended for export outside of Canada.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;In the event of any breach by the Company of any
product warranty (whether by reason of defective materials, production faults or otherwise), the Company&#x2019;s liability is limited
to, at Company&#x2019;s option, (i) replacement of the product(s) in question, or (ii) reimbursement of the purchase price. The Company
carries product liability insurance and is not liable for products&#x2019; failure to comply with the warranty of products if the failure
or damage arises because of the customer&#x2019;s negligence, deliberate damage, misuse or failure to store the products in conditions
per Health Canada specifications. The Company is not liable (whether in contract, in tort or otherwise) for any (i) indirect, special
or consequential loss or damage, or (ii) loss of profit, goodwill, business or revenue (in each case whether direct or indirect). These
conditions also apply to any replacement products supplied by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company warrants to the customer that, at
the time of delivery, the products are compliant with all mandatory quality standards required by applicable regulatory and legal requirements.
In return, the customer is required to warrant to the Company that it holds all relevant permits and approvals required under applicable
laws to purchase, store, distribute, sell and use the Company&#x2019;s products. Visible defects or damages must be reported to the Company
in writing immediately, but no later than five (5) business days after receipt of the products. Hidden defects must be reported to the
Company in writing immediately, but no later than five (5) business days after the customer becomes aware of such defects. The Company
is not be deemed to be in breach of the terms or otherwise liable to customer for any delay in performance or non-performance of its obligations
due to circumstances beyond its control, including but not limited to, acts of God, floods, droughts, earthquakes or other natural disasters,
terrorist attacks, wars, preparations for war, armed conflicts, civil commotions or riots, epidemics or pandemics, fires, strikes, lockouts,
shortages of material or labor, breakdown or damage to machinery or equipment, accidents, any law or governmental order or other regulations
or action taken by a governmental entity, or default of any third party suppliers or provider of services or products, or any causes not
within the Company&#x2019;s control.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000628">&lt;p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_zReBenJzGuG8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_863_zVrQsWh3ZXef"&gt;LEASES&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes and measures its leases
in accordance with &lt;i&gt;ASC 842 &#x2013; Leases&lt;/i&gt;. The Company is a lessee in a non-cancellable operating lease for office space. The Company
determines if an arrangement is a lease, or contains a lease, at inception of a contract and when the terms of an existing contract are
changed. The Company recognizes a lease liability and a right-of-use (ROU) asset at the commencement date. The lease liability is initially
and subsequently recognized based on the present value of its future lease payments. Variable payments are included in the future lease
payments when those variable payments depend on an index or a rate. The discount rate is the implicit rate if it is readily determinable
or otherwise the Company uses its incremental borrowing rate. The implicit rates of the Company's lease are not readily determinable and
accordingly, the Company uses its incremental borrowing rate based on the information available at the commencement date for all leases.
The Company&#x2019;s incremental borrowing rate for a lease is the 6% interest it would have to pay on a collateralized basis to borrow
an amount equal to the lease payments under similar terms and in a similar economic environment. The ROU asset is subsequently measured
throughout the lease term at the remaining amount (i.e. present value of the remaining lease payments), plus unamortized initial direct
costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received, and any impairment
recognized. Lease cost for lease payments is recognized on a straight-line basis over the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company has elected, for all underlying classes
of assets, not to recognize ROU assets and lease liabilities for short-term leases that have a lease term of 12 months or less at lease
commencement, and do not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. The Company
recognizes the lease cost associated with its short-term leases on a straight-line basis over the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Under the available practical expedient, we account
for the lease and non-lease components as a single lease component for all classes of underlying assets as both a lessee and lessor. Further,
we elected a short-term lease exception policy on all classes of underlying assets, permitting us to not apply the recognition requirements&#160;of
this standard to short-term leases (i.e. leases with terms of 12 months or less).&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000630">&lt;p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zbAdSEayDv92" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;i&gt;&lt;span id="xdx_869_zpTUaX0BKCC6"&gt;RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;i&gt;ASU
2023-09 &#x2013; Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&lt;/i&gt; enhances the transparency and decision usefulness
of income tax disclosures. Adjustments to the annual disclosure of income taxes include: (1) a tabular rate reconciliation comprised
of eight specific categories, (2) incomes taxes paid, disaggregated between significant national, state, and foreign jurisdictions, (3)
eliminates requirements to disclose the nature and estimate of reasonably possible changes to unrecognized tax benefits in the next 12
months or that an estimated range cannot be made, and (4) adds a requirement to disclose income (or loss) from continuing operations
before income tax expense (or benefit) by national and foreign, and income tax expense (or benefit) from continuing operations disaggregated
between national, state and foreign. The &lt;i&gt;ASU 2023-09&lt;/i&gt; is effective for public business entities for fiscal years beginning on or
after December 15, 2024, and for all other entities for fiscal years beginning on or after December 31, 2025, with early adoption permitted.
The amendments in &lt;i&gt;ASU 2023-09&lt;/i&gt; were adopted by the Company on a prospective&#160;basis. There was no material change&#160;to the
Company's financial statements reporting as a result of adopting &lt;i&gt;ASU 2023-09&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;i&gt;ASU
2024-03 &#x2013; Income Statement (Reporting Comprehensive Income) Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation
of Income Statement Expenses&lt;/i&gt;, requires disaggregation of specific expense categories in the notes to the financial statements and
a qualitative description of the remaining expense amounts not separately disaggregated. This standard is effective for annual reporting
periods beginning after December 15. 2026, and requires prospective application with the option to apply it retrospectively. We intend
to adopt this standard in our Annual Report on Form 10-K for the year ending December 31. 2027.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company has implemented all other new accounting
pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements
that have been issued that might have a material impact on its financial position or results of operations.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000636">&lt;p id="xdx_80D_eus-gaap--MergersAcquisitionsAndDispositionsDisclosuresTextBlock_zQcKcggUnAX8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 3 &#x2013;
&lt;span id="xdx_82D_zlJRNplSnCq3"&gt;Acquisition of Nora Pharma Inc.&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;On October 20, 2022, the Company acquired all of
the issued and outstanding shares of Nora Pharma Inc. (&#x201c;Nora Pharma&#x201d;), a Canadian privately held pharmaceutical company. The
purchase price for the shares was $&lt;span id="xdx_90C_eus-gaap--BusinessCombinationConsiderationTransferred1_pp0p0_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zRmts2czf7Ag" title="Purchase price of shares"&gt;18,860,637&lt;/span&gt; which was paid in cash ($&lt;span id="xdx_902_eus-gaap--PaymentsToAcquireBusinessesGross_pp0p0_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zkK2Pvvvv9h5" title="Payments to acquire shares"&gt;14,346,637&lt;/span&gt;) and by the issuance of &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zs6biGNvBj76" title="Stock issued for acquisition"&gt;1,850&lt;/span&gt; shares of the Company&#x2019;s
common stock valued at $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20221019__20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zR1HMq5jpAf5" title="Stock issued for acquisition, value"&gt;4,514,000&lt;/span&gt; or $2,440.00 per share. Nora Pharma sells generic pharmaceutical products in Canada. Nora Pharma&#x2019;s
operations are authorized by a Drug Establishment License issued by Health Canada.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;As part of the consideration for Nora Pharma, the
Company agreed to a $&lt;span id="xdx_90E_ecustom--EarnoutPayable_iI_uCAD_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember__srt--CounterpartyNameAxis__custom--MalekChamounMember_zXh3kKIAPNMj" title="Earnout payable"&gt;5,000,000&lt;/span&gt; CAD ($&lt;span id="xdx_90A_ecustom--EarnoutPayable_iI_uUSD_c20221020__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember__srt--CounterpartyNameAxis__custom--MalekChamounMember_zwMaoaN2vc5e" title="Earnout payable"&gt;3,632,000&lt;/span&gt; USD) earnout amount payable to Mr. Malek Chamoun, the seller of Nora Pharma. The earnout
is payable in the form of twenty (20) payments of $250,000 CAD for every $1,000,000 CAD increase in gross sales (as defined in the Purchase
Agreement) above Nora Pharma&#x2019;s June 30, 2022 gross sales, provided that his employment with the Company is not terminated pursuant
to the Company&#x2019;s employment agreement with him. The total earnout amount of $3,632,000 has been recorded as a salary payable. During
the fiscal year ended December 31, 2023, the Company paid an earnout amount of $&lt;span id="xdx_90E_ecustom--EarnoutLiabilityExpenseFirstInstallment_uCAD_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zRQ0sscXVxxd" title="Earnout liability expense, first installment"&gt;1,426,914&lt;/span&gt; CAD (approximately $&lt;span id="xdx_903_ecustom--EarnoutLiabilityExpenseFirstInstallment_uUSD_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zPq9GLcPrndi"&gt;1,036,500&lt;/span&gt; USD) for the fiscal
year ended December 31, 2022. On April 22, 2024, the Company paid another earnout amount of $&lt;span id="xdx_902_ecustom--EarnoutLiabilityExpenseSecondInstallment_uCAD_c20240421__20240422__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zOHJn8V4G7f9" title="Earnout liability expense, second installment"&gt;3,093,878&lt;/span&gt; CAD (approximately $&lt;span id="xdx_902_ecustom--EarnoutLiabilityExpenseSecondInstallment_uUSD_c20240421__20240422__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_znsXS3kmYCk8"&gt;2,247,400&lt;/span&gt; USD)
for the fiscal year ended December 31, 2023. As of December 31, 2025, the remaining earnout balance was $&lt;span id="xdx_90F_ecustom--EarnoutLiabilityBalance_uCAD_c20250101__20251231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_zKxlzBBpqfc1" title="Remaining earnout balance"&gt;479,208&lt;/span&gt; CAD ($&lt;span id="xdx_908_ecustom--EarnoutLiabilityBalance_uUSD_c20250101__20251231__us-gaap--BusinessAcquisitionAxis__custom--NoraPharmaMember_znJt8oQQGAxj"&gt;295,797&lt;/span&gt; USD).
This remaining earnout amount is currently in dispute following dismissal of Mr. Chamoun by the Company on April 14, 2025 (See Note 17).&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2022-10-192022-10-20_custom_NoraPharmaMember"
      decimals="0"
      id="Fact000638"
      unitRef="USD">18860637</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="From2022-10-192022-10-20_custom_NoraPharmaMember"
      decimals="0"
      id="Fact000640"
      unitRef="USD">14346637</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-10-192022-10-20_custom_NoraPharmaMember"
      decimals="INF"
      id="Fact000642"
      unitRef="Shares">1850</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2022-10-192022-10-20_custom_NoraPharmaMember"
      decimals="0"
      id="Fact000644"
      unitRef="USD">4514000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <SBFM:EarnoutPayable
      contextRef="AsOf2022-10-20_custom_NoraPharmaMember_custom_MalekChamounMember"
      decimals="0"
      id="Fact000646"
      unitRef="CAD">5000000</SBFM:EarnoutPayable>
    <SBFM:EarnoutPayable
      contextRef="AsOf2022-10-20_custom_NoraPharmaMember_custom_MalekChamounMember"
      decimals="0"
      id="Fact000648"
      unitRef="USD">3632000</SBFM:EarnoutPayable>
    <SBFM:EarnoutLiabilityExpenseFirstInstallment
      contextRef="From2023-01-012023-12-31_custom_NoraPharmaMember"
      decimals="0"
      id="Fact000650"
      unitRef="CAD">1426914</SBFM:EarnoutLiabilityExpenseFirstInstallment>
    <SBFM:EarnoutLiabilityExpenseFirstInstallment
      contextRef="From2023-01-012023-12-31_custom_NoraPharmaMember"
      decimals="0"
      id="Fact000651"
      unitRef="USD">1036500</SBFM:EarnoutLiabilityExpenseFirstInstallment>
    <SBFM:EarnoutLiabilityExpenseSecondInstallment
      contextRef="From2024-04-212024-04-22_custom_NoraPharmaMember"
      decimals="0"
      id="Fact000653"
      unitRef="CAD">3093878</SBFM:EarnoutLiabilityExpenseSecondInstallment>
    <SBFM:EarnoutLiabilityExpenseSecondInstallment
      contextRef="From2024-04-212024-04-22_custom_NoraPharmaMember"
      decimals="0"
      id="Fact000654"
      unitRef="USD">2247400</SBFM:EarnoutLiabilityExpenseSecondInstallment>
    <SBFM:EarnoutLiabilityBalance
      contextRef="From2025-01-012025-12-31_custom_NoraPharmaMember"
      decimals="0"
      id="Fact000656"
      unitRef="CAD">479208</SBFM:EarnoutLiabilityBalance>
    <SBFM:EarnoutLiabilityBalance
      contextRef="From2025-01-012025-12-31_custom_NoraPharmaMember"
      decimals="0"
      id="Fact000657"
      unitRef="USD">295797</SBFM:EarnoutLiabilityBalance>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000659">&lt;p id="xdx_805_eus-gaap--IntangibleAssetsDisclosureTextBlock_z2mEREOVVzc4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 4 &#x2013; &lt;span id="xdx_828_zdbwXSAMzRD3"&gt;Intangible
Assets&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;Intangible assets consisted of the following:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z5D12SH1l7Tf" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details - Intangible assets)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B8_zARQeKuiadCk"&gt;&lt;b style="display: none"&gt;Schedule of intangible assets&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 83%"&gt;&lt;span style="font-size: 9pt"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_c20240101__20241231_z4aIpydvROwc" style="width: 13%; text-align: right" title="Intangible assets gross beginning"&gt;&lt;span style="font-size: 9pt"&gt;1,444,259&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 9pt"&gt;License fees additions&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20240101__20241231_zKT7dd1swT83" style="border-bottom: Black 1pt solid; text-align: right" title="Dossier fee additions"&gt;&lt;span style="font-size: 9pt"&gt;1,651,617&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20240101__20241231_znMab21WM46e" style="text-align: right" title="Intangible assets gross ending"&gt;&lt;span style="font-size: 9pt"&gt;3,095,876&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 9pt"&gt;Less: accumulated
    amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20241231_zm6JDlrF9s19" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization"&gt;&lt;span style="font-size: 9pt"&gt;(76,159&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 9pt"&gt;Intangible assets,
    net at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20241231_z7M0m6T2UhO1" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;3,019,717&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_c20250101__20251231_zVAzTGr1F4T8" style="text-align: right" title="Intangible assets gross beginning"&gt;&lt;span style="font-size: 9pt"&gt;3,019,717&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;License fees additions&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20250101__20251231_zN0uT8HFEKZk" style="border-bottom: Black 1pt solid; text-align: right" title="Dossier fee additions"&gt;&lt;span style="font-size: 9pt"&gt;774,355&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;Balance at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20250101__20251231_zK6DyE1AxOJc" style="text-align: right" title="Intangible assets gross ending"&gt;&lt;span style="font-size: 9pt"&gt;3,794,072&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Less: impairment*&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ImpairmentOfIntangibleAssetFinitelived_c20250101__20251231_fKg_____zeMZ3FRiKHQb" style="text-align: right" title="Impairment"&gt;&lt;span style="font-size: 9pt"&gt;(1,748,247&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20251231_zpoSTbAJblHf" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization"&gt;&lt;span style="font-size: 9pt"&gt;(156,455&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 9pt"&gt;Intangible assets,
    net at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20251231_zldscGOvl866" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;1,889,370&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;*
The impairment was a result of the determination by the Company that certain product licenses could not be commercialized&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8AF_zJZdm9rd5sle" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The amortization amounts of intangible assets for
2025 and 2024 were $&lt;span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_c20250101__20251231_zxwDWScR5nFk" title="Amortization of Intangible assets"&gt;37,758&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231_zRNxRPGX66F"&gt;77,009&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2025, the estimated amortization
expense of the Company&#x2019;s intangible assets for each of the next five years is as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zf7fcQ3rgnga" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details - Amortization expense)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BF_z0VaQsmwAtLl" style="display: none"&gt;Schedule of estimated amortization
expense&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20251231_zoyGnTrrT71j" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 83%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; width: 13%"&gt;212,414&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;2027&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;212,414&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;2028&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;212,414&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;2029&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;212,414&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;2030&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;58,093&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_zXrdwrP36e45" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;











</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000661">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z5D12SH1l7Tf" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details - Intangible assets)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B8_zARQeKuiadCk"&gt;&lt;b style="display: none"&gt;Schedule of intangible assets&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 83%"&gt;&lt;span style="font-size: 9pt"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_c20240101__20241231_z4aIpydvROwc" style="width: 13%; text-align: right" title="Intangible assets gross beginning"&gt;&lt;span style="font-size: 9pt"&gt;1,444,259&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 9pt"&gt;License fees additions&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20240101__20241231_zKT7dd1swT83" style="border-bottom: Black 1pt solid; text-align: right" title="Dossier fee additions"&gt;&lt;span style="font-size: 9pt"&gt;1,651,617&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20240101__20241231_znMab21WM46e" style="text-align: right" title="Intangible assets gross ending"&gt;&lt;span style="font-size: 9pt"&gt;3,095,876&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 9pt"&gt;Less: accumulated
    amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20241231_zm6JDlrF9s19" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization"&gt;&lt;span style="font-size: 9pt"&gt;(76,159&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 9pt"&gt;Intangible assets,
    net at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20241231_z7M0m6T2UhO1" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;3,019,717&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_c20250101__20251231_zVAzTGr1F4T8" style="text-align: right" title="Intangible assets gross beginning"&gt;&lt;span style="font-size: 9pt"&gt;3,019,717&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;License fees additions&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c20250101__20251231_zN0uT8HFEKZk" style="border-bottom: Black 1pt solid; text-align: right" title="Dossier fee additions"&gt;&lt;span style="font-size: 9pt"&gt;774,355&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;Balance at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_c20250101__20251231_zK6DyE1AxOJc" style="text-align: right" title="Intangible assets gross ending"&gt;&lt;span style="font-size: 9pt"&gt;3,794,072&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Less: impairment*&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ImpairmentOfIntangibleAssetFinitelived_c20250101__20251231_fKg_____zeMZ3FRiKHQb" style="text-align: right" title="Impairment"&gt;&lt;span style="font-size: 9pt"&gt;(1,748,247&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20251231_zpoSTbAJblHf" style="border-bottom: Black 1pt solid; text-align: right" title="Less accumulated amortization"&gt;&lt;span style="font-size: 9pt"&gt;(156,455&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 9pt"&gt;Intangible assets,
    net at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20251231_zldscGOvl866" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;1,889,370&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;*
The impairment was a result of the determination by the Company that certain product licenses could not be commercialized&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000663"
      unitRef="USD">1444259</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000665"
      unitRef="USD">1651617</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000667"
      unitRef="USD">3095876</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000669"
      unitRef="USD">76159</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000670"
      unitRef="USD">3019717</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000672"
      unitRef="USD">3019717</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000674"
      unitRef="USD">774355</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000676"
      unitRef="USD">3794072</us-gaap:FiniteLivedIntangibleAssetsGross>
    <SBFM:ImpairmentOfIntangibleAssetFinitelived
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000678"
      unitRef="USD">-1748247</SBFM:ImpairmentOfIntangibleAssetFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000680"
      unitRef="USD">156455</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000681"
      unitRef="USD">1889370</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000683"
      unitRef="USD">37758</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000684"
      unitRef="USD">77009</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000686">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zf7fcQ3rgnga" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details - Amortization expense)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BF_z0VaQsmwAtLl" style="display: none"&gt;Schedule of estimated amortization
expense&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20251231_zoyGnTrrT71j" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 83%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; width: 13%"&gt;212,414&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;2027&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;212,414&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;2028&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;212,414&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;2029&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;212,414&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;2030&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;58,093&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000688"
      unitRef="USD">212414</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000690"
      unitRef="USD">212414</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000692"
      unitRef="USD">212414</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000694"
      unitRef="USD">212414</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000696"
      unitRef="USD">58093</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000702">&lt;p id="xdx_802_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zRh2S5yqMTT8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 5 &#x2013; &lt;span id="xdx_82B_zjR8nuLXTQP9"&gt;Plant, Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Property, plant and equipment are stated at cost.
Depreciation of property, plant and equipment begins in the month when the asset is placed into service and is provided using the straight-line
method for financial reporting purposes at rates based on the estimated useful lives of the assets. Estimated useful lives range from
three to twenty years. Property, plant and equipment consist of the following:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_zjSmaOzymed" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Plant, Property and Equipment (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B9_zlLqrsze668d"&gt;&lt;b style="display: none"&gt;Schedule
    of plant property and equipment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20251231_zvUW7nf8qT7e" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20241231_zRS5duG11dCj" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z7e2Z7PTzGSb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%"&gt;&lt;span style="font-size: 9pt"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;335,464&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;336,880&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zkRaJyW5vgFa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;69,139&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;53,531&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zq8i8exjRqcf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;45,462&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;50,686&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_d0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zz9eiYVtLt0e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;92,706&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;88,306&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zdbJw2YZbrW9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;507,478&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;353,185&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzbhx_zZL0hAVXmCg1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;1,070,249&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;882,588&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzbhx_zyAwf42kNNNg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;(512,879&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;(336,533&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzbhx_zZLDdgCzEJBk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Plant, property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;557,370&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;546,055&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8AE_zGrR8IoOi7Gd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Depreciation expense for the years ended December
31, 2025 and 2024 amounted to $&lt;span id="xdx_909_eus-gaap--Depreciation_c20250101__20251231_z4FNJqlfh329" title="Depreciation expense"&gt;176,346&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--Depreciation_c20240101__20241231_zD3aplQ5nBld" title="Depreciation expense"&gt;146,518&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000704">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_zjSmaOzymed" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Plant, Property and Equipment (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B9_zlLqrsze668d"&gt;&lt;b style="display: none"&gt;Schedule
    of plant property and equipment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20251231_zvUW7nf8qT7e" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20241231_zRS5duG11dCj" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z7e2Z7PTzGSb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%"&gt;&lt;span style="font-size: 9pt"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;335,464&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;336,880&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zkRaJyW5vgFa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;69,139&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;53,531&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zq8i8exjRqcf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;45,462&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;50,686&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_d0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zz9eiYVtLt0e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;92,706&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;88,306&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zdbJw2YZbrW9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;507,478&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;353,185&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzbhx_zZL0hAVXmCg1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;1,070,249&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;882,588&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzbhx_zyAwf42kNNNg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;(512,879&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;(336,533&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzbhx_zZLDdgCzEJBk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Plant, property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;557,370&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;546,055&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31_us-gaap_EquipmentMember"
      decimals="0"
      id="Fact000706"
      unitRef="USD">335464</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_EquipmentMember"
      decimals="0"
      id="Fact000707"
      unitRef="USD">336880</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="Fact000709"
      unitRef="USD">69139</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="Fact000710"
      unitRef="USD">53531</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact000712"
      unitRef="USD">45462</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact000713"
      unitRef="USD">50686</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000715"
      unitRef="USD">92706</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000716"
      unitRef="USD">88306</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31_us-gaap_VehiclesMember"
      decimals="0"
      id="Fact000718"
      unitRef="USD">507478</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_VehiclesMember"
      decimals="0"
      id="Fact000719"
      unitRef="USD">353185</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000721"
      unitRef="USD">1070249</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000722"
      unitRef="USD">882588</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000724"
      unitRef="USD">512879</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000725"
      unitRef="USD">336533</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000727"
      unitRef="USD">557370</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000728"
      unitRef="USD">546055</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000730"
      unitRef="USD">176346</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000732"
      unitRef="USD">146518</us-gaap:Depreciation>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000734">&lt;p id="xdx_808_eus-gaap--InventoryDisclosureTextBlock_zKBbxEOIXoZi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 6 &#x2013; &lt;span id="xdx_821_zZtP34jTZS07"&gt;Inventory&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Inventory
consists solely of finished goods purchased for resale. Inventory is stated at the lower of cost or net realizable value. Cost represents
the amount paid to acquire the finished goods. The Company uses the first in, first out (FIFO) method to determine cost. Under the FIFO
method, the earliest purchased units are deemed sold first, so ending inventory reflects the most recent purchase costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;The
Company evaluates inventory for potential obsolescence based on a combination of factors, including (i) aging, (ii) historical sell-through
patterns, and (iii) product-specific considerations. When estimated net realizable value is lower than cost, the Company records an allowance
for obsolescence for the difference. Write-downs are recorded within cost of goods sold and are not subsequently reversed.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;Inventory is comprised of the following:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zzDX5BpbkvF5" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventory (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;span id="xdx_8BB_zZZ30kgCSXL" style="display: none"&gt;Schedule of inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20251231_zTt1XC2RFmy7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20241231_zE9klaG2m0zd" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2025&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_z7NvjDWLhkHc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;13,947,178&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;11,278,105&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--AllowanceForObsoleteInventory_iI_d0_msARNCzj7C_z4r2TebdB9h3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Allowance for obsolete inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;(475,153&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--InventoryNet_iI_zb69lc9SnqR3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Total Inventory, net of allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;13,472,025&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;11,278,105&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zZaFdlvlFle9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000736">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zzDX5BpbkvF5" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventory (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;span id="xdx_8BB_zZZ30kgCSXL" style="display: none"&gt;Schedule of inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20251231_zTt1XC2RFmy7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20241231_zE9klaG2m0zd" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;2025&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_z7NvjDWLhkHc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;13,947,178&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;11,278,105&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--AllowanceForObsoleteInventory_iI_d0_msARNCzj7C_z4r2TebdB9h3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Allowance for obsolete inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;(475,153&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--InventoryNet_iI_zb69lc9SnqR3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Total Inventory, net of allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;13,472,025&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;11,278,105&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000738"
      unitRef="USD">13947178</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000739"
      unitRef="USD">11278105</us-gaap:InventoryFinishedGoods>
    <SBFM:AllowanceForObsoleteInventory
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000741"
      unitRef="USD">-475153</SBFM:AllowanceForObsoleteInventory>
    <SBFM:AllowanceForObsoleteInventory
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000742"
      unitRef="USD">0</SBFM:AllowanceForObsoleteInventory>
    <us-gaap:InventoryNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000744"
      unitRef="USD">13472025</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000745"
      unitRef="USD">11278105</us-gaap:InventoryNet>
    <SBFM:PrepaidExpensesTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000747">&lt;p id="xdx_80E_ecustom--PrepaidExpensesTextBlock_zqxLm2EPLgt7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 7 &#x2013; &lt;span id="xdx_824_zoAcQy2ygSli"&gt;Prepaid Expenses&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;The prepaid
expenses category is comprised of the following:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zLKcxzx2pJ75" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Prepaid Expenses (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="display: none; font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;span id="xdx_8BF_zJvwc6gQePH2"&gt;Schedule of prepaid expenses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20251231_zCqB86j6PFKg" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_zkK5Cxcj0Ih4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;b&gt;Year Ended
    December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PrepaidTaxes_iI_z3TGIVrV5W42" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Prepaid taxes&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;206,242&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;657,437&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--PermitsAndInsurance_iI_z2a3zSdH9Dj2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Permits and insurance &lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;486,797&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;399,176&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OtherPrepaidExpenseCurrent_iI_zz3lDFPZE9q8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Other prepaid
    expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;105,345&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;76,684&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PrepaidExpenseCurrent_iI_zC6hejyG8Qj1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;798,384&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;1,133,297&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_z4boHq19UqJ6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;













</SBFM:PrepaidExpensesTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000749">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zLKcxzx2pJ75" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Prepaid Expenses (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="display: none; font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;span id="xdx_8BF_zJvwc6gQePH2"&gt;Schedule of prepaid expenses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20251231_zCqB86j6PFKg" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_zkK5Cxcj0Ih4" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;b&gt;Year Ended
    December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PrepaidTaxes_iI_z3TGIVrV5W42" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Prepaid taxes&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;206,242&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;657,437&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--PermitsAndInsurance_iI_z2a3zSdH9Dj2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Permits and insurance &lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;486,797&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;399,176&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OtherPrepaidExpenseCurrent_iI_zz3lDFPZE9q8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Other prepaid
    expenses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;105,345&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;76,684&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PrepaidExpenseCurrent_iI_zC6hejyG8Qj1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;798,384&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;1,133,297&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidTaxes
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000751"
      unitRef="USD">206242</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000752"
      unitRef="USD">657437</us-gaap:PrepaidTaxes>
    <SBFM:PermitsAndInsurance
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000754"
      unitRef="USD">486797</SBFM:PermitsAndInsurance>
    <SBFM:PermitsAndInsurance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000755"
      unitRef="USD">399176</SBFM:PermitsAndInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000757"
      unitRef="USD">105345</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000758"
      unitRef="USD">76684</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000760"
      unitRef="USD">798384</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000761"
      unitRef="USD">1133297</us-gaap:PrepaidExpenseCurrent>
    <SBFM:CostOfSalesDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000768">&lt;p id="xdx_805_ecustom--CostOfSalesDisclosureTextBlock_ziIO0NtSCv85" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 8 &#x2013; &lt;span id="xdx_824_zXXPCUiHwTt4"&gt;Cost of Sales&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Cost of Sales is accounted for in accordance with
&lt;i&gt;ASC 705 &#x2013; Cost of Sales and Services&lt;/i&gt;. The Company purchases all commercial inventory as finished pharmaceutical products
from third party suppliers and does not conduct internal manufacturing.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;These costs are capitalized into inventory in accordance
with &lt;i&gt;ASC 330&lt;/i&gt; and recognized in Cost of Sales when control of the related inventory transfers to the customer under &lt;i&gt;ASC 606&lt;/i&gt;.
Inventory is recorded at cost.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluates inventory for excess, expiration,
and obsolescence at each reporting period. Inventory that becomes unsalable due to shelf-life limitations, regulatory changes, product
discontinuation, or forecasted demand shortfalls is written down to its net realizable value, with the charge recorded in Cost of Sales.
Previously recorded write downs are not reversed.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;The Company&#x2019;s Cost of Sales category is comprised of the following:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfCostOfSalesTableTextBlock_zgmBqlypqjnf" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Cost of Sales (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span id="xdx_8B4_zkM25TGXKVBf" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;b style="display: none"&gt;Schedule
    of cost of sales&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; font-weight: bold"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Finished
    goods&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_900_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--FinishedGoodsMember_zC1dpV2q2owh" title="Cost of goods sold"&gt;8,866,208&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90E_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--FinishedGoodsMember_z9mxmdsKwta" title="Cost of goods sold"&gt;8,116,534&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Professional allowances&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_906_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--ProfessionalAllowancesMember_zCxI0iKKSX13" title="Cost of goods sold"&gt;11,909,812&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_905_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--ProfessionalAllowancesMember_zs0JDixty4Ej" title="Cost of goods sold"&gt;13,714,009&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Other allowances&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90B_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--OtherAllowancesMember_zyhSFVWnzerc" title="Cost of goods sold"&gt;1,086,575&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90E_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--OtherAllowancesMember_ztAj2iFrvpwd" title="Cost of goods sold"&gt;666,913&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Wholesalers&#x2019; fees
    &amp;amp; discounts&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_909_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--WholesalersFeesAndDiscountsMember_z2pShOzDa9V3" title="Cost of goods sold"&gt;650,333&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_902_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--WholesalersFeesAndDiscountsMember_z5LsYYEpljC4" title="Cost of goods sold"&gt;1,699,286&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Inventory adjustment&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_905_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--InventoryAdjustmentMember_zhrPlvUarXTc" title="Cost of goods sold"&gt;1,162,303&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90C_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--InventoryAdjustmentMember_zmHR2saVlJXi" title="Cost of goods sold"&gt;236,555&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;Freight&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90A_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--FreightMember_zjsLYsmhbVm9" title="Cost of goods sold"&gt;374,983&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_907_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--FreightMember_zxd9h50SYTR6" title="Cost of goods sold"&gt;438,105&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90B_eus-gaap--CostOfRevenue_c20250101__20251231_zM9dDu1Rudqd" title="Cost of goods sold"&gt;24,050,214&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_903_eus-gaap--CostOfRevenue_c20240101__20241231_zcoORuRVF9Ie" title="Cost of goods sold"&gt;24,204,489&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zBbqsG7Nvcp6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</SBFM:CostOfSalesDisclosureTextBlock>
    <SBFM:ScheduleOfCostOfSalesTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000770">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfCostOfSalesTableTextBlock_zgmBqlypqjnf" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Cost of Sales (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span id="xdx_8B4_zkM25TGXKVBf" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;b style="display: none"&gt;Schedule
    of cost of sales&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; font-weight: bold"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Finished
    goods&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_900_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--FinishedGoodsMember_zC1dpV2q2owh" title="Cost of goods sold"&gt;8,866,208&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90E_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--FinishedGoodsMember_z9mxmdsKwta" title="Cost of goods sold"&gt;8,116,534&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Professional allowances&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_906_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--ProfessionalAllowancesMember_zCxI0iKKSX13" title="Cost of goods sold"&gt;11,909,812&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_905_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--ProfessionalAllowancesMember_zs0JDixty4Ej" title="Cost of goods sold"&gt;13,714,009&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Other allowances&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90B_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--OtherAllowancesMember_zyhSFVWnzerc" title="Cost of goods sold"&gt;1,086,575&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90E_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--OtherAllowancesMember_ztAj2iFrvpwd" title="Cost of goods sold"&gt;666,913&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Wholesalers&#x2019; fees
    &amp;amp; discounts&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_909_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--WholesalersFeesAndDiscountsMember_z2pShOzDa9V3" title="Cost of goods sold"&gt;650,333&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_902_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--WholesalersFeesAndDiscountsMember_z5LsYYEpljC4" title="Cost of goods sold"&gt;1,699,286&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Inventory adjustment&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_905_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--InventoryAdjustmentMember_zhrPlvUarXTc" title="Cost of goods sold"&gt;1,162,303&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90C_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--InventoryAdjustmentMember_zmHR2saVlJXi" title="Cost of goods sold"&gt;236,555&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;Freight&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90A_eus-gaap--CostOfRevenue_c20250101__20251231__us-gaap--TransactionTypeAxis__custom--FreightMember_zjsLYsmhbVm9" title="Cost of goods sold"&gt;374,983&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_907_eus-gaap--CostOfRevenue_c20240101__20241231__us-gaap--TransactionTypeAxis__custom--FreightMember_zxd9h50SYTR6" title="Cost of goods sold"&gt;438,105&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_90B_eus-gaap--CostOfRevenue_c20250101__20251231_zM9dDu1Rudqd" title="Cost of goods sold"&gt;24,050,214&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_903_eus-gaap--CostOfRevenue_c20240101__20241231_zcoORuRVF9Ie" title="Cost of goods sold"&gt;24,204,489&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Arial, Helvetica, Sans-Serif, Serif; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</SBFM:ScheduleOfCostOfSalesTableTextBlock>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-12-31_custom_FinishedGoodsMember"
      decimals="0"
      id="Fact000772"
      unitRef="USD">8866208</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31_custom_FinishedGoodsMember"
      decimals="0"
      id="Fact000774"
      unitRef="USD">8116534</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-12-31_custom_ProfessionalAllowancesMember"
      decimals="0"
      id="Fact000776"
      unitRef="USD">11909812</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31_custom_ProfessionalAllowancesMember"
      decimals="0"
      id="Fact000778"
      unitRef="USD">13714009</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-12-31_custom_OtherAllowancesMember"
      decimals="0"
      id="Fact000780"
      unitRef="USD">1086575</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31_custom_OtherAllowancesMember"
      decimals="0"
      id="Fact000782"
      unitRef="USD">666913</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-12-31_custom_WholesalersFeesAndDiscountsMember"
      decimals="0"
      id="Fact000784"
      unitRef="USD">650333</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31_custom_WholesalersFeesAndDiscountsMember"
      decimals="0"
      id="Fact000786"
      unitRef="USD">1699286</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-12-31_custom_InventoryAdjustmentMember"
      decimals="0"
      id="Fact000788"
      unitRef="USD">1162303</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31_custom_InventoryAdjustmentMember"
      decimals="0"
      id="Fact000790"
      unitRef="USD">236555</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-12-31_custom_FreightMember"
      decimals="0"
      id="Fact000792"
      unitRef="USD">374983</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31_custom_FreightMember"
      decimals="0"
      id="Fact000794"
      unitRef="USD">438105</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000796"
      unitRef="USD">24050214</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000798"
      unitRef="USD">24204489</us-gaap:CostOfRevenue>
    <SBFM:ReverseStockSplitTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000800">&lt;p id="xdx_802_ecustom--ReverseStockSplitTextBlock_zWkkHCKauZLh" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 9 &#x2013; &lt;span id="xdx_823_z5z1WmLA0ma5"&gt;Reverse
Stock Splits&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Effective April 17, 2024 and August 8, 2024, the
Company completed 1-for-100 and 1-for-20 reverse splits of its common stock, respectively. The Company had previously completed three
(3) reverse stock splits including a 1-for-200 reverse split on February 9, 2022, and two 1-for-20 reverse splits, one in 2019 and the
other in 2020. The Company&#x2019;s financial statements included in this report reflect all five (5) reverse stock splits on a retroactive
basis for all periods presented and for all references to common stock, unless specifically stated otherwise.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</SBFM:ReverseStockSplitTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000802">&lt;p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zi58iXrIyqS1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 10
&#x2013; &lt;span id="xdx_82B_zHnnICAzdPLi"&gt;Capital Stock&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s authorized capital is comprised
of &lt;span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_z0fbd8yM9eBd" title="Common stock, shares authorized"&gt;3,000,000,000&lt;/span&gt; shares of common stock, par value $&lt;span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zd4VxAqWgQo3" title="Common stock, par value"&gt;0.001&lt;/span&gt;, and &lt;span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__srt--TitleOfIndividualAxis__srt--DirectorMember_z1z5qw0yfv29" title="Preferred stock, shares authorized"&gt;30,000,000&lt;/span&gt; shares of preferred stock, $&lt;span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20251231__srt--TitleOfIndividualAxis__srt--DirectorMember_zoH6tYku8qHj" title="Preferred stock, par value"&gt;0.10&lt;/span&gt; par value. As of December 31,
2024, the Company had authorized &lt;span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsOXxx3CwFR4" title="Preferred stock, shares authorized"&gt;&lt;span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zQBeJgrHXgD4" title="Preferred stock, shares authorized"&gt;1,000,000&lt;/span&gt;&lt;/span&gt; shares of Series B Preferred Stock. The Series B Preferred Stock is
non-convertible and non-redeemable. It has a liquidation preference equal to the stated value of $0.10 per share, relative to the common
stock and gives the holder the right to 1,000 votes per share. As of December 31, 2024 and 2025, &lt;span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zFFQB1KPsCd" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zYJw5jdOWqSg" title="Preferred stock, shares outstanding"&gt;130,000&lt;/span&gt;&lt;/span&gt; shares of Series B Preferred
Stock were outstanding and held by the Company&#x2019;s Chief Executive Officer.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;On February 8, 2024, the Company issued &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240207__20240208__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zfX9WH8kZwkf" title="Number of shares issued"&gt;20,000&lt;/span&gt;
shares of Series B Preferred Stock to the Company&#x2019;s CEO for a purchase price of $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_c20240208__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zcBt4d5s17Vf" title="Purchase price"&gt;0.10&lt;/span&gt; per share.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;













&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;On February 15, 2024, the Company completed an
underwritten public offering and in connection therewith it issued an aggregate of &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240214__20240215__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zNJ7oVUUTGuj" title="Number of shares issued"&gt;35,714&lt;/span&gt; shares of common stock and received $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueOther_c20240214__20240215__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zjHAGmTfxaI2" title="Net proceeds"&gt;8,522,411&lt;/span&gt;
in net proceeds. In connection with this offering, the Company issued 22,500 pre-funded warrants (the &#x201c;2024 Pre-Funded Warrants&#x201d;)
exercisable at $2.00 per share, 3,986 Series A Warrants exercisable at $4,200.00 per share (subject to adjustment), or pursuant to an
alternative cashless exercise provision, and 7,973 Series B Warrants exercisable at $4,760.00 per share, subject to adjustment. As of
December 31, 2025, &lt;span id="xdx_907_ecustom--WarrantsExercisedDescription_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrants2024Member_zsSdIGPHoF34" title="Warrants exercised, description"&gt;(i) all of the 2024 Pre-Funded Warrants have been exercised resulting in the Company receiving net proceeds of $45,000,
(ii) all of the Series A Warrants have been exercised pursuant to the alternative cashless provision resulting in the Company receiving
$0 in proceeds, and (iii) 15,577,965 Series B Warrants remained outstanding and their exercise price had been adjusted to $2.07 as a result
of two reverse stock splits and a financing event which were conducted subsequent to their issuance. The Series B Warrants expire in February
2029.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;On March 4, 2024, the Company issued &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240303__20240304__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z8DuwQhlX4Ng" title="Number of shares issued"&gt;100,000&lt;/span&gt; shares
of Series B Preferred Stock to the Company&#x2019;s CEO for a purchase price of $&lt;span id="xdx_906_eus-gaap--SharePrice_iI_c20240304__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zeVMQgiqxrql" title="Purchase price"&gt;0.10&lt;/span&gt; per share.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;In April and May 2024, the Company issued &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240401__20240430__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zbePDqyRZeA4" title="Conversion of common stock shares"&gt;&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240501__20240531__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zdXZcGIjTTdh" title="Conversion of common stock shares"&gt;1,120,784&lt;/span&gt;
&lt;/span&gt;shares of common stock in connection with the cashless exercise of all of the Series A Warrants and received $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20240401__20240430__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z6bzCt8v7Npc" title="Conversion of common stock value"&gt;&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20240501__20240531__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zlVYWmjiBJ6" title="Conversion of common stock value"&gt;0&lt;/span&gt;&lt;/span&gt; in proceeds.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;On August 16, 2024, the Company issued &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_c20240815__20240816__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zptbds4nuwSe" title="Stock issued for rounding of reverse stock split"&gt;150,285&lt;/span&gt;
shares of common stock in connection with the rounding up of fractional shares following the reverse stock splits of April 17, 2024 and
August 8, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;In August and September 2024, the Company issued
&lt;span id="xdx_90E_eus-gaap--ConversionOfStockSharesIssued1_c20240901__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zMU8Unl40ZQa" title="Stock converted, shares issued"&gt;&lt;span id="xdx_90B_eus-gaap--ConversionOfStockSharesIssued1_c20240801__20240831__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zPWsDy7BKUIi" title="Stock converted, shares issued"&gt;678,865&lt;/span&gt;&lt;/span&gt; shares of common stock in connection with the exercise of &lt;span id="xdx_908_eus-gaap--ConversionOfStockSharesConverted1_c20240801__20240831__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_znpKqGJ0kTfe" title="Stock converted, shares converted"&gt;&lt;span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_c20240901__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zNBbYxF9Vjqe" title="Stock converted, shares converted"&gt;678,865&lt;/span&gt;&lt;/span&gt; Series B Warrants and received aggregate net proceed of $&lt;span id="xdx_905_eus-gaap--ProceedsFromWarrantExercises_c20240801__20240831__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_z5xVQehkhFD6" title="Proceeds from warrant exercise"&gt;&lt;span id="xdx_903_eus-gaap--ProceedsFromWarrantExercises_c20240901__20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zbqIe079Tna2" title="Proceeds from warrant exercise"&gt;1,895,610&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;In November and December 2024, the Company issued
&lt;span id="xdx_901_eus-gaap--ConversionOfStockSharesIssued1_c20241101__20241130__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z184pmA3llJb" title="Stock converted, shares issued"&gt;&lt;span id="xdx_906_eus-gaap--ConversionOfStockSharesIssued1_c20241201__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zcTWT2m5ik3i" title="Stock converted, shares issued"&gt;580,438&lt;/span&gt;&lt;/span&gt; shares of common stock in connection with the exercise of &lt;span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_c20241101__20241130__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zZsP9zfSo6Fk" title="Stock converted, shares converted"&gt;&lt;span id="xdx_908_eus-gaap--ConversionOfStockSharesConverted1_c20241201__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zprm6LxHDT2b" title="Stock converted, shares converted"&gt;580,438&lt;/span&gt;&lt;/span&gt; Series B Warrants and received aggregate net proceeds of $&lt;span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_c20241101__20241130__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zw9eCDOydvV7" title="Proceeds from warrant exercise"&gt;&lt;span id="xdx_901_eus-gaap--ProceedsFromWarrantExercises_c20241201__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_z0jCTUFOJi18" title="Proceeds from warrant exercise"&gt;1,618,203&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;On January 3, 2025, the Company issued &lt;span id="xdx_907_eus-gaap--ConversionOfStockSharesIssued1_c20250102__20250103__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zGbX01e4TyVg" title="Stock converted, shares issued"&gt;127,443&lt;/span&gt;
shares of common stock upon the exercise of &lt;span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_c20250102__20250103__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zUVgoF5uOtX6" title="Stock converted, shares converted"&gt;127,443&lt;/span&gt; Series B Warrants and received $&lt;span id="xdx_90A_eus-gaap--ProceedsFromWarrantExercises_c20250102__20250103__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zSxXHUNs7rj9" title="Proceeds from warrant exercise"&gt;355,298&lt;/span&gt; in net proceeds.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;On April 2, 2025, the Company issued &lt;span id="xdx_90B_eus-gaap--ConversionOfStockSharesIssued1_c20250401__20250402__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z0pUfwZa0caj" title="Stock converted, shares issued"&gt;660,000&lt;/span&gt; shares
of common stock upon the exercise of &lt;span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_c20250401__20250402__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zOCNsWtlQjda" title="Stock converted, shares converted"&gt;660,000&lt;/span&gt; Series B Warrants and received $&lt;span id="xdx_905_eus-gaap--ProceedsFromWarrantExercises_c20250401__20250402__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zpUNKJxKvvJd" title="Proceeds from warrant exercise"&gt;1,840,014&lt;/span&gt; in net proceeds.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;On April 3, 2025, the Company issued an aggregate
of &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250401__20250403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zefPwnICdhZf" title="Aggregate shares Issued"&gt;1,188,404&lt;/span&gt; shares of common stock in connection with a registered direct offering and received $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250401__20250403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zN63QBwvR8Pe" title="Net proceeds"&gt;1,828,596&lt;/span&gt; in net proceeds.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;On October 16, 2025, the Company issued &lt;span id="xdx_90F_eus-gaap--ConversionOfStockSharesIssued1_c20251015__20251016__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zKR72AEXwusd" title="Stock converted, shares issued"&gt;350,000&lt;/span&gt;
shares of common stock upon the exercise of &lt;span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_c20251015__20251016__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zeFsW2GdBZ83" title="Stock converted, shares converted"&gt;350,000&lt;/span&gt; Series B Warrants and received net proceeds of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20251015__20251016__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zEz7ARazH0Pf" title="Net proceeds"&gt;724,500&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2025 and 2024, the Company had
&lt;span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20251231_z9Vn7ak7e3m8"&gt;&lt;span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20251231_zJXXdPx7mFSk"&gt;4,905,945&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20241231_zQYqgpEw6MMd" title="Common stock, shares issued"&gt;&lt;span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_z5wFqj3DAH9" title="Common stock, shares outstanding"&gt;2,580,098&lt;/span&gt;&lt;/span&gt; shares of common stock issued and outstanding, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company has declared no dividends since inception.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;













</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000804"
      unitRef="Shares">3000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000806"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31_srt_DirectorMember"
      decimals="INF"
      id="Fact000808"
      unitRef="Shares">30000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31_srt_DirectorMember"
      decimals="INF"
      id="Fact000810"
      unitRef="USDPShares">0.10</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000812"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000814"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact000816"
      unitRef="Shares">130000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact000818"
      unitRef="Shares">130000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-02-072024-02-08_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact000820"
      unitRef="Shares">20000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:SharePrice
      contextRef="AsOf2024-02-08_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact000822"
      unitRef="USDPShares">0.10</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-02-142024-02-15_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000829"
      unitRef="Shares">35714</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-02-142024-02-15_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000831"
      unitRef="USD">8522411</us-gaap:StockIssuedDuringPeriodValueOther>
    <SBFM:WarrantsExercisedDescription
      contextRef="From2025-01-012025-12-31_custom_PreFundedWarrants2024Member"
      id="Fact000833">(i) all of the 2024 Pre-Funded Warrants have been exercised resulting in the Company receiving net proceeds of $45,000,
(ii) all of the Series A Warrants have been exercised pursuant to the alternative cashless provision resulting in the Company receiving
$0 in proceeds, and (iii) 15,577,965 Series B Warrants remained outstanding and their exercise price had been adjusted to $2.07 as a result
of two reverse stock splits and a financing event which were conducted subsequent to their issuance. The Series B Warrants expire in February
2029.</SBFM:WarrantsExercisedDescription>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-03-032024-03-04_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact000835"
      unitRef="Shares">100000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:SharePrice
      contextRef="AsOf2024-03-04_us-gaap_SeriesBPreferredStockMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact000837"
      unitRef="USDPShares">0.10</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-04-012024-04-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000839"
      unitRef="Shares">1120784</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-05-012024-05-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000841"
      unitRef="Shares">1120784</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-04-012024-04-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000843"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-05-012024-05-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000845"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
      contextRef="From2024-08-152024-08-16_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000847"
      unitRef="Shares">150285</us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2024-09-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000849"
      unitRef="Shares">678865</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2024-08-012024-08-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000851"
      unitRef="Shares">678865</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2024-08-012024-08-31_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000853"
      unitRef="Shares">678865</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2024-09-012024-09-30_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000855"
      unitRef="Shares">678865</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-08-012024-08-31_custom_SeriesBWarrantsMember614656125"
      decimals="0"
      id="Fact000857"
      unitRef="USD">1895610</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-09-012024-09-30_custom_SeriesBWarrantsMember614656125"
      decimals="0"
      id="Fact000859"
      unitRef="USD">1895610</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2024-11-012024-11-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000861"
      unitRef="Shares">580438</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2024-12-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000863"
      unitRef="Shares">580438</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2024-11-012024-11-30_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000865"
      unitRef="Shares">580438</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2024-12-012024-12-31_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000867"
      unitRef="Shares">580438</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-11-012024-11-30_custom_SeriesBWarrantsMember614656125"
      decimals="0"
      id="Fact000869"
      unitRef="USD">1618203</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-12-012024-12-31_custom_SeriesBWarrantsMember614656125"
      decimals="0"
      id="Fact000871"
      unitRef="USD">1618203</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2025-01-022025-01-03_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000873"
      unitRef="Shares">127443</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2025-01-022025-01-03_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000875"
      unitRef="Shares">127443</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-01-022025-01-03_custom_SeriesBWarrantsMember614656140"
      decimals="0"
      id="Fact000877"
      unitRef="USD">355298</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2025-04-012025-04-02_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000879"
      unitRef="Shares">660000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2025-04-012025-04-02_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000881"
      unitRef="Shares">660000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-04-012025-04-02_custom_SeriesBWarrantsMember614656140"
      decimals="0"
      id="Fact000883"
      unitRef="USD">1840014</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-04-012025-04-03_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember"
      decimals="INF"
      id="Fact000885"
      unitRef="Shares">1188404</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-04-012025-04-03_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember"
      decimals="0"
      id="Fact000887"
      unitRef="USD">1828596</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2025-10-152025-10-16_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000889"
      unitRef="Shares">350000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2025-10-152025-10-16_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000891"
      unitRef="Shares">350000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-10-152025-10-16_us-gaap_CommonStockMember_custom_RegisteredDirectOfferingMember"
      decimals="0"
      id="Fact000893"
      unitRef="USD">724500</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000894"
      unitRef="Shares">4905945</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000895"
      unitRef="Shares">4905945</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000897"
      unitRef="Shares">2580098</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000899"
      unitRef="Shares">2580098</us-gaap:CommonStockSharesOutstanding>
    <SBFM:WarrantsDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000906">&lt;p id="xdx_806_ecustom--WarrantsDisclosureTextBlock_zGrqruCEMns2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 11 &#x2013;&lt;span id="xdx_82F_zPQEzVKBpmsg"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for issued warrants either
as a liability or equity in accordance with &lt;i&gt;ASC 480-10&lt;/i&gt; or &lt;i&gt;ASC 815-40&lt;/i&gt;. Under &lt;i&gt;ASC 480-10&lt;/i&gt;, warrants are considered a
liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants
do not meet liability classification under &lt;i&gt;ASC 480-10&lt;/i&gt;, the Company considers the requirements of &lt;i&gt;ASC 815-40&lt;/i&gt; to determine
whether the warrants should be classified as a liability or as equity. Under &lt;i&gt;ASC 815-40&lt;/i&gt;, contracts that may require settlement
for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured
at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance
date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under
&lt;i&gt;ASC 815-40&lt;/i&gt;, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed
to its common stock and whether the warrants are classified as equity under &lt;i&gt;ASC 815-40&lt;/i&gt; or other applicable GAAP standard. Equity-classified
warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;In 2022, 2023, 2024, and 2025, the Company completed
six (6) financing events, and in connection therewith, it issued warrants as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfWarrantsIssuedWithFinancingTableTextBlock_zf23S3xtYnR7" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details - Warrants issued with financing)"&gt;
  &lt;tr style="background-color: White"&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span id="xdx_8BD_zxaUosbINNi9" style="display: none"&gt;Schedule of warrants issued with financing&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 37%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;b&gt;Issuance
    Date/Type&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 1%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 20%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 1%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 20%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;b&gt;Exercise
    Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 1%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 20%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;b&gt;Expiry
    Date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Feb 17, 2022 (&#x201c;Tradeable
    Warrants&#x201d;)*&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_fKg_____zRJmmhSDjxg1" style="vertical-align: top" title="Warrants outstanding"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;2,051&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_zJ7hQBUczKVc" title="Warrant expiration date"&gt;4,440.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_902_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_zri3sNVV0BEa" title="Warrant expiration date"&gt;February 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: White"&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Mar 14, 2022 (&#x201c;2022
    Pre-Funded Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zXkDAJSSNTp3" style="vertical-align: top" title="Warrants outstanding"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;1,846&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_z5lKbZ3mE7i8" title="Warrant expiration date"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_908_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zgAd3WXF37Hg" title="Warrant expiration date"&gt;Unlimited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Mar 14, 2022 (&#x201c;Investor
    Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_fKio___z8rlX91kfMUa"&gt;1,801&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zIt7rRkk6wih"&gt;4,440.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_900_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zjycrXvHyRde"&gt;March 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: White"&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Apr 28, 2022 (&#x201c;April
    Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zIAC9PaveSzf" style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;4,862&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zPyZpyxtyOff"&gt;7,520.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90C_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zRQVtHaNJxX"&gt;April 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;May 16, 2023 (&#x201c;May
    Pre-Funded Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_zhANlkukxRal" style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;1,751&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_z9abUUb14TMg"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90F_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_zs5tHlVRMsq4"&gt;Unlimited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: White"&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;May 16, 2023 (&#x201c;May
    Investor Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zHNYOdyTqTik" style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;5,952&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zodUIQszAYXd"&gt;1,180.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_903_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zpUGWEvueJ71"&gt;November 2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Feb 15, 2024 (&#x201c;2024
    Pre-Funded Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_zSD89QoTOAje" style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;22,500&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_z6dzjg7bJ2Zj"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_900_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_zThqiw8IEW6f"&gt;Unlimited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: White"&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Feb 15, 2024 (&#x201c;Series
    A Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_fKio___zTZixmjv9x1f"&gt;3,986&lt;/span&gt;**&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_z2bD7SjgAQW1"&gt;4,200.00&lt;/span&gt;**&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90D_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_zbw4SgeKDOe2"&gt;August 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Feb 15, 2024 (&#x201c;Series
    B Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_fKio___zLPvVuZuWsVb"&gt;7,973&lt;/span&gt;**&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_z2EsF8yAYUS8"&gt;4,760.00&lt;/span&gt;**&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_901_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zEtNA3TLnbPa"&gt;February 2029&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: White"&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Apr
    03, 2025 (&#x201c;2025 Pre-Funded Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_zF0lbbU5ssCl" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;260,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_zUagTailpb3i" title="Exercise price"&gt;0.001&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90E_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_z4xq5njTl4u3"&gt;Unlimited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 8pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 13px"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;These warrants trade under
    the ticker symbol SBFMW&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;**&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;Subject to adjustment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AE_zeMQyOuCKpVg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;On February 11, 2024, the Company redeemed all
of the April Warrants and all of the May Investor Warrants for an aggregate purchase price of $&lt;span id="xdx_90D_eus-gaap--PaymentsForRepurchaseOfWarrants_pp0p0_c20240210__20240211__us-gaap--AwardTypeAxis__custom--AprilWarrantsAndMayInvestorWarrantsMember_zwrDE7NyoSma" title="Payments for repurchase of warrants"&gt;3,139,651&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2025, all of the 2022 Pre-Funded
Warrants, all of the May Pre-Funded Warrants, all of the 2024 Pre-Funded Warrants, all of the 2025 Pre-Funded Warrants, a total of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_z4vMiyLrFuwe" title="Warrants exercised"&gt;1,569&lt;/span&gt;
Tradeable Warrants, &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zZ3YufmJwMCb" title="Warrants exercised"&gt;1,401&lt;/span&gt; Investor Warrants, all of the Series A Warrants, and &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_z4Zh4CZNMvl9" title="Warrants exercised"&gt;2,269,303&lt;/span&gt; Series B Warrants (as adjusted) were exercised
resulting in aggregate net proceeds of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromWarrantExercises_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zC3F4enTucr4" title="Proceeds from warrant exercises"&gt;18,136,992&lt;/span&gt; received by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s outstanding warrants as of
December 31, 2025 consisted of the following:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zeYsZQUP4hv7" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details - Warrants outstanding)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8BA_z1RvAy1G5Fde"&gt;&lt;span style="display: none; font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; color: White"&gt;Schedule of warrants outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;b&gt;Type&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;b&gt;Expiry Date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 25%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Tradeable Warrants*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_fKg_____z3IDyqg91rhe" style="width: 24%" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;482&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_fKg_____zS5tu4SC2Mhh" style="width: 24%" title="Warrant exercise price"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$220.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_908_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_fKg_____zJXIKtPODttg" title="Expiry date"&gt;February 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Investor Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_fKio___z1FzCr0udrfb"&gt;400&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_fKio___z5jwWjBD1aOh"&gt;4,000.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_909_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_zI17tbbMeEag"&gt;March 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Series B Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_fKioq_zddOnbprW6S4"&gt;15,227,962&lt;/span&gt;**&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_fKioq_zzomno5A8t3g"&gt;2.07&lt;/span&gt;**&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90A_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_zowPp9E6Wrl9" title="Expiry date"&gt;February 2029&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 12px"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 8pt"&gt;These warrants trade under the
        ticker symbol SBFMW&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;**&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;As adjusted following the financing event of April 3,
    2025 and subject to further adjustment of the number of warrants and exercise price upon certain corporate actions such that the
    aggregate exercise price of the warrants remains unchanged&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A0_zHP2e4LMlrh4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;











</SBFM:WarrantsDisclosureTextBlock>
    <SBFM:ScheduleOfWarrantsIssuedWithFinancingTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000908">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfWarrantsIssuedWithFinancingTableTextBlock_zf23S3xtYnR7" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details - Warrants issued with financing)"&gt;
  &lt;tr style="background-color: White"&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span id="xdx_8BD_zxaUosbINNi9" style="display: none"&gt;Schedule of warrants issued with financing&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 37%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;b&gt;Issuance
    Date/Type&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 1%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 20%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 1%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 20%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;b&gt;Exercise
    Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 1%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid; width: 20%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;b&gt;Expiry
    Date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Feb 17, 2022 (&#x201c;Tradeable
    Warrants&#x201d;)*&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_fKg_____zRJmmhSDjxg1" style="vertical-align: top" title="Warrants outstanding"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;2,051&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_zJ7hQBUczKVc" title="Warrant expiration date"&gt;4,440.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_902_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrantsMember_zri3sNVV0BEa" title="Warrant expiration date"&gt;February 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: White"&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Mar 14, 2022 (&#x201c;2022
    Pre-Funded Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zXkDAJSSNTp3" style="vertical-align: top" title="Warrants outstanding"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;1,846&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_z5lKbZ3mE7i8" title="Warrant expiration date"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_908_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PreFunded2022WarrantsMember_zgAd3WXF37Hg" title="Warrant expiration date"&gt;Unlimited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Mar 14, 2022 (&#x201c;Investor
    Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_fKio___z8rlX91kfMUa"&gt;1,801&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zIt7rRkk6wih"&gt;4,440.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_900_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrantsMember_zjycrXvHyRde"&gt;March 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: White"&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Apr 28, 2022 (&#x201c;April
    Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zIAC9PaveSzf" style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;4,862&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zPyZpyxtyOff"&gt;7,520.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90C_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--AprilWarrantsMember_zRQVtHaNJxX"&gt;April 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;May 16, 2023 (&#x201c;May
    Pre-Funded Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_zhANlkukxRal" style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;1,751&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_z9abUUb14TMg"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90F_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MayPreFundedWarrantsMember_zs5tHlVRMsq4"&gt;Unlimited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: White"&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;May 16, 2023 (&#x201c;May
    Investor Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zHNYOdyTqTik" style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;5,952&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zodUIQszAYXd"&gt;1,180.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_903_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--MayInvestorWarrantsMember_zpUGWEvueJ71"&gt;November 2028&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Feb 15, 2024 (&#x201c;2024
    Pre-Funded Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_zSD89QoTOAje" style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;22,500&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_z6dzjg7bJ2Zj"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_900_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PreFunded2024WarrantsMember_zThqiw8IEW6f"&gt;Unlimited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: White"&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Feb 15, 2024 (&#x201c;Series
    A Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_fKio___zTZixmjv9x1f"&gt;3,986&lt;/span&gt;**&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_z2bD7SjgAQW1"&gt;4,200.00&lt;/span&gt;**&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90D_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeriesAWarrantsMember_zbw4SgeKDOe2"&gt;August 2026&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Feb 15, 2024 (&#x201c;Series
    B Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_fKio___zLPvVuZuWsVb"&gt;7,973&lt;/span&gt;**&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_z2EsF8yAYUS8"&gt;4,760.00&lt;/span&gt;**&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_901_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsMember_zEtNA3TLnbPa"&gt;February 2029&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: White"&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Apr
    03, 2025 (&#x201c;2025 Pre-Funded Warrants&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_zF0lbbU5ssCl" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;260,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_zUagTailpb3i" title="Exercise price"&gt;0.001&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90E_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PreFunded2025WarrantsMember_z4xq5njTl4u3"&gt;Unlimited&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 8pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 13px"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;These warrants trade under
    the ticker symbol SBFMW&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;**&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;Subject to adjustment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</SBFM:ScheduleOfWarrantsIssuedWithFinancingTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_TradeableWarrantsMember"
      decimals="INF"
      id="Fact000910"
      unitRef="Shares">2051</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_TradeableWarrantsMember"
      decimals="INF"
      id="Fact000912"
      unitRef="USDPShares">4440.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2025-01-012025-12-31_custom_TradeableWarrantsMember"
      id="Fact000914">February 2027</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_PreFunded2022WarrantsMember"
      decimals="INF"
      id="Fact000916"
      unitRef="Shares">1846</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_PreFunded2022WarrantsMember"
      decimals="INF"
      id="Fact000918"
      unitRef="USDPShares">2.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2025-01-012025-12-31_custom_PreFunded2022WarrantsMember"
      id="Fact000920">Unlimited</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_InvestorWarrantsMember"
      decimals="INF"
      id="Fact000921"
      unitRef="Shares">1801</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_InvestorWarrantsMember"
      decimals="INF"
      id="Fact000922"
      unitRef="USDPShares">4440.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2025-01-012025-12-31_custom_InvestorWarrantsMember"
      id="Fact000923">March 2027</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_AprilWarrantsMember"
      decimals="INF"
      id="Fact000924"
      unitRef="Shares">4862</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_AprilWarrantsMember"
      decimals="INF"
      id="Fact000925"
      unitRef="USDPShares">7520.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2025-01-012025-12-31_custom_AprilWarrantsMember"
      id="Fact000926">April 2027</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_MayPreFundedWarrantsMember"
      decimals="INF"
      id="Fact000927"
      unitRef="Shares">1751</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_MayPreFundedWarrantsMember"
      decimals="INF"
      id="Fact000928"
      unitRef="USDPShares">2.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2025-01-012025-12-31_custom_MayPreFundedWarrantsMember"
      id="Fact000929">Unlimited</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_MayInvestorWarrantsMember"
      decimals="INF"
      id="Fact000930"
      unitRef="Shares">5952</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_MayInvestorWarrantsMember"
      decimals="INF"
      id="Fact000931"
      unitRef="USDPShares">1180.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2025-01-012025-12-31_custom_MayInvestorWarrantsMember"
      id="Fact000932">November 2028</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_PreFunded2024WarrantsMember"
      decimals="INF"
      id="Fact000933"
      unitRef="Shares">22500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_PreFunded2024WarrantsMember"
      decimals="INF"
      id="Fact000934"
      unitRef="USDPShares">2.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2025-01-012025-12-31_custom_PreFunded2024WarrantsMember"
      id="Fact000935">Unlimited</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact000936"
      unitRef="Shares">3986</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact000937"
      unitRef="USDPShares">4200.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2025-01-012025-12-31_custom_SeriesAWarrantsMember"
      id="Fact000938">August 2026</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000939"
      unitRef="Shares">7973</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000940"
      unitRef="USDPShares">4760.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2025-01-012025-12-31_custom_SeriesBWarrantsMember"
      id="Fact000941">February 2029</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_PreFunded2025WarrantsMember"
      decimals="INF"
      id="Fact000942"
      unitRef="Shares">260000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_PreFunded2025WarrantsMember"
      decimals="INF"
      id="Fact000944"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2025-01-012025-12-31_custom_PreFunded2025WarrantsMember"
      id="Fact000945">Unlimited</SBFM:WarrantExpirationDate>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="From2024-02-102024-02-11_custom_AprilWarrantsAndMayInvestorWarrantsMember"
      decimals="0"
      id="Fact000947"
      unitRef="USD">3139651</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2025-01-012025-12-31_custom_TradeableWarrantsMember"
      decimals="INF"
      id="Fact000949"
      unitRef="Shares">1569</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2025-01-012025-12-31_custom_InvestorWarrantsMember"
      decimals="INF"
      id="Fact000951"
      unitRef="Shares">1401</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2025-01-012025-12-31_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000953"
      unitRef="Shares">2269303</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-01-012025-12-31_custom_SeriesBWarrantsMember"
      decimals="0"
      id="Fact000955"
      unitRef="USD">18136992</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000957">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zeYsZQUP4hv7" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details - Warrants outstanding)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td id="xdx_8BA_z1RvAy1G5Fde"&gt;&lt;span style="display: none; font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; color: White"&gt;Schedule of warrants outstanding&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;b&gt;Type&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;b&gt;Expiry Date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 25%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Tradeable Warrants*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_fKg_____z3IDyqg91rhe" style="width: 24%" title="Number of warrants outstanding"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;482&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_fKg_____zS5tu4SC2Mhh" style="width: 24%" title="Warrant exercise price"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$220.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_908_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--TradeableWarrants1Member_fKg_____zJXIKtPODttg" title="Expiry date"&gt;February 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Investor Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_fKio___z1FzCr0udrfb"&gt;400&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_fKio___z5jwWjBD1aOh"&gt;4,000.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_909_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--InvestorWarrants1Member_zI17tbbMeEag"&gt;March 2027&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Series B Warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_fKioq_zddOnbprW6S4"&gt;15,227,962&lt;/span&gt;**&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;$&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_fKioq_zzomno5A8t3g"&gt;2.07&lt;/span&gt;**&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90A_ecustom--WarrantExpirationDate_c20250101__20251231__us-gaap--AwardTypeAxis__custom--SeriesBWarrants1Member_zowPp9E6Wrl9" title="Expiry date"&gt;February 2029&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 12px"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 8pt"&gt;These warrants trade under the
        ticker symbol SBFMW&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;**&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"&gt;As adjusted following the financing event of April 3,
    2025 and subject to further adjustment of the number of warrants and exercise price upon certain corporate actions such that the
    aggregate exercise price of the warrants remains unchanged&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_TradeableWarrants1Member"
      decimals="INF"
      id="Fact000959"
      unitRef="Shares">482</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_TradeableWarrants1Member"
      decimals="INF"
      id="Fact000961"
      unitRef="USDPShares">220.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2025-01-012025-12-31_custom_TradeableWarrants1Member"
      id="Fact000963">February 2027</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_InvestorWarrants1Member"
      decimals="INF"
      id="Fact000964"
      unitRef="Shares">400</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_InvestorWarrants1Member"
      decimals="INF"
      id="Fact000965"
      unitRef="USDPShares">4000.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2025-01-012025-12-31_custom_InvestorWarrants1Member"
      id="Fact000966">March 2027</SBFM:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_SeriesBWarrants1Member"
      decimals="INF"
      id="Fact000967"
      unitRef="Shares">15227962</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesBWarrants1Member"
      decimals="INF"
      id="Fact000968"
      unitRef="USDPShares">2.07</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SBFM:WarrantExpirationDate
      contextRef="From2025-01-012025-12-31_custom_SeriesBWarrants1Member"
      id="Fact000970">February 2029</SBFM:WarrantExpirationDate>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000976">&lt;p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zFlbt1QS4vtg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 12 &#x2013;
&lt;span id="xdx_82D_zapNf0OBUWMh"&gt;Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The following table* sets forth the computation
of basic net income (loss) per share:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zoF14LQs6e9c" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings Per Share (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span id="xdx_8BB_zcB3fbVL3Pg3" style="display: none"&gt;Schedule of computation of basic and diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20251231_zNjJZReYAdP8" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20241231_zQ8xUjEedt1i" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zo9DXGDEbT0a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Net gain (loss) attributable to common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;(5,975,352&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;(5,134,116&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;Weighted average outstanding shares of common stock (Basic)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20251231_zjgPcCo4Jch9" title="Weighted average common shares outstanding - basic"&gt;4,157,086&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_zr4GvQjHOk55" title="Weighted average common shares outstanding - basic"&gt;701,749&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Net gain (loss) per share attributable
    to common stock  (Basic)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20250101__20251231_zagpytq9nff6" title="Basic gain (loss) per share attributable to common stock"&gt;(1.44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_901_eus-gaap--EarningsPerShareBasic_c20240101__20241231_z7kjPcFLEWhe" title="Basic gain (loss) per share attributable to common stock"&gt;(7.32&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;* Diluted net
gain (loss) per share is not included in this table as the Company incurred net losses for the years ended December 31, 2025 and 2024
and inclusion of dilutive instruments would have an anti-dilutive effect.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A3_zCFUPMs9CN7f" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000978">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zoF14LQs6e9c" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings Per Share (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span id="xdx_8BB_zcB3fbVL3Pg3" style="display: none"&gt;Schedule of computation of basic and diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20251231_zNjJZReYAdP8" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20241231_zQ8xUjEedt1i" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zo9DXGDEbT0a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Net gain (loss) attributable to common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;(5,975,352&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;(5,134,116&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;Weighted average outstanding shares of common stock (Basic)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20251231_zjgPcCo4Jch9" title="Weighted average common shares outstanding - basic"&gt;4,157,086&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_zr4GvQjHOk55" title="Weighted average common shares outstanding - basic"&gt;701,749&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Net gain (loss) per share attributable
    to common stock  (Basic)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20250101__20251231_zagpytq9nff6" title="Basic gain (loss) per share attributable to common stock"&gt;(1.44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span id="xdx_901_eus-gaap--EarningsPerShareBasic_c20240101__20241231_z7kjPcFLEWhe" title="Basic gain (loss) per share attributable to common stock"&gt;(7.32&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;* Diluted net
gain (loss) per share is not included in this table as the Company incurred net losses for the years ended December 31, 2025 and 2024
and inclusion of dilutive instruments would have an anti-dilutive effect.&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000980"
      unitRef="USD">-5975352</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000981"
      unitRef="USD">-5134116</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000983"
      unitRef="Shares">4157086</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000985"
      unitRef="Shares">701749</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000987"
      unitRef="USDPShares">-1.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000989"
      unitRef="USDPShares">-7.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000991">&lt;p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zYOM4SNbtj6i" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 13 &#x2013; &lt;span id="xdx_821_zS1RCCDP2ao8"&gt;Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The components of the provision for income taxes
were as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zSlolKCSNVKe" style="font: 10pt Arial, Helvetica, Sans-Serif, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Provision for income taxes)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 10pt; font-weight: 400; font-style: normal"&gt;&lt;span id="xdx_8BE_z17siEj3VfHj" style="display: none"&gt;Schedule of provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20250101__20251231_zOXxjZTzzVy2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20240101__20241231_zm6eTh6hwpOc" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Year
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zp47PcoK83yj" style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: 400; font-style: normal"&gt;&lt;span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CurrentFederalTaxExpenseBenefit_d0_zAWQxDmAgCH9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-weight: 400; font-style: normal"&gt;&lt;span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_d0_zX7IUdAka1La" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 66%; font-weight: 400; font-style: normal"&gt;&lt;span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CurrentForeignTaxExpenseBenefit_d0_z3sNsCXyXvja" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; padding-left: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(73,330&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(90,434&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--CurrentIncomeTaxExpenseBenefits_d0_zeSEQn5bbZNc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(73,330&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(90,384&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ComponentsOfDeferredTaxAssetsAbstract_iB_zhxWm94QytN5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: 400; font-style: normal"&gt;&lt;span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif"&gt;Deferred:
    &lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_d0_zpRTBkbCCAw8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-weight: 400; font-style: normal"&gt;&lt;span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_d0_zA2OB1a7umil" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-weight: 400; font-style: normal"&gt;&lt;span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_zBz31bBeriqh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; padding-left: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;94,939&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(144,474&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_zMkegtqPYTm3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Total Deferred&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;94,939&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(144,474&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_z2C16lRLK7cf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; font-weight: 400; font-style: normal; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif"&gt;Total
    Income Tax Expense / (Benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;21,609&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(234,858&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: normal 400 10pt Arial, Helvetica, Sans-Serif, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: normal 400 10pt Arial, Helvetica, Sans-Serif"&gt;The
Company&#x2019;s effective tax rate differs from the federal statutory rate as follows:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zTmAjy5a8YKd" style="font: 10pt Arial, Helvetica, Sans-Serif, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Reconcilation of tax rate)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B0_zNWpTBKDYc86" style="display: none"&gt;Schedule of income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20250101__20251231_zrNuxyoK5bN1" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20240101__20241231_zFU0USJw6U14" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;b&gt;Year Ended December 31, &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_iN_di_msITEBzYLG_zFtvPdBPSJog" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 40%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Pre-Tax Book Income&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(1,250,286&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 11%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_mataxrate_c20250101__20251231_zRkHIWzlSJlj" title="Pre-Tax Book Income, Rate"&gt;21.00&lt;/span&gt;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 11%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(1,121,714&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 11%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_mataxrate_c20240101__20241231_z3jMSOJZlTR6" title="Pre-Tax Book Income, Rate"&gt;20.89&lt;/span&gt;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzYLG_z6Ud25g2ZyKb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;State and Local Income Taxes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;44,533&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_mataxrate_c20250101__20251231_zbEQIRyNVuIk" title="State Taxes, Rate"&gt;(0.75&lt;/span&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_mataxrate_c20240101__20241231_z0tOZ8ZIqWw1" title="State and Local Income Taxes, Rate"&gt;0.00&lt;/span&gt;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory_maITEBzYLG_z28KOH3J5tX7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Effect of Rates Different than
    Statutory&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;151,341&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;span id="xdx_902_ecustom--EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate_dp_mataxrate_c20250101__20251231_zP0lUII4to5f" title="Effect of Rates Different than Statutory, Rate"&gt;(2.54&lt;/span&gt;%)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;62,181&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_907_ecustom--EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate_dp_mataxrate_c20240101__20241231_zRDxIr2Jtrt8" title="Effect of Rates Different than Statutory, Rate"&gt;(1.16&lt;/span&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--IncomeTaxReconciliationOtherForeignTaxes_d0_maITEBzYLG_zVnKryNCUFYe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Other Foreign Taxes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_900_ecustom--EffectiveIncomeTaxRateReconciliationOtherForeignTaxes_dp_mataxrate_c20250101__20251231_zUrzTEU1Yw4l" title="State Taxes, Rate"&gt;0.00&lt;/span&gt;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(119,181&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_902_ecustom--EffectiveIncomeTaxRateReconciliationOtherForeignTaxes_dp_mataxrate_c20240101__20241231_zAdyo88InPP9" title="Other Foreign Taxes, Rate"&gt;2.22&lt;/span&gt;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzYLG_zk77XgudRr45" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Permanent Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;54,987&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_dp_mataxrate_c20250101__20251231_zM923qvT7u55" title="Permanent Adjustments, Rate"&gt;(0.92&lt;/span&gt;%&lt;/span&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;56,092&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_dp_mataxrate_c20240101__20241231_zQnsZlYTq2i8" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(1.04&lt;/span&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzYLG_zUmJGP63IfH5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Change in Valuation Allowance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;1,107,342&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_mataxrate_c20250101__20251231_zsD04FbHJr6f" title="Change in Valuation Allowance, Rate"&gt;(18.60&lt;/span&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;569,920&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_mataxrate_c20240101__20241231_zwVv6mm2wQOe" title="Change in Valuation Allowance, Rate"&gt;(10.62&lt;/span&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_d0_maITEBzYLG_zt1G3pOi6Eeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Rate Change&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_mataxrate_c20250101__20251231_zqndcwtTjTB" title="Rate Change, Rate"&gt;0.00&lt;/span&gt;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;149,237&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_mataxrate_c20240101__20241231_zuIZwvmx65D" title="Rate Change, Rate"&gt;(2.78&lt;/span&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_maITEBzYLG_zOGC9gT7DcM4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Prior Year True up&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(86,308&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_mataxrate_c20250101__20251231_zR2fzaodesGl" title="Provision to Return Adjustments, Rate"&gt;1.45&lt;/span&gt;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;156,540&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_mataxrate_c20240101__20241231_zRuwRHMimiHh" title="Prior Year True up, Rate"&gt;(2.92&lt;/span&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationOtherAdjustments_d0_maITEBzYLG_zA6W4drHzp4e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp0_mataxrate_c20250101__20251231_zwfOu8U4fay7" title="Other Adjustments, Rate"&gt;&#x2013;&lt;/span&gt;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;12,027&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_mataxrate_c20240101__20241231_zqGqjYo6fMk7" title="Other, Rate"&gt;(0.22&lt;/span&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_pp0p0_mtITEBzYLG_zaUaz0m7oDMd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right; padding-bottom: 2.5pt"&gt;&lt;b style="display: none"&gt;Total&lt;/b&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;21,609&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt; &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_mttaxrate_c20250101__20251231_zLjVKxhpO4Wc" title="Total effective income tax rate, Rate"&gt;(0.36&lt;/span&gt;%)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(234,858&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_mttaxrate_c20240101__20241231_znXbb0haqTy6" title="Total effective income tax rate, Rate"&gt;4.37&lt;/span&gt;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A6_zf9SNAK5SOCc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;The
components of the net deferred tax assets were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zyfgIXjQsyG6" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Deferred taxes)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BE_zGTqCJT2qOo7" style="display: none"&gt;Schedule of components of net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20251231_zpE8XPcZsNDk" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20241231_zlfIv9iz8Auc" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredIncomeTaxesAbstract_iB_z3tOGuZyfitk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Deferred Tax Assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zumjhyC9af99" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 66%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Net Operating Loss, Credits and Carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;7,785,678&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;6,460,638&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_d0_zC53hPzKoThc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Fixed Assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;2,818&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_zINrGFdrD3j8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-size: 9pt"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;622,658&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;614,734&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DeferredTaxAssetsResearchAndDevelopment_iI_zOzxtS8zokq9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Research and Development&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;25,327&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;25,327&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsOther_iI_d0_z23gL0zjQm7c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Other deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;95,935&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_zAqY8dWeHgh2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Lease Liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;9,232&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;252,407&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zF9fhMMOVcX8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Valuation Allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;(8,445,713&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;(6,967,294&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iI_d0_zWlV9hzfx5nj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Total Deferred Tax Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;481,747&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_ziAh1nkWfpwb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Deferred Tax Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesOther_iI_d0_zqjk0J8O8p0b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Other deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;(67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_di0_z98JcGBP3jWh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Fixed Assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;(141,396&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di0_zh5BCO1c8kO3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-size: 9pt"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di0_zSMMie9sK3N6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;(248,050&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxLiabilities_iNI_di0_z5MQhd60g1R5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Total Deferred Tax Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;(389,513&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredIncomeTaxesAndOtherAssetsNoncurrent_iI_d0_zadJx6S3mESd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Net Deferred Tax Liability&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;92,234&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A3_zPggAiyFUOj9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;











&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;As
of December 31, 2025, the Company has federal, state, foreign and provincial net operating loss carryforwards of approximately $&lt;span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn6n6_c20251231_zGbcM7DUTP12" title="Federal net operating loss carryforwards"&gt;26&lt;/span&gt;
million, $&lt;span id="xdx_901_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn5n6_c20251231_zLnKEUaF7xj4" title="State net operating loss carryforwards"&gt;16.1&lt;/span&gt; million, $&lt;span id="xdx_906_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pn5n6_c20251231_zXl85m5cDOt" title="Foreign net operating loss carryforwards"&gt;4.3&lt;/span&gt; million, and $&lt;span id="xdx_908_ecustom--DeferredTaxAssetsOperatingLossCarryforwardsProvincial_iI_pn5n6_c20251231_zep7R5qkfs63" title="Provincial net operating loss carryforwards"&gt;3.3&lt;/span&gt; million, respectively. Of the federal net operating loss forwards, approximately $&lt;span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_pn5n6_c20251231_z5ewUNrOqC6j" title="Net operating loss carryforwards, subject to expiration"&gt;9.4&lt;/span&gt;
million have expiration dates from 2027 to 2037. The remainder can be carried forward indefinitely but limited to 80% of taxable
income. The foreign and provincial net operating loss carryforwards have a carryforward period of 20 years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of a deferred tax asset
will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during
the periods in which those temporary differences are deductible. In making this determination, management considers all available positive
and negative evidence affecting specific deferred assets, including the Company's past and anticipated future performance, the reversal
of deferred tax liabilities, the length of carry&#173;back and carry-forward periods, and the implementation of the tax planning strategies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Objective positive evidence is necessary to support a conclusion that a valuation allowance is not needed for all or a portion of deferred
tax assets when significant negative evidence exists. Cumulative losses in recent years are the most compelling form of negative evidence
considered by management in making this determination. For the years ended December 31, 2025 and 2024, management has determined that
based on all available evidence, a valuation allowance of $&lt;span id="xdx_904_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_dxL_c20251231_zglVmE607M4e" title="Valuation allowance::XDX::8445713"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1167"&gt;8.4&lt;/span&gt;&lt;/span&gt; million and $&lt;span id="xdx_904_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_dxL_c20241231_zwlfUzfonkV1" title="Valuation allowance::XDX::6967294"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1169"&gt;7.0&lt;/span&gt;&lt;/span&gt;, respectively is appropriate.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s evaluation of uncertain tax matters was performed for tax years ended through December 31, 2025. Generally, the Company
is subject to U.S. audit for the years ended December 31, 2024, 2023, and 2022 and may be subject to examination for amounts relating to
net operating loss carryforwards generated in periods prior to December 31, 2024. The company is subject to Canada audit for the years
ended December 31, 2024, 2023, 2022 and 2021 for Sunshine Biopharma Canada Inc and subject to Canada audit for the years ended December
31, 2024, 2023 and 2022 and June 30, 2022 for Nora Pharma Inc and may be subject to examination for amounts relating to net operating
loss carryforwards generated in periods prior to December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;On July 4, 2025, the One Big Beautiful Bill Act ("OBBBA") was enacted in the U.S. The OBBBA makes permanent key elements of the Tax Cuts
and Jobs Act, including 100% bonus depreciation, domestic research cost expensing, and the business interest expense limitation. ASC Topic
740, Income Taxes, requires the tax effects of changes in tax rates and laws to be recognized in the period in which the legislation is
enacted. Those effects, both current tax and deferred tax, are reported as part of continuing operations. The Company is currently assessing the impact of OBBBA on its Consolidated
Financial Statements but currently does not believe that the OBBBA will have a material impact on the Company's income tax expense.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000993">&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zSlolKCSNVKe" style="font: 10pt Arial, Helvetica, Sans-Serif, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Provision for income taxes)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 10pt; font-weight: 400; font-style: normal"&gt;&lt;span id="xdx_8BE_z17siEj3VfHj" style="display: none"&gt;Schedule of provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20250101__20251231_zOXxjZTzzVy2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20240101__20241231_zm6eTh6hwpOc" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Year
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zp47PcoK83yj" style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: 400; font-style: normal"&gt;&lt;span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CurrentFederalTaxExpenseBenefit_d0_zAWQxDmAgCH9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-weight: 400; font-style: normal"&gt;&lt;span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_d0_zX7IUdAka1La" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 66%; font-weight: 400; font-style: normal"&gt;&lt;span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CurrentForeignTaxExpenseBenefit_d0_z3sNsCXyXvja" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; padding-left: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(73,330&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(90,434&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--CurrentIncomeTaxExpenseBenefits_d0_zeSEQn5bbZNc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(73,330&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(90,384&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ComponentsOfDeferredTaxAssetsAbstract_iB_zhxWm94QytN5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: 400; font-style: normal"&gt;&lt;span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif"&gt;Deferred:
    &lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_d0_zpRTBkbCCAw8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-weight: 400; font-style: normal"&gt;&lt;span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_d0_zA2OB1a7umil" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-weight: 400; font-style: normal"&gt;&lt;span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_zBz31bBeriqh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; padding-left: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;94,939&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(144,474&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_zMkegtqPYTm3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Total Deferred&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;94,939&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(144,474&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_z2C16lRLK7cf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; font-weight: 400; font-style: normal; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font: normal 400 9pt Arial, Helvetica, Sans-Serif"&gt;Total
    Income Tax Expense / (Benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;21,609&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(234,858&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000998"
      unitRef="USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000999"
      unitRef="USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001001"
      unitRef="USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001002"
      unitRef="USD">50</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001004"
      unitRef="USD">-73330</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001005"
      unitRef="USD">-90434</us-gaap:CurrentForeignTaxExpenseBenefit>
    <SBFM:CurrentIncomeTaxExpenseBenefits
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001007"
      unitRef="USD">-73330</SBFM:CurrentIncomeTaxExpenseBenefits>
    <SBFM:CurrentIncomeTaxExpenseBenefits
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001008"
      unitRef="USD">-90384</SBFM:CurrentIncomeTaxExpenseBenefits>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001013"
      unitRef="USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001014"
      unitRef="USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001016"
      unitRef="USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001017"
      unitRef="USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001019"
      unitRef="USD">94939</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001020"
      unitRef="USD">-144474</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001022"
      unitRef="USD">94939</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001023"
      unitRef="USD">-144474</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001025"
      unitRef="USD">21609</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001026"
      unitRef="USD">-234858</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001032">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zTmAjy5a8YKd" style="font: 10pt Arial, Helvetica, Sans-Serif, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Reconcilation of tax rate)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B0_zNWpTBKDYc86" style="display: none"&gt;Schedule of income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20250101__20251231_zrNuxyoK5bN1" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20240101__20241231_zFU0USJw6U14" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;b&gt;Year Ended December 31, &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_iN_di_msITEBzYLG_zFtvPdBPSJog" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 40%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Pre-Tax Book Income&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(1,250,286&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 11%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_mataxrate_c20250101__20251231_zRkHIWzlSJlj" title="Pre-Tax Book Income, Rate"&gt;21.00&lt;/span&gt;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 11%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(1,121,714&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 11%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_mataxrate_c20240101__20241231_z3jMSOJZlTR6" title="Pre-Tax Book Income, Rate"&gt;20.89&lt;/span&gt;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzYLG_z6Ud25g2ZyKb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;State and Local Income Taxes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;44,533&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_mataxrate_c20250101__20251231_zbEQIRyNVuIk" title="State Taxes, Rate"&gt;(0.75&lt;/span&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_mataxrate_c20240101__20241231_z0tOZ8ZIqWw1" title="State and Local Income Taxes, Rate"&gt;0.00&lt;/span&gt;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory_maITEBzYLG_z28KOH3J5tX7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Effect of Rates Different than
    Statutory&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;151,341&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&lt;span id="xdx_902_ecustom--EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate_dp_mataxrate_c20250101__20251231_zP0lUII4to5f" title="Effect of Rates Different than Statutory, Rate"&gt;(2.54&lt;/span&gt;%)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;62,181&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_907_ecustom--EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate_dp_mataxrate_c20240101__20241231_zRDxIr2Jtrt8" title="Effect of Rates Different than Statutory, Rate"&gt;(1.16&lt;/span&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--IncomeTaxReconciliationOtherForeignTaxes_d0_maITEBzYLG_zVnKryNCUFYe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Other Foreign Taxes&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_900_ecustom--EffectiveIncomeTaxRateReconciliationOtherForeignTaxes_dp_mataxrate_c20250101__20251231_zUrzTEU1Yw4l" title="State Taxes, Rate"&gt;0.00&lt;/span&gt;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(119,181&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_902_ecustom--EffectiveIncomeTaxRateReconciliationOtherForeignTaxes_dp_mataxrate_c20240101__20241231_zAdyo88InPP9" title="Other Foreign Taxes, Rate"&gt;2.22&lt;/span&gt;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_maITEBzYLG_zk77XgudRr45" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Permanent Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;54,987&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_dp_mataxrate_c20250101__20251231_zM923qvT7u55" title="Permanent Adjustments, Rate"&gt;(0.92&lt;/span&gt;%&lt;/span&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;56,092&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_dp_mataxrate_c20240101__20241231_zQnsZlYTq2i8" style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(1.04&lt;/span&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzYLG_zUmJGP63IfH5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Change in Valuation Allowance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;1,107,342&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_mataxrate_c20250101__20251231_zsD04FbHJr6f" title="Change in Valuation Allowance, Rate"&gt;(18.60&lt;/span&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;569,920&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_mataxrate_c20240101__20241231_zwVv6mm2wQOe" title="Change in Valuation Allowance, Rate"&gt;(10.62&lt;/span&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_d0_maITEBzYLG_zt1G3pOi6Eeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Rate Change&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_mataxrate_c20250101__20251231_zqndcwtTjTB" title="Rate Change, Rate"&gt;0.00&lt;/span&gt;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;149,237&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_mataxrate_c20240101__20241231_zuIZwvmx65D" title="Rate Change, Rate"&gt;(2.78&lt;/span&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_maITEBzYLG_zOGC9gT7DcM4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Prior Year True up&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(86,308&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_mataxrate_c20250101__20251231_zR2fzaodesGl" title="Provision to Return Adjustments, Rate"&gt;1.45&lt;/span&gt;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;156,540&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_mataxrate_c20240101__20241231_zRuwRHMimiHh" title="Prior Year True up, Rate"&gt;(2.92&lt;/span&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationOtherAdjustments_d0_maITEBzYLG_zA6W4drHzp4e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp0_mataxrate_c20250101__20251231_zwfOu8U4fay7" title="Other Adjustments, Rate"&gt;&#x2013;&lt;/span&gt;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;12,027&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_mataxrate_c20240101__20241231_zqGqjYo6fMk7" title="Other, Rate"&gt;(0.22&lt;/span&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_pp0p0_mtITEBzYLG_zaUaz0m7oDMd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right; padding-bottom: 2.5pt"&gt;&lt;b style="display: none"&gt;Total&lt;/b&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;21,609&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt; &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_mttaxrate_c20250101__20251231_zLjVKxhpO4Wc" title="Total effective income tax rate, Rate"&gt;(0.36&lt;/span&gt;%)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;(234,858&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&lt;span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_mttaxrate_c20240101__20241231_znXbb0haqTy6" title="Total effective income tax rate, Rate"&gt;4.37&lt;/span&gt;%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001034"
      unitRef="USD">1250286</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001037"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001035"
      unitRef="USD">1121714</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001039"
      unitRef="Pure">0.2089</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001041"
      unitRef="USD">44533</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001044"
      unitRef="Pure">-0.0075</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001042"
      unitRef="USD">40</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001046"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <SBFM:IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001048"
      unitRef="USD">151341</SBFM:IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory>
    <SBFM:EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001051"
      unitRef="Pure">-0.0254</SBFM:EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate>
    <SBFM:IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001049"
      unitRef="USD">62181</SBFM:IncomeTaxReconciliationEffectOfRatesDifferentThanStatutory>
    <SBFM:EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001053"
      unitRef="Pure">-0.0116</SBFM:EffectiveIncomeTaxRateReconciliationEffectOfRatesDifferentThanStatutoryRate>
    <SBFM:IncomeTaxReconciliationOtherForeignTaxes
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001055"
      unitRef="USD">0</SBFM:IncomeTaxReconciliationOtherForeignTaxes>
    <SBFM:EffectiveIncomeTaxRateReconciliationOtherForeignTaxes
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001058"
      unitRef="Pure">0.0000</SBFM:EffectiveIncomeTaxRateReconciliationOtherForeignTaxes>
    <SBFM:IncomeTaxReconciliationOtherForeignTaxes
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001056"
      unitRef="USD">-119181</SBFM:IncomeTaxReconciliationOtherForeignTaxes>
    <SBFM:EffectiveIncomeTaxRateReconciliationOtherForeignTaxes
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001060"
      unitRef="Pure">0.0222</SBFM:EffectiveIncomeTaxRateReconciliationOtherForeignTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001062"
      unitRef="USD">54987</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001065"
      unitRef="Pure">-0.0092</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001063"
      unitRef="USD">56092</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001066"
      unitRef="Pure">-0.0104</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001068"
      unitRef="USD">1107342</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001071"
      unitRef="Pure">-0.1860</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001069"
      unitRef="USD">569920</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001073"
      unitRef="Pure">-0.1062</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001075"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001078"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001076"
      unitRef="USD">149237</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001080"
      unitRef="Pure">-0.0278</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001082"
      unitRef="USD">-86308</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001085"
      unitRef="Pure">0.0145</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001083"
      unitRef="USD">156540</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001087"
      unitRef="Pure">-0.0292</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001089"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001092"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001090"
      unitRef="USD">12027</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001094"
      unitRef="Pure">-0.0022</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001096"
      unitRef="USD">21609</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001099"
      unitRef="Pure">-0.0036</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001097"
      unitRef="USD">-234858</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001101"
      unitRef="Pure">0.0437</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001103">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zyfgIXjQsyG6" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details - Deferred taxes)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BE_zGTqCJT2qOo7" style="display: none"&gt;Schedule of components of net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20251231_zpE8XPcZsNDk" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20241231_zlfIv9iz8Auc" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredIncomeTaxesAbstract_iB_z3tOGuZyfitk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Deferred Tax Assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zumjhyC9af99" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 66%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Net Operating Loss, Credits and Carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;7,785,678&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;6,460,638&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_d0_zC53hPzKoThc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Fixed Assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;2,818&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_zINrGFdrD3j8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-size: 9pt"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;622,658&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;614,734&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DeferredTaxAssetsResearchAndDevelopment_iI_zOzxtS8zokq9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Research and Development&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;25,327&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;25,327&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsOther_iI_d0_z23gL0zjQm7c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Other deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;95,935&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_zAqY8dWeHgh2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Lease Liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;9,232&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;252,407&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zF9fhMMOVcX8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Valuation Allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;(8,445,713&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;(6,967,294&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iI_d0_zWlV9hzfx5nj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Total Deferred Tax Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;481,747&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_ziAh1nkWfpwb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Deferred Tax Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesOther_iI_d0_zqjk0J8O8p0b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Other deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;(67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_di0_z98JcGBP3jWh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Fixed Assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;(141,396&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di0_zh5BCO1c8kO3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-size: 9pt"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di0_zSMMie9sK3N6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;(248,050&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxLiabilities_iNI_di0_z5MQhd60g1R5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Total Deferred Tax Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;(389,513&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredIncomeTaxesAndOtherAssetsNoncurrent_iI_d0_zadJx6S3mESd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;Net Deferred Tax Liability&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 9pt"&gt;92,234&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001108"
      unitRef="USD">7785678</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001109"
      unitRef="USD">6460638</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001111"
      unitRef="USD">2818</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001112"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001114"
      unitRef="USD">622658</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001115"
      unitRef="USD">614734</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <SBFM:DeferredTaxAssetsResearchAndDevelopment
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001117"
      unitRef="USD">25327</SBFM:DeferredTaxAssetsResearchAndDevelopment>
    <SBFM:DeferredTaxAssetsResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001118"
      unitRef="USD">25327</SBFM:DeferredTaxAssetsResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001120"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001121"
      unitRef="USD">95935</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001123"
      unitRef="USD">9232</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001124"
      unitRef="USD">252407</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001126"
      unitRef="USD">8445713</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001127"
      unitRef="USD">6967294</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001129"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001130"
      unitRef="USD">481747</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001135"
      unitRef="USD">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001136"
      unitRef="USD">-67</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001138"
      unitRef="USD">-0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001139"
      unitRef="USD">141396</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001141"
      unitRef="USD">-0</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001142"
      unitRef="USD">-0</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001144"
      unitRef="USD">-0</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001145"
      unitRef="USD">248050</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001147"
      unitRef="USD">-0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001148"
      unitRef="USD">389513</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001150"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001151"
      unitRef="USD">92234</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="AsOf2025-12-31"
      decimals="-6"
      id="Fact001157"
      unitRef="USD">26000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact001159"
      unitRef="USD">16100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact001161"
      unitRef="USD">4300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <SBFM:DeferredTaxAssetsOperatingLossCarryforwardsProvincial
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact001163"
      unitRef="USD">3300000</SBFM:DeferredTaxAssetsOperatingLossCarryforwardsProvincial>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact001165"
      unitRef="USD">9400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001171">&lt;p id="xdx_805_eus-gaap--LesseeOperatingLeasesTextBlock_ziG7oyeejZJ6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 14 &#x2013;
&lt;span id="xdx_82A_zNY5ZuryDKA3"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company has obligations as a lessee for office
space with initial non-cancellable terms in excess of one year. The Company classified the lease as an operating lease. The lease contains
a renewal option for a period of five years. Because the Company is certain to exercise the renewal option, the optional period is included
in determining the lease term, and associated payments under the renewal option are included in the lease payments. The Company&#x2019;s
lease does not include termination options for either party to the lease or restrictive financial or other covenants. Payments due under
the lease contract include fixed payments plus a variable Payment. The Company&#x2019;s office space lease requires it to make variable
payments for the Company&#x2019;s proportionate share of building&#x2019;s property taxes, insurance, and common area maintenance. These
variable lease payments are not included in lease payments used to determine lease liability and are recognized as variable costs when
incurred.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Amounts reported on the balance sheet as of December
31, 2025 were as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--LeaseCostTableTextBlock_zc5uTDlVwVO2" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Lease information)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B2_z8a10fbE4Kuk" style="display: none"&gt;Schedule of lease information&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 83%; text-align: left"&gt;Operating lease ROU asset&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20251231_znN516YrLZJb" title="Operating lease ROU asset"&gt;778,846&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating Lease liability - Short-term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20251231_zMXZ6W1tW7o3" title="Operating Lease liability - Short-term"&gt;215,637&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease liability - Long-term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20251231_zHoAs1t7ojK8" title="Operating lease liability - Long-term"&gt;596,785&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Remaining lease term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20251231_zBrTXHZBaedd" title="Remaining lease term"&gt;4
                                            &lt;/span&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20251231_zVqM28wFKSg5" title="Discount rate"&gt;6&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z0CpgakbkrMe" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Amounts disclosed for ROU assets obtained in exchange
for lease obligations and reductions of ROU assets resulting from reductions of lease obligations include amounts reduced from the carrying
amount of ROU assets resulting from deferred rent.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Maturities of lease liabilities under non-cancellable
operating leases at December 31, 2025 are as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zbpnS8ofBPqj" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Maturities of lease payments)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BA_zXSZyhv1lWr4" style="display: none"&gt;Schedule of maturities of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20251231_zx3GPLCsdNae" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zZNf4PRdSUIh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 83%; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;215,637&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zU1z62k9eUm5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;204,428&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_zVnXlJT7ckKj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;193,794&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_zMgDYshGGD1g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;183,705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_zlXmjXveiLUj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Thereafter&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;14,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001177">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--LeaseCostTableTextBlock_zc5uTDlVwVO2" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Lease information)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B2_z8a10fbE4Kuk" style="display: none"&gt;Schedule of lease information&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 83%; text-align: left"&gt;Operating lease ROU asset&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20251231_znN516YrLZJb" title="Operating lease ROU asset"&gt;778,846&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating Lease liability - Short-term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20251231_zMXZ6W1tW7o3" title="Operating Lease liability - Short-term"&gt;215,637&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease liability - Long-term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20251231_zHoAs1t7ojK8" title="Operating lease liability - Long-term"&gt;596,785&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Remaining lease term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20251231_zBrTXHZBaedd" title="Remaining lease term"&gt;4
                                            &lt;/span&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20251231_zVqM28wFKSg5" title="Discount rate"&gt;6&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001179"
      unitRef="USD">778846</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001181"
      unitRef="USD">215637</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001183"
      unitRef="USD">596785</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="AsOf2025-12-31" id="Fact001185">P4Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001187"
      unitRef="Pure">0.06</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001189">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zbpnS8ofBPqj" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Maturities of lease payments)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BA_zXSZyhv1lWr4" style="display: none"&gt;Schedule of maturities of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20251231_zx3GPLCsdNae" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zZNf4PRdSUIh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 83%; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;215,637&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zU1z62k9eUm5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;204,428&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_zVnXlJT7ckKj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;193,794&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_zMgDYshGGD1g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;183,705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_zlXmjXveiLUj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Thereafter&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;14,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001191"
      unitRef="USD">215637</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001193"
      unitRef="USD">204428</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001195"
      unitRef="USD">193794</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001197"
      unitRef="USD">183705</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <SBFM:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001199"
      unitRef="USD">14858</SBFM:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001201">&lt;p id="xdx_807_eus-gaap--SegmentReportingDisclosureTextBlock_zpkUJLDQCeZg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 15 &#x2013; &lt;span id="xdx_829_z1PD5yhen4h2"&gt;Segment
Reporting&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company operates as &lt;span id="xdx_90D_eus-gaap--NumberOfOperatingSegments_dxH_uSegment_c20250101__20251231_zYmrM12qvzRf" title="Number of operating segments::XDX::1"&gt;one&lt;/span&gt; operating segment,
which is also its &lt;span id="xdx_90D_eus-gaap--NumberOfReportableSegments_dxH_uSegment_c20250101__20251231_zcP1UQUfp83e" title="Number of reportable segments::XDX::1"&gt;one&lt;/span&gt; reportable segment, as the Chief Executive Officer, acting as the Chief Operating Decision Maker (&#x201c;CODM&#x201d;),
evaluates financial performance and allocates resources on a consolidated, enterprise-wide basis. The Company&#x2019;s operations are
managed as an integrated pharmaceutical business focused on the research, development, and commercialization of prescription drugs and
supplements.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;Although the Company conducts activities through
multiple legal entities &#x2014; including Sunshine Biopharma Inc. (U.S.), Sunshine Biopharma Canada Inc. (Canada), and Nora Pharma Inc.
(Canada) &#x2014; these entities operate under a unified management structure with shared economic characteristics, common product development
objectives, and centralized decision making. As such, they do not meet the criteria for separate operating segments under &lt;i&gt;ASC 280
&#x2013; Segment Reporting&lt;/i&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with &lt;i&gt;ASU 2023-07&lt;/i&gt;, the Company
provides the following information regarding its single reportable segment:&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Measure of Segment Profit (Loss): The CODM evaluates
performance using consolidated operating income (loss), which is consistent with the amounts presented in the accompanying consolidated
financial statements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Significant Segment Expenses: Research and development
expenses, and supply chain costs, selling and marketing expenses, and general and administrative expenses are all incurred and reviewed
on a consolidated basis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Other Segment Items: Interest income, interest
expense, foreign exchange gains and losses, and other non-operating items are also managed and reviewed on a consolidated basis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;Reconciliation: As the Company has only one reportable
segment, no additional reconciliation to consolidated totals is required beyond what is presented in the consolidated statements of operations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s operations are conducted primarily
in Canada and substantially all long-lived assets are located in this jurisdiction. Revenues are generated from customers located in Canada.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <SBFM:ManagementAndDirectorCompensationTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001211">&lt;p id="xdx_80F_ecustom--ManagementAndDirectorCompensationTextBlock_zr12By3LXNae" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 16 &#x2013;
&lt;span id="xdx_82E_zN8xqraR0XQ7"&gt;Management and Director Compensation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company paid its officers cash compensation
totaling $&lt;span id="xdx_90A_eus-gaap--SalariesWagesAndOfficersCompensation_c20250101__20251231_z4PAnRiwzvof" title="Officers compensation"&gt;1,425,942&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--SalariesWagesAndOfficersCompensation_c20240101__20241231_zv4d9zDbhIp3" title="Officers compensation"&gt;1,850,243&lt;/span&gt; for the years ended December 31, 2025 and 2024, respectively. Of these amounts attributable to the
Company&#x2019;s CEO, $&lt;span id="xdx_902_eus-gaap--SalariesWagesAndOfficersCompensation_c20250101__20251231__custom--RelatedPartyTransactionsByRelatedPartyAxis__custom--AdvanomicsCorporationMember_zxq9MLmBdXe2" title="Officers compensation"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--SalariesWagesAndOfficersCompensation_c20240101__20241231__custom--RelatedPartyTransactionsByRelatedPartyAxis__custom--AdvanomicsCorporationMember_zYPQLvDpSqH" title="Officers compensation"&gt;800,000&lt;/span&gt;, respectively was paid to Advanomics Corporation, a company controlled by the CEO of the Company.
In addition, the Company&#x2019;s CEO was paid $12,000 in 2024 through the issuance of 120,000 shares of Series B Preferred Stock valued
at $12,000.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;The Company paid its five directors cash compensation
of $80,000 each, totaling $&lt;span id="xdx_907_eus-gaap--NoninterestExpenseDirectorsFees_c20250101__20251231_zpBJvn9CC8ki" title="Directors compensation"&gt;&lt;span id="xdx_90F_eus-gaap--NoninterestExpenseDirectorsFees_c20240101__20241231_zZ6M8ehV1rYd" title="Directors compensation"&gt;400,000&lt;/span&gt;&lt;/span&gt; for each of the years ended December 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;


</SBFM:ManagementAndDirectorCompensationTextBlock>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001213"
      unitRef="USD">1425942</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001215"
      unitRef="USD">1850243</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2025-01-012025-12-31_custom_AdvanomicsCorporationMember"
      decimals="0"
      id="Fact001217"
      unitRef="USD">0</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2024-01-012024-12-31_custom_AdvanomicsCorporationMember"
      decimals="0"
      id="Fact001219"
      unitRef="USD">800000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001221"
      unitRef="USD">400000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:NoninterestExpenseDirectorsFees
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001223"
      unitRef="USD">400000</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001225">&lt;p id="xdx_80A_eus-gaap--LegalMattersAndContingenciesTextBlock_zFb4Kc5Apiod" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 17 &#x2013;
&lt;span id="xdx_821_z30YGgVgpD5e"&gt;Legal Matters&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;On
                                            April 14, 2025, the Company terminated the employment of Mr. Malek Chamoun, president of
                                            the Company&#x2019;s wholly owned Canadian subsidiary, Nora Pharma. On April 17, 2025, the
                                            Company received a demand letter (the &#x201c;Demand Letter&#x201d;) from the attorneys of
                                            Mr. Chamoun requesting that the Company pay to Mr. Chamoun $7,307,025 CAD (approximately
                                            $5,300,000 USD) within five (5) days. In response to the Demand Letter, the Company issued
                                            a letter on May 1, 2025 advising that the demands contained in the Demand Letter, including
                                            the sum of $7,307,025 CAD (approximately $5,300,000 USD), are completely unfounded and that
                                            it intends to defend itself vigorously. No provision or accrual was made in the financial
                                            statements for any litigation liability or legal expense which the Company may incur in connection
                                            with this alleged claim.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001227">&lt;p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_zswwIHfzg0ah" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #00487F"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Note 18 &#x2013;
&lt;span id="xdx_821_z5DPDOoBmWii"&gt;Subsequent Events&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Arial, Helvetica, Sans-Serif"&gt;On
                                            January 16, 2026, the Company received a demand letter from the attorneys of Mr. Andrew Telsey,
                                            the Company&#x2019;s former legal counsel, asserting that the Company and Mr. Telsey executed
                                            an employment agreement and demanding payment of $3,645,750 from the Company based on the
                                            Company&#x2019;s alleged termination of the purported employment agreement without cause.
                                            The Company believes this demand is without merit and has never executed an employment agreement
                                            with Mr. Telsey. On that basis, among other factors, the Company filed a complaint against
                                            Mr. Telsey on February 6, 2026 in the circuit court of the 7&lt;sup&gt;th&lt;/sup&gt; judicial district
                                            in Broward County, Florida seeking a declaratory judgment providing that (i) the purported
                                            employment agreement is of no legal effect and is not binding upon the Company, (ii) no monies
                                            are owed by the Company to Mr. Telsey under the purported employment agreement, (iii) the
                                            Company should be awarded its attorney&#x2019;s fees and costs, and (iv) the Company should
                                            be awarded such other relief as the court deems just and proper. On March 30, 2026, the court granted the Company&#x2019;s motion for entry of default and entered a default and
final judgment in favor of the Company. Pursuant to the court&#x2019;s order, the court declared that the purported employment agreement
is of no legal effect and not binding on the Company, because the Company never executed the agreement, the Company did not breach the
purported employment agreement, and no monies are owed by the Company to Mr. Telsey under the purported employment agreement. The court
retained jurisdiction on the issues of entitlement and amount of attorney&#x2019;s fees and costs to the Company as the prevailing party. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;
&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2025-10-012025-12-31" id="Fact001228">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2025-10-012025-12-31" id="Fact001229">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2025-10-012025-12-31" id="Fact001230">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2025-10-012025-12-31" id="Fact001231">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="From2025-01-01to2025-12-31" id="Fact001232">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:AwardTmgMnpiDiscTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001233">We do not maintain any policies or practices regarding the timing of option or SAR grants in relation to the disclosure
of material nonpublic information because we do not utilize these forms of compensation and we do not currently anticipate granting stock
options or SARs in the foreseeable future.</ecd:AwardTmgMnpiDiscTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
